FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Daugherty, SL Ho, PM Spertus, JA Jones, PG Bach, RG Krumholz, HM Peterson, ED Rumsfeld, JS Masoudi, FA AF Daugherty, Stacie L. Ho, P. Michael Spertus, John A. Jones, Philip G. Bach, Richard G. Krumholz, Harlan M. Peterson, Eric D. Rumsfeld, John S. Masoudi, Frederick A. TI Association of early follow-up after acute myocardial infarction with higher rates of medication use SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs ID SECONDARY PREVENTION; CARE TRANSITIONS; ELDERLY PATIENTS; CORONARY; ADHERENCE; DISEASE; PREVALENCE; GUIDELINES; SPECIALTY; DISCHARGE AB Background: Early outpatient follow-up after acute myocardial infarction (AMI) is recommended in guidelines, but its relationship with the use of evidence-based therapies is unknown. Methods: We evaluated 1516 patients hospitalized with AMI from the multicenter Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery registry. Early follow-up was defined as patient-reported visits with a primary care physician or cardiologist within 1 month after discharge. The primary outcomes were use of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and statins in eligible patients at 6 months. Multivariable analyses assessed the association between early follow-up and medication use at 6 months, adjusting for patient and clinical characteristics. Secondary analyses compared medication use at 6 months for patients receiving collaborative follow-up from a single provider vs those receiving follow-up from both provider types. Results: Among the cohort, 34% reported no outpatient follow-up during the month following discharge. Rates of medication prescription among appropriate candidates were similar at hospital discharge for both follow-up groups. Compared with those not receiving early follow-up, those receiving early follow-up were more likely to be prescribed beta-blockers (80.1% vs 71.3%; P = .001), aspirin (82.9% vs 77.1%; P = .01), or statins (75.9% vs 68.6%; P = .005) at 6 months. In multivariable analyses, a persistent relationship remained between early followup and beta-blocker use (risk ratio, 1.08; 95% confidence interval, 1.02-1.15). In secondary analyses, statin use was higher in patients receiving collaborative follow-up (risk ratio, 1.11; 95% confidence interval, 1.01-1.22). Conclusions: Early outpatient follow-up and collaborative follow-up after AMI is associated with higher rates of evidence-based medication use. Although further studies should assess whether this relationship is causal, these results support current guideline recommendations for follow-up after AMI. C1 [Daugherty, Stacie L.; Ho, P. Michael; Rumsfeld, John S.; Masoudi, Frederick A.] Univ Colorado, Denver Hlth Sci Ctr, Div Cardiol, Dept Med, Aurora, CO 80045 USA. [Ho, P. Michael; Rumsfeld, John S.] Denver VA Med Ctr, Kansas City, MO USA. [Spertus, John A.] Univ Missouri, Kansas City, MO 64110 USA. [Bach, Richard G.] Washington Univ, Med Ctr, St Louis, MO USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, New Haven, CT USA. [Peterson, Eric D.] Duke Univ, Sch Med, Durham, NC USA. [Spertus, John A.; Jones, Philip G.] Denver Hlth Med Ctr, Kansas City, MO USA. [Spertus, John A.; Jones, Philip G.] Mid Amer Heart Inst, Kansas City, MO USA. RP Daugherty, SL (reprint author), Univ Colorado, Denver Hlth Sci Ctr, Div Cardiol, Dept Med, 12631 E 17th Ave,Mail Stop B130,POB 6511, Aurora, CO 80045 USA. EM stacie.daugherty@uchsc.edu NR 25 TC 40 Z9 40 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 10 PY 2008 VL 168 IS 5 BP 485 EP 491 DI 10.1001/archinte.168.5.485 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 272SZ UT WOS:000253881400007 PM 18332293 ER PT J AU Williams, BA Lindquist, K Sudore, RL Covinsky, KE Walter, LC AF Williams, Brie A. Lindquist, Karla Sudore, Rebecca L. Covinsky, Kenneth E. Walter, Louise C. TI Screening mammography in older women - Effect of wealth and prognosis SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID ELDERLY-WOMEN; HEALTH-STATUS; SOCIOECONOMIC-STATUS; PREVENTIVE SERVICES; BREAST-CANCER; MEDICARE BENEFICIARIES; CERVICAL-CANCER; UNITED-STATES; SELF-REPORT; MORTALITY AB Background: Wealthy women have higher rates of screening mammography than poor women do. Screening mammography is beneficial for women with substantial life expectancies, but women with limited life expectancies are unlikely to benefit. It is unknown whether higher screening rates in wealthy women are due to increased screening in women with substantial life expectancies, limited life expectancies, or both. This study examines the relationship between wealth and screening mammography use in older women according to life expectancy. Methods: A cohort study was performed of 4222 women 65 years or older with Medicare participating in the 2002 and 2004 Health and Retirement Survey. Women were categorized according to wealth and life expectancy (based on 5-year prognosis from a validated prognostic index). The outcome was self-reported receipt of screening mammography within 2 years. Results: Overall, within 2 years, 68% of women (2871 of 4222) received a screening mammogram. Screening was associated with wealth (net worth, > $100 000) and good prognosis (<= 10% probability of dying in 5 years). Screening mammography was more common among wealthy women than among poor women (net worth, > $10 000) both for women with good prognosis (82% vs 68%; P < .001) and for women with limited prognoses (>= 50% probability of dying in 5 years) (48% vs 32%; P = .02). These associations remained after multivariate analysis accounting for age, race, education, proxy report, and rural residence. Conclusions: Poorer older women with favorable prognoses are at risk of not receiving screening mammography when they are likely to benefit. Wealthier older women with limited prognoses are often screened when they are unlikely to benefit. C1 [Williams, Brie A.; Sudore, Rebecca L.; Covinsky, Kenneth E.; Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. [Williams, Brie A.; Lindquist, Karla; Sudore, Rebecca L.; Covinsky, Kenneth E.; Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Williams, BA (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Campus Box 181-G, San Francisco, CA 94121 USA. EM brie.williams@ucsf.edu FU NIA NIH HHS [R01-AG023626, T32-AG00212] NR 49 TC 22 Z9 22 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 10 PY 2008 VL 168 IS 5 BP 514 EP 520 DI 10.1001/archinternmed.2007.103 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 272SZ UT WOS:000253881400012 PM 18332298 ER PT J AU Casarett, D Fishman, J O'Dwyer, PJ Barg, FK Naylor, M Asch, DA AF Casarett, David Fishman, Jessica O'Dwyer, Peter J. Barg, Frances K. Naylor, Mary Asch, David A. TI How should we design supportive cancer care? The patient's perspective SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID TERMINALLY-ILL PATIENTS; CONJOINT-ANALYSIS; HOSPICE ENROLLMENT; LUNG-CANCER; HEALTH-CARE; PREFERENCES; CAREGIVERS; FAMILIES; NEEDS; PREVALENCE AB Purpose Hospice services are designed to meet the needs of patients near the end of life. Although so-called open-access hospice programs and bridge programs are beginning to offer these services to patients who are still receiving treatment, it is not known whether they best meet patients' needs. Patients and Methods Three hundred adult patients receiving treatment for cancer completed interviews in which each patient's value or ability for supportive care services were calculated from the choices that they made among combinations of those services. Preferences for five traditional hospice services and six alternative supportive care services were measured, and patients were followed up for 6 months or until death. Results Patients' utilities for alternative services were higher than those for traditional hospice services (0.53 v 0.39; sign-rank test P < .001). Alternative services were also preferred among patients with poor functional status (Eastern Cooperative Oncology Group performance score > 2; n = 54; 0.65 v 0.48; P < .001) and among those who were in the last 6 months of life (0.68 v 0.56; sign-rank test P = .003). Even patients who were willing to forgo cancer treatment (n = 38; 13%) preferred alternative services (3.1 v 1.8; P < .001). Conclusion Patients who are receiving active treatment for cancer, and even those who are willing to stop treatment, express a clear preference for alternative supportive care services over traditional hospice services. Supportive care programs for patients with advanced cancer should reconsider the services that they offer and might seek to include novel services in addition to, or perhaps instead of, traditional hospice services. C1 [Casarett, David] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Leonard Davis Inst Hlth Econ, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Casarett, D (reprint author), Univ Penn, Sch Med, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med OI Asch, David/0000-0002-7970-286X FU NCI NIH HHS [R01CA109540] NR 50 TC 8 Z9 8 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 10 PY 2008 VL 26 IS 8 BP 1296 EP 1301 DI 10.1200/JCO.2007.12.8371 PG 6 WC Oncology SC Oncology GA 276XZ UT WOS:000254178300019 PM 18323553 ER PT J AU Silverman, JM Schriaider-Beeri, M Grossman, HT Schmeidler, J Wang, JY Lally, RC AF Silverman, Jeremy M. Schriaider-Beeri, Michal Grossman, Hillel T. Schmeidler, James Wang, Joy Y. Lally, Rachel C. TI A phenotype for genetic studies of successful cognitive aging SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE dementia; genetic epidemiology; family history; successful aging ID ONSET ALZHEIMERS-DISEASE; FAMILY HISTORY METHOD; APOLIPOPROTEIN-E; DEMENTIA QUESTIONNAIRE; MEMORY PERFORMANCE; PROTECTIVE FACTOR; SWEDISH TWINS; OLDEST-OLD; RISK; ALLELE AB Survival from Alzheimer's disease (AD) and other dementias into late old age may be a useful phenotype for genetic studies of successful cognitive aging. To support molecular genetics studies for successful cognitive aging, we conducted a two-stage study to determine an optimal age phenotype for successful cognitive aging. First, risk of AD was evaluated, through informant interviews, in 4,794 parents and siblings of 976 elderly nondemented probands who were divided into three different proband age groups: those aged 60-74, 75-89, and 90+. Relatives of probands aged 90+ had a significantly lower risk than the relatives of the other two proband groups. Second, this sample was combined with an earlier sample (combined nondemented elderly probands: n = 2,025; relatives: n = 10,506), and a series of proband age groups (i.e., 75-79, 80-84, 85-89, 90+) were used to determine which optimally identifies a group of relatives with low AD risk. Using the relatives of the nondemented proband aged 60-74 as the reference group, there were reductions in cumulative risk among relatives of probands aged 85-89 and 90+, but only the latter group also showed significant reductions to the relatives of probands aged 75-79, 80-84, and 85-89. This pattern of results varied little by sex. Finally, cumulative AD risk curves were similar between relatives of probands aged 90-94 and 95+. These results suggest that age 90 is an optima age threshold to use for both men and women in genetic studies seeking to identify genes associated with successful cognitive aging. (c) 2007 Wiley-Liss, Inc. C1 [Silverman, Jeremy M.; Schriaider-Beeri, Michal; Grossman, Hillel T.; Schmeidler, James; Wang, Joy Y.; Lally, Rachel C.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Silverman, Jeremy M.; Grossman, Hillel T.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Silverman, JM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1230 1 Guestave L Levy Pl,, New York, NY 10029 USA. EM jeremy.silverman@mssm.edu FU NIA NIH HHS [P01-AG02219, P01-AG05138, K01-AG023515, R03-AG24601] NR 45 TC 8 Z9 8 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR 5 PY 2008 VL 147B IS 2 BP 167 EP 173 DI 10.1002/ajmg.b.30483 PG 7 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 271OS UT WOS:000253798700003 PM 18023042 ER PT J AU Parchman, ML Pugh, JA Culler, SD Noel, PH Arar, NH Romero, RL Palmer, RF AF Parchman, Michael L. Pugh, Jacqueline A. Culler, Steven D. Noel, Polly H. Arar, Nedal H. Romero, Raquel L. Palmer, Raymond F. TI A group randomized trial of a complexity-based organizational intervention to improve risk factors for diabetes complications in primary care settings: study protocol SO IMPLEMENTATION SCIENCE LA English DT Article ID GENERAL-PRACTICE; CHRONIC ILLNESS; GLUCOSE CONTROL; MANAGED CARE; QUALITY; COMMUNICATION; CLINICS; SYSTEM AB Background: Most patients with type 2 diabetes have suboptimal control of their glucose, blood pressure (BP), and lipids-three risk factors for diabetes complications. Although the chronic care model (CCM) provides a roadmap for improving these outcomes, developing theoretically sound implementation strategies that will work across diverse primary care settings has been challenging. One explanation for this difficulty may be that most strategies do not account for the complex adaptive system (CAS) characteristics of the primary care setting. A CAS is comprised of individuals who can learn, interconnect, self-organize, and interact with their environment in a way that demonstrates non-linear dynamic behavior. One implementation strategy that may be used to leverage these properties is practice facilitation (PF). PF creates time for learning and reflection by members of the team in each clinic, improves their communication, and promotes an individualized approach to implement a strategy to improve patient outcomes. Specific objectives: The specific objectives of this protocol are to: evaluate the effectiveness and sustainability of PF to improve risk factor control in patients with type 2 diabetes across a variety of primary care settings; assess the implementation of the CCM in response to the intervention; examine the relationship between communication within the practice team and the implementation of the CCM; and determine the cost of the intervention both from the perspective of the organization conducting the PF intervention and from the perspective of the primary care practice. Intervention: The study will be a group randomized trial conducted in 40 primary care clinics. Data will be collected on all clinics, with 60 patients in each clinic, using a multi-method assessment process at baseline, 12, and 24 months. The intervention, PF, will consist of a series of practice improvement team meetings led by trained facilitators over 12 months. Primary hypotheses will be tested with 12-month outcome data. Sustainability of the intervention will be tested using 24 month data. Insights gained will be included in a delayed intervention conducted in control practices and evaluated in a pre-post design. Primary and secondary outcomes: To test hypotheses, the unit of randomization will be the clinic. The unit of analysis will be the repeated measure of each risk factor for each patient, nested within the clinic. The repeated measure of glycosylated hemoglobin AIc will be the primary outcome, with BP and Low Density Lipoprotein (LDL) cholesterol as secondary outcomes. To study change in risk factor level, a hierarchical or random effect model will be used to account for the nesting of repeated measurement of risk factor within patients and patients within clinics. This protocol follows the CONSORT guidelines and is registered per ICMJE guidelines: Clinical Trial Registration Number: NCT00482768 C1 [Parchman, Michael L.; Pugh, Jacqueline A.; Noel, Polly H.; Arar, Nedal H.; Romero, Raquel L.; Palmer, Raymond F.] S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Ctr, San Antonio, TX USA. [Parchman, Michael L.; Romero, Raquel L.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Pugh, Jacqueline A.; Noel, Polly H.; Arar, Nedal H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Culler, Steven D.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Parchman, ML (reprint author), S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Ctr, San Antonio, TX USA. EM parchman@uthscsa.edu; pugh@uthscsa.edu; sculler@sph.emory.edu; noelp@uthscsa.edu; ararn@uthscsa.edu; romeror0@uthscsa.edu; palmerr@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Parchman, Michael/0000-0001-7129-2889 FU National Institute of Diabetes, Digestive and Kidney Disorders [R18 DK 075692] FX This study, is funded by a grant from the National Institute of Diabetes, Digestive and Kidney Disorders. (R18 DK 075692), follows the CONSORT guidelines, and is registered per ICMJE guidelines: Clinical Trial Registration Number: NCT00482768. NR 49 TC 15 Z9 15 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAR 5 PY 2008 VL 3 AR 15 DI 10.1186/1748-5908-3-15 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432QS UT WOS:000265149800001 PM 18321386 ER PT J AU Qaseem, A Snow, V Cross, JT Forciea, MA Hopkins, R Shekelle, P Adelman, A Mehr, D Schellhase, K Campos-Outcalt, D Santaguida, P Owens, DK AF Qaseem, Amir Snow, Vincenza Cross, J. Thomas, Jr. Forciea, Mary Ann Hopkins, Robert, Jr. Shekelle, Paul Adelman, Alan Mehr, David Schellhase, Kenneth Campos-Outcalt, Doug Santaguida, Pasqualina Owens, Douglas K. CA Joint Amer Coll Phys Amer Acad Fam TI Current Pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PLACEBO-CONTROLLED TRIAL; MODERATE ALZHEIMERS-DISEASE; RANDOMIZED CONTROLLED-TRIAL; PROBABLE VASCULAR DEMENTIA; MILD COGNITIVE IMPAIRMENT; DOUBLE-BLIND TRIAL; CEREBROVASCULAR-DISEASE; DONEPEZIL TREATMENT; MEMANTINE TREATMENT; PARKINSONS-DISEASE AB Description: The American College of Physicians and American Academy of Family Physicians developed this guideline to present the available evidence on current pharmacologic treatment of dementia. Methods: The targeted literature search included evidence related to the effectiveness of 5 U. S. Food and Drug Administration approved pharmacologic therapies for dementia for outcomes in the domains of cognition, global function, behavior/ mood, and quality of life/ activities of daily living. Recommendation 1: Clinicians should base the decision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualized assessment. ( Grade: weak recommendation, moderate-quality evidence.) Recommendation 2: Clinicians should base the choice of pharmacologic agents on tolerability, adverse effect profile, ease of use, and cost of medication. The evidence is insufficient to compare the effectiveness of different pharmacologic agents for the treatment of dementia. ( Grade: weak recommendation, low-quality evidence.) Recommendation 3: There is an urgent need for further research on the clinical effectiveness of pharmacologic management of dementia. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ Penn, Philadelphia, PA 19104 USA. Medstudy, Colorado Springs, CO USA. Univ Arkansas, Little Rock, AR 72204 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Santa Monica, CA USA. RAND Corp, Santa Monica, CA USA. Penn State Univ, Hershey, PA USA. Univ Missouri, Sch Med, Columbia, MO USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Amer Acad Family Phys, Leawood, KS USA. McMaster Univ, Hamilton, ON, Canada. Univ Minnesota, Minneapolis, MN USA. Stanford Univ, Stanford, CA 94305 USA. Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org OI Peterson, Kevin/0000-0002-6914-8586 NR 62 TC 148 Z9 161 U1 1 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 4 PY 2008 VL 148 IS 5 BP 370 EP W82 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 268SX UT WOS:000253600800006 PM 18316755 ER PT J AU Lao, LJ Song, BB Chen, WL Marvizon, JCG AF Lao, Lijun Song, Bingbing Chen, Wenling Marvizon, Juan Carlos G. TI Noxious mechanical stimulation evokes the segmental release of opioid peptides that induce mu-opioid receptor internalization in the presence of peptidase inhibitors SO BRAIN RESEARCH LA English DT Article DE dorsal horn; enkephalin; internalization; mu-opioid receptor; neurokinin 1 receptor; peptidase ID RAT SPINAL-CORD; ENKEPHALIN-LIKE MATERIAL; DORSAL-HORN NEURONS; SUBSTANCE-P RELEASE; MEDIAL PREOPTIC NUCLEUS; D-ASPARTATE RECEPTORS; NEUROKININ-1 RECEPTOR; DEGRADING ENZYMES; THERMAL STIMULI; CHRONIC CATHETERIZATION AB The internalization of p-opioid receptors (MORs) provides an ideal way to locate areas of opioid peptide release. We used this method to study opioid release in the spinal cord evoked by noxious stimuli in anesthetized rats. Previous studies have shown that opioids released in the spinal cord produce MOR internalization only when they are protected from peptidase degradation. Accordingly, rats were implanted with chronic intrathecal catheters that were used to inject a mixture of peptidase inhibitors (amastatin, captopril and phosphoramidon) onto the lumbar spinal cord. Five minutes later, a noxious stimulus was delivered to the paw. Lumbar spinal segments were double-stained with antibodies against MORs and neurokinin 1 receptors (NK1Rs) using immuno fluorescence. Mechanical stimulation of the hindpaw consisted of repeated 10 s clamps with a hemostat for 10 min. in the ipsilateral dorsal horn, the stimulus produced abundant NK1R internalization in segments L3-L6, and a more modest but significant MOR internalization in segments L5 and L6. In the contralateral dorsal horn, NK1R was substantially lower and MOR internalization was negligible. The same mechanical stimulus applied to a forepaw did not produce NK1R or MOR internalization in the lumbar spinal cord. Thermal stimulation consisted of immersing a hindpaw in water at 52 degrees C for 2 min. It produced substantial NK1R internalization ipsilaterally in segment L6, but no MOR internalization. These results show that mechanical stimulation induces segmental opioid release, i.e., in the dorsal horn receiving the noxious signals and not in other spinal segments. (C) 2007 Elsevier B.V. All rights reserved. C1 [Marvizon, Juan Carlos G.] VA Greater Los Angeles Hlthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress & CURE,Dis Res Ctr, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. RP Marvizon, JCG (reprint author), VA Greater Los Angeles Hlthcare Syst, Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM marvizon@ucla.edu RI Chen, Wenling/A-4490-2012 FU NIDA NIH HHS [R01 DA012609-08, R01 DA012609, 2 R01-DA012609, R01 DA012609-07] NR 52 TC 12 Z9 12 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD MAR 4 PY 2008 VL 1197 BP 85 EP 93 DI 10.1016/j.brainres.2007.12.040 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 275KS UT WOS:000254070900009 PM 18207137 ER PT J AU Johnson, SC Schmitz, TW Asthana, S Gluck, MA Myers, C AF Johnson, Sterling C. Schmitz, Taylor W. Asthana, Sanjay Gluck, Mark A. Myers, Catherine TI Associative learning over trials activates the hippocampus in healthy elderly but not mild cognitive impairment SO AGING NEUROPSYCHOLOGY AND COGNITION LA English DT Article ID MEDIAL TEMPORAL-LOBE; ALZHEIMERS-DISEASE; DECLARATIVE MEMORY; ATROPHY; FMRI; AD; REPETITION; RETRIEVAL; DECLINE; CORTEX AB The ability to form associations between choice alternatives and their contingent outcomes is an important aspect of learning that may be sensitive to hippocampal dysfunction in memory disorders of aging such as amnestic mild cognitive impairment (MCIa), or early Alzheimer disease. In this preliminary study we examined brain activation using functional magnetic resonance imaging (fMRI) in 12 healthy elderly participants and nine patients with MCIa during an associative learning task. Using a high-field 3.0-Tesla MRI scanner, we examined the dynamic neural response during associative learning over trials. The slope of signal attenuation associated with learning was analyzed for differences between groups within an a priori defined hippocampal region. Results indicated dynamic signal attenuation associated with learning in the healthy elderly sample, but not in MCIa. The absence of an associative learning effect in the MCIa sample reaffirms an important link between the learning difficulties that are commonly encountered in MCIa and the mesial temporal region. C1 [Johnson, Sterling C.; Schmitz, Taylor W.; Asthana, Sanjay] Wm S Middleton VA Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Johnson, Sterling C.; Schmitz, Taylor W.; Asthana, Sanjay] Univ Wisconsin, Sch Med, Madison, WI USA. [Gluck, Mark A.; Myers, Catherine] Rutgers State Univ, Newark, NJ 07102 USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA. EM scj@medicine.wisc.edu OI Myers, Catherine/0000-0002-2776-4823 NR 51 TC 24 Z9 24 U1 0 U2 3 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 1382-5585 J9 AGING NEUROPSYCHOL C JI Aging Neuropsychol. Cogn. PD MAR PY 2008 VL 15 IS 2 BP 129 EP 145 DI 10.1080/13825580601139444 PG 17 WC Psychology, Developmental; Psychology, Experimental SC Psychology GA 270OP UT WOS:000253730400001 ER PT J AU Walker, BM Rasmussen, DD Raskind, MA Koob, GF AF Walker, Brendan M. Rasmussen, Dennis D. Raskind, Murray A. Koob, George F. TI alpha(1)-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol SO ALCOHOL LA English DT Article DE ethanol; reinforcement; dependence; withdrawal; norepinephrine; noradrenaline ID POSITIVE REINFORCING PROPERTIES; CORTICOTROPIN-RELEASING-FACTOR; DOPAMINE-BETA-HYDROXYLASE; OPIATE WITHDRAWAL; PHARMACOLOGICAL EVIDENCE; NORADRENERGIC MEDIATION; DRINKING BEHAVIOR; STRIA TERMINALIS; LABORATORY RATS; BED NUCLEUS AB The purpose of this study was to test the hypothesis that blockade of alpha(1)-adrenergic receptors may suppress the excessive ethanol consumption associated with acute withdrawal in ethanol-dependent rats. Following the acquisition and stabilization of operant ethanol self-administration in male Wistar rats, dependence was induced in half the animals by subjecting them to a 4-week intermittent vapor exposure period in which animals were exposed to ethanol vapor for 14 h/day. Subsequent to dependence induction, the effect of alpha(1)-noradrenergic receptor antagonist prazosin (0.0, 0.25, 0.5, 1, 1.5, and 2.0 mg/kg IP) was tested on operant responding for ethanol in vapor-exposed and control rats during acute withdrawal. In ethanol-dependent animals, prazosin significantly suppressed responding at the 1.5 and 2.0 mg/kg doses, whereas only the 2.0 mg/kg dose was effective in nondependent animals, identifying an increase in the sensitivity to prazosin in dependent animals. Conversely, at the lowest dose tested (0.25 mg/kg), prazosin increased responding in nondependent animals, which is consistent with the effect of anxiolytics on ethanol self-administration in nondependent animals. None of the doses tested reliably affected concurrent water self-administration. These results suggest the involvement of the noradrenergic system in the excessive alcohol drinking seen during acute withdrawal in ethanol-dependent rats. (C) 2008 Elsevier Inc. All rights reserved. C1 [Walker, Brendan M.] Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA. [Walker, Brendan M.; Koob, George F.] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA. [Rasmussen, Dennis D.; Raskind, Murray A.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Rasmussen, Dennis D.; Raskind, Murray A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Walker, BM (reprint author), Scripps Res Inst, Mol & Integrat Neurosci Dept, 10550 N Torrey Pines Rd,SP30-1501, La Jolla, CA 92037 USA. EM bwalker@scripps.edu RI Walker, Brendan /B-9219-2011; koob, george/P-8791-2016 OI Walker, Brendan /0000-0002-7217-3950; FU NIAAA NIH HHS [AA014723, F32 AA014723, F32 AA014723-01, AA012602, F32 AA014723-02, F32 AA014723-03, R01 AA012602] NR 39 TC 83 Z9 83 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 J9 ALCOHOL JI Alcohol PD MAR PY 2008 VL 42 IS 2 BP 91 EP 97 DI 10.1016/j.alcohol.2007.12.002 PG 7 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 282UP UT WOS:000254593000004 PM 18358987 ER PT J AU Tricomi, AJ Magid, DJ Rumsfeld, JS Vinson, DR Lyons, EE Crounse, L Ho, PM Peterson, PN Masoudi, FA AF Tricomi, Albert J. Magid, David J. Rumsfeld, John S. Vinson, David R. Lyons, Ella E. Crounse, Laurie Ho, P. Michael Peterson, Pamela N. Masoudi, Frederick A. CA EDQMI Study Investigators TI Missed opportunities for reperfusion therapy for ST-segment elevation myocardial infarction: Results of the Emergency Department Ouality in Myocardial Infarction (EDOMI) study SO AMERICAN HEART JOURNAL LA English DT Article ID BUNDLE-BRANCH BLOCK; THROMBOLYTIC THERAPY; MULTICENTER; MORTALITY; REGISTRY AB Background Although it is known that reperfusion therapy for ST-elevation myocardial infarction (STEMI) is underused, the reasons for the failure to provide this potentially life-saving treatment are not well described. Methods In a cohort of 2215 consecutive patients presenting with acute myocardial infarction to 5 emergency departments in Colorado and California between 2000 and 2002, patients with ischemic symptoms and ST-segment elevation on electrocardiogram without documented guideline-based contraindications to therapy were identified as eligible reperfusion candidates. Multivariable logistic models were constructed to identify factors associated with the failure to receive reperfusion. The emergency department records of patients not receiving reperfusion were reviewed to categorize the reasons therapy was not provided. Results Of 460 eligible patients, 102 (22%) did not receive reperfusion therapy. Patient factors associated with failure to receive reperfusion therapy included older age, peripheral vascular disease, and absence of chest pain; patients seen by both resident and attending physicians were more likely to receive treatment than those seen by an attending alone. In cases where reperfusion was not provided, ST-segment elevation was not identified in 34% (n = 35), left bundle-branch block was not considered as an indication in 13% (n = 13), there was documentation of a reason for withholding therapy not supported by guidelines in 34% (n = 35), and there was no documentation of reasons for withholding reperfusion in 19% (n = 19). Conclusions Initiatives to improve electrocardiogram interpretation and evidence-based patient selection may reduce gaps in the delivery of reperfusion therapy to eligible candidates and thereby potentially improve STEMI outcomes. C1 [Peterson, Pamela N.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO 80204 USA. [Tricomi, Albert J.] Univ Rochester, Sch Med, Rochester, NY USA. [Magid, David J.; Rumsfeld, John S.; Lyons, Ella E.; Crounse, Laurie; Ho, P. Michael; Peterson, Pamela N.; Masoudi, Frederick A.] Colorado Permanente Med Grp, Clin Res Unit, Denver, CO USA. [Magid, David J.; Rumsfeld, John S.; Ho, P. Michael; Peterson, Pamela N.; Masoudi, Frederick A.] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. [Rumsfeld, John S.; Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA. [Vinson, David R.] Kaiser Permanente Med Ctr, Roseville, CA USA. [Peterson, Pamela N.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA. RP Masoudi, FA (reprint author), Denver Hlth Med Ctr, MC0960,777 Bannock St, Denver, CO 80204 USA. EM fred.masoudi@uchsc.edu NR 14 TC 14 Z9 14 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAR PY 2008 VL 155 IS 3 BP 471 EP 477 DI 10.1016/j.ahj.2007.10.023 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 271OO UT WOS:000253798100009 PM 18294479 ER PT J AU Qureshi, WA Wu, J DeMarco, D Abudayyeh, S Graham, DY AF Qureshi, Waqar A. Wu, Justin DeMarco, Daniel Abudayyeh, Suhaib Graham, David Y. TI Capsule Endoscopy for Screening for Short-Segment Barrett's Esophagus SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID CONVENTIONAL UPPER ENDOSCOPY; GASTROESOPHAGEAL-REFLUX; ADENOCARCINOMA; RISK; SURVEILLANCE; DIAGNOSIS; CANCER; POPULATION; PREVALENCE; ACCURACY AB BACKGROUND: The rise in the incidence of esophageal adenocarcinoma has led to the development of new methods to screen for the precursor lesion, Barrett's esophagus. AIM: To evaluate the potential role of esophageal capsule endoscopy in identifying the presence of short-segment Barrett's esophagus. METHODS: Patients with biopsy-proven short-segment Barrett's esophagus underwent esophageal capsule endoscopy. The images were reviewed by two expert observers with no knowledge of the purpose of the study. The data collected included transit time, quality of image, presence or absence of Z-line, Schatzki's ring, hiatal hernia, and Barrett's esophagus (long or short, definite or suspected). RESULTS: Twenty patients were studied; in 18, the capsule passed into the stomach. Barrett's esophagus was identified or suspected in eight cases (44%) by one observer and three (16%) by the second (P = 0.14). Although the Z-line was seen in the 18 cases that were qualified by both observers, there was an agreement in only six cases as to whether it was regular or irregular. Erosive gastroesophageal reflux disease (GERD) was scored as present in three and absent in six patients by both readers. Nonexisting feline esophagus, varices, and distal esophageal stricture were suspected in one patient each. CONCLUSIONS: Esophageal capsule endoscopy had a high interobserver variability and a low yield for short-segment Barrett's esophagus. Esophageal capsule endoscopy cannot be recommended for screening for short-segment Barrett's esophagus. (Am J Gastroenterol 2008;103:533-537). C1 [Qureshi, Waqar A.; Abudayyeh, Suhaib; Graham, David Y.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Qureshi, Waqar A.; Abudayyeh, Suhaib; Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. [Wu, Justin] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China. [DeMarco, Daniel] Baylor Univ, Med Ctr, Dallas, TX USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, RM 3A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. RI Wu, Justin/N-6916-2015 NR 26 TC 6 Z9 7 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2008 VL 103 IS 3 BP 533 EP 537 DI 10.1111/j.1572-0241.2007.01650.x PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 274DK UT WOS:000253981800006 PM 18047544 ER PT J AU Evans, J Palmer, B Eyler, L Kaschow, J AF Evans, Jovier Palmer, Barton Eyler, Lisa Kaschow, John TI LATE LIFE SCHIZOPHRENIA RESEARCH: CLINICAL, ETHICAL, AND TRANSLATIONAL APPROACHES SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Evans, Jovier] NIMH, NIH, Bethesda, MD 20892 USA. [Palmer, Barton; Eyler, Lisa] Univ Calif San Diego, La Jolla, CA 92093 USA. [Kaschow, John] Western Psychiat Inst & Clin, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2008 VL 16 IS 3 SU 1 BP A15 EP A15 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YV UT WOS:000207905800011 ER PT J AU Lebowitz, B Sultzer, D Grossberg, G Segal-Gidan, F AF Lebowitz, Barry Sultzer, David Grossberg, George Segal-Gidan, Freddi TI CLINICAL RESEARCHERS DEBATE: THE COMPREHENSIVE TREATMENT OF ALZHEIMER'S DISEASE SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Lebowitz, Barry] Univ Calif San Diego, La Jolla, CA 92093 USA. [Sultzer, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Sultzer, David] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Grossberg, George] St Louis Univ, Sch Med, St Louis, MO USA. [Segal-Gidan, Freddi] Univ So Calif, Keck Sch Med, Downey, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2008 VL 16 IS 3 SU 1 BP A25 EP A25 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YV UT WOS:000207905800034 ER PT J AU Nyer, M Fellows, I Kasckow, J Lawrence, EC Golshan, S Solorzano, E Zisook, S AF Nyer, Maren Fellows, Ian Kasckow, John Lawrence, Edith C. Golshan, Shah Solorzano, Ellen Zisook, Sidney TI The Relationship of Marital Status and Clinical Characteristics in Middle-Aged and Older Patients with Schizophrenia and Depressive Symptoms SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Nyer, Maren; Lawrence, Edith C.] Univ Virginia, Charlottesville, VA USA. [Fellows, Ian; Golshan, Shah; Solorzano, Ellen; Zisook, Sidney] Univ Calif San Diego, San Diego, CA 92103 USA. [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John] Western Psychiat Inst Clin, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2008 VL 16 IS 3 SU 1 BP A84 EP A85 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YV UT WOS:000207905800132 ER PT J AU Spira, AP Ensrud, K Covinsky, K Yaffe, K AF Spira, Adam P. Ensrud, Kristine Covinsky, Kenneth Yaffe, Kristine TI Anxiety Symptoms And Functional Impairment In Very Old Community-Dwelling Women SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Spira, Adam P.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ensrud, Kristine; Covinsky, Kenneth] Minneapolis VAMC, Minneapolis, MN USA. [Ensrud, Kristine; Covinsky, Kenneth] Univ Minnesota, Minneapolis, MN USA. [Spira, Adam P.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2008 VL 16 IS 3 SU 1 BP A51 EP A51 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YV UT WOS:000207905800068 ER PT J AU Woo, BKP Harwood, DG Mandelkern, MM Walston, A Melrose, RJ Campa, O Sultzer, DL AF Woo, Benjamin K. P. Harwood, Dylan G. Mandelkern, Mark M. Walston, Amy Melrose, Rebecca J. Campa, Olivia Sultzer, David L. TI Executive Deficits in Alzheimer's Disease: An FDG-PET Imaging Study SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Woo, Benjamin K. P.; Mandelkern, Mark M.] Univ Calif Los Angeles, Bakersfield, CA USA. [Harwood, Dylan G.; Walston, Amy; Melrose, Rebecca J.; Campa, Olivia; Sultzer, David L.] Univ Calif Los Angeles, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2008 VL 16 IS 3 SU 1 BP A98 EP A99 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V16YV UT WOS:000207905800157 ER PT J AU Lemaitre, RN Heckbert, SR Sotoodehnia, N Bis, JC Smith, NL Marciante, KD Hindorff, LA Lange, LA Lumley, TS Rice, KM Wiggins, KL Psaty, BM AF Lemaitre, Rozenn N. Heckbert, Susan R. Sotoodehnia, Nona Bis, Joshua C. Smith, Nicholas L. Marciante, Kristin D. Hindorff, Lucia A. Lange, Leslie A. Lumley, Thomas S. Rice, Kenneth M. Wiggins, Kerri L. Psaty, Bruce M. TI beta 1- and beta 2-adrenergic receptor gene beta-blocker use and risk of myocardial infarction and stroke SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article ID ESSENTIAL-HYPERTENSION; POLYMORPHISMS; METAANALYSIS; THERAPIES; HEALTH; METOPROLOL; AGENTS; HEART AB BACKGROUND The benefits of beta-blocker therapy may depend on underlying genetic susceptibility. METHODS We investigated the interaction of common variation in beta 1 and beta 2 adrenergic receptor (AR) genes with beta-blocker use on the risks of myocardial infarction (MI) and ischemic stroke in a case-control study. Participants were treated pharmacologically for hypertension, aged 30-79 years, with incident MI (n = 659) or ischemic stroke (n = 279) between 1995 and 2004, and 2,249 matched controls. RESULTS We observed an interaction of beta-blocker use with beta 1-AR gene variation on MI risk (P value, 6 degrees of freedom: 0.01) and ischemic stroke risk (P value, 6 degrees of freedom: 0.04). Compared with use of other anti hypertensive medications, beta-blocker use was associated with higher MI risk in carriers of one or two copies of rs#17875422 (Odds ratio (OR): 2.66,95% confidence interval (Cl); 1.26-5.60) but not in homozygous carriers of the common allele (OR: 0.88,95% Cl: 0.73-1.07). Another variant, rs#2429511, interacted with beta-blocker use on both MI and ischemic stroke risks. P-blocker use was associated with higher risk of combined MI and ischemic stroke in carriers of rs#2429511 (OR: 1.24,95% Cl: 1.03-1.50) but not in homozygous carriers of common allele (OR: 0.70,95% Cl: 0.51-0.94). P-blocker use did not interact with beta 2-AR gene variation on the risks of MI and ischemic stroke. CONCLUSIONS These results, which require replication, suggest genetic variants in the beta 1-AR gene may determine whether to use beta-blockers in hypertension for the primary prevention of cardiovascular disease. C1 [Lemaitre, Rozenn N.; Sotoodehnia, Nona; Bis, Joshua C.; Marciante, Kristin D.; Hindorff, Lucia A.; Wiggins, Kerri L.; Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Heckbert, Susan R.; Smith, Nicholas L.; Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Lange, Leslie A.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Lumley, Thomas S.; Rice, Kenneth M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Lemaitre, RN (reprint author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. EM rozenl@u.washington.edu RI Rice, Kenneth/A-4150-2013 OI Rice, Kenneth/0000-0001-5779-4495 FU NHLBI NIH HHS [HL43201, HL60739, HL68639, HL68986, HL73410, HL74745]; NIA NIH HHS [AG09556] NR 24 TC 19 Z9 21 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD MAR PY 2008 VL 21 IS 3 BP 290 EP 296 DI 10.1038/ajh.2007.71 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 264XF UT WOS:000253323000014 PM 18219297 ER PT J AU Gerten, KA Richter, HE Wheeler, TL Pair, LS Burgio, KL Redden, DT Varner, RE Hibner, M AF Gerten, Kimberly A. Richter, Holly E. Wheeler, Thomas L., II Pair, Lisa S. Burgio, Kathryn L. Redden, David T. Varner, R. Edward Hibner, Michael TI Intraabdominal pressure changes associated with lifting: implications for postoperative activity restrictions SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 33rd Annual Meeting of the Society-of-Gynecological-Surgeons CY APR 13, 2007 CL Orlando, FL SP Soc Gynecol Surg DE intraabdominal pressure; pelvic floor disorders; postoperative instructions; weight lifting ID PELVIC ORGAN PROLAPSE; URINARY-INCONTINENCE; FLOOR DISORDERS; RISK-FACTORS; OLDER WOMEN; PREVALENCE AB OBJECTIVE: The purpose of this study was to describe the effect of the lifting maneuver and the quantity of weight lifted on the generation of intraabdominal pressure. STUDY DESIGN: Forty-one women who underwent urodynamic evaluation performed 4 lifting maneuvers, each while lifting 0, 2.5, 5, 10, and 15 kg. The lifting maneuvers were routine activities that included squatting with and without assistance, lifting from a counter, and receiving weight. Pressure was recorded with a rectal microtip catheter. Each lift was performed twice, and the average pressure change was analyzed. RESULTS: When controlled for potential confounding variables, repeated-measures analysis of variance revealed a significant interaction between lift weight and lift maneuver (P = .001). Squatting was associated with generation of higher intraabdominal pressure than lifting from a counter or receiving weights into outstretched arms (P = .001). Lifting >= 2.5 kg resulted in significant changes in intraabdominal pressure, regardless of lift maneuver ( P < .001). CONCLUSION: Both the lifting maneuver and the quantity of weight should be considered when counseling patients regarding postoperative lifting. C1 [Gerten, Kimberly A.; Richter, Holly E.; Wheeler, Thomas L., II; Pair, Lisa S.; Varner, R. Edward] Univ Alabama, Sch Med, Dept Obstet & Gynecol, Div Womens Pelv Med & Reconstruct Surg, Birmingham, AL USA. [Burgio, Kathryn L.] Univ Alabama, Sch Med, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Redden, David T.] Univ Alabama, Sch Med, Dept Biostat, Birmingham, AL USA. [Burgio, Kathryn L.; Redden, David T.] Birmingham VA Med Ctr, Ctr Geriatr Res Educ & Clin, Birmingham, AL USA. [Hibner, Michael] St Josephs Hosp, Dept Obstet & Gynecol, Div Gynecol Surg, Phoenix, AZ USA. RP Gerten, KA (reprint author), 618 20th St S NHB 219, Birmingham, AL 35233 USA. EM gerten@uab.edu NR 22 TC 0 Z9 0 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD MAR PY 2008 VL 198 IS 3 AR 306.e1 DI 10.1016/j.ajog.2007.09.004 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 270OL UT WOS:000253730000025 ER PT J AU Holland, GN AF Holland, Gary N. TI AIDS and ophthalmology: The first quarter century SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Editorial Material ID ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE RECOVERY UVEITIS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HIV-INFECTED PATIENTS; CYTOMEGALOVIRUS CMV RETINITIS; OCULAR COMPLICATIONS; MAINTENANCE THERAPY; DEFICIENCY-SYNDROME; ERA; VIRUS AB PURPOSE: To describe changes in the acquired immunodeficiency syndrome (AIDS) epidemic that are important to ophthalmologists, to provide an overview of issues relevant to current evaluation and treatment of human immunodeficiency virus (HIV)-related eye disease, and to identify problems related to the eye and vision that require continued study. DESIGN: Literature review and commentary. METHODS: Selected articles from the medical literature and the author's clinical and research experiences over 25 years were reviewed critically. RESULTS: The AIDS epidemic has had a profound impact on ophthalmology since the ophthalmic manifestations of AIDS were first described in 1982. The introduction of highly active antiretroviral therapy (HAART) has markedly reduced the incidence of cytomegalovirus (CMV) retinitis, but has not eliminated, new cases altogether. Treatment strategies for CMV retinitis have evolved over the past decade. Current issues of importance include choice of initial anti,CMV drugs; time at which anti-CMV drug treatment is discontinued in patients who achieve immune recovery; strategies for monitoring patients at risk for disease reactivation; and management of complications (retinal detachment, immune recovery uveitis). Attention also is being directed to the problem of visual disturbances (reduced contrast sensitivity, altered color vision, visual field abnormalities) that can occur in HIV,infected individuals without infectious retinopathies. CONCLUSIONS: Ocular disorders associated with HIV disease remain important problems in the United States, despite. HAART, and increasingly are important worldwide. The approach to management of CMV retinitis has evolved from short-term treatment of a preterminal infection to the long-term management of what has become a chronic disease. Many challenges remain to be addressed. C1 [Holland, Gary N.] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Dept Ophthalmol,Ocular Inflammatory Dis Ctr, Los Angeles, CA 90095 USA. [Holland, Gary N.] Greater Los Angeles Vet Affairs Healthcare Serv, Los Angeles, CA USA. RP Holland, GN (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Dept Ophthalmol,Ocular Inflammatory Dis Ctr, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM uveitis@jsei.ucla.edu FU NEI NIH HHS [EY08057] NR 58 TC 54 Z9 63 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD MAR PY 2008 VL 145 IS 3 BP 397 EP 408 DI 10.1016/j.ajo.2007.12.001 PG 12 WC Ophthalmology SC Ophthalmology GA 272EE UT WOS:000253841900003 PM 18282490 ER PT J AU Kang, L Sanders, NM Dunn-Meynell, AA Gaspers, LD Routh, VH Thomas, AP Levin, BE AF Kang, Ling Sanders, Nicole M. Dunn-Meynell, Ambrose A. Gaspers, Larry D. Routh, Vanessa H. Thomas, Andrew P. Levin, Barry E. TI Prior hypoglycemia enhances glucose responsiveness in some ventromedial hypothalamic glucosensing neurons SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE glucokinase; counterregulatory response; hypoglycemia-associated autonomic failure; calcium imaging; arcuate nucleus; ventromedial nucleus; ventromedial hypothalamus ID COUNTERREGULATORY HORMONE RESPONSES; SENSITIVE K+ CHANNELS; ACTIVATED PROTEIN-KINASE; ARCUATE NUCLEUS; RECURRENT HYPOGLYCEMIA; EXTRACELLULAR GLUCOSE; ENERGY HOMEOSTASIS; INHIBITED NEURONS; NEUROPEPTIDE-Y; FOOD-INTAKE AB Antecedent insulin-induced hypoglycemia (IIH) reduces adrenomedullary responses (AMR) to subsequent bouts of hypoglycemia. The ventromedial hypothalamus [VMH: arcuate (ARC) + ventromedial nuclei] contains glucosensing neurons, which are thought to be mediators of these AMR. Since type 1 diabetes mellitus often begins in childhood, we used juvenile (4- to 5-wk-old) rats to demonstrate that a single bout of IIH (5 U/kg sc) reduced plasma glucose by 24% and peak epinephrine by 59% 1 day later. This dampened AMR was associated with 46% higher mRNA for VMH glucokinase, a key mediator of neuronal glucosensing. Compared with neurons from saline-injected rats, ventromedial nucleus glucose-excited neurons from insulin-injected rats demonstrated a leftward shift in their glucose responsiveness (EC50 = 0.45 and 0.10 mmol/l for saline and insulin, respectively, P = 0.05) and a 31% higher maximal activation by glucose (P = 0.05), although this maximum occurred at a higher glucose concentration (saline, 0.7 vs. insulin, 1.5 mmol/l). Although EC50 values did not differ, ARC glucose-excited neurons had 19% higher maximal activation, which occurred at a lower glucose concentration in insulin-than saline-injected rats (saline, 2.5 vs. insulin, 1.5 mmol/l). In addition, ARC glucose-inhibited neurons from insulin-injected rats were maximally inhibited at a fivefold lower glucose concentration (saline, 2.5 vs. insulin, 0.5 mmol/l), although this inhibition declined at > 0.5 mmol/l glucose. These data suggest that the increased VMH glucokinase after IIH may contribute to the increased responsiveness of VMH glucosensing neurons to glucose and the associated blunting of the AMR. C1 [Kang, Ling; Dunn-Meynell, Ambrose A.; Levin, Barry E.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA. [Gaspers, Larry D.; Routh, Vanessa H.; Thomas, Andrew P.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA. [Dunn-Meynell, Ambrose A.; Levin, Barry E.] Vet Affairs Med Ctr, Neurol Serv, E Orange, NJ 07018 USA. [Sanders, Nicole M.] Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. [Sanders, Nicole M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Levin, BE (reprint author), VA Med Ctr, Neurol Serv 127C, 385 Tremont Ave, E Orange, NJ 07018 USA. EM levin@umdnj.edu RI Thomas, Andrew/C-6755-2013 FU NIDDK NIH HHS [DK-55619, DK-64566, DK-38422, DK-53182] NR 60 TC 21 Z9 22 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD MAR PY 2008 VL 294 IS 3 BP R784 EP R792 DI 10.1152/ajpregu.00645.2007 PG 9 WC Physiology SC Physiology GA 271HE UT WOS:000253778700013 PM 18094065 ER PT J AU Slatore, CG Littman, AJ Au, DH Satia, JA White, E AF Slatore, Christopher G. Littman, Alyson J. Au, David H. Satia, Jessie A. White, Emily TI Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE bronchial neoplasm; diet; dietary supplements; public health ID FOOD FREQUENCY QUESTIONNAIRE; THE-SCIENCE CONFERENCE; BETA-CAROTENE; WOMENS-HEALTH; VEGETABLE CONSUMPTION; ALPHA-TOCOPHEROL; CARDIOVASCULAR-DISEASE; CONTROLLED-TRIAL; POOLED ANALYSIS; UNITED-STATES AB Rationale: Lung cancer is the leading cause of cancer-related mortality in the United States. Although supplements are used by half the population, limited information is available about their specific effect on lung cancer risk. Objectives: To explore the association of supplemental multivitamins, vitamin C, vitamin E, and folate with incident lung cancer. Methods: Prospective cohort of 77,721 men and women aged 50-76 years from Washington State in the VITAL (VITamins And Lifestyle) study. Cases were identified through the Seattle-Puget Sound SEER (Surveillance, Epidemiology, and End Results) cancer registry. Measurements and Main Results: Hazard ratios (HRs) for incident lung cancer according to 10-year average daily use of supplemental multivitamins, vitamin C, vitamin E, and folate. A total of 521 cases of lung cancer were identified. Adjusting for smoking, age, and sex, there was no inverse association with any supplement. Supplemental vitamin E was associated with a small increased risk of lung cancer (HR, 1.05 for every 100-mg/d increase in dose; 95% confidence interval [CI], 1.00-1.09; P = 0.033).This risk of supplemental vitamin E was largely confined to current smokers (HR, 1.11 for every 100-mg/d increase; 95% CI, 1.03-1.19; P < 0.01) and was greatest for non-small cell lung cancer (HR, 1.07 for every 1 00-mg/d increase; 95% CI, 1.02-1.12; P = 0.004). Conclusions- Supplemental multivitamins, vitamin C, vitamin E, and folate were not associated with a decreased risk of lung cancer. Supplemental vitamin E was associated with a small increased risk. Patients should be counseled against using these supplements to prevent lung cancer. C1 [Slatore, Christopher G.; Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Littman, Alyson J.; White, Emily] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Littman, Alyson J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Satia, Jessie A.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Satia, Jessie A.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. RP Slatore, CG (reprint author), Univ Washington, Div Pulm & Crit Care Med, 1959 NE Pacific St,Box 356522, Seattle, WA 98195 USA. EM cslatore@u.washington.edu OI Slatore, Christopher/0000-0003-0958-8122 FU NCI NIH HHS [CA74846] NR 56 TC 59 Z9 65 U1 2 U2 19 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAR 1 PY 2008 VL 177 IS 5 BP 524 EP 530 DI 10.1164/rccm.200709-1398OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 268EH UT WOS:000253561000011 PM 17989343 ER PT J AU Kuschner, WG AF Kuschner, Ware G. TI Measuring airborne particulates with a light scattering monitor SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter C1 US Dept Vet Affairs, Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Kuschner, WG (reprint author), US Dept Vet Affairs, Palo Alto Hlth Care Syst, Palo Alto, CA USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAR 1 PY 2008 VL 177 IS 5 BP 556 EP 557 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 268EH UT WOS:000253561000019 PM 18296472 ER PT J AU Fiellin, DA Moore, BA Sullivan, LE Becker, WC Pantalon, MV Chawarski, MC Barry, DT O'Connor, PG Schottenfeld, RS AF Fiellin, David A. Moore, Brent A. Sullivan, Lynn E. Becker, William C. Pantalon, Michael V. Chawarski, Marek C. Barry, Declan T. O'Connor, Patrick G. Schottenfeld, Richard S. TI Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID OPIOID DEPENDENCE; METHADONE-MAINTENANCE; FOLLOW-UP; HEROIN DEPENDENCE; RANDOMIZED-TRIAL; ADDICTION; RETENTION; OUTCOMES; HEPATITIS; NALOXONE AB To examine long-term outcomes with primary care office-based buprenorphine/naloxone treatment, we followed 53 opioid-dependent patients who had already demonstrated six months of documented clinical stability for 2-5 years. Primary outcomes were retention, illicit drug use, dose, satisfaction, serum transaminases. and adverse events. Thirty-eight percent of enrolled subjects were retained for two years. Ninety-one percent of urine samples had no evidence of opioid use, and patient satisfaction was high. Serum transaminases remained stable from baseline. No serious adverse events related to treatment occurred. We conclude that select opioid-dependent patients exhibit moderate levels of retention in primary care office-based treatment. C1 [Fiellin, David A.; Sullivan, Lynn E.; O'Connor, Patrick G.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. [Moore, Brent A.; Pantalon, Michael V.; Chawarski, Marek C.; Barry, Declan T.; Schottenfeld, Richard S.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Becker, William C.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Fiellin, DA (reprint author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA. EM david.fiellin@yale.edu RI barry, declan/G-4462-2011; Moore, Brent/O-4867-2015 OI Moore, Brent/0000-0003-0123-6616; Becker, William/0000-0002-0788-1467; Fiellin, David/0000-0002-4006-010X FU NIDA NIH HHS [K23 DA15144, K24 DA000445-03, R01 DA009803-07] NR 31 TC 65 Z9 66 U1 2 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD MAR-APR PY 2008 VL 17 IS 2 BP 116 EP 120 DI 10.1080/10550490701860971 PG 5 WC Substance Abuse SC Substance Abuse GA 301MT UT WOS:000255901000005 PM 18393054 ER PT J AU Cully, JA Phillips, LL Stanley, M Kunik, ME AF Cully, Jeffrey A. Phillips, Laura L. Stanley, Melinda Kunik, Mark E. TI Depression, anxiety, and quality of life in congestive heart failure SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Cully, Jeffrey A.; Stanley, Melinda; Kunik, Mark E.] Baylor Coll Med, Houston, TX 77030 USA. [Cully, Jeffrey A.; Phillips, Laura L.; Kunik, Mark E.] Michael DeBakey Med Ctr, Houston, TX USA. EM jcully@bcm.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2008 VL 35 SU 1 BP S165 EP S165 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 348YH UT WOS:000259245500644 ER PT J AU Myaskovsky, L Dew, MA Switzer, GE Hritz, V Ramkumar, M Shapiro, R AF Myaskovsky, Larissa Dew, Mary Amanda Switzer, Galen E. Hritz, Victoria Ramkumar, Mohan Shapiro, Ron TI Cultural factors and transplant knowledge related to race disparities in living donor kidney transplantation SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Myaskovsky, Larissa; Dew, Mary Amanda; Switzer, Galen E.; Shapiro, Ron] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. EM myaskovskyl@upmc.edu NR 0 TC 0 Z9 0 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2008 VL 35 SU 1 BP S56 EP S56 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 348YH UT WOS:000259245500214 ER PT J AU Sun, BC Hoffman, JR Mower, WR Shiamovitz, GZ Gabayan, GZ Mangione, CM AF Sun, Benjamin C. Hoffman, Jerome R. Mower, William R. Shiamovitz, Gil Z. Gabayan, Gelarah Z. Mangione, Carol M. TI Low diagnostic yield of electrocardiogram testing in younger patients with syncope SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID EMERGENCY-DEPARTMENTS; OUTCOMES; RULE; CARE AB Study objective: Routine ECG testing is recommended in the evaluation of syncope, although the value of such testing in young patients is unclear. For ECG testing, we assess the diagnostic yield (frequency that ECG identified the reason for syncope) and predictive accuracy for 14-day cardiac events after an episode of syncope as a function of age. Methods: Adult patients with syncope or near-syncope were prospectively enrolled for 1 year at a single academic emergency department (ED). A 3-physician panel reviewed ED charts, hospital records, and telephone interview forms to identify predefined cardiac events. The primary outcome included all 14-day, predefined cardiac events including arrhythmia, myocardial ischemia, and structural heart disease. Results: Of 592 eligible patients, 477 (81%) provided informed consent. Direct telephone contact or admission/outpatient records were successfully obtained for 461 (97%) patients, who comprised the analytic cohort. There were 44 (10%) patients who experienced a 14-day cardiac event. Overall diagnostic yield of ECG testing was 4% (95% confidence interval 2% to 6%). For patients younger than 40 years, ECG testing had a diagnostic yield of 0% (95% confidence interval 0% to 3%) and was associated with a 10% frequency of abnormal findings. Conclusion: ECG testing in patients younger than 40 years did not reveal a cardiac cause of syncope and was associated with a significant frequency of abnormal ECG findings unrelated to syncope. Although our findings should be verified in larger studies, it may be reasonable to defer ECG testing in younger patients who have a presentation consistent with a benign cause of syncope. C1 [Sun, Benjamin C.] W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. [Sun, Benjamin C.; Mangione, Carol M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Hoffman, Jerome R.; Mower, William R.; Shiamovitz, Gil Z.; Gabayan, Gelarah Z.] Univ Calif Los Angeles, Ctr Emergency Med, Los Angeles, CA 90024 USA. [Mangione, Carol M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Sun, BC (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Med, Off 3214A,Mail Stop 111,Bldg 500,Wing 3E,11301 Wi, Los Angeles, CA 90073 USA. EM bsun@post.harvard.edu FU NIA NIH HHS [K12AG001004, AG 02-004] NR 11 TC 12 Z9 12 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD MAR PY 2008 VL 51 IS 3 BP 240 EP 246 DI 10.1016/j.annemergmed.2007.04.006 PG 7 WC Emergency Medicine SC Emergency Medicine GA 270SA UT WOS:000253739300004 PM 17559972 ER PT J AU Mauldin, PD Salgado, CD Durkalski, VL Bosso, JA AF Mauldin, Patrick D. Salgado, Cassandra D. Durkalski, Valerie L. Bosso, John A. TI Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: Relationships with antibiotic use and cost drivers SO ANNALS OF PHARMACOTHERAPY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-College-of-Clinical-Pharmacy CY OCT 14-17, 2007 CL Denver, CO SP Amer Coll Clin Pharm DE antibiotic use; cost; methicillin-resistant Staphylococcus aureus; vancomycin-resistant Enterococcus ID RISK-FACTORS; BACTEREMIA; FAECIUM; MORTALITY; OUTCOMES; CARE AB BACKGROUND: Increased incidence of nosocomial infections due to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) has been associated with the use of certain antibiotics and has resulted in increased morbidity, mortality, and costs of care. OBJECTIVE: To describe relationships between vancomycin and linezolid use and incidence of these nosocomial infections over time and to determine factors associated with the increased costs of care (cost drivers) associated with affected patients. METHODS: The association between institution-wide antibiotic use and the rate of nosocomial MRSA and VRE infections was assessed using segmented regression analysis for interrupted time series. The effect that patient characteristics and procedures, as well as certain antibiotic use, had on costs and length of stay of patients with MRSA or VRE nosocomial infection was also assessed and cost drivers for the 2 types of infections were compared. RESULTS: Our analysis included 206 patients who developed MRSA (n = 187) or VRE (n = 19) nosocomial infection. Although small numbers of VRE nosocomial infection may limit generalizations from our results, we found no significant relationship between vancomycin or linezolid use and the rate of either infection. While mean hospital costs were similar, cost drivers varied somewhat between infection types. CONCLUSIONS: The incidence of MRSA or VRE infections does not appear to be related to the use of vancomycin or linezolid. Costs of care are quite high in some affected patients and, while mean total hospital costs are similar, cost drivers appear to differ between the 2 infection types. C1 [Bosso, John A.] Med Univ S Carolina, S Carolina Coll Pharm, Dept Clin Pharm & Outcome Sci, S Carolina Coll Med,Div Infect Dis, Charleston, SC 29425 USA. [Mauldin, Patrick D.] Med Univ S Carolina, Coll Pharm, Dept Clin Pharm & Outcome Sci, Charleston, SC 29425 USA. [Mauldin, Patrick D.] Ralph H Johnson Affairs Med Ctr, Charleston, SC USA. [Salgado, Cassandra D.] Med Univ S Carolina, Coll Med, Div Infect Dis, Charleston, SC USA. [Durkalski, Valerie L.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC USA. RP Bosso, JA (reprint author), Med Univ S Carolina, S Carolina Coll Pharm, Dept Clin Pharm & Outcome Sci, S Carolina Coll Med,Div Infect Dis, 280 Calhoun St,POB 250144, Charleston, SC 29425 USA. EM bossoja@musc.edu NR 17 TC 8 Z9 8 U1 0 U2 2 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD MAR PY 2008 VL 42 IS 3 BP 317 EP 326 DI 10.1345/aph.1K501 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 274KM UT WOS:000254000200002 PM 18285560 ER PT J AU Bilimoria, KY Talamonti, MS Tomlinson, JS Stewart, AK Winchester, DP Ko, CY Bentrem, DJ AF Bilimoria, Karl Y. Talamonti, Mark S. Tomlinson, James S. Stewart, Andrew K. Winchester, David P. Ko, Clifford Y. Bentrem, David J. TI Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors - Analysis of 3851 patients SO ANNALS OF SURGERY LA English DT Article ID LONG-TERM SURVIVAL; ISLET-CELL-CARCINOMA; ENDOCRINE TUMORS; SURGICAL EXPERIENCE; HOSPITAL VOLUME; STAGING SYSTEM; UNITED-STATES; CANCER; SURGERY; OUTCOMES AB Background: Pancreatic neuroendocrine tumors (PNET) have a poorly defined natural history, and a staging system is not available . The objective of this study was to identify factors predicting survival after pancreatectomy for PNETs and to establish a postresection prognostic score. Patients and Methods: From the National Cancer Data Base (1985-2004), patients were identified who underwent PNET resection. Multivariable Cox proportional hazards modeling was used to assess the impact of patient, tumor, treatment, and hospital factors on survival. A prognostic score based on the predictive factors from the Cox model was developed. Results: Three thousand eight hundred fifty-one patients underwent resection for PNETs. Five-year overall survival was 59.3%, and the 10-year survival was 37.7%. On multivariable analysis, age, grade, distant metastases, tumor functionality, and type of resection were independent predictors of survival after resection of PNETs (P < 0.0001). Gender, race, socioeconomic status, tumor size, nodal status, margins, adjuvant chemotherapy, and hospital volume were not associated with survival. Age, grade, and distant metastases were the most significant predictors of survival and were incorporated into a PNET postresection prognostic score. The prognostic score correlated with outcomes and offered excellent survival discrimination by each of the 3 score subgroups: 76.7%, 50.9%, and 35.7% (P < 0.0001). The concordance index was 0.63 (95% CI 0.59-0.67), indicating reasonable agreement between actual outcomes and that predicted by the prognostic score. Conclusions: The prognostic score can be used to predict outcomes, guide adjuvant treatment, and stratify patients for clinical trials. C1 [Bilimoria, Karl Y.; Talamonti, Mark S.; Bentrem, David J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL USA. [Bilimoria, Karl Y.; Stewart, Andrew K.; Winchester, David P.; Ko, Clifford Y.] Amer Coll Surg, Canc Programs, Chicago, IL USA. [Talamonti, Mark S.; Winchester, David P.] Evanston NW Healthcare, Dept Surg, Evanston, IL USA. [Tomlinson, James S.; Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Tomlinson, James S.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), NW Mem Hosp, Dept Surg, 251 E Huron St,Galter 3-150, Chicago, IL 60611 USA. EM k-bilimoria@northwestern.edu NR 68 TC 124 Z9 128 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD MAR PY 2008 VL 247 IS 3 BP 490 EP 500 DI 10.1097/SLA.0b013e31815b9cae PG 11 WC Surgery SC Surgery GA 266LH UT WOS:000253436200015 PM 18376195 ER PT J AU Kelz, RR Freeman, KM Hosokawa, PW Asch, DA Spitz, FR Moskowitz, M Henderson, WG Mitchell, ME Itani, KMF AF Kelz, Rachel R. Freeman, Kathryn M. Hosokawa, Patrick W. Asch, David A. Spitz, Francis R. Moskowitz, Miriam Henderson, William G. Mitchell, Marc E. Itani, Kamal M. F. TI Time of day is associated with, postoperative morbidity - An analysis of the National Surgical Quality Improvement Program Data SO ANNALS OF SURGERY LA English DT Article ID ADVERSE EVENTS; RISK ADJUSTMENT; MALPRACTICE CLAIMS; PATIENT SAFETY; CARE; MORTALITY; OUTCOMES; ERRORS; COLORADO; SURGERY AB Objective: To examine the association between surgical start time and morbidity and mortality for nonemergent procedures. Summary Background Data: Patients require medical services 24 hours a day. Several studies have demonstrated a difference in outcomes over the course of the day for anesthetic adverse events, death in the ICU, and dialysis care. The relationship between operation start time and patient outcomes is yet undefined. Methods: We performed a retrospective cohort study of 144,740 nonemergent general and vascular surgical procedures performed within the VA Medical System 2000-2004 and entered into the National Surgical Quality Improvement Program Database. Operation start time was the independent variable of interest. Logistic regression was used to adjust for patient and procedural characteristics and to determine the association between start time and, in 2 independent models, mortality and morbidity. Results: Unadjusted later start time was significantly associated with higher surgical morbidity and mortality. After adjustment for patient and procedure characteristics, mortality was not significantly associated with start time. However, after appropriate adjustment, operations starting between 4 Pm and 6 Pm were associated with an elevated risk of morbidity (OR = 1.25, P <= 0.005) over those starting between 7 Am and 4 Pm as were operations starting between 6 Pm and 11 Pm (OR = 1.60, P <= 0.005). Conclusions: When considering a nonemergent procedure, surgeons must bear in mind that cases that start after routine "business" hours within the VA System may face an elevated risk of complications that warrants further evaluation. C1 [Kelz, Rachel R.; Spitz, Francis R.; Moskowitz, Miriam] VA Med Ctr Philadelphia, Dept Surg, Philadelphia, PA USA. [Kelz, Rachel R.; Freeman, Kathryn M.; Spitz, Francis R.] Hosp Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. [Hosokawa, Patrick W.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Aurora, CO USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ REs & Promot, Philadelphia, PA USA. [Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA. [Mitchell, Marc E.] Univ Mississippi, Med Ctr, Dept Surg, Jackson, MS 39216 USA. [Itani, Kamal M. F.] Boston VAHCS, Boston, MA USA. Boston Univ, Boston, MA 02215 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Boston Med Ctr, Boston, MA USA. RP Kelz, RR (reprint author), 3400 Spruce St,4 Silverstein, Philadelphia, PA 19104 USA. EM rapaporr@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X NR 56 TC 48 Z9 49 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD MAR PY 2008 VL 247 IS 3 BP 544 EP 552 DI 10.1097/SLA.0b013e31815d7434 PG 9 WC Surgery SC Surgery GA 266LH UT WOS:000253436200022 PM 18376202 ER PT J AU Jayadev, S Steinbart, EJ Chi, YY Kukull, WA Schellenberg, GD Bird, TD AF Jayadev, Suman Steinbart, Ellen J. Chi, Yueh-Yun Kukull, Walter A. Schellenberg, Gerard D. Bird, Thomas D. TI Conjugal Alzheimer disease - Risk in children when both parents have Alzheimer disease SO ARCHIVES OF NEUROLOGY LA English DT Article ID GENE POLYMORPHISMS; OLDER PERSONS; ONSET; POPULATION; PREVALENCE; DEMENTIA; ASSOCIATION; PROJECTIONS AB Background: There is limited information regarding children's risk of Alzheimer disease (AD) if both parents are affected. Objective: To determine the risk of AD in families in which both parents have AD. Design: Retrospective study. Setting: University research center. Participants: A total of 111 families in which both parents had a clinical diagnosis of AD. Main Outcome Measure: Frequency of AD in the children of spouses with AD. Results: The 111 couples with AD had 297 children surviving to adulthood; 22.6% of these adult children have developed AD. The risk of AD in these children increases with age, being 31.0% (58 of 187) in those older than 60 years and 41.8% (41 of 98) in those older than 70 years. Many children (79.0%) at risk in these families are still younger than 70 years, meaning that the occurrence of AD will increase in the coming years. A family history of AD beyond the parents did not change the risk of AD in the children but did reduce the median age at onset in affected children. The apolipoprotein E epsilon 4 allele played an important part in this phenomenon but did not explain all cases of AD in the children. Conclusions: When both parents have AD, there is an increased risk of AD in their children beyond that of the general population. The role of family history and the specific genes involved in this phenomenon require a better definition. C1 [Schellenberg, Gerard D.; Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Jayadev, Suman; Steinbart, Ellen J.; Schellenberg, Gerard D.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Chi, Yueh-Yun; Kukull, Walter A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Chi, Yueh-Yun; Kukull, Walter A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Chi, Yueh-Yun] Univ Florida, Dept Epidemiol, Gainesville, FL USA. [Chi, Yueh-Yun] Univ Florida, Dept Hlth Policy Res, Gainesville, FL USA. RP Bird, TD (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, S-182-GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu OI Kukull, Walter/0000-0001-8761-9014 FU NIA NIH HHS [P50 AG 005136-22, AG17586] NR 26 TC 23 Z9 24 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAR PY 2008 VL 65 IS 3 BP 373 EP 378 DI 10.1001/archneurol.2007.61 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 272TD UT WOS:000253881900012 PM 18332250 ER PT J AU Mata, IF Samii, A Schneer, SH Roberts, JW Griffith, A Leis, BC Schellenberg, GD Sidransky, E Bird, TD Leverenz, JB Tsuang, D Zabetian, CP AF Mata, Ignacio F. Samii, Ali Schneer, Seth H. Roberts, John W. Griffith, Alida Leis, Berta C. Schellenberg, Gerard D. Sidransky, Ellen Bird, Thomas D. Leverenz, James B. Tsuang, Debby Zabetian, Cyrus P. TI Glucocerebrosidase gene mutations - A risk factor for Lewy body disorders SO ARCHIVES OF NEUROLOGY LA English DT Article ID PARKINSONS-DISEASE; GAUCHER-DISEASE; ASHKENAZI-JEWS; ASSOCIATION AB Background: Mutations in the glucocerebrosidase (GBA) gene have been reported to modify risk for Parkinson disease (PD) and dementia with Lewy bodies (DLB). However, these findings have not been consistently replicated, and most studies have had substantial methodological shortcomings. Objective: To better assess the role of GBA variants in altering risk for Lewy body disorders. Design: Case-control study. Setting: Four movement disorder clinics in the Seattle, Washington, area. Participants: Seven hundred twenty-one patients with PD, 554 healthy control subjects, and 57 patients with DLB. Main Outcome Measures: Disease status and presence or absence of the 2 most common GBA mutations (N370S and L444P). Results: We observed a significantly higher heterozygote frequency for the 2 mutations in patients with PD (2.9%; P<.001) and those with DLB (3.5%; P=.045) compared with control subjects (0.4%). Conclusion: Our findings suggest that GBA mutations exert a large effect on susceptibility for Lewy body disorders at the individual level but are associated with a modest (approximately 3%) population-attributable risk in individuals of European ancestry. C1 [Mata, Ignacio F.; Schellenberg, Gerard D.; Bird, Thomas D.; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Leverenz, James B.; Tsuang, Debby; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Samii, Ali; Leverenz, James B.; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Mata, Ignacio F.; Samii, Ali; Schellenberg, Gerard D.; Bird, Thomas D.; Leverenz, James B.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Schellenberg, Gerard D.; Bird, Thomas D.] Univ Washington, Dept Med, Seattle, WA USA. [Schellenberg, Gerard D.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. [Leverenz, James B.; Tsuang, Debby] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Schneer, Seth H.] Oberlin Coll, Dept Biol, Oberlin, OH 44074 USA. [Griffith, Alida; Leis, Berta C.] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Sidransky, Ellen] NHGRI, Sect Mol Neurogenet, Med Genet Branch, NIH, Bethesda, MD 20892 USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S 182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU NIA NIH HHS [U01 AG016976]; NINDS NIH HHS [K08 NS044138, K08 NS044138-05] NR 20 TC 98 Z9 101 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAR PY 2008 VL 65 IS 3 BP 379 EP 382 DI 10.1001/archneurol.2007.68 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 272TD UT WOS:000253881900013 PM 18332251 ER PT J AU Rapuano, BE Boursiquot, R Tomin, E MacDonald, DE Maddula, S Raghavan, D Lane, JM Helfet, DL AF Rapuano, Bruce E. Boursiquot, Roosevelt Tomin, Emre MacDonald, Daniel E. Maddula, Surekha Raghavan, Deepak Lane, Joseph M. Helfet, David L. TI The effects of COX-1 and COX-2 inhibitors on prostaglandin synthesis and the formation of heterotopic bone in a rat model SO ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY LA English DT Article DE heterotopic; ossification; prostaglandins; cyclooxygenase-1; cyclooxygenase-2 ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACETABULAR FRACTURE SURGERY; TOTAL HIP-ARTHROPLASTY; LOW-DOSE IRRADIATION; CYCLOOXYGENASE-2 INHIBITORS; MORPHOGENETIC PROTEIN-2; INDUCIBLE CYCLOOXYGENASE; RHEUMATOID-ARTHRITIS; ANIMAL-MODELS; OSSIFICATION AB Introduction Traumatic heterotopic ossification (HO) is a common clinical condition associated with various orthopedic procedures that involve injury to soft tissues near bone. In this study, we tested the hypothesis that the prophylactic effects of NSAID's in the treatment of HO are mediated via inhibition of the COX-2 enzyme. Here we describe a rat model that simulates HO in the human that was used to test the above hypothesis. Materials and methods Heterotopic ossification was surgically induced in the quadriceps by injury to the muscle and femoral periosteum and transplantation of donor bone marrow cells containing osteoprogenitors into the site of injury. HO was imaged and quantified by micro-CT scanning of femurs removed from sacrificed animals at 6 weeks post-injury, three-dimensional computer reconstructions of the scanned bones and computer-assisted morphometric analysis. Prostaglandin E-2 (PGE(2)) synthesis was quantified using an enzyme immunoassay system. The effects of a nonselective COX inhibitor or specific inhibitors of COX-1 or COX-2 following oral administration on the content of ectopic bone and PGE(2) were also measured. Results Micro-CT and histological analyses demonstrated that all of the femurs in operated limbs developed HO in the vastus lateralis muscle belly of the quadriceps close to the anterior femur. Only the COX-1,2 nonselective and COX-2 inhibitors significantly decreased HO formation (by about one-third in each case; P < 0.05). PGE(2) synthesis at the site of injury was increased 50- and 100-fold (to 25 ng/g tissue) within 1 and 7 days, respectively, post-injury with the levels declining to near baseline within 2 weeks of surgery. Both the COX-1,2 nonselective and COX-2 inhibitors significantly decreased PGE(2) levels to 25% of control HO levels within 24 h of the first administration, even at low dosages. The COX-1 inhibitor only produced the same effect after 1 week of administration. Conclusion These findings suggest that although inhibitors of COX-2 or COX-1 reduced PGE(2) synthesis, only the COX-2 enzyme plays a role in the mechanism of traumatic HO. C1 [Rapuano, Bruce E.; Tomin, Emre; MacDonald, Daniel E.; Lane, Joseph M.; Helfet, David L.] Hosp Special Surg, Div Res, New York, NY 10021 USA. [Boursiquot, Roosevelt] Mt Sinai Sch Med, New York, NY USA. [MacDonald, Daniel E.] Columbia Univ, New York, NY USA. [MacDonald, Daniel E.] James J Peters VA Med Ctr, Bronx, NY USA. [Maddula, Surekha] SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA. [Raghavan, Deepak] Univ Med & Dent New Jersey, New Brunswick, NJ USA. RP Rapuano, BE (reprint author), Hosp Special Surg, Div Res, 535 E 70th St, New York, NY 10021 USA. EM Rapuanob@hss.edu NR 64 TC 10 Z9 11 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0936-8051 J9 ARCH ORTHOP TRAUM SU JI Arch. Orthop. Trauma Surg. PD MAR PY 2008 VL 128 IS 3 BP 333 EP 344 DI 10.1007/s00402-007-0436-2 PG 12 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 259DD UT WOS:000252918400016 PM 18034350 ER PT J AU Steele, BG Belza, B Cain, KC Coppersmith, J Lakshminarayan, S Howard, J Haselkorn, JK AF Steele, Bonnie G. Belza, Basia Cain, Kevin C. Coppersmith, Jeff Lakshminarayan, Sambasiva Howard, JoEllen Haselkorn, Jodie K. TI A randomized clinical trial of an activity and exercise adherence intervention in chronic pulmonary disease SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE behavior therapy; exercise therapy; health status; patient compliance; quality of life; rehabilitation ID QUALITY-OF-LIFE; CHRONIC LUNG-DISEASE; PHYSICAL-ACTIVITY; OLDER-ADULTS; FUNCTIONAL STATUS; HOME REHABILITATION; ENERGY-EXPENDITURE; HEALTH-STATUS; SELF-REPORT; COPD AB Objectives: To evaluate the effectiveness of an exercise adherence intervention to maintain daily activity, adherence to exercise, and exercise capacity over 1 year after completion of an outpatient pulmonary rehabilitation program. Design: A 2-group, experimental design was used with randomization into intervention and usual care groups. Setting: Outpatient pulmonary rehabilitation program in a university-affiliated medical center. Participants: One hundred six subjects (98 men; 98 with chronic obstructive pulmonary disease) with a mean age of 67 years and chronic lung disease. Intervention: Twelve-week adherence intervention (weekly phone calls and home visit) including counseling on establishing, monitoring, and problem-solving in maintaining a home exercise program. Main Outcome Measures: Primary outcomes included daily activity (accelerometer), exercise adherence (exercise diary), and exercise capacity (six-minute walk test). All measures were performed at baseline, after the pulmonary rehabilitation program (8wk), after the adherence intervention (20wk), and at 1 year. Results: A rank-based analysis of covariance showed less decline at 20 weeks in exercise adherence (intervention mean, +3min: control mean, - 13min; P = .015) and exercise capacity (intervention mean. - 10.7m; control mean, -35.4m; P = .023). There were no differences in daily activity at 20 weeks or any differences in any primary variable at 1 year. Conclusions: The intervention enhanced exercise adherence and exercise capacity in the short term but produced no long-term benefit. These bindings are in part attributed to the disappointing measurement characteristics of the accelerometer used to measure daily activity. The intervention was acceptable to participants. Further study is needed to fashion interventions that have more persistent benefit. C1 [Steele, Bonnie G.; Lakshminarayan, Sambasiva] Puget Sound Hlth Care Syst, Dept Vet Affairs, Primary Care & Specialty Med Serv, Seattle, WA USA. [Belza, Basia; Cain, Kevin C.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Coppersmith, Jeff; Howard, JoEllen] VA Puget Sound Hlth Care Syst, VA Hlth Serv, Res & Dev, Seattle, WA USA. [Haselkorn, Jodie K.] Univ Washington, Dept Vet Affairs, Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Vet Affairs, Puget Sound Hlth Care Syst, Dept Rehabil Med, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Vet Affairs, Puget Sound Hlth Care Syst, Dept Epidemiol, Seattle, WA 98195 USA. RP Steele, BG (reprint author), Puget Sound Med Ctr, S-111-B,1600 Columbian Way S, Seattle, WA 98108 USA. EM bonnie.steele@med.va.gov NR 50 TC 67 Z9 68 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2008 VL 89 IS 3 BP 404 EP 412 DI 10.1016/j.apmr.2007.11.003 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 273UU UT WOS:000253958100003 PM 18295615 ER PT J AU Kim, J Brienza, DM Lynch, RA Cooper, RA Boninger, ML AF Kim, Jongbae Brienza, David M. Lynch, Robert A. Cooper, Rory A. Boninger, Michael L. TI Effectiveness evaluation of a remote accessibility assessment system for wheelchair users using virtualized reality SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT Conference of the Rehabilitation-Engineering-and-Assistive-Technology-Society-of-North-Ame rica CY JUN 22-26, 2006 CL Atlanta, GA SP Rehab Engn & Assistive Technol Soc N Amer DE disabled persons; imaging; three-dimensional; rehabilitation; wheelchairs ID TELEREHABILITATION AB Objective: To determine the value of the Remote Accessibility Assessment System (RAAS), a 3-dimensional (3D) image reconstruction technology designed to analyze accessibility of the target built environment in a virtualized reality, in assessing a built environment's accessibility by calculating the congruence level between the RAAS and conventional in-person method. Design: Repeated-measures (within-subject) design. Setting: A university research laboratory. Participants: Three homes for people who use wheeled mobility devices. Intervention: Home physical environment was divided into several potential problem areas such as entrance, hallway, bathroom, and living room. Each area was identified by several tasks that might be performed in it. All possible tasks in each area within each home were evaluated using 2 methods: RAAS and the conventional in-person assessment. The evaluations were performed by a different home modification specialist for each method. Main Outcome Measures: Conventional in-person assessments Were cross-tabulated with assessments from RAAS, with which there are 4 possible assessment combinations. A true positive (checked-checked) occurs when the RAAS method checks the target task as problematic and it is also checked as problematic by the conventional in-person method. True negative (not checked-not checked), false positive (not checked-checked), and false negative (checked-not checked) were also identified as the same way. Results: The proportion of overall agreement was high at 94.1% and the overall sensitivity and specificity was 95.6% and 90.3%. respectively. A significant K coefficient of 857 and the 95% confidence interval of the odds ratio of 104.062 to 404.921 were calculated and a high level of overall agreement rate was shown. A high P value (.868) of the McNemar test implied that there was no marginal homogeneity, that is, no tendency to identify the task incorrectly in the positive or negative direction. Conclusions: This system proved that virtualized reality and 3D reconstruction technology may provide an effective means to investigate the architectural features of a built environment without an expert visiting the site. This system could become an efficient tool for the service provider and can provide expert service to underserved clients that would otherwise be unavailable. C1 [Kim, Jongbae; Brienza, David M.; Cooper, Rory A.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Kim, Jongbae; Brienza, David M.; Cooper, Rory A.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, VA Ctr Excellence Wheelchairs & Assoc Rehabil Eng, Pittsburgh, PA 15206 USA. [Kim, Jongbae; Brienza, David M.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Lynch, Robert A.] Lynch & Assoc, Pittsburgh, PA USA. RP Kim, J (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 151R-1,7180 Highland Dr Bldg 4,2nd Fl E, Pittsburgh, PA 15206 USA. EM jbkim@pitt.edu OI Boninger, Michael/0000-0001-6966-919X NR 25 TC 2 Z9 2 U1 2 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2008 VL 89 IS 3 BP 470 EP 479 DI 10.1016/j.apmr.2007.08.158 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 273UU UT WOS:000253958100013 PM 18295625 ER PT J AU Gallagher, RM Rosenthal, LJ AF Gallagher, Rollin M. Rosenthal, Lisa J. TI Chronic pain and opiates: balancing pain control and risks in long-term opioid treatment SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Review DE analgesics; opioids; pain; rehabilitation ID POSTHERPETIC NEURALGIA; NONMALIGNANT PAIN; NEUROPATHIC PAIN; CONTROLLED-TRIAL; PRIMARY-CARE; DOUBLE-BLIND; BACK-PAIN; MEDICINE; EFFICACY; POPULATION AB The risks and benefits of opioid analgesics for chronic pain conditions and diseases are discussed in the context of the concern about the public health problems of poorly managed pain and prescription drug abuse and addiction. New strategies for risk management in treating patients with chronic pain are described. Opioids for chronic pain may be used effectively in the context of clinical strategies for risk management and selectively tailored, biopsychosocial pain management. Overall Article Objective: To present the case for balanced use of opioid therapy in the treatment of chronic pain conditions. C1 [Gallagher, Rollin M.] Philadelphia VA Med Ctr, Pain Serv, Philadelphia, PA 19104 USA. [Gallagher, Rollin M.; Rosenthal, Lisa J.] Univ Penn, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Philadelphia VA Med Ctr, Pain Serv, Univ & Woodland Aves, Philadelphia, PA 19104 USA. EM rgallagh@mail.med.upenn.edu NR 59 TC 26 Z9 26 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2008 VL 89 IS 3 SU 1 BP S77 EP S82 DI 10.1016/j.apmr.2007.12.003 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 276TX UT WOS:000254167100014 PM 18295655 ER PT J AU Chu, A Ahn, H Halwan, B Kalmin, B Artifon, ELA Barkun, A Lagoudakis, MG Kumar, A AF Chu, Adrienne Ahn, Hongshik Halwan, Bhawna Kalmin, Bruce Artifon, Everson L. A. Barkun, Alan Lagoudakis, Michail G. Kumar, Atul TI A decision support system to facilitate management of patients with acute gastrointestinal bleeding SO ARTIFICIAL INTELLIGENCE IN MEDICINE LA English DT Article DE class prediction; cross validation; gastrointestinal bleeding; machine learning ID ARTIFICIAL NEURAL-NETWORK; CLINICAL GUIDELINE; HOSPITAL LENGTH; HEMORRHAGE; RISK; PREDICTORS; MORTALITY; DIAGNOSIS; ENDOSCOPY; MODELS AB Objective: To develop a model to predict the bleeding source and identify the cohort amongst patients with acute gastrointestinal bleeding (GIB) who require urgent intervention, including endoscopy. Patients with acute GIB, an unpredictable event, are most commonly evaluated and managed by non-gastroenterologists. Rapid and consistently reliable risk stratification of patients with acute GIB for urgent endoscopy may potentially improve outcomes amongst such patients by targeting scarce health-care resources to those who need it the most. Design and methods: Using ICD-9 codes for acute GIB, 189 patients with acute GIB and all. available data variables required to develop and test models were identified from a hospital medical records database. Data on 122 patients was utilized for development of the model and on 67 patients utilized to perform comparative analysis of the models. Clinical data such as presenting signs and symptoms, demographic data, presence of co-morbidities, laboratory data and corresponding endoscopic diagnosis and outcomes were collected. Clinical data and endoscopic diagnosis collected for each patient was utilized to retrospectively ascertain optimal management for each patient. Clinical presentations and corresponding treatment was utilized as training examples. Eight mathematical models including artificial neural network (ANN), support vector machine (SVM), k-nearest neighbor, linear discriminant analysis (LDA), shrunken centroid (SC), random forest (RF), logistic regression, and boosting were trained and tested. The performance of these models was compared using standard statistical analysis and ROC curves. Results: Overall the random forest model best predicted the source, need for resuscitation, and disposition with accuracies of approximately 80% or higher (accuracy for endoscopy was greater than 75%). The area under ROC curve for RF was greater than 0.85, indicating excellent performance by the random forest model Conclusion: While most mathematical models are effective as a decision support system for evaluation and management of patients with acute GIB, in our testing, the RF model consistently demonstrated the best performance. Amongst patients presenting with acute GIB, mathematical models may facilitate the identification of the source of GIB, need for intervention and allow optimization of care and healthcare resource allocation; these however require further validation. (c) 2007 Elsevier B.V. All rights reserved. C1 [Kumar, Atul] SUNY Stony Brook, US Dept Vet Affairs, Stony Brook, NY 11794 USA. [Chu, Adrienne; Ahn, Hongshik] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA. [Halwan, Bhawna] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Kalmin, Bruce] Med Univ S Carolina, Div Gastroenterol, Charleston, SC 29425 USA. [Artifon, Everson L. A.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. [Barkun, Alan] McGill Univ, Montreal, PQ H3A 2T5, Canada. [Lagoudakis, Michail G.] Tech Univ Crete, Intelligent Syst Lab, Dept Elect & Comp Engn, Kounoupidiana 73100, Chania Hellas, Greece. RP Kumar, A (reprint author), SUNY Stony Brook, US Dept Vet Affairs, Stony Brook, NY 11794 USA. EM atul.kumar2@va.gov RI Lagoudakis, Michail/C-5145-2008 NR 41 TC 28 Z9 28 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0933-3657 J9 ARTIF INTELL MED JI Artif. Intell. Med. PD MAR PY 2008 VL 42 IS 3 BP 247 EP 259 DI 10.1016/j.artmed.2007.10.003 PG 13 WC Computer Science, Artificial Intelligence; Engineering, Biomedical; Medical Informatics SC Computer Science; Engineering; Medical Informatics GA 279UD UT WOS:000254379400006 PM 18063351 ER PT J AU Bowie, CR Leung, WW Reichenberg, A McClure, MM Patterson, TL Heaton, RK Harvey, PD AF Bowie, Christopher R. Leung, Winnie W. Reichenberg, Abraham McClure, Margaret M. Patterson, Thomas L. Heaton, Robert K. Harvey, Philip D. TI Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures SO BIOLOGICAL PSYCHIATRY LA English DT Article DE cognition; disability; functional outcome; neuropsychology; schizophrenia ID NEUROCOGNITIVE DEFICITS; CLINICAL SYMPTOMS; SOCIAL COGNITION; OLDER PATIENTS; MENTALLY-ILL; PERFORMANCE; SKILLS; OUTPATIENTS; OUTCOMES; TASKS AB Background: Significant neuropsychological (NP) and functional deficits are found in most schizophrenia patients. Previous studies have left questions as to whether global NP impairment or discrete domains affect functional outcomes, and none have addressed distinctions within and between ability and performance domains. This study examined the different predictive relationships between NP domains, functional competence, social competence, symptoms, and real-world behavior in domains of work skills, interpersonal relationships, and community activities. Methods: Two hundred twenty-two schizophrenic outpatients were tested with an NP battery and performance-based measures of functional and social competence and rated for positive, negative, and depressive symptoms. Case managers generated ratings of three functional disability domains. Results: Four cognitive factors were derived from factor analysis. Path analyses revealed both direct and mediated effects of NP on real-world outcomes. All NP domains predicted functional competence, but only processing speed and attention/working memory predicted social competence. Both competence measures mediated the effects of NP on community activities and work skills, but only social competence predicted interpersonal behaviors. The attention/working memory domain was directly related to work skills, executive functions had a direct effect on interpersonal behaviors, and processing speed had direct effects on all three real-world behaviors. Symptoms were directly related to outcomes, with fewer relationships with competence. Conclusions: Differential predictors of functional competence and performance were found from discrete NP domains. Separating competence and performance provides a more precise perspective on correlates of disability. Changes in specific NP or functional skills might improve specific outcomes, rather than promoting global functional improvement. C1 [Bowie, Christopher R.; Leung, Winnie W.; Reichenberg, Abraham; McClure, Margaret M.; Harvey, Philip D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Bowie, Christopher R.; Leung, Winnie W.; McClure, Margaret M.] James J Peters Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Leung, Winnie W.; McClure, Margaret M.] Univ Calif San Diego, Educ Clin Ctr, Vet Affairs Vet Integrat Serv Network 3 Mental Il, San Diego, CA USA. [Patterson, Thomas L.; Heaton, Robert K.] Univ Calif San Diego, San Diego Med Ctr, Dept Psychiat, San Diego, CA USA. RP Bowie, CR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,4th Floor,Box 1230, New York, NY 10029 USA. EM christopher.bowie@mssm.edu FU NIMH NIH HHS [MH 63116, R01 MH063116, R01 MH063116-05, R01 MH078737, MH 36692, R01 MH078775] NR 40 TC 272 Z9 277 U1 5 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 1 PY 2008 VL 63 IS 5 BP 505 EP 511 DI 10.1016/j.biopsych.2007.05.022 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 263ZZ UT WOS:000253256300010 PM 17662256 ER PT J AU Matthews, AM Huckans, MS Blackwell, AD Hauser, P AF Matthews, Annette M. Huckans, Marilyn S. Blackwell, Aaron D. Hauser, Peter TI Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; comorbidity; epidemiology; hepatitis C; interferon; mental health; mood disorders; substance use disorders; United States Department of Veterans Affairs ID UNITED-STATES; VIRUS-INFECTION; PREVALENCE; ILLNESS; VETERANS AB Objectives: To determine and compare hepatitis C (HCV) screening and testing rates among four groups: those with (i) bipolar disorder [BD group (history of BD but no substance use disorder)]; (ii) substance use disorders [SUD group (history of SUD but no BD)]; (iii) co-occurring disorders [DD group (history of both BD and an SUD)]; and (iv) a control group (no history of either bipolar disorder or substance use disorder). Our hypothesis was that HCV antibody testing rates and HCV prevalence would be higher in the BD, SUD, and DD groups than the control group. Methods: Data were retrospectively collected on 325,410 patients seen between 1998 and 2004 within facilities and clinics of the Veterans Integrated Service Network (VISN) 20 Northwest Veterans Health Care Administration from electronic medical records. HCV screening and prevalence rates were compared between the BD, SUD, DD, and control groups. Odds ratios and relative risks were determined and compared between groups. Results: Patients in the BD, SUD, and DD groups had been tested at a higher rate than controls and were at increased risk for HCV infection compared with controls. These high-risk groups had a 1.31-fold, 4.86-fold, and 5.46-fold increase in the relative risk of HCV infection, respectively. Overall, compared to the control group, the relative risk of a patient having HCV if he or she had BD (with or without an SUD) was 3.6. Conclusions: Patients with BD and comorbid SUD had an over fourfold increase in relative risk for HCV than our control group and a similar risk as patients in our SUD group. Furthermore, even if bipolar patients did not have a comorbid SUD (the BD group), their relative risk of HCV was significantly higher than that of the control group. This suggests that patients with BD, particularly those with a comorbid SUD, should be screened and tested for HCV. C1 [Matthews, Annette M.; Huckans, Marilyn S.; Hauser, Peter] Oregon Hlth & Sci Univ, NW Hepatatis C Resource Ctr, Portland, OR USA. [Matthews, Annette M.; Huckans, Marilyn S.; Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. [Matthews, Annette M.; Huckans, Marilyn S.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. [Blackwell, Aaron D.] Univ Oregon, Dept Anthropol, Eugene, OR 97403 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Jens Lab, Portland, OR USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Div Gastroenterol, Portland, OR USA. RP Matthews, AM (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,PO Box 1035 V3MHC, Portland, OR 97202 USA. EM annette.matthews@med.va.gov; peter.hauser2@med.va.gov RI Blackwell, Aaron/B-5258-2008 OI Blackwell, Aaron/0000-0002-5871-9865 NR 26 TC 20 Z9 20 U1 2 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD MAR PY 2008 VL 10 IS 2 BP 266 EP 270 DI 10.1111/j.1399-5618.2007.00472.x PG 5 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 260AN UT WOS:000252982300005 PM 18271905 ER PT J AU Misra, S Socherman, R Park, BS Hauser, P Ganzini, L AF Misra, Sahana Socherman, Robert Park, Byung S. Hauser, Peter Ganzini, Linda TI Influence of mood state on capacity to consent to research in patients with bipolar disorder SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; clinical trials; decision-making capacity ID INFORMED-CONSENT; MENTAL-ILLNESS; SCHIZOPHRENIA; COMPETENCE; PARTICIPATION; ISSUES AB Objectives: Experts have debated the ability of patients with bipolar illness to consent to research participation when manic. We compared 25 euthymic bipolar and 26 manic bipolar patients in their understanding of three hypothetical studies of varying complexity. Methods: Hypothetical studies were presented as written informed consent forms, which were reread up to three times. Questions included assessment of hypothetical study purposes, procedures, risks and benefits, and voluntariness of participation. Results: After adjusting for educational level, subjects with mania had lower mean understanding scores for all three hypothetical studies compared to euthymic subjects on initial assessment. By the end of Trial 3 of each hypothetical study, there were no significant differences between groups. The proportion of subjects with mania who met predetermined pass criteria for sufficient understanding was lower than the proportion of euthymic subjects on initial assessment of the first hypothetical study, but not the other hypothetical studies (odds ratio = 0.24; 95% confidence interval = 0.07 - 0.8; p = 0.02). Both groups exhibited an increase in the pass proportion by the end of the third trial for each hypothetical study with no significant differences between groups. Conclusions: We conclude that subjects with mania exhibited significantly poorer levels of understanding of relevant information in hypothetical research consent forms compared to euthymic subjects when initially presented with research information. The improvement in manic patients' understanding scores with the iterative review of consent forms suggests that many manic patients may be able to consent to research protocols containing an educational intervention as a part of the informed consent process. C1 [Misra, Sahana; Socherman, Robert; Hauser, Peter; Ganzini, Linda] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR USA. [Misra, Sahana; Socherman, Robert] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. [Park, Byung S.] Oregon Hlth & Sci Univ, OHSU Canc Inst, Bioinformat & Biostat Shared Resource, Portland, OR USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Mood Disorders Res & Treatment Ctr, Portland, OR USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat Behav Neurosci & Med, Portland, OR USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Comorbid Mental & Phys Disorders, Columbia Ctr Stud Chronic, Portland, OR USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat & Med, Portland, OR USA. RP Misra, S (reprint author), Portland VAMC P3MHDC, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM misras@ohsu.edu OI /0000-0003-3516-7516 NR 16 TC 11 Z9 11 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD MAR PY 2008 VL 10 IS 2 BP 303 EP 309 DI 10.1111/j.1399-5618.2007.00525.x PG 7 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 260AN UT WOS:000252982300010 PM 18271910 ER PT J AU Sadetsky, N Lubeck, DP Pasta, DJ Latini, DM DuChane, J Carroll, PR AF Sadetsky, Natalia Lubeck, Deborah P. Pasta, David J. Latini, David M. DuChane, Janeen Carroll, Peter R. TI Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor SO BJU INTERNATIONAL LA English DT Article DE insurance status; quality of life; prostatic neoplasms ID HEALTH-INSURANCE; RADICAL PROSTATECTOMY; SOCIOECONOMIC-STATUS; LOW-INCOME; COVERAGE; CARCINOMA; RISK; MORTALITY; VETERANS; OUTCOMES AB OBJECTIVE To evaluate the effect of medical insurance coverage on health-related quality of life (HRQoL) outcomes in men newly diagnosed with prostate cancer, as insurance status has been shown to be related to clinical presentation, and types of treatments received for localized prostate cancer, but the relationship of insurance and QoL has not been explored sufficiently. PATIENTS AND METHODS Data from the Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE), a national longitudinal database registry of men with prostate cancer, were used for this study. Men who were newly diagnosed at entry to CaPSURE and completed one questionnaire before treatment, and one or more afterwards, were included. Insurance groups specific to age distribution of the study population were assessed, i.e. Medicare, preferred provider organizations (PPOs), health maintenance organizations (HMOs), fee for service (FFS), and the Veterans Administration (VA) for the younger group, and Medicare only, Medicare plus supplement (+S), and HMO/PPO for the older group. Associations between patients' clinical and sociodemographic characteristics and insurance status were evaluated by chi-square and analysis of variance. Relationships between insurance status and HRQoL outcomes over time were evaluated by multivariate mixed model. RESULTS Of 2258 men who met the study criteria, 1259 were younger and 999 were older than 65 years. More than half of the younger patients belonged to an HMO or PPO (42.2% and 32.5%, respectively), with the remainder distributed between Medicare, FFS and VA. In the older group most men belonged to Medicare only and the Medicare +S groups (22.4% and 58.8%, respectively). There was greater variation in clinical risk categories at presentation by insurance groups in the younger group. In the multivariate analysis, insurance status was significantly associated with changes in most HRQoL outcomes over time in the younger group, while in the older patients the effect of insurance diminished. Men in the VA and Medicare systems had lower scores at baseline and a steeper decline in Physical Function, Role Physical, Role Emotional, Social Function, Bodily Pain, Vitality, and General Health domains over time, controlling for type of initial treatment received, timing of HRQoL assessment, number of comorbidities, clinical risk at presentation, and income. CONCLUSION Insurance was independently related to changes in a wide range of HRQoL outcomes in men aged < 65 years treated for prostate cancer. With the latest advances in early diagnosis and treatment of prostate cancer, clinicians and researchers should be aware of the specific groups of patients who are more vulnerable to the adverse effects of treatment and subsequent decline in functioning. The present findings could provide important tools for understanding the process of recovery after treatment for prostate cancer, and identifying needs for specific services. C1 [Sadetsky, Natalia; Lubeck, Deborah P.; Pasta, David J.; Carroll, Peter R.] Univ Calif San Francisco, Ctr Comprehens Canc, Urol Outcomes Res Grp, Program Urol Oncol,Dept Urol, San Francisco, CA 94143 USA. [Latini, David M.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Latini, David M.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. [DuChane, Janeen] TAP Pharmaceut Prod Inc, Lake Forest, IL USA. RP Sadetsky, N (reprint author), Box 0738,1600 Divisadero St,Suite B642, San Francisco, CA 94115 USA. EM nsadetsky@urology.ucsf.edu OI Latini, David/0000-0002-6161-4861; Pasta, David/0000-0003-2637-9293 FU PHS HHS [P50 C89520] NR 34 TC 8 Z9 8 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1464-4096 J9 BJU INT JI BJU Int. PD MAR PY 2008 VL 101 IS 6 BP 691 EP 697 DI 10.1111/j.1464-410X.2007.07353.x PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 263YA UT WOS:000253251200007 PM 18291018 ER PT J AU Khatibi, A Naseri, A Stewart, JM AF Khatibi, A. Naseri, A. Stewart, J. M. TI Rate of rhegmatogenous retinal detachment after resident-performed cataract surgery is similar to that of experienced surgeons SO BRITISH JOURNAL OF OPHTHALMOLOGY LA English DT Letter ID RISK-FACTORS C1 [Khatibi, A.; Naseri, A.; Stewart, J. M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Naseri, A.] San Francisco VA Med Ctr, Dept Ophthalmol, San Francisco, CA USA. [Stewart, J. M.] San Francisco Gen Hosp, Dept Ophthalmol, San Francisco, CA 94110 USA. RP Stewart, JM (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,Room K301, San Francisco, CA 94143 USA. EM stewartj@vision.ucsf.edu NR 8 TC 5 Z9 5 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0007-1161 J9 BRIT J OPHTHALMOL JI Br. J. Ophthalmol. PD MAR PY 2008 VL 92 IS 3 BP 438 EP 438 DI 10.1136/bjo.2007.125633 PG 1 WC Ophthalmology SC Ophthalmology GA 274HG UT WOS:000253991800043 PM 18314410 ER PT J AU Waldman, KL AF Waldman, Karen L. TI Treating victims of mass disaster and terrorism SO BULLETIN OF THE MENNINGER CLINIC LA English DT Book Review C1 [Waldman, Karen L.] Michael E Debakey Vet Affairs Med Ctr, Mental Hlth Care Line CMHP 116, Houston, TX 77030 USA. RP Waldman, KL (reprint author), Michael E Debakey Vet Affairs Med Ctr, Mental Hlth Care Line CMHP 116, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM waldman.Karen@med.va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0025-9284 J9 B MENNINGER CLIN JI Bull. Menninger Clin. PD SPR PY 2008 VL 72 IS 2 BP 149 EP 149 PG 1 WC Psychiatry; Psychology, Psychoanalysis SC Psychiatry; Psychology GA 330UR UT WOS:000257968800004 ER PT J AU Yabroff, KR Harlan, LC Clegg, LX Ballard-Barbash, R Stevens, J Weaver, DL AF Yabroff, K. Robin Harlan, Linda C. Clegg, Limin X. Ballard-Barbash, Rachel Stevens, Jennifer Weaver, Donald L. TI Is mode of breast cancer detection associated with cancer treatment in the united states? SO CANCER LA English DT Article DE mammography; breast cancer detection; breast cancer/detection; tamoxifen; chemotherapy; practice guidelines ID RANDOMIZED-TRIALS; ADJUVANT THERAPY; OLDER WOMEN; MAMMOGRAPHY; SURVIVAL; PATTERNS; PREDICTORS; RECURRENCE; TAMOXIFEN; INTERVAL AB BACKGROUND. The prognosis for women who have breast cancer detected by mammography is more favorable than that for women who have breast cancer detected by other methods, even after controlling for tumor characteristics. In the current study, the authors explored whether detection by mammography was associated with greater use of guideline-consistent breast cancer treatment among patients with recently diagnosed breast cancer in the United States. METHODS. The authors evaluated the association between mode of breast cancer detection (mammography vs other) and use of guideline-consistent treatment in 1006 women aged >= 40 years who were diagnosed in 2000. These patients were sampled from the Surveillance, Epidemiology, and End Results Program as part of the Patterns of Care studies. The analyses controlled for the potential confounders of clinical, demographic, and health system characteristics in multivariate logistic regression models. RESULTS. Breast cancer patients who were diagnosed by mammography were more likely to be aged >= 55 years, to have lower stage disease, and to be treated in larger hospitals than patients who were diagnosed by other methods (P <.05). Women whose breast cancer was diagnosed by a method other than mammography were more likely to receive guideline-consistent treatment than women who were diagnosed by mammography in unadjusted (odds ratio, 1.39; 95% confidence interval, 1.07-1.80) and multivariate analyses (odds ratio, 1.43; 95% confidence interval, 1.05-1.95). CONCLUSIONS. The current results indicated that women who had breast cancer detected by methods other than mammography were slightly more likely to receive guideline-consistent therapy than women who had breast cancer detected by mammography. Future research exploring mode of detection, guideline-consistent treatment, and survival among patients with recently diagnosed breast cancer may inform understanding of factors associated with breast cancer prognosis. C1 [Yabroff, K. Robin; Harlan, Linda C.; Clegg, Limin X.; Ballard-Barbash, Rachel] NCI, Div Canc Control & Populat Sci, Appl Res Program, Bethesda, MD 20892 USA. [Clegg, Limin X.] US Dept Vet Affairs, Off Healthcare Inspect, Off Inspector Gen, Washington, DC USA. [Stevens, Jennifer] Informat Management Serv Inc, Silver Spring, MD USA. [Weaver, Donald L.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA. RP Yabroff, KR (reprint author), NCI, Div Canc Control & Populat Sci, Appl Res Program, Execut Plaza N,Room 4005,6130 Execut Blvd,MSC 734, Bethesda, MD 20892 USA. EM Yabroffr@mail.nih.gov OI Yabroff, K. Robin/0000-0003-0644-5572 FU NCI NIH HHS [N01 PC 67010, N01 PC 67009, N01 PC 67000, N01 PC 67005, N01 PC 67006, N01 PC 67008, N01 PC 65064, N01 PC 65107, N01 PC 67001, N01 PC 67007] NR 35 TC 4 Z9 5 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD MAR 1 PY 2008 VL 112 IS 5 BP 1011 EP 1019 DI 10.1002/cncr.23260 PG 9 WC Oncology SC Oncology GA 268HA UT WOS:000253569100009 PM 18189297 ER PT J AU Feng, QH Hawes, SE Stern, JE Wiens, L Lu, H Dong, ZM Jordanj, CD Kiviatl, NB Vesselle, H AF Feng, Qinghua Hawes, Stephen E. Stern, Joshua E. Wiens, Linda Lu, Hiep Dong, Zhao Ming Jordanj, C. Diana Kiviatl, Nancy B. Vesselle, Hubert TI DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID GENE PROMOTER METHYLATION; POSITRON-EMISSION-TOMOGRAPHY; ABERRANT METHYLATION; CPG ISLANDS; FLUORODEOXYGLUCOSE UPTAKE; EARLY-DIAGNOSIS; MULTIPLE GENES; HYPERMETHYLATION; ADENOCARCINOMA; P16(INK4A) AB We used MethyLight assays to analyze DNA methylation status of 27 genes on 49 paired cancerous and noncancerous tissue samples from non-small cell lung cancer (NSCLC) patients who underwent surgical resection. Seven genes (RARB, BVES, CDKN2A, KCNH5, RASSF1, CDH13, and RUNX) were found to be methylated significantly more frequently in tumor tissues than in noncancerous tissues. Only methylation of CCND2 and APC was frequently detected in both cancerous and noncancerous tissues, supporting the hypothesis that the methylation of these two genes is a preneoplastic change and may be associated with tobacco smoking exposure. Methylation of any one of eight genes (RASSF1, DAPK1, BVES, CDH13, MGMT, KCNH5, RARB, or CDH1) was present in 80% of NSCLC tissues but only in 14% of noncancerous tissues. Detection of methylation of these genes in blood might have utility in monitoring and detecting tumor recurrence in early-stage NSCLC after curative surgical resection. C1 [Wiens, Linda; Vesselle, Hubert] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Feng, Qinghua; Stern, Joshua E.; Lu, Hiep; Jordanj, C. Diana; Kiviatl, Nancy B.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Hawes, Stephen E.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA. [Dong, Zhao Ming] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Vesselle, H (reprint author), Univ Washington, Sch Med, Dept Radiol, Box 357115, Seattle, WA 98195 USA. EM vesselle@u.washington.edu FU NCI NIH HHS [CA115559, CA107264, CA80907, R01 CA080907, R01 CA080907-04, R01 CA107264, R01 CA107264-05, R01 CA115559, R01 CA115559-05] NR 42 TC 96 Z9 101 U1 0 U2 11 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAR PY 2008 VL 17 IS 3 BP 645 EP 654 DI 10.1158/1055-9965.EPI-07-2518 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 279RZ UT WOS:000254373600024 PM 18349282 ER PT J AU Bai, T Luoh, SW AF Bai, Tao Luoh, Shiuh-Wen TI GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation SO CARCINOGENESIS LA English DT Article ID HER2-POSITIVE BREAST-CANCER; CELL-MIGRATION; ADJUVANT CHEMOTHERAPY; ADAPTER PROTEIN; GENE-EXPRESSION; TYROSINE KINASE; ERBB2 AMPLICON; OVARIAN-CANCER; RECEPTOR; AMPLIFICATION AB Growth factor receptor-bound protein-7 (GRB-7), an adaptor molecule, can interact with multiple signal transduction molecules. GRB-7 is amplified concurrently with HER-2/Neu in most, if not all, of breast cancer with chromosome 17q11-21 amplification. GRB-7 gene amplification is associated with RNA over-expression. We show GRB-7 protein is over-expressed by immunoblotting in breast cancer cell lines and primary breast tumors with HER-2/Neu protein over-expression. Over-expression of GRB-7 in MCF-7 breast cancer cells that over-express HER-2/Neu leads to activation of tyrosine phosphorylation of HER-2/Neu. Knockdown of GRB-7 expression in SKBR-3 breast cancer cells with naturally occurring HER-2/Neu gene amplification decreases tyrosine phosphorylation of HER-2/Neu. Activation of HER-2/Neu phosphorylation is associated with increase in tyrosine phosphorylation of phosphoinositide-specific lipase C-gamma-1 (PLC-gamma-1) and recruitment of PLC-gamma-1 to HER-2/Neu protein molecule. Activation of downstream protein kinase C (PKC) pathway is evidenced by increase in the phosphorylation of a common PKC substrate-myristoylated alanine-rich protein kinase C substrate (MARCKS). In addition, over-expression of GRB-7 in MCF-7 breast cancer cells that over-express HER-2/Neu leads to activation of AKT phosphorylation. Knockdown of GRB-7 expression in MB-453 and SKBR-3 breast cancer cells results in decrease in AKT phosphorylation. GRB-7 over-expression therefore facilitates activation of phosphorylation of HER-2/Neu and AKT in breast cancer cells with HER-2/Neu over-expression. GRB-7 over-expression in MCF-7 cells over-expressing HER-2/Neu leads to morphologic change of cells and promotes tumor xenograft growth in nude mice. GRB-7 over-expression therefore plays pivotal roles in activating signal transduction and promoting tumor growth in breast cancer cells with chromosome 17q11-21 amplification. C1 [Bai, Tao; Luoh, Shiuh-Wen] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Hematol & Med Oncol, Portland, OR 97239 USA. RP Luoh, SW (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Hematol & Med Oncol, Portland, OR 97239 USA. EM luohs@ohsu.edu FU NCI NIH HHS [P30CA069533] NR 40 TC 33 Z9 37 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD MAR PY 2008 VL 29 IS 3 BP 473 EP 479 DI 10.1093/carcin/bgm221 PG 7 WC Oncology SC Oncology GA 274NP UT WOS:000254008300003 PM 17916906 ER PT J AU Ray, CE Prochazka, A AF Ray, Charles E., Jr. Prochazka, Allan TI The need for anticoagulation following inferior vena cava filter placement: Systematic review SO CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article DE anticoagulation; evidence-based medicine; IVC filters; venous interruption ID TECH-LGM FILTER; GREENFIELD FILTER; PULMONARY-EMBOLISM; INTERRUPTION; THROMBOSIS; DEVICES; THROMBOEMBOLISM; COMPLICATIONS; PREVENTION; EXPERIENCE AB Purpose To perform a systemic review to determine the effect of anticoagulation on the rates of venous thromboembolism (pulmonary embolus, deep venous thrombosis, inferior vena cava (IVC) filter thrombosis) following placement of an IVC filter. Methods A comprehensive computerized literature search was performed to identify relevant articles. Data were abstracted by two reviewers. Studies were included if it could be determined whether or not subjects received anticoagulation following filter placement, and if follow-up data were presented. A meta-analysis of patients from all included studies was performed. A total of 14 articles were included in the final analysis, but the data from only nine articles could be used in the meta-analysis; five studies were excluded because they did not present raw data which could be analyzed in the meta-analysis. A total of 1,369 subjects were included in the final meta-analysis. Results The summary odds ratio for the effect of anticoagulation on venous thromboembolism rates following filter deployment was 0.639 (95% CI 0.351 to 1.159, p = 0.141). There was significant heterogeneity in the results from different studies [Q statistic of 15.95 (p = 0.043)]. Following the meta-analysis, there was a trend toward decreased venous thromboembolism rates in patients with post-filter anticoagulation (12.3% vs. 15.8%), but the result failed to reach statistical significance. Conclusion Inferior vena cava filters can be placed in patients who cannot receive concomitant anticoagulation without placing them at significantly higher risk of development of venous thromboembolism. C1 [Ray, Charles E., Jr.] Univ Colorado Denver & Hlth Sci Ctr, Dept Radiol, Aurora, CO 80045 USA. [Ray, Charles E., Jr.] Univ Colorado Denver & Hlth Sci Ctr, Dept Clin Sci, Aurora, CO 80045 USA. [Prochazka, Allan] Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Aurora, CO USA. [Prochazka, Allan] Denver VA Med Ctr, Dept Ambulatory Care, Denver, CO USA. RP Ray, CE (reprint author), Univ Colorado Denver & Hlth Sci Ctr, Dept Radiol, Mail Stop C276,Leprino Off Bldg,12401 E 17th Ave, Aurora, CO 80045 USA. EM charles.ray@uchsc.edu NR 40 TC 21 Z9 24 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0174-1551 J9 CARDIOVASC INTER RAD JI Cardiovasc. Interv. Radiol. PD MAR PY 2008 VL 31 IS 2 BP 316 EP 324 DI 10.1007/s00270-007-9244-x PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 275QT UT WOS:000254087400011 PM 18080710 ER PT J AU Noonan, EJ Fournier, G Hightower, LE AF Noonan, Emily J. Fournier, Gregory Hightower, Lawrence E. TI Surface expression of Hsp70B' in response to proteasome inhibition in human colon cells SO CELL STRESS & CHAPERONES LA English DT Article DE cell surface; Hsp70B'; proteasome inhibitor; colon cells; phylogeny ID HEAT-SHOCK-PROTEIN; INDUCIBLE IMMUNOGENIC DETERMINANT; NATURAL-KILLER-CELLS; HUMAN TUMOR-CELLS; HEAT-SHOCK-PROTEIN-70 HSP70; SARCOMA-CELLS; LYSIS; FAMILY; RECOGNITION; SENSITIVITY AB Hsp70B' was expressed on the surface of HT-29 and CRL-1809 but not SW-480 human colon cell lines in response to proteasome inhibition as detected using flow cytometry. Surface expression was not detected under non-stress conditions nor was heat shock an inducer of surface expression in the three cell lines tested. Phylogenetic analysis indicated that the Hsp70B' protein sequence was most closely related to another major inducible human Hsp70, Hsp72. Hsp70B' appeared to be recently diverged, as homologs for Hsp70B' have not been found in rodents. Hsp72 and Hsp70B' shared 100% amino acid sequence identity in their predicted peptide-binding regions suggesting that they bind the same peptide substrates, perhaps in extracellular antigen presentation. Amino acid sequence differences were concentrated in the lid regions and the C-terminal domains raising the possibility that Hsp72 and Hsp70B' bind different co-chaperones or cell surface receptors. C1 [Noonan, Emily J.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Noonan, Emily J.; Fournier, Gregory; Hightower, Lawrence E.] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA. RP Noonan, EJ (reprint author), San Francisco VA Med Ctr, 4150 Clement St 151H, San Francisco, CA 94121 USA. EM emily.noonan@gmail.com FU NIEHS NIH HHS [ES03828, P30 ES003828] NR 25 TC 19 Z9 19 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1355-8145 J9 CELL STRESS CHAPERON JI Cell Stress Chaperones PD MAR PY 2008 VL 13 IS 1 BP 105 EP 110 DI 10.1007/s12192-007-0003-3 PG 6 WC Cell Biology SC Cell Biology GA 275QV UT WOS:000254087600012 PM 18347947 ER PT J AU Restrepo, MI Mortensen, EM Velez, JA Frei, C Anzueto, A AF Restrepo, Marcos I. Mortensen, Eric M. Velez, Jose A. Frei, Christopher Anzueto, Antonio TI A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU SO CHEST LA English DT Article DE critical care; ICU; microbiology; mortality; outcome and process assessment; pneumonia ID INTENSIVE-CARE-UNIT; ANTIMICROBIAL THERAPY; RISK-FACTORS; PROGNOSIS; EPIDEMIOLOGY; MANAGEMENT; GUIDELINES; MORTALITY; OUTCOMES; ADULTS AB Background: Limited information is available on the health-care utilization of hospitalized patients with community-acquired pneumonia (CAP) depending on the location of care. Our aim was to compare the clinical characteristics, etiologies, and outcomes of patients with CAP who were admitted to the ICU with those admitted who were to the ward service. Methods: A retrospective cohort study, at two tertiary teaching hospitals, one of which was a Veterans Affairs hospital, and the other a county hospital. Eligible subjects had been admitted to the hospital with a diagnosis of CAP between January 1, 1999, and December 31, 2001, had A confirmatory chest radiograph, and a hospital discharge International Classification of Diseases, ninth revision, diagnosis of pneumonia. Subjects were excluded from the study if they had designated "comfort measures only" or had been transferred from another acute care hospital or were nursing home patients. Bivariate and multivariable analysis evaluated 30-day and 90-day mortality as the dependent measures. Results: Data were abstracted on 730 patients (ICU, 145 patients; wards, 585 patients). Compared to ward patients, ICU patients were more likely to be male (p = 0.001), and to have congestive heart failure (p = 0.01) and COPD (p = 0.01). ICU patients also had higher mean pneumonia severity index scores (112 [SD, 35] vs 83 [SD, 30], respectively; p = 0.02). Patients admitted to the ICU had a longer mean length of hospital stay (12 days [SD, 10 days] vs 7 days [SD, 17 days], respectively; p = 0.07), and a higher 30-day mortality rate (23% vs 4%, respectively; p < 0.001) and 90-day mortality rate (28% vs 8%, respectively; p < 0.001) compared to ward patients. Conclusions: ICU patients present with more severe disease and more comorbidities. ICU patients stay longer in the hospital and have a much higher mortality rate when compared to ward patients. Management strategies should be designed to improve clinical outcomes in ICU patients. C1 [Restrepo, Marcos I.; Mortensen, Eric M.] S Texas Vet Hlth Care Syst, ALMD, VERDICT 11C6, San Antonio, TX 78229 USA. [Velez, Jose A.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Frei, Christopher] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharm, San Antonio, TX 78229 USA. RP Restrepo, MI (reprint author), S Texas Vet Hlth Care Syst, ALMD, VERDICT 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM rostrepom@uthsca.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563 FU Howard Hughes Medical Institute [00378-001] NR 32 TC 82 Z9 90 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD MAR PY 2008 VL 133 IS 3 BP 610 EP 617 DI 10.1378/chest.07-1456 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 273LV UT WOS:000253933300007 PM 17989157 ER PT J AU Restrepo, MI Bienen, T Mortensen, EM Anzueto, A Metersky, ML Escalante, P Wunderink, RG Mangura, BT AF Restrepo, Marcos I. Bienen, Thomas Mortensen, Eric M. Anzueto, Antonio Metersky, Mark L. Escalante, Patricio Wunderink, Richard G. Mangura, Bonita T. CA Amer Coll Chest Phys TI Evaluation of ICU admission criteria and diagnostic methods for patients with severe community-acquired pneumonia - Current practice survey SO CHEST LA English DT Letter ID GUIDELINES; MANAGEMENT C1 [Restrepo, Marcos I.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Restrepo, Marcos I.; Bienen, Thomas; Mortensen, Eric M.; Anzueto, Antonio; Metersky, Mark L.; Escalante, Patricio; Wunderink, Richard G.; Mangura, Bonita T.; Amer Coll Chest Phys] Amer Coll Chest Phys, Chest Infect Network, San Antonio, TX USA. RP Restrepo, MI (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, 7400 Merton Minton Blvd 11c6, San Antonio, TX USA. EM RESTREP0M@uthscsa.edn RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563; Wunderink, Richard/0000-0002-8527-4195 NR 4 TC 6 Z9 6 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD MAR PY 2008 VL 133 IS 3 BP 828 EP 829 DI 10.1378/chest.07-2887 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 273LV UT WOS:000253933300040 PM 18321916 ER PT J AU Doungchawee, G Kositanont, U Niwetpathomwat, A Inwisai, T Sagarasaeranee, P Haake, DA AF Doungchawee, Galayanee Kositanont, Uraiwan Niwetpathomwat, Anuchai Inwisai, Tasanee Sagarasaeranee, Plyyonk Haake, David A. TI Early diagnosis of leptospirosis by immunoglobulin M immunoblot testing SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID MICROSCOPIC AGGLUTINATION-TEST; SURFACE-EXPOSED LIPOPROTEIN; HUMAN IMMUNE-RESPONSE; OUTER-MEMBRANE; CONTROLLED-TRIAL; PROTEINS; INFECTION; SERODIAGNOSIS; ANTIBODY; ANTIGEN AB There is an urgent need for the development of serodiagnostic approaches with improved sensitivity for patients with acute leptospirosis. Immunoblots were performed on 188 sera collected from 74 patients with laboratory-confirmed early leptospiral infection to detect immunoglobulin M (IgM) antibodies to antigens pooled from 10 leptospiral strains prevalent in Thailand. Sera from patients with other febrile diseases served as controls. IgM reactivity to seven distinct antigens, with apparent molecular masses of 14 to 18, 19 to 23, 24 to 30, 32, 35/36, 37, and 41/42 kDa, was observed. The low-molecular-mass 14- to 18-kDa band was the most frequently detected antigen, being recognized in sera from 82.4% of patients during the first 3 days after the onset of symptoms. We evaluated the accuracy of the IgM immunoblot (IgM-IB) test by using reactivity to the 14- to 18-kDa band and/or at least two bands among the 19- to 23-, 24- to 30-, 32-, 35/36-, 37-, and 41/42- kDa antigens as the diagnostic criterion. The sensitivities of the IgM-IB test and the microscopic agglutination test (MAT) were 88.2% and 2.0%, respectively, with sera from patients 1 to 3 days after the onset of symptoms. In contrast, the IgM-IB test was positive with only 2/48 (4.2%) sera from patients with other febrile illnesses. The high sensitivity and specificity of the IgM-IB test for acute leptospirosis would provide greatly improved diagnostic accuracy for identification of patients who would benefit from early antibiotic intervention. In addition, the antigens identified by the IgM-IB test may serve as components of a rapid, accurate, point-of-care diagnostic test for early leptospirosis. C1 [Doungchawee, Galayanee; Niwetpathomwat, Anuchai; Inwisai, Tasanee] Mahidol Univ, Fac Sci, Dept Pathol, Bangkok 10400, Thailand. [Kositanont, Uraiwan] Mahidol Univ, Siriraj Hosp, Dept Microbiol, Fac Med, Bangkok 10700, Thailand. [Sagarasaeranee, Plyyonk] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Doungchawee, G (reprint author), Mahidol Univ, Fac Sci, Dept Pathol, Bangkok 10400, Thailand. EM scgdu@mahidol.ac.th OI Doungchawee, Galayanee/0000-0002-7463-8096 FU Department of Disease Control; Ministry of Public Health, Thailand; VA Medical Research funds; NIH/NIAID [AI-34431] FX We are grateful to Albert I. Ko and Visith Thongboonkerd for their useful comments. We thank Oranard Wattanawong and the staff of the Department of Disease Control, Ministry of Public Health, Kannika Niwatayakul of Loei Provincial Hospital, Thailand, and Apichat Pradermwong and Kanjana Sirisidth of Mahidol University.; This study was supported by grants from the Department of Disease Control, Ministry of Public Health, Thailand. D. A. H. was supported by VA Medical Research funds and by NIH/NIAID grant AI-34431. NR 48 TC 14 Z9 14 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAR PY 2008 VL 15 IS 3 BP 492 EP 498 DI 10.1128/CVI.00152-07 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 340TA UT WOS:000258666700014 PM 18184827 ER PT J AU Watnick, S Stooksbury, M Winter, R Riscoe, M Cohen, DM AF Watnick, Suzanne Stooksbury, Michael Winter, Rolf Riscoe, Michael Cohen, David M. TI White thrombus formation in blood tubing lines in a chronic hemodialysis unit SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; PARTICULATE MATTER; EPOETIN; ANEMIA AB Background and objectives: Previous reports have described white particulate matter in banked blood components, but no prior public reports describe such matter in blood tubing during the course of routine in-center hemodialysis. This report describes the events, investigations, and preliminary conclusions associated with the spontaneous formation of adherent white thrombus in the venous and arterial blood lines during routine in-center hemodialysis treatments. Design setting, participants, & measurements: This investigation occurred at the Portland Veterans Administration Medical Center (PVAMC) Hemodialysis Unit from October 2006 through April 2007. Sixty-eight variables regarding demographics, medical history and dialysis treatments were collected on our 34 chronic hemodialysis outpatients. Results: Over a 5-wk interval, 62% (21 of 34) of the chronic hemodialysis patients unexpectedly developed a white precipitate adhering to the lumenal surface of their dialysis blood tubing, with 73 of 580 chronic dialysis treatments exhibiting the phenomenon. Microscopic and biochemical analyses were consistent with white thrombus, formed by an aggregation of platelets and fibrin. An alert was issued and other in-center hemodialysis units noted similar findings. This was remedied by the removal of specific tubing. Conclusions: Both patient-specific and tubing-specific factors may have been operative. Although patient safety was not adversely affected, assessment of clinical and manufacturing variables potentially affecting platelet activation is warranted. C1 [Watnick, Suzanne; Cohen, David M.] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA. [Winter, Rolf; Riscoe, Michael] Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. [Watnick, Suzanne; Stooksbury, Michael; Cohen, David M.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR USA. RP Watnick, S (reprint author), PVAMC, Dialysis Unit, P3 NEPH,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM watnicks@ohsu.edu NR 12 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAR PY 2008 VL 3 IS 2 BP 382 EP 386 DI 10.2215/CJN.03540807 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 270GS UT WOS:000253709800012 PM 18184880 ER PT J AU Mittalhenkle, A Stehman-Breen, CO Shlipak, MG Fried, LF Katz, R Young, BA Seliger, S Gillen, D Newman, AB Psaty, BM Siscovick, D AF Mittalhenkle, Anuja Stehman-Breen, Catherine O. Shlipak, Michael G. Fried, Linda F. Katz, Ronit Young, Bessie A. Seliger, Stephen Gillen, Daniel Newman, Anne B. Psaty, Bruce M. Siscovick, David TI Cardiovascular risk factors and incident acute renal failure in older adults: The cardiovascular health study SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID C-REACTIVE PROTEIN; ACUTE KIDNEY INJURY; INFLAMMATION; CLASSIFICATION; INSUFFICIENCY; MULTICENTER; VALIDATION; MORTALITY; DIALYSIS; THERAPY AB Background and objectives: Although the elderly are at increased risk for acute renal failure, few prospective studies have identified risk factors for acute renal failure in the elderly. Design, setting, participants, & measurements: The associations of cardiovascular disease risk factors, subclinical cardiovascular disease, and clinical coronary heart disease with the risk for development of acute renal failure were examined in older adults in the Cardiovascular Health Study, a prospective cohort study of community-dwelling older adults. Incident hospitalized cases of acute renal failure were identified through hospital discharge International Classification of Diseases, Ninth Revision codes and confirmed through physician diagnoses of acute renal failure in discharge summaries. Results: Acute renal failure developed in 225 (3.9%) of the 5731 patients during a median follow-up period of 10.2 yr. In multivariate analyses, diabetes, current smoking, hypertension, C-reactive protein, and fibrinogen were associated with acute renal failure. Prevalent coronary heart disease was associated with incident acute renal failure, and among patients without prevalent coronary heart disease, subclinical vascular disease measures were also associated with acute renal failure: Low ankle-arm index (<= 0.9), common carotid intima-media thickness, and internal carotid intima-media thickness. Conclusions: In this large, population-based, prospective cohort study, cardiovascular risk factors and both subclinical and clinical vascular disease were associated with incident acute renal failure in the elderly. C1 [Mittalhenkle, Anuja; Seliger, Stephen] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Stehman-Breen, Catherine O.; Psaty, Bruce M.; Siscovick, David] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Katz, Ronit; Gillen, Daniel] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Young, Bessie A.; Psaty, Bruce M.; Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Stehman-Breen, Catherine O.] Amgen Inc, Thousand Oaks, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Vet Adm Med Ctr, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. [Newman, Anne B.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Newman, Anne B.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Mittalhenkle, A (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Mail Code MQ360,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM mittalhe@ohsu.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [N01 HC015103, N01 HC035129, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01HC85079, N01HC85086, R01 HL073208]; NIDDK NIH HHS [DK07721, T32 DK007721] NR 31 TC 22 Z9 22 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAR PY 2008 VL 3 IS 2 BP 450 EP 456 DI 10.2215/CJN.02610607 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 270GS UT WOS:000253709800022 PM 18256380 ER PT J AU Carr, M Goudreau, K Gauthier, PA Mitchell, MG AF Carr, Marcia Goudreau, Kelly Gauthier, Paul Andre Mitchell, Mitzi G. TI CNS practice, education, and regulation: An international collaboration between Canada and the united states SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Carr, Marcia] Burnaby Hosp, Burnaby, BC, Canada. [Goudreau, Kelly] Portland VA Med Ctr, Portland, OR USA. [Gauthier, Paul Andre; Mitchell, Mitzi G.] York Univ, Toronto, ON M3J 2R7, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2008 VL 22 IS 2 BP 90 EP 90 PG 1 WC Nursing SC Nursing GA 268FS UT WOS:000253565200014 ER PT J AU Banks, MA Butler, ND Morrison, D Rossi, KA AF Banks, Melanie A. Butler, Nichole D. Morrison, Dolores Rossi, Karen A. TI From CNS graduate to board-certified CNS: The road to certification SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Banks, Melanie A.; Butler, Nichole D.; Morrison, Dolores; Rossi, Karen A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2008 VL 22 IS 2 BP 93 EP 93 PG 1 WC Nursing SC Nursing GA 268FS UT WOS:000253565200025 ER PT J AU Mendez, MF Shapira, JS AF Mendez, Mario F. Shapira, Jill S. TI The spectrum of recurrent thoughts and behaviors in frontotemporal dementia SO CNS SPECTRUMS LA English DT Article ID OBSESSIVE-COMPULSIVE DISORDER; FRONTAL-LOBE DEGENERATION; ALZHEIMERS-DISEASE; CLINICAL-FEATURES; SEMANTIC DEMENTIA; TEMPORAL VARIANT; PICKS-DISEASE; BRAIN-INJURY; SYMPTOMS; DIAGNOSIS AB This article describes the spectrum of recurrent thoughts and behaviors that can result from frontotemporal dementia (FTD) and its variants. Although repetitive behaviors can result from a range of brain disorders, FTD is the most common neurologic cause of new-onset recurrent thoughts and behaviors in middle or late life. Patients with FTD can manifest typical or bizarre compulsions, hoarding, verbal and motor stereotypies and complex tics; self-injurious acts, perseverations; and fixed, obsessional thoughts. The frequency and variability of these repetitive behaviors suggest a common disturbance of orbitofrontal-basal ganglia circuits involved in response inhibition. The amelioration of these recurrent events with the administration of serotonin selective reuptake inhibitors further suggests a serotonergic deficit. C1 [Mendez, Mario F.] Vet Affairs Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA 90073 USA. [Mendez, Mario F.; Shapira, Jill S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Mendez, MF (reprint author), Vet Affairs Greater Los Angeles Healthcare, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu; jshapira@ucla.edu NR 67 TC 18 Z9 19 U1 1 U2 5 PU M B L COMMUNICATIONS, INC PI NEW YORK PA 333 HUDSON ST, 7TH FLOOR, NEW YORK, NY 10013 USA SN 1092-8529 J9 CNS SPECTRUMS JI CNS Spectr. PD MAR PY 2008 VL 13 IS 3 BP 202 EP 208 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 282KN UT WOS:000254566800009 PM 18323753 ER PT J AU Shepherd, R Macer, JL Grady, D AF Shepherd, Rodger Macer, Judith L. Grady, Deborah TI Planning for closeout - From Day One SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE clinical trials; closeout; contingency planning ID RANDOMIZED CONTROLLED TRIAL; ESTROGEN PLUS PROGESTIN; HEART-ATTACK TRIAL; POSTMENOPAUSAL WOMEN; OPERATIONAL ASPECTS; EARLY TERMINATION; CLINICAL-TRIALS; FOLLOW-UP; HYPERTENSION; OUTCOMES AB Clinical trials are often stopped prematurely by Data and Safety Monitoring Boards, sponsors, or the investigators for reasons such as unexpected harmful effects of the intervention, clear lack of benefit, or futility due to sluggish recruitment or an unexpectedly low outcome rate in the placebo group. Planning for closeout, however, usually does not begin until after the trial is well underway. This article describes the experience of the Heart and Estrogen/progestin Replacement Study (HERS) investigators when data from the first year of follow-up revealed a clear but non-significant divergence in outcome rates between the treatment groups, and planning for early closure was initiated. Three advantages of beginning early to plan for closeout are described and approaches to planning closeout are suggested. (C) 2007 Elsevier Inc. All rights reserved. C1 [Grady, Deborah] UCSF, Womens Hlth Clin Res Ctr, San Francisco, CA 94115 USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. RP Grady, D (reprint author), UCSF, Womens Hlth Clin Res Ctr, 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA. EM Deborah.Grady@ucsf.edu NR 19 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2008 VL 29 IS 2 BP 136 EP 139 DI 10.1016/j.cct.2007.06.001 PG 4 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 276BZ UT WOS:000254117600006 PM 17644047 ER PT J AU Schwab, P Klein, RF AF Schwab, Pascale Klein, Robert F. TI Nonpharmacological approaches to improve bone health and reduce osteoporosis SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE bone health; exercise; osteoporosis; rehabilitation ID RANDOMIZED CONTROLLED-TRIAL; FEMORAL-NECK FRACTURE; QUALITY-OF-LIFE; HIP FRACTURE; POSTMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY; FOLLOW-UP; COMPRESSION FRACTURES; ELDERLY INDIVIDUALS; WEIGHT-BEARING AB Purpose of review With an aging population, osteoporosis has become a public health concern and an area of increased awareness among both patients and medical practitioners. Timely screening and pharmacologic treatment of low bone mass effectively reduces fracture risk. Nonpharmacologic interventions, however, deserve equal emphasis both in the prevention and treatment of osteoporosis. Recent findings Recent advances in bone biology have established that exercise in the form of short, repetitive mechanical loading leads to the greatest gains in bone strength. As demonstrated by both observational and randomized exercise intervention trials, these gains are best achieved in childhood but can be maintained in adulthood with continued regular weight-bearing exercise. In the later years, evidence supports the implementation of balance training to decrease fall risk, especially in elderly patients with low bone mass. Following an osteoporotic fracture, a multidisciplinary rehabilitation program with an emphasis on early mobilization, fall prevention, use of orthoses, and noninvasive surgical procedures is emerging as a promising approach. Summary Clinically, these findings should imply greater emphasis on high impact exercise during skeletal growth and on maintenance of weight bearing and balance training in the later years. Future research should examine the effect of these interventions on fracture prevention. C1 [Schwab, Pascale] Oregon Hlth & Sci Univ, Div Arthritis & Rheumat Dis, Portland, OR 97239 USA. [Schwab, Pascale; Klein, Robert F.] Portland VA Med Ctr, Portland, OR USA. [Klein, Robert F.] Oregon Hlth & Sci Univ, Div Endocrinol Diabet & Clin Nutr, Portland, OR USA. RP Schwab, P (reprint author), Oregon Hlth & Sci Univ, Div Arthritis & Rheumat Dis, 3181 SW Sam Jackson Pk Rd,OP09, Portland, OR 97239 USA. EM schwabp@ohsu.edu FU NIAMS NIH HHS [R01 AR044659-08, R01 AR044659] NR 46 TC 19 Z9 21 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 J9 CURR OPIN RHEUMATOL JI CURR. OPIN. RHEUMATOL. PD MAR PY 2008 VL 20 IS 2 BP 213 EP 217 PG 5 WC Rheumatology SC Rheumatology GA 266YW UT WOS:000253475200016 PM 18349754 ER PT J AU Williams, BR Woodby, LL Bailey, FA Burgio, KL AF Williams, Beverly R. Woodby, Lesa L. Bailey, F. Amos Burgio, Kathryn L. TI Identifying and responding to ethical and methodological issues in after-death interviews with next-of-kin SO DEATH STUDIES LA English DT Review ID BEREAVED FAMILY-MEMBERS; INFORMAL CAREGIVERS SATISFACTION; RANDOMIZED CONTROLLED-TRIAL; DYING CANCER-PATIENTS; PALLIATIVE CARE; LIFE CARE; QUALITATIVE RESEARCH; PATIENTS PAIN; ILL PATIENTS; EVENT SCALE AB After-death research with next-of-kin can enhance our understanding of end-of-life care and translate into better services for dying persons and their survivors. This article describes ethical and methodological issues that emerged in a pilot of a face-to-face interview guide designed to elicit next-of-kin's perceptions of end-of-life care. The pilot study was part of a larger Veterans Affairs (VA) Health Services Research protocol to improve end-of-life care in VA Medical Centers. By deconstructing the research process from an ethical perspective and engaging in critical self-assessment, the authors aim to inform other researchers of potential problems involved in after-death research with next-of-kin. C1 [Williams, Beverly R.; Woodby, Lesa L.; Bailey, F. Amos; Burgio, Kathryn L.] Birmingham Atlanta Geriatr Res Educ Clin Ctr GREC, Dept Vet Affairs Med Ctr, Birmingham, AL USA. [Williams, Beverly R.; Woodby, Lesa L.; Bailey, F. Amos; Burgio, Kathryn L.] Univ Alabama, Dept Med, Div Gerontol Geriat & Palliat Care, Birmingham, AL USA. RP Williams, BR (reprint author), Birmingham VA Med Ctr, Dept Vet Affairs, 700 S 19th St,11-G, Birmingham, AL 35233 USA. EM beverly.williams3@va.gov NR 117 TC 18 Z9 18 U1 0 U2 4 PU BRUNNER/MAZEL INC PI BRISTOL PA 1900 FROST RD, STE 101, BRISTOL, PA 19007-1598 USA SN 0748-1187 J9 DEATH STUD JI Death Stud. PD MAR PY 2008 VL 32 IS 3 BP 197 EP 236 DI 10.1080/07481180701881297 PG 40 WC Psychology, Multidisciplinary; Social Issues; Social Sciences, Biomedical SC Psychology; Social Issues; Biomedical Social Sciences GA 285BG UT WOS:000254751700001 PM 18705168 ER PT J AU Shapiro, A Matheny, M Zhang, Y Tumer, N Cheng, KY Rogrigues, E Zolotukhin, S Scarpace, PJ AF Shapiro, Alexandra Matheny, Michael Zhang, Yi Tumer, Nihal Cheng, Kit-Yan Rogrigues, Enda Zolotukhin, Sergei Scarpace, Philip J. TI Synergy between leptin therapy and a seemingly negligible amount of voluntary wheel running prevents progression of dietary obesity in leptin-resistant rats SO DIABETES LA English DT Article ID 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; SIGNAL-TRANSDUCTION; VISCERAL OBESITY; BODY-WEIGHT; MICE; RESPONSES; EXERCISE; PURIFICATION; INHIBITION; EXPRESSION AB OBJECTIVE-We examined whether chronic leptin treatment of diet-induced obese rats promotes or alleviates the susceptibility to continued high-fat feeding. Second, we examined if voluntary wheel running is beneficial in reducing the trajectory of weight gain in high-fat-raised leptin-resistant rats. RESEARCH DESIGN AND METHODS-Sprague-Dawley rats were fed a standard diet or a high-fat diet for 5 months, and then hypothalamic leptin overexpression was induced through central administration of adeno-associated virus-encoding leptin while continuing either the standard or high-fat diet. Two weeks later, half of the rats in each group were provided access to running wheels for 38 days while being maintained on either a standard or high-fat diet. RESULTS-In standard diet-raised rats, either wheel running or leptin reduced the trajectory of weight gain, and the combined effect of both treatments was additive. In high-fat-raised leptin-resistant rats, leptin overexpression first transiently reduced weight gain but then accelerated the weight gain twofold over controls. Wheel running in high-fat-raised rats was sixfold less than in standard diet-raised rats and did not affect weight gain. Surprisingly, wheel running plus leptin completely prevented weight gain. This synergy was associated with enhanced hypothalamic signal transducer and activator of transcription (STAT) 3 phosphorylation and suppressor of cytokine signaling 3 expression in wheel running plus leptin compared with leptin-treated sedentary high-fat counterparts. This enhanced STAT3 signaling associated with the combination treatment occurred only in high-fat-raised, leptin-resistant rats and not in standard diet-raised, leptin-responsive rats. CONCLUSIONS-Chronic leptin treatment in diet-induced obese rats accelerates dietary obesity. However, leptin combined with wheel running prevents further dietary weight gain. Thus, this combination therapy may be a viable antiobesity treatment. C1 [Shapiro, Alexandra; Matheny, Michael; Zhang, Yi; Tumer, Nihal; Cheng, Kit-Yan; Rogrigues, Enda; Scarpace, Philip J.] Univ Florida, Dept Pharm & Therapeut, Gainesville, FL 32610 USA. [Zhang, Yi; Tumer, Nihal] US Dept Vet Affairs, Med Ctr, Gainesville, FL USA. [Tumer, Nihal; Scarpace, Philip J.] Univ Florida, Coll Med, Dept Aging & Geriatr, Gainesville, FL USA. [Zolotukhin, Sergei] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL USA. RP Scarpace, PJ (reprint author), Univ Florida, Dept Pharm & Therapeut, Box 100267, Gainesville, FL 32610 USA. EM scarpace@ufi.edu FU NIA NIH HHS [AG-26159, P30 AG028740]; NIDDK NIH HHS [R01 DK62302] NR 35 TC 23 Z9 23 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD MAR PY 2008 VL 57 IS 3 BP 614 EP 622 DI 10.2337/db07-0863 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 271PJ UT WOS:000253800900015 PM 18086903 ER PT J AU Schwartz, AV Vittinghoff, E Sellmeyer, DE Feingold, KR de Rekeneire, N Strotmeyer, ES Shorr, RI Vinik, AI Odden, MC Park, SW Faulkner, KA Harris, TB AF Schwartz, Ann V. Vittinghoff, Eric Sellmeyer, Deborah E. Feingold, Kenneth R. de Rekeneire, Nathalie Strotmeyer, Elsa S. Shorr, Ronald I. Vinik, Aaron I. Odden, Michelle C. Park, Seok Won Faulkner, Kimberly A. Harris, Tamara B. CA Hlth Aging Body Composition Study TI Diabetes-related complications, glycemic control, and falls in older adults SO DIABETES CARE LA English DT Article; Proceedings Paper CT 27th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 23-27, 2005 CL Nashville, TN SP Amer Soc Bone & Mineral Res ID CREATININE CLEARANCE; ELDERLY RESIDENTS; WOMENS HEALTH; RISK-FACTORS; CYSTATIN-C; NEUROPATHY; MEN; AGE AB OBJECTIVE - Older adults with type 2 diabetes are more likely to fall, but little is known about risk factors for falls in this population. We determined whether diabetes-related complications or treatments are associated with risk of falls in older diabetic adults. RESEARCH DESIGN AND METHODS -In the Health, Aging, and Body Composition cohort of well-functioning older adults participants reported falls in the previous year at annual visits. Odds ratios (ORs) for more frequent falls among 446 diabetic participants whose mean age was 73.6 years, with an average follow-up of 4.9 years, were estimated with continuation ratio models. RESULTS - in the first year, 24% reported falling; 22, 26, 3 1, and 30% fell in subsequent years. In adjusted models, reduced peroneal nerve response amplitude (OR 1.50 -95% CI 1.07-2.12], worst quartile versus others); higher cystatin-C, a marker of reduced renal function (1.38 [1.11-1.71], for 1 SD increase); poorer contrast sensitivity (1.41 [0.97-2.04], worst quartile versus others); and low A1C in insulin users (4.36 [1.32-14.461, A1C <= 6 vs. >8%) were associated with risk of falls. In those using oral hypoglycemic medications but not insulin, low A1C was not associated With risk of falls (1.29 [0.65-2.54], A1C <= 6 vs. >8%). Adjustment for physical performance explained some, but not all, of these associations. CONCLUSIONS - in older diabetic adults, reducing diabetes-related complications may prevent falls. Achieving lower A1C levels with oral hypoglycemic medications was not associated with more frequent falls, but, among those using insulin, A1C <= 6% increased risk of falls. C1 [Schwartz, Ann V.; Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA. [Sellmeyer, Deborah E.; Feingold, Kenneth R.] Univ Calif San Francisco, Dept Med, Div Endocrinol, San Francisco, CA 94107 USA. [de Rekeneire, Nathalie; Harris, Tamara B.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Strotmeyer, Elsa S.; Park, Seok Won; Faulkner, Kimberly A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Shorr, Ronald I.] Univ Florida, Div Geriatr, Dept Aging & Geriatr Res, Gainesville, FL USA. [Vinik, Aaron I.] Eastern Virginia Med Sch, Strelitz Diabet Inst, Dept Internal Med, Norfolk, VA 23501 USA. [Vinik, Aaron I.] Eastern Virginia Med Sch, Dept Anat & Pathol, Norfolk, VA 23501 USA. [Odden, Michelle C.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Park, Seok Won] Pochon CHA Univ, Dept Internal Med, Gyeonggi Do, South Korea. RP Schwartz, AV (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 185 Berry St, San Francisco, CA 94107 USA. EM aschwartz@psg.ucsf.edu RI Strotmeyer, Elsa/F-3015-2014 OI Strotmeyer, Elsa/0000-0002-4093-6036 FU Intramural NIH HHS; NIA NIH HHS [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIDDK NIH HHS [R21 DK064597, R21 DK064597-02] NR 31 TC 142 Z9 144 U1 1 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2008 VL 31 IS 3 BP 391 EP 396 DI 10.2337/dc07-1152 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 271PL UT WOS:000253801100003 PM 18056893 ER PT J AU Haas, LB AF Haas, Linda B. TI The role of the diabetes educator - Patient case scenarios SO DIABETES EDUCATOR LA English DT Article ID PREVENTING CARDIOVASCULAR-DISEASE; AMERICAN-HEART-ASSOCIATION; METABOLIC SYNDROME; RISK-FACTORS; INFLAMMATION; OBESITY; CALL AB Therapeutic lifestyle intervention, with a focus on weight loss, is the cornerstone of cardiometabolic risk factor reduction, but many patients find it difficult to make the changes that are needed to achieve meaningful improvements in risk markers. There are a variety of pharmacologic options for the management of individual risk factors, such as hypertension, dyslipidemia, and insulin resistance. However, agents that are currently available to assist patients in their weight loss efforts are limited by their potential for adverse effects. The American Association of Diabetes Educators ( AADE) has identified 7 behavioral targets of self- management, the AADE7 (TM) Self-Care Behaviors, which include healthy eating, being active, monitoring, taking medications, problem solving, healthy coping, and reducing risk factors. The case scenarios in the article illustrate some of the challenges clinicians face in managing cardiometabolic risk factor reduction in the context of these recommended behaviors. A common theme among these cases is the importance of assessing patients' understanding, beliefs, and readiness to change their behaviors. C1 Seattle Div, VA Puget Sound HCS, Seattle, WA 98108 USA. RP Haas, LB (reprint author), Seattle Div, VA Puget Sound HCS, S-118,1660 S Columbian Way, Seattle, WA 98108 USA. EM Linda.haas@va.gov NR 19 TC 0 Z9 0 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 J9 DIABETES EDUCATOR JI Diabetes Educ. PD MAR-APR PY 2008 VL 34 SU 2 BP 32S EP 36S DI 10.1177/0145721708316769 PG 5 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA 288PS UT WOS:000254998900002 ER PT J AU Tobi, M Kam, M Ullah, N Qureshi, K Yordanova, V Hatfield, J Fligiel, SEG Sochacki, P McGarrity, T Cole, C Lawson, M Jacoby, R AF Tobi, Martin Kam, Michael Ullah, Nadeem Qureshi, Kashif Yordanova, Violeta Hatfield, James Fligiel, Suzanne E. G. Sochacki, Paula McGarrity, Thomas Cole, Carolyn Lawson, Michael Jacoby, Russell TI An anti-adenoma antibody, adnab-9, may reflect the risk for neoplastic progression in familial hamartomatous polyposis syndromes SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Adnab-9; Peutz-Jeghers syndrome; familial juvenile polyposis; anti-alpha-defensin 5; Paneth-like cells ID PEUTZ-JEGHERS-SYNDROME; MONOCLONAL-ANTIBODY; JUVENILE POLYPOSIS; MARKER; GENE; CYCLOOXYGENASE-2; CANCER; CELLS AB Patients with the hamartomatous polyposis Peutz-Jeghers and familial juvenile polyposis syndromes are predisposed to colorectal cancer but lack early genetic alterations found in adenomatous premalignant lesions. We studied hamartomatous polyps for the expression of an early preneoplastic colorectal neoplasia risk marker also found in familial adenomatous polyposis patients. Retrospective, genetic, and hospital archival tissue immunohistochemistry using Adnab-9, a premalignant marker often found in Paneth-like cells (PCs), was performed on sections of polyps from eight patients with Peutz-Jeghers syndrome, eight patients with familial juvenile polyposis, and 36 hyperplastic polyp control sections. Anti-alpha-defensin 5 (AD5), a universal PC marker, was also used to label a subgroup of sections. Hamartomatous polyposis patients also underwent specific genetic analysis. Eighty-nine percent of Peutz-Jeghers syndrome polyps labeled with Adnab-9 compared with 63% for AD5; 88% of familial juvenile polyposis sections also labeled with Adnab-9. Of the 36 hyperplastic polyp sections, only four (11%) labeled with Adnab-9 and one (3%) with AD5. Adnab-9 labeling of PCs in the epithelial elements of hamartomatous colonic lesions of hereditary hamartomatous syndrome patients reflects the predisposition to colorectal cancer, further justifying early intervention strategies. C1 [Tobi, Martin] Philadelphia VAMC, Sect Gastroenterol MED 3GI, Philadelphia, PA 19104 USA. [Tobi, Martin; Kam, Michael; Ullah, Nadeem; Qureshi, Kashif; Yordanova, Violeta; Hatfield, James; Fligiel, Suzanne E. G.; Sochacki, Paula] Wayne State Univ, Sch Med, John D Dingell VAMC Dept Med, Detroit, MI USA. [Tobi, Martin; Kam, Michael; Ullah, Nadeem; Qureshi, Kashif; Yordanova, Violeta; Hatfield, James; Fligiel, Suzanne E. G.; Sochacki, Paula] Wayne State Univ, Sch Med, John D Dingell VAMC Dept Gastroenterol, Detroit, MI USA. [Tobi, Martin; Kam, Michael; Ullah, Nadeem; Qureshi, Kashif; Yordanova, Violeta; Hatfield, James; Fligiel, Suzanne E. G.; Sochacki, Paula] Wayne State Univ, Sch Med, John D Dingell VAMC Dept Pathol, Detroit, MI USA. [McGarrity, Thomas] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Med, Hershey, PA 17033 USA. [Cole, Carolyn; Jacoby, Russell] Univ Wisconsin, Ctr Comprehens Canc, William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Lawson, Michael] Kaiser Permanente, Med Grp, Sacramento, CA USA. RP Tobi, M (reprint author), Philadelphia VAMC, Sect Gastroenterol MED 3GI, Philadelphia, PA 19104 USA. EM martin.tobi@va.gov NR 23 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAR PY 2008 VL 53 IS 3 BP 723 EP 729 DI 10.1007/s10620-007-9947-5 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 268HK UT WOS:000253570700018 PM 17934846 ER PT J AU Hewitt, A Hind, J Kays, S Nicosia, M Doyle, J Tompkins, W Gangnon, R Robbins, J AF Hewitt, Angela Hind, Jacqueline Kays, Stephanie Nicosia, Mark Doyle, John Tompkins, Willis Gangnon, Ronald Robbins, JoAnne TI Standardized instrument for lingual pressure measurement SO DYSPHAGIA LA English DT Article DE dysphagia; exercise; sampling rate; tongue strength; tongue pressure; biofeedback; deglutition; deglutition disorders ID SWALLOWING DISORDERS; EXERCISE AB Disease-related atrophy of the tongue muscles can lead to diminished lingual strength and swallowing difficulties. The devastating physical and social consequences resulting from this condition of oropharyngeal dysphagia have prompted investigators to study the effects of tongue exercise in improving lingual strength. We developed the Madison Oral Strengthening Therapeutic (MOST) device, which provides replicable mouth placement, portability, affordability, and a simple user interface. Our study (1) compared the MOST to the Iowa Oral Performance Instrument (IOPI), a commercial pressure-measuring device, and (2) identified the optimal tongue pressure sampling rate for isometric exercises. While initial use of the MOST is focused on evaluating and treating swallowing problems, it is anticipated that its greatest impact will be the prevention of lingual muscle mass and related strength diminishment, which occurs even in the exponentially increasing population of healthy aging adults. C1 [Hewitt, Angela; Hind, Jacqueline; Kays, Stephanie; Nicosia, Mark; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. [Nicosia, Mark] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA. [Gangnon, Ronald] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA. [Doyle, John] Univ Wisconsin, Dept Surg, Madison, WI 53706 USA. [Hewitt, Angela; Hind, Jacqueline; Kays, Stephanie; Robbins, JoAnne] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Hewitt, Angela; Tompkins, Willis] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA. RP Robbins, J (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, 2500 Overlook Terrace,GRECC 11G, Madison, WI 53705 USA. EM jrobbin2@wisc.edu NR 14 TC 16 Z9 24 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0179-051X J9 DYSPHAGIA JI Dysphagia PD MAR PY 2008 VL 23 IS 1 BP 16 EP 25 DI 10.1007/s00455-007-9089-0 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA 259DN UT WOS:000252919400003 PM 17602265 ER PT J AU Bautista, JF Kelly, JA Harley, JB Gray-McGuire, C AF Bautista, Jocelyn F. Kelly, Jennifer A. Harley, John B. Gray-McGuire, Courtney TI Addressing genetic heterogeneity in complex disease: Finding seizure genes in systemic lupus erythematosus SO EPILEPSIA LA English DT Article DE linkage; lupus; seizures; genetic; covariates ID REVISED CRITERIA; LINKAGE; CLASSIFICATION; MODEL AB Complex genetic disease is inherently difficult to study due to an imperfect relationship between genotype and phenotype. One important reason for this imperfect relationship is genetic heterogeneity, the occurrence of different genetic factors underlying the same clinical syndrome. One method of addressing genetic heterogeneity is covariate-based linkage analysis, which allows the use of additional phenotypic features to define genetically distinct subsets of patients. Systemic lupus erythematosus (SLE) is one example of a complex genetic disease affecting multiple organ systems including the central nervous system. We report here the use of covariate-based linkage analysis to detect a potential genetic locus on chromosome 15 influencing the development of seizures in individuals with SLE. The use of covariates increases the power to detect linkage in the presence of genetic heterogeneity. C1 [Bautista, Jocelyn F.] Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA. [Kelly, Jennifer A.; Harley, John B.] Oklahoma Med Res Fdn, Arthritis & Immunol Res Program, Oklahoma City, OK USA. [Harley, John B.] Univ Oklahoma, Dept Med, Oklahoma City, OK USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Gray-McGuire, Courtney] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. RP Bautista, JF (reprint author), Cleveland Clin Fdn, Dept Neurol, 9500 Euclid Ave, Cleveland, OH 44195 USA. EM bautisj@ccf.org FU NCRR NIH HHS [RR03655, RR020143, RR03655-15]; NIAID NIH HHS [AI24717, AI31584]; NIAMS NIH HHS [P30 AR053483, AR-6-2277, AR 048940, AR-5-2221, AR42460, AR049084] NR 7 TC 7 Z9 7 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD MAR PY 2008 VL 49 IS 3 BP 527 EP 530 DI 10.1111/j.1528-1167.2007.01453.x PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 266ZP UT WOS:000253477800021 PM 18070094 ER PT J AU Ellis, C Egede, LE AF Ellis, Charles Egede, Leonard E. TI Racial/ethnic differences in stroke awareness among veterans SO ETHNICITY & DISEASE LA English DT Article DE stroke; ethnicity; health disparities; survey research; health education ID AMERICAN-HEART-ASSOCIATION; RISK-FACTOR SURVEY; WARNING SIGNS; ISCHEMIC-STROKE; RACIAL DISPARITIES; UNITED-STATES; KNOWLEDGE; CARE; POPULATION; EMERGENCY AB Objectives: To examine racial/ethnic differences in stroke recognition and knowledge of appropriate first action if someone was having a stroke. Methods: We examined data from 36,150 veterans from the 2003 Behavioral Risk Factor ICIT Surveillance System (BRFSS). Respondents indicated recognition of five stroke warning signs/symptoms and first action they would take if someone were having a stroke. Multiple logistic regression was used to assess the independent effect of race/ethnicity on stroke recognition and appropriate first action, controlling for relevant covariates. Results: Most respondents recognized at least one warning sign: 96% recognized sudden confusion or trouble speaking; 97% recognized sudden facial, arm, or leg weakness; 88% recognized sudden vision loss; 94% recognized sudden trouble walking; and 80% recognized sudden headache; 86% recognized calling 911 as the appropriate first action. However, only 17% recognized all five warning signs/symptoms, and only 15% recognized all five warning signs/symptoms and would call 911 as the first action. In multivariate models with Whites as reference, Hispanics (OR .34, 95% Cl .22-.51) and Others (OR .68, 95% Cl .50-.92) were less likely to recognize all five stroke warning signs/ symptoms. Hispanics (OR .37, 95% Cl.24-.58) and Others (OR .68, 95% Cl .48-.96) were less likely to recognize all five warning signs/ symptoms and call 911 as the first action. Conclusions: Most veterans recognize individual stroke warning signs, but very few recognize all five and would take appropriate action to call 911 in the event of a stroke. Low rates of stroke recognition and taking appropriate action are more pronounced in racial/ethnic minority veterans. C1 [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dsipar Res, Charleston, SC 29425 USA. [Ellis, Charles] Med Univ S Carolina, Dept Rehabil Sci, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Ctr Hlth Dsipar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu NR 36 TC 9 Z9 9 U1 0 U2 1 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SPR PY 2008 VL 18 IS 2 BP 198 EP 203 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 286YH UT WOS:000254882200013 PM 18507274 ER PT J AU Pang, PS Cleland, JGF Teerlink, JR Collins, SP Lindsell, CJ Sopko, G Peacock, WF Fonarow, GC Aldeen, AZ Kirk, JD Storrow, AB Tavares, M Mebazaa, A Roland, E Massie, BM Maisel, AS Komajda, M Filippatos, G Gheorghiade, M AF Pang, Peter S. Cleland, John G. F. Teerlink, John R. Collins, Sean P. Lindsell, Christopher J. Sopko, George Peacock, W. Frank Fonarow, Gregg C. Aldeen, Amer Z. Kirk, J. Douglas Storrow, Alan B. Tavares, Miguel Mebazaa, Alexandre Roland, Edmond Massie, Barry M. Maisel, Alan S. Komajda, Michel Filippatos, Gerasimos Gheorghiade, Mihai CA Acute Heart Failure Syndromes Int TI A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach SO EUROPEAN HEART JOURNAL LA English DT Article DE heart failure; clinical trials; dyspnoea ID RANDOMIZED CONTROLLED-TRIALS; NATRIURETIC PEPTIDE; TEZOSENTAN; NESIRITIDE; OUTCOMES; DIAGNOSIS; DESIGN; RISK; ANTAGONIST; RATIONALE AB Dyspnoea is the most common presenting symptom amongst patients with acute heart failure syndromes (AHFS). It is distressing to patients and therefore an important target for treatment in clinical practice, clinical trials, and for regulatory approval of novel agents. Despite its importance as a treatment target, no consensus exists on how to assess dyspnoea in this setting. There is a considerable uncertainty about the reproducibility of the various instruments used to measure dyspnoea, their ability to reflect changes in symptoms and whether they accurately reflect the patient's experience. Little attempt has been made to ensure consistent implementation with respect to patients' posture during assessment or timing in relationship to therapy. There is also limited understanding of how rapidly and completely dyspnoea responds to standard therapy. A standardized method with which to assess dyspnoea is required for clinical trials of AHFS in order to ensure uniform collection of data on a key endpoint. We propose the Provocative Dyspnoea Assessment, a method of measurement that combines sequential dyspnoea provocation by positioning and walking with a dyspnoea self assessment using a five-point Likert scale, to yield a final Dyspnoea Severity Score. This proposed tool requires detailed validation but has face validity for the uniform assessment of dyspnoea. C1 [Cleland, John G. F.; Aldeen, Amer Z.] Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull, Yorks, England. [Pang, Peter S.; Aldeen, Amer Z.] Northwestern Univ, Feinberg Sch Med, Dept Emergency Med, Chicago, IL 60611 USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94143 USA. [Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Collins, Sean P.; Lindsell, Christopher J.] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA. [Sopko, George] Natl Inst Hlth, Bethesda, MD USA. [Peacock, W. Frank] Cleveland Clin, Dept Emergency Med, Cleveland, OH 44106 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA. [Kirk, J. Douglas] Univ Calif Davis, Med Ctr, Dept Emergency Med, Sacramento, CA 95817 USA. [Storrow, Alan B.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN USA. [Tavares, Miguel] Hosp Geral Santo Antonio, Dept Anesthesiol & Crit Care, Oporto, Portugal. [Mebazaa, Alexandre] Hop Lariboisiere, Dept Anesthesiol & Crit Care Med, F-75475 Paris, France. [Roland, Edmond] Agcy Francaise Secur Sanit Prod Sante, Paris, France. [Maisel, Alan S.] Univ Calif San Diego, Vet Affairs San Diego Hlth Care Syst, Dept Med, Div Cardiol, San Diego, CA 92103 USA. [Komajda, Michel] Univ Paris 06, Dept Cardiol, Paris, France. [Komajda, Michel] Hop La Pitie Salpetriere, Paris, France. [Filippatos, Gerasimos] Athens Univ Hosp, Heart Failure Unit, Dept Cardiol, Attikon, Greece. [Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Cardiol, Chicago, IL 60611 USA. RP Cleland, JGF (reprint author), Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull, Yorks, England. EM j.g.cleland@hull.ac.uk RI Teerlink, John/D-2986-2012; Lainscak, Mitja/F-3237-2015 OI Lindsell, Christopher/0000-0002-3297-2811; Cleland, John/0000-0002-1471-7016 NR 37 TC 76 Z9 77 U1 1 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD MAR PY 2008 VL 29 IS 6 BP 816 EP 824 DI 10.1093/eurheartj/ehn048 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 278NL UT WOS:000254293500021 PM 18310669 ER PT J AU Baron, JH Sonnenberg, A AF Baron, Jeremy Hugh Sonnenberg, Amnon TI Hospital admissions and primary care attendances for nonulcer dyspepsia, reflux oesophagitis and peptic ulcer in Scotland 1981-2004 SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE deprivation; duodenal ulcer; dyspepsia; gastric ulcer; gastro-oesophageal reflux disease; Helicobacter pylori; social class; time trends ID DUODENAL-ULCER; DISEASE; PREVALENCE; MORTALITY; SYMPTOMS; OBESITY; TRENDS AB Aim The aim of this study was to assess the recent time trends of oesophageal disorders, nonulcer dyspepsia, gastric and duodenal ulcer in the light of such risk factors as age, sex, deprivation and urban versus rural residence. Methods The Scottish National Health Service provided diagnostic data on all admissions to all Scottish hospitals from 1981 to 2004 and patient visits to general practitioners (GP) from 1998 to 2004. Results In the last quarter of a century in Scotland, there were sevenfold increases in annual hospitalizations for dyspepsia (from 900 to 6000 per million population) and for oesophageal disorders (from 500 to 3700). Annual hospitalisations for gastric and duodenal ulcer changed from 590 to 1100 and from 1400 to 1130 per million population, respectively. The variation of hospital admissions for dyspepsia among various Scottish regions closely matched the variation of deprivation among them. GP contacts for dyspepsia (27600 per million population) and oesophageal disorders (10000) were common compared with relatively infrequent contacts for gastric ulcer (500) and duodenal ulcer (11200). Dyspepsia showed a rise of GP contacts with increasing scores of deprivation. This rise occurred similarly among urban and rural residents and applied to data for each individual year between 1998 until 2004. None of the other diagnoses showed any clear-cut correlation with grade of deprivation. Conclusion Gastric and duodenal ulcer are relatively rare causes for hospital admission as well as outpatient physician visits. Their former predominant role in upper gastrointestinal disease has been replaced by gastro-oesophageal reflux disease and nonulcer dyspepsia, both increasing sevenfold in the last quarter of a century. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Baron, Jeremy Hugh] New York & Imperial Coll, Mt Sinai Sch Med, London, England. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW,US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 29 TC 10 Z9 10 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-691X J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD MAR PY 2008 VL 20 IS 3 BP 180 EP 186 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 325ZP UT WOS:000257628000006 PM 18301297 ER PT J AU El Jamali, A Valente, AJ Lechleiter, JD Gamez, MJ Pearson, DW Nauseef, WM Clark, RA AF El Jamali, Amina Valente, Anthony J. Lechleiter, James D. Gamez, Maria J. Pearson, Doran W. Nauseef, William M. Clark, Robert A. TI Novel redox-dependent regulation of NOX5 by the tyrosine kinase c-Abl SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE NADPH oxidase; NOX5; hydrogen peroxide; signaling; c-Abl; superoxide; calcium; free radicals ID NF-KAPPA-B; HYDROGEN-PEROXIDE; GROWTH-FACTORS; HEMATOPOIETIC-CELLS; ENDOTHELIAL-CELLS; MYC EXPRESSION; ANGIOTENSIN-II; NADPH OXIDASES; DNA-SYNTHESIS; ACTIVATION AB We investigated the mechanism of H(2)O(2) activation of the Ca(2+)-regulated NADPH oxidase NOX5. H(2)O(2) induced a transient, dose-dependent increase in superoxide production in K562 cells expressing NOX5. Confocal studies demonstrated that the initial calcium influx generated by H(2)O(2) is amplified by a feedback mechanism involving NOX5-dependent superoxide production and H(2)O(2). H(2)O(2) NOX5 activation was inhibited by extracellular Ca(2+) chelators, a pharmacological inhibitor of c-Abl, and overexpression of kinase-dead c-Abl. Transfected kinase-active GFP-c-Abl colocalized with vesicular sites of superoxide production in a Ca(2+)-dependent manner. In contrast to H(2)O(2), the Ca(2+) ionophore ionomycin induced NOX5 activity independent of c-Abl. Immunoprecipitation of cell lysates revealed that active GFP-c-Abl formed oligomers with endogenous c-Abl and that phosphorylation of both proteins was increased by H(2)O(2) treatment. Furthermore, H(2)O(2)-induced NOX5 activity correlated with increased localization of c-Abl to the membrane fraction, and NOX5 proteins could be coimmunoprecipitated with GFP-Abl proteins. Our data demonstrate for the first time that NOX5 is activated by c-Abl through a Ca(2+)-mediated, redox-dependent signaling pathway and suggest a functional association between NOX5 NADPH oxidase and c-Abl. (c) 2007 Elsevier Inc. All rights reserved. C1 [El Jamali, Amina; Valente, Anthony J.; Gamez, Maria J.; Pearson, Doran W.; Clark, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [El Jamali, Amina; Valente, Anthony J.; Lechleiter, James D.; Gamez, Maria J.; Pearson, Doran W.; Clark, Robert A.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Lechleiter, James D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Nauseef, William M.] Univ Iowa, Dept Med, Inflammat Program, Iowa City, IA 52241 USA. [Nauseef, William M.] Vet Adm Med Ctr, Iowa City, IA 52241 USA. RP El Jamali, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM AkoulouzeBik@uthscsa.edu FU BLRD VA [I01 BX000513]; NCI NIH HHS [P30 CA054174, P30 CA 054174]; NIA NIH HHS [AG 019519, P01 AG 019316, P01 AG019316, P30 AG 013319, P30 AG013319, R01 AG019519]; NIAID NIH HHS [AI 020866, AI 034879, R01 AI020866, R01 AI020866-18, R01 AI034879, R37 AI020866, R56 AI034879] NR 47 TC 52 Z9 52 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD MAR 1 PY 2008 VL 44 IS 5 BP 868 EP 881 DI 10.1016/j.freeradbiomed.2007.11.020 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 265OI UT WOS:000253369000013 PM 18160052 ER PT J AU Sonnenberg, A Amorosi, SL Lacey, MJ Lieberman, DA AF Sonnenberg, Amnon Amorosi, Stacey L. Lacey, Michael J. Lieberman, David A. TI Patterns of endoscopy in the United States: analysis of data from the Centers for Medicare and Medicaid Services and the National Endoscopic Database SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID COLORECTAL-CANCER; PEPTIC-ULCER; HEALTH-CARE; COLONOSCOPY; DISEASE; TRENDS; DISPARITIES; POPULATION; COMMUNITY; INSURANCE AB Background: Patterns of GI endoscopy are influenced by the underlying epidemiology of GI disease, as well as by policy and practice guidelines. Objective: To compare practice patterns of GI endoscopy between two large national databases of the United States. Design: Descriptive database analysis. Setting: A 5% sample of the entire U.S. Medicare population (Centers for Medicare and Medicaid Services, CMS data files) and endoscopic data repository of U.S. gastroenterology practices (Clinical Outcomes Research Initiative, CORI database) from 1999 to 2003. Patients: The study population included 1,121,215 Medicare and 635,573 CORI patients undergoing various types of GI endoscopy. Interventions: EGD, colonoscopy, and flexible sigmoidoscopy. Main Outcome Measurements: Patient demographics, endoscopic diagnoses, time trends of diagnoses. Results: A colonoscopy was the most common endoscopic procedure performed (CMS 53%, CORI 58%), followed by an EGD (37%, 32%), and a flexible sigmoidoscopy (10%, 10%). In the CMS data, women accounted for 59% of the EGDs, 57% of the colonoscopies, and 56% of the flexible sigmoidoscopies, and in the CORI data, the corresponding numbers were 57%, 55%, and 54%, respectively. Compared with their distribution in the U.S. census population, nonwhite patients in both databases under-went relatively more EGDs and fewer colonoscopies. The most common upper-GI diagnosis was GERD, followed by GI bleeding, gastric ulcer, and duodenal ulcer. The most common lower-GI diagnosis was colorectal polyp. Over the period of 1999 to 2003, the rates of colorectal cancer diagnosed with colonoscopy declined. Limitations: Only a limited amount of information about individual patients was retrievable from the electronic databases. Conclusions: A colonoscopy is now the most common endoscopic procedure in the United States. Women undergo both upper and lower endoscopic procedures more often than men. Nonwhite patients are underrepresented in the use of colonoscopy relative to the prevalence of nonwhite persons in the U.S. population. Increased use of a colonoscopy for colon screening and surveillance has been associated with a decreased rate of cancer diagnosis. C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Boston Sci Corp, Natick, MA USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Veterans Hosp Rd, Portland, OR 97239 USA. FU NIDDK NIH HHS [U01-DK057132-06A1] NR 23 TC 66 Z9 68 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2008 VL 67 IS 3 BP 489 EP 496 DI 10.1016/j.gie.2007.08.041 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 270WL UT WOS:000253750800018 PM 18179793 ER PT J AU Leung, FW AF Leung, Felix W. TI Should minimization of cardiopulmonary unplanned events be an option as a quality indicator in colonoscopy performed for colorectal cancer screening? SO GASTROINTESTINAL ENDOSCOPY LA English DT Letter ID UNSEDATED COLONOSCOPY; ENDOSCOPY; SEDATION C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, N Hills Ambulatory Care Ctr, Div Gastroenterol, Sepulveda, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, North Hills, CA USA. RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, N Hills Ambulatory Care Ctr, Div Gastroenterol, Sepulveda, CA USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2008 VL 67 IS 3 BP 579 EP 580 DI 10.1016/j.gie.2007.09.012 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 270WL UT WOS:000253750800053 PM 18294530 ER PT J AU Morasco, BJ Dobscha, SK AF Morasco, Benjamin J. Dobscha, Steven K. TI Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE chronic pain; opiates; medication misuse; substance use disorder; primary care ID CHRONIC NONMALIGNANT PAIN; MEDICALLY ILL PATIENTS; CHRONIC NONCANCER PAIN; ABUSE SCREENING-TEST; OPIOID THERAPY; METHADONE-MAINTENANCE; MUSCULOSKELETAL PAIN; BACK-PAIN; ADDICTION; PREVALENCE AB Objective: The goal of this paper was to examine the relationship between history of substance use disorder (SUD) and self-reported prescription medication misuse in 127 primary care patients who receive opioid medications for treatment of chronic pain. Method: Participants completed measures of pain location, pain intensity, disability due to pain, and misuse of prescription medications. Other measures included demographic characteristics, psychiatric symptomatology and quality of life. Results: Seventy-eight percent of participants reported at least one indicator of medication misuse in the prior year. After adjusting for age and clinical factors (pain severity, depression severity, current alcohol or substance use disorder), participants with SUD history were significantly more likely than participants without SUD history to report borrowing pain medications from others (OR=6.62, 95% CI=1.430.7) and requesting an early refill of pain medication (OR=3.86, 95% 0=1.5-9.6). Conclusions: Misuse of prescription medications is a concern among primary care patients with chronic pain. Participants with a lifetime history of SUD are more likely to endorse some aberrant medication;related behaviors. Patients with SUD histories should be carefully evaluated for medication misuse potential and may require more intense assessment and follow-up. Published by Elsevier Inc. C1 [Morasco, Benjamin J.; Dobscha, Steven K.] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97219 USA. [Morasco, Benjamin J.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Dobscha, Steven K.] Portland VA Med Ctr, Columbia Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97219 USA. RP Morasco, BJ (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97219 USA. EM benjamin.morasco@va.gov NR 47 TC 49 Z9 50 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAR-APR PY 2008 VL 30 IS 2 BP 93 EP 99 DI 10.1016/j.genhosppsych.2007.12.004 PG 7 WC Psychiatry SC Psychiatry GA 270WK UT WOS:000253750700001 PM 18291290 ER PT J AU Leibowitz, RQ Jeffreys, MD Copeland, LA Noel, PH AF Leibowitz, Ruth Q. Jeffreys, Matthew D. Copeland, Laurel A. Noel, Polly H. TI Veterans' disclosure of trauma to healthcare providers SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE trauma; PTSD; disclosure; health communication ID POSTTRAUMATIC-STRESS-DISORDER; ADMINISTERED PTSD SCALE; MENTAL-HEALTH; FEMALE VETERANS; HELP-SEEKING; SYMPTOMS; ASSOCIATION; DEPRESSION; ANXIETY; ABUSE AB Objective: The purpose of this study is to gain a better understanding of patients' trauma disclosure to health professionals. Method: A convenience sample of 173 veterans in outpatient treatment for posttraumatic stress disorder (PTSD) in the Veterans Health Administration completed surveys querying trauma history, reasons for trauma disclosure and perceived provider responses. Results: For half of the participants, a healthcare provider was the first person to whom they disclosed. Reasons were primarily external, such as pressure from others. Although 72% were glad to disclose, 45% perceived at least one negative provider response. Conclusion: Patients disclose to a wide range of provider types and perceive varied responses. Providers' awareness of the need to be sensitive to trauma disclosure could facilitate treatment for PTSD. Published by Elsevier Inc. C1 [Leibowitz, Ruth Q.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Jeffreys, Matthew D.] S Texas Vet Hlth Care Syst, Dept Psychiat, San Antonio, TX 78229 USA. [Jeffreys, Matthew D.; Copeland, Laurel A.; Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Copeland, Laurel A.] S Texas Vet Hlth Care Syst, VERDICT HSR&D, San Antonio, TX 78229 USA. [Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Leibowitz, RQ (reprint author), Vet Adm Med Ctr, Portland Div, POB 1034 P3MHDC, Portland, OR 97207 USA. EM Dr.Leibq@hotmail.com OI Copeland, Laurel/0000-0002-9478-0209 NR 22 TC 14 Z9 14 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAR-APR PY 2008 VL 30 IS 2 BP 100 EP 103 DI 10.1016/j.genhosppsych.2007.11.004 PG 4 WC Psychiatry SC Psychiatry GA 270WK UT WOS:000253750700002 PM 18291291 ER PT J AU Nery, FG Monkul, ES Hatch, JP Fonseca, M Zunta-Soares, GB Frey, BN Bowden, CL Soares, JC AF Nery, Fabiano G. Monkul, Emel S. Hatch, John P. Fonseca, Manoela Zunta-Soares, Giovana B. Frey, Benicio N. Bowden, Charles L. Soares, Jair C. TI Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study SO HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL LA English DT Article DE bipolar disorder; bipolar depression; randomized-controlled trials; anti-inflammatory agents; cyclooxygenase-2 inhibitors; celecoxib ID ANTIDEPRESSANT TREATMENT; MAJOR DEPRESSION; RATING-SCALE; CYCLOOXYGENASE-2; INHIBITION; BRAIN; SCHIZOPHRENIA; THERAPY; PROSTAGLANDIN-E2; AUGMENTATION AB Objective To investigate whether the cox-2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases. Methods We studied 28 DSM-IV BD patients who were experiencing a depressive or mixed episode and were on a stable dose of a mood stabilizer or atypical antipsychotic medication. Subjects were randomized to receive 6 weeks of double-blind placebo or celecoxib (400 mg/day) treatment. Current mood stabilizer or antipsychotic medication remained at the same doses during the trial. Results Intention-to-treat analysis showed that the patients receiving celecoxib had lower Hamilton Depression Rating Scale (HamD) scores after 1 week of treatment compared to the patients receiving placebo, but this difference was not statistically significant (p=0.09). The improvement in the first week of treatment was statistically significant when the analysis included only the subjects who completed the full 6-week trial (p=0.03). The two groups did not differ significantly on depressive or manic symptoms from the second week until the end of the trial. Celecoxib was well tolerated with the exception of two subjects who dropped out of the study due to rash. Conclusions Our findings suggest that adjunctive treatment with celecoxib may produce a rapid-onset antidepressant effect in BD patients experiencing depressive or mixed episodes. Copyright (C) 2008 John Wiley & Sons, Ltd. C1 [Nery, Fabiano G.; Monkul, Emel S.; Hatch, John P.; Fonseca, Manoela; Frey, Benicio N.; Bowden, Charles L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Nery, Fabiano G.; Monkul, Emel S.; Fonseca, Manoela] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Nery, Fabiano G.] Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat,Bipolar Disorder Res Program, Sao Paulo, Brazil. [Hatch, John P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA. [Frey, Benicio N.] Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, RS, Brazil. [Frey, Benicio N.] Hosp Clin Porto Alegre, Bipolar Disorders Program, Porto Alegre, RS, Brazil. [Zunta-Soares, Giovana B.; Soares, Jair C.] Univ N Carolina, Sch Med, Ctr Excellence Res & Treatment Bipolar Disorders, Dept Psychiat, Chapel Hill, NC 27599 USA. RP Soares, JC (reprint author), Univ N Carolina, Sch Med, UNC Ctr Excellence Res & Treatment Bipolar Disord, Dept Psychiat, 10616 Neurosci Hosp,CB 7160, Chapel Hill, NC 27599 USA. EM jsoares@med.unc.edu FU NCRR NIH HHS [M01-RR-01346, RR-20571] NR 36 TC 139 Z9 146 U1 1 U2 6 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6222 J9 HUM PSYCHOPHARM CLIN JI Hum. Psychopharmacol.-Clin. Exp. PD MAR PY 2008 VL 23 IS 2 BP 87 EP 94 DI 10.1002/hup.912 PG 8 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology GA 282VY UT WOS:000254596500002 PM 18172906 ER PT J AU Simpson, R AF Simpson, Richard TI Making better decisions SO IEEE ENGINEERING IN MEDICINE AND BIOLOGY MAGAZINE LA English DT Article ID INFORMATION; JUDGMENTS; ACCURACY; OUTCOMES; CHOICE; PROBABILITY; CONFIDENCE; STRATEGIES; BIAS C1 VA Pittsburgh Healthcare, Human Engn Labs, Pittsburgh, PA 15260 USA. RP Simpson, R (reprint author), VA Pittsburgh Healthcare, Human Engn Labs, Pittsburgh, PA 15260 USA. EM ris20@pitt.edu NR 35 TC 2 Z9 3 U1 0 U2 1 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0739-5175 J9 IEEE ENG MED BIOL JI IEEE Eng. Med. Biol. Mag. PD MAR-APR PY 2008 VL 27 IS 2 BP 23 EP 28 DI 10.1109/EMB.200790794 PG 6 WC Engineering, Biomedical; Medical Informatics SC Engineering; Medical Informatics GA 277NT UT WOS:000254220900006 PM 18463018 ER PT J AU Seibel, EJ Carroll, RE Dominitz, JA Johnston, RS Melville, CD Lee, CM Seitz, SM Kimmey, MB AF Seibel, Eric J. Carroll, Robert E. Dominitz, Jason A. Johnston, Richard S. Melville, C. David Lee, Cameron M. Seitz, Steven M. Kimmey, Michael B. TI Tethered capsule endoscopy, a low-cost and high-performance alternative technology for the screening of esophageal cancer and Barrett's esophagus SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE biomedical image processing; biomedical imaging; cancer; medical diagnosis; optical imaging ID HIGH-GRADE DYSPLASIA; INTESTINAL METAPLASIA; ADENOCARCINOMA; ESOPHAGOSCOPY; DIAGNOSIS; PATTERNS; UTILITY; SYSTEM AB Esophageal cancer is currently the fastest growing cancer in the United States. To help combat the recent rise in morbidity, our laboratory has developed a low-cost tethered capsule endoscope system (TCE) aimed at improving early detection of esophageal cancer. The TCE contains a resonant fiberoptic laser scanner (1.6 mm O.D.) which fits into 6.4-mm easy-to-swallow capsule at the distal tip. The tethered portion contains a single mode optical fiber multiplexed to three laser diodes at the proximal end. This design offers two main advantages over current endoscope technology. First, because of its small size, the TCE can be swallowed with minimal patient discomfort, thereby obviating sedation. Second, by imaging via directed laser light, the TCE is strategically positioned to employ several burgeoning laser-based diagnostic technologies, such as narrow-band, hyperspectral, and fluorescence imaging. It is believed that the combination of such imaging techniques with novel biomarkers of dysplasia will greatly assist in identifying precancerous; conditions such as Barrett's esophagus (BE). As the probe is swallowed, the fiber scanner captures high resolution, wide-field color images of the gastroesophageal junction (500 lines at 0.05-mm resolution) currently at 15-Hz frame rate. Video images are recorded as the capsule is slowly retracted by its tether. Accompanying software generates panoramic images from the video output by mosaicing individual frames to aid in pattern recognition. This initial report describes the rationale for the unique TCE system design, results from preliminary testing in vitro and in vivo, and discussion on the merits of this new platform technology as a basis for developing a low-cost screening program for esophageal cancer. C1 [Seibel, Eric J.] Univ Washington, Dept Mech Engn, Human Photon Lab, Seattle, WA 98195 USA. [Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Seitz, Steven M.] Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA. [Kimmey, Michael B.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Seibel, EJ (reprint author), Univ Washington, Dept Mech Engn, Human Photon Lab, Box 352600, Seattle, WA 98195 USA. EM eseibel@u.washington.edu; carroll@eecs.berkeley.edu; jason.dominitz@va.gov; rsj3@u.washington.edu; dmelvill@u.washington.edu; lee101@u.washington.edu; seitz@cs.washington.edu; kimmey@u.washington.edu OI Dominitz, Jason/0000-0002-8070-7086 FU NCI NIH HHS [R21CA110184] NR 33 TC 37 Z9 39 U1 0 U2 5 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD MAR PY 2008 VL 55 IS 3 BP 1032 EP 1042 DI 10.1109/TBME.2008.915680 PG 11 WC Engineering, Biomedical SC Engineering GA 270PX UT WOS:000253733800020 PM 18334395 ER PT J AU Aubin, PM Cowley, MS Ledoux, WR AF Aubin, Patrick M. Cowley, Matthew S. Ledoux, William R. TI Gait simulation via a 6-DOF parallel robot with iterative learning control SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE gait simulation; iterative learning control; kinematics; kinetics; prosthetics ID CADAVER MODEL; STANCE PHASE; IN-VITRO AB We have developed a robotic gait simulator (RGS) by lever-aging a 6-degree of freedom parallel robot, with the goal of overcoming three significant challenges of gait simulation, including: 1) operating at near physiologically correct velocities; 2) inputting full scale ground reaction forces; and 3) simulating motion in all three planes (sagittal, coronal and transverse). The robot will eventually be employed with cadaveric specimens, but as a means of exploring the capability of the system, we have first used it with a prosthetic foot. Gait data were recorded from one transtibial amputee using a motion analysis system and force plate. Using the same prosthetic foot as the subject, the RGS accurately reproduced the recorded kinematics and kinetics and the appropriate vertical ground reaction force was realized with a proportional iterative learning controller. After six gait iterations the controller reduced the root mean square (RMS) error between the simulated and in situ vertical ground reaction force to 35 N during a 1.5 s simulation of the stance phase of gait with a prosthetic foot. This paper addresses the design, methodology and validation of the novel RGS. C1 [Aubin, Patrick M.; Cowley, Matthew S.; Ledoux, William R.] VA Puget Sound Hlth Care Syst, VA RR&D Ctr Excellence Limb Loss Prevent & Prosth, Seattle, WA 98108 USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Aubin, Patrick M.] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound Hlth Care Syst, VA RR&D Ctr Excellence Limb Loss Prevent & Prosth, 1660 S Columbian Way,MS 151, Seattle, WA 98108 USA. EM paubin@u.washington.edu; matthew.cowley@comcast.net; wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 6 TC 21 Z9 23 U1 3 U2 12 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD MAR PY 2008 VL 55 IS 3 BP 1237 EP 1240 DI 10.1109/TBME.2007.908072 PG 4 WC Engineering, Biomedical SC Engineering GA 270PX UT WOS:000253733800046 PM 18334421 ER PT J AU Evans, CT LaVela, SL Weaver, FM Priebe, M Sandford, P Niemiec, P Miskevics, S Parada, JP AF Evans, Charlesnika T. LaVela, Sherri L. Weaver, Frances M. Priebe, Michael Sandford, Paul Niemiec, Pamela Miskevics, Scott Parada, Jorge P. TI Epidemiology of hospital-acquired infections in veterans with spinal cord injury and disorder SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT 16th Annual Conference of the Society-for-Healthcare-Epidemiology-of-America CY MAR 18-21, 2006 CL Chicago, IL SP Soc Healthcare Epidemiol Amer ID INTENSIVE-CARE UNITS; NOSOCOMIAL INFECTIONS; REHABILITATION UNIT; CDC DEFINITIONS; SURVEILLANCE; PATHOGENS; LENGTH; IMPACT; STAY; COST AB Objective. To describe the epidemiology of hospital-acquired infections (HAIs) in veterans with spinal cord injury and disorder (SCI&D). Design. Retrospective medical record review. Setting. Midwestern Department of Veterans Affairs spinal cord injury center. Participants. A total of 226 patients with SCI&D hospitalized at least once during a 2-year period (October 1, 2001, through September 30, 2003). Results. A total of 549 hospitalizations were included in the analysis (mean duration of hospitalization, 33.7 days); an HAI occurred during 182 (33.2%) of these hospitalizations. A total of 657 HAIs occurred during 18,517 patient-days in the hospital ( incidence rate, 35.5 HAIs per 1,000 patient-days). Almost half of the 226 patients had at least 1 HAI; the mean number of HAIs among these patients was 6.0 HAIs per patient. The most common HAIs were urinary tract infection (164 [25.0%]of the 657 HAIs; incidence rate, 8.9 cases per 1,000 patient-days), bloodstream infection (111 [16.9%]; incidence rate, 6.0 cases per 1,000 patient-days), and bone and joint infection (103 [15.7%]; incidence rate, 5.6 cases per 1,000 patient-days). The most common culture isolates were gram-positive bacteria (1,082 [45.6%] of 2,307 isolates), including Staphylococcus aureus, and gram-negative bacteria (1,033 [43.6%] of isolates), including Pseudomonas aeruginosa. Multivariable regression demonstrated that predictors of HAI were longer length of hospital stay (P=.002), community-acquired infection (P=.007), and use of a urinary invasive device (P =.01) or respiratory invasive device (P =.04). Conclusions. The overall incidence of HAIs in persons with SCI&D was higher than that reported for other populations, confirming the increased risk of HAI in persons with spinal cord injury. The increased risk associated with longer length of stay and with community-acquired infection suggests that strategies are needed to reduce the duration of hospitalization and to effectively treat community-acquired infection, to decrease infection rates. There is significant room for improvement in reducing the incidence of HAIs in this population. C1 [Evans, Charlesnika T.; LaVela, Sherri L.; Weaver, Frances M.; Miskevics, Scott; Parada, Jorge P.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care,Dept Vet Affair, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA. [Niemiec, Pamela] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Infect Control Sect, Hines, IL 60141 USA. [LaVela, Sherri L.] Univ Illinois, Ctr Res Hlth & Aging, Chicago, IL USA. [Weaver, Frances M.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. [Weaver, Frances M.] Northwestern Univ, Inst Hlth Serv & Policy Res, Chicago, IL 60611 USA. [Parada, Jorge P.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. [Priebe, Michael] Mayo Clin, Rochester, MN USA. [Sandford, Paul] Med Coll Wisconsin, Clement J Zablocki Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Milwaukee, WI 53226 USA. RP Evans, CT (reprint author), Edward J Hines Jr Vet Affairs Hosp 151H, 5th Ave & Roosevelt Rd,POB 5000,Room D302, Hines, IL 60141 USA. EM Charlesnika.Evans@va.gov NR 32 TC 27 Z9 28 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAR PY 2008 VL 29 IS 3 BP 234 EP 242 DI 10.1086/527509 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 271VO UT WOS:000253817000006 PM 18248306 ER PT J AU Gasink, LB Singer, K Fishman, NO Holmes, WC Weiner, MG Bilker, WB Lautenbach, E AF Gasink, Leanne B. Singer, Karyn Fishman, Neil O. Holmes, William C. Weiner, Mark G. Bilker, Warren B. Lautenbach, Ebbing TI Contact isolation for infection control in hospitalized patients: Is patient satisfaction affected? SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; PSYCHOLOGICAL IMPACT AB The effects of contact isolation on patient satisfaction are unknown. We performed a cross-sectional survey and found that most patients lack education and knowledge regarding isolation but feel that it improves their care. In multivariable analysis, isolated patients were not less satisfied with inpatient care than were nonisolated patients. C1 [Gasink, Leanne B.; Singer, Karyn; Fishman, Neil O.; Lautenbach, Ebbing] Univ Penn, Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Holmes, William C.; Weiner, Mark G.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Holmes, William C.; Bilker, Warren B.; Lautenbach, Ebbing] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Dept Med, Philadelphia, PA 19104 USA. [Gasink, Leanne B.; Holmes, William C.; Bilker, Warren B.; Lautenbach, Ebbing] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Holmes, William C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Gasink, LB (reprint author), Hosp Univ Penn, 3400 Spruce St,3 Silverstein Pavilion,Suite E, Philadelphia, PA 19104 USA. EM leanne.gasink@uphs.upenn.edu FU NIAID NIH HHS [T32 AI055435] NR 10 TC 30 Z9 30 U1 1 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAR PY 2008 VL 29 IS 3 BP 275 EP 278 DI 10.1086/527508 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 271VO UT WOS:000253817000012 PM 18205528 ER PT J AU Sharma, N Thomas, S Ho, L Reyes, DC AF Sharma, Naresh Thomas, Sunil Ho, Lap Reyes, Dillenia C. TI Immunomodulation with glatiramer acetate prevents long-term inflammatory pain SO INTERNATIONAL JOURNAL OF NEUROSCIENCE LA English DT Article DE cyclooxygenase; fractalkine; glatiramer acetate; pain ID PROINFLAMMATORY CYTOKINE EXPRESSION; DORSAL-ROOT GANGLIA; CYCLOOXYGENASE INHIBITORS; NEUROTROPHIC FACTOR; NERVE INJURY; SPINAL-CORD; T-CELLS; RECEPTOR; FRACTALKINE; ACTIVATION AB The potential application of glatiramer acetate (GA) therapy as a safe pharmacological treatment for the attenuation or prevention of long-term inflammatory pain in a rat model was explored. Peripheral inflammatory pain was induced by an injection of Complete Freund's Adjuvant (CFA) into the plantar surface of the hind paw. Genome-wide DNA microarray studies were used to survey molecular mechanisms involved in long-term GA analgesic responses. Administration of a single or double subcutaneous injection of GA before, or immediately after, intraplantar injection of pro-inflarnmatory CFA significantly attenuated allodynia and hyperalgesic pain responses up to similar to 3 weeks after CFA treatment. These beneficial effects of GA immunization therapy coincided with the attenuation of expression of the chemotactic fractalkine chemokine (CX3CL 1) in the dorsal horn of the lumbar spinal cord (L4-L5) in response to CFA treatment, assessed by DNA microarray and confirmed immunocytochemically (ICC). This study is consistent with the hypothesis that a novel mechanism through which GA immunization therapy may beneficially influence long-term allodynia and hyperalgesia is through central regulation of fractalkine-mediated responses. C1 [Sharma, Naresh; Thomas, Sunil; Reyes, Dillenia C.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Ho, Lap] James J Peters Vet Affairs Med Ctr, Geriat Res & Clin Ctr, Bronx, NY USA. RP Sharma, N (reprint author), Mt Sinai Sch Med, Dept Psychiat, E Bldg,Room 10-70 1 Levy Pl, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu NR 25 TC 3 Z9 3 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0020-7454 J9 INT J NEUROSCI JI Int. J. Neurosci. PD MAR PY 2008 VL 118 IS 3 BP 433 EP 453 DI 10.1080/00207450701849018 PG 21 WC Neurosciences SC Neurosciences & Neurology GA 270KV UT WOS:000253720600010 PM 18300014 ER PT J AU Oesterle, EC Campbell, S Taylor, RR Forge, A Hume, CR AF Oesterle, Elizabeth C. Campbell, Sean Taylor, Ruth R. Forge, Andrew Hume, Clifford R. TI Sox2 and Jagged1 expression in normal and drug-damaged adult mouse inner ear SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY LA English DT Review DE ototoxicity; aminoglycoside; cochlea; vestibular; supporting cell; hair cell ID HAIR CELL REGENERATION; AVIAN AUDITORY EPITHELIUM; CALCIUM-BINDING PROTEINS; EMBRYONIC STEM-CELLS; GROWTH-FACTOR-ALPHA; K-CL COTRANSPORTER; SENSORY EPITHELIA; ETHACRYNIC-ACID; STRIA VASCULARIS; HEARING-LOSS AB Inner ear hair cells detect environmental signals associated with hearing, balance, and body orientation. In humans and other mammals, significant hair cell loss leads to irreversible hearing and balance deficits, whereas hair cell loss in nonmammalian vertebrates is repaired by the spontaneous generation of replacement hair cells. Research in mammalian hair cell regeneration is hampered by the lack of in vivo damage models for the adult mouse inner ear and the paucity of cell-type-specific markers for non-sensory cells within the sensory receptor epithelia. The present study delineates a protocol to drug damage the adult mouse auditory epithelium (organ of Corti) in situ and uses this protocol to investigate Sox2 and Jagged1 expression in damaged inner ear sensory epithelia. In other tissues, the transcription factor Sox2 and a ligand member of the Notch signaling pathway, Jagged1, are involved in regenerative processes. Both are involved in early inner ear development and are expressed in developing support cells, but little is known about their expressions in the adult. We describe a nonsurgical technique for inducing hair cell damage in adult mouse organ of Corti by a single high-dose injection of the aminoglycoside kanamycin followed by a single injection of the loop diuretic furosemide. This drug combination causes the rapid death of outer hair cells throughout the cochlea. Using immunocytochemical techniques, Sox2 is shown to be expressed specifically in support cells in normal adult mouse inner ear and is not affected by drug damage. Sox2 is absent from auditory hair cells, but is expressed in a subset of vestibular hair cells. Double-labeling experiments with Sox2 and calbindin suggest Sox2-positive hair cells are Type II. Jagged1 is also expressed in support cells in the adult ear and is not affected by drug damage. Sox2 and Jagged1 may be involved in the maintenance of support cells in adult mouse inner ear. C1 [Oesterle, Elizabeth C.; Campbell, Sean; Hume, Clifford R.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Virginia Merrill Bloedel Hearing Res Ctr, Seattle, WA 98195 USA. [Taylor, Ruth R.; Forge, Andrew] UCL Ear Inst, Ctr Auditory Res, London WC1X 8EE, England. [Hume, Clifford R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Oesterle, EC (reprint author), Univ Washington, Dept Otolaryngol Head & Neck Surg, Virginia Merrill Bloedel Hearing Res Ctr, CHDD CD176 Box 357923, Seattle, WA 98195 USA. EM oesterle@u.washington.edu FU Action on Hearing Loss [G27]; NICHD NIH HHS [P30 HD002274, P30HD002274]; NIDCD NIH HHS [P30 DC004661, P30DC04661, R01 DC003944, R01DC03944] NR 139 TC 99 Z9 103 U1 2 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1525-3961 J9 JARO-J ASSOC RES OTO JI JARO PD MAR PY 2008 VL 9 IS 1 BP 65 EP 89 DI 10.1007/s10162-007-0106-7 PG 25 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 275CA UT WOS:000254048300006 PM 18157569 ER PT J AU Gupta, RS Zhang, XY Sharp, LK Shannon, JJ Weiss, KB AF Gupta, Ruchi S. Zhang, Xingyou Sharp, Lisa K. Shannon, John J. Weiss, Kevin B. TI Geographic variability in childhood asthma prevalence in Chicago SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE asthma; children; disparities; neighborhood variability; asthma prevalence ID SCHOOL-AGE-CHILDREN; INNER-CITY ASTHMA; HOUSE-DUST MITE; SOCIOECONOMIC-STATUS; AIR-POLLUTION; BIRTH-COHORT; ENVIRONMENTAL EXPOSURE; LOGISTIC-REGRESSION; ALLERGEN EXPOSURE; TOBACCO-SMOKE AB Background: Childhood asthma prevalence has been shown to be higher in urban communities overall without an understanding of differences by neighborhood. Objective: To characterize the geographic variability of childhood asthma prevalence among neighborhoods in Chicago. Methods: Asthma screening was conducted among children attending 105 Chicago schools as part of the Chicago Initiative to Raise Asthma Health Equity. Additional child information included age, sex, race/ethnicity, and household members with asthma. Surveys were geocoded and linked with neighborhoods. Neighborhood information on race, education, and income was based on 2000 census data. Bivariate and multilevel analyses were performed. Results: Of the 48,917 surveys, 41,255 (84.3%) were geocoded into 287 neighborhoods. Asthma prevalence among all children was 12.9%. Asthma rates varied among neighborhoods from 0% to 44% (interquartile range, 8% to 24%). Asthma prevalence (mean, SD, range) in predominantly black neighborhoods (19.9, +/- 7, 4% to 44%) was higher than in predominantly white neighborhoods (11.4, +/- 4.7, 2% to 30%) and predominantly Hispanic neighborhoods (12.1, +/- 6.8, 0% to 29%). Although sex, age, household members with asthma, and neighborhood income significantly affected asthma prevalence, they did not explain the differences seen between neighborhoods. Race explained a significant proportion (about 80%) but not all of this variation. Conclusion: Childhood asthma prevalence varies widely by neighborhood within this urban environment. Adjacent areas in Chicago were identified with significantly different asthma prevalence. A better understanding of the effect of neighborhood characteristics may lend insight into potential interventions to reduce childhood asthma. C1 [Gupta, Ruchi S.] Childrens Mem Hosp, Smith Child Hlth Res Program, Chicago, IL 60614 USA. [Gupta, Ruchi S.; Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA. [Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA. [Zhang, Xingyou] Amer Acad Family Phys, Policy Studies Family Med & Primary Care, Robert Graham Ctr, Washington, DC USA. [Sharp, Lisa K.] Univ Illinois, Sect Hlth Promot, Dept Med, Chicago, IL 60680 USA. [Shannon, John J.] Cook Cty Hosp, Dept Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Weiss, Kevin B.] US Dept Vet Affairs, Midwest Ctr Hlth Serv & Policy Res, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Gupta, RS (reprint author), Childrens Mem Hosp, Smith Child Hlth Res Program, 2300 Childrens Plaza,Box 157, Chicago, IL 60614 USA. EM r-gupta@northwestern.edu FU NHLBI NIH HHS [5U01 HL072478-05]; NICHD NIH HHS [K12 HD052902] NR 55 TC 43 Z9 44 U1 5 U2 11 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAR PY 2008 VL 121 IS 3 BP 639 EP 645 DI 10.1016/j.jaci.2007.11.036 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA 273GR UT WOS:000253918900015 PM 18243285 ER PT J AU Darouiche, RO Mansouri, MD Gawande, PV Madhyastha, S AF Darouiche, Rabih O. Mansouri, Mohammad D. Gawande, Purushottam V. Madhyastha, Srinivasa TI Efficacy of combination of chlorhexidine and protamine sulphate against device-associated pathogens SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE device-related infections; antimicrobial activity; Escherichia coli ID STAPHYLOCOCCUS-AUREUS; SURGICAL IMPLANTS; BIOFILM FORMATION; URINARY CATHETER; CONTROLLED TRIAL; IN-VIVO; INFECTIONS; INHIBITION; BACTERIA; CELLS AB Objectives: The objectives of this study were to examine: (i) the potential in vitro synergy of combining protamine sulphate (PS) with chlorhexidine (CHX); (ii) the in vitro spectrum and durability of antimicrobial activity of CHX + PS-coated catheters; and (iii) the in vivo efficacy of CHX + PS-coated catheters in comparison with silver-hydrogel-coated and uncoated catheters. Methods: The potential synergistic antimicrobial and antibiofilm activities of CHX and PS were investigated in vitro by the MIC and biofilm assays. The spectrum and durability of antimicrobial activity of CHX + PS-coated catheters were studied in vitro by using a serial plate transfer method. The in vivo efficacy of CHX + PS-coated catheters was assessed in a rabbit model against Escherichia coli. Results: In vitro studies showed that the combination of CHX + PS has a synergistic inhibitory effect on E. coli and provides a significant synergistic antibiofilm and antimicrobial activity against E. coli, Pseudomonas aeruginosa and Staphylococcus epidermidis. Furthermore, catheters coated with CHX + PS provided a broad-spectrum and enduring in vitro antimicrobial activity over a 10 day period. The in vivo efficacy study demonstrated that subcutaneously implanted CHX + PS-coated catheters in rabbits are significantly less likely to become colonized (2/28 = 7%) than either silver-hydrogel-coated (25/28 = 89%; P < 0.001) or uncoated catheters (18/28 = 64%; P < 0.001) by E. coli. Conclusions: The synergistic, broad-spectrum and durable in vitro activity of the CHX + PS combination and the robust in vivo efficacy of catheters coated with this unique composition encourage clinical evaluation of this innovative approach. C1 [Darouiche, Rabih O.; Mansouri, Mohammad D.] Michael E Debakey Vet Affairs Med Ctr, Ctr Prostheses Infect & Infect Dis Sect, Houston, TX 77030 USA. [Darouiche, Rabih O.; Mansouri, Mohammad D.] Baylor Coll Med, Houston, TX 77030 USA. [Gawande, Purushottam V.; Madhyastha, Srinivasa] Kane Biotech Inc, Winnipeg, MB R3T 6C6, Canada. RP Darouiche, RO (reprint author), Michael E Debakey Vet Affairs Med Ctr, Ctr Prostheses Infect & Infect Dis Sect, Houston, TX 77030 USA. EM rdarouiche@aol.com RI Gawande, Purushottam/C-5487-2014 OI Gawande, Purushottam/0000-0001-8675-9293 NR 37 TC 36 Z9 36 U1 0 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD MAR PY 2008 VL 61 IS 3 BP 651 EP 657 DI 10.1093/jac/dkn006 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 267DX UT WOS:000253490800028 PM 18258612 ER PT J AU Kratz, M Purnell, JQ Breen, PA Thomas, KK Utzschneider, KM Carr, DB Kahn, SE Hughes, JP Rutledge, EA Van Yserloo, B Yukawa, M Weigle, DS AF Kratz, Mario Purnell, Jonathan Q. Breen, Patricia A. Thomas, Katherine K. Utzschneider, Kristina M. Carr, Darcy B. Kahn, Steven E. Hughes, James P. Rutledge, Elizabeth A. Van Yserloo, Brian Yukawa, Michi Weigle, David S. TI Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; HIV PROTEASE INHIBITORS; INSULIN-RESISTANCE; INFECTED PATIENTS; FAT DISTRIBUTION; LIPODYSTROPHY; DIFFERENTIATION; SENSITIVITY; ADIPOCYTES; RITONAVIR AB Context: The expression of adipogenic genes in sc adipose tissue has been reported to be lower among patients with HIV-associated lipoatrophy than HIV-uninfected controls. It is unclear whether this is a result or cause of lipoatrophy. Objective: The objective of the study was to investigate the temporal relationships among changes in adipogenic gene expression in sc adipose tissue and changes in body fat distribution and metabolic complications in HIV-infected subjects on antiretroviral therapy. Design: This was a prospective longitudinal study. Setting: The study was conducted at HIV clinics in Seattle, Washington. Participants: The study population included 31 HIV-infected and 12 control subjects. Interventions: Subjects were followed up for 12 months after they initiated or modified their existing antiretroviral regimen. Main Outcome Measures: Changes in body composition, plasma lipids, insulin sensitivity, and gene expression in sc abdominal and thigh adipose tissue. Results: Subjects who developed lipoatrophy (n = 10) had elevated fasting triglycerides [3.16 (SD 2.79) mmol/liter] and reduced insulin sensitivity as measured by frequently sampled iv glucose tolerance test [1.89 (SD 1.27) X 10(-4) min(-1)/mu U center dot ml] after 12 months, whereas those without lipoatrophy (n = 21) did not show any metabolic complications [triglycerides 1.32 (SD 0.58) mmol/liter, P = 0.01 vs. lipoatrophy; insulin sensitivity 3.52 (SD 1.91) X 10(-4) min(-1)/mu U center dot ml, P = 0.01 vs. lipoatrophy]. In subjects developing lipoatrophy, the expression of genes involved in adipocyte differentiation, lipid uptake, and local cortisol production in thigh adipose tissue was significantly reduced already at the 2-month visit, several months before any loss of extremity fat mass was evident. Conclusions: In HIV-infected subjects, lipoatrophy is associated with elevated fasting triglycerides and insulin resistance and might be caused by a direct or indirect effect of antiretroviral drugs on sc adipocyte differentiation. C1 [Kratz, Mario; Breen, Patricia A.; Utzschneider, Kristina M.; Kahn, Steven E.; Weigle, David S.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98109 USA. [Thomas, Katherine K.] Univ Washington, Dept Allergy & Infect Dis, Seattle, WA 98109 USA. [Carr, Darcy B.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98109 USA. [Yukawa, Michi] Univ Washington, Dept Gerontol & Geriat Med, Seattle, WA 98109 USA. [Rutledge, Elizabeth A.; Van Yserloo, Brian] Vet Affairs Puget Sound Hlth Care Syst, Dept Biostat, Diabet Endocrinol Res Ctr, Seattle, WA 98108 USA. [Purnell, Jonathan Q.] Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol Diabet & Clin Nutr, Portland, OR 97239 USA. RP Kratz, M (reprint author), Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Mail Stop M4-B402,1100 Fairview Ave N, Seattle, WA 98109 USA. EM mkratz@fhcrc.org OI Kahn, Steven/0000-0001-7307-9002 FU NCRR NIH HHS [M01-RR-00037, M01 RR000037]; NIDDK NIH HHS [1 K24 DK02860, 1 R01 DK55460, 5-P30-DK17047, K24 DK002860, P30 DK017047, P30 DK035816, P30-DK035816, R01 DK055460] NR 26 TC 12 Z9 12 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 2008 VL 93 IS 3 BP 959 EP 966 DI 10.1210/jc.2007-0197 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 271XT UT WOS:000253822700048 PM 18089690 ER PT J AU Bagby, GC AF Bagby, Grover C. TI Discovering early molecular determinants of leukemogenesis SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Editorial Material ID SEVERE CONGENITAL NEUTROPENIA; UNFOLDED PROTEIN RESPONSE; FANCONI-ANEMIA; LEUKEMIC CLONES; MUTATIONS; APOPTOSIS; ELASTASE; INDUCE; CELLS; VIVO AB Truncating mutations of the G-CSF receptor are found during disease course in nearly half of all patients with severe congenital neutropenia. In this issue of the JCI, Liu et al. demonstrate that these mutations confer a competitive clonal advantage upon HSCs in mice and that the advantage is conditional because it is observed only in the presence of the ligand G-CSF (see the related article beginning on page 946). Once activated, the mutant receptor requires the function of Stat5 in order to effect clonal expansion of this stem cell population. The results support the notion that early molecular steps in this and other neoplastic processes represent adaptations in which, through somatic mutations, "unfit" stem cells gain a measure of fitness by altering their relationships with their microenvironment. C1 [Bagby, Grover C.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Bagby, Grover C.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. [Bagby, Grover C.] NW Vet Affairs Canc Res Ctr, Portland, OR USA. RP Bagby, GC (reprint author), Portland VA Med Ctr, Mol Oncol Res Lab, Mailstop R&D2,Bldg 103,Room E221B,3710 SW Vet Hos, Portland, OR 97239 USA. EM grover@ohsu.edu OI Bagby, Grover/0000-0001-6830-2046 FU NHLBI NIH HHS [P01 HL048546, R01 HL072321] NR 20 TC 7 Z9 8 U1 0 U2 0 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD MAR PY 2008 VL 118 IS 3 BP 847 EP 850 DI 10.1172/JCI35109 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 269JX UT WOS:000253646400009 PM 18292805 ER PT J AU Gorelick, F Pandol, S Thrower, E AF Gorelick, Fred Pandol, Stephen Thrower, Edwin TI Protein kinase C in the pancreatic acinar cell SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article; Proceedings Paper CT 2nd International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis CY OCT 18-19, 2007 CL Kobe, JAPAN SP Japanese Soc Gastroenterol, Japan Soc Hepatol DE alcohol; cholecystokinin; chymotrypsin; ethanol; protease ID KAPPA-B ACTIVATION; INDUCED ZYMOGEN ACTIVATION; PKC-DELTA; CHOLECYSTOKININ; CERULEIN; PHOSPHORYLATION; EXOCYTOSIS; ISOFORMS; CAMP; TRANSLOCATION AB Pathological activation of selective signaling molecules within the pancreatic acinar cell mediates the development of acute pancreatitis. Some of the key early acinar cell events include activation of proteases, inhibition of apical secretion, and elaboration of inflammatory mediators. Previous studies have shown that supraphysiological concentrations of cholecystokinin (CCK) that can cause pancreatitis in vivo, also initiate these pathological responses in dispersed groups of acinar cells (acini). Protein kinase C (PKC) regulates many cellular events and a role for this family of signaling molecules has been described in some of the pathological responses of pancreatitis. Notably, ethanol can activate specific PKC isoforms and sensitize the acinar cells to the pathological effects of CCK. Our preliminary studies in isolated pancreatic acini and a cell-free reconstitution system suggest that PKC can mediate protease activation in the acinar cell. These findings may be relevant to the pathogenesis of pancreatitis from alcohol and other etiologies. C1 [Gorelick, Fred; Thrower, Edwin] Connecticut VA Healthcare, Dept Internal Med, West Haven, CT USA. [Gorelick, Fred; Thrower, Edwin] Yale Univ, West Haven, CT USA. [Pandol, Stephen] VA Greater Los Angeles, Los Angeles, CA USA. RP Thrower, E (reprint author), Yale Univ, Sch Med, VA Healthcare Syst CT, Gl Res Lab, Bldg 4,950 Campbell Ave, West Haven, CT 06516 USA. EM edwin.thrower@yale.edu NR 31 TC 13 Z9 14 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD MAR PY 2008 VL 23 SU 1 BP S37 EP S41 DI 10.1111/j.1440-1746.2007.05282.x PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 284VT UT WOS:000254735700007 PM 18336661 ER PT J AU Odinokova, IV Sung, KF Mareninova, OA Hermann, K Gukovsky, I Gukovskaya, AS AF Odinokova, Irina V. Sung, Kai-Feng Mareninova, Olga A. Hermann, Kip Gukovsky, Ilya Gukovskaya, Anna S. TI Mitochondrial mechanisms of death responses in pancreatitis SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article; Proceedings Paper CT 2nd International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis CY OCT 18-19, 2007 CL Kobe, JAPAN SP Japanese Soc Gastroenterol, Japan Soc Hepatol DE apoptosis; calcium; cytochrome c release; mitochondrial membrane potential; necrosis; pancreatic mitochondria; permeability transition pore; reactive oxygen species ID PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; ACID ETHYL-ESTERS; CELL-DEATH; ACINAR-CELLS; MEMBRANE PERMEABILIZATION; CYCLOPHILIN-D; EARLY EVENTS; APOPTOSIS; NECROSIS AB Pancreatitis is a severe and frequently lethal disorder, a major cause of which is alcohol abuse. Parenchymal cell death is a major complication of pancreatitis. In experimental models of acute pancreatitis, acinar cells have been shown to die through both necrosis and apoptosis, the two principal pathways of cell death. The severity of experimental acute pancreatitis correlates directly with the extent of necrosis and inversely with apoptosis. Thus, understanding the regulation of apoptosis and necrosis is becoming exceedingly important in investigations of the pathogenesis and treatment of pancreatitis. Over the past decade, the mitochondria have emerged as a master regulator of cell death in various physiological and pathological processes. Release of mitochondrial cytochrome c into the cytosol is a central event in apoptosis, whereas mitochondrial depolarization resulting in ATP depletion leads to necrosis. The present review focuses on the mitochondrial mechanisms of death responses in pancreatitis, with emphasis on mitochondrial membrane permeabilization and its role in the balance between apoptosis and necrosis in acute pancreatitis, and alcohol's effects on death responses of pancreatitis. C1 [Odinokova, Irina V.; Sung, Kai-Feng; Mareninova, Olga A.; Hermann, Kip; Gukovsky, Ilya; Gukovskaya, Anna S.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, USC Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90073 USA. RP Gukovskaya, AS (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, USC Res Ctr Alcohol Liver & Pancreat Dis, 11301 Wilshire Blvd,Blg 258,Rm 340, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu NR 48 TC 16 Z9 18 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD MAR PY 2008 VL 23 SU 1 BP S25 EP S30 DI 10.1111/j.1440-1746.2007.05271.x PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 284VT UT WOS:000254735700005 PM 18336659 ER PT J AU Defonseka, AM Cheng, ET AF Defonseka, A. M. Cheng, E. T. TI A new form of diabetic neuropathy: Metformin-induced vitamin B12 deficiency SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Defonseka, A. M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Cheng, E. T.] Greater Los Angeles Vet Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 102 EP 102 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100037 ER PT J AU Mendenhall, DA Altman, L Bean-Mayberry, B Dumitru, D AF Mendenhall, D. A. Altman, L. Bean-Mayberry, B. Dumitru, D. TI Acute onset virilism - A possibly hairy diagnosis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Mendenhall, D. A.] W Los Angeles Vet Affairs Med Ctr, Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Altman, L.; Dumitru, D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bean-Mayberry, B.] VA Greater Los Angeles Hlth Serv Res & Dev, Ctr Excellence, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 112 EP 112 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100065 ER PT J AU Rhee, CM Cedfeldt, AS AF Rhee, C. M. Cedfeldt, A. S. TI Blinded by the bladder SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Rhee, C. M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Cedfeldt, A. S.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 125 EP 125 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100100 ER PT J AU Appelle, NA Shunk, RL Kohlwes, JR AF Appelle, N. A. Shunk, R. L. Kohlwes, J. R. TI Accuracy and improvement in ekg interpretation by internal medicine housestaff: A classroom-based approach for teaching EKG interpretation SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Appelle, N. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shunk, R. L.] UCSF, VAMC, San Francisco, CA USA. [Kohlwes, J. R.] UCSF, San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 193 EP 194 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100288 ER PT J AU Bray-Hall, ST Abraham, A Aagaard, EM AF Bray-Hall, S. T. Abraham, A. Aagaard, E. M. TI Development of a transitions in care curriculum for medical students SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Bray-Hall, S. T.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Abraham, A.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Aagaard, E. M.] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 198 EP 199 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100301 ER PT J AU Carpenter, LE Chang, A Johnston, B Lee, K Singh, B Chou, CL AF Carpenter, L. E. Chang, A. Johnston, B. Lee, K. Singh, B. Chou, C. L. TI Longitudinal groups across clerkships for third-year medical students enhance reflection about professional development SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Carpenter, L. E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Chang, A.; Johnston, B.; Lee, K.; Singh, B.; Chou, C. L.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 205 EP 205 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100317 ER PT J AU Halvorson, S Cedfeldt, AS AF Halvorson, S. Cedfeldt, A. S. TI "Rational RX: Mind over marketing" a freely accessible, web-based curriculum for internal medicine residents SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Halvorson, S.] Oregon Hlth & Sci Univ, Portland VA Res Fdn, Portland, OR 97201 USA. [Cedfeldt, A. S.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 216 EP 216 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100347 ER PT J AU Volpp, KG John, L Norton, L Fassbender, J Troxel, A Loewenstein, GF AF Volpp, K. G. John, L. Norton, L. Fassbender, J. Troxel, A. Loewenstein, G. F. TI A randomized controlled trial of strategies for weight loss SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Volpp, K. G.; Norton, L.] Univ Penn, Sch Med, CHERP, Philadelphia VAMC, Philadelphia, PA 19104 USA. [Volpp, K. G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [John, L.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 239 EP 239 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100411 ER PT J AU Singh, H Petersen, LA Daci, K Collins, C Petersen, NJ Shethia, A El-Serag, H AF Singh, H. Petersen, L. A. Daci, K. Collins, C. Petersen, N. J. Shethia, A. El-Serag, H. TI An evaluation of missed opportunities in colorectal cancer diagnosis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Singh, H.; Petersen, L. A.; Petersen, N. J.; Shethia, A.; El-Serag, H.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Daci, K.; Collins, C.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 247 EP 247 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100432 ER PT J AU Steinman, M Yang, K Byron, SC Maselli, J Gonzales, R AF Steinman, M. Yang, K. Byron, S. C. Maselli, J. Gonzales, R. TI Antibiotic utilization among health plans in the united states: Implications for quality, cost, and public health SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Steinman, M.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Byron, S. C.] Natl Comm Qual Assurance, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 247 EP 247 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100433 ER PT J AU Lorenz, KA Sherbourne, CD Shugarman, LR Meredith, LS Rubenstein, LV Wen, L Cohen, A Goebel, J Lanto, A Asch, SM AF Lorenz, K. A. Sherbourne, C. D. Shugarman, L. R. Meredith, L. S. Rubenstein, L. V. Wen, L. Cohen, A. Goebel, J. Lanto, A. Asch, S. M. TI Are primary care physicians more likely to address painful symptoms in seriously ill patients? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Lorenz, K. A.; Rubenstein, L. V.; Asch, S. M.] Univ Calif Los Angeles, RAND Corp, VA Greater Los Angeles, Los Angeles, CA USA. [Sherbourne, C. D.; Shugarman, L. R.; Meredith, L. S.] RAND Corp, Santa Monica, CA USA. [Wen, L.] VA Long Beach, Long Beach, CA USA. [Goebel, J.] CSULB, Sch Nursing, Long Beach, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 249 EP 249 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100439 ER PT J AU Pollack, C Mallya, G Polsky, D AF Pollack, C. Mallya, G. Polsky, D. TI Are physicians ready to practice in a consumer-driven environment? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Pollack, C.] Univ Penn, Philadelphia VA Med Ctr, RWJ Clin Scholar, Philadelphia, PA 19104 USA. [Polsky, D.] Philadelphia VAMC CHERP, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 249 EP 249 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100438 ER PT J AU Bokhour, BG Solomon, JL Knapp, H Asch, SM Gifford, AL AF Bokhour, B. G. Solomon, J. L. Knapp, H. Asch, S. M. Gifford, A. L. TI Barriers and facilitators to routine HIV testing in VA primary care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Bokhour, B. G.; Solomon, J. L.; Gifford, A. L.] ENRM VA Med Ctr, Bedford, MA USA. [Knapp, H.; Asch, S. M.] Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 256 EP 256 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100457 ER PT J AU Shackelford, JM Ling, B AF Shackelford, J. M. Ling, B. TI Colorectal cancer screening among US military veterans: Have we reached a ceiling? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Shackelford, J. M.; Ling, B.] Univ Pittsburgh, Med Ctr, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 267 EP 268 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100489 ER PT J AU Bryson, CL Sharp, ND Perkins, M Blough, D Liu, F Boyko, EJ Maciejewski, ML AF Bryson, C. L. Sharp, N. D. Perkins, M. Blough, D. Liu, F. Boyko, E. J. Maciejewski, M. L. TI Combined medication adherence to cardiovascular risk reduction therapy SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Bryson, C. L.; Sharp, N. D.; Perkins, M.; Liu, F.] Univ Washington, Hlth Serv Res & Dev Ctr Excellence, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Maciejewski, M. L.] Durham VAMC, Hlth Serv Res & Dev, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 268 EP 268 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100490 ER PT J AU Singh, H Mani, S Espadas, D Franklin, V Petersen, LA AF Singh, H. Mani, S. Espadas, D. Franklin, V. Petersen, L. A. TI Communication ambiguity in an advanced computerized order-entry system SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Singh, H.; Mani, S.; Espadas, D.; Petersen, L. A.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Singh, H.; Mani, S.; Espadas, D.; Petersen, L. A.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 268 EP 268 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100491 ER PT J AU Ling, B Trauth, JM Fine, MJ Mor, MK Braddock, CH Bereknyei, S Weissfeld, J Schoen, R Whittle, J AF Ling, B. Trauth, J. M. Fine, M. J. Mor, M. K. Braddock, C. H. Bereknyei, S. Weissfeld, J. Schoen, R. Whittle, J. TI Communications on colorectal and prostate cancer screening: Are patient perceptions consistent with actual information exchanged SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Mor, M. K.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Ling, B.; Fine, M. J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Mor, M. K.] Pittsburgh VA Hlth Care Syst, Pittsburgh, PA USA. [Braddock, C. H.; Bereknyei, S.] Stanford Univ, Palo Alto, CA 94304 USA. [Whittle, J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 269 EP 269 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100492 ER PT J AU Volpp, KG Rosenbaum, P Rosen, A Romano, PS Bellini, LM Itani, KM Cen, L Shoshan, O Halenar, M Silber, JH AF Volpp, K. G. Rosenbaum, P. Rosen, A. Romano, P. S. Bellini, L. M. Itani, K. M. Cen, L. Shoshan, O. Halenar, M. Silber, J. H. TI Did high-risk patients experience worse outcomes under ACGME duty hour rules? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Volpp, K. G.] Univ Penn, Sch Med, CHERP, VAMC, Philadelphia, PA 19104 USA. [Rosenbaum, P.] Univ Penn Wharton Sch, Philadelphia, PA USA. [Rosen, A.] Boston Univ, Boston, MA 02215 USA. [Rosen, A.] Bedford VA, Boston, MA 02215 USA. [Romano, P. S.] Univ Calif Davis, Sacramento, CA 95817 USA. [Bellini, L. M.] Univ Penn, Philadelphia, PA 19104 USA. [Cen, L.] VAMC, CHERP, Philadelphia, PA USA. [Shoshan, O.; Halenar, M.; Silber, J. H.] Childrens Hosp Philadelphia, COR, Philadelphia, PA 19104 USA. [Silber, J. H.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Silber, J. H.] Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. RI Romano, Patrick/N-4225-2014 OI Romano, Patrick/0000-0001-6749-3979 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 280 EP 281 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100522 ER PT J AU Haskell, SG Bean-Mayberry, B Gordon, K AF Haskell, S. G. Bean-Mayberry, B. Gordon, K. TI Discontinuing post-menopausal hormone therapy: Does taper versus abrupt withdrawal matter? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Haskell, S. G.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Bean-Mayberry, B.] VA Greater Los Angeles Hlth Serv Res & Dev, Los Angeles, CA USA. [Gordon, K.] VA Connecticut, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 282 EP 283 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100527 ER PT J AU Hausmann, L Kresevic, D Cohen, PZ Grant, R Kwoh, C Mor, M Geng, M Ling, BS Ibrahim, SA AF Hausmann, L. Kresevic, D. Cohen, P. Z. Grant, R. Kwoh, C. Mor, M. Geng, M. Ling, B. S. Ibrahim, S. A. TI Doctor-patient communication and the racial disparity in recommendations for joint replacement SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Hausmann, L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kresevic, D.; Grant, R.] Case Western Reserve Univ Hosp, Med Ctr, Louis Stokes DVA Med Ctr, Cleveland, OH 44106 USA. [Cohen, P. Z.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Kwoh, C.; Mor, M.; Geng, M.; Ling, B. S.; Ibrahim, S. A.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 287 EP 288 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100539 ER PT J AU Pollack, C Groeneveld, P Chantal, M Putt, M Liao, K Armstrong, K AF Pollack, C. Groeneveld, P. Chantal, M. Putt, M. Liao, K. Armstrong, K. TI Does hospital racial composition affect the treatment men receive for localized prostate cancer? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Pollack, C.] Philadelphia VA Hosp, Philadelphia, PA USA. [Groeneveld, P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Chantal, M.; Putt, M.; Liao, K.; Armstrong, K.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 289 EP 289 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100544 ER PT J AU Bean-Mayberry, B Yano, EM Mor, MK Wang, M Fine, MJ AF Bean-Mayberry, B. Yano, E. M. Mor, M. K. Wang, M. Fine, M. J. TI Does race affect cancer screening among women in VA care? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Bean-Mayberry, B.; Yano, E. M.; Wang, M.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. [Mor, M. K.; Fine, M. J.] VA Pittsburgh Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Mor, M. K.; Fine, M. J.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 291 EP 291 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100549 ER PT J AU Cook, RL Mcginnis, KA Fiellin, DA Goulet, JL Gordon, AJ Samet, J Mattocks, K Crystal, S Kraemer, KL Braithwaite, S Rodriquez-Barradas, M Justice, AC AF Cook, R. L. Mcginnis, K. A. Fiellin, D. A. Goulet, J. L. Gordon, A. J. Samet, J. Mattocks, K. Crystal, S. Kraemer, K. L. Braithwaite, S. Rodriquez-Barradas, M. Justice, A. C. TI Erectile dysfunction drug use and risky sexual behavior in HIV+ and HIV- men SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Cook, R. L.] Univ Florida, Gainesville, FL USA. [Mcginnis, K. A.; Gordon, A. J.; Kraemer, K. L.] Univ Pittsburgh, Pittsburgh, PA USA. [Fiellin, D. A.] Yale Univ, New Haven, CT USA. [Goulet, J. L.; Mattocks, K.; Braithwaite, S.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Samet, J.] Boston Univ, Boston, MA 02215 USA. [Crystal, S.] Rutgers State Univ, New Brunswick, NJ 08903 USA. [Rodriquez-Barradas, M.] Debakey VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 298 EP 299 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100569 ER PT J AU Frank, D Rees, C Young, B AF Frank, D. Rees, C. Young, B. TI Experiences of discrimination and self-reported health in a diverse population of diabetic veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Frank, D.] VA Puget Sound, Seattle, WA USA. [Young, B.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 301 EP 301 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100575 ER PT J AU Volpp, KG Pauly, MV Troxel, A Glick, H Weiner, J Asch, DA Deguzman, J Wan, F Audrain, J AF Volpp, K. G. Pauly, M. V. Troxel, A. Glick, H. Weiner, J. Asch, D. A. Deguzman, J. Wan, F. Audrain, J. TI Financial incentives for smoking cessation SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Volpp, K. G.; Asch, D. A.] Univ Penn, Sch Med, CHERP, Philadelphia VAMC, Philadelphia, PA 19104 USA. [Volpp, K. G.; Pauly, M. V.; Troxel, A.; Glick, H.; Weiner, J.; Asch, D. A.; Deguzman, J.; Wan, F.; Audrain, J.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 304 EP 304 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100585 ER PT J AU Majesko, AA Mcginnis, K Ibrahim, S Butt, AA AF Majesko, A. A. Mcginnis, K. Ibrahim, S. Butt, A. A. TI Gender and prevalence of major comorbidities among patients with hepatitis C. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Majesko, A. A.; Butt, A. A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Mcginnis, K.; Ibrahim, S.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 306 EP 306 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100590 ER PT J AU Korthuis, PT Zephyrin, LC Fleishman, JA Saha, S Josephs, JS Mcgrath, MM Hellinger, J Gebo, KA AF Korthuis, P. T. Zephyrin, L. C. Fleishman, J. A. Saha, S. Josephs, J. S. Mcgrath, M. M. Hellinger, J. Gebo, K. A. CA Hiv Res Network TI Health related quality of life in HIV-infected patients: The role of substance use SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Korthuis, P. T.; Saha, S.; Mcgrath, M. M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Zephyrin, L. C.] Columbia Univ, Dept Gynecol & Obstet, New York, NY USA. [Fleishman, J. A.] Agcy Healthcare Res & Qual, Rockville, MD USA. [Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Josephs, J. S.; Gebo, K. A.; Hiv Res Network] Johns Hopkins Univ, Baltimore, MD USA. [Hellinger, J.] Community Med Alliance, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 312 EP 312 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100606 ER PT J AU Lorenz, KA Sherbourne, CD Shugarman, LR Rubenstein, LV Wen, L Cohen, A Goebel, J Lanto, A Asch, S AF Lorenz, K. A. Sherbourne, C. D. Shugarman, L. R. Rubenstein, L. V. Wen, L. Cohen, A. Goebel, J. Lanto, A. Asch, S. TI How can we improve the accuracy of routine pain screening? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Lorenz, K. A.; Rubenstein, L. V.; Asch, S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Lorenz, K. A.; Rubenstein, L. V.; Asch, S.] RAND Corp, Los Angeles, CA USA. [Lorenz, K. A.; Rubenstein, L. V.; Cohen, A.; Lanto, A.; Asch, S.] VA Greater Los Angeles, Los Angeles, CA USA. [Sherbourne, C. D.; Shugarman, L. R.] RAND Corp, Santa Monica, CA USA. [Wen, L.] VA Long Beach, Long Beach, CA USA. [Goebel, J.] CSULB, Sch Nursing, Long Beach, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 317 EP 317 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100620 ER PT J AU Leykum, L Piwinski, S Pao, W Huerta, V Ray, N Arevalo, T AF Leykum, L. Piwinski, S. Pao, W. Huerta, V. Ray, N. Arevalo, T. TI Impact of a hospalist-run observation unit on length of stay SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Leykum, L.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Pao, W.; Huerta, V.; Ray, N.] Univ Hlth Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 320 EP 320 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100628 ER PT J AU Volpp, K Rosen, A Romano, PS Itani, KM Mi, L Even-Shoshan, O Halenar, M Silber, JH AF Volpp, K. Rosen, A. Romano, P. S. Itani, K. M. Mi, L. Even-Shoshan, O. Halenar, M. Silber, J. H. TI Impact of ACGME duty hour rules on prolonged length of stay among medicare patients SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Volpp, K.] Philadelphia VAMC, CHERP, Philadelphia, PA USA. [Volpp, K.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Rosen, A.] Bedford VA, Boston, MA USA. [Rosen, A.] Boston Univ, Boston, MA 02215 USA. [Romano, P. S.] Univ Calif Davis, Sacramento, CA 95817 USA. [Itani, K. M.] Boston VA, Boston, MA USA. [Mi, L.; Even-Shoshan, O.; Halenar, M.] Childrens Hosp Philadelphia, COR, Philadelphia, PA 19104 USA. [Silber, J. H.] Univ Penn, Wharton Sch, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RI Romano, Patrick/N-4225-2014 OI Romano, Patrick/0000-0001-6749-3979 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 320 EP 320 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100629 ER PT J AU Mortensen, E Restrepo, M Pugh, J Anzueto, A AF Mortensen, E. Restrepo, M. Pugh, J. Anzueto, A. TI Impact of prior outpatient antibiotic use on mortality for patients hospitalized with community acquired pneumonia SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Mortensen, E.] UTHSCSA, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, M.; Pugh, J.; Anzueto, A.] Audie L Murphy VA Hosp, San Antonio, TX USA. [Restrepo, M.; Pugh, J.; Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 322 EP 322 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100633 ER PT J AU Federman, A Halm, EA Sano, M Safran, DG Siu, AL AF Federman, A. Halm, E. A. Sano, M. Safran, D. G. Siu, A. L. TI Impaired cognitive performance is associated with limited health literacy in older adults SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Federman, A.; Halm, E. A.] Mt Sinai Sch Med, New York, NY USA. [Sano, M.; Siu, A. L.] James J Peters Vet Adm Med Ctr, New York, NY USA. [Safran, D. G.] Tufts Univ, Boston, MA 02111 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 324 EP 324 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100639 ER PT J AU Salanitro, AH Safford, MM Houston, TK Williams, J Kiefe, CI Ovalle, F Allison, JJ Estrada, CA AF Salanitro, A. H. Safford, M. M. Houston, T. K. Williams, J. Kiefe, C. I. Ovalle, F. Allison, J. J. Estrada, C. A. TI Is patient complexity associated with physician performance on diabetes measures? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Salanitro, A. H.; Estrada, C. A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Safford, M. M.; Houston, T. K.; Williams, J.; Kiefe, C. I.; Ovalle, F.; Allison, J. J.] Univ Birmingham, Birmingham, AL USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 335 EP 336 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100671 ER PT J AU Gopal, RK Miyoshi, TJ Glasheen, JJ Prochazka, AV AF Gopal, R. K. Miyoshi, T. J. Glasheen, J. J. Prochazka, A. V. TI Long-term impact of resident work-hour restrictions on burnout SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Gopal, R. K.; Prochazka, A. V.] Denver VAMC, Denver, CO USA. [Miyoshi, T. J.] Univ Rochester, Rochester, NY USA. [Glasheen, J. J.] UCHSC, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 340 EP 340 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100683 ER PT J AU Saha, S Wimmers, PF Guiton, G Wilkerson, L AF Saha, S. Wimmers, P. F. Guiton, G. Wilkerson, L. TI Medical school diversity and educational outcomes in the United States SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Wimmers, P. F.; Wilkerson, L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Guiton, G.] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 344 EP 344 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100695 ER PT J AU Bryson, CL Au, DH Sun, H Williams, EC Kivlahan, DR Bradley, KA AF Bryson, C. L. Au, D. H. Sun, H. Williams, E. C. Kivlahan, D. R. Bradley, K. A. TI Medication adherence decreases with increasing AUDIT-C alcohol screening scores SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Bryson, C. L.; Au, D. H.; Sun, H.; Williams, E. C.; Kivlahan, D. R.; Bradley, K. A.] Univ Washington, VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 346 EP 346 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100700 ER PT J AU Cohen, BE Kim, SE Gima, KS Bertenthal, D Marmar, CR Seal, KH AF Cohen, B. E. Kim, S. E. Gima, K. S. Bertenthal, D. Marmar, C. R. Seal, K. H. TI Mental health disorders and PTSD increase non-mental health services utilization: A study of 180,324 veterans returning from Iraq and Afghanistan seen at department of veterans affairs facilities SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Cohen, B. E.; Kim, S. E.; Bertenthal, D.; Marmar, C. R.; Seal, K. H.] Univ Calif San Francisco, San Francisco SF VA Med Ctr, San Francisco, CA 94143 USA. [Gima, K. S.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 347 EP 348 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100704 ER PT J AU Yee, EF White, RE Lee, SJ Yano, E Washington, D Murata, GH Handanos, C Hoffman, RM AF Yee, E. F. White, R. E. Lee, S. J. Yano, E. Washington, D. Murata, G. H. Handanos, C. Hoffman, R. M. TI Mental illness and pain as barriers to cancer screening in women SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Yee, E. F.; Murata, G. H.; Handanos, C.; Hoffman, R. M.] New Mexico VA Hlth Care Syst, Albuquerque, NM USA. [White, R. E.] Lovelace Clin Fdn, Albuquerque, NM USA. [Lee, S. J.] Univ New Mexico, Albuquerque, NM 87131 USA. [Yano, E.] VA Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA. [Washington, D.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 348 EP 348 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100705 ER PT J AU Steinman, M Goldstein, MK AF Steinman, M. Goldstein, M. K. TI New methods for performance measurement in hypertension: Results from an expert panel SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Steinman, M.] UCSF, San Francisco VAMC, San Francisco, CA USA. [Goldstein, M. K.] Stanford Univ, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 351 EP 351 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100713 ER PT J AU Long, JA Kimmel, SE Yang, W Troxel, A Volpp, K AF Long, J. A. Kimmel, S. E. Yang, W. Troxel, A. Volpp, K. TI Novel predictors of medication adherence among veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Long, J. A.; Volpp, K.] VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Kimmel, S. E.; Yang, W.; Troxel, A.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 352 EP 352 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100717 ER PT J AU Hausmann, L Kresevic, D Cohen, PZ Grant, R Zickmund, S Mor, M Geng, M Gordon, HS Ibrahim, SA AF Hausmann, L. Kresevic, D. Cohen, P. Z. Grant, R. Zickmund, S. Mor, M. Geng, M. Gordon, H. S. Ibrahim, S. A. TI Patient race and doctor-patient communication in the orthopedic setting SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Hausmann, L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kresevic, D.; Grant, R.] Univ Hosp Case Med Ctr, Louis Stokes DVA Med Ctr, Cleveland, OH USA. [Cohen, P. Z.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Mor, M.; Geng, M.; Ibrahim, S. A.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, H. S.] Univ Illinois, Jesse Brown VAMC, Chicago, IL USA. RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 358 EP 358 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100733 ER PT J AU Saha, S Korthuis, PT Sharp, V Cohn, JA Haidet, PM Moore, RD Beach, MC AF Saha, S. Korthuis, P. T. Sharp, V. Cohn, J. A. Haidet, P. M. Moore, R. D. Beach, M. C. TI Patient-provider cultural dissimilarity and racial disparities in HIV care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Korthuis, P. T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Cohn, J. A.] Wayne State Univ, Detroit, MI USA. [Sharp, V.] Columbia Univ, St Lukes Roosevelt Hosp, New York, NY USA. [Haidet, P. M.] Baylor Coll Med, Houston, TX 77030 USA. [Moore, R. D.; Beach, M. C.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 359 EP 360 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100737 ER PT J AU Starrels, JL Barg, FK Metlay, JP AF Starrels, J. L. Barg, F. K. Metlay, J. P. TI Patterns and determinants of inappropriate antibiotic use among injection drug users SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Starrels, J. L.; Metlay, J. P.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Barg, F. K.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 361 EP 361 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100740 ER PT J AU Barrett, TW Mori, M Malley, JPO AF Barrett, T. W. Mori, M. Malley, J. P. O' TI Perioperative beta-blockers and statins and effects of withdrawal or initiation on short term mortality after vascular surgery SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Barrett, T. W.] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA. [Barrett, T. W.] Portland VA Med Ctr, Sect Gen Med, Portland, OR USA. [Mori, M.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97201 USA. [Malley, J. P. O'] Oregon Hlth & Sci Univ, Ctr Biostat Comp & Informat Biol & Med, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 363 EP 363 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100747 ER PT J AU Lawrence, VA Hazuda, HP Cornell, JE AF Lawrence, V. A. Hazuda, H. P. Cornell, J. E. TI Perioperative depression and elders' recovery after major open abdominal surgery SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Lawrence, V. A.; Hazuda, H. P.; Cornell, J. E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lawrence, V. A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 363 EP 364 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100748 ER PT J AU Weiner, MG Field, S Garvin, JH Holmes, JH Synnestvedt, M Long, JA AF Weiner, M. G. Field, S. Garvin, J. H. Holmes, J. H. Synnestvedt, M. Long, J. A. TI Persistently elevated HBA1C: Poor quality doctors or challenging patients? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Weiner, M. G.; Field, S.; Holmes, J. H.; Synnestvedt, M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Garvin, J. H.; Long, J. A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 364 EP 365 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100750 ER PT J AU Gordon, AJ Hilton, M Haas, GL Andree, T Goldstein, G AF Gordon, A. J. Hilton, M. Haas, G. L. Andree, T. Goldstein, G. TI Personal, medical, and healthcare utilization differences between metropolitan and non-metropolitan homeless veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Gordon, A. J.; Haas, G. L.; Goldstein, G.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 365 EP 365 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100751 ER PT J AU Grosheider, T Luther, J Ramgopal, R Gordon, AJ AF Grosheider, T. Luther, J. Ramgopal, R. Gordon, A. J. TI Physician attitudes towards harm reduction in office-based opioid agonist therapy SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Grosheider, T.; Luther, J.; Ramgopal, R.; Gordon, A. J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 366 EP 367 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100755 ER PT J AU Saha, S Korthuis, PT Cohn, JA Sharp, V Moore, RD Beach, MC AF Saha, S. Korthuis, P. T. Cohn, J. A. Sharp, V. Moore, R. D. Beach, M. C. TI Physician cultural competence, patient self-management, and clinical outcomes among persons living with HIV/AIDS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Korthuis, P. T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Cohn, J. A.] Wayne State Univ, Detroit, MI USA. [Sharp, V.] St Lukes & Roosevelt Hosp, New York, NY USA. [Moore, R. D.; Beach, M. C.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 367 EP 368 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100758 ER PT J AU Kressin, NR Glickman, M Orner, MB Manze, M Berlowitz, DR AF Kressin, N. R. Glickman, M. Orner, M. B. Manze, M. Berlowitz, D. R. TI Predicting blood pressure control: Is race, or factors associated with race, more important? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Kressin, N. R.; Berlowitz, D. R.] Boston Univ, Bedford, MA USA. [Manze, M.] Boston Univ, Med Ctr, Boston, MA 02215 USA. [Orner, M. B.] US Dept Vet Affairs, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 372 EP 373 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100771 ER PT J AU Aujesky, D Mor, MK Geng, M Fine, MJ Ibrahim, SA AF Aujesky, D. Mor, M. K. Geng, M. Fine, M. J. Ibrahim, S. A. TI Predictors of hospital readmission after acute pulmonary embolism SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Aujesky, D.] Univ Lausanne, Lausanne, Switzerland. [Mor, M. K.; Geng, M.; Fine, M. J.; Ibrahim, S. A.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Mor, M. K.; Geng, M.; Fine, M. J.; Ibrahim, S. A.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 375 EP 375 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100778 ER PT J AU Sherman, SE Cummins, S Finney, J Kalra, P Kuschner, W York, L Zhu, S AF Sherman, S. E. Cummins, S. Finney, J. Kalra, P. Kuschner, W. York, L. Zhu, S. TI Preliminary results from a study of telephone care coordination for smoking cessation SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Sherman, S. E.] New York Harbor Healthcare Syst, New York, NY USA. [Finney, J.] Stanford Univ, Menlo Pk, CA USA. [Kalra, P.] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Kuschner, W.] Stanford Univ, Stanford, CA 94305 USA. [York, L.] VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 376 EP 377 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100782 ER PT J AU Beste, LA Sun, H Maynard, C Bishop, MJ Henderson, W Schifftner, T Hughes, G Todd-Sternberg, J Kivlahan, DR Hawkins, E Harris, A Debenedetti, A Bradley, K AF Beste, L. A. Sun, H. Maynard, C. Bishop, M. J. Henderson, W. Schifftner, T. Hughes, G. Todd-Sternberg, J. Kivlahan, D. R. Hawkins, E. Harris, A. Debenedetti, A. Bradley, K. TI Prevalence of alcohol misuse in patients undergoing common surgeries in VA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Beste, L. A.; Sun, H.; Maynard, C.; Todd-Sternberg, J.; Hawkins, E.; Debenedetti, A.; Bradley, K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Bishop, M. J.; Hughes, G.; Kivlahan, D. R.] Univ Washington, Seattle, WA 98195 USA. [Henderson, W.; Schifftner, T.] VA Fitzimmons, Natl Surgical Qual Improvement Program, Aurora, CO USA. [Harris, A.] VA Palo Alto, Palo Alto, CA USA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 377 EP 377 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100784 ER PT J AU Kertesz, SG Hwang, SW Ritchey, FJ Lagory, M AF Kertesz, S. G. Hwang, S. W. Ritchey, F. J. Lagory, M. TI Priced out of the safety net? Declining access to health care among birmingham's homeless, 1995-2005 SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Kertesz, S. G.] U Alabama, Birmingham VAMC, Birmingham, AL USA. [Hwang, S. W.] Univ Toronto, Toronto, ON, Canada. [Ritchey, F. J.; Lagory, M.] Univ Alabama, Birmingham, AL USA. RI Hwang, Stephen/D-2297-2011 OI Hwang, Stephen/0000-0002-1276-1101 NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 379 EP 380 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100790 ER PT J AU Kansagara, DL Ramsay, RS Labby, D Bricker, S Saha, S AF Kansagara, D. L. Ramsay, R. S. Labby, D. Bricker, S. Saha, S. TI Prospective cohort study of a post-hospital discharge intervention in chronically ill medicaid patients SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Kansagara, D. L.; Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Ramsay, R. S.; Labby, D.] CareOregon, Portland, OR USA. [Bricker, S.] Texas Hlth & Human Serv Commissi, Austin, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 382 EP 383 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100798 ER PT J AU Zickmund, S Tirado, C Campbell, S Weinrieb, R AF Zickmund, S. Tirado, C. Campbell, S. Weinrieb, R. TI Provider communication cited as barrier to antiviral therapy for hepatitis C-infected methadone using patients SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Zickmund, S.] Univ Pittsburgh, Pittsburgh, PA USA. [Tirado, C.] Univ Texas Southwestern, Dallas, TX USA. [Campbell, S.] Univ Penn, Philadelphia, PA 19104 USA. [Weinrieb, R.] VA Philadelphia Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 383 EP 383 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100799 ER PT J AU Mourad, M Kohlwes, J AF Mourad, M. Kohlwes, J. TI See one, do one, teach one - An evaluation of procedural skills education during internal medicine residency SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Kohlwes, J.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 398 EP 398 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100841 ER PT J AU Pollack, C Mallya, G Polsky, D AF Pollack, C. Mallya, G. Polsky, D. TI The impact of consumer-directed healthplans and patient socioeconomic status on physician recommendations for colorectal cancer screening SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Pollack, C.; Mallya, G.] Univ Penn, Philadelphia VA Med Ctr, RWJ Clin Scholars Program, Philadelphia, PA 19104 USA. [Polsky, D.] Philadelphia VAMC, CHERP, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 414 EP 414 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100886 ER PT J AU Korthuis, PT Saha, S Moore, RD Cohn, JA Sharp, V Beach, MC AF Korthuis, P. T. Saha, S. Moore, R. D. Cohn, J. A. Sharp, V. Beach, M. C. TI The impact of substance use on communication quality SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Korthuis, P. T.; Saha, S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Moore, R. D.; Beach, M. C.] Johns Hopkins Univ, Baltimore, MD USA. [Cohn, J. A.] Wayne State Univ, Detroit, MI USA. [Sharp, V.] St Lukes & Roosevelt Hosp, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 417 EP 417 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100893 ER PT J AU Haskell, SG Bean-Mayberry, B AF Haskell, S. G. Bean-Mayberry, B. TI The National Women Veterans hormone replacement therapy survey: Factors associated with continuing hormone therapy SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Haskell, S. G.] VA CT Healthcare Syst, West Haven, CT USA. [Bean-Mayberry, B.] VA Greater Los Angeles Hlth Serv Res & Dev, Ctr Excellence, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 418 EP 419 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100897 ER PT J AU Korthuis, PT Saha, S Moore, RD Cohn, JA Sharp, V Beach, MC AF Korthuis, P. T. Saha, S. Moore, R. D. Cohn, J. A. Sharp, V. Beach, M. C. TI The role of communication self-efficacy in patient comfort discussing substance use issues SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Korthuis, P. T.; Saha, S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Saha, S.] Portland VA Med Ctr, Portland, OR USA. [Cohn, J. A.] Wayne State Univ, Detroit, MI USA. [Sharp, V.] St Lukes Roosevelt Hosp, New York, NY 10025 USA. [Moore, R. D.; Beach, M. C.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 423 EP 424 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100911 ER PT J AU Aujesky, D Stone, RA Geng, M Obrosky, DS Fine, MJ Ibrahim, SA AF Aujesky, D. Stone, R. A. Geng, M. Obrosky, D. S. Fine, M. J. Ibrahim, S. A. TI Thrombolytic therapy and mortality in patients with acute pulmonary embolism SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Aujesky, D.] Univ Lausanne, Lausanne, Switzerland. [Stone, R. A.; Geng, M.; Obrosky, D. S.; Fine, M. J.; Ibrahim, S. A.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Stone, R. A.; Geng, M.; Obrosky, D. S.; Fine, M. J.; Ibrahim, S. A.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 425 EP 425 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100915 ER PT J AU Gordon, AJ Kavanaugh, G Paidisetty, S Ramgopal, R Liberto, JG AF Gordon, A. J. Kavanaugh, G. Paidisetty, S. Ramgopal, R. Liberto, J. G. TI Translating research into practice: Facilitators and barriers of implementing buprenorphine in the Veteran Health Administration SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 31st Annual Meeting of the Society-of-General-Internal-Medicine CY APR 09-12, 2008 CL Pittsburgh, PA SP Soc Gen Internal Med C1 [Gordon, A. J.; Paidisetty, S.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kavanaugh, G.; Liberto, J. G.] Univ Maryland, VA Maryland Healthcare Syst, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2008 VL 23 SU 2 BP 426 EP 426 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 277TH UT WOS:000254237100917 ER PT J AU Spira, AP Friedman, L Aulakh, JS Lee, T Sheikh, JI Yesavage, JA AF Spira, Adam P. Friedman, Leah Aulakh, Jasdeep S. Lee, Tina Sheikh, Javaid I. Yesavage, Jerome A. TI Subclinical anxiety symptoms, sleep, and daytime dysfunction in older adults with primary insomnia SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article; Proceedings Paper CT 20th Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 17-22, 2006 CL Salt Lake City, UT SP Associated Profess Sleep Soc DE anxiety; depression; insomnia actigraphy ID DSM-IV; PREVALENCE; DISORDERS AB "Both Insomnia complaints and anxiety-related distress are common in older adults, and are associated with poor daytime functioning. We investigated whether subclinical levels of anxiety were associated with sleep disturbance and daytime functioning in older adults who met diagnostic criteria for primary insomnia, and therefore but did not meet criteria for depression or an anxiety disorder. After adjustment for depressive symptoms, elevated state anxiety was associated with higher levels of wake after sleep onset (measured by both actigraphy and sleep log) and and shorter sleep sleep onset latency (measured by sleep log). Higher levels of trait anxiety were associated with greater wake after sleep onset (measured by sleep log). Elevated state and trait anxiety were associated with worse and social functioning, and higher levels of trait anxiety were associated with worse role functioning. Thus, subclinical anxiety symptoms may be an important target for clinical intervention to improve sleep and functioning in older adults with primary insomnia.". C1 [Spira, Adam P.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Spira, Adam P.] San Francisco VA Med Ctr, San Francisco, CA USA. [Friedman, Leah; Aulakh, Jasdeep S.; Sheikh, Javaid I.; Yesavage, Jerome A.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Aulakh, Jasdeep S.; Lee, Tina; Sheikh, Javaid I.; Yesavage, Jerome A.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Spira, AP (reprint author), 4150 Clement St,181-G, San Francisco, CA USA. EM adam.spira@ucsf.edu FU NIA NIH HHS [AG 12914] NR 19 TC 7 Z9 8 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD MAR PY 2008 VL 21 IS 1 BP 56 EP 60 DI 10.1177/0891988707311043 PG 5 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 266SQ UT WOS:000253457700008 PM 18287171 ER PT J AU Ramirez, AM Chaya, CJ Gordon, LK Giaconi, JA AF Ramirez, Adilana M. Chaya, Craig J. Gordon, Lynn K. Giaconi, JoAnn A. TI A comparison of semiautomated versus manual goldmann kinetic perimetry in patients with visually significant glaucoma SO JOURNAL OF GLAUCOMA LA English DT Article DE perimetry; Goldmann; octopus; glaucoma ID LONG-TERM FLUCTUATION; FIELD; VARIABILITY; THRESHOLD AB Purpose: To determine if semiautomated kinetic perimetry (SKP) is reproducible and comparable to Goldmann manual kinetic perimetry (GVF). Methods: Glaucoma patients were recruited to perform visual field testing using GVF and SKP. Specific isopters were tested, quantified, and compared. Visual field patterns were analyzed for shape and defect. Results: Ten patients (16 eyes) underwent visual field studies using SKP and GVF, and 8 patients completed a second SKP on a different day. Individual isopter areas were similar between GVF and SKP, although 60% of isopters were larger oil SKP by ail average of 15%. This was statistically significant for the smaller isopters, I4e (P = 0.02) and I2e (P = 0.05). Retesting with SKP on a separate day, showed similar isopter areas (P values = 0.3 to 1.0), however, the exact location of isopters in degrees from central fixation tended to vary with the smaller test object sizes. Isopler position in degrees from the central axis agreed in at least 3 quadrants in approximately 65% of fields compared. SKP visual field defects and patterns were similar between test strategies. Conclusions: SKP and GVF testing produce similar visual field results in glaucoma patients, and SKP testing seems to be reliable and reproducible in this population. However, overlapping isopters, typically associated with nonorgamic vision loss, and jagged isopters were sometimes observed in SK P visual fields. Further study of SKP is needed to explore these findings. C1 [Ramirez, Adilana M.; Gordon, Lynn K.; Giaconi, JoAnn A.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Chaya, Craig J.] Greater Los Angeles VA Healthcare Syst, Dept Med, Los Angeles, CA USA. [Gordon, Lynn K.; Giaconi, JoAnn A.] Greater Los Angeles VA Healthcare Syst, Ophthalmol Sect, Los Angeles, CA USA. RP Giaconi, JA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, 100 Stein Pl, Los Angeles, CA 90095 USA. EM giaconi@jsei.ucla.edu NR 16 TC 8 Z9 9 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1057-0829 J9 J GLAUCOMA JI J. Glaucoma PD MAR PY 2008 VL 17 IS 2 BP 111 EP 117 PG 7 WC Ophthalmology SC Ophthalmology GA 280FZ UT WOS:000254412400005 PM 18344756 ER PT J AU Horner, MD Selassie, AW Lineberry, L Ferguson, PL Labbate, LA AF Horner, Michael D. Selassie, Anbesaw W. Lineberry, Lee Ferguson, Pamela L. Labbate, Lawrence A. TI Predictors of psychological symptoms 1 year after traumatic brain injury: A population-based, epidemiological study SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE anxiety; brain damage; chronic; depression; epidemiologic studies,follow-up studies; mood disorders ID NATIONAL PROBABILITY SAMPLE; AMERICAN DRINKING PRACTICES; PSYCHIATRIC-DISORDERS; HEAD-INJURY; AXIS-I; DEPRESSION; REHABILITATION; QUESTIONNAIRE; INDIVIDUALS; OUTPATIENTS AB Objective: To examine self-reported psychological symptoms 1 year after traumatic brain injury (TBI) in a populationbased sample. Participants: There were 1560 adults who had sustained TBI. Design: A telephone survey with questions about recent mood and anxiety symptoms, and diagnoses since TBI. Polychotomous logistic regression with 3 response levels (probable, possible, and no mood or anxiety symptoms) identified predictors of psychological symptoms. Results: Overall, 40% of participants had clinically significant mood or anxiety symptoms-12.6% with probable symptoms and 27.5% with possible symptoms. Main risk factors for probable symptoms included younger age, poor physical functioning, inadequate social support, and being a white woman. Other risk factors included being retired or unemployed, and pre-TBI psychiatric disorder or multiple concussions. Conclusions: These findings suggest the need for careful screening of persons with TBI who are at particular risk of developing psychological symptoms, and persons who have recently sustained TBI and their families to be educated about the possibility of developing such symptoms. C1 [Horner, Michael D.; Labbate, Lawrence A.] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. [Horner, Michael D.; Labbate, Lawrence A.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Selassie, Anbesaw W.; Lineberry, Lee; Ferguson, Pamela L.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. RP Horner, MD (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM hornermd@musc.edu NR 49 TC 15 Z9 16 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAR-APR PY 2008 VL 23 IS 2 BP 74 EP 83 DI 10.1097/01.HTR.0000314526.01006.c8 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 280KW UT WOS:000254426700002 PM 18362761 ER PT J AU Boyko, EJ Barr, ELM Zimmet, PZ Shaw, JE AF Boyko, E. J. Barr, E. L. M. Zimmet, P. Z. Shaw, J. E. TI Two-hour glucose predicts the development of hypertension over 5 years: the AusDiab study SO JOURNAL OF HUMAN HYPERTENSION LA English DT Article DE glucose; epidemiology; insulin; risk factors ID ENDOTHELIUM-DEPENDENT VASODILATION; IMPAIRED FASTING GLUCOSE; DISEASE RISK-FACTORS; LIFE-STYLE; CARDIOVASCULAR-DISEASE; AUSTRALIAN ADULTS; FOLLOW-UP; TOLERANCE; HYPERGLYCEMIA; OBESITY AB Elevated 2-h plasma glucose concentration (2hPG) from an oral glucose tolerance (OGTT) test more strongly predicts risk of subsequent cardiovascular disease than fasting plasma glucose (FPG), but the association between these glucose measurements and hypertension risk is less clear. We examined the association between 2hPG, FPG and risk of hypertension. We conducted a prospective observational study (The Australian Diabetes, Obesity and Lifestyle Study-AusDiab) among 4413 Australian residents who attended a baseline (1999 2000) and follow-up (2004-2005) examinations. Measurements included blood pressure (mean of two readings), 75 g OGTT, fasting insulin, anthropometrics, dietary and alcohol intake, medical history and physical activity. Hypertension was defined as a systolic blood pressure (SBP)>= 140 or a diastolic blood pressure (DBP)>= 90mm Hg or treatment with medication for hypertension. HOMA-S was calculated as a measure of insulin sensitivity using the HOMA2 calculator. Hypertension developed in 14% of the 4306 subjects available for this analysis. Higher 2hPG was significantly related to greater risk of hypertension after adjustment for age, gender, FPG, BMI (baseline and difference), waist circumference (baseline and difference), education, exercise, alcohol intake, baseline SBP and smoking (OR (95% CI) 1.12 (1.01 to 1.23)), but no significant association was seen between FPG and hypertension in this model (1.02 (0.88-1.19)). Further adjustment for HOMA-S did not change these findings. Higher baseline 2hPG was more strongly associated with an increase in SBP than in DBP over 5 years. We conclude that higher 2hPG predicted future hypertension occurrence in this population. C1 [Boyko, E. J.] Univ Washington, Dept Med, Seattle ERIC, Seattle, WA 98101 USA. [Boyko, E. J.; Barr, E. L. M.; Zimmet, P. Z.; Shaw, J. E.] Int Diabet Inst, Caulfield, Vic, Australia. [Boyko, E. J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. RP Boyko, EJ (reprint author), Univ Washington, Dept Med, Seattle ERIC, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eboyko@u.washington.edu RI Shaw, Jonathan/E-7388-2010 OI Shaw, Jonathan/0000-0002-6187-2203; Boyko, Edward/0000-0002-3695-192X NR 43 TC 12 Z9 16 U1 2 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9240 J9 J HUM HYPERTENS JI J. Hum. Hypertens. PD MAR PY 2008 VL 22 IS 3 BP 168 EP 176 DI 10.1038/sj.jhh.1002316 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 262HA UT WOS:000253138400003 PM 18046430 ER PT J AU Schmader, K Gnann, JW Watson, CP AF Schmader, Kenneth Gnann, John W., Jr. Watson, C. Peter TI The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; NOTTINGHAM HEALTH PROFILE; POSTHERPETIC NEURALGIA; RISK-FACTORS; DOUBLE-BLIND; NEUROPATHIC PAIN; ANTIRETROVIRAL THERAPY; OLDER-ADULTS AB Worldwide, herpes zoster (HZ) affects millions of patients (particularly older adults) annually and causes significant suffering due to acute and chronic pain, or postherpetic neuralgia (PHN). The objective of this article is to explain the rationale for the HZ vaccine by summarizing data on the epidemiology of HZ in the immunocompetent host, with a focus on recent incidence and risk factor studies; to review information on the burden of HZ; and to discuss the challenges of lessening the morbidity of the disease. The incidence and severity of HZ and PHN are highest in older adults. Given the central nervous system damage caused by HZ, the difficulty of adequately treating HZ to prevent PHN, and the intractability of PHN, the advent of the HZ vaccine appears to be a crucial innovation for preventing HZ and PHN. C1 [Schmader, Kenneth] Durham Vet Affairs Med Ctr, GRECC, Durham, NC USA. [Schmader, Kenneth] Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27706 USA. [Schmader, Kenneth] Duke Univ, Med Ctr, Div Geriatr, Dept Med, Durham, NC 27706 USA. [Gnann, John W., Jr.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Gnann, John W., Jr.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Watson, C. Peter] Univ Toronto, Dept Med, Toronto, ON, Canada. RP Schmader, K (reprint author), Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr 182, Durham, NC 27705 USA. EM schma001@mc.duke.edu FU NIAID NIH HHS [K24-AI-51324-03] NR 59 TC 60 Z9 63 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 1 PY 2008 VL 197 SU 2 BP S207 EP S215 DI 10.1086/522152 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 271FF UT WOS:000253773600032 PM 18419399 ER PT J AU Winn, RA Tennis, M Sergew, A Williams, L Randall, J Van Scoyk, M AF Winn, R. A. Tennis, M. Sergew, A. Williams, L. Randall, J. Van Scoyk, M. TI Prostacyclin and its synthetic analogues are small molecule agonists of frizzled 9 mediating growth inhibition of non small cell lung cancer cells SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Annual Combined Meeting of the Central-Society-for-Clinical-Reseach/Midwestern Section of the American-Federation-for-Medical-Research CY APR 24-25, 2008 CL Chicago, IL SP Cent Soc Clin Res, Amer Federat Med Res, Midwestern Sect C1 [Winn, R. A.; Tennis, M.; Sergew, A.; Williams, L.; Randall, J.; Van Scoyk, M.] Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 2008 VL 56 IS 3 MA 109 BP 648 EP 648 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 273FY UT WOS:000253917000124 ER PT J AU Crawford, DC Nord, AS Badzioch, MD Ranchalis, J McKinstry, LA Ahearn, M Bertucci, C Shephard, C Wong, M Rieder, MJ Schellenberg, GD Nickerson, DA Heagerty, PJ Wijsman, EM Jarvik, GP AF Crawford, Dana C. Nord, Alex S. Badzioch, Michael D. Ranchalis, Jane McKinstry, Laura A. Ahearn, Magdalena Bertucci, Caterina Shephard, Cynthia Wong, Michelle Rieder, Mark J. Schellenberg, Gerard D. Nickerson, Deborah A. Heagerty, Patrick J. Wijsman, Ellen M. Jarvik, Gail P. TI A common VLDLR polymorphism interacts with APOE genotype in the prediction of carotid artery disease risk SO JOURNAL OF LIPID RESEARCH LA English DT Article DE very low density lipoprotein receptor; apolipoprotein E; body mass index; triglycerides ID APOLIPOPROTEIN-E POLYMORPHISM; DENSITY-LIPOPROTEIN RECEPTOR; INTIMA-MEDIA THICKNESS; CORONARY-HEART-DISEASE; WALL THICKNESS; HEMODIALYSIS-PATIENTS; GENETIC ASSOCIATION; CARDIOVASCULAR-DISEASE; ASYMPTOMATIC ADULTS; CHOLESTEROL LEVELS AB The genetic factors associated with carotid artery disease (CAAD) are not fully known. Because of its role in lipid metabolism, we hypothesized that common genetic variation in the very low density lipoprotein receptor (VLDLR) gene is associated with severe CAAD (> 80% stenosis), body mass index (BMI), and lipid traits in humans. VLDLR was resequenced for variation discovery in 92 subjects, and single nucleotide polymorphisms (tagSNPs) were chosen for genotyping in a larger cohort (n = 1,027). Of the 17 tagSNPs genotyped, one tagSNP (SNP 1226; rs1454626) located in the 5' flanking region of VLDLR was associated with CAAD, BMI, and LDL-associated apolipoprotein B (apoB). We also identified receptor-ligand genetic interactions between VLDLR 1226 and APOE genotype for predicting CAAD case status.jr These findings may further our understanding of VLDLR function, its ligand APOE, and ultimately the pathogenesis of CAAD in the general population. C1 [Nord, Alex S.; Badzioch, Michael D.; Ranchalis, Jane; McKinstry, Laura A.; Schellenberg, Gerard D.; Wijsman, Ellen M.; Jarvik, Gail P.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Crawford, Dana C.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Ctr Human Genet Res, Nashville, TN 37232 USA. [Ahearn, Magdalena; Bertucci, Caterina; Shephard, Cynthia; Wong, Michelle; Rieder, Mark J.; Nickerson, Deborah A.] Univ Washington, Div Med Genet, Dept Genome Sci, Seattle, WA 98195 USA. [Heagerty, Patrick J.; Wijsman, Ellen M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Schellenberg, Gerard D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Schellenberg, Gerard D.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Jarvik, GP (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. EM pair@u.wasliington.edu RI Jarvik, Gail/N-6476-2014; Crawford, Dana/C-1054-2012 OI Jarvik, Gail/0000-0002-6710-8708; Wijsman, Ellen/0000-0002-2725-6669; FU NHLBI NIH HHS [R01 HL-67406, P01 HL-30086, R01 HL-074366, U01 HL-66682, U01 HL-66728]; NIEHS NIH HHS [N01 ES-15478] NR 74 TC 14 Z9 14 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD MAR PY 2008 VL 49 IS 3 BP 588 EP 596 DI 10.1194/jlr.M700409-JLR200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 266EY UT WOS:000253418500012 PM 18056683 ER PT J AU Xu, C Houck, JR Fan, WH Wang, P Chen, Y Upton, M Futran, ND Schwartz, SM Zhao, LP Chen, C Mendez, E AF Xu, Chang Houck, John R. Fan, Wenhong Wang, Pei Chen, Yu Upton, Melissa Futran, Neal D. Schwartz, Stephen M. Zhao, Lue P. Chen, Chu Mendez, Eduardo TI Simultaneous isolation of DNA and RNA from the same cell population obtained by laser capture microdissection for genome and transcriptome profiling SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Article ID PROSTATE-CANCER; TUMOR SAMPLES; TISSUE; HETEROGENEITY; AMPLIFICATION; CARCINOMA AB Laser capture microdissection (LCM) is used extensively for genome and transcriptome profiling. Traditionally, however, DNA and RNA are purified from separate populations of LCM-harvested cells, limiting the strength of inferences about the relationship between gene expression and gene sequence variation. There have been no published protocols for the simultaneous isolation of DNA and RNA from the same cells that are obtained by LCM of patient tissue specimens. Here we report an adaptation of the Qiagen AllPrep method that allows the purification of DNA and RNA from the same LCM-harvested cells. We compared DNA and RNA purified by the QIAamp DNA Micro kit and the PicoPure RNA Isolation kit, respectively, from LCM-collected cells from adjacent tissue sections of the same specimen. The adapted method yields 90% of DNA and 38% of RNA compared with the individual methods. When tested with the GeneChip 250K Nsp Array, the concordance rate of the single nucleotide polymorphism heterozygosity calls was 98%. when tested with the GeneChip U133 Plus 2.0 Array, the correlation coefficient of the raw gene expression was 97%. Thus, we developed a method to obtain both DNA and RNA material from a single population of LCM-harvested cells and herein discuss the strengths and limitations of this methodology. C1 [Xu, Chang; Futran, Neal D.; Chen, Chu; Mendez, Eduardo] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Upton, Melissa] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Zhao, Lue P.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Houck, John R.; Chen, Yu; Futran, Neal D.; Schwartz, Stephen M.; Zhao, Lue P.; Chen, Chu; Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98104 USA. [Fan, Wenhong; Zhao, Lue P.] Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98104 USA. [Wang, Pei] Fred Hutchinson Canc Res Ctr, Program Canc Prevent, Seattle, WA 98104 USA. [Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. RP Mendez, E (reprint author), Univ Washington, Dept Otolaryngol Head & Neck Surg, 1959 NE Pacific St,Box 356515, Seattle, WA 98195 USA. EM edmendez@u.washington.edu FU NCI NIH HHS [R01 CA 095419, R01 CA095419]; NCRR NIH HHS [K12 RR023265, 5 K12 RR023265-04] NR 20 TC 14 Z9 15 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 J9 J MOL DIAGN JI J. Mol. Diagn. PD MAR PY 2008 VL 10 IS 2 BP 129 EP 134 DI 10.2353/jmoldx.2008.070131 PG 6 WC Pathology SC Pathology GA 272QM UT WOS:000253874500003 PM 18258925 ER PT J AU Shimazaki, K Jirawuthiworavong, GV Heckenlively, JR Gordon, LK AF Shimazaki, Kaori Jirawuthiworavong, Guy V. Heckenlively, John R. Gordon, Lynn K. TI Frequency of anti-retinal antibodies in normal human serum SO JOURNAL OF NEURO-OPHTHALMOLOGY LA English DT Article ID CANCER-ASSOCIATED RETINOPATHY; CELL LUNG-CANCER; ANTIRECOVERIN AUTOANTIBODIES; AUTOIMMUNE RETINOPATHY; RECOVERIN ANTIBODIES; APOPTOTIC DEATH; BIPOLAR CELLS; CAR SYNDROME; OPTIC-NERVE; IN-VIVO AB Background: Anti-retinal antibodies have been described in the context of autoimmune retinopathies and are often presumed to be pathogenic or disease associated. However, full characterization of patterns of anti-retinal antibody reactivity in normal human serum has been limited. The purpose of this work was to identify the profile of anti-retinal IgG antibodies in serum used as controls in laboratory testing. Methods: Normal human sera used in commercial diagnostic laboratories were tested for the presence of immunoreactivity against soluble human retinal proteins using Western blot analysis of fractionated soluble human retinal proteins. Reactivity was quantified using computerized densitometry, and the level of reactivity was standardized relative to a control positive serum with known reactivity against recoverin, Results: Some anti-retinal reactivity was observed in the majority of all tested normal sera. Reactivity against one to two protein bands was observed in 33%. Reactivity against five or more distinct bands was observed in 22%. There was a tendency for serum from women to react with three or more protein bands compared with serum from men. Conclusions: The presence of anti-retinal antibodies is observed in a majority of normal control human sera, suggesting that identification of new candidate retinal autoantigens should be cautiously interpreted and subject to rigorous testing for disease association. Additional studies will aid development of a standardized protocol for validation of potential pathogenic seroreactivity. C1 [Shimazaki, Kaori] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA. [Jirawuthiworavong, Guy V.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Heckenlively, John R.] Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Gordon, LK (reprint author), 100 Stein Plaza, Los Angeles, CA 90095 USA. EM lgordon@ucla.edu FU NEI NIH HHS [T32 EY07026-28] NR 35 TC 29 Z9 29 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-8022 J9 J NEURO-OPHTHALMOL JI J. Neuro-Ophthal. PD MAR PY 2008 VL 28 IS 1 BP 5 EP 11 DI 10.1097/WNO.0b013e318167549f PG 7 WC Clinical Neurology; Ophthalmology SC Neurosciences & Neurology; Ophthalmology GA 271ZW UT WOS:000253828200002 PM 18347451 ER PT J AU Yao, JK Messamore, E AF Yao, J. K. Messamore, E. TI Arachidonic acid and niacin sensitivity in schizophrenia SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 39th Annual Meeting of the American-Society-for-Neurochemistry CY MAR 01-05, 2008 CL San Antonio, TX SP Amer Soc Neurochem C1 [Messamore, E.] Portland VA Med Ctr, Portland, OR USA. [Yao, J. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Yao, J. K.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2008 VL 104 SU 1 BP 35 EP 36 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 257RI UT WOS:000252815800087 ER PT J AU Burns, MR Solowska, JM Falnikar, A Himes, TB Morfini, GA Brady, ST Baas, PW AF Burns, M. R. Solowska, J. M. Falnikar, A. Himes, T. B. Morfini, G. A. Brady, S. T. Baas, P. W. TI Pathogenic spastin alters neurite morphology and inhibits fast axonal transport SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 39th Annual Meeting of the American-Society-for-Neurochemistry CY MAR 01-05, 2008 CL San Antonio, TX SP Amer Soc Neurochem C1 [Burns, M. R.; Morfini, G. A.; Brady, S. T.] Univ Illinois Chicago, Coll Med, Chicago, IL USA. [Solowska, J. M.; Falnikar, A.; Baas, P. W.] Drexel Univ, Coll Med, Philadelphia, PA USA. [Himes, T. B.] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2008 VL 104 SU 1 BP 130 EP 130 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 257RI UT WOS:000252815800318 ER PT J AU Goody, RJ Schittone, SA Tyler, KL AF Goody, Robin J. Schittone, Stephanie A. Tyler, Kenneth L. TI Experimental reovirus-induced acute flaccid paralysis and spinal motor neuron cell death SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE acute flaccid paralysis; apoptosis; motor neurons; reovirus; viral myelitis ID CENTRAL-NERVOUS-SYSTEM; SINDBIS VIRUS-INFECTION; WEST-NILE ENCEPHALITIS; CORD-INJURY; INDUCED APOPTOSIS; CALPAIN; MICE; PATHOGENESIS; ISCHEMIA; MOUSE AB Acute flaccid paralysis (AFP) describes the loss of motor function in 1 or more limbs commonly associated with viral infection and destruction of motor neurons in the anterior horns of the spinal cord. Therapy is limited, and the development of effective treatments is hampered by a lack of experimental models. Reovirus infection of neonatal mice provides a model for the study of CNS viral infection pathogenesis. Injection of the Reovirus serot Type 3 strains Abney T3A) or Dearing (T3D) into the hindlimb of 1-day-old mice resulted in the development of AFP in more than 90% of infected mice. Acute flaccid paralysis began in the ipsilateral hindlimb at 8 to 0 days postinfection and progressed to paraplegia 24 hours later. Paralysis correlated with injury, neuron loss, and spread of viral ntigen first to the ipsilateral and then to the contralateral anterior horns. As demonstrated by the activation of caspase 3 and its olocalization with viral antigen in the anterior horn and concompitant cleavage of poly-(adenosine diphosphate-ribose) polymerase, AFP was associated with apoptosis. Calpain activity and inducible nitric oxide synthase expression were both elevated in the spinal,chords of paralyzed animals. This study represents the first detailed characterization of a novel and highly efficient experimental model,of virus-induced AFP that will facilitate evaluation of therapeutic strategies targeting virus-induced paralysis. C1 [Goody, Robin J.; Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Dept Neurol B182, Denver, CO 80262 USA. [Schittone, Stephanie A.; Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol B182, 4200 E 9th Ave, Denver, CO 80262 USA. EM Ken.Tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NINDS NIH HHS [5R01NS050138, R01 NS051403, R01 NS050138-04, R01 NS051403-03, 1R01NS051403, R01 NS050138] NR 41 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD MAR PY 2008 VL 67 IS 3 BP 231 EP 239 DI 10.1097/NEN.0b013e31816564f0 PG 9 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 268DC UT WOS:000253557500006 PM 18344914 ER PT J AU Mendez, MF Lauterbach, EC Sampson, SM AF Mendez, Mario F. Lauterbach, Edward C. Sampson, Shirlene M. CA ANPA Comm Res TI An evidence-based review of the psychopathology of frontotemporal dementia: A report of the ANPA Committee on Research SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Review ID FRONTAL-LOBE DEMENTIA; NON-ALZHEIMER TYPE; CLINICAL DIAGNOSTIC-CRITERIA; PROGRESSIVE SUPRANUCLEAR PALSY; RANDOMIZED CONTROLLED-TRIAL; KLUVER-BUCY-SYNDROME; PICKS-DISEASE; VASCULAR DEMENTIA; TEMPORAL VARIANT; CORTICOBASAL DEGENERATION AB The Committee on Research of the American Neuropsychiatric Association conducted a review of the noncognitive neuropsychiatric manifestations of frontotemporal dementia. The Committee on Research searched reviews and several online databases for all pertinent publications. Single case reports without pathology were excluded, except for psychosis, where single cases made up much of the literature. The strongest evidence supports an association of frontotemporal dementia with the following behaviors: apathy-abulia; disinhibition-impulsivity; loss of insight and self-referential behavior; decreased emotion and empathy; violation of social and moral norms; changes in dietary or eating behavior; and repetitive behaviors. Frontotemporal dementia is less frequently associated with anxiety and mood disorders, which may be a prodrome or risk factor, and rarely presents with delusions or hallucinations. The results of this review highlight the distinct neuropsychiatric manifestations of frontotemporal dementia and the need to reconsider the current diagnostic criteria for this disorder. C1 [Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, Los Angeles, CA 90073 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA 90024 USA. [Lauterbach, Edward C.] Mercer Univ, Dept Psychiat & Behav Sci, Macon, GA 31207 USA. [Sampson, Shirlene M.] Mayo Clin, Dept Psychiat, Rochester, MN USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu NR 191 TC 57 Z9 58 U1 4 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SPR PY 2008 VL 20 IS 2 BP 130 EP 149 DI 10.1176/appi.neuropsych.20.2.130 PG 20 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 331DC UT WOS:000257991900002 PM 18451185 ER PT J AU Mendez, MF Shapira, JS Licht, EA AF Mendez, Mario F. Shapira, Jill S. Licht, Eliot A. TI "Denkfaulheit" in frontotemporal dementia: A preliminary analysis SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID CLINICAL-FEATURES; PICKS-DISEASE; WORK GROUP; CONSENSUS; DIAGNOSIS; CRITERIA AB The initial recognition of frontotemporal dementia is often difficult. Frontotemporal dementia presents with subtle personality changes in the absence of a definitive biomarker. The authors report an analysis of cognitive shallowness, or "Denkfaulheit," in patients with frontotemporal dementia early in its course. C1 [Mendez, Mario F.; Shapira, Jill S.; Licht, Eliot A.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA USA. [Mendez, Mario F.; Shapira, Jill S.; Licht, Eliot A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Mendez, Mario F.; Shapira, Jill S.; Licht, Eliot A.] Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Mmendez@UCLA.edu NR 15 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SPR PY 2008 VL 20 IS 2 BP 219 EP 222 DI 10.1176/appi.neuropsych.20.2.219 PG 4 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 331DC UT WOS:000257991900010 PM 18451193 ER PT J AU Lauriat, TL Shiue, L Haroutunian, V Verbitsky, M Ares, M Ospina, L McInnes, LA AF Lauriat, Tara L. Shiue, Lily Haroutunian, Vahram Verbitsky, Miguel Ares, Manuel, Jr. Ospina, Luz McInnes, L. Alison TI Developmental expression profile of quaking, a candidate gene for schizophrenia, and its target genes in human prefrontal cortex and hippocampus shows regional specificity SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE myelin; human development; splicing; schizophrenia ID CENTRAL-NERVOUS-SYSTEM; ANTERIOR CINGULATE CORTEX; MULTIPLE BRAIN-REGIONS; MYELINATION-RELATED GENES; RNA-BINDING PROTEINS; MESSENGER-RNA; BASIC-PROTEIN; PROTEOLIPID PROTEIN; BIPOLAR DISORDER; QKI AB Decreased expression of oligodendrocyte/myelin-related (OMR) genes, including quaking (QKI), is a consistent finding in gene expression studies of post-mortem brain from subjects with schizophrenia, and these changes are most prominent in the hippocampus vs. the prefrontal cortex (PFC). Although expression of QKI and other OMR genes has been examined in rodents, little is known about their developmental trajectory in the human brain. Therefore, we examined expression of QKI and several putative mRNA targets of QKI in human PFC and hippocampus at different ages. The pattern of QKI expression in the PFC resembled that reported in rodents, with high QKI-5 in the fetal brain and an increase in QKI-6 and QKI-7 during the period of active myelination, although QKI-5 expression did not decrease substantially during postnatal development in the PFC in humans as it does in rodent brain. Most of the putative QKI target genes also showed linear increases in expression with increasing age in the PFC. In contrast, expression of these genes showed little evidence of developmental regulation in the hippocampus. Correlations between expression levels of the nuclear vs. cytoplasmic QKI isoforms, and putative splicing targets of the former, also differed between tissues. Thus, we speculate that a robust increase in OMR gene expression normally occurs with age in the PFC, but not in the hippocampus, which may explain why decreases in OMR gene expression in schizophrenia are more pronounced in the latter tissue. We also suggest that OMR transcripts might be processed by different splicing proteins in different tissues. (c) 2007 Wiley-Liss, Inc. C1 [Lauriat, Tara L.; Haroutunian, Vahram; Verbitsky, Miguel; Ospina, Luz; McInnes, L. Alison] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Shiue, Lily; Ares, Manuel, Jr.] Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA. [Haroutunian, Vahram] Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [McInnes, L. Alison] Mt Sinai Sch Med, Dept Genet & Gen Sci, New York, NY USA. RP McInnes, LA (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1229, New York, NY 10029 USA. EM alison.mcinnes@mssm.edu OI Lauriat, Tara/0000-0003-0729-9386; Ares, Manny/0000-0002-2552-9168 FU NIMH NIH HHS [MH064673, MH0066392, MH074026] NR 49 TC 17 Z9 17 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD MAR PY 2008 VL 86 IS 4 BP 785 EP 796 DI 10.1002/jnr.21534 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 273WC UT WOS:000253961700006 PM 17918747 ER PT J AU Skittone, LK Liu, XH Tseng, A Kim, HT AF Skittone, Laura K. Liu, Xuhui Tseng, Alice Kim, Hubert T. TI Matrix metalloproteinase-2 expression and promoter/enhancer activity in skeletal muscle atrophy SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE transgenic mice; matrix metalloproteinase-2; muscular atrophy; disuse; Achilles tendon ID REPERFUSION INJURY; ACID-PHOSPHATASE; RATS; MATRIX-METALLOPROTEINASE-2; INHIBITOR; PATHWAYS; ISCHEMIA; MMP-2 AB Matrix metalloproteinase-2 (MMP-2) appears to be the dominant MMP activated during skeletal muscle atrophy. However, little is known about cell-specific regulatory mechanisms of MMP-2 transcription in vivo. In this study, we used a mouse model of muscle atrophy induced by complete Achilles tendon transection. Time-dependent muscle weight loss, nuclei density reduction, and extracellular matrix degeneration were observed consistently after Achilles tendon transection. Increased MMP-2 expression was confirmed at the mRNA and protein level. Experiments using transgenic mice with a MMP-2 promoter/enhancer reporter construct demonstrated markedly increased MMP-2 promoter/enhancer activity in atrophic skeletal muscle. Tissue-specific upregulation of MMP-2 promoter activity was observed not only in myocytes, but also in blood vessels, nerve, and fascia. The transcription factors c-Jun and FosB were expressed at high levels in atrophic muscle, suggesting a role in MMP-2 upregulation. These findings show that increased MMP-2 activity in disused atrophic muscle and supporting tissues is regulated, at least in part, by increased MMP-2 promoter/enhancer activity. (C) 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. C1 [Skittone, Laura K.; Tseng, Alice; Kim, Hubert T.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Liu, Xuhui; Kim, Hubert T.] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94143 USA. RP Kim, HT (reprint author), San Francisco VA Med Ctr, 4150 Clement St,112, San Francisco, CA 94121 USA. EM kimh@orthosurg.ucsf.edu NR 20 TC 18 Z9 19 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD MAR PY 2008 VL 26 IS 3 BP 357 EP 363 DI 10.1002/jor.20513 PG 7 WC Orthopedics SC Orthopedics GA 264XW UT WOS:000253324700011 PM 17960656 ER PT J AU Wu, P Lorenz, KA Chodosh, J AF Wu, Pauline Lorenz, Karl A. Chodosh, Joshua TI Advance care planning among the oldest old SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriat Soc ID OF-LIFE CARE; DECISION-MAKING; END; QUALITY; DIRECTIVES; TRIAL AB Objectives: To describe end-of-life advance care planning among the oldest-old (those >= 85 years) and to identify patient characteristics and healthcare utilization patterns associated with likelihood of care planning documentation. Design: Medical charts were abstracted for evidence of advance care planning documentation (including surrogate for health care decisions) and linked to patient demographic, clinical, and health utilization characteristics. Setting: Veterans Affairs Greater Los Angeles Healthcare System (VA GLAHS). Participants: All Veterans (n = 175) aged >= 85 who died between September 1999 and October 2000 and used services at the VA GLAHS in the last year of life. Measurements: The association of patient demographic, clinical, and health care utilization characteristics with documentation of advance care planning and surrogates was modeled using multivariate logistic regression. Results: Among veterans (mean age at death, 89.4 +/- 3.8 years), 50 of 149 (34%) electronic available records had documented care preferences whereas 68 (46%) had documentation of surrogates. Considering demographic, clinical, and service use characteristics, only age (adjusted odds ratio [AOR]: 1.1 per year; 95% confidence interval [CI]: 1.0-1.2) and outpatient visits (AOR: 1.6 per quartile of general and geriatric medicine visit frequency; 95% CI: 1.1-2.3) were associated with advance directive completion. A multivariable regression model using the same predictors to predict documentation of surrogates found similar associations with total outpatient visits (AOR: 1.5; 95% CI: 1.0-2.0) and general and geriatric medicine utilization. (AOR: 1.4; 95% CI: 1.0-2.0). Conclusion: Even in a health care system known for high-quality chronic illness care, documentation of advance care planning and selected proxies for health care decisions at the end of life was infrequent. Outpatient primary care and geriatric providers' visits were more frequent among those who had documented advance care planning, suggesting that involvement of these practitioners may improve end-of-life care. C1 [Wu, Pauline] Univ Med & Dent New Jersey, Sch Osteopath Med, Stratford, NJ 08084 USA. [Wu, Pauline] UCLA San Fernando Valley, Dept Psychiat, North Hills, CA USA. [Lorenz, Karl A.; Chodosh, Joshua] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. [Chodosh, Joshua] VA Greater Los Angeles Geriatr Res Educ & Clin Ct, Sepulveda, CA USA. [Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA. RP Chodosh, J (reprint author), VA Greater Los Angeles Healthcare Syst, GRECC, 11301 Wilshire Blvd,Mail Code 11G, Los Angeles, CA 90073 USA. EM jchodosh@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 NR 26 TC 12 Z9 12 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2008 VL 11 IS 2 BP 152 EP 157 DI 10.1089/jpm.2007.0134 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 283QM UT WOS:000254651600008 PM 18333727 ER PT J AU Sekerak, RJ Zimmermann, KP AF Sekerak, R. J. Zimmermann, K. P. TI Chin-up strength tests: does stature matter? SO JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS LA English DT Article DE physical fitness; muscle strength; exercise physiology ID BODY-SIZE; MOVEMENT PERFORMANCE; MUSCLE STRENGTH AB Aim. Many organizations place high value on employee physical fitness and use standardized physical fitness tests (PFT) to quantify it. The chin-up strength test is an example of such a test. Participants' anecdotal reports raise some concern that the latter is inherently biased against tall individuals. A demonstration that tall individuals are less likely than short individuals to achieve maximum score on a chin-up strength test, and modified scoring tables that equalize this likelihood across the stature range are sought. Methods. A statistical summary of 85 chin-up test outcomes is analyzed for likelihood of maximum scores as a function of stature. Scoring tables modified by reducing the number of chin-ups required for maximum score in a ratio inverse to a fixed power of the stature ratios are introduced. Results. Statistical analysis shows that short individuals are more likely to achieve maximum chin-up test scores (P<0.05). Stature adjusted scoring tables are shown to neutralize this trend. Conclusion. Current scoring standards for chin-up strength tests favor short statures. Bias-free chin-up strength tests can be achieved by using stature-adjusted scoring tables. Similar bias problems may exist for other strength tests. C1 [Sekerak, R. J.] Waikato Hosp, Rehabil Serv, Hamilton, New Zealand. [Zimmermann, K. P.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Zimmermann, K. P.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. RP Zimmermann, KP (reprint author), MEDVAMC, RCL 117,2002 Holcombe, Houston, TX 77030 USA. EM zimmermann.kunop@med.va.gov NR 16 TC 0 Z9 0 U1 1 U2 5 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0022-4707 J9 J SPORT MED PHYS FIT JI J. Sports Med. Phys. Fit. PD MAR PY 2008 VL 48 IS 1 BP 37 EP 42 PG 6 WC Sport Sciences SC Sport Sciences GA 333IT UT WOS:000258146900006 PM 18212708 ER PT J AU Laber, K Veatch, LM Lopez, MF Mulligan, JK Lathers, DMR AF Laber, Kathy Veatch, Lynn M. Lopez, Marcelo F. Mulligan, Jennifer K. Lathers, Deanne M. R. TI Effects of housing density on weight gain, immune function, behavior, and plasma corticosterone concentrations in BALB/c and C57BL/6 mice SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE LA English DT Article ID INBRED MOUSE STRAINS; CAGE FLOOR SPACE; DENDRITIC CELLS; ADULT MICE; STRESSOR; ANXIETY; INFECTION; EXPOSURE; NOVELTY AB The Guide for the Care and Use of Laboratory Animals contains recommended housing densities for rodent species that are commonly used by the scientific community. However, at the time of the Guide's publication, housing density recommendations were based heavily on the professional judgment of qualified scientists. Some scientists therefore question whether rodents can be housed at greater densities, whereas others wonder whether the space currently provided for rodents is sufficient. The present study was designed to determine the effect of housing adult female BALB/c- and C57BL/6-mice in standard 75-in(2) (484-cm(2)) ventilated cages at various housing densities (n = 2, 5, and 10 mice/cage). Measures of weight gain, plasma corticosterone, behavior, and immune parameters were evaluated at 7,28, and 70 d after housing allocation. Housing BALB/c mice at 10/cage had negative effects on weight gain, corticosterone, behavior, and immune parameters. Housing C57BL/6 mice at 10/cage did not affect immune function or weight gain, although behavior and corticosterone showed statistical trends implying a negative effect Differences associated with housing densities of 2 and 5 mice/cage were less robust for all variables measured. We conclude that housing female BALB/c mice at 10 mice/cage (that is, at twice the Guide-recommended density) affects their physiology. We also conclude that mice vary in their responses in the parameters measured. These observations support the conclusion that it will be extremely challenging to scientifically determine an optimal cage density standard that can be uniformly applied across all mouse strains. C1 [Laber, Kathy; Veatch, Lynn M.; Lopez, Marcelo F.; Mulligan, Jennifer K.; Lathers, Deanne M. R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Laber, Kathy; Veatch, Lynn M.; Lathers, Deanne M. R.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Laber, K (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. EM laberlk@musc.edu NR 36 TC 26 Z9 26 U1 1 U2 4 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1559-6109 J9 J AM ASSOC LAB ANIM JI J. Amer. Assoc. Lab. Anim. Sci. PD MAR PY 2008 VL 47 IS 2 BP 16 EP 23 PG 8 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 279OJ UT WOS:000254364200003 PM 18351717 ER PT J AU White, HK Levy, C AF White, Heidi K. Levy, Cari TI AMDA foundation futures: Inspiring the next generation of long-term care physicians SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Editorial Material C1 [White, Heidi K.] Duke Univ, Sch Med, Div Geriatr, Durham, NC 27710 USA. [White, Heidi K.] VA Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Levy, Cari] Denver Vet Affairs Med Ctr, Denver, CO USA. [Levy, Cari] Univ Colorado, Denver, CO 80202 USA. [Levy, Cari] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP White, HK (reprint author), Duke Univ, Sch Med, Div Geriatr, Box 3003, Durham, NC 27710 USA. EM White031@mc.duke.edu NR 0 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAR PY 2008 VL 9 IS 3 BP 147 EP 148 DI 10.1016/j.jamda.2007.12.094 PG 2 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 272AA UT WOS:000253828600003 PM 18294595 ER PT J AU Ix, JH Katz, R Kestenbaum, B Fried, LF Kramer, H Stehman-Breen, C Shlipak, MG AF Ix, Joachim H. Katz, Ronit Kestenbaum, Bryan Fried, Linda F. Kramer, Holly Stehman-Breen, Catherine Shlipak, Michael G. TI Association of mild to moderate kidney dysfunction and coronary calcification SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CYSTATIN-C CONCENTRATION; GLOMERULAR-FILTRATION-RATE; BEAM COMPUTED-TOMOGRAPHY; ARTERY CALCIFICATION; HEART-FAILURE; CARDIOVASCULAR EVENTS; SERUM CREATININE; RENAL-DISEASE; ATHEROSCLEROSIS MESA; ELDERLY PERSONS AB Coronary artery calcification (CAC) is prevalent and predicts mortality among patients with ESRD, but whether less severe kidney dysfunction is associated with CAC is uncertain. To address this question, 6749 participants of the Multi-Ethnic Study of Atherosclerosis, who were middle-aged and without known cardiovascular disease, were evaluated. Renal function was categorized by cystatin C quartiles and estimated GFR (eGFR; < to > 60 ml/min per 1.73 m(2)), and CAC was evaluated by computed tomography (CT). Fifty percent of participants had CAC, mean cystatin C was 0.90 mg/L and 10% had eGFR < 60 ml/min per 1.73 m(2). In unadjusted analysis, kidney dysfunction by either measure was strongly associated with CAC; however, the associations were lost after adjustment for age, gender, race, hypertension, and IL-6 (relative risk 1.04 [95% confidence interval 0.97 to 1.11] for the highest cystatin C quartile compared with the lowest, and relative risk 1.03 [95% confidence interval 0.98 to 1.08) for eGFR below compared with above 60 m/min per 1.73 m(2)). Similarly, neither higher cystatin C nor eGFR < 60 was associated with severity of CAC. These results suggest that a higher burden of CAC is unlikely to explain the association between mild to moderate kidney dysfunction and cardiovascular mortality. C1 [Ix, Joachim H.; Shlipak, Michael G.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Kestenbaum, Bryan] Univ Washington, Dept Med, Seattle, WA USA. [Kestenbaum, Bryan] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Stehman-Breen, Catherine] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Med Serv, Pittsburgh, PA USA. [Kramer, Holly] Loyola Univ, Dept Med, Maywood, IL 60153 USA. [Kramer, Holly] Loyola Univ, Div Nephrol, Maywood, IL 60153 USA. [Stehman-Breen, Catherine] Amgen Thousand Oaks, Oakland, CA USA. [Shlipak, Michael G.] Univ Calif San Diego, Dept Epidemiol & Biostat, San Diego, CA 92103 USA. [Shlipak, Michael G.] Vet Affairs Med Ctr, San Diego, CA 92161 USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu OI Kramer, Holly/0000-0002-6374-837X FU NHLBI NIH HHS [N01-HC-95169, N01-HC-95159, N01-HC-95165, N01HC95159, N01HC95165, N01HC95169] NR 48 TC 42 Z9 44 U1 1 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAR PY 2008 VL 19 IS 3 BP 579 EP 585 DI 10.1681/ASN.2007070765 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 270AD UT WOS:000253691200024 PM 18235089 ER PT J AU Howieson, DB Carlson, NE Moore, MM Wasserman, D Abendroth, CD Payne-Murphy, J Kaye, JA AF Howieson, Diane B. Carlson, Nichole E. Moore, M. Milar Wasserman, Dara Abendroth, Cena D. Payne-Murphy, Jessica Kaye, Jeffrey A. TI Trajectory of mild cognitive impairment onset SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article; Proceedings Paper CT 59th Annual Meeting of the American-Academy-of-Neurology CY APR 28-MAY 05, 2007 CL Boston, MA SP Amer Acad Neurol DE dementia; Alzheimer disease; aging; aged 80 and over; episodic memory; longitudinal studies ID PRECLINICAL ALZHEIMERS-DISEASE; HEALTHY OLDEST-OLD; APOLIPOPROTEIN-E; DEMENTIA; DECLINE; PREDICTORS AB The objective was to identify the trajectories of onset of memory and other cognitive loss in persons destined to develop mild cognitive impairment (MCI) or dementia. Healthy, community dwelling, cognitively intact elders (if 156. mean a,,e at entry = 83 years) were examined annually for ail average of greater than 7 years. Those who developed at least two consecutive Clinical Dementia Ratings >= 0.5 were classified as having MCI. Longitudinal mixed effects models with a change point were used to model the aging process in those with and without an MCI diagnosis during follow-up and to model the rate of change relative to the age of onset of MCI. MCI had a preclinical stage of accelerated cognitive loss that was observed 3 to 4 years before the diagnosis of MCI on tests of verbal memory, animal trial fluency, and visuospatial constructions. Evidence from memory performance before the change point suggests that a slow decline in memory precedes the period of accelerated decline in the development of MCI. Aging transitions leading to MCI and dementia are characterized by unique linear and nonlinear cognitive changes in several domains that precede the diagnosis of MCI and dementia by at least several years. C1 [Howieson, Diane B.; Moore, M. Milar; Wasserman, Dara; Abendroth, Cena D.; Payne-Murphy, Jessica; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Carlson, Nichole E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA. [Kaye, Jeffrey A.] Portland VA Med Ctr, Portland, OR USA. RP Howieson, DB (reprint author), Oregon Hlth & Sci Univ, Dept Neurol CR131, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM howiesod@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU NCRR NIH HHS [MO1 RR00334]; NIA NIH HHS [P30 AG008017] NR 30 TC 74 Z9 75 U1 0 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD MAR PY 2008 VL 14 IS 2 BP 192 EP 198 DI 10.1017/S1355617708080375 PG 7 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 338VJ UT WOS:000258537200002 PM 18282317 ER PT J AU Jaroszewski, DE Huh, J Chu, D Malaisrie, SC Riffel, AD Gordon, HS Wang, XL Bakaeen, F AF Jaroszewski, Dawn E. Huh, Joseph Chu, Danny Malaisrie, S. Chris Riffel, Anthony D. Gordon, Howard S. Wang, Xing Li Bakaeen, Faisal TI Utility of detailed preoperative cardiac testing and incidence of post-thoracotomy myocardial infarction SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 33rd Annual Meeting of the Western-Thoracic-Surgical-Association CY JUN 27-30, 2007 CL Santa Ana Pueblo, NM SP Western Thorac Surg Assoc ID PERIOPERATIVE CARDIOVASCULAR EVALUATION; MAJOR VASCULAR-SURGERY; NONCARDIAC SURGERY; RISK; REVASCULARIZATION; GUIDELINES; INDEX AB Objective: Recent literature has questioned the efficacy of routine detailed preoperative cardiac ischemia testing and preoperative cardiac intervention before noncardiac surgical procedures. Methods: We performed a retrospective review of patients undergoing thoracotomy (n = 294) between January of 1999 and January of 2005. Results: The median age was 62 years. Detailed preoperative cardiac testing was performed on 184 patients (63%) and went beyond a thorough history, physical examination, and electrocardiogram to include at least one of the following: dobutamine stress echo (n = 116), nuclear stress test (n = 66), treadmill test (n = 8), and coronary angiogram (n = 40). Evidence for coronary disease was detected in 43% of tests (99/230) performed. Revascularization was performed in 10% of all patients (4/40) who underwent coronary angiography. Postoperative myocardial infarction occurred in 7 patients (2.4%) with 4 myocardial infarction-related mortalities. No significant difference was found in the incidence of myocardial infarction in patients with (n = 184) or without (n = 110) detailed preoperative cardiac testing (3.3% vs 0.9%, P = .29). Of the 4 patients (1.4%) who underwent revascularization to treat coronary lesions identified during prethoracotomy workup, 2 had a myocardial infarction, 1 of which was caused by thrombosis of a coronary stent. In the subset of patients who underwent lobectomy (n = 149), detailed cardiac testing was performed on 107 patients (72%). The incidence of myocardial infarction was similar in tested and untested patients (2.8% vs 2.4% respectively, P = 1.0). Conclusion: Selective use of detailed preoperative cardiac testing refines risk stratification and identifies patients for corrective cardiac interventions; however, it did not prove fully protective against myocardial infarction after thoracotomy in our study. C1 [Jaroszewski, Dawn E.; Huh, Joseph; Chu, Danny; Malaisrie, S. Chris; Riffel, Anthony D.; Gordon, Howard S.; Wang, Xing Li; Bakaeen, Faisal] Baylor Coll Med, Dept Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Jaroszewski, Dawn E.] Mayo Clin, Phoenix, AZ USA. RP Bakaeen, F (reprint author), Baylor Coll Med, Dept Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM fbakaeen@bcm.edu RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 21 TC 6 Z9 6 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2008 VL 135 IS 3 BP 648 EP 655 DI 10.1016/j.jtcvs.2007.09.021 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 272LG UT WOS:000253860300034 PM 18329488 ER PT J AU Stenstrom, DA Muldoon, LL Armijo-Medina, H Watnick, S Doolittle, ND Kaufman, JA Peterson, DR Bubalo, J Neuwelt, EA AF Stenstrom, David A. Muldoon, Leslie L. Armijo-Medina, Hector Watnick, Suzanne Doolittle, Nancy D. Kaufman, John A. Peterson, Darryl R. Bubalo, Joseph Neuwelt, Edward A. TI N-acetylcysteine use to prevent contrast medium-induced nephropathy: Premature phase III trials SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; RADIOCONTRAST-INDUCED NEPHROPATHY; PERFORMANCE LIQUID-CHROMATOGRAPHY; AGENT-ASSOCIATED NEPHROTOXICITY; RENAL-FUNCTION; RADIOGRAPHIC-CONTRAST; CORONARY-ANGIOGRAPHY; CARDIAC-CATHETERIZATION; ORAL ACETYLCYSTEINE; INTRAVENOUS ROUTE AB To date there has been no general consensus regarding the effectiveness of N-acetylcysteine as a protective therapy against contrast medium-induced nephropathy. Several phase III clinical trials have been conducted without a proper understanding of N-acetylcysteine pharmacology, particularly with regard to first-pass hepatic metabolism. A review was conducted of the literature concerning contrast medium-induced nephropathy and new studies of human N-acetylcysteine pharmacology were performed. After an analysis was performed, it was concluded that further phase I and phase 11 trials are needed. The efficacy of N-acetylcysteine in the prevention of contrast medium-induced nephropathy may be demonstrated with the use of higher doses than used in earlier studies, in combination with parenteral administration. C1 [Stenstrom, David A.; Muldoon, Leslie L.; Armijo-Medina, Hector; Doolittle, Nancy D.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97239 USA. [Muldoon, Leslie L.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA. [Kaufman, John A.] Oregon Hlth & Sci Univ, Dept Angiog, Portland, OR 97239 USA. [Bubalo, Joseph] Oregon Hlth & Sci Univ, Dept Pharm, Portland, OR 97239 USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. [Watnick, Suzanne] Div Hosp & Specialty Med, Nephrol Sect, Portland, OR USA. [Peterson, Darryl R.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Physiol & Biophys, N Chicago, IL USA. RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pkwy,L603, Portland, OR 97239 USA. EM neuwelte@ohsu.edu FU NINDS NIH HHS [NS33618, NS44687] NR 75 TC 13 Z9 13 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD MAR PY 2008 VL 19 IS 3 BP 309 EP 318 DI 10.1016/j.jvir.2007.11.003 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 271KV UT WOS:000253788200001 PM 18295688 ER PT J AU Sobkin, PR Bloom, AI Wilson, MW LaBerge, JM Hastings, GS Gordon, RL Brody, LA Sawhney, R Kerlan, RK AF Sobkin, Paul R. Bloom, Allan I. Wilson, Mark W. LaBerge, Jeanne M. Hastings, Geoff S. Gordon, Roy L. Brody, Lynn A. Sawhney, Rajiv Kerlan, Robert K., Jr. TI Massive abdominal wall hemorrhage from injury to the inferior epigastric artery: A retrospective review SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Review ID PSEUDOANEURYSM; PARACENTESIS; COMPLICATION; ANGIOGRAPHY; MANAGEMENT; DIAGNOSIS; HEMATOMA AB PURPOSE: To identify the etiology of inferior epigastric artery injury (IEAI) in patients referred to the interventional radiology service and determine the efficacy of diagnostic imaging and embolization in these patients. MATERIALS AND METHODS: A retrospective review of patients referred to the interventional radiology departments at three university-affiliated hospitals from 1995 through 2007 was performed. Patients were identified and data were extracted from case log books and the electronic medical record. RESULTS: Twenty IEAIs were identified in 19 patients. The etiology of arterial injury was paracentesis in eight (40%), surgical trauma in three (15%), percutaneous drain placement in three (15%), blunt trauma in two (10%), subcutaneous injection in one (5%), stabbing in one (5%), and unknown in two (10%). Fifteen of 19 patients (79%) had an underlying coagulopathy. The diagnosis was confirmed by contrast medium-enhanced computed tomography (CT) in 14 (70%), tagged red blood cell scan in two (10%), and noncontrast CT in one (5%). Three patients (15%) had no diagnostic imaging. Contrast medium-enhanced CT showed active extravasation in nine of 14 patients (64%) and 13 of 14 exhibited active extravasation on subsequent arteriography. The sensitivity and specificity of contrast medium-enhanced CT for demonstrating active arterial bleeding were 70% and 100%, respectively. All 20 IEAIs were treated With transcatheter embolization, with an overall success rate of 90% and no complications. CONCLUSIONS: IEAI is most often an iatrogenic injury in a coagulopathic patient. Contrast medium-enhanced CT can be diagnostic for active bleeding, but in the setting of ongoing hemorrhage a negative study result should not preclude arteriography. Embolization is an effective means to control hemorrhage. C1 [Sobkin, Paul R.; Bloom, Allan I.; LaBerge, Jeanne M.; Gordon, Roy L.; Brody, Lynn A.; Kerlan, Robert K., Jr.] Univ Calif San Francisco, Dept Radiol, Sect Intervent Radiol, San Francisco, CA 94143 USA. [Wilson, Mark W.] San Francisco Gen Hosp, Sect Intervent Radiol, San Francisco, CA 94110 USA. [Sawhney, Rajiv] San Francisco Vet Adm Med Ctr, Sect Intervent Radiol, San Francisco, CA USA. [Hastings, Geoff S.] Kaiser Permanente Med Ctr, Sect Intervent Radiol, Oakland, CA USA. RP Bloom, AI (reprint author), Hassadah Univ, Med Ctr, Dept Radiol, POB 12000, IL-91120 Jerusalem, Israel. EM allan@hassadah.org.il NR 14 TC 13 Z9 13 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD MAR PY 2008 VL 19 IS 3 BP 327 EP 332 DI 10.1016/j.jvir.2007.11.004 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 271KV UT WOS:000253788200003 PM 18295690 ER PT J AU Blutt, SE Warfield, KL Estes, MK Conner, ME AF Blutt, Sarah E. Warfield, Kelly L. Estes, Mary K. Conner, Margaret E. TI Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity SO JOURNAL OF VIROLOGY LA English DT Article ID INTRANASAL IMMUNIZATION; EPITHELIAL-CELLS; CAPSID PROTEINS; VP6 PROTEIN; INFECTION; MICE; DISEASE; LYMPHOCYTES; EXPRESSION; EFFICACY AB Correlates of protection from rotavirus infection are controversial. We compared the roles of B and T lymphocytes in protective immunity induced either by intranasally administered nonreplicating viruslike particles or inactivated virus or by orally administered marine rotavirus. We found that protection induced by nonreplicating vaccines requires CD4(+) T cells and CD40/CD40L. In contrast, T cells were not required for short-term protective immunity induced by infection, but both T-cell-dependent and -independent mechanisms contributed to long-term maintenance of protection. Our findings indicate that more than one marker of protective immunity exists and that these markers depend on the vaccine that is administered. C1 [Blutt, Sarah E.; Warfield, Kelly L.; Estes, Mary K.; Conner, Margaret E.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Blutt, Sarah E.; Conner, Margaret E.] Michael E Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Conner, ME (reprint author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA. EM mconner@bcm.edu FU NIAID NIH HHS [R01 AI080656, R01 AI024998, R21 AI024998, F32 AI010604, AI10604]; NIDDK NIH HHS [DK56338, P30 DK056338] NR 24 TC 11 Z9 11 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2008 VL 82 IS 6 BP 3135 EP 3138 DI 10.1128/JVI.01727-07 PG 4 WC Virology SC Virology GA 270AB UT WOS:000253691000052 PM 18184712 ER PT J AU Kerwin, WS Oikawa, M Yuan, C Jarvik, GP Hatsukami, TS AF Kerwin, W. S. Oikawa, M. Yuan, C. Jarvik, G. P. Hatsukami, T. S. TI MR imaging of adventitial vasa vasorum in carotid atherosclerosis SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE dynamic contrast-enhanced MRI; atherosclerosis; vasa vasorum; kinetic model; carotid artery ID CONTRAST-ENHANCED MRI; IN-VIVO; KINETIC-PARAMETERS; PLAQUE MORPHOLOGY; HIGH-RESOLUTION; FIBROUS-CAP; NEOVASCULARIZATION; ANGIOGENESIS; INFLAMMATION; LESIONS AB Vasa vasorum in the adventitia of atherosclerotic arteries may play a role in plaque progression. In this investigation, a method for characterizing vasa vasorum in the carotid artery is proposed, in which the perfusion properties of the adventitia are probed via dynamic contrast-enhanced (DCE) MRI. A parametric "vasa vasorum image" is automatically generated that depicts the plasma volume (v(p)) and transfer constant (K-trans). The average K-trans within the adventitia is proposed as a quantitative measurement related to the extent of the vasa vasorum. In 25 subjects with lesions meeting the requirements for carotid endarterectomy (CEA) significantly higher adventitial K-trans of 0.155 +/- 0.045 min(-1) was observed, compared to 0.122 +/- 0.029 min(-1) in the remaining 20 subjects with moderate disease (P < 0.01). In the 25 subjects with endarterectomy specimens, histological evaluation showed that adventitial K-trans was significantly correlated with the amount of neovasculature (R = 0.41; P = 0.04) and macrophages (R = 0.49; P = 0.01) in the excised plaque. In the remaining 20 subjects without histology, elevated adventitial Ktrans was significantly correlated with the log of C-reactive protein (CRP) levels (R = 0.57, P = 0.01) and was elevated in active smokers compared to nonsmokers (0.141 +/- 0.036 vs. 0.111 +/- 0.017 min(-1); P = 0.02). Because these factors are all associated with higher risk of atherosclerotic complications, these results suggest that adventitial K-trans may be a marker of risk as well. C1 [Kerwin, W. S.; Oikawa, M.; Yuan, C.] Univ Washington, Dept Radiol, Seattle, WA 98109 USA. [Jarvik, G. P.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Hatsukami, T. S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Hatsukami, T. S.] NIH, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Kerwin, WS (reprint author), Univ Washington, Dept Radiol, 815 Mercer St,Box 358050, Seattle, WA 98109 USA. EM bkerwin@u.washington.edu RI Jarvik, Gail/N-6476-2014 OI Jarvik, Gail/0000-0002-6710-8708 FU NHLBI NIH HHS [R01 HL067406, P01 HL072262, R01 HL073401] NR 40 TC 97 Z9 103 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD MAR PY 2008 VL 59 IS 3 BP 507 EP 514 DI 10.1002/mrm.21532 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 272SX UT WOS:000253881200010 PM 18306402 ER PT J AU Ross, JS Keyhani, S Keenan, PS Bernheim, SM Penrod, JD Boockvar, KS Krumhoz, HM Siu, AL AF Ross, Joseph S. Keyhani, Salomeh Keenan, Patricia S. Bernheim, Susannah M. Penrod, Joan D. Boockvar, Kenneth S. Krumhoz, Harlan M. Siu, Albert L. TI Dual use of veterans affairs services and use of recommended ambulatory care SO MEDICAL CARE LA English DT Article DE quality of health care; United States Department of Veterans Affairs; preventive health services; chronic disease; ambulatory care ID ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; MEDICARE HMOS; PREVENTIVE SERVICES; SYSTEM UTILIZATION; DIABETES CARE; HEALTH; VA; ACCESS; CANCER AB Background: Use of more than one health care system to obtain care is common among adults receiving care within the Veterans Affairs (VA) medical system. It is not known what effect using care from multiple sources has on the quality of care patients receive. Objectives: To examine whether use of recommended ambulatory care services differs between exclusive and dual VA users. Methods: Cross-sectional analysis of the 2004 Behavior Risk Factor Surveillance System, a nationally-representative survey of community-dwelling adults aged 18 years or older. Our outcome measures were self-reported use of 18 recommended services for cancer prevention, cardiovascular risk reduction, diabetes management, and infectious disease prevention. We used multivariable logistic regression to examine the association between exclusive and dual VA use and use of recommended ambulatory services. Results: There were 3470 exclusive VA users and 4523 dual VA users. Dual users were significantly more likely to be older and white, have higher incomes, have graduated from college, and be insured when compared with exclusive VA users. In unadjusted analyses, dual users received higher rates of recommended services. After adjustment for patient characteristics, use of recommended services was largely similar among exclusive and dual VA users. Exclusive VA users reported 14% greater use of breast cancer screening and 10% greater use of cholesterol monitoring among patients with hypercholesterolemia, and 6% lower use of prostate cancer screening and 7% lower use of influenza vaccination. Conclusions: After adjustment for patient characteristics, exclusive and dual VA users reported similar rates of recommended ambulatory service use. C1 [Ross, Joseph S.; Keyhani, Salomeh; Penrod, Joan D.; Boockvar, Kenneth S.; Siu, Albert L.] James J Peters Vet Adm Med Ctr, HSR&D Targeted Res Enhancement Program, Bronx, NY 10468 USA. [Ross, Joseph S.; Keyhani, Salomeh; Penrod, Joan D.; Boockvar, Kenneth S.; Siu, Albert L.] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. [Ross, Joseph S.; Penrod, Joan D.; Boockvar, Kenneth S.; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Keyhani, Salomeh] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY USA. [Keenan, Patricia S.; Krumhoz, Harlan M.] Yale Univ, Sch Med, Div Hlth Policy& Adm, Dept Epidemiol & Publ Hlth, New Haven, CT USA. [Bernheim, Susannah M.] Yale Univ, Sch Med, Sect Geriatr, Dept Internal Med, New Haven, CT USA. [Krumhoz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA. [Krumhoz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Dept Internal Med, New Haven, CT USA. [Krumhoz, Harlan M.] Yale New Haven Hosp Ctr Outcomes Res & Evaluat, New Haven, CT USA. RP Ross, JS (reprint author), James J Peters Vet Adm Med Ctr, HSR&D Targeted Res Enhancement Program, 130 W Kingsbridge Rd,Room 4A-17, Bronx, NY 10468 USA. EM joseph.ross@va.gov OI Boockvar, Kenneth/0000-0003-1165-5558 NR 54 TC 15 Z9 15 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAR PY 2008 VL 46 IS 3 BP 309 EP 316 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 269QX UT WOS:000253665200011 PM 18388846 ER PT J AU Taylor, AB Meyer, B Leal, BZ Kottter, P Schirf, V Demeler, B Hart, PJ Entian, KD Wohnert, J AF Taylor, Alexander B. Meyer, Britta Leal, Belinda Z. Koettter, Peter Schirf, Virgil Demeler, Borries Hart, P. John Entian, Karl-Dieter Woehnert, Jens TI The crystal structure of Nep1 reveals an extended SPOUT-class methyltransferase fold and a pre-organized SAM-binding site SO NUCLEIC ACIDS RESEARCH LA English DT Article ID DEEP TREFOIL KNOT; RIBOSOMAL-RNA; ANGSTROM RESOLUTION; POSTTRANSCRIPTIONAL MODIFICATIONS; MESSENGER-RNA; ACTIVE-SITE; SUBUNIT; PROTEIN; YEAST; METHYLATION AB Ribosome biogenesis in eukaryotes requires the participation of a large number of ribosome assembly factors. The highly conserved eukaryotic nucleolar protein Nep1 has an essential but unknown function in 18S rRNA processing and ribosome biogenesis. In Saccharomyces cerevisiae the malfunction of a temperature-sensitive Nep1 protein ( nep1-1(ts)) was suppressed by the addition of S-adenosylmethionine (SAM). This suggests the participation of Nep1 in a methyltransferase reaction during ribosome biogenesis. In addition, yeast Nep1 binds to a 6-nt RNA-binding motif also found in 18S rRNA and facilitates the incorporation of ribosomal protein Rps19 during the formation of pre-ribosomes. Here, we present the X-ray structure of the Nep1 homolog from the archae-bacterium Methanocaldococcus jannaschii in its free form (2.2A resolution) and bound to the S-adenosylmethionine analog S-adenosylhomocysteine (SAH, 2.15 angstrom resolution) and the antibiotic and general methyltransferase inhibitor sinefungin ( 2.25 angstrom resolution). The structure reveals a fold which is very similar to the conserved core fold of the SPOUT-class methyltransferases but contains a novel extension of this common core fold. SAH and sinefungin bind to Nep1 at a preformed binding C1 [Taylor, Alexander B.; Leal, Belinda Z.; Schirf, Virgil; Demeler, Borries; Hart, P. John; Woehnert, Jens] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, X Ray Crystallog Core Lab, San Antonio, TX 78229 USA. [Meyer, Britta; Koettter, Peter; Entian, Karl-Dieter] Univ Frankfurt, Excellence Ctr Macromol Complexes, D-60438 Frankfurt, Germany. [Meyer, Britta; Koettter, Peter; Entian, Karl-Dieter] Univ Frankfurt, Inst Mol Biowissenschaften, D-60438 Frankfurt, Germany. [Schirf, Virgil; Demeler, Borries] Univ Texas Hlth Sci Ctr San Antonio, Ctr Analyt Ultracentrifugat Macromol Assemblies, San Antonio, TX USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Wohnert, J (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM entian@bio.uni-frankfurt.de; jewoe@biochem.uthscsa.edu RI Entian, Karl-Dieter/D-3080-2011 NR 57 TC 23 Z9 27 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD MAR PY 2008 VL 36 IS 5 BP 1542 EP 1554 DI 10.1093/nar/gkm1172 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 278NY UT WOS:000254294800021 PM 18208838 ER PT J AU Strandberg, L Mellstrom, D Ljunggren, O Grundberg, E Karlsson, MK Holmberg, AH Orwoll, ES Eriksson, AL Svedberg, J Bengtsson, M Ohlsson, C Jansson, JO AF Strandberg, Louise Mellstrom, Dan Ljunggren, Osten Grundberg, Elin Karlsson, Magnus K. Holmberg, Anna H. Orwoll, Eric S. Eriksson, Anna L. Svedberg, Johan Bengtsson, Magnus Ohlsson, Claes Jansson, John-Olov TI IL6 and IL1B Polymorphisms are associated with fat mass in older men: The MrOS study Sweden SO OBESITY LA English DT Article ID MATURE-ONSET OBESITY; INTERLEUKIN-1-BETA GENE; PROMOTER; MICE; EXPRESSION; TRANSCRIPTION; DISEASES; LEPTIN; SYSTEM AB There is growing evidence that immune functions are linked to the regulation of body fat. Our studies of knockout mice indicate that both endogenous interleukin (IL)-6 and IL-1 can suppress mature-onset obesity. We now investigated whether four common polymorphisms of the IL6 and IL1 systems are associated with the fat mass measured with dual-energy X-ray absorptiometry (DXA) in elderly men (n = 3,014). The study subjects were from the Swedish part of the MrOS multicenter population study and 69-81 years of age. The IL6-174 G>C (Minor allele frequency (MAF) = 48%) gene promoter polymorphism was associated with the primary outcome total fat mass (P = 0.006) and regional fat masses, but not with lean body mass. The IL1B-31T>C (MAF = 34%) polymorphism was also associated with total fat (P = 0.007) and regional fat masses, but not lean body mass. The IL-1 receptor antagonist (IL-1ra) gene (IL1RN) + 2018 T>C (MAF = 27%) polymorphism (in linkage disequilibrium (LD) with a well-studied variable number tandem repeat of 86 base pair (bp)) and IL1B + 3953 C>T (MAF = 26%) polymorphism were not associated with total fat mass. In conclusion, the IL-1 and IL-6 systems, shown to suppress mature-onset obesity in experimental animals, contain gene polymorphisms that are associated with fat, but not lean, mass in elderly men. C1 [Strandberg, Louise; Svedberg, Johan; Bengtsson, Magnus; Jansson, John-Olov] Univ Gothenburg, Inst Neurosci & Physiol Endocrinol, Sahlgrenska Acad, Gothenburg, Sweden. [Mellstrom, Dan; Eriksson, Anna L.; Ohlsson, Claes] Sahlgrens Univ Hosp, Sahlgrenska Acad, Ctr Bone Res, Gothenburg, Sweden. [Ljunggren, Osten; Grundberg, Elin] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Karlsson, Magnus K.; Holmberg, Anna H.] Lund Univ, Dept Clin Sci, Clin & Mol Osteoporosis Res Unit, Lund, Sweden. [Karlsson, Magnus K.; Holmberg, Anna H.] Malmo Univ Hosp, Dept Orthopaed, Malmo, Sweden. [Orwoll, Eric S.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Portland, OR 97201 USA. [Orwoll, Eric S.] Portland VA Med Ctr, Portland, OR USA. RP Jansson, JO (reprint author), Univ Gothenburg, Inst Neurosci & Physiol Endocrinol, Sahlgrenska Acad, Gothenburg, Sweden. EM JOJ@medic.gu.se OI Grahnemo, Louise/0000-0001-5276-6612; Orwoll, Eric/0000-0002-8520-7355 NR 22 TC 24 Z9 25 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD MAR PY 2008 VL 16 IS 3 BP 710 EP 713 DI 10.1038/oby.2007.95 PG 4 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 271YA UT WOS:000253823400031 PM 18239554 ER PT J AU Marsh, RA Lucky, AW Walsh, TJ Pacheco, MC Rinaldi, MG Mailler-Savage, E Puel, A Casanova, JL Bleesing, JJ Filippi, MD Williams, DA Daines, MO Filipovich, AH AF Marsh, Rebecca A. Lucky, Anne W. Walsh, Thomas J. Pacheco, M. Cristina Rinaldi, Michael G. Mailler-Savage, Erica Puel, Anne Casanova, Jean-Laurent Bleesing, Jack J. Filippi, Marie-Dominique Williams, David A. Daines, Michael O. Filipovich, Alexandra H. TI Cutaneous infection with Metarhizium anisopliae in a patient with hypohidrotic ectodermal dysplasia and immune deficiency SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Letter ID METARRHIZIUM-ANISOPLIAE C1 [Marsh, Rebecca A.; Bleesing, Jack J.; Filipovich, Alexandra H.] Cincinnati Childrens Hosp, Div Hematol Oncol, Med Ctr, Cincinnati, OH USA. [Lucky, Anne W.] Cincinnati Childrens Hosp, Med Ctr, Div Dermatol, Cincinnati, OH USA. [Walsh, Thomas J.] NCI, Pediat Oncol Branch, Immunocompromised Host Sect, Bethesda, MD 20892 USA. [Pacheco, M. Cristina] Childrens Hosp, Minneapolis, MN USA. [Pacheco, M. Cristina] Clin Minnesota, Minneapolis, MN USA. [Rinaldi, Michael G.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, Lab Serv, San Antonio, TX 78229 USA. [Mailler-Savage, Erica] Univ Cincinnati, Dept Dermatol, Cincinnati, OH USA. [Puel, Anne] Univ Paris 05, INSERM, Lab Human Genet Infect Dis, Necker Med Sch, Paris, France. [Casanova, Jean-Laurent] Univ Paris 05, INSERM, Lab Human Genet Infect Dis & Pediat Hematol Immun, Necker Med Sch, Paris, France. [Filippi, Marie-Dominique; Williams, David A.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati Childrens Res Fdn, Div Expt Hematol, Cincinnati, OH USA. [Daines, Michael O.] Univ Arizona, Med Ctr, Dept Pediat, Tucson, AZ 85721 USA. RP Marsh, RA (reprint author), Cincinnati Childrens Hosp, Div Hematol Oncol, Med Ctr, Cincinnati, OH USA. OI Daines, Michael/0000-0003-2464-9034 NR 5 TC 6 Z9 6 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2008 VL 27 IS 3 BP 283 EP 284 PG 2 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 269PN UT WOS:000253661500023 PM 18277915 ER PT J AU Ogura, E Kageyama, K Hanada, K Kasckow, J Suda, T AF Ogura, Eriko Kageyama, Kazunori Hanada, Komaki Kasckow, John Suda, Toshihiro TI Effects of estradiol on regulation of corticotropin-releasing factor gene and interleukin-6 production via estrogen receptor type beta in hypothalamic 4B cells SO PEPTIDES LA English DT Article DE estradiol; corticotropin-releasing factor; interleukin-6; gene transcription; hypothalamus; stress ID PITUITARY-ADRENAL AXIS; MONOPHOSPHATE-RESPONSIVE ELEMENT; HORMONE PROMOTER ACTIVITY; MESSENGER-RNA EXPRESSION; CENTRAL-NERVOUS-SYSTEM; RAT HYPOTHALAMUS; PLASMA INTERLEUKIN-6; ER-ALPHA; VASOPRESSIN; PATHWAY AB Corticotropin-releasing factor (CRF) is produced in the hypothalamic paraventricular nucleus (PVN) in response to stress and stimulates the release of adrenocorticotropic hormone in the corticotrophs. Estrogens acting centrally are able to modulate the stress responses. In fact, direct estrogenic regulation of CRF gene expression has been demonstrated in various tissues. However, the mechanisms responsible for the actions of estrogens on CRF regulation in the PVN remain undetermined. We investigated whether estradiol (E2) contributes to the regulation of CRF gene and promoter activity in hypothalamic 4B cells. Furthermore, the involvement of E2 in the regulation of interleukin (IL)-6 and its role in hypothalamic 4B cells was explored. We demonstrated the dominant expression of estrogen receptor type beta (ER beta) and found that a physiologically relevant dose of E2 and an ER beta agonist stimulated CRF gene transcription in hypothalamic 4B cells. E2 stimulated IL-6 transcriptional activity via ER beta, and subsequently the levels of IL-6 mRNA and protein. We also found that treatment with IL-6 significantly reduced cell viability. Thus, these data suggest the important effects of E2 on the regulation of CRF gene and IL-6 production via ER beta in hypothalamic 4B cells. (c) 2007 Elsevier Inc. All rights reserved. C1 [Kasckow, John] Univ Pittsburgh, Western Psychiat Inst & Clin, Pittsburgh, PA 15206 USA. [Kasckow, John] Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15206 USA. [Ogura, Eriko; Kageyama, Kazunori; Hanada, Komaki; Suda, Toshihiro] Hirosaki Univ, Grad Sch Med, Dept Endocrinol & Metab, Hirosaki, Aomori 0368562, Japan. RP Kageyama, K (reprint author), Hirosaki Univ, Grad Sch Med, Dept Endocrinol & Metab, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan. EM kkageyama@hkg.odn.ne.jp NR 45 TC 16 Z9 16 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD MAR PY 2008 VL 29 IS 3 BP 456 EP 464 DI 10.1016/j.peptides.2007.11.007 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 287JE UT WOS:000254912600018 PM 18160129 ER PT J AU Nguyen, SI Eaton, SA Bain, AM Rahman, AP Payne, KD Bedimo, R Herrington, JD Maclayton, DO Rodriguez-Barradas, MC Busti, AJ AF Nguyen, Scan I. Eaton, Susan A. Bain, Amy M. Rahman, Anita P. Payne, Kenna D. Bedimo, Roger Herrington, Jon D. Maclayton, Darego O. Rodriguez-Barradas, Maria C. Busti, Anthony J. TI Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active Antiretroviral therapy in patients with human immunodeficiency virus SO PHARMACOTHERAPY LA English DT Article; Proceedings Paper CT Annual Scientific Sessions of the National-Lipid-Association CY MAY 31-JUN 04, 2007 CL Scottsdale, AZ SP Natl Lipid Assoc DE atazanavir; ritonavir; protease inhibitor; human immunodeficiency virus; HIV; dyslipidemia; antiretroviral therapy ID PROTEASE INHIBITOR THERAPY; HIV-INFECTED PATIENTS; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; PERIPHERAL LIPODYSTROPHY; METABOLIC ABNORMALITIES; INCREASED RISK; HYPERLIPIDEMIA; LIPOPROTEIN AB Study Objective. To evaluate the efficacy, safety, and lipid-lowering effects after switching from a non-atazanavir-containing, protease inhibitor-based highly active antiretroviral therapy (HAART) to atazanavir-ritonavir-based HAART in patients infected with human immunodeficiency virus (HIV). Design. Multicenter, noncontrolled, retrospective study. Setting. Three tertiary teaching hospitals. Patients. Thirty-six patients with HIV infection, aged 18 years or older, who were receiving non-atazanavir-containing, protease inhibitor-based HAART that was switched to atazanavir 300 mg-ritonavir 100 mg-based HAART without changes in nucleoside reverse transcriptase inhibitors and confounders known to Alter serum lipid levels. Measurements and Main Results. Lipid profiles measured 4 weeks-6 months before the switch, as well as follow-up lipid profiles measured 4 weeks-6 months after receiving the new HAART regimen, were evaluated. The switch resulted in the following changes in lipid levels: total cholesterol -9% (p=0.002), low-density lipoprotein cholesterol -13% (p<0.001), high-density lipoprotein cholesterol (HDL) -2% (p=0.431), triglycerides -23% (p=0.007), non-HDL -11% (p=0.002), total cholesterol:HDL ratio -10% (p=0.004), and triglyceride:HDL ratio -24% (p=0.019). A subgroup analysis was conducted on the lipid profiles of nine patients who stilt met the strict inclusion and exclusion criteria up to 9 months after the switch; it showed that the reductions in their lipid profiles were sustained. In addition, 33% more patients achieved their National Cholesterol Education Panel (NCEP) Adult Treatment Panel (ATP) III cholesterol goals. No significant changes were noted in median (interquartile range) CD4(+) counts (372 [236-551] and 361 [217-464] cells/mm(3), p=0.118) or in number of patients with undetectable HIV viral loads ([defined as < 50 copies/ml] 32/36 and 31/36 patients, p>0.05) between baseline and after the switch, respectively Conclusion. Switching to an atazanavir-ritonavir-based HAART regimen was associated with significant improvement in lipid profiles, similar to those seen in clinical trials, without compromising safety or viral and immunologic control. In addition, more patients were able to achieve their NCEP ATP III goals. C1 [Nguyen, Scan I.; Eaton, Susan A.; Bain, Amy M.; Rahman, Anita P.; Payne, Kenna D.; Busti, Anthony J.] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dallas, TX 75216 USA. [Bain, Amy M.; Rahman, Anita P.; Payne, Kenna D.; Bedimo, Roger; Busti, Anthony J.] N Texas Vet Affairs Med Ctr, Dallas, TX USA. [Bedimo, Roger] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Herrington, Jon D.] Scott & White Mem Hosp & Clin, Temple, TX 76508 USA. [Maclayton, Darego O.] Texas So Univ, Coll Pharm & Hlth Sci, Houston, TX 77004 USA. [Maclayton, Darego O.; Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Maclayton, Darego O.; Rodriguez-Barradas, Maria C.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Busti, AJ (reprint author), Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dallas Ft Worth Reg Campus,4500 S Lancaster Rd,Bl, Dallas, TX 75216 USA. EM anthony.busti@ttuhsc.edu NR 41 TC 21 Z9 21 U1 0 U2 1 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD MAR PY 2008 VL 28 IS 3 BP 323 EP 330 DI 10.1592/phco.28.3.323 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 269PM UT WOS:000253661400006 PM 18294112 ER PT J AU Katyar, SK Meleth, S Sharma, SD AF Katyar, Santosh K. Meleth, Sreelatha Sharma, Som D. TI Silymarin, a flavonoid from milk thistle (Silybum marianum L.), inhibits UV-induced oxidative stress through targeting infiltrating CD11b(+) cells in mouse skin SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Article ID TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE; TYPE-3 COMPLEMENT RECEPTOR; ANTIGEN-PRESENTING CELLS; ULTRAVIOLET-RADIATION; INFLAMMATORY CELLS; IMMUNE SUPPRESSION; IRRADIATED SKIN; TUMOR-GROWTH; IN-VIVO; PHOTOCARCINOGENESIS AB Phytochemicals have shown promise in inhibiting UV-induced oxidative stress, and therefore are considered as potent inhibitors of UV-induced oxidative stress-mediated skin diseases. We have shown previously that topical treatment of sillymarin, a flavonoid from milk thistle (Silybum marianum), inhibits UV-induced oxidative stress in mouse skin. However, the cellular targets responsible for the inhibition of UV-induced oxidative stress by silymarin are not clearly defined. To address this issue, C3H/HeN mice were UV irradiated (go mJ cm(-2)) with or without topical treatment with silymarin (1 mg cm(-2) skin area). Mice were killed 48 h later and skin samples collected. Flow cytometric analysis of viable dermal cells revealed that the number of infiltrating CD11b+ cells were the major source of oxidative stress (31.8%) in UV-irradiated skin compared with non-UV-exposed skin (0.4%). Treatment of sillymarin inhibited UV-induced oxidative stress through inhibition of infiltrating CD11b+ cells. The analysis of myeloperoxidase also indicated that silymarin significantly (P < 0.001) decreased UV-induced infiltration of leukocytes, and this effect of sillymarin was similar to that of intraperitoneal treatment of mice with monoclonal antibodies to CD11b. The inhibitory effect of silymarin, regardless of whether it is topically treated before or after UV irradiation, was of similar magnitude. Intraperitoneal administration of monoclonal antibodies to CD11b (rat IgG2b) to C3H/HeN mice inhibited UVB-induced oxidative stress generated by both epidermal and dermal cells as is evident by relative fluorescence intensity of oxidized rhodamine. Similar to the effect of anti-CD11b, sillymarin also inhibited UV-induced oxidative stress in both epidermal and dermal cells. Further, CD11b+ and CD11b- cell subsets from UV-treated or silymarin + UV-treated mice were separated by immunomagnetic cell isolation technique from total epidermal and dermal single cell suspensions and analyzed for reactive oxygen species (ROS)/H2O2 production. Analytic data revealed that CD11b+ cell population from UV-irradiated skin resulted in significantly higher production of ROS in both epidermis and dermis than CD11b- cell population, and that silymarin inhibited UV-induced oxidative stress through targeting infiltrating the CD11b+ cell type in the skin. C1 [Katyar, Santosh K.; Sharma, Som D.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA. [Katyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. RP Katyar, SK (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. EM skatiyar@uab.edu NR 28 TC 0 Z9 0 U1 2 U2 5 PU AMER SOC PHOTOBIOLOGY PI AUGUSTA PA BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158 USA SN 0031-8655 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD MAR-APR PY 2008 VL 84 IS 2 BP 266 EP 271 DI 10.1111/j.1751-1097.2007.00241.x PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 270UZ UT WOS:000253747000003 ER PT J AU Yusuf, N Katiyar, SK Elmets, CA AF Yusuf, Nabiha Katiyar, Santosh K. Elmets, Craig A. TI The immunosuppressive effects of phthalocyanine photodynamic therapy in mice are mediated by CD4(+) and CD8(+) T cells and can be adoptively transferred to naive recipients SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Article ID POPULATIONS; INDUCTION; ABSENCE AB Photodynamic therapy (PDT) is a promising treatment modality for malignant tumors but it is also immunosuppressive which may reduce its therapeutic efficacy. The purpose of our study was to elucidate the role of CD4(+) and CD8(+) T cells in PDT immunosuppression. Using silicon phthalocyanine 4 (Pc4) as photosensitizer, nontumor-bearing CD4 knockout (CD4(-/-)) mice and their wild type (WT) counterparts were subjected to Pc4-PDT in a manner identical to that used for tumor regression (1 cm spot size, 0.5 mg kg(-1) Pc4, 110 J cm(-2) light) to assess the effect of Pc4-PDT on cell-mediated immunity. There was a decrease in immunosuppression in CD4(-/-) mice compared with WT mice. We next examined the role of CD8(+) T cells in Pc4-PDT-induced immunosuppression using CD8(-/-) mice following the same treatment regimen used for CD4(-/-) mice. Similar to CD4(-/-) mice, CD8(-/-) mice exhibited less immunosuppression than WT mice. Pc4-PDT-induced immunosuppression could be adoptively transferred with spleen cells from Pc4-PDT treated donor mice to syngenic naive recipients (P < 0.05) and was mediated primarily by T cells, although macrophages were also found to play a role. Procedures that limit PDT-induced immunosuppression but do not affect PDT-induced regression of tumors may prove superior to PDT alone in promoting long-term antitumor responses. C1 [Yusuf, Nabiha; Katiyar, Santosh K.; Elmets, Craig A.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Yusuf, Nabiha; Katiyar, Santosh K.; Elmets, Craig A.] Univ Alabama, Skin Dis Res Ctr, Birmingham, AL 35294 USA. [Yusuf, Nabiha; Katiyar, Santosh K.; Elmets, Craig A.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Elmets, CA (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. EM celmets@uab.edu NR 22 TC 16 Z9 17 U1 1 U2 1 PU AMER SOC PHOTOBIOLOGY PI AUGUSTA PA BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158 USA SN 0031-8655 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD MAR-APR PY 2008 VL 84 IS 2 BP 366 EP 370 DI 10.1111/j.1751-1097.2007.00270.x PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 270UZ UT WOS:000253747000014 PM 18208456 ER PT J AU Pilcher, CD Wong, JK Pillai, SK AF Pilcher, Christopher D. Wong, Joseph K. Pillai, Satish K. TI Inferring HIV transmission dynamics from phylogenetic sequence relationships SO PLOS MEDICINE LA English DT Editorial Material ID INFECTION; RESISTANCE; TYPE-1; RATES C1 [Pilcher, Christopher D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Wong, Joseph K.; Pillai, Satish K.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Pilcher, CD (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. EM cpilcher@php.ucsf.edu FU NIDA NIH HHS [K01 DA024654]; NIMH NIH HHS [R01 MH068686]; NINDS NIH HHS [R01 NS051132] NR 14 TC 2 Z9 4 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD MAR PY 2008 VL 5 IS 3 BP 350 EP 352 AR 069 DI 10.1371/journal.pmed.0050069 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 287PL UT WOS:000254928900006 PM 18351799 ER PT J AU Hammad, SM Crellin, HG Wu, BX Melton, J Anelli, V Obeid, LM AF Hammad, Samar M. Crellin, Heather G. Wu, Bill X. Melton, Jessica Anelli, Viviana Obeid, Lina M. TI Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages SO PROSTAGLANDINS & OTHER LIPID MEDIATORS LA English DT Article DE sphingosine kinase; sphingosine 1 phosphate; inflammation; TNF; LPS; apoptosis ID SIGNAL-TRANSDUCTION; MONOCYTIC CELLS; TNF-ALPHA; KAPPA-B; KINASE; ACTIVATION; RECEPTORS; 1-PHOSPHATE; SURVIVAL; EXPRESSION AB Sphingosine kinase 1 (SK1) and its product sphingosine-1-phosphate (SIP) have been implicated in the regulation of many cellular processes including growth regulation, protection from apoptosis, stimulation of angiogenesis, and most recently as mediators of the TNF-alpha inflammatory response. In this study we set out to examine the role of SK1/S1P in the RAW macrophage response to the potent inflammatory stimulus lipopolysaccharide (LPS). We show that LPS increases cellular levels of SK1 message and protein. This increase is at the transcriptional level and is accompanied by increased SK activity and generation of S1P. S1P is able to cause increases in COX-2 and PGE2 levels in RAW cells. Knockdown of SK1 using siRNA is able to inhibit the TNF but not the LPS inflammatory response. Moreover, knockdown of SK1 enhances both TNF- and LPS-induced apoptosis. These data indicate that there is a dual and distinct role for SK1 and S1P in the TNF and the LPS inflammatory pathways. (C) 2007 Elsevier Inc. All rights reserved. C1 [Obeid, Lina M.] Med Univ S Carolina, Dept Med, Div Gen Internal Med Geriatr, Charleston, SC 29403 USA. [Obeid, Lina M.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Hammad, Samar M.] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29403 USA. [Crellin, Heather G.; Wu, Bill X.; Anelli, Viviana; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA. [Melton, Jessica] Med Univ S Carolina, Coll Grad Studies, Summer Undergrad Res Program, Charleston, SC 29403 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med Geriatr, POB 250779, Charleston, SC 29403 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA097132, P01 CA097132-01A10003]; NIGMS NIH HHS [R01 GM062887, R01 GM062887-07] NR 37 TC 47 Z9 48 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-8823 J9 PROSTAG OTH LIPID M JI Prostaglandins Other Lipid Mediat. PD MAR PY 2008 VL 85 IS 3-4 BP 107 EP 114 DI 10.1016/j.prostaglandins.2007.11.002 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 286CS UT WOS:000254823700005 PM 18166496 ER PT J AU Henderson, C Bainbridge, J Keaton, K Kenton, M Guz, M Kanis, B AF Henderson, Claire Bainbridge, Jay Keaton, Kim Kenton, Martha Guz, Meghan Kanis, Becky TI The use of data to assist in the design of a new service system for homeless veterans in new york city SO PSYCHIATRIC QUARTERLY LA English DT Article DE homelessness; veterans; transitional housing AB Objective Operation Home is an agreement between the City of New York and the US Department of Veterans Affairs to design a new service system to help end veteran homelessness in New York City. The authors' task was to obtain data to inform the design of this new system. Methods A variety of methods were used. The group reviewed relevant literature and data from street homeless survey samples, analyzed shelter data, and consulted with VA homeless program staff on the findings. We then surveyed case managers at a veterans' shelter regarding their clients and determined their housing eligibility using a standardized logic model, and led two focus groups of veterans at this shelter regarding their views of the current shelter system and services for homeless veterans and how these might be improved. Results Among those resident in shelters during 2006, 37.2% of self-identified veterans compared to 0.9% of others reported their prior residence as supported housing, suggesting the need for more intensive case management at veterans' supported housing sites to help them sustain their tenure. The lack of interconnectedness among the various information systems made it more difficult to collect and analyze pertinent data. To begin to address this, a data match was undertaken to estimate the proportion of veterans resident in the veterans' shelter who were not in receipt of VA benefits to which they may be entitled. Conclusion The data obtained through collaboration between staff from NYC's Department of Homelessness Services, US Department of Veterans Affairs facilities in the New York/New Jersey region and Common Ground Community led to information that informed the evaluation design of the new system. The identification of gaps in available data on homeless veterans will lead to projects both to improve and share data. C1 [Henderson, Claire] James J Peters VA Med Ctr, VISN MIRECC 3, Bronx, NY 10468 USA. [Keaton, Kim; Guz, Meghan] New York City Dept Homeless Serv, Qual Assurance Program Evaluat & Policy Anal Unit, Div Adult Serv, New York, NY USA. [Kenton, Martha] New York City Dept Homeless Serv, Tech Assistance & Training Div Adult Serv, New York, NY USA. [Kanis, Becky] Common Ground Community, New York, NY USA. RP Henderson, C (reprint author), James J Peters VA Med Ctr, VISN MIRECC 3, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Rosalind.Henderson@va.gov NR 5 TC 2 Z9 2 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0033-2720 J9 PSYCHIAT QUART JI Psychiatr. Q. PD MAR PY 2008 VL 79 IS 1 BP 3 EP 17 DI 10.1007/s11126-007-9060-0 PG 15 WC Psychiatry SC Psychiatry GA 270YK UT WOS:000253755900002 PM 18060499 ER PT J AU Henderson, C Bainbridge, J Keaton, K Kenton, M Guz, M Kanis, B AF Henderson, Claire Bainbridge, Jay Keaton, Kim Kenton, Martha Guz, Meghan Kanis, Becky TI The use of data to assist in the design of a new service system for homeless veterans in New York City (vol 79, pg 19, 2008) SO PSYCHIATRIC QUARTERLY LA English DT Correction C1 [Henderson, Claire] James J Peters VA Med Ctr, VISN MIRECC 3, Bronx, NY 10468 USA. [Kenton, Martha; Guz, Meghan] Ney York City Dept Homeless Serv, Qual Assurance Program Evaluat & Policy Anal Unit, Div Adult Serv, New York, NY USA. [Kenton, Martha] Ney York City Dept Homeless Serv, Tech Assistance & Training Div Adult Serv, New York, NY USA. [Kanis, Becky] Common Ground Community, New York, NY USA. RP Henderson, C (reprint author), James J Peters VA Med Ctr, VISN MIRECC 3, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Rosalind.Henderson@va.gov RI Henderson, Claire/E-4664-2010 OI Henderson, Claire/0000-0002-6998-5659 NR 1 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0033-2720 J9 PSYCHIAT QUART JI Psychiatr. Q. PD MAR PY 2008 VL 79 IS 1 BP 19 EP 19 DI 10.1007/s11126-007-9066-7 PG 1 WC Psychiatry SC Psychiatry GA 270YK UT WOS:000253755900003 ER PT J AU Leontieva, L Dimmock, JA Gately, PW Gallinger, L Ploutz-Snyder, R Batki, SL AF Leontieva, Luba Dimmock, Jacqueline A. Gately, Paul W. Gallinger, Lisa Ploutz-Snyder, Robert Batki, Steven L. TI Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders SO PSYCHIATRIC SERVICES LA English DT Article ID PATIENT FACTORS; REINFORCEMENT; ABUSE; METAANALYSIS; INDIVIDUALS; DEPENDENCE; ABSTINENCE; ADHERENCE AB Objective: This study assessed the feasibility of voucher-based incentives for attendance for directly observed naltrexone treatment in a controlled trial for alcohol use disorders in schizophrenia. Methods: Cash-value voucher-based incentives were contingent on attendance at three research visits per week over 12 weeks for 61 participants. Vouchers increased in value based on consecutive attendance. Missed visits resulted in reduction of voucher value. Results: Participants attended 82% of all research visits. Average value of vouchers earned was $330 (78% of the maximum possible). Psychotic symptom severity at baseline did not affect the utilization of vouchers, and 94% of participants perceived the incentive system as helpful. Conclusions: The incentive system was well accepted and used despite psychosis severity, and the attendance rate was high, although causality between incentives and attendance could not be examined. A voucherbased incentive system for attendance can be successfully applied in a clinical trial for alcohol dependence treatment in schizophrenia. C1 [Leontieva, Luba; Dimmock, Jacqueline A.; Gately, Paul W.; Gallinger, Lisa] SUNY Syracuse, Upstate Med Ctr, Dept Psychiat, Syracuse, NY 13210 USA. [Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Leontieva, L (reprint author), SUNY Syracuse, Upstate Med Ctr, Dept Psychiat, 750 E Adams St, Syracuse, NY 13210 USA. EM leontiel@upstate.edu FU NIAAA NIH HHS [R01-AA-013655] NR 15 TC 2 Z9 2 U1 4 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2008 VL 59 IS 3 BP 310 EP 314 DI 10.1176/appi.ps.59.3.310 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 271KX UT WOS:000253788400015 PM 18308913 ER PT J AU Zhu, BJ Ascher-Svanum, H Shi, LZ Faries, D Montgomery, W Marder, SR AF Zhu, Baojin Ascher-Svanum, Haya Shi, Lizheng Faries, Douglas Montgomery, William Marder, Stephen R. TI Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia SO PSYCHIATRIC SERVICES LA English DT Article ID HOSPITALIZATION; DRUGS AB Objective: This study compared the time to discontinuation for any reason of first-generation antipsychotics-in oral versus depot formulation-in the usual care of schizophrenia. Methods: This study used data from a three-year, prospective, nonrandomized, noninterventional, multisite study of schizophrenia. Participants initiated on oral haloperidol or fluphenazine (N=202) were compared with those initiated on haloperidol or fluphenazine in depot formulation (N=97) on time to all-cause discontinuation for one year after initiation, by using Kaplan-Meier survival analysis, a Cox proportional hazards regression model, and propensity score-adjusted bootstrap resampling methods. Results: Compared with participants treated with the oral formulation, those treated with depot first-generation antipsychotics had a significantly longer mean time to all-cause medication discontinuation and were twice as likely to stay on the medication. Conclusion: In the usual care of schizophrenia, treatment with first-generation antipsychotics in depot formulation appears to be associated with longer time to all-cause medication discontinuation compared with oral formulation of the same medication. C1 [Zhu, Baojin; Ascher-Svanum, Haya; Faries, Douglas; Montgomery, William] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA. [Shi, Lizheng] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Marder, Stephen R.] Univ Calif Los Angeles, Sch Med, Dept Psychiat, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90024 USA. [Marder, Stephen R.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. RP Ascher-Svanum, H (reprint author), Eli Lilly & Co, Lilly Corp Ctr, Drop 4133, Indianapolis, IN 46285 USA. EM haya@lilly.com NR 10 TC 36 Z9 36 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2008 VL 59 IS 3 BP 315 EP 317 DI 10.1176/appi.ps.59.3.315 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 271KX UT WOS:000253788400016 PM 18308914 ER PT J AU Rodriguez, KL Gambino, FJ Butow, PN Hagerty, RG Arnold, RM AF Rodriguez, Ken L. Gambino, Frank J. Butow, Phyllis N. Hagerty, Rebecca G. Arnold, Robert M. TI 'It's going to shorten your life': framing of oncologist-patient communication about prognosis SO PSYCHO-ONCOLOGY LA English DT Article DE communication; prognosis; care : terminal; death; qualitative research ID EARLY BREAST-CANCER; TREATMENT PREFERENCES; CARE; INFORMATION; DIAGNOSIS; MESSAGES; LANGUAGE; DISEASE; WOMEN; TRIAL AB In this qualitative study, we used grounded theory techniques to analyze transcripts of 29 first-time encounters between oncologists and patients referred to them with previously diagnosed, incurable cancer. We found that 23 (79%) of the transcripts included 166 examples of prognostic talk. The language used ranged from general to personal, with 25% of statements mentioning no patients (e.g., 'the tumor will usually come back'), 13% mentioning patients other than the current patient (e.g., 'some patients with tumor response will be around for 2-5 years'), 11% mentioning the current patient in the context of others (e.g., 'on average, people like you live a couple of years'), and 51% directly focusing on the patient (e.g., 'this thing's going to kill you eventually'). More statements pertained to treatment-related prognosis than to disease-related prognosis (67 versus 33%). While 31% of statements focused on negative outcomes (loss framing), the remainder either focused on positive outcomes (gain framing) or discussed a combination of positive and negative outcomes (mixed framing). When discussions focused on negative outcomes, general and indirect language was commonly used, perhaps to buffer the patient from news of the poor prognosis. Copyright (C) 2007 John Wiley & Sons, Ltd. C1 [Rodriguez, Ken L.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA 15240 USA. [Rodriguez, Ken L.; Arnold, Robert M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Rodriguez, Ken L.; Arnold, Robert M.] Univ Pittsburgh, Ctr Bioeth & Hlth Law, Pittsburgh, PA USA. [Gambino, Frank J.] Carnegie Mellon Univ, Dept English, Pittsburgh, PA 15213 USA. [Butow, Phyllis N.; Hagerty, Rebecca G.] Univ Sydney, Sch Psychol, Med Psychol Res Unit, Sydney, NSW 2006, Australia. RP Rodriguez, KL (reprint author), VA Pittsburgh Healthcare Syst, CHERP, 151C U,Univ Dr C,Bldg 28,Rm,1A115, Pittsburgh, PA 15240 USA. EM Keri.Rodriguez@va.gov FU NCATS NIH HHS [UL1 TR000005]; NCI NIH HHS [3R01 CA100387-03S1] NR 38 TC 9 Z9 9 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOL JI Psycho-Oncol. PD MAR PY 2008 VL 17 IS 3 BP 219 EP 225 DI 10.1002/pon.1223 PG 7 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 280GJ UT WOS:000254413400002 PM 17575562 ER PT J AU Kunik, ME Veazey, C Cully, JA Souchek, J Graham, DP Hopko, D Carter, R Sharafkhaneh, A Goepfert, EJ Wray, N Stanley, MA AF Kunik, M. E. Veazey, C. Cully, J. A. Souchek, J. Graham, D. P. Hopko, D. Carter, R. Sharafkhaneh, A. Goepfert, E. J. Wray, N. Stanley, M. A. TI COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: a randomized controlled trial SO PSYCHOLOGICAL MEDICINE LA English DT Article DE anxiety; chronic obstructive pulmonary disease; cognitive behavioral therapy; depression ID OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; OLDER MEDICAL PATIENTS; GENERALIZED ANXIETY; PRIMARY-CARE; ELDERLY-PATIENTS; HEALTH-STATUS; PREVALENCE; MANAGEMENT; INVENTORY AB Background. Chronic obstructive pulmonary disease (COPD) affects 14 to 20 million Americans and is associated with increased prevalence of affective disorders, contributing significantly to disability. This study compared cognitive behavioral therapy (CBT) group treatment for anxiety and depression with COPI) education for COPI) patients with moderate-to-severe anxiety and/or depressive symptoms. Method. A randomized controlled trial (RCT) was conducted between 11 July 2002 and 30 April 2005 at the Michael E. DeBakey VA Medical Center, Houston, TX. Participants were 238 patients treated for COPD the year before, with forced expiratory value in 1 second (FEV)(1)/forced vital capacity (FVC) < 70% and FEVI < 70% predicted, and symptoms of moderate anxiety and/or moderate depression, who were being treated by a primary care provider or pulmonologist. Participants attended eight sessions of CBT or COPD education. Assessments were at baseline, at 4 and 8 weeks, and 4,8 and 12 months. Primary outcomes were disease-specific and generic quality of life (QoL) [Chronic Respiratory Questionnaire (CRQ) and Medical Outcomes Survey Short Form-36 (SF-36) respectively]. Secondary outcomes were anxiety [Beck Anxiety Inventory (BAI)], depressive symptoms [Beck Depression Inventory-II (BDI-II)], 6-minute walk distance (6MWD) and use of health services. Results. Both treatments significantly improved QoL, anxiety and depression (p<0.005) over 8 weeks; the rate of change did not differ between groups. Improvements were maintained with no significant change during follow-up. Ratios of post- to pretreatment use of health services were equal to 1 for both groups. Conclusions. CBT group treatment and COPD education can achieve sustainable improvements in QoL for COPI) patients experiencing moderate-to-severe symptoms of depression or anxiety. C1 [Kunik, M. E.; Cully, J. A.; Souchek, J.; Graham, D. P.; Wray, N.; Stanley, M. A.] Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. [Kunik, M. E.; Cully, J. A.; Souchek, J.; Graham, D. P.; Sharafkhaneh, A.; Wray, N.; Stanley, M. A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Kunik, M. E.; Cully, J. A.; Graham, D. P.; Goepfert, E. J.; Stanley, M. A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Kunik, M. E.; Souchek, J.; Sharafkhaneh, A.; Wray, N.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Veazey, C.] NW State Univ Louisiana, Natchitoches, LA USA. [Hopko, D.] Univ Tennessee, Dept Psychol, Knoxville, TN 37996 USA. [Carter, R.] Texas Tech Univ, Lubbock, TX 79409 USA. RP Kunik, ME (reprint author), Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. EM mkunik@bcm.tmc.edu RI Graham, David /J-1158-2014; Wray, Naomi/C-8639-2015 OI Wray, Naomi/0000-0001-7421-3357 NR 60 TC 85 Z9 88 U1 2 U2 26 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD MAR PY 2008 VL 38 IS 3 BP 385 EP 396 DI 10.1017/S0033291707001687 PG 12 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 281FF UT WOS:000254481600010 PM 17922939 ER PT J AU Labarere, J Bosson, JL Francois, P Fine, MJ AF Labarere, J. Bosson, J. -L. Francois, P. Fine, M. J. TI Propensity score analysis in observational research: Application to a study of prophylaxis against venous thromboembolism SO REVUE DE MEDECINE INTERNE LA French DT Article DE propensity score; observational studies; adjustment; venous thromboembolism ID OUTCOMES; BIAS; INPATIENTS AB Introduction. - In observational studies, a significant difference in the outcomes between treated and untreated patients may be observed in absence of treatment effect and caused by differences in baseline characteristics. Exegesis. - Propensity score analysis is a post hoe adjustment method which consists in deriving the conditional probability of receiving the treatment for a patient given his measured baseline characteristics (i.e., the propensity score). Matching each treated patient to an untreated one who has the nearest propensity score tends to balance baseline characteristics between the two groups and reduce the risk for overt bias. Then, the outcomes can be compared between matched treated and untreated patients. Conclusion. - Propensity score analysis is relevant for clinical conditions and treatments for which randomized controlled trials are unlikely to be conducted. However, propensity analysis cannot adjust for unmeasured characteristics and sensitivity analysis should be performed to assess how sensitive the conclusions are to potential confounding factors. (C) 2007 Publie par Elsevier Masson SAS. C1 [Labarere, J.; Bosson, J. -L.; Francois, P.] Univ Grenoble 1, Lab THEMAS, TIMC, CNRS,UMR 5525,Ctr Hosp, F-38043 Grenoble, France. [Labarere, J.; Francois, P.] Univ Grenoble 1, Ctr Hosp, Unite Evaluat Med, F-38043 Grenoble, France. [Fine, M. J.] Univ Pittsburgh, VA Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Fine, M. J.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15240 USA. RP Labarere, J (reprint author), Univ Grenoble 1, Lab THEMAS, TIMC, CNRS,UMR 5525,Ctr Hosp, F-38043 Grenoble, France. EM jlabarere@chu-grenoble.fr RI Labarere, Jose/N-1688-2014 OI Labarere, Jose/0000-0001-7621-6586 NR 12 TC 2 Z9 2 U1 1 U2 3 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0248-8663 J9 REV MED INTERNE JI Rev. Med. Interne PD MAR PY 2008 VL 29 IS 3 BP 255 EP 258 DI 10.1016/j.revmed.2007.08.001 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 274XQ UT WOS:000254036500020 PM 17976869 ER PT J AU van Erp, TGM Lesh, TA Knowlton, BJ Bearden, CE Hardt, M Karlsgodt, KH Shirinyan, D Rao, V Green, MF Subotnik, KL Nuechterlein, K Cannon, TD AF van Erp, Theo G. M. Lesh, Tyler A. Knowlton, Barbara J. Bearden, Carrie E. Hardt, Molly Karlsgodt, Katherine H. Shirinyan, David Rao, Vikas Green, Michael F. Subotnik, Kenneth L. Nuechterlein, Keith Cannon, Tyrone D. TI Remember and know judgments during recognition in chronic schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; psychosis; chronic; memory; episodic; recognition; recollection; familiarity; context; remember; know ID SIGNAL-DETECTION-THEORY; CONSCIOUS RECOLLECTION; DECISION-PROCESSES; MEMORY; FAMILIARITY; METAANALYSIS; IMPAIRMENT; MECHANISMS; AWARENESS; DEFICITS AB Deficits in learning and memory are among the most robust correlates of schizophrenia. It has been hypothesized that these deficits are in part due to reduced conscious recollection and increased reliance on familiarity assessment as a basis for retrieval. The Remember-Know (R-K) paradigm was administered to 35 patients with chronic schizophrenia and 35 healthy controls. In addition to making "remember" and "know" judgments, the participants were asked to make forced-choice recognition judgments with regard to details about the learning episode. Analyses comparing response types showed a significant reduction in "remember" responses and a significant increase in "know" responses in schizophrenia patients relative to controls. Both patients and controls recalled more details of the learning episode for "remember" compared to "know" responses, although, in particular for "remember" responses, patients recalled fewer details compared with controls. Notably, patients recognized fewer inter-item but not intra-item stimulus features compared with controls. These findings suggest deficits in organizing and integrating relational information during the learning episode and/or using relational information for retrieval. A Dual-Process Signal Detection interpretation of these findings suggests that recollection in chronic schizophrenia is significantly reduced, while familiarity is not. Additionally, a unidimensional Signal Detection Theory interpretation suggests that chronic schizophrenia patients show a reduction in memory strength, and an altered criterion on the memory strength distribution for detecting new compared with old stimuli but not for detecting stimuli that are remembered versus familiar. Taken together, these findings are consistent with a deficit in recollection and increased reliance on familiarity in making recognition memory judgments in chronic schizophrenia. (C) 2007 Elsevier B.V All rights reserved. C1 [van Erp, Theo G. M.; Lesh, Tyler A.; Knowlton, Barbara J.; Bearden, Carrie E.; Hardt, Molly; Karlsgodt, Katherine H.; Shirinyan, David; Rao, Vikas; Nuechterlein, Keith; Cannon, Tyrone D.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Bearden, Carrie E.; Green, Michael F.; Nuechterlein, Keith; Cannon, Tyrone D.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP van Erp, TGM (reprint author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA. EM vanerp@psych.ucla.edu RI Karlsgodt, Katherine/H-2964-2013 OI Karlsgodt, Katherine/0000-0003-3332-4231; Lesh, Tyler/0000-0002-6160-3927 FU NCRR NIH HHS [RR021992, U24 RR021992]; NIGMS NIH HHS [GM072978]; NIMH NIH HHS [R01 MH065079-01A1, MH066286, MH65079, P50 MH066286, P50 MH066286-01A1, P50 MH066286-01A10002, R01 MH065079] NR 48 TC 32 Z9 32 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAR PY 2008 VL 100 IS 1-3 BP 181 EP 190 DI 10.1016/j.schres.2007.09.021 PG 10 WC Psychiatry SC Psychiatry GA 284RB UT WOS:000254722400017 PM 17964760 ER PT J AU Hoggard, J Saad, T Schon, D Vesely, TM Royer, T AF Hoggard, Jeffrey Saad, Theodore Schon, Don Vesely, Thomas M. Royer, Tim TI Guidelines for venous access in patients with chronic kidney disease SO SEMINARS IN DIALYSIS LA English DT Article ID INSERTED CENTRAL CATHETERS AB At the time of hemodialysis vascular access evaluation, many chronic kidney disease patients already have iatrogenic injury to their veins which impedes the surgical construction of an arteriovenous fistula (AVF). Achieving the important goal of a greater prevalence of arteriovenous fistulae in the US hemodialysis population will require identification of those patients prior to reaching end-stage renal disease and an educational and procedural system for preserving their veins. C1 [Hoggard, Jeffrey] Eastern Nephrol Associates PLLC, Greenville, NC USA. [Saad, Theodore] Nephrol Christiana Care Hlth Syst, Dept Med, Nephrol Associates PA, Newark, DE USA. [Schon, Don] Arizona Kidney Dis & Hypertens Surg Ctr, Phoenix, AZ USA. [Vesely, Thomas M.] Vascular Access Ctr, Frontenac, MO USA. [Royer, Tim] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Hoggard, J (reprint author), 1776 Blue Banks Fram Rd, Greenville, NC 27834 USA. EM jhoggard@suddenlink.net NR 16 TC 40 Z9 40 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD MAR-APR PY 2008 VL 21 IS 2 BP 186 EP 191 DI 10.1111/j.1525-139X.2008.00421.x PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 277DS UT WOS:000254193500017 PM 18364015 ER PT J AU Conhaim, RL Kluesner, KA Watson, KE Munoz-del-Rio, A Heisey, DM Harms, BA AF Conhaim, Robert L. Kluesner, Karr A. Watson, Kai E. Munoz-del-Rio, Alejandro Heisey, Dennis M. Harms, Bruce A. TI Hemorrhage progressively disturbs interalveolar perfusion in the lungs of rats SO SHOCK LA English DT Article DE pulmonary circulation; microvascular perfusion; perfusion distribution; dispersion index analysis ID PULMONARY BLOOD-FLOW; SHOCK; HETEROGENEITY AB Acute hemorrhage is often followed by devastating lung injury. However, why blood loss should lead to lung injury is not known. One possibility is that hemorrhage rapidly disturbs the distribution of microvascular perfusion at the alveolar level, which may be a triggering event for subsequent injury. We showed previously that a 30% blood loss in rats caused significant maldistribution of interalveolar perfusion within 45 min (J Trauma 60:158, 2006). In this report, we describe results of further exploration of this phenomenon. We wanted to know if perfusion distribution was disturbed at 15 min, when vascular pressures were significantly reduced by the blood loss, compared with those at 45 min, when the pressures had returned substantially toward normal. We hemorrhaged rats by removing 30% of their blood volume. We quantified interalveolar perfusion distribution by statistically analyzing the trapping patterns of 4-mu m-diameter fluorescent latex particles infused into the pulmonary circulation 15 (red particles) and 45 min (green particles) after blood removal. We used confocal fluorescence microscopy to digitally image the trapping patterns in sections of the air-dried lungs and used pattern analysis to quantify the patterns in tissue image volumes that ranged from 1,300 alveoli to less than 1 alveolus. LogDI, a measure of perfusion maldistribution, increased from 1.00 +/- 0.15 at 15 min after blood loss to 1.62 +/- 0.24 at 45 min (P < 0.001). These values were 0.86 +/- 0.22 (15 min) and 1.12 +/- 0.24 (45 min) in control rats (P = 0.03). Hemorrhage caused the green (45 min)-to-red (15 min) particle distance to decrease from 35.9 +/- 6.5 to 28.0 +/- 5.1 mu m (P = 0.024) and the red-to-green particle distance to remain unchanged (30.2 +/- 5.7 mu m [red]; 31.5 +/- 10.0 mu m [green] [n.s.]). We conclude that hemorrhage caused a progressive increase in interalveolar perfusion maldistribution over 45 min that did not correspond to reduced arterial pressures or altered blood gases. Our particle distance measurements led us to further conclude that this maldistribution occurred in areas that were perfused at 15 min rather than in previously unperfused areas. C1 [Conhaim, Robert L.; Kluesner, Karr A.; Watson, Kai E.; Munoz-del-Rio, Alejandro; Heisey, Dennis M.; Harms, Bruce A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. [Conhaim, Robert L.; Kluesner, Karr A.; Watson, Kai E.; Munoz-del-Rio, Alejandro; Heisey, Dennis M.; Harms, Bruce A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Conhaim, RL (reprint author), H5-301-BX3236,600 Highland Ave, Madison, WI 53792 USA. EM conhaim@surgery.wisc.edu NR 19 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD MAR PY 2008 VL 29 IS 3 BP 410 EP 416 DI 10.1097/shk.0b013618145042 PG 7 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 265VZ UT WOS:000253391100016 PM 17704732 ER PT J AU Brzczinski, WA Basile, J AF Brzczinski, Walter A. Basile, Jan TI Effect of angiotensin receptor blockade and anti hypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: A randomized trial SO SOUTHERN MEDICAL JOURNAL LA English DT Editorial Material C1 [Brzczinski, Walter A.; Basile, Jan] Med Univ S Carolina, Dept Med, Ralph H Johnson VA Med Ctr, Div Gen Internal Med,Primary Care Serv Line, Charleston, SC 29401 USA. RP Basile, J (reprint author), Med Univ S Carolina, Dept Med, Ralph H Johnson VA Med Ctr, Div Gen Internal Med,Primary Care Serv Line, 109 Bee St, Charleston, SC 29401 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD MAR PY 2008 VL 101 IS 3 BP 220 EP 221 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 272OI UT WOS:000253868700002 ER PT J AU Dominguez, EP Barshes, NR Sherman, V Albo, D Kougias, P Chen, C Sweeney, JF Lin, PH AF Dominguez, Edward P. Barshes, Neal R. Sherman, Vadim Albo, Daniel Kougias, Panagiotis Chen, Changyi Sweeney, John F. Lin, Peter H. TI Effect of catheter-directed arterial embolization and laparoscopic endovascular stapling on stapled vessel integrity in a porcine model SO VASCULAR LA English DT Article DE endovascular staplers; laparoscopic splenectomy; platinum coils; polyvinyl alcohol particles; polyvinyl alcohol embolization particle; splenic artery embolization ID ASSISTED SPLENECTOMY; CONTOUR EMBOLI; COMPLICATIONS; EXPERIENCE; OCCLUSION AB Arterial embolization is a frequently performed adjunctive maneuver prior to laparoscopic splenectomy or nephrectomy to facilitate laparoscopic dissection and reduce intraoperative bleeding. However, little is known regarding the effect of laparoscopic stapling across thrombosed vessels with imbedded embolic materials. This study analyzed the stapled line integrity by comparing visceral arteries treated with either platinum coils or polyvinyl alcohol (PVA) particles. Using a porcine model, 30 visceral vessels including splenic and renal arteries were treated with either coil or PVA embolization, which was followed by laparoscopic stapling. Vessel integrity and bursting pressure analysis was performed using an in vitro flow circuitry. The mean bursting pressure of the coil and the PVA group was 158 +/- 56 and 350 +/- 34 mm Hg, respectively (p < .001). The lowest bursting pressure in the coil and the PVA group was 70 and 280 mm Hg, respectively. The highest bursting pressure in the coil and the PVA group was 225 and 420 mm Hg, respectively. The bursting pressure in the splenic artery between the PVA and the coil group was 345 +/- 29 and 150 +/- 54 mm Hg, respectively (p < .001). Significant difference in the bursting pressure in the renal artery was noted in the PVA and the coil group, which was 350 +/- 40 and 160 +/- 40 mm Hg, respectively (p < .001). Our findings showed that preoperative coil embolization followed by laparoscopic vessel stapling sustained a poor busting pressure. Such a practice appears to be unsafe based on our findings and should be performed with caution in a clinical setting. C1 [Dominguez, Edward P.; Barshes, Neal R.; Sherman, Vadim; Albo, Daniel; Kougias, Panagiotis; Chen, Changyi; Lin, Peter H.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Dominguez, Edward P.; Barshes, Neal R.; Sherman, Vadim; Albo, Daniel; Kougias, Panagiotis; Chen, Changyi; Lin, Peter H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Sweeney, John F.] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA. RP Lin, PH (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Hauston VAMC 112,2002 Holcomb Blvd, Houston, TX 77030 USA. EM plin@bcm.edu FU NHLBI NIH HHS [HL076345] NR 20 TC 0 Z9 0 U1 0 U2 0 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1708-5381 J9 VASCULAR JI Vascular PD MAR-APR PY 2008 VL 16 IS 2 BP 80 EP 84 DI 10.2310/6670.2008.00016 PG 5 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 300QS UT WOS:000255840900003 PM 18377836 ER PT J AU Bates-Jensen, BM McCreath, HE Pongquan, V Apeles, NCR AF Bates-Jensen, Barbara M. McCreath, Heather E. Pongquan, Voranan Apeles, Neil Christopher R. TI Subepidermal moisture differentiates erythema and stage I pressure ulcers in nursing home residents SO WOUND REPAIR AND REGENERATION LA English DT Article ID BRADEN SCALE; PREDICTIVE-VALIDITY; RISK-FACTORS; SORE RISK; RELIABILITY; QUALITY; CARE; DIAGNOSIS; CLASSIFICATION; MULTISITE AB The objective of this descriptive cohort study was to examine the relationship between subepidermal moisture (SEM) and visual assessment of early pressure ulcers (PUs) in 31 nursing home (NH) residents residing in two NHs. Concurrent visual assessments and SEM were obtained at the sacrum, right and left trochanters, buttocks, and ischium weekly for 20 weeks. Visual assessment was rated as normal, erythema, stage I PU, or stage II+ PU. SEM, measured with a dermal phase meter where higher readings indicate greater SEM (range: 0-999 dermal phase units [DPU]), was modeled as a predictor of concurrent visual assessment of skin damage and erythema and stage I PUs at the sacrum 1 week later with covariate PU risk. Participants had a mean age of 84.1 years, were 83% female, 72% non-Hispanic white. SEM was lowest for normal skin (104 DPU, SD 114), higher for erythema (185 DPU, SD 138), stage I PUs (264 DPU, SD 208), and highest for stage II+ PUs (727 DPU, SD 287) across all sites (all p < 0.01). SEM was responsive to visual assessment changes, differentiated between erythema and stage I PU, and higher SEM predicted greater likelihood of erythema/stage I PU at the sacrum the next week (odds ratio=1.32 for every 100 DPU increase, p=0.03). SEM was associated with concurrent skin damage and future (1 week later) development of sacral erythema/stage I PUs. SEM differentiates between erythema and stage I PUs. SEM may assist in predicting early PU damage, allowing for earlier intervention to prevent PUs. C1 [Bates-Jensen, Barbara M.; Pongquan, Voranan] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Bates-Jensen, Barbara M.; McCreath, Heather E.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. [Bates-Jensen, Barbara M.] Vet Adm Greater Los Angeles Healthcare Syst, Ctr Clin, Los Angeles, CA USA. [Apeles, Neil Christopher R.] Valley Presbyterian Hosp, Van Nuys, CA USA. RP Bates-Jensen, BM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Sch Nursing, VA Greater Los Angeles,Clin Ctr,CWOCN, 5-594 Factor Bldg,700 Tiverton Ave, Los Angeles, CA 90095 USA. EM bbatesjensen@sonnet.ucla.edu NR 57 TC 14 Z9 15 U1 2 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1067-1927 J9 WOUND REPAIR REGEN JI Wound Repair Regen. PD MAR-APR PY 2008 VL 16 IS 2 BP 189 EP 197 DI 10.1111/j.1524-475X.2008.00359.x PG 9 WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery GA 271AJ UT WOS:000253761000008 PM 18318804 ER PT J AU Gazdzinski, S Durazzo, TC Yeh, PH Hardin, D Banys, P Meyerhoff, DJ AF Gazdzinski, Stefan Durazzo, Timothy C. Yeh, Ping-Hong Hardin, Dawn Banys, Peter Meyerhoff, Dieter J. TI Chronic cigarette smoking modulates injury and short-term recovery of the medial temporal lobe in alcoholics SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE hippocampus; magnetic resonance imaging; magnetic resonance spectroscopy; abstinence from alcohol; learning and memory; recovery ID MAGNETIC-RESONANCE-SPECTROSCOPY; POSTTRAUMATIC-STRESS-DISORDER; CHRONIC ETHANOL-CONSUMPTION; ILLICIT STIMULANT ABUSERS; HIPPOCAMPAL VOLUME; MAJOR DEPRESSION; COGNITIVE PERFORMANCE; ABSTINENT ALCOHOLICS; ADULT NEUROGENESIS; METABOLITE CHANGES AB Memory function is largely mediated by the medial temporal lobe (MTL), and its compromise has been observed in alcohol dependence and chronic cigarette smoking. The effects of heavy alcohol consumption and chronic smoking on hippocampal volumes and MTL metabolites and their recovery during abstinence from alcohol have not been assessed. Mate alcoholics in treatment (ALC) [13 smokers (sALC) and 11 non-smokers (nsALC)] underwent quantitative magnetic resonance imaging and short-echo proton magnetic resonance spectroscopic imaging at I week and I month of sobriety. Outcome measures were compared with 14 age-matched, non-smoking light-drinkers and were related to visuospatial learning and memory. Over I month of abstinence, N-acetyl-aspartate, a neuronal marker, and membrane-associated choline-containing metabolites normalized in the MTL of nsALC subjects, but remained low in the MTL of sALC subjects. Metabolite concentration changes in both groups were associated with improvements in visuospatial memory. Hippocampal volumes increased in both groups during abstinence, but increasing volumes correlated with visuospatial memory improvements only in nsALC subjects. In summary, chronic cigarette stroking in alcohol-dependent men appears to have adverse effects on MTL metabolite recovery during short-term sobriety. These data may also have implications for other conditions with established MTL involvement and significant smoking co-morbidity, such as schizophrenia-spectrum and mood disorders. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Gazdzinski, Stefan; Durazzo, Timothy C.; Yeh, Ping-Hong; Hardin, Dawn; Meyerhoff, Dieter J.] San Francisco Vet Adm Med Ctr, Magnet Resonance Unit, San Francisco, CA 94121 USA. [Banys, Peter; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Banys, Peter] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Gazdzinski, S (reprint author), San Francisco Vet Adm Med Ctr, Magnet Resonance Unit, 4150 Clement St 114M, San Francisco, CA 94121 USA. EM spg@itsa.ucsf.edu FU NIAAA NIH HHS [AA 10788, R01 AA010788, R01 AA010788-06, R01 AA010788-07, R01 AA010788-08, R01 AA010788-09, R01 AA010788-10, R01 AA010788-11, R01 AA010788-12] NR 84 TC 38 Z9 38 U1 1 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD FEB 28 PY 2008 VL 162 IS 2 BP 133 EP 145 DI 10.1016/j.pscychresns.2007.04.003 PG 13 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 272GH UT WOS:000253847400005 PM 18178068 ER PT J AU Solowska, JM Morfini, G Falnikar, A Himes, BT Brady, ST Huang, D Baas, PW AF Solowska, Joanna M. Morfini, Gerardo Falnikar, Aditi Himes, B. Timothy Brady, Scott T. Huang, Dongyang Baas, Peter W. TI Quantitative and functional analyses of spastin in the nervous system: Implications for hereditary spastic paraplegia SO JOURNAL OF NEUROSCIENCE LA English DT Article DE microtubule; neuron; axon; spastin; katanin; hereditary spastic paraplegia ID FAST AXONAL-TRANSPORT; MICROTUBULE-SEVERING PROTEIN; INTRAGENIC MODIFIERS; ANDROGEN RECEPTOR; VESICLE MOTILITY; SPG4 MUTATIONS; GENE-MUTATIONS; KATANIN; IDENTIFICATION; EXPRESSION AB Spastin and P60-katanin are two distinct microtubule-severing proteins. Autosomal dominant mutations in the SPG4 locus corresponding to spastin are the most common cause of hereditary spastic paraplegia ( HSP), a neurodegenerative disease that afflicts the adult corticospinal tracts. Here we sought to evaluate whether SPG4-based HSP is best understood as a " loss-of-function" disease. Using various rat tissues, we found that P60-katanin levels are much higher than spastin levels during development. In the adult, P60-katanin levels plunge dramatically but spastin levels decline only slightly. Quantitative data of spastin expression in specific regions of the nervous system failed to reveal any obvious explanation for the selective sensitivity of adult corticospinal tracts to loss of spastin activity. An alternative explanation relates to the fact that the mammalian spastin gene has two start codons, resulting in a 616 amino acid protein called M1 and a slightly shorter protein called M85. We found that M1 is almost absent from developing neurons and most adult neurons but comprises 20-25% of the spastin in the adult spinal cord, the location of the axons that degenerate during HSP. Experimental expression in cultured neurons of a short dysfunctional M1 polypeptide ( but not a short dysfunctional M85 peptide) is deleterious to normal axonal growth. In squid axoplasm, the M1 peptide dramatically inhibits fast axonal transport, whereas the M85 peptide does not. These results are consistent with a " gain-of-function" mechanism underlying HSP wherein spastin mutations produce a cytotoxic protein in the case of M1 but not M85. C1 [Solowska, Joanna M.; Falnikar, Aditi; Himes, B. Timothy; Baas, Peter W.] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA. [Morfini, Gerardo; Brady, Scott T.; Huang, Dongyang] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA. [Himes, B. Timothy] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Morfini, G (reprint author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA. EM gmorfini@uic.edu; pbaas@drexelmed.edu FU NINDS NIH HHS [R01 NS023320, R01 NS023320-17, R01 NS023868, R01 NS023868-21, R01 NS041170, R01 NS041170-06] NR 49 TC 52 Z9 53 U1 0 U2 5 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD FEB 27 PY 2008 VL 28 IS 9 BP 2147 EP 2157 DI 10.1523/JNEUROSCI.3159-07.2008 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 268AC UT WOS:000253549300016 PM 18305248 ER PT J AU Cornia, PB Lipsky, BA Gonzales, R AF Cornia, Paul B. Lipsky, Benjamin A. Gonzales, Ralph TI Nothing to cough at - Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Cornia, Paul B.; Lipsky, Benjamin A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Gonzales, Ralph] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Cornia, PB (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM paul.cornia@med.va.gov RI Lipsky, Benjamin/B-4645-2013 NR 1 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 21 PY 2008 VL 358 IS 8 BP 857 EP 857 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 264AN UT WOS:000253257700030 ER PT J AU Ko, DT Wang, Y Alter, DA Curtis, JP Rathore, SS Stukel, TA Masoudi, FA Ross, JS Foody, JM Krumholz, HM AF Ko, Dennis T. Wang, Yongfei Alter, David A. Curtis, Jeptha P. Rathore, Salf S. Stukel, Therese A. Masoudi, Fredrick A. Ross, Joseph S. Foody, JoAnne M. Krumholz, Harlan M. TI Regional variation in cardiac catheterization appropriateness and baseline risk after acute myocardial infarction SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES COMMITTEE; ACUTE CORONARY EVENTS; BYPASS GRAFT-SURGERY; NEW-YORK-STATE; AMERICAN-COLLEGE; ELDERLY-PATIENTS; GLOBAL REGISTRY; UNITED-STATES; OUTCOMES AB Objectives We evaluated whether appropriateness and baseline risk of cardiac catheterization varied according to regional intensity of invasive therapy after acute myocardial infarction (AMI), and whether AMI mortality varied according to invasive intensity regions. Background Marked regional variations exist in cardiac invasive procedure use after AMI within the U.S. Methods We performed an analysis of 44,639 Medicare fee-for-service beneficiaries hospitalized with AMI between 1998 and 2001. Invasive procedure intensity was determined based on overall cardiac catheterization rates for Medicare enrollees. Cardiac catheterization appropriateness was determined by the American College of Cardiology/American Heart Association classification and baseline risk was estimated using the GRACE (Global Registry of Acute Coronary Events) risk score. The primary outcomes of the study were cardiac catheterization use within 60 days and 3-year mortality after hospital admission. Results Higher invasive intensity regions were more likely to perform cardiac catheterizations on class I patients (appropriate) (RR 1.38, 95% confidence interval [CI] 1.27 to 1.48), class II patients (equivocal) (RR 1.42, 95% CI 1.31 to 1.53), and class III patients (inappropriate) (RR 1.29, 95% 0.97 to 1.67) compared with low-intensity regions after adjusting for patient and physician characteristics. The overall cardiac catheterization use was 5.2% lower for each increase in GRACE risk decile, and this relationship was observed similarly in all regions. Risk-standardized mortality rates of AMI patients at 3 years were not substantially different between regions. Conclusions Although higher-risk patients and those with more appropriate indications may have the most to benefit from an invasive strategy after AMI, we found that higher-invasive regions do not differentiate procedure selection based on the patients' appropriateness or their baseline risks. C1 [Ko, Dennis T.; Alter, David A.; Stukel, Therese A.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada. [Ko, Dennis T.] Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON M4N 3M5, Canada. [Wang, Yongfei; Curtis, Jeptha P.; Rathore, Salf S.; Foody, JoAnne M.; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. [Masoudi, Fredrick A.] Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Dept Med, Denver, CO USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Ross, Joseph S.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Dept Epidemiol & Publ Hlth,Sect Hlth Policy & Adm, New Haven, CT USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Ko, DT (reprint author), Inst Clin Evaluat Sci G1 06, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada. EM dennis.ko@ices.on.ca OI Ko, Dennis/0000-0001-6840-8051 NR 31 TC 42 Z9 44 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 19 PY 2008 VL 51 IS 7 BP 716 EP 723 DI 10.1016/j.jacc.2007.10.039 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 265JE UT WOS:000253354100006 PM 18279735 ER PT J AU Orengo, JP Chambon, P Metzger, D Mosier, DR Snipes, GJ Cooper, TA AF Orengo, James P. Chambon, Pierre Metzger, Daniel Mosier, Dennis R. Snipes, G. Jackson Cooper, Thomas A. TI Expanded CTG repeats within the DMPK 3 ' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE alternative splicing; CUG-binding protein 1; muscleblind-like 1; muscle atrophy; microsatellite expansion ID PRE-MESSENGER-RNA; BINDING PROTEIN; NUCLEAR FOCI; STRIATED-MUSCLE; IN-VIVO; MICE; CUGBP1; TYPE-1; RECEPTOR; OVEREXPRESSION AB Severe skeletal muscle wasting is the most debilitating symptom experienced by individuals with myotonic dystrophy type 1 (DM1). We present a DM1 mouse model with inducible and skeletal muscle-specific expression of large tracts of CTG repeats in the context of DMPK exon 15. These mice recapitulate many findings associated with DM1 skeletal muscle, such as CUG RNA foci with Muscleblind-like 1 (MBNL1) protein colocalization, misregulation of developmentally regulated alternative splicing events, myotonia, characteristic histological abnormalities, and increased CUGBP1 protein levels. Importantly, this DM1 mouse model recapitulates severe muscle wasting, which has not been reported in models in which depletion of MBNL1 is the main feature. Using these mice, we discovered previously undescribed alternative splicing events that are responsive to CUGBP1 and not MBNL, and these events were found to be misregulated in individuals with DM1. Our results indicate that increased CUGBP1 protein levels are associated with DMPK-CUG RNA expression, suggesting a role for CUGBP1-specific splicing or cytoplasmic functions in muscle wasting. C1 [Orengo, James P.; Snipes, G. Jackson; Cooper, Thomas A.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Orengo, James P.; Cooper, Thomas A.] Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA. [Mosier, Dennis R.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Snipes, G. Jackson] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA. [Mosier, Dennis R.] ME Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Chambon, Pierre; Metzger, Daniel] Coll France, Unite Mixte Rech,Inst Genet & Biol Mol & Cellulai, Ctr Natl Rech Sci,Dept Physiol Genet,U596, Inst Natl Sante & Rech Med, F-67400 Illkirch Graffenstaden, France. [Chambon, Pierre; Metzger, Daniel] Univ Strasbourg 1, F-67000 Strasbourg, France. RP Cooper, TA (reprint author), Baylor Coll Med, Dept Pathol, 1 Baylor Pl, Houston, TX 77030 USA. EM tcooper@bcm.edu FU NIAMS NIH HHS [R01AR45653, R01 AR045653] NR 42 TC 103 Z9 106 U1 0 U2 4 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 19 PY 2008 VL 105 IS 7 BP 2646 EP 2651 DI 10.1073/pnas.0708519105 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 266XB UT WOS:000253469900071 PM 18272483 ER PT J AU White, DL Li, D Nurgalieva, Z El-Serag, HB AF White, Donna L. Li, Donghui Nurgalieva, Zhannat El-Serag, Hashem B. TI Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: A HuGE systematic review and meta-analysis SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Review DE carcinoma; hepatocellular; epidemiology; genetics; glutathione S-transferase pi; glutathione transferase; humans; liver neoplasms; meta-analysis ID HEPATITIS-B CARRIERS; ALCOHOLIC LIVER-DISEASE; COMPLEX DISEASES; NULL GENOTYPES; UNITED-STATES; POLYMORPHISMS; SUSCEPTIBILITY; GSTM1; M1; AFLATOXIN AB The authors performed a systematic review and meta-analysis to determine the effect of polymorphisms in genes encoding glutathione S-transferases (GSTs), phase II isoenzymes involved in cellular detoxification, on risk of hepatocellular carcinoma (HCC). Fifteen eligible studies were identified: 14 evaluated GSTM1; 13, GSTT1; three, GSTP1; and one each evaluated GSTM2, GSTM3, GSTA1, GSTA4, GSTO1, and GSTO2, respectively. All were case-control studies performed in populations with high (Asian, African) and medium (European) HCC incidence rates. Random-effects meta-analyses suggested a small excess risk of HCC with GSTT1 null (odds ratio (OR) = 1.19, 95% confidence interval (CI): 0.99, 1.44) and possibly GSTM1 null (OR = 1.16, 95% CI: 0.89, 1.53) genotypes. Cumulative meta-analyses demonstrated that both pooled estimators generally trended toward a small excess risk with publication of more recent studies. Results for GSTP1 A313G suggested no excess risk (OR = 0.75, 95% CI: 0.50, 1.15). A number of potentially interesting gene-gene and gene-environment interactions were reported, but these were too few and inconsistent to allow meta-analysis. The overall results suggest that there may be a small excess risk of HCC in individuals with GSTT1 null and possibly also with GSTM1 null genotypes. However, given the relatively limited total number of subjects examined and observed between-study heterogeneity, chance could not be excluded. C1 [White, Donna L.; Nurgalieva, Zhannat; El-Serag, Hashem B.] Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. [White, Donna L.; Nurgalieva, Zhannat; El-Serag, Hashem B.] Michael E DeBakey Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. [White, Donna L.; Nurgalieva, Zhannat; El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA. [Li, Donghui] MD Anderson Canc Ctr, Houston, TX USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, Room 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 75 TC 74 Z9 77 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD FEB 15 PY 2008 VL 167 IS 4 BP 377 EP 389 DI 10.1093/aje/kwm315 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 263WC UT WOS:000253246200001 PM 18065725 ER PT J AU Lieberman-Blum, SS Kang, L Kugler, A Khalifa, M Schiller, DS AF Lieberman-Blum, Sharon S. Kang, Lillian Kugler, Anne Khalifa, Marwa Schiller, Daryl S. TI Making the most of your residency SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Editorial Material C1 [Lieberman-Blum, Sharon S.] James J Peters VA Med Ctr, Bronx, NY USA. [Kang, Lillian] St John Fisher Coll, Wegmans Sch Pharm, Rochester, NY 14618 USA. [Kugler, Anne] Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA. [Schiller, Daryl S.] St Barnabas Hosp, Livingston, NJ USA. RP Lieberman-Blum, SS (reprint author), James J Peters VA Med Ctr, Bronx, NY USA. EM DSchiller@sbhcs.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD FEB 15 PY 2008 VL 65 IS 4 BP 293 EP 295 DI 10.2146/ajhp070452 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 263JR UT WOS:000253213900007 PM 18238765 ER PT J AU Tyner, JW Walters, DK Willis, SG Luttropp, M Oost, J Loriaux, M Erickson, H Corbin, AS O'Hare, T Heinrich, MC Deininger, MW Druker, BJ AF Tyner, Jeffrey W. Walters, Denise K. Willis, Stephanie G. Luttropp, Mary Oost, Jason Loriaux, Marc Erickson, Heidi Corbin, Amie S. O'Hare, Thomas Heinrich, Michael C. Deininger, Michael W. Druker, Brian J. TI RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia SO BLOOD LA English DT Article ID STEM-CELL FACTOR; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; JAK2 V617F MUTATION; GENOME-WIDE RNAI; CONSTITUTIVE ACTIVATION; C-KIT; MOLECULAR TARGETS; KINASE INHIBITOR AB Despite vast improvements in our understanding of cancer genetics, a large percentage of cancer cases present without knowledge of the causative genetic events. Tyrosine kinases are frequently implicated in the pathogenesis of numerous types of cancer, but identification and validation of tyrosine kinase targets in cancer can be a time-consuming process. We report the establishment of an efficient, functional screening assay using RNA! technology to directly assess and compare the effect of individually targeting each member of the tyrosine kinase family. We demonstrate that siRNA screening can identify tyrosine kinase targets containing activating mutations in Janus kinase (JAK) 3 (A572V) in CMK cells and c-KIT (V560G) in HMC1.1 cells. In addition, this assay identifies targets that do not contain mutations, such as JAM and the focal adhesion kinases (FAK), that are crucial to the survival of the cancer cells. This technique, with additional development, might eventually offer the potential to match specific therapies with individual patients based on a functional assay. C1 [Tyner, Jeffrey W.; Walters, Denise K.; Willis, Stephanie G.; Luttropp, Mary; Oost, Jason; Loriaux, Marc; Erickson, Heidi; Corbin, Amie S.; O'Hare, Thomas; Heinrich, Michael C.; Deininger, Michael W.; Druker, Brian J.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Walters, Denise K.; O'Hare, Thomas; Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA. [Loriaux, Marc] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. RP Druker, BJ (reprint author), Basic Sci 5390,Mailcode L592,3181 SW Sam Jackson, Portland, OR 97239 USA. EM drukerb@ohsu.edu OI Tyner, Jeffrey/0000-0002-2133-0960 FU Howard Hughes Medical Institute; NCATS NIH HHS [UL1 TR000128] NR 57 TC 46 Z9 46 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD FEB 15 PY 2008 VL 111 IS 4 BP 2238 EP 2245 DI 10.1182/blood-2007-06-097253 PG 8 WC Hematology SC Hematology GA 263XZ UT WOS:000253251100074 PM 18025156 ER PT J AU Al-Noori, S Sanders, NM Taborsky, GJ Wilkinson, CW Fiylewicz, DP AF Al-Noori, Salwa Sanders, Nicole M. Taborsky, Gerald J., Jr. Wilkinson, Charles W. Fiylewicz, Dianne P. TI Acute THPVP inactivation decreases the glucagon and sympathoadrenal responses to recurrent hypoglycemia SO BRAIN RESEARCH LA English DT Article DE rat; posterior paraventricular nucleus of the thalamus (THPVP); hypoglycernia; catecholamine; stress; glucagon ID PARAVENTRICULAR THALAMIC NUCLEUS; CHRONICALLY STRESSED RATS; PREFRONTAL CORTEX; MIDLINE THALAMUS; EFFECTIVE SPREAD; CORTICOSTERONE; ACTIVATION; NEURONS; AFFERENTS; LIDOCAINE AB The posterior paraventricular nucleus of the thalamus (THPVP) has been identified as a forebrain region that modulates the central nervous system (CNS) response to recurrent experiences of stressors. The THPVP is activated in response to a single (SH) or recurrent (RH) experience of the metabolic stress of hypoglycemia. In this study, we evaluated whether temporary experimental inactivation of the THPVP would modify the neuroendocrine response to SH or RH. Infusion of lidocaine (LIDO) or vehicle had no effect on the neuroendocrine response to SH, comparable to findings with other stressors. THPVP vehicle infusion concomitant with RH resulted in a prevention of the expected impairment of neuroendocrine responses, relative to SH. LIDO infusion with RH resulted in significantly decreased glucagon and sympathoadrenal responses, relative to SH. These results suggest that the THPVP may contribute to the sympathoadrenal stimulation induced by hypoglycemia; and emphasizes that the THPVP is a forebrain region that may contribute to the coordinated CNS response to metabolic stressors. (c) 2008 Published by Elsevier B.V. C1 [Al-Noori, Salwa; Wilkinson, Charles W.; Fiylewicz, Dianne P.] VA Puget Sound Hlth Care Syst, Div Endocrinol Metab & Geriatr Res, Seattle, WA 98108 USA. [Sanders, Nicole M.; Taborsky, Gerald J., Jr.; Fiylewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Taborsky, Gerald J., Jr.; Fiylewicz, Dianne P.] Univ Washington, Dept Med, Seattle, WA USA. [Wilkinson, Charles W.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle, WA USA. RP Al-Noori, S (reprint author), VA Puget Sound Hlth Care Syst, Div Endocrinol Metab & Geriatr Res, Metab Endocrinol 151,1660 So Columbian Way, Seattle, WA 98108 USA. EM saan@u.washington.edu FU NIDDK NIH HHS [R01 DK040963, R01 DK050154-10, DK40963, R01 DK050154]; PHS HHS [R21-062446] NR 33 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD FEB 15 PY 2008 VL 1194 BP 65 EP 72 DI 10.1016/j.brainres.2007.11.040 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 274ML UT WOS:000254005300008 PM 18191818 ER PT J AU Jasti, H Mortensen, EM Obrosky, DS Kapoor, WN Fine, MJ AF Jasti, Harish Mortensen, Eric M. Obrosky, David Scott Kapoor, Wishwa N. Fine, Michael J. TI Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID SOCIOECONOMIC-STATUS; MEDICARE POPULATION; EARLY READMISSION; HEART-FAILURE; CARE; DISCHARGE; QUALITY; OUTCOMES; SERVICE; TRIAL AB Background. Rehospitalization after inpatient treatment of community-acquired pneumonia occurs in one-tenth of all hospitalizations, but the clinical circumstances surrounding readmission to the hospital have not been well studied. The objective of this study was to identify the causes and risk factors for rehospitalization of inpatients with community-acquired pneumonia. Methods. This project was performed as part of a randomized, multicenter, controlled trial of the implementation of practice guidelines to reduce the duration of intravenous antibiotic therapy and duration of hospitalization for patients who have received a clinical and radiographic diagnosis of pneumonia. The trial was conducted at 7 hospitals in Pittsburgh, Pennsylvania, from February 1998 through March 1999. The primary outcome for these analyses was rehospitalization within 30 days after the index hospitalization. Two physicians independently assigned the cause of rehospitalization as pneumonia related, comorbidity related, or both; consensus was reached for all assignments. Patient demographic characteristics and clinical factors independently associated with rehospitalization were identified using multiple logistic regression analysis. Results. Of the 577 patients discharged after hospitalization for community-acquired pneumonia, 70 (12%) were rehospitalized within 30 days. The median time to rehospitalization was 8 days (interquartile range, 4-13 days). Overall, 52 rehospitalizations (74%) were comorbidity related, and 14 (20%) were pneumonia related. The most frequent comorbid conditions responsible for rehospitalization were cardiovascular (n=19), pulmonary (n=6), and neurological () in origin. Less than a high school education (odds ratio, 2.0; 95% confidence interval, 1.1-3.4), unemployment (odds ratio, 3.7; 95% confidence interval, 1.1-12.3), coronary artery disease (odds ratio, 2.7; 95% confidence interval, 1.5-4.7), and chronic obstructive pulmonary disease (odds ratio, 2.3; 95% confidence interval, 1.3-4.1) were independently associated with rehospitalization. Conclusions. The majority of rehospitalizations following pneumonia are comorbidity related and are the result of underlying cardiopulmonary and/or neurologic diseases. Careful attention to the clinical stability of patients with these coexisting conditions at and following hospital discharge may decrease the frequency of rehospitalization of patients with community-acquired pneumonia. C1 [Obrosky, David Scott; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promat, Pittsburgh, PA 15240 USA. [Jasti, Harish; Obrosky, David Scott; Kapoor, Wishwa N.; Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. [Mortensen, Eric M.] Audie L Murphy Vet Affairs Hosp, Vet Evidencebased Res Disseminat & Implementat Ct, San Antonio, TX USA. [Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Gen Internal Med, San Antonio, TX USA. RP Fine, MJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promat, 151 C-U,Univ Dr C MB 28,1A102, Pittsburgh, PA 15240 USA. EM finemj@upmc.edu OI Mortensen, Eric/0000-0002-3880-5563 FU AHRQ HHS [F32 HS00135, R01 HS08282]; NIAID NIH HHS [5K24 AI01769] NR 26 TC 65 Z9 66 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2008 VL 46 IS 4 BP 550 EP 556 DI 10.1086/526526 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 254WB UT WOS:000252617600011 PM 18194099 ER PT J AU Brown, AH Cohen, AN Chinman, MJ Kessler, C Young, AS AF Brown, Alison H. Cohen, Amy N. Chinman, Matthew J. Kessler, Christopher Young, Alexander S. TI EQUIP: Implementing chronic care principles and applying formative evaluation methods to improve care for schizophrenia: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID RESEARCH-TEAM PORT; CONCEPTUAL-FRAMEWORK; TREATMENT RECOMMENDATIONS; CHRONIC ILLNESS; QUALITY; OUTCOMES; HEALTH; TECHNOLOGY; GUIDELINE; PROGRAM AB Background: This paper presents a case study that demonstrates the evolution of a project entitled "Enhancing Quality of care In Psychosis" (EQUIP) that began approximately when the U. S. Department of Veterans Affairs' Quality Enhancement Research Initiative (QUERI), and implementation science were emerging. EQUIP developed methods and tools to implement chronic illness care principles in the treatment of schizophrenia, and evaluated this implementation using a small-scale controlled trial. The next iteration of the project, EQUIP-2, was further informed by implementation science and the use of QUERI tools. Methods: This paper reports the background, development, results and implications of EQUIP, and also describes ongoing work in the second phase of the project (EQUIP-2). The EQUIP intervention uses implementation strategies and tools to increase the adoption and implementation of chronic illness care principles. In EQUIP-2, these strategies and tools are conceptually grounded in a stages-of-change model, and include clinical and delivery system interventions and adoption/ implementation tools. Formative evaluation occurs in conjunction with the intervention, and includes developmental, progress-focused, implementation-focused, and interpretive evaluation. Results: Evaluation of EQUIP provided an understanding of quality gaps and how to address related problems in schizophrenia. EQUIP showed that solutions to quality problems in schizophrenia differ by treatment domain and are exacerbated by a lack of awareness of evidence-based practices. EQUIP also showed that improving care requires creating resources for physicians to help them easily implement practice changes, plus intensive education as well as product champions who help physicians use these resources. Organizational changes, such as the addition of care managers and informatics systems, were shown to help physicians with identifying problems, making referrals, and monitoring follow-up. In EQUIP-2, which is currently in progress, these initial findings were used to develop a more comprehensive approach to implementing and evaluating the chronic illness care model. Discussion: In QUERI, small-scale projects contribute to the development and enhancement of hands-on, action-oriented service-directed projects that are grounded in current implementation science. This project supports the concept that QUERI tools can be useful in implementing complex care models oriented toward evidence-based improvement of clinical care. C1 [Brown, Alison H.; Cohen, Amy N.; Chinman, Matthew J.; Young, Alexander S.] VA Desert Pacific Mental Illness Res Educ & Clin, Los Angeles, CA USA. [Kessler, Christopher] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Brown, Alison H.; Cohen, Amy N.; Young, Alexander S.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Chinman, Matthew J.] RAND Corp, Santa Monica, CA USA. RP Brown, AH (reprint author), VA Desert Pacific Mental Illness Res Educ & Clin, Los Angeles, CA USA. EM alisonh@ucla.edu; amy.cohen@va.gov; chinman@rand.org; Christopher.Kessler@va.gov; ayoung@ucla.edu RI Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 FU Department of Veterans Affairs through the Health Services Research & Development Service [RCD 00-033, CPI 99-383]; Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC); National Institute of Mental Health (NIMH) UCLA- RAND Center for Research on Quality in Managed Care [MH 068639] FX This project was supported by the Department of Veterans Affairs through the Health Services Research & Development Service (RCD 00-033 and CPI 99-383) and the Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC); and by the National Institute of Mental Health (NIMH) UCLA- RAND Center for Research on Quality in Managed Care (MH 068639). NR 41 TC 15 Z9 15 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD FEB 15 PY 2008 VL 3 AR 9 DI 10.1186/1748-5908-3-9 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432QO UT WOS:000265149400002 PM 18279505 ER PT J AU Chaney, E Rabuck, LG Uman, J Mittman, DC Simons, C Simon, BF Ritchie, M Cody, M Rubenstein, LV AF Chaney, Edmund Rabuck, Laura G. Uman, Jane Mittman, Deborah C. Simons, Carol Simon, Barbara F. Ritchie, Mona Cody, Marisue Rubenstein, Lisa V. TI Human subjects protection issues in QUERI implementation research: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID HEALTH-SERVICES RESEARCH; RE-AIM FRAMEWORK; QUALITY IMPROVEMENT; MULTICENTER; BOARD; IMPACT; INTERVENTIONS; OVERSIGHT; BENEFITS; TRIALS AB Background: Human Subjects protections approaches, specifically those relating to research review board oversight, vary throughout the world. While all are designed to protect participants involved in research, the structure and specifics of these institutional review boards (IRBs) can and do differ. This variation affects all types of research, particularly implementation research. Methods: In 2001, we began a series of inter-related studies on implementing evidence-based collaborative care for depression in Veterans Health Administration primary care. We have submitted more than 100 IRB applications, amendments, and renewals, and in doing so, we have interacted with 13 VA and University IRBs across the United States (U. S.). We present four overarching IRB-related themes encountered throughout the implementation of our projects, and within each theme, identify key challenges and suggest approaches that have proved useful. Where applicable, we showcase process aids developed to assist in resolving a particular IRB challenge. Results: There are issues unique to implementation research, as this type of research may not fit within the traditional Human Subjects paradigm used to assess clinical trials. Risks in implementation research are generally related to breaches of confidentiality, rather than health risks associated with traditional clinical trials. The implementation-specific challenges discussed are: external validity considerations, Plan-Do-Study-Act cycles, risk-benefit issues, the multiple roles of researchers and subjects, and system-level unit of analysis. Discussion: Specific aspects of implementation research interact with variations in knowledge, procedures, and regulatory interpretations across IRBs to affect the implementation and study of best methods to increase evidence-based practice. Through lack of unambiguous guidelines and local liability concerns, IRBs are often at risk of applying both variable and inappropriate or unnecessary standards to implementation research that are not consistent with the spirit of the Belmont Report (a summary of basic ethical principles identified by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research), and which impede the conduct of evidence-based quality improvement research. While there are promising developments in the IRB community, it is incumbent upon implementation researchers to interact with IRBs in a manner that assists appropriate risk-benefit determinations and helps prevent the process from having a negative impact on efforts to reduce the lag in implementing best practices. C1 [Chaney, Edmund; Rabuck, Laura G.; Uman, Jane; Simons, Carol] VA Puget Sound Hlth Care Syst, HSR&D NW Ctr Excellence Outcomes Res Older Adults, Seattle, WA USA. [Chaney, Edmund] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Mittman, Deborah C.; Simon, Barbara F.; Rubenstein, Lisa V.] VA Greater Angeles Healthcare Syst, VA Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. [Ritchie, Mona] Cent Arkansas Vet Healthcare Syst, HSR&D Ctr Mental Healthcare & Outcomes Res, Little Rock, AR USA. [Cody, Marisue] VA Off Res & Dev, COACH, Washington, DC USA. [Rubenstein, Lisa V.] RAND Hlth Program, Santa Monica, CA USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Chaney, E (reprint author), VA Puget Sound Hlth Care Syst, HSR&D NW Ctr Excellence Outcomes Res Older Adults, Metropolitan Pk W,1100 Olive Way 1400, Seattle, WA USA. EM chaney@u.washington.edu; Laura.Rabuck@va.gov; Jane.Uman@va.gov; Debbie.Mittman@va.gov; Carol.Simons@va.gov; Barbara.Simon@va.gov; RitchieMonaJ@uams.edu; Marisue.Cody@va.gov; lisar@rand.org FU U. S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [MNT 03-215] FX The research reported here and the production of this manuscript was supported by U. S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, MNT 03-215. All authors are ( or were) VA employees at the time this paper was written. In order to receive VA funding, all VA studies must undergo scientific review internal to the VA ( which includes a general review of the study design, plan for data collection, etc). Data analysis, the decision to publish, etc are left to the discretion of the study's Investigators. However, it should be noted that the findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily, represent the views of the U. S. Department of Veterans Affairs. NR 33 TC 10 Z9 11 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD FEB 15 PY 2008 VL 3 AR 10 DI 10.1186/1748-5908-3-10 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432QO UT WOS:000265149400003 PM 18279507 ER PT J AU Chandrasekar, B Patel, DN Mummidi, S Kim, JW Clark, RA Valente, AJ AF Chandrasekar, Bysani Patel, Devang N. Mummidi, Srinivas Kim, Jae-Woo Clark, Robert A. Valente, Anthony J. TI Interleukin-18 suppresses adiponectin expression in 3T3-L1 adipocytes via a novel signal transduction pathway involving ERK1/2-dependent NFATc4 phosphorylation SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; CCAAT/ENHANCER BINDING-PROTEIN; VASCULAR INFLAMMATORY MARKERS; ADIPOSE-SPECIFIC PROTEIN; CORONARY-ARTERY-DISEASE; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; INSULIN-RESISTANCE; WEIGHT-LOSS AB An inverse correlation between the pro-inflammatory cytokine interleukin-18 and the anti-atherogenic adipokine adiponectin has been reported in the chronic pathological conditions obesity, insulin resistance, coronary artery disease, and metabolic syndrome. We investigated whether this relationship is coincidental or has a causal basis. Here we show that interleukin-18 (IL-18) suppresses adiponectin transcription, mRNA expression, and secretion by 3T3-L1 adipocytes. IL-18 suppresses adiponectin promoter-reporter activity, an effect reversed by deletion or mutation of the NFATc4 core DNA-binding site. IL-18 induces NFATc4 phosphorylation (Ser(676)), nuclear translocation, and in vivo DNA binding. IL-18 induces ERK1/2 phosphorylation and enzyme activity, and pretreatment with the MEK inhibitor U0126, ERK1/2 inhibitor PD98059, or small interference RNA targeted to ERK1/2 attenuates ERK1/2 activation and NFATc4 phosphorylation. Finally, inhibition of ERK1/2 or NFATc4 knockdown reverses IL-18-mediated adiponectin suppression. In contrast to its inhibitory effects on adiponectin expression, IL-18 potently stimulates PAI-1 secretion. These data demonstrate for the first time that IL-18 selectively suppresses adiponectin expression via ERK1/2-dependent NFATc4 activation and suggest that the inverse relationship observed between IL-18 and adiponectin in various chronic pathological conditions is causally related. Thus, targeting IL-18 expression may enhance adiponectin expression and mitigate disease progression. C1 [Chandrasekar, Bysani; Patel, Devang N.; Mummidi, Srinivas; Clark, Robert A.; Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Chandrasekar, Bysani; Mummidi, Srinivas; Clark, Robert A.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. [Kim, Jae-Woo] Yonsei Univ, Coll Med, Med Res Ctr Chron Metab Dis, Dept Biochem & Mol Biol, Seoul 120752, South Korea. RP Chandrasekar, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chandraseka@uthscsa.edu RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 NR 56 TC 24 Z9 26 U1 1 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 15 PY 2008 VL 283 IS 7 BP 4200 EP 4209 DI 10.1074/jbc.M708142200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 261MO UT WOS:000253083500055 PM 18086672 ER PT J AU Hellman, NE SpectorO, J Robinson, J Zuo, XF Saunier, S Antignac, C Tobias, JW Lipschutz, JH AF Hellman, Nathan E. SpectorO, June Robinson, Jonathan Zuo, Xiaofeng Saunier, Sophie Antignac, Corinne Tobias, John W. Lipschutz, Joshua H. TI Matrix metalloproteinase 13 (MMP13) and tissue inhibitor of matrix metalloproteinase 1 (TIMP1), regulated by the MAPK pathway, are both necessary for Madin-Darby canine kidney tubulogenesis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID HEPATOCYTE GROWTH-FACTOR; POLARIZED EPITHELIAL-CELLS; MATRIX METALLOPROTEINASES; IN-VITRO; BRANCHING MORPHOGENESIS; COLLAGEN ACCUMULATION; RNA INTERFERENCE; MOUSE KIDNEY; MDCK CELLS; LINE MDCK AB A classic model of tubulogenesis utilizes Madin-Darby canine kidney (MDCK) cells. MDCK cells form monoclonal cysts in three-dimensional collagen and tubulate in response to hepatocyte growth factor, which activates multiple signaling pathways, including the mitogen-activated protein kinase (MAPK) pathway. It was shown previously that MAPK activation is necessary and sufficient to induce the first stage of tubulogenesis, the partial epithelial to mesenchymal transition (p-EMT), whereas matrix metalloproteinases (MMPs) are necessary for the second redifferentiation stage. To identify specific MMP genes, their regulators, tissue inhibitors of matrix metalloproteinases (TIMPs), and the molecular pathways by which they are activated, we used two distinct MAPK inhibitors and a technique we have termed subtraction pathway microarray analysis. Of the 19 MMPs and 3 TIMPs present on the Canine Genome 2.0 Array, MMP13 and TIMP1 were up-regulated 198- and 169-fold, respectively, via the MAPK pathway. This was confirmed by two-dimensional and three-dimensional real time PCR, as well as in MDCK cells inducible for the MAPK gene Raf. Knockdown of MMP13 using short hairpin RNA prevented progression past the initial phase of p-EMT. Knockdown of TIMP1 prevented normal cystogenesis, although the initial phase of p-EMT did occasionally occur. The MMP13 knockdown phenotype is likely because of decreased collagenase activity, whereas the TIMP1 knockdown phenotype appears due to increased apoptosis. These data suggest a model, which may also be important for development of other branched organs, whereby the MAPK pathway controls both MDCK p-EMT and redifferentiation, in part by activating MMP13 and TIMP1. C1 [Hellman, Nathan E.; SpectorO, June; Robinson, Jonathan; Zuo, Xiaofeng; Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Lipschutz, Joshua H.] Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA. [Lipschutz, Joshua H.] Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Saunier, Sophie; Antignac, Corinne] Univ Paris 05, Hop Necker Enfants Malades, INSERM, U 574, F-75015 Paris, France. [Tobias, John W.] Univ Penn, Genom Inst Bioinformat Core, Philadelphia, PA 19104 USA. RP Lipschutz, JH (reprint author), 431 Hill Pavil,380 S Univ Ave, Philadelphia, PA 19104 USA. EM jhlipsch@mail.med.upenn.edu FU NIDDK NIH HHS [DK069909, DK070980] NR 58 TC 34 Z9 34 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 15 PY 2008 VL 283 IS 7 BP 4272 EP 4282 DI 10.1074/jbc.M708027200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 261MO UT WOS:000253083500062 PM 18039671 ER PT J AU Bischoff, DS Zhu, JH Makhijani, NS Kumar, A Yamaguchi, DT AF Bischoff, D. S. Zhu, J. H. Makhijani, N. S. Kumar, A. Yamaguchi, D. T. TI Angiogenic CXC chemokione expression during differentiation of human mesenchymal stem cells towards the osteoblastic lineage SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE ELR+ CXC chemokines; human mesenchymal stem cells; osteoblastic differentiation; dexamethasone; HMEC-1 angiogenesis ID NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; MARROW STROMAL CELLS; GROWTH-FACTOR; GENE-EXPRESSION; OSTEOGENIC DIFFERENTIATION; RHEUMATOID-ARTHRITIS; SIGNALING PATHWAYS; INTERLEUKIN-8 GENE; ENDOTHELIAL-CELLS AB The potential role of ELR+ CXC chemokines in early events in bone repair was studied using human mesenchymal stem cells(hMSCs). Inflammation, which occurs in the initial phase of tissue healing in general, is critical to bone repair. Release of cytokines from infiltrating immune cells and injured bone can lead to recruitment of MSCs to the region of repair. CXC chemokines bearing the Glu-Leu-Arg (ELR) motif are also released by inflammatory cells and serve as angiogenic factors stimulating chemotaxis and proliferation of endothelial cells. hMSCs, induced to differentiate with osteogenic medium (OGM) containing ascorbate, P-glycerophosphate (beta-GP), and dexamethasone (DEX), showed an increase in mRNA and protein secretion of the ELR+ CXC chemokines CXCL8 and CXCL1. CXCL8 mRNA half-life studies reveal an increase in mRNA stability upon OGM stimulation. Increased expression and secretion is a result of DEX in OGM and is dose-dependent. Inhibition of the glucocorticoid receptor with mifepristone only partially inhibits DEX-stimulated CXCL8 expression indicating both glucocorticoid receptor dependent and independent pathways. Treatment with signal transduction inhibitors demonstrate that this expression is due to activation of the ERK and p38 mitogen-activated protein kinase (MAPR) pathways and is mediated through the G(alpha i)-coupled receptors. Angiogenesis assays demonstrate that OGM-stimulated conditioned media containing secreted CXCL8 and CXCL1 can induce angiogenesis of human microvascular endothelial cells in an in vitro Matrigel assay. C1 [Bischoff, D. S.; Zhu, J. H.; Makhijani, N. S.; Kumar, A.; Yamaguchi, D. T.] Vet Adm Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Bischoff, D. S.; Yamaguchi, D. T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Yamaguchi, DT (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dean.yamaguchi@med.va.gov NR 47 TC 12 Z9 13 U1 0 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD FEB 15 PY 2008 VL 103 IS 3 BP 812 EP 824 DI 10.1002/jcb.21450 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 262EW UT WOS:000253132800011 PM 17583554 ER PT J AU Dracheva, S Chin, B Haroutunian, V AF Dracheva, Stella Chin, Benjamin Haroutunian, Vahram TI Altered serotonin 2C receptor RNA splicing in suicide: association with editing SO NEUROREPORT LA English DT Article DE mRNA editing; serotonin 2C receptor; splice variant; suicide ID PRE-MESSENGER-RNA; SITE SELECTION; GENE; IDENTIFICATION; MUTATION; VARIANT; ROLES AB In an earlier study, we showed increases in serotonin 2C receptor (5-HT2CR) pre-mRNA editing in prefrontal cortex that were specific to suicide victims irrespective of associated psychiatric diagnoses. Here we demonstrate that the ratio between the two 5-HT2CR splice variants is increased in people who committed suicide, but does not vary among the diagnostic groups. This provides further evidence for suicide-specific neurobiology and suggests that, as it was previously shown in vitro, 5-HT2CR editing modulates its splicing in human brain. The association analysis indicates, however, that the efficiency of 5-HT2CR editing is an imperfect predictor of the splicing outcome, and that splice site selection is only partially controlled by the level of editing in vivo. C1 [Dracheva, Stella; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Dracheva, Stella; Chin, Benjamin; Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Dracheva, S (reprint author), Vet Adm Med Ctr, 4F-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Stella.Dracheva@mssm.edu NR 23 TC 24 Z9 26 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD FEB 12 PY 2008 VL 19 IS 3 BP 379 EP 382 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 264PR UT WOS:000253301400023 PM 18303585 ER PT J AU Anelli, V Gault, CR Cheng, AB Obeid, LM AF Anelli, Viviana Gault, Christopher R. Cheng, Amy B. Obeid, Lina M. TI Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; FACTOR-INDUCED ACTIVATION; INDUCIBLE FACTOR-ALPHA; HUMAN BREAST-CANCER; SPHINGOSINE-1-PHOSPHATE RECEPTOR; FUNCTIONAL-CHARACTERIZATION; EXTRACELLULAR RELEASE; MOLECULAR-CLONING; KINASE EXPRESSION AB Sphingosine 1-phosphate (S1P), a sphingolipid metabolite that plays an important role in the regulation of cell survival, growth, migration, and angiogenesis, acts both inside the cells and as an extracellular mediator through binding to five G protein-coupled receptors (S1P(1-5)). Sphingosine kinase 1 (SK1), the enzyme responsible for S1P production, is overexpressed in many solid tumors, including gliomas. One common feature of these tumors is the presence of "hypoxic regions," characterized by cells expressing high levels of hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha, two transcription regulators that modulate the levels of proteins with crucial roles in tumor progression. So far, nothing is known about the role and the regulation of SK1 during tumor-induced hypoxia or about SK1 regulation and HIFs. Here we investigated the role of HIF-1 alpha and HIF-2 alpha in the regulation of SK1 during hypoxic stress in glioma-derived U87MG cells. We report that hypoxia increases SK1 mRNA levels, protein expression, and enzyme activity, followed by intracellular S1P production and S1P release. Interestingly, knockdown of HIF-2 alpha by small interfering RNA abolished the induction of SK1 and the production of extracellular S1P after CoCl2 treatment, whereas HIF-1 alpha small interfering RNA resulted in an increase of HIF-2 alpha and of SK1 protein levels. Moreover, using chromatin immunoprecipitation analysis, we demonstrate that HIF-2 alpha binds the SK1 promoter. Functionally, we demonstrate that conditioned medium from hypoxia-treated tumor cells results in neoangiogenesis in human umbilical vein endothelial cells in a S1P receptor-dependent manner. These studies provide evidence of a link between S1P production as a potent angiogenic agent and the hypoxic phenotype observed in many tumors. C1 [Obeid, Lina M.] Ralph H Johnson Affairs Med Ctr, Charleston, SC 29401 USA. [Gault, Christopher R.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Anelli, Viviana; Cheng, Amy B.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Anelli, Viviana] Univ Milan, Dept Med Chem Biochem & Biotechnol, I-20090 Milan, Italy. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med Geriatr, POB 250779, Charleston, SC 29403 USA. EM obeid@musc.edu FU NCI NIH HHS [P01 CA097132]; NIGMS NIH HHS [R01 GM062887] NR 62 TC 75 Z9 76 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 8 PY 2008 VL 283 IS 6 BP 3365 EP 3375 DI 10.1074/jbc.M708241200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 261MJ UT WOS:000253083000041 PM 18055454 ER PT J AU Ho, PM Peterson, ED Wang, L Magid, DJ Fihn, SD Larsen, GC Jesse, RA Rumsfeld, JS AF Ho, P. Michael Peterson, Eric D. Wang, Li Magid, David J. Fihn, Stephan D. Larsen, Greg C. Jesse, Robert A. Rumsfeld, John S. TI Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ORAL ANTIPLATELET THERAPY; PLATELET ACTIVATION; CONTROLLED TRIAL; ASPIRIN THERAPY; ISCHEMIC-STROKE; UNSTABLE ANGINA; ARTERY-DISEASE; DRUG-THERAPY; WITHDRAWAL; HEPARIN AB Context It is unknown whether patients are at increased short- term risk for adverse events following clopidogrel cessation. Objective To assess the rates of adverse events after stopping treatment with clopidogrel in a national sample of patients with acute coronary syndrome ( ACS). Design, Setting, and Patients Retrospective cohort study of 3137 patients with ACS discharged from 127 Veterans Affairs hospitals between October 1, 2003, and March 31, 2005, with posthospital treatment with clopidogrel. Main Outcome Measure Rate of all- cause mortality or acute myocardial infarction ( AMI) after stopping treatment with clopidogrel. Results Mean ( SD) follow- up after stopping treatment with clopidogrel was 196 ( 152) days for medically treated patients with ACS without stents ( n= 1568) and 203 ( 148) days for patients with ACS treated with percutaneous coronary intervention ( PCI) ( n= 1569). Among medically treated patients, mean ( SD) duration of clopidogrel treatment was 302 ( 151) days and death or AMI occurred in 17.1%( n= 268) of patients, with 60.8%( n= 163) of events occurring during 0 to 90 days, 21.3% ( n= 57) during 91 to 180 days, and 9.7% ( n= 26) during 181 to 270 days after stopping treatment with clopidogrel. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90- day interval after stopping treatment with clopidogrel was associated with a significantly higher risk of adverse events ( incidence rate ratio [ IRR], 1.98; 95% confidence interval [ CI], 1.46- 2.69 vs the interval of 91- 180 days). Similarly, among PCI- treated patients with ACS, mean( SD) duration of clopidogrel treatment was 278 ( 169) days and death or AMI occurred in 7.9% ( n= 124) of patients, with 58.9% ( n= 73) of events occurring during 0 to 90 days, 23.4% ( n= 29) during 91 to 180 days, and 6.5% ( n= 8) during 181 to 270 days after stopping clopidogrel treatment. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90- day interval after stopping clopidogrel treatment was associated with a significantly higher risk of adverse events ( IRR, 1.82; 95% CI, 1.17- 2.83). Conclusions We observed a clustering of adverse events in the initial 90 days after stopping clopidogrel among both medically treated and PCI- treated patients with ACS, supporting the possibility of a clopidogrel rebound effect. Additional studies are needed to confirm the clustering of events after stopping clopidogrel, including associations with cardiovascular mortality and reasons for stopping clopidogrel, as well as to determine the mechanism of this phenomenon, and to identify strategies to reduce early events after clopidogrel cessation. C1 [Ho, P. Michael; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO 80220 USA. [Ho, P. Michael; Magid, David J.; Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA. [Wang, Li; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Ho, P. Michael; Magid, David J.; Rumsfeld, John S.] Kaiser Permanente Colorado, Inst Hlth Res, Aurora, CO USA. [Larsen, Greg C.] VA Med Ctr, Portland, OR USA. [Jesse, Robert A.] Richmond VA Med Ctr, Richmond, VA USA. [Jesse, Robert A.] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. RP Rumsfeld, JS (reprint author), Denver VA Med Ctr, 111B,1055 Clermont St, Denver, CO 80220 USA. EM John.Rumsfeld@va.gov NR 33 TC 219 Z9 231 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 6 PY 2008 VL 299 IS 5 BP 532 EP 539 DI 10.1001/jama.299.5.532 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 258RB UT WOS:000252886100018 PM 18252883 ER PT J AU Braithwaite, RS Roberts, MS Chang, CCH Goetz, MB Gibert, CL Rodrigue-Barradas, MC Shechter, S Schaefer, A Nucifora, K Koppenhaver, R Justice, AC AF Braithwaite, R. Scott Roberts, Mark S. Chang, Chung Chou H. Goetz, Matthew Bidwell Gibert, Cynthia L. Rodrigue-Barradas, Maria C. Shechter, Steven Schaefer, Andrew Nucifora, Kimberly Koppenhaver, Robert Justice, Amy C. TI Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: A decision model SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 CELL COUNT; VIROLOGICAL FAILURE; COST-EFFECTIVENESS; INFECTION; OUTCOMES; COHORT; RESISTANCE; ADULTS AB Background: The optimal threshold for initiating HIV treatment is unclear. Objective: To compare different thresholds for initiating HIV treatment. Design: A validated computer simulation was used to weigh important harms from earlier initiation of antiretroviral therapy (toxicity, side effects, and resistance accumulation) against important benefits (decreased HIV-related mortality). Data Sources: Veterans Aging Cohort Study (5742 HIV-infected patients and 11 484 matched uninfected controls) and published reports. Target Population: Individuals with newly diagnosed chronic HIV infection and varying viral loads (10 000, 30 000, 100 000, and 300 000 copies/mL) and ages (30, 40, and 50 years). Time Horizon: Unlimited. Perspective: Societal. Intervention: Alternative thresholds for initiating antiretroviral therapy (CD4 counts of 200, 350, and 500 cells/mm(3)). Outcome Measures: Life-years and quality-adjusted life-years (QALYs). Results of Base-Case Analysis: Although the simulation was biased against earlier treatment initiation because it used an upper-bound assumption for therapy-related toxicity, earlier treatment increased life expectancy and QALYs at age 30 years regardless of viral load (life expectancies with CD4 initiation thresholds of 500, 350, and 200 cells/mm(3) were 18.2 years, 17.6 years, and 17.2 years, respectively, for a viral load of 10 000 copies/mL and 17.3 years, 15.9 years, and 14.5 years, respectively, for a viral load of 300000 copies/mL), and increased life expectancies at age 40 years if viral loads were greater than 30000 copies/mL (life expectancies were 12.5 years, 12.0 years, and 11.4 years, respectively, for a viral load of 300000 copies/mL). Results of Sensitivity Analysis: Findings favoring early treatment were generally robust. Limitations: Results favoring later treatment may not be valid. The findings may not be generalizable to women. Conclusion: This simulation suggests that earlier initiation of combination antiretroviral therapy is often favored compared with current recommendations. C1 [Braithwaite, R. Scott] Yale Univ, West Haven, CT 06516 USA. Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. George Washington Univ, Washington, DC USA. Vet Affairs Med Ctr, Washington, DC 20422 USA. Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. RP Braithwaite, RS (reprint author), Yale Univ, 950 Campbell Ave, West Haven, CT 06516 USA. EM Ronald.Braithwaite@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU NCATS NIH HHS [UL1 TR000005]; NIAAA NIH HHS [U10 AA013566, 2U10 AA13566, K23 AA014483, K23 AA14483-01, U10 AA013566-07] NR 30 TC 38 Z9 38 U1 1 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 5 PY 2008 VL 148 IS 3 BP 178 EP 185 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 258DX UT WOS:000252849700002 PM 18252681 ER PT J AU MacLean, C Newberry, S Maglione, M McMahon, M Ranganath, V Suttorp, M Mojica, W Timmer, M Alexander, A McNamara, M Desai, SB Zhou, A Chen, S Carter, J Tringale, C Valentine, D Johnsen, B Grossman, J AF MacLean, Catherine Newberry, Sydne Maglione, Margaret McMahon, Maureen Ranganath, Veena Suttorp, Marika Mojica, Walter Timmer, Martha Alexander, Alicia McNamara, Melissa Desai, Sheetal B. Zhou, Annie Chen, Susan Carter, Jason Tringale, Carlo Valentine, Di Johnsen, Breanne Grossman, Jennifer TI Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; CORTICOSTEROID-INDUCED OSTEOPOROSIS; CYCLICAL ETIDRONATE THERAPY; EARLY POSTMENOPAUSAL WOMEN; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; HORMONE REPLACEMENT THERAPY; VITAMIN-D SUPPLEMENTATION; PRIMARY BILIARY-CIRRHOSIS; ESTROGEN PLUS PROGESTIN AB Background: Although several agents are available to treat osteoporosis, the relative efficacy and toxicity of these agents when used to prevent fractures has not been well described. Purpose: To compare the benefits in fracture reduction and the harms from adverse events of various therapies for osteoporosis. Data Sources: MEDLINE (1966 to November 2007) and other selected databases were searched for English-language studies. Study Selection: For the efficacy analysis, investigators selected studies that reported the rate of or risk for fractures. For the adverse event analysis, they selected studies that reported the relationship between an agent and cardiovascular, thromboembolic, or upper gastrointestinal events; malignant conditions; and osteonecrosis. Data Extraction: Using a standardized protocol, investigators abstracted data on fractures and adverse events, agents and comparators, study design, and variables of methodological quality. Data Synthesis: Good evidence suggests that alendronate, etidronate, ibandronate, risedronate, zoledronic acid, estrogen, parathyroid hormone (1-34), and raloxifene prevent vertebral fractures more than placebo; the evidence for calcitonin was fair. Good evidence suggests that alendronate, risedronate, and estrogen prevent hip fractures more than placebo; the evidence for zoledronic acid was fair. The effects of vitamin D varied with dose, analogue, and study population for both vertebral and hip fractures. Raloxifene, estrogen, and estrogen-progestin increased the risk for thromboembolic events, and etidronate increased the risk for esophageal ulcerations and gastrointestinal perforations, ulcerations, and bleeding. Limitation: Few studies have directly compared different agents or classes of agents used to treat osteoporosis. Conclusion: Although good evidence suggests that many agents are effective in preventing osteoporotic fractures, the data are insufficient to determine the relative efficacy or safety of these agents. C1 [Maglione, Margaret] RAND Corp, MPP, So California Evidence Based Practice Ctr, Santa Monica, CA 90401 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. RP Maglione, M (reprint author), RAND Corp, MPP, So California Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90401 USA. EM maglione@rand.org FU PHS HHS [290-02-003] NR 162 TC 279 Z9 295 U1 5 U2 26 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 5 PY 2008 VL 148 IS 3 BP 197 EP 213 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA 258DX UT WOS:000252849700004 PM 18087050 ER PT J AU Reger, MA Watson, GS Green, PS Wilkinson, CW Baker, LD Cholerton, B Fishel, MA Plymate, SR Breitner, JCS DeGroodt, W Mehta, P Craft, S AF Reger, M. A. Watson, G. S. Green, P. S. Wilkinson, C. W. Baker, L. D. Cholerton, B. Fishel, M. A. Plymate, S. R. Breitner, J. C. S. DeGroodt, W. Mehta, P. Craft, S. TI Intranasal insulin improves cognition and modulates beta-amyloid in early AD SO NEUROLOGY LA English DT Article ID APOLIPOPROTEIN-E GENOTYPE; ALZHEIMERS-DISEASE; DEGRADING ENZYME; OLDER-ADULTS; DEMENTIA; MEMORY; PERFORMANCE; MECHANISMS; MUTATIONS; A-BETA-42 AB Background: Reduced brain insulin signaling and low CSF-to-plasma insulin ratios have been observed in patients with Alzheimer disease (AD). Furthermore, intracerebroventricular or IV insulin administration improve memory, alter evoked potentials, and modulate neurotransmitters, possibly by augmenting low brain levels. After intranasal administration, insulin-like peptides follow extracellular pathways to the brain within 15 minutes. Objective: We tested the hypothesis that daily intranasal insulin treatment would facilitate cognition in patients with early AD or its prodrome, amnestic mild cognitive impairment (MCI). The proportion of verbal information retained after a delay period was the planned primary outcome measure. Secondary outcome measures included attention, caregiver rating of functional status, and plasma levels of insulin, glucose, beta-amyloid, and cortisol. Methods: Twenty-five participants were randomly assigned to receive either placebo (n = 12) or 20 IU BID intranasal insulin treatment (n = 13) using an electronic atomizer, and 24 participants completed the study. Participants, caregivers, and all clinical evaluators were blinded to treatment assignment. Cognitive measures and blood were obtained at baseline and after 21 days of treatment. Results: Fasting plasma glucose and insulin were unchanged with treatment. The insulin-treated group retained more verbal information after a delay compared with the placebo-assigned group (p = 0.0374). Insulin-treated subjects also showed improved attention (p = 0.0108) and functional status (p = 0.0410). Insulin treatment raised fasting plasma concentrations of the short form of the beta-amyloid peptide (A beta 40; p = 0.0471) without affecting the longer isoform (A beta 42), resulting in an increased A beta 40/42 ratio (p = 0.0207). Conclusions: The results of this pilot study support further investigation of the benefits of intranasal insulin for patients with Alzheimer disease, and suggest that intranasal peptide administration may be a novel approach to the treatment of neurodegenerative disorders. C1 [Reger, M. A.; Watson, G. S.; Wilkinson, C. W.; Baker, L. D.; Cholerton, B.; Breitner, J. C. S.; Craft, S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Green, P. S.; Plymate, S. R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Fishel, M. A.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Watson, G. S.; Wilkinson, C. W.; Baker, L. D.; Cholerton, B.; Fishel, M. A.; Plymate, S. R.; Breitner, J. C. S.; DeGroodt, W.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Green, P. S.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [DeGroodt, W.] Kurve Technol Inc, Bothell, WA USA. [Mehta, P.] Dept Immunol, Staten Isl, NY USA. [Reger, M. A.; Watson, G. S.; Green, P. S.; Wilkinson, C. W.; Baker, L. D.; Cholerton, B.; Fishel, M. A.; Plymate, S. R.; Breitner, J. C. S.; DeGroodt, W.; Mehta, P.; Craft, S.] Inst Basic Res Dev Disabilit, Staten Isl, NY USA. RP Craft, S (reprint author), VAPSHCS, GRECC S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM scraft@u.washington.edu FU NIA NIH HHS [R01 AG027415] NR 28 TC 362 Z9 374 U1 5 U2 30 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 5 PY 2008 VL 70 IS 6 BP 440 EP 448 DI 10.1212/01.WNL.0000265401.62434.36 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 258TS UT WOS:000252893000006 PM 17942819 ER PT J AU Ting, HH Roe, MT Gersh, BJ Spertus, JA Rumsfeld, JS Ou, FS Kao, J Long, KH Holmes, DR Peterson, ED AF Ting, Henry H. Roe, Matthew T. Gersh, Bernard J. Spertus, John A. Rumsfeld, John S. Ou, Fang-Shu Kao, John Long, Kirsten Hall Holmes, David R., Jr. Peterson, Eric D. CA NCDR TI Factors associated with off-label use of drug-muting stents in patients with ST-elevation myocardial infarction SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID SIROLIMUS-ELUTING STENTS; BARE-METAL STENTS; ACUTE CORONARY SYNDROMES; UNCOATED STENTS; THROMBOSIS; OUTCOMES; PREDICTORS; REGISTRY; TRIALS; HEALTH AB Drug-eluting stents (DESs) are used in > 80% of percutaneous coronary intervention (PCI) procedures; however, up to 2/3 are used for off-label indications. Factors associated with DES use in patients with ST-elevation myocardial infarction (STEMI) are not known in contemporary clinical practice. We analyzed temporal trends, geographic patterns, and sociodemographic factors associated with off-label use of DESs in patients undergoing primary PCI for STEMI from July 2004 to March 2006 in the National Cardiovascular Data Registry (NCDR). The main outcome of this study was receipt of any DES, and the candidate independent variables were sociodemographic, hospital, clinical, and procedural variables. We also analyzed temporal trends and geographic patterns for use of DESs. A total of 30,235 patients with STEMI underwent primary PCI with use of DESs (84%) or bare metal stents (16%). Adoption of DESs was rapid but varied widely as a function of geographic location. After adjusting for clinical and procedural variables, older age was associated with lower use (odds ratio [OR] 0.94, 95% confidence interval [CI] 0.91 to 0.98), whereas white race (OR 1.14, 95% CI 1.03 to 1.27), commercial insurance (OR 1.22, 95% CI 1.11 to 1.34), and the west census region (OR 137, 95% CI 1.04 to 1.81) were associated with higher use of DESs. In conclusion, adoption of DESs was rapid in patients with STEMI, but geographic location and sociodemographic and hospital factors were associated with the use DESs. (c) 2008 Elsevier Inc. All rights reserved. C1 [Ting, Henry H.; Gersh, Bernard J.; Holmes, David R., Jr.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA. [Long, Kirsten Hall] Mayo Clin, Hlth Care Policy & Res, Rochester, MN USA. [Roe, Matthew T.; Ou, Fang-Shu; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA. [Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Spertus, John A.] Univ Missouri, Kansas City, MO 64110 USA. [Rumsfeld, John S.] Univ Colorado, Denver, CO 80202 USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Kao, John] Univ Illinois, Div Cardiol, Chicago, IL USA. RP Ting, HH (reprint author), Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA. EM ting.henry@mayo.edu NR 30 TC 8 Z9 8 U1 1 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD FEB 1 PY 2008 VL 101 IS 3 BP 286 EP 292 DI 10.1016/j.amjcard.2007.09.084 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 259EY UT WOS:000252923100002 PM 18237586 ER PT J AU Abraham, NS Hartman, C Castillo, D Richardson, P Smalley, W AF Abraham, Neena S. Hartman, Christine Castillo, Diana Richardson, Peter Smalley, Walter TI Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT 71st Annual Meeting of the American-College-of-Gastroenterology CY OCT 20-25, 2006 CL Las Vegas, NV SP Amer Coll Gastroenterol ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PEPTIC-ULCER DISEASE; PROTON-PUMP INHIBITORS; GASTROINTESTINAL COMPLICATIONS; HELICOBACTER-PYLORI; PHARMACY RECORDS; RISK PATIENTS; ASPIRIN USE; PREVENTION; ADHERENCE AB OBJECTIVES: Our aim was to quantify the effect of provider adherence on the risk of NSAID-related upper gastrointestinal events (UGIE). METHODS: We identified from national pharmacy records veterans >= 65 yr prescribed an NSAID, a coxib, or salicylate (> 325 mg/day) at any Veterans Affairs (VA) facility (January 1, 2000 to December 31, 2002). Prescription fill data were linked in longitudinal fashion to VA inpatient, outpatient, and death files and merged with demographic, inpatient, outpatient, and provider data from Medicare. Each person-day of follow-up was assessed for exposure to NSAID alone, NSAID+proton pump inhibitor (PPI), coxib, or coxib+PPI. UGIE was defined using our published, validated algorithm. Unadjusted incidence density ratios were calculated for the 365 days following exposure. We assessed risk of UGIE using Cox proportional hazards models, while adjusting for demographics, UGIE risk factors, comorbidity, prescription channeling (i.e., propensity score), geographic location, and multiple time-dependent pharmacological covariates, including aspirin, steroids, anticoagulants, antiplatelets, statins, and selective serotonin reuptake inhibitors. RESULTS: In our cohort of 481,980 (97.8% male, 85.3% white, mean age 73.9, standard deviation 5.6), a safer strategy was prescribed for 19.8%, and 2,753 UGIE occurred in 220,662 person-years of follow-up. When adjusted for prescription channeling, confounders, and effect modification-associated PPI, risk of UGIE was 1.8 (95% confidence interval [CI] 1.6-2.0) on NSAID alone, :1.8 (95% CI 1.5-2.0) on coxib alone, 1.1 (95% CI 0.7-4.6) on NSAID+PPI, and 1.1 (0.6-5.2) on coxib+PPI. When the analysis was adjusted for cumulative percent time spent on a PPI, risk of UGIE decreased from HR 3.0 (95% CI 2.6-3.7) when a PPI was prescribed 0-20% of the time to 1.1 (95% CI 1.0-1.3) when a PPI was prescribed 80-100% of the time. CONCLUSIONS: Provider adherence to safer NSAID prescribing strategies is associated with fewer UGIE among the elderly. An adherent strategy lowers, but does not eliminate, risk of an NSAID-related UGIE. C1 [Abraham, Neena S.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Abraham, Neena S.] Baylor Coll Med, Houston, TX 77030 USA. [Abraham, Neena S.; Hartman, Christine; Castillo, Diana; Richardson, Peter] Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Smalley, Walter] Vanderbilt Univ, Nashville, TN USA. [Smalley, Walter] VA TVHS GRECC, Nashville, TN USA. RP Abraham, NS (reprint author), Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,152, Houston, TX 77030 USA. NR 40 TC 38 Z9 38 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2008 VL 103 IS 2 BP 323 EP 332 DI 10.1111/j.1572-0241.2007.01595.x PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 260ZU UT WOS:000253049700011 PM 18289200 ER PT J AU Moran, A Simon, JA Pickering, TG Krauss, RM AF Moran, Andrew Simon, Joel A. Pickering, Thomas G. Krauss, Ronald M. CA HARP Study Investigators TI Response to "Is There Overlap in Blood-pressure Response to the Blockers of the Renin - Angiotensin System Between Lower and Higher Renin Subjects?" SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Letter ID HYPERTENSION C1 [Moran, Andrew] Columbia Univ, Div Gen Med, Dept Med, New York, NY 10027 USA. [Simon, Joel A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Simon, Joel A.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Pickering, Thomas G.] Columbia Univ, Dept Med, New York, NY USA. [Pickering, Thomas G.] Columbia Univ, Ctr Behav Cardiovasc Hlth, New York, NY USA. [Krauss, Ronald M.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA. RP Moran, A (reprint author), Columbia Univ, Div Gen Med, Dept Med, New York, NY 10027 USA. EM aem35@columbia.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD FEB PY 2008 VL 21 IS 2 BP 132 EP 132 DI 10.1038/ajh.2007.42 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 254XR UT WOS:000252621800005 ER PT J AU Han, JK Feliciano, Z Bersohn, M AF Han, Janet Konkamol Feliciano, Zenaida Bersohn, Malcolm TI Hidden in plain sight SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID PACEMAKER LEAD C1 [Han, Janet Konkamol; Feliciano, Zenaida; Bersohn, Malcolm] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Cardiol, Los Angeles, CA 90073 USA. RP Han, JK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Cardiol, 11301 Wilshire Blvd 111E, Los Angeles, CA 90073 USA. EM midge_jkh@yahoo.com NR 6 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD FEB PY 2008 VL 121 IS 2 BP 117 EP 118 DI 10.1016/j.amjmed.2007.08.030 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 259RM UT WOS:000252956400009 PM 18261499 ER PT J AU Schmalz, SL Reddy, PR Hutchens, KA Liu, J AF Schmalz, Sara L. Reddy, Proddutur Raghuveer Hutchens, Kelli Ann Liu, Jayson TI Multilocular thymic cyst presenting as acute chest pain SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter C1 [Schmalz, Sara L.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Reddy, Proddutur Raghuveer] Edward Hines Jr VA Hosp, Dept Med, Cardiol Sect, Hines, IL USA. [Hutchens, Kelli Ann] Edward Hines Jr VA Hosp, Dept Pathol, Hines, IL USA. [Liu, Jayson] Edward Hines Jr VA Hosp, Dept Med, Cardiol Sect, Hines, IL USA. RP Schmalz, SL (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 4 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD FEB PY 2008 VL 121 IS 2 BP E5 EP E6 DI 10.1016/j.amjmed.2007.08.039 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 259RM UT WOS:000252956400018 PM 18261488 ER PT J AU Deschamps, AM Zavadzkas, J Murphy, RL Koval, CN McLean, JE Jeffords, L Saunders, SM Sheats, NJ Stroud, RE Spinale, FG AF Deschamps, Anne M. Zavadzkas, Juozas Murphy, Rebecca L. Koval, Christine N. McLean, Julie E. Jeffords, Laura Saunders, Stuart M. Sheats, Nina J. Stroud, Robert E. Spinale, Francis G. TI Interruption of endothelin signaling modifies membrane type 1 matrix metalloproteinase activity during ischemia and reperfusion SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE myocardial interstitium; microdialysis; protein kinase C; phosphorylation; ischemia-reperfusion ID PROTEIN-KINASE-C; ACUTE MYOCARDIAL-INFARCTION; CARDIOPLEGIC ARREST; TISSUE INHIBITOR; HEART-FAILURE; CELL-SURFACE; ACTIVATION; EXPRESSION; MT1-MMP; MYOCYTE AB The matrix metalloproteinases ( MMPs), in particular, membrane type 1 MMP (MT1-MMP), are increased in the context of myocardial ischemia and reperfusion (I/R) and likely contribute to myocardial dysfunction. One potential upstream induction mechanism for MT1-MMP is endothelin (ET) release and subsequent protein kinase C (PKC) activation. Modulation of ET and PKC signaling with respect to MT1-MMP activity with I/R has yet to be explored. Accordingly, this study examined in vivo MT1-MMP activation during I/R following modification of ET signaling and PKC activation. With the use of a novel fluorogenic microdialysis system, myocardial interstitial MT1-MMP activity was measured in pigs ( 30 kg; n = 9) during I/R (90 min I/120 min R). Local ETA receptor antagonism (BQ-123, 1 mu M) and PKC inhibition (chelerythrine, 1 mu M) were performed in parallel microdialysis probes. MT1-MMP activity was increased during I/R by 122 +/- 10% ( P < 0.05) and was unchanged from baseline with ET antagonism and/or PKC inhibition. Selective PKC isoform induction occurred such that PKC-beta II increased by 198 +/- 31% ( P < 0.05). MT1-MMP phosphothreonine, a putative PKC phosphorylation site, was increased by 121 +/- 8% ( P < 0.05) in the I/R region. These studies demonstrate for the first time that increased interstitial MT1-MMP activity during I/ R is a result of the ET/ PKC pathway and may be due to enhanced phosphorylation of MT1-MMP. These findings identify multiple potential targets for modulating a local proteolytic pathway operative during I/R. C1 [Deschamps, Anne M.; Zavadzkas, Juozas; Murphy, Rebecca L.; Koval, Christine N.; McLean, Julie E.; Jeffords, Laura; Saunders, Stuart M.; Sheats, Nina J.; Stroud, Robert E.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29403 USA. [Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, 114 Doughty St,Rm 625,Strom Thurmond Res Bldg, Charleston, SC 29403 USA. EM wilburnm@musc.edu OI Deschamps, Anne/0000-0001-7415-1408 FU NHLBI NIH HHS [HL-45024, P01-HL-48788, HL-57952, R01 HL057952-09, P01 HL048788, T32 HL007260, R03 HL097012, HL-97012, R01 HL057952, HL-07260, R01 HL059165, HL-59165] NR 48 TC 12 Z9 12 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD FEB PY 2008 VL 294 IS 2 BP H875 EP H883 DI 10.1152/ajpheart.00918.2007 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 261IN UT WOS:000253072400039 PM 18065523 ER PT J AU Mehta, NK Chang, VW AF Mehta, Neil K. Chang, Virginia W. TI Weight status and restaurant availability - A multilevel analysis SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; FAST-FOOD RESTAURANTS; BODY-MASS INDEX; US ADULTS; PHYSICAL-ACTIVITY; OBESITY; HEALTH; NEIGHBORHOOD; PREVALENCE; ENVIRONMENT AB Background: Empiric studies find that contextual factors affect individual weight status over and above individual socioeconomic characteristics. Given increasing levels of obesity, researchers are examining how the food environment contributes to unhealthy weight status. An important change to this environment is the increasing availability of away-from-home eating establishments such as restaurants. Methods: This study analyzed the relationship between the restaurant environment and weight status across counties in the United States. Individual data from the 2002-2006 Behavioral Risk Factor Surveillance System (N=714,054) were linked with restaurant data from the 2002 U.S. Economic Census. Fast-food and full-service restaurant density, along with restaurant mix (the ratio of fast-food to full-service restaurants), were assessed. Results: Fast-food restaurant density and a higher ratio of fast-food to full-service restaurants were associated with higher individual-level weight status (BMI and the risk of being obese). In contrast, a higher density of full-service restaurants was associated with lower weight status. Conclusions: Area-level restaurant mix emerged as an important correlate of weight status, with components of the restaurant environment exhibiting differential associations. Hence, it is the availability of fast-food relative to other away from-home choices that appears salient for unhealthy weight outcomes. Areas with a high density of full-service restaurants were indicative of a more healthful eating environment, suggesting a need for research into the comparative healthfulness of foods served at different types of restaurants. Future prospective studies are required to delineate causal pathways. C1 [Mehta, Neil K.; Chang, Virginia W.] Univ Penn, Ctr Populat Studies, Grad Grp Demog, Philadelphia, PA 19104 USA. [Chang, Virginia W.] Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA. [Chang, Virginia W.] Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Chang, Virginia W.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Mehta, NK (reprint author), Univ Penn, Ctr Populat Studies, Grad Grp Demog, 239 MvNeil Bldg,3718 Locust Walk, Philadelphia, PA 19104 USA. EM nmehta@sas.upenn.edu FU NIA NIH HHS [T32 AG000177, T32 AG000177-19]; NICHD NIH HHS [K12 HD043459, K12HD043459] NR 43 TC 121 Z9 125 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2008 VL 34 IS 2 BP 127 EP 133 DI 10.1016/j.amepre.2007.09.031 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 256VP UT WOS:000252758300006 PM 18201642 ER PT J AU Kern, RS Nuechterlein, KH Green, MF Laade, LE Fenton, WS Gold, JM Keefe, RSE Mesholam-Gately, R Mintz, J Seidman, LJ Stover, E Marder, SR AF Kern, Robert S. Nuechterlein, Keith H. Green, Michael F. Laade, Lyle E. Fenton, Wayne S. Gold, James M. Keefe, Richard S. E. Mesholam-Gately, Raquelle Mintz, Jim Seidman, Larry J. Stover, Ellen Marder, Stephen R. TI The MATRICS consensus cognitive battery, part 2: Co-norming and standardization SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID CLINICAL-TRIALS; SCHIZOPHRENIA; NEUROPSYCHOLOGISTS; PERFORMANCE AB Objective: The consensus cognitive battery developed by the National Institute of Mental Health's (NIMH's) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative includes 10 independently developed tests that are recommended as the standard battery for clinical trials of cognition-enhancing interventions for schizophrenia. To facilitate interpretation of results from the MATRICS Consensus Cognitive Battery using a common scaling across tests, normative data were obtained from a single representative U.S. community sample with the battery administered as a unit. Method: The MATRICS Consensus Cognitive Battery was administered to 300 individuals from the general community at five sites in differing geographic regions. For each site, recruitment was stratified by age, gender, and education. A scientific survey sampling method was used to help avoid sampling bias. The battery was administered in a standard order to each participant in a single session lasting approximately 60 minutes. Descriptive data were generated, and age, gender, and education effects on performance were examined. Results: Prominent age and education effects were observed across tests. The results for gender differed by measure, suggesting the need for age and gender corrections in clinical trials. The MATRICS Consensus Cognitive Battery components were co-normed, with allowance for demographic corrections. Conclusions: Co-norming a battery such as the MATRICS Consensus Cognitive Battery, comprising tests from independent test developers each with their own set of norms, facilitates valid interpretation of test scores and communication of findings across studies. These normative data will aid in estimating the magnitude of change during clinical trials of cognition-enhancing agents and make it possible to derive more directly interpretable composite scores. C1 Univ Calif Los Angeles, Geffen Sch Med, Dept Psychol, Los Angeles, CA USA. Univ Calif Los Angeles, Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Kansas, Sch Med, Wichita, KS 67214 USA. Univ Maryland, Dept Psychiat, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA. NIMH, Bethesda, MD 20892 USA. Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. Beth Israel Deaconess Med Ctr, Div Publ Psychiat, Massachusetts Mental Hlth Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Ctr, MIRECC 210 A,Bldg 210,Rm 116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rkern@ucla.edu FU NIMH NIH HHS [N01MH22006] NR 28 TC 183 Z9 195 U1 2 U2 12 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD FEB PY 2008 VL 165 IS 2 BP 214 EP 220 DI 10.1176/appi.ajp.2007.07010043 PG 7 WC Psychiatry SC Psychiatry GA 260ZV UT WOS:000253049800013 PM 18172018 ER PT J AU Green, MF Nuechterlein, KH Kern, RS Baade, LE Fenton, WS Gold, JM Keefe, RSE Mesholam-Gately, R Seidman, L Stover, E Marder, SR AF Green, Michael F. Nuechterlein, Keith H. Kern, Robert S. Baade, Lyle E. Fenton, Wayne S. Gold, James M. Keefe, Richard S. E. Mesholam-Gately, Raquelle Seidman, LarryJ Stover, Ellen Marder, Stephen R. TI Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS psychometric and standardization study SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID COGNITION; PERFORMANCE; PROGRAMS; CAPACITY; WORKSHOP; SUPPORT; SCALE AB Objective: During the consensus meetings of the National Institute of Mental Health Measurement and Treatment Research to Improve Cognition in Schizophrenia (NIMH-MATRICS) Initiative, the U.S. Food and Drug Administration took the position that a drug for this purpose should show changes on 1) an accepted consensus cognitive performance measure and 2) an additional measure (i. e., a co-primary) that is considered functionally meaningful. The goal of the current study was to describe steps to evaluate four potential co-primary measures for psychometric properties and validity. Method: As part of the five-site MATRICS Psychometric and Standardization Study (PASS), two measures of functional capacity and two interview-based measures of cognition were evaluated in 176 patients with schizophrenia (167 of these patients were retested 4 weeks later). Results: Data are presented for each co-primary measure for test-retest reliability, utility as a repeated measure, relationship to cognitive performance, relationship to functioning, tolerability/practicality, and number of missing data. Conclusions: Psychometric properties of all of the measures were considered acceptable, and the measures were generally comparable across the various criteria, except that the functional capacity measures had stronger relationships to cognitive performance and fewer missing data. The development and evaluation of potential co-primary measures is still at an early stage, and it was decided not to endorse a single measure for clinical trials at this point. The current findings offer the initial steps to identify functionally meaningful co-primary measures in this area and will help to guide further evaluation of such measures. C1 [Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Geffen Sch Med, Dept Psychol, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Kansas, Sch Med, Wichita, KS 67214 USA. NIMH, Bethesda, MD 20892 USA. Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA. Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. Beth Israel Deaconess Med Ctr, Dept Psychiat, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Green, MF (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Geffen Sch Med, 300 Med Plaza,Rm 2263, Los Angeles, CA 90095 USA. EM mgreen@ucla.edu FU NIMH NIH HHS [N01MH22006] NR 21 TC 113 Z9 120 U1 5 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD FEB PY 2008 VL 165 IS 2 BP 221 EP 228 DI 10.1176/appi.ajp.2007.07010089 PG 8 WC Psychiatry SC Psychiatry GA 260ZV UT WOS:000253049800014 PM 18172017 ER PT J AU Bluthenthal, RN Heinzerling, KG Anderson, R Flynn, NM Kral, AH AF Bluthenthal, Ricky N. Heinzerling, Keith G. Anderson, Rachel Flynn, Neil M. Kral, Alex H. TI Approval of syringe exchange programs in California: Results from a local approach to HIV prevention SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; NEEDLE-EXCHANGE; ACCESS; INFECTIONS; RISK AB Objectives. We studied the effect of local approval of syringe exchange programs in California (through Assembly AB136) on program availability and performance. Methods. We determined the number of active syringe exchange programs in California by conducting Internet searches and obtaining information from the state and from local programs. To track changes in program availability and performance between 2000 and 2002, we interviewed 24 program directors annually for 3 years about program characteristics, syringe exchange policies, law enforcement contact, and other issues. We conducted multivariate analyses to determine whether AB136 approval status was associated with changes in performance. Results. Fifteen local governments (13 counties and 2 cities) enacted the new law by 2002, and operating syringe exchange programs increased from 24 to 35. The proportion of these programs that were not locally approved declined from 54% to 40%. No new approved programs were started in high-need counties. Total syringes exchanged increased by more than 1 million per year, average annual budgets increased by more than 50%, and police harassment of the program volunteers, clients, and operators declined. Improvements at approved syringe exchange programs accounted for these changes. Conclusions. Statewide approval and funding appears necessary to further syringe exchange availability in California. C1 [Bluthenthal, Ricky N.] RAND Corp, Hlth Program, Santa Monica, CA 90407 USA. [Bluthenthal, Ricky N.] RAND Corp, Drug Policy Res Ctr, Santa Monica, CA 90407 USA. [Bluthenthal, Ricky N.] Calif State Univ Dominguez Hills, Dept Sociol, Carson, CA 90747 USA. [Heinzerling, Keith G.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Heinzerling, Keith G.] Univ Calif Los Angeles, Integrated Substance Abuse Res Programs, Los Angeles, CA 90024 USA. [Heinzerling, Keith G.] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Anderson, Rachel; Flynn, Neil M.] Univ Calif Davis, Sch Med, Div Internal Med, Dept Infect Dis, Davis, CA 95616 USA. [Kral, Alex H.] RTI Int, Urban Hlth Program, San Francisco, CA USA. [Kral, Alex H.] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. RP Bluthenthal, RN (reprint author), RAND Corp, Hlth Program, 1776 Main S,POB 2138, Santa Monica, CA 90407 USA. EM rickyb@rand.org OI Bluthenthal, Ricky/0000-0003-3491-1702 FU NIDA NIH HHS [R01 DA014210, R01 DA14210]; PHS HHS [R06/CCR918667] NR 34 TC 12 Z9 12 U1 1 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2008 VL 98 IS 2 BP 278 EP 283 DI 10.2105/AJPH.2005.080770 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 257XU UT WOS:000252833400020 PM 17538068 ER PT J AU Jonsson, S Varella-Garcia, M Miller, YE Wolf, HJ Byers, T Braudrick, S Kiatsimkul, P Lewis, M Kennedy, TC Keith, RL Bjornsson, J Mcwilliams, A Lam, S Hirsch, FR Franklin, WA AF Jonsson, Steinn Varella-Garcia, Marileila Miller, York E. Wolf, Holly J. Byers, Tim Braudrick, Sarah Kiatsimkul, Porntip Lewis, Marina Kennedy, Timothy C. Keith, Robert L. Bjornsson, Johannes Mcwilliams, Annette Lam, Stephen Hirsch, Fred R. Franklin, Wilbur A. TI Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE chromosomal aneusomy; fluorescence in situ hybridization; carcinoma in situ; premalignancy ID IN-SITU HYBRIDIZATION; PRENEOPLASTIC LESIONS; COMPUTED-TOMOGRAPHY; FLUORESCENCE; CARCINOMA; CYTOLOGY; SMOKERS; RISK; ABNORMALITIES; ORGANIZATION AB Rationale: The development of lung cancer (LC) is accompanied by field changes in the airway mucosa that may have prognostic importance. Objectives: To compare patients with prevalent LC to control subjects regarding their histologic dysplasia scores and chromosomal aneusomy as measured by fluorescence in situ hybridization (FISH). Methods: The most advanced bronchial histology lesion was assessed from each of 44 LC cases and 90 cancer-free control subjects using a four-color FISH probe set encompassing the chromosome 6 centromere, 5p15.2, 7p12 (epidermal growth factor receptor), and 8q24 v-myc myelocytomatosis viral oncogene homolog (MYC) sequences. Histology grades were coded as dysplasia (moderate or severe) or carcinoma in situ (CIS). Measurements and Main Results: CIS was the highest histologic grade for 32 subjects, and dysplasia was the highest grade for 102 subjects (54 moderate, 48 severe). Chromosomal aneusomy was seen in 64% of the LC cases, but in only 31% of the control subjects (odds ratio [OR], 4.68; 95% confidence interval [CI]. 1.97-11.04). Among those with any level of dysplasia, the OR for positive FISH and LC was 2.28 (95% Cl, 0.75-6.86). Among those with CIS, the OR for positive FISH and LC was 5.84 (95% Cl, 1.31-26.01). Conclusions: Chromosomal aneusomy is associated with LC. Prospective examination of aneusomy as a precursor lesion that predicts LC is needed. C1 [Jonsson, Steinn; Varella-Garcia, Marileila; Miller, York E.; Kiatsimkul, Porntip; Lewis, Marina; Keith, Robert L.; Hirsch, Fred R.] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO USA. [Jonsson, Steinn] Univ Iceland, Dept Med, Reykjavik, Iceland. [Miller, York E.; Keith, Robert L.] Denver Vet Affairs Med Ctr, Div Pulm, Denver, CO USA. [Byers, Tim; Braudrick, Sarah] Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biostat, Denver, CO 80045 USA. [Kennedy, Timothy C.] Presbyterian St Lukes Med Ctr 1, Dept Med, Div Pulm, Denver, CO USA. [Bjornsson, Johannes] Univ Iceland Hosp, Dept Pathol, Reykjavik, Iceland. [Mcwilliams, Annette; Lam, Stephen] British Columbia Canc Agcy, Dept Resp Med, Vancouver, BC V5Z 4E6, Canada. [Hirsch, Fred R.; Franklin, Wilbur A.] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO USA. RP Varella-Garcia, M (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Med Med Oncol, Campus Box 6511,Mail Box 8117, Aurora, CO 80045 USA. EM marileila.garcia@uchsc.edu FU NCI NIH HHS [P01-CA58187, U01-CA85070, P30-CA46934] NR 30 TC 24 Z9 24 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2008 VL 177 IS 3 BP 342 EP 347 DI 10.1164/rccm.200708-1142OC PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 255IC UT WOS:000252650600016 PM 17989344 ER PT J AU Streblow, DN Kreklywich, CN Andoh, T Moses, AV Dumortier, J Smith, PP Defilippis, V Fruh, K Nelson, JA Orloff, SL AF Streblow, D. N. Kreklywich, C. N. Andoh, T. Moses, A. V. Dumortier, J. Smith, P. P. Defilippis, V. Fruh, K. Nelson, J. A. Orloff, S. L. TI The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE accelerated rejection; allograft vasculopathy; angiogenesis; arrays; cardiac allograft rejection; cardiac allograft vasculopathy; chronic allograft rejection; cyclosporine A; cytomegalovirus (CMV); cytomegalovirus infection; transplant vascular sclerosis; virus ID CYTOMEGALO-VIRUS INFECTION; CHRONIC REJECTION; SMALL-BOWEL; CORONARY-ARTERIES; HEART-TRANSPLANTS; GROWTH-FACTORS; ELUTING STENT; ATHEROSCLEROSIS; EXPRESSION; DISEASE AB Human cytomegalovirus (HCMV) accelerates transplant vascular sclerosis (TVS), a consequence of angiogenesis (AG) and wound repair (WR). While HCMV can be localized to TVS lesions, the low number of infected cells suggests a global effect on target tissues. We used microarray analysis followed by real-time-polymerase chain reaction (RT-PCR) in an RCMV-accelerated TVS rat cardiac transplant model to determine whether CMV activates host WR and AG factors. Dysregulated cellular genes in allografts from RCMV-infected recipients were compared to those from uninfected recipients and native hearts. We demonstrated that RCMV upregulates the genes involved in WR and AG, which was highest during the critical time of TVS acceleration (21-28 days). Using a standard in vitro AG assay, virus and serum-free supernatants collected at 48 h postinfection significantly induced endothelial cell (EC) migration, branching and tubule formation compared to supernatants from mock-infected cells. Supernatants from ultraviolet (UV)-inactivated RCMV-infected cells failed to induce AG, indicating that virus replication is required. Upregulation of WR and AG genes occurs during the critical period of CMV-accelerated TVS. Targeting these genes may prevent this process and improve allograft survival. C1 [Orloff, S. L.] Portland VA Med Ctr, Portland, OR 97239 USA. [Kreklywich, C. N.; Andoh, T.; Fruh, K.; Nelson, J. A.; Orloff, S. L.] Oregon Hlth & Sci Univ, Dept Med Microbiol & Immunol, Portland, OR 97201 USA. [Orloff, S. L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. [Streblow, D. N.; Moses, A. V.; Dumortier, J.; Smith, P. P.; Defilippis, V.; Fruh, K.; Nelson, J. A.] Oregon Hlth & Sci Univ, Vaccine& Gene Therapy Inst, Portland, OR 97201 USA. RP Orloff, SL (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. EM orloffs@ohsu.edu FU NCRR NIH HHS [P51 RR000163-496162, P51 RR000163, P51 RR000163-486828]; NHLBI NIH HHS [R01 HL085451, HL66238-01, HL083194]; NIAID NIH HHS [R01 AI070890-01A2, R01 AI070890] NR 31 TC 28 Z9 28 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD FEB PY 2008 VL 8 IS 2 BP 277 EP 287 DI 10.1111/j.1600-6143.2007.02062.x PG 11 WC Surgery; Transplantation SC Surgery; Transplantation GA 252DD UT WOS:000252424300005 PM 18093265 ER PT J AU Sayers, SL Riegel, B Pawlowski, S Coyne, JC Samaha, FF AF Sayers, Steven L. Riegel, Barbara Pawlowski, Stephanie Coyne, James C. Samaha, Frederick F. TI Social support and self-care of patients with heart failure SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE heart failure; social support; self-care ID MULTIDIMENSIONAL SCALE; COGNITIVE IMPAIRMENT; ENHANCING RECOVERY; HEALTH BEHAVIORS; VALIDATION; MANAGEMENT; ADHERENCE; DISEASE; KIN; DEPRESSION AB Background Social support can influence treatment adherence of patients with chronic illnesses, which may explain the positive effects of social support on heart failure (HF) outcomes. Purpose To investigate the effects of social support among patients with HF, we examined whether aspects of social support were associated with self-care, including medication adherence, dietary adherence, and HF symptom monitoring functions. Methods We recruited 74 patients with HF from cardiology clinics of a Veterans Affairs Medical Center and a university-affiliated hospital, and tested the relationships between social support and the patients' self-care. Results Consistent with previous research in older adults, family members, especially spouses, were often involved in the medical care of patients with chronic HF and provided a range of levels of support to patients. Self-care was generally poor, as measured across several self-care domains. Perceived social support was moderately associated with relatively better self-reported medication and dietary adherence, and other aspects of self-care such as daily weighing. Conclusions These findings suggest that a relatively higher level of self-care is an important correlate of social support and may explain how social support influences HF outcomes. This study also suggests that family members should play a greater part in clinical care focused on improving self-care. C1 [Sayers, Steven L.; Pawlowski, Stephanie; Coyne, James C.; Samaha, Frederick F.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Riegel, Barbara; Pawlowski, Stephanie; Coyne, James C.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Sayers, SL (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. EM steven.sayers@va.gov NR 51 TC 94 Z9 99 U1 7 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD FEB PY 2008 VL 35 IS 1 BP 70 EP 79 DI 10.1007/s12160-007-9003-x PG 10 WC Psychology, Multidisciplinary SC Psychology GA 268IQ UT WOS:000253573900008 PM 18347906 ER PT J AU Mann, M Tendulkar, A Birger, N Howard, C Ratcliffe, MB AF Mann, Michael Tendulkar, Amod Birger, Noy Howard, Cheryl Ratcliffe, Mark B. TI National institutes of health funding for surgical research SO ANNALS OF SURGERY LA English DT Article ID TRANSLATIONAL RESEARCH; PHYSICIAN-SCIENTIST; SURGEON; TRENDS AB Objective: The objective was to compare National Institutes of Health (NIH) funding rates and application success rates among surgeon and nonsurgeon-scientists over the past 2 decades. Summary Background Data: Surgeons may be capable of accelerating the translation of basic research into new clinical therapies. Nevertheless, most surgeon-scientists believe they are at a disadvantage in competing for peer-reviewed funding, despite a recent emphasis on "translational science" by organizations such as the NIH. Methods: We accessed databases from the NIH and the American Association of Medical Colleges. Results: Although total competing NIH awards rose 79.2% from 5608 to 10,052, the much smaller number of surgical awards increased only by 41.4% from 157 to 222. There was a small but statistically significant difference between total NIH and surgical application success rates (29% vs. 25%, P < 0.01). However, the persistently low percent of NIH funding going to surgical investigators was due primarily to the very small number of surgical applications, and to a much smaller increase in the absolute number of applications over time (464 vs. 23,847). As a result, the number of grants per 100 faculty members, was more than 4 times higher among nonsurgical than surgical faculties at US medical schools. Conclusion: NIH funding to academic surgeons is declining relative to their nonsurgical colleagues. This trend will likely be reversed only by an increase in the number of grant applications submitted by surgeon-scientists. Structural changes in surgical training programs, and in the economics of academic surgery, may support a greater contribution of surgeon-scientists to the success of translational research. C1 [Mann, Michael; Birger, Noy; Ratcliffe, Mark B.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Mann, Michael; Tendulkar, Amod; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Howard, Cheryl] NHLBI, Div Sci Program Operat, Bethesda, MD 20892 USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@med.va.gov NR 15 TC 52 Z9 52 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD FEB PY 2008 VL 247 IS 2 BP 217 EP 221 DI 10.1097/SLA.0b013e3181568e26 PG 5 WC Surgery SC Surgery GA 256VR UT WOS:000252758500003 PM 18216525 ER PT J AU Bilimoria, KY Bentrem, DJ Feinglass, JM Stewart, AK Winchester, DP Talamonti, MS Ko, CY AF Bilimoria, K. Y. Bentrem, D. J. Feinglass, J. M. Stewart, A. K. Winchester, D. P. Talamonti, M. S. Ko, C. Y. TI Directing surgical quality improvement initiatives in the United States: Comparison of perioperative mortality and long-term survival for cancer surgery SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 61st Annual Cancer Symposium of the Society-of-Surgical-Oncology CY MAR 13-16, 2008 CL Chicago, IL SP Soc Surg Oncol C1 [Bilimoria, K. Y.; Stewart, A. K.] Amer Coll Surg, Canc Programs, Chicago, IL USA. [Bentrem, D. J.; Feinglass, J. M.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL USA. [Winchester, D. P.; Talamonti, M. S.] Evanston Northwest Healthcare, Dept Surg, Evanston, IL USA. [Ko, C. Y.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2008 VL 15 SU 2 BP 18 EP 19 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 258RT UT WOS:000252887900056 ER PT J AU Glass, E Iker, E AF Glass, E. Iker, E. TI The role of SPECT-CT in lymphatic mapping SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 6th Biennial International-Sentinel-Node-Society Meeting CY FEB 18-20, 2008 CL Sydney, AUSTRALIA SP Int Sentinel Node Soc C1 [Glass, E.] John Wayne Canc Inst, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Iker, E.] Lymphedema Ctr So Calif, Santa Monica, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2008 VL 15 SU 1 BP 19 EP 19 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 263DK UT WOS:000253197600048 ER PT J AU Bilimoria, KY Bentrem, DJ Ko, CY Winchester, DP Stewart, AK Talamonti, MS Halverson, A AF Bilimoria, K. Y. Bentrem, D. J. Ko, C. Y. Winchester, D. P. Stewart, A. K. Talamonti, M. S. Halverson, A. TI Anal cancer in the United States: Utilization and outcomes of recommended treatment SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 61st Annual Cancer Symposium of the Society-of-Surgical-Oncology CY MAR 13-16, 2008 CL Chicago, IL SP Soc Surg Oncol C1 [Bilimoria, K. Y.; Winchester, D. P.; Stewart, A. K.] Northwestern Univ, Amer Coll Surg, Feinberg Sch Med, Dept Surg,Canc Programs, Chicago, IL USA. [Bentrem, D. J.; Talamonti, M. S.; Halverson, A.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL USA. [Ko, C. Y.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2008 VL 15 SU 2 BP 21 EP 22 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 258RT UT WOS:000252887900065 ER PT J AU Pessler, F Ogdie, A Diaz-Torne, C Dai, L Yu, X Einhorn, E Gay, S Schumacher, HR AF Pessler, F. Ogdie, A. Diaz-Torne, C. Dai, L. Yu, X. Einhorn, E. Gay, S. Schumacher, H. R. TI Subintimal Ki-67 as a synovial tissue biomarker for inflammatory arthropathies SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID HISTOPATHOLOGICAL GRADING SYSTEM; RHEUMATOID-ARTHRITIS; IMMUNOHISTOCHEMICAL ANALYSIS; REACTIVE ARTHRITIS; EXPRESSION; CELLS; PROLIFERATION; IGV(H) AB Objectives: Ki-67 is expressed in the nuclei of dividing cells and can be used to assess proliferation of synovial inflammatory and stromal cells. We evaluated subintimal Ki-67+ cell density as a tissue biomarker for inflammatory arthropathies and compared it to subintimal CD68, a synovial biomarker of RA. Methods: Subintimal Ki-67+ and CD68+ cell densities were measured immunohistochemically in synovial specimens obtained from patients with rheumatoid arthritis (RA; n = 19), osteoarthritis (OA; n = 18), "non-inflammatory'' orthopaedic arthropathies ( avascular necrosis, meniscus injury, femur fracture; n = 16), chronic septic arthritis ( n = 9), and histologically normal synovium (n = 10). Results were correlated with a histological synovitis score. Utilising the areas under receiver operating characteristic curves (AUCs), we compared the abilities of Ki-67 and CD68 to differentiate among these arthropathies. Results: Ki-67 was expressed widely in the subintima of inflamed specimens and in RA pannus invading hard tissues. Compared to normal controls, it was highly overexpressed in RA (26.6-fold) and chronic septic arthritis (55-fold), and mildly elevated in OA ( 3.9-fold) and orthopaedic arthropathies (2.1-fold). Ki-67 and CD68 differentiated similarly well between RA and OA (AUC: Ki-67 = 0.91, CD68 = 0.94), Ki-67 better between chronic septic arthritis and RA, and CD68 better between OA and normal controls. Ki-67 (r = 0.80) and CD68 (r = 0.79) correlated positively with the synovitis score. Conclusions: Subintimal Ki-67 was overexpressed in inflammatory arthropathies, distinguished among differentially inflamed arthropathies, and correlated positively with the histological severity of synovitis. It may prove useful in synovial tissue classification and as a synovial marker of disease activity in clinical trials when biopsies are available. C1 [Pessler, F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Ogdie, A.; Diaz-Torne, C.; Dai, L.; Yu, X.; Schumacher, H. R.] Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Einhorn, E.] Philadelphia VA Med Ctr, Dept Pathol, Philadelphia, PA USA. [Gay, S.] Univ Zurich, WHO Collaborating Ctr Mol Biol & Novel Therapeut, CH-8006 Zurich, Switzerland. RP Pessler, F (reprint author), Tech Univ Dresden, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany. EM frank.pessler@uniklinikum-dresden.de OI Cesar, Diaz-Torne/0000-0001-6275-7699; Ogdie, Alexis/0000-0002-4639-0775 FU NCI NIH HHS [T32-CA 09140]; NIAMS NIH HHS [T32-AR 007442] NR 22 TC 21 Z9 22 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD FEB PY 2008 VL 67 IS 2 BP 162 EP 167 DI 10.1136/ard.2007.071670 PG 6 WC Rheumatology SC Rheumatology GA 250LN UT WOS:000252301700005 PM 17613556 ER PT J AU Kontoyiannis, DP Lewis, RE Alexander, BD Lortholary, O Dromer, F Gupta, KL John, GT del Busto, R Klintmalm, GB Somani, J Lyon, GM Pursell, K Stosor, V Munoz, P Limaye, AP Kalil, AC Pruett, TL Garcia-Diaz, J Humar, A Houston, S House, AA Wray, D Orloff, S Dowdy, LA Fisher, RA Heitman, J Albert, ND Wagener, MM Singh, N AF Kontoyiannis, Dimitrios P. Lewis, Russell E. Alexander, Barbara D. Lortholary, Olivier Dromer, Francoise Gupta, Krishan L. John, George T. del Busto, Ramon Klintmalm, Goran B. Somani, Jyoti Lyon, G. Marshall Pursell, Kenneth Stosor, Valentina Munoz, Patricia Limaye, Ajit P. Kalil, Andre C. Pruett, Timothy L. Garcia-Diaz, Julia Humar, Atul Houston, Sally House, Andrew A. Wray, Dannah Orloff, Susan Dowdy, Lorraine A. Fisher, Robert A. Heitman, Joseph Albert, Nathaniel D. Wagener, Marilyn M. Singh, Nina TI Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with Cryptococcosis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID CANDIDA-ALBICANS; SUSCEPTIBILITY; FLUCONAZOLE; VORICONAZOLE; COMBINATION; VIRULENCE; TOR AB Synergistic interactions were observed between CIs and antifungal agents against 53 (90%) of 59 Cryptococcus neoformans isolates from solid organ transplant recipients with cryptococcosis and may account for better outcomes in patients with cryptococcosis receiving these immunosuppressive agents. C1 [Kontoyiannis, Dimitrios P.; Lewis, Russell E.; Albert, Nathaniel D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Alexander, Barbara D.] Duke Univ, Med Ctr, Durham, NC USA. [Lortholary, Olivier; Dromer, Francoise; Heitman, Joseph] Inst Pasteur, Paris, France. [Lortholary, Olivier; Heitman, Joseph] Hop Necker Enfants Malad, Fac Med Paris Descartes, Paris, France. [Gupta, Krishan L.] Postgrad Inst Med Educ & Res, Chandigarh 160012, India. [John, George T.] Christian Med Coll & Hosp, Vellore 632004, Tamil Nadu, India. [del Busto, Ramon] Henry Ford Hosp, Detroit, MI 48202 USA. [Klintmalm, Goran B.] Baylor Univ, Med Ctr, Dallas, TX USA. [Somani, Jyoti; Lyon, G. Marshall] Emory Univ, Atlanta, GA 30322 USA. [Pursell, Kenneth] Univ Chicago, Chicago, IL 60637 USA. [Stosor, Valentina] Northwestern Univ, Chicago, IL 60611 USA. [Munoz, Patricia] Hosp Gen Univ Gregorio Maranon, Madrid, Spain. [Limaye, Ajit P.] Univ Washington, Seattle, WA 98195 USA. [Kalil, Andre C.] Univ Nebraska, Omaha, NE 68182 USA. [Pruett, Timothy L.] Univ Virginia, Charlottesville, VA USA. [Garcia-Diaz, Julia] Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA. [Humar, Atul] Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada. [Houston, Sally] Univ S Florida, Tampa, FL USA. [House, Andrew A.] Univ Western Ontario, London, ON, Canada. [Wray, Dannah] Med Univ S Carolina, Charleston, SC 29425 USA. [Orloff, Susan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dowdy, Lorraine A.] Univ Miami, Miami, FL 33152 USA. [Fisher, Robert A.] Virginia Commonwealth Univ, Richmond, VA USA. [Wagener, Marilyn M.; Singh, Nina] VA Med Ctr, Pittsburgh, PA USA. [Wagener, Marilyn M.; Singh, Nina] Univ Pittsburgh, Med Ctr, VA Pittsburgh Healthcare Syst, Infect Dis Sect 2A 137, Pittsburgh, PA 15240 USA. RP Kontoyiannis, DP (reprint author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Box 402, Houston, TX 77030 USA. EM dkontoyi@mdanderson.org; nis5@pitt.edu RI Garcia-Diaz, Julia/D-3555-2011 OI Lewis, Russell/0000-0002-2002-4339; Munoz Garcia, Patricia Carmen/0000-0001-5706-5583 FU NIAID NIH HHS [R01 AI 054719-01, R01 AI054719] NR 23 TC 42 Z9 43 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD FEB PY 2008 VL 52 IS 2 BP 735 EP 738 DI 10.1128/AAC.00990-07 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 256JN UT WOS:000252724800051 PM 18070977 ER PT J AU Kouba, DJ Fincher, EF Moy, RL AF Kouba, David J. Fincher, Edgar F. Moy, Ronald L. TI Nevus of Ota successfully treated by fractional photothermolysis using a fractionated 1440-nm Nd : YAG laser SO ARCHIVES OF DERMATOLOGY LA English DT Article ID SWITCHED RUBY-LASER; ACQUIRED BILATERAL NEVUS; DERMAL MELANOCYTOSIS; ALEXANDRITE; TRIAL; MACULES C1 [Kouba, David J.] Henry Ford Hlth Syst, Detroit, MI USA. [Fincher, Edgar F.; Moy, Ronald L.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Fincher, Edgar F.; Moy, Ronald L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Moy, RL (reprint author), Moy Fincher Med Grp, 100 UCLA Med Plaza,Suite 590, Los Angeles, CA 90024 USA. EM rmoy@ucla.edu NR 24 TC 29 Z9 30 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD FEB PY 2008 VL 144 IS 2 BP 156 EP 158 DI 10.1001/archdermatol.2007.49 PG 3 WC Dermatology SC Dermatology GA 262RE UT WOS:000253164900002 PM 18283171 ER PT J AU Gunzler, SA Koudelka, C Carlson, NE Pavel, M Nutt, JG AF Gunzler, Steven A. Koudelka, Caroline Carlson, Nichole E. Pavel, Misha Nutt, John G. TI Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study SO ARCHIVES OF NEUROLOGY LA English DT Article ID MOTOR FLUCTUATIONS; IN-VIVO; DISEASE; LEVODOPA; RECEPTORS; DETERIORATION; PERGOLIDE; MICE AB Objective: To determine whether low concentrations of a dopamine agonist worsen parkinsonism, which would suggest that activation of presynaptic dopamine autoreceptors causes a super-off state. Design: Randomized, double-blind, placebo-controlled, crossover clinical trial. Setting: Academic movement disorders center. Patients: Patients with Parkinson disease and motor fluctuations. Intervention: Fourteen patients with Parkinson disease and motor fluctuations were randomized to receive 1 of 6 possible sequences of placebo, low-dose (subthreshold) apomorphine hydrochloride, and high-dose (threshold to suprathreshold) apomorphine hydrochloride infusions. Subthreshold doses of apomorphine hydrochloride (12.5 mu g/kg/h every 2 hours and 25 mu g/kg/h every 2 hours), threshold to suprathreshold doses of apomorphine hydrochloride (50 mu g/kg/h every 2 hours and 100 mu g/kg/h every 2 hours), and placebo were infused for 4 hours daily for 3 consecutive days. Main Outcome Measures: Finger and foot tapping rates. Results: There was no decline in finger or foot tapping rates during the low-dose apomorphine hydrochloride infusions relative to placebo. The high-dose infusions increased foot tapping (P < .001) and trended toward increasing finger tapping compared with placebo infusions. Conclusions: Subthreshold concentrations of apomorphine did not worsen parkinsonism, suggesting that presynaptic dopamine autoreceptors are not important to the motor response in moderate to advanced Parkinson disease. Trial Registration: clinicaltrials.gov Identifier: NCT00472355. C1 [Gunzler, Steven A.] Univ Hosp Case Med Ctr, Neurol Inst, Movement Disorders Ctr, Cleveland, OH 44106 USA. [Gunzler, Steven A.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. [Gunzler, Steven A.; Nutt, John G.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. [Gunzler, Steven A.; Nutt, John G.] Oregon Hlth & Sci Univ, Parkinson Ctr Oregon, Portland, OR 97201 USA. [Koudelka, Caroline] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR 97201 USA. [Carlson, Nichole E.] Oregon Hlth & Sci Univ, Div Biostat, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Pavel, Misha] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA. RP Gunzler, SA (reprint author), Univ Hosp Case Med Ctr, Neurol Inst, Movement Disorders Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM steven.gunzler@uhhospitals.org FU NCRR NIH HHS [UL1 RR 024140-01, UL1 RR024140]; NINDS NIH HHS [R01 NS021062, R01 NS021062-22] NR 21 TC 4 Z9 4 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD FEB PY 2008 VL 65 IS 2 BP 193 EP 198 DI 10.1001/archneurol.2007.58 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 261DH UT WOS:000253058800004 PM 18268187 ER PT J AU Harris, GF Anderson, ME Lee, JH AF Harris, George F. Anderson, Mary E. Lee, John H. TI The effect of proteasome inhibition on p53 degradation and proliferation in tonsil epithelial cells SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Head-and-Neck-Society/Research Workshop on the Biology, Prevention and Treatment of Head and Neck Cancer CY AUG 17-20, 2006 CL Chicago, IL SP Amer Head & Neck Soc ID HUMAN-PAPILLOMAVIRUS TYPE-16; NECK-CANCER; MEDIATED DEGRADATION; HEAD; E6; CARCINOMA; COMPLEX; RISK; IMMORTALIZATION; UBIQUITINATION AB Objective: To determine whether proteasome inhibition could reverse E6-mediated p53 degradation, cause selective growth inhibition, and induce apoptosis in human papillomavirus E6-transformed primary tonsil epithelial cells. Design: Primary human and mouse tonsil epithelial cell lines were transformed with a retrovirus containing human papillomavirus 16 oncogenes. MG132 was used to inhibit proteasome degradation in vitro and in vivo, and biochemical assays regarding p53 and apoptosis were performed. Results: In cells that express E6, proteasome inhibition with MG132 restored p53 protein levels and decreased proliferation in a dose-dependent fashion that was significantly more pronounced compared with controls. However, inhibition of proliferation occurred at a lower concentration than restoration of p53 protein expression. Also, wild-type and p53 knockout mouse tonsil epithelial cells that express E6 had near-identical inhibition of growth, suggesting that growth inhibition was p53 independent. In vivo studies did not demonstrate any growth inhibition. Conclusion: The findings suggest that proteasome inhibition preferentially inhibits proliferation in cells expressing E6 through a p53-independent mechanism. C1 [Harris, George F.; Lee, John H.] Univ Iowa, Dept Otolaryngol Head & Neck Surg, Iowa City, IA 52242 USA. [Anderson, Mary E.; Lee, John H.] Vet Hlth Adm, Dept Otolaryngol, US Dept Vet Affairs, Iowa City, IA USA. RP Lee, JH (reprint author), Univ Iowa, Dept Otolaryngol Head & Neck Surg, 200 Hawkins Dr, Iowa City, IA 52242 USA. EM john-h-lee@uiowa.edu FU NIDCD NIH HHS [5-T32-DC000040, 1-K08-DC0005627-1] NR 27 TC 4 Z9 4 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD FEB PY 2008 VL 134 IS 2 BP 157 EP 163 DI 10.1001/archoto.2007.37 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 262RG UT WOS:000253165100008 PM 18283158 ER PT J AU Bair-Merritt, MH Feudtner, C Localio, AR Feinstein, JA Rubin, D Holmes, WC AF Bair-Merritt, Megan H. Feudtner, Chris Localio, A. Russell Feinstein, Jamie A. Rubin, David Holmes, William C. TI Health care use of children whose female caregivers have intimate partner violence histories SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID MATERNAL DEPRESSIVE SYMPTOMS; DOMESTIC VIOLENCE; YOUNG-CHILDREN; WOMEN; EMERGENCY; EXPERIENCES; PREVALENCE; INJURIES; EXPOSURE; ASTHMA AB Objective: To determine whether prior exposure to intimate partner violence ( IPV) is associated with children's subsequent emergency department ( ED) visits and hospitalizations. Design: Retrospective cohort study. Setting: The National Survey of Child and Adolescent Well-Being, a nationally representative sample of children reported to Child Protective Services between 1999 and 2000. Participants: Families of children reported to Child Protective Services who were assessed through comprehensive caregiver interviews at baseline and 18 and 36 months. Main Exposure: Severe or minor IPV, as measured by the Conflict Tactics Scale 1. Main Outcome Measures: Number of ED visits or hospitalizations from baseline to the 18-month assessment ( interval 1, n= 2689) and from the 18-month to the 36-month assessment ( interval 2, n= 2546). Results: Compared with children whose female caregivers reported no IPV at baseline, children whose female caregivers disclosed severe IPV at baseline had significantly higher rates of ED visits over both subsequent intervals ( interval 1, incidence rate ratio [ IRR], 2.0; 95% confidence interval [ CI], 1.3-2.9; interval 2, IRR, 1.9; 95% CI, 1.2-3.0). In contrast, rates of hospitalizations were lower in the second interval for children whose female caregivers disclosed minor IPV as compared with no IPV at baseline ( IRR, 0.2; 95% CI, 0.1-0.6). Conclusions: Further research is required to elucidate the complex relationship between IPV and child health care use. Such an understanding will facilitate identification of sites within the health care system where effective interventions for children exposed to IPV, and their caregivers, might be located. C1 [Bair-Merritt, Megan H.] Johns Hopkins Sch Med, Div Gen Pediat & Adolescent Med, Baltimore, MD 21287 USA. [Bair-Merritt, Megan H.; Feudtner, Chris; Feinstein, Jamie A.; Rubin, David] Univ Penn, Childrens Hosp Philadelphia, Div Gen Pediat, Pediat Generalist Res Grp, Philadelphia, PA 19104 USA. [Holmes, William C.] Univ Penn, Vet Adm Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. [Holmes, William C.] Univ Penn, Dept Med, Hosp Univ Penn, Philadelphia, PA 19104 USA. [Feudtner, Chris; Localio, A. Russell; Rubin, David; Holmes, William C.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Feudtner, Chris] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Bair-Merritt, MH (reprint author), Johns Hopkins Sch Med, Div Gen Pediat & Adolescent Med, 200 N Wolfe St,Off 2021, Baltimore, MD 21287 USA. EM mbairme1@jhmi.edu OI Bair-Merritt, Megan/0000-0002-1876-9817; Feinstein, James/0000-0003-3074-8805 FU PHS HHS [2T32 HP 10026-10] NR 34 TC 6 Z9 6 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD FEB PY 2008 VL 162 IS 2 BP 134 EP 139 DI 10.1001/archpediatrics.2007.32 PG 6 WC Pediatrics SC Pediatrics GA 258HU UT WOS:000252859800006 PM 18250237 ER PT J AU Cowan, RE Boninger, ML Sawatzky, BJ Mazoyer, BD Cooper, RA AF Cowan, Rachel E. Boninger, Michael L. Sawatzky, Bonita J. Mazoyer, Brian D. Cooper, Rory A. TI Preliminary outcomes of the SmartWheel Users' Group database: a proposed framework for clinicians to objectively evaluate manual wheelchair propulsion SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE biomechanics; engineering; insurance; rehabilitation; wheelchairs ID SPINAL-CORD INJURIES; PUSHRIM FORCES; SEAT POSITION; ENERGY-COST; BIOMECHANICS; MOBILITY; LEVEL; DISABILITY; KINETICS; HEALTH AB Objectives: To describe a standard clinical protocol for the objective assessment of manual wheelchair propulsion; to establish preliminary values for temporal and kinetic parameters derived from the protocol; and to develop graphical references and a proposed application process for use by clinicians. Design: Case series. Setting: Six research institutions that collect kinetic wheelchair propulsion data and contribute that data to an international data pool. Participants: Subjects with spinal cord injury (N= 128). Interventions: Subjects propelled a wheelchair from a stationary position to a self-selected velocity across a hard tile surface, a low pile carpet, and up an Americans with Disabilities Act-compliant ramp. Unilateral kinetic data were obtained from subjects using a force and moment sensing pushrim. Main Outcome Measures: Differences in self-selected velocity, peak resultant force, push frequency, and stroke length across all surfaces, relationship between (1) weight-normalized peak resultant force and self-selected velocity and (2) push frequency and self-selected velocity. Results: Graphical references were generated for potential clinical use based on the relation between body weight-normalized peak resultant force, push frequency, and velocity. Self-selected velocity decreased (ramp < carpet < tile), peak resultant forces increased (ramp > carpet > tile), and push frequency and stroke length remained unchanged when compared across the different surfaces. Weight-normalized peak resultant force was a significant predictor of velocity on tile and ramp. Push frequency was a significant predictor of velocity on tile, car-pet, and ramp. Conclusions: We present preliminary data generated from a clinically practical manual wheelchair propulsion evaluation protocol and we describe a proposed method for clinicians to objectively evaluate manual wheelchair propulsion. C1 [Cowan, Rachel E.; Boninger, Michael L.; Cooper, Rory A.] VA Pittsburgh Hlth Care Syst, Human Engn Res Lab, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA. [Cowan, Rachel E.; Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA USA. [Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Boninger, Michael L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Cowan, Rachel E.; Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Sawatzky, Bonita J.] Univ British Columbia, Fac Med, Dept Orthopaed, Vancouver, BC, Canada. [Mazoyer, Brian D.] Banner Good Samaritan Rehabil Inst, Phoenix, AZ USA. RP Boninger, ML (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Lab, Ctr Excellence Wheelchairs & Related Technol, 5180 Highland Dr,151R-1, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu RI Mazoyer, Bernard/B-6303-2012 OI Mazoyer, Bernard/0000-0003-0970-2837; Boninger, Michael/0000-0001-6966-919X FU NICHD NIH HHS [1 F31 HD053986-01]; PHS HHS [H133N000019] NR 40 TC 37 Z9 37 U1 1 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2008 VL 89 IS 2 BP 260 EP 268 DI 10.1016/j.apmr.2007.08.141 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 260OD UT WOS:000253018700009 PM 18226649 ER PT J AU Hussain, R Cevallos, ME Darouiche, RO Trautner, BW AF Hussain, Rahat Cevallos, Manuel E. Darouiche, Rabih O. Trautner, Barbara W. TI Gram-negative intravascular catheter-related bacteremia in patients with spinal cord injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT 44th Annual Meeting of the Infectious-Diseases-Society-of-America CY OCT 12-15, 2006 CL Toronto, CANADA SP Infect Dis Soc Amer DE bacteremia; rehabilitation; spinal cord injuries ID BLOOD-STREAM INFECTIONS; INTENSIVE-CARE UNITS; DECUBITUS ULCERS; BACTERIURIA; PATHOGENESIS; MORTALITY AB Objective: To determine whether the prevalence of gram-negative catheter-related bloodstream infection (CRBSI) is higher in patients with spinal cord injury (SCI) than in patients without SCI. Design: Retrospective chart review from August 1998 to August 2006. Setting: A Veterans Affairs medical center, which serves as a tertiary care medical center to over 500 veterans with SCI and is the primary Source of health care for veterans in southeast Texas. Participants: All hospitalized patients who had an International Classification of Diseases, Ninth Revision, code for bacteremia associated with their hospital stay. Interventions: Not applicable. Main Outcome Measure: The proportion of CRBSI caused by gram-negative organisms in the SCI patients to the proportion of CRBSI caused by gram-negative organisms in the non-SCI patients. Results: Eight (42%) of 19 episodes of CRBSI in the SCI were caused by a gram-negative organism as compared with 4 (11%) of 36 infections in the non-SCI group (P<.01). Factors associated with having a grain-negative organism rather than a grain-positive organism as the causative agent of CRBSI were SCI, femoral catheter site, prolonged hospitalization, decubitus Ulcer, and urinary catheter. Conclusions: In Our medical center, patients with SCI who develop CRBSI are more likely to have an infection with a gram-negative organism than are patients without SCI. This knowledge may guide initial empirical therapy of suspected bloodstream infection. C1 [Hussain, Rahat] Univ Texas Houston, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA. [Cevallos, Manuel E.; Darouiche, Rabih O.; Trautner, Barbara W.] Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA. [Darouiche, Rabih O.; Trautner, Barbara W.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Trautner, BW (reprint author), MEDVAMC, Spinal Cord Injury 128, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM trautner@bcm.edu FU NICHD NIH HHS [HD42014]; VA [VA B4087R] NR 23 TC 5 Z9 5 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2008 VL 89 IS 2 BP 339 EP 342 DI 10.1016/j.apmr.2007.08.151 PG 4 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 260OD UT WOS:000253018700020 PM 18226660 ER PT J AU Toro, JJ Westbrook, SD Kirkpatrick, WR Fothergill, AW Patterson, TF Redding, SW Freytes, CO AF Toro, J. J. Westbrook, S. D. Kirkpatrick, W. R. Fothergill, A. W. Patterson, T. F. Redding, S. W. Freytes, C. O. TI CURRENT EPIDEMIOLOGY OF ORAL CANDIDA COLONIZATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LONGITUDINAL, PROSPECTIVE STUDY SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation CY FEB 13-17, 2008 CL San Diego, CA SP Amer Soc Blood & Marrow Transplantat C1 [Toro, J. J.; Westbrook, S. D.; Patterson, T. F.; Redding, S. W.; Freytes, C. O.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Toro, J. J.; Westbrook, S. D.; Kirkpatrick, W. R.; Fothergill, A. W.; Patterson, T. F.; Redding, S. W.; Freytes, C. O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2008 VL 14 IS 2 SU 2 MA 263 BP 97 EP 97 DI 10.1016/j.bbmt.2007.12.272 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 364IT UT WOS:000260330100264 ER PT J AU Laport, GG Sandmaier, BM Storer, BE Scott, BL Stuart, MJ Lange, T Maris, MB Agura, ED Chauncey, TR Wong, RM Forman, SJ Petersen, FB Wade, JC Epner, E Bruno, B Bethge, WA Curtin, PT Maloney, DG Blume, KG Storb, RF AF Laport, Ginna G. Sandmaier, Brenda M. Storer, Barry E. Scott, Bart L. Stuart, Monic J. Lange, Thoralf Maris, Michael B. Agura, Edward D. Chauncey, Thomas R. Wong, Ruby M. Forman, Stephen J. Petersen, Finn B. Wade, James C. Epner, Elliot Bruno, Benedetto Bethge, Wolfgang A. Curtin, Peter T. Maloney, David G. Blume, Karl G. Storb, Rainer F. TI Reduced-intensity conditioning follow by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE reduced-intensity conditioning; nonmyeloablative transplantation; myelodysplastic syndrome; myeloproliferative disorders; allogeneic ID ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; HLA-IDENTICAL SIBLINGS; EUROPEAN GROUP; WORKING PARTY; MULTILINEAGE DYSPLASIA; RETROSPECTIVE ANALYSIS; MYCOPHENOLATE-MOFETIL AB Allogeneic hematopoietic cell transplantation (HCT) is the only curative strategy for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD). We report the results of 148 patients (median age = 59 years old) with de novo MDS (n = 40), acute myelogenous leukemia (AML) after antecedent MDS/MPD (n = 49), treatment-related MDS (t-MDS) (n = 25), MPD (n = 27), and chronic myelomonocytic leukemia (CMML) (n = 7) who underwent allogeneic HCT using a conditioning regimen of low-dose total body irradiation (TBI) alone (200 cGy) on day 0 (n = 5) or with the addition of fludarabine (Flu) 30 mg/m(2)/day on days -4 to -2 (n = 143). Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil (AIMF). Seventy-five patients (51%) received an allograft from a matched related donor (MRD), and 73 patients (49%) were recipients of unrelated donor (URD) grafts. There was no significant difference in the incidence of acute (gr II-IV) and chronic extensive graft-versus-host disease (aGVHD, cGVHD) between the recipients of related and unrelated donor grafts. By day +28, 75% of patients demonstrated mixed T cell chimerism. Graft rejection was seen in 15% of patients. With a median follow-up of 47 (range: 6-89) months, the 3-year relapse-free survival (RFS) and overall survival (OS) are both 27% for all patients, with a relapse incidence of 41%. The 3-year RFS for the patients with de novo MDS, AML after antecedent MDS/MPD, t-MDS, MPD, and CMML were 22%, 20%, 29%, 37%, and 43%, respectively, and the 3-year OS was 20%, 23%, 27%, 43%, and 43%, respectively. The 3-year nonrelapse mortality (NRM) was 32%. Factors associated with a lower risk of relapse were the development of extensive cGVHD and having a low risk or intermediate-1 risk International Prognostic Score for the de novo AIDS patients. Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for conventional HCT but for whom relapse is the leading cause of treatment failure. (c) 2008 American Society for Blood and Marrow Transplantation. C1 [Laport, Ginna G.; Stuart, Monic J.; Wong, Ruby M.; Blume, Karl G.] Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, 300 Pasteur Dr,Rm H3249, Stanford, CA 94305 USA. [Sandmaier, Brenda M.; Storer, Barry E.; Scott, Bart L.; Maloney, David G.; Storb, Rainer F.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Maris, Michael B.; Chauncey, Thomas R.] Vet Affairs Puget Sound Hlth Care syst, Seattle, WA USA. [Wade, James C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Petersen, Finn B.] Univ Utah, Salt Lake City, UT USA. [Bethge, Wolfgang A.] Univ Tubingen, Tubingen, Germany. [Epner, Elliot] Univ Arizona, Tucson, AZ USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Curtin, Peter T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Forman, Stephen J.] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Lange, Thoralf] Univ Leipzig, Leipzig, Germany. [Agura, Edward D.] Baylor Univ, Med Ctr, Dallas, TX USA. RP Laport, GG (reprint author), Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, 300 Pasteur Dr,Rm H3249, Stanford, CA 94305 USA. EM glaport@stanford.edu FU NCI NIH HHS [P30 CA015704, CA15704, CA18029, CA78902, CA92058, K23 CA092058, K23 CA092058-01, P01 CA018029, P01 CA018029-250002, P01 CA018029-270047, P01 CA049605, P01 CA049605-14, P01 CA078902, P01 CA078902-09, P01-CA 49605, P30 CA015704-31]; NHLBI NIH HHS [HL36444, P01 HL036444, P01 HL036444-27] NR 35 TC 91 Z9 94 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2008 VL 14 IS 2 BP 246 EP 255 DI 10.1016/j.bbmt.2007.11.012 PG 10 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 264FH UT WOS:000253271100009 PM 18215785 ER PT J AU Dewey, CM Coverdale, JH Ismail, NJ Culberson, JW Thompson, BM Patton, CS Friedland, JA AF Dewey, Charlene M. Coverdale, John H. Ismail, Nadia J. Culberson, John W. Thompson, Britta M. Patton, Cynthia S. Friedland, Joan A. TI Residents-as-teachers programs in psychiatry: A systematic review SO CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE LA English DT Review DE residents; teaching skills; residents as teachers; psychiatry; assessments ID MEDICAL-STUDENTS; RANDOMIZED-TRIAL; TRAINING-PROGRAM; TEACHING SKILLS; ATTITUDES; INSTRUMENT AB Objectives: Because psychiatry residents have important roles as teachers and significant opportunities to contribute to medical student education, we set out to: identify all randomized control trials (RCT) for residents' teaching skills programs in psychiatry and to identify the efficacy of those interventions for improving teaching skills; identify the strengths and weaknesses of the available studies across medical disciplines; and identify currently available methods for enhancing residents' teaching skills for residents training in psychiatry. Methods: The published English-language literature was searched using PubMed, Social Sciences Index, and PsycINFO databases, with key search words including: residents, teaching skills, residents as teachers, psychiatry, and assessments. Both RCT and controlled, nonrandomized trials of residents' teaching programs directed to enhance residents' teaching skills were selected and critically appraised. Results: Of 13 trials identified and reviewed, most included residents in internal medicine. Only one included psychiatry residents and assessed their ability to teach interviewing skills to medical students. Along with other studies, this study demonstrated improvement in residents' teaching skills. Overall, interventions and outcome measures were heterogeneous while the quality of methodologies varied. Five studies were of higher quality, representing examples of quality educational research. Several described group differences, blinding, good follow-up, and use of valid, reliable tools. Conclusions: Only one trial exists that incorporated psychiatry residents. Significant opportunity to advance educational research in this field exists. Psychiatry residency program directors should incorporate high-quality methodologies and can benefit from the findings of trials in other disciplines. C1 [Dewey, Charlene M.] Vanderbilt Univ, Sch Med, Off Teaching & Learning Med, Nashville, TN 37232 USA. [Coverdale, John H.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. [Coverdale, John H.] Baylor Coll Med, Ctr Eth, Houston, TX 77030 USA. [Ismail, Nadia J.] Baylor Coll Med, Dept Med, Gen Internal Med Sect, Houston, TX 77030 USA. [Culberson, John W.] Baylor Coll Med, Dept Med, Sect Geriatr, Houston, TX USA. [Thompson, Britta M.; Patton, Cynthia S.] Baylor Coll Med, Off Curriculum, Relationship Ctr Transformat Curriculum, Houston, TX USA. [Friedland, Joan A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Dewey, CM (reprint author), Vanderbilt Univ, Sch Med, Off Teaching & Learning Med, 3402 MRB-4, Nashville, TN 37232 USA. EM charlene.dewey@vanderbilt.edu FU NHLBI NIH HHS [5 K07 HL082629-01] NR 36 TC 19 Z9 19 U1 0 U2 3 PU CANADIAN PSYCHIATRIC ASSOC PI OTTAWA PA 141 LAURIER AVENUE WEST, STE 701, OTTAWA, ONTARIO K1P 5J3, CANADA SN 0706-7437 J9 CAN J PSYCHIAT JI Can. J. Psychiat.-Rev. Can. Psychiat. PD FEB PY 2008 VL 53 IS 2 BP 77 EP 84 PG 8 WC Psychiatry SC Psychiatry GA 269RS UT WOS:000253667900002 PM 18357925 ER PT J AU Suswam, E Li, YY Zhang, XW Gillespie, GY Li, XL Shacka, JJ Lu, L Zheng, L King, PH AF Suswam, Esther Li, Yanyan Zhang, Xiaowen Gillespie, G. Yancey Li, Xuelin Shacka, John J. Lu, Liang Zheng, Lei King, Peter H. TI Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells SO CANCER RESEARCH LA English DT Article ID ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA STABILITY; RICH ELEMENT; POSTTRANSCRIPTIONAL REGULATION; BINDING PROTEINS; UP-REGULATION; BRAIN-TUMORS; FACTOR-ALPHA; TNF-ALPHA AB Malignant gliomas are highly aggressive tumors of the central nervous system that rely on production of growth factors for tumor progression. Vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and tumor necrosis factor-alpha, for example, are up-regulated in these tumors to promote angiogenesis and proliferation. RNA stability, mediated through adenine and uridine-rich elements (ARE) in the 3' untranslated region, is a critical control point for regulating these growth factors. RNA half-life is predominantly governed by a balance between stabilizing and destabilizing factors that bind to ARE. We have previously shown that the stabilizing factor HuR is overexpressed in malignant gliomas and linked to RNA stabilization of angiogenic growth factors. Here, we report that the destabilizing factor tristetraprolin (TTP) is also ubiquitously expressed in primary malignant glioma tissues and cell lines. In contrast to benign astrogliotic tissues, however, the protein was hyperphosphorylated, with evidence implicating the p38/mitogen-activated protein kinase (MAPK) pathway. Conditional overexpression of TTP as a transgene in malignant glioma cells led to RNA destabilization of IL-8 and VEGF and down-regulation of protein production. Analysis of in vivo RNA binding indicated a shift of mRNA toward ectopic TTP and away from endogenous HuR. This biochemical phenotype was associated with a decrease in cell proliferation, loss of cell viability, and apoptosis. We postulate that hyperphosphorylation of TTP via p38/MAPK promotes progression of malignant gliomas by negatively regulating its RNA destabilizing function. C1 [Suswam, Esther; Li, Yanyan; Zhang, Xiaowen; Li, Xuelin; Lu, Liang; Zheng, Lei; King, Peter H.] Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. [King, Peter H.] Univ Alabama, Dept Genet, Birmingham, AL 35294 USA. [King, Peter H.] Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA. [Gillespie, G. Yancey] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA. [Shacka, John J.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Gillespie, G. Yancey] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. [Li, Yanyan; Zhang, Xiaowen; Li, Xuelin; Shacka, John J.; Lu, Liang; Zheng, Lei; King, Peter H.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP King, PH (reprint author), Univ Alabama, Dept Neurol, SC 200,1530 3rd Ave S, Birmingham, AL 35294 USA. EM pking@uab.edu FU NCI NIH HHS [P50 CA097247, P50 CA097247-04S1] NR 48 TC 72 Z9 77 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD FEB 1 PY 2008 VL 68 IS 3 BP 674 EP 682 DI 10.1158/0008-5472.CAN-07-2751 PG 9 WC Oncology SC Oncology GA 259QD UT WOS:000252952900009 PM 18245466 ER PT J AU Roodman, GD Dougall, WC AF Roodman, G. David Dougall, William C. TI RANK ligand as a therapeutic target for bone metastases and multiple myeloma SO CANCER TREATMENT REVIEWS LA English DT Review DE RANK; RANKL; OPG; bone metastasis; osteoclast; skeletal complications; breast cancer; prostate cancer; multiple myeloma ID FACTOR-KAPPA-B; OSTEOCLAST DIFFERENTIATION FACTOR; SOLUBLE RECEPTOR ACTIVATOR; SKELETAL TUMOR BURDEN; PROSTATE-CANCER BONE; FORMATION IN-VITRO; NF-KB LIGAND; BREAST-CANCER; OSTEOPROTEGERIN LIGAND; SERUM OSTEOPROTEGERIN AB Osteoclastic bone resorption is a critical component of sketetal. complications of malignancy including fracture, bone pain, hypercalcemia, and spinal cord compression. Three proteins, RANKL, RANK, and OPG have been recently identified as key determinants of osteoclastogenesis and the regulation of bone resorption. Both RANKL and OPG can be aberrantly regulated in the cancer setting and function as important gatekeepers of tumor-induced osteolytic bone disease. RANKL-induced osteoclastogenesis not only mediates osteolytic bone disease, but also contributes to the pathogenesis of osteoblastic bone disease resulting from tumors. In addition, an important role was recently described for bone marrow derived RANKL to mediate the bone-specific tropism of RANK-expressing tumor cells. This manuscript will review how RANKL contributes to skeletal complications of cancer and the development of targeted, mechanism-based drugs that inhibit RANKL. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Dougall, William C.] Amgen Washington, Dept Canc Biol, Seattle, WA 98119 USA. [Roodman, G. David] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15240 USA. [Roodman, G. David] VA Pittsburgh Healthcare Syst, Vet Adm Med Ctr, Res & Dev 151U, Pittsburgh, PA 15240 USA. RP Dougall, WC (reprint author), Amgen Washington, Dept Canc Biol, 1201 Amgen Court W, Seattle, WA 98119 USA. EM roodmangd@upmc.edu; dougattw@amgen.com NR 95 TC 60 Z9 67 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0305-7372 J9 CANCER TREAT REV JI Cancer Treat. Rev. PD FEB PY 2008 VL 34 IS 1 BP 92 EP 101 DI 10.1016/j.ctrv.2007.09.002 PG 10 WC Oncology SC Oncology GA 267YG UT WOS:000253544500008 PM 17964729 ER PT J AU Das, F Ghosh-Choudhury, N Mahimainathan, L Venkatesan, B Feliers, D Riley, DJ Kasinath, BS Choudhury, GG AF Das, Falguni Ghosh-Choudhury, Nandini Mahimainathan, Lenin Venkatesan, Balachandar Feliers, Denis Riley, Daniel J. Kasinath, Balakuntalam S. Choudhury, Goutam Ghosh TI Raptor-rictor axis in TGF beta-induced protein synthesis SO CELLULAR SIGNALLING LA English DT Article DE mTORC1; mTORC2; tuberin; 4EBP-1; eIF4E; S6 kinase; Akt ID MESSENGER-RNA TRANSLATION; TUBEROUS SCLEROSIS COMPLEX; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR PTEN; INDUCED DNA-SYNTHESIS; CELL-GROWTH; MESANGIAL CELLS; DIABETIC-NEPHROPATHY; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAY AB Transforming growth factor-beta (TGF beta) stimulates pathological renal cell hypertrophy for which increased protein synthesis is critical. The mechanism of TGF beta-induced protein synthesis is not known, but PI 3 kinase-dependent Akt kinase activity is necessary. We investigated the contribution of downstream effectors of Akt in TGF beta-stimulated protein synthesis. TGF beta increased inactivating phosphorylation of Akt substrate tuberin in a PI 3 kinase/Akt dependent manner, resulting in activation of mTOR kinase. mTOR activity increased phosphorylation of S6 kinase and the translation repressor 4EBP-1, which were sensitive to inhibition of both PI 3 kinase and Akt. mTOR inhibitor rapamycin and a dominant negative mutant of mTOR suppressed TGF beta-induced phosphorylation of S6 kinase and 4EBP-1. PI 3 kinase/Akt and mTOR regulated dissociation of 4EBP-1 from eIF4E to make the latter available for binding to eIF4E. mTOR and 4EBP-1 modulated TGF beta-induced protein synthesis. mTOR is present in two multi protein complexes, mTORCI and mTORC2. Raptor and rictor are part of mTORCI and mTORC2, respectively. shRNA-mediated downregulation of raptor inhibited TGF beta-stimulatcd mTOR kinase activity, resulting in inhibition of phosphorylation of S6 kinase and 4EBP-1. Raptor shRNA also prevented protein synthesis in response to TGF. Downregulation of rictor inhibited serine 473 phosphorylation of Akt without any effect on phosphorylation of its substrate, tuberin. Furthermore, rictor shRNA increased phosphorylation of S6 kinase and 4EBP-1 in TGF beta -independent manner, resulting in increased protein synthesis. Thus mTORC1 function is essential for TGF beta-induced protein synthesis. Our data also provide novel evidence that rictor negatively regulates TORC1 activity to control basal protein synthesis, thus conferring tight control on cellular hypertrophy. (C) 2007 Elsevier Inc. All rights reserved. C1 [Das, Falguni; Mahimainathan, Lenin; Venkatesan, Balachandar; Feliers, Denis; Riley, Daniel J.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, George OBrien Kidney Ctr, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU NIAMS NIH HHS [NIH R01 AR52425]; NIDDK NIH HHS [NIH R01 DK077295, R01 DK50190] NR 91 TC 50 Z9 52 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 J9 CELL SIGNAL JI Cell. Signal. PD FEB PY 2008 VL 20 IS 2 BP 409 EP 423 DI 10.1016/j.cellsig.2007.10.027 PG 15 WC Cell Biology SC Cell Biology GA 260RH UT WOS:000253027400014 PM 18068336 ER PT J AU Downes, KJ Metlay, JP Bell, LM McGowan, KL Elliott, MR Shah, SS AF Downes, Kevin J. Metlay, Joshua P. Bell, Louis M. McGowan, Karin L. Elliott, Michael R. Shah, Samir S. TI Polymicrobial bloodstream infections among children and adolescents with central venous catheters evaluated in ambulatory care SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID PEDIATRIC-PATIENTS; RISK-FACTORS; BACTEREMIA; PREVENTION; MORTALITY; COMPLICATIONS; EPIDEMIOLOGY; HOSPITALS AB Background. Bloodstream infections (BSIs) are an ever-present concern for clinicians evaluating ill-appearing pediatric patients with central venous catheters (CVCs) in the ambulatory care setting. Methods. We performed a case-control study of a cohort of 200 pediatric patients who were evaluated in the ambulatory care setting and who were found to have laboratory-confirmed BSI in the context of a CVC. This study sought to compare patients with polymicrobial versus monomicrobial BSIs to identify potential risk factors for polymicrobial BSI. Results. Of the 200 patients enrolled in the study, 73 (37%) had a polymicrobial BSI. Patients with polymicrobial BSI were more likely than those with monomicrobial BSI to be younger (P = .002) and less likely to have been recently discharged from the hospital (P = .01). The odds of a polymicrobial BSI were >4 times greater for patients aged < 3 years than for those aged >= 3 years (odds ratio, 4.54; 95% confidence interval, 1.68-12.29), and the odds were 50% lower for those discharged from the hospital in the prior 7 days than for those without recent hospitalization (odds ratio, 0.46; 95% confidence interval, 0.22-0.95) after controlling for an underlying cancer diagnosis and the time of year during which a patient presented. Recent antibiotic use, recent BSI, duration that the CVC had been in place, and underlying gastrointestinal dysfunction were not associated with a risk of polymicrobial BSI. Conclusions. Younger children and those who had not recently been discharged from the hospital had an increased risk of developing catheter-related polymicrobial BSI. Special consideration should be given to the increased likelihood of polymicrobial BSIs in these pediatric patients when initiating empirical antimicrobial therapy. C1 [Downes, Kevin J.; Bell, Louis M.; Shah, Samir S.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [McGowan, Karin L.] Childrens Hosp Philadelphia, Clin Microbiol Lab, Philadelphia, PA 19104 USA. [Metlay, Joshua P.; Shah, Samir S.] Univ Penn, Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA. [Bell, Louis M.; Shah, Samir S.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [McGowan, Karin L.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Metlay, Joshua P.; Shah, Samir S.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Metlay, Joshua P.; Shah, Samir S.] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Elliott, Michael R.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Elliott, Michael R.] Univ Michigan, Inst Social Res, Survey Methodol Program, Ann Arbor, MI USA. RP Shah, SS (reprint author), Childrens Hosp Philadelphia, Div Infect Dis, Rm 1526,N Campus,34th St,Civic Ctr Blvd, Philadelphia, PA 19104 USA. EM shahs@email.chop.edu OI Shah, Samir/0000-0001-7902-7000 NR 26 TC 21 Z9 21 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2008 VL 46 IS 3 BP 387 EP 394 DI 10.1086/525265 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 249IJ UT WOS:000252221200006 PM 18181737 ER PT J AU Mansouri, MD Darouiche, RO AF Mansouri, M. D. Darouiche, R. O. TI In-vitro activity and in-vivo efficacy of catheters impregnated with chloroxylenol and thymol against uropathogens SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Letter ID STAPHYLOCOCCUS-AUREUS INFECTION C1 [Mansouri, M. D.; Darouiche, R. O.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Mansouri, M. D.; Darouiche, R. O.] Baylor Coll Med, Ctr Prostheses Infect, Houston, TX 77030 USA. RP Mansouri, MD (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM mansouri@bcm.edu NR 13 TC 7 Z9 7 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1198-743X J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD FEB PY 2008 VL 14 IS 2 BP 190 EP 192 DI 10.1111/j.1469-0691.2007.01894.x PG 3 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 247ZA UT WOS:000252119900018 PM 18042195 ER PT J AU Danek, A Bader, B Walker, RH AF Danek, Adrian Bader, Benedikt Walker, Ruth H. TI Neuroacanthocytosis SO CLINICS LA English DT Letter ID CHOREA-ACANTHOCYTOSIS C1 [Danek, Adrian] Univ Munich, Neurol Klin & Poliklin, Munich, Germany. [Bader, Benedikt] Univ Munich, Zentrum Neuropathol & Prionforsch, Munich, Germany. [Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. RP Danek, A (reprint author), Univ Munich, Neurol Klin & Poliklin, Munich, Germany. RI Danek, Adrian/G-7339-2011 OI Danek, Adrian/0000-0001-8857-5383 NR 4 TC 0 Z9 0 U1 0 U2 0 PU HOSPITAL CLINICAS, UNIV SAO PAULO PI SAO PAULO PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL SN 1807-5932 J9 CLINICS JI Clinics PD FEB PY 2008 VL 63 IS 1 BP 135 EP 135 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 278YH UT WOS:000254321700021 PM 18297217 ER PT J AU Garcia, AD AF Garcia, Aimee Dinorah TI The effect of chronic disorders on sleep in the elderly SO CLINICS IN GERIATRIC MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; NURSING-HOME RESIDENTS; RESTLESS LEGS SYNDROME; CHRONIC PAIN PATIENTS; PARKINSONS-DISEASE; CHRONIC INSOMNIA; PSYCHIATRIC-DISORDERS; RHEUMATOID-ARTHRITIS; ALZHEIMERS-DISEASE AB Sleep disorders are increasingly common as people age. Along with the numerous physiologic changes that occur with aging, sleep patterns are also altered. Inability to get to sleep, shorter sleep times, and changes in the normal circadian patterns can have an impact on an individual's overall well being. In addition, many common chronic conditions, such as chronic obstructive pulmonary disease, diabetes, dementia, chronic pain, and cancer, that are more common in the elderly, can also have significant effects on sleep and increase the prevalence of insomnia as compared with the general population. This is a result not only of the chronic medical illnesses themselves, but of the psychologic and social factors associated with the disease processes. C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Garcia, AD (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe ECL 110, Houston, TX 77030 USA. EM aimeeg@bcm.tmc.edu NR 98 TC 11 Z9 14 U1 1 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD FEB PY 2008 VL 24 IS 1 BP 27 EP + DI 10.1016/j.cger.2007.08.008 PG 13 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 246TB UT WOS:000252028900004 PM 18035229 ER PT J AU Martin, JL Ancoli-Israel, S AF Martin, Jennifer L. Ancoli-Israel, Sonia TI Sleep disturbances in long-term care SO CLINICS IN GERIATRIC MEDICINE LA English DT Article ID NURSING-HOME RESIDENTS; ACTIVITY RHYTHM DISTURBANCES; MINIMUM DATA SET; ENVIRONMENTAL INTERVENTION; ALZHEIMERS-DISEASE; SEDATIVE-HYPNOTICS; CIRCADIAN-RHYTHMS; HIP-FRACTURES; OLDER-PEOPLE; LIGHT AB Nighttime sleep disruption is characteristic of long-term care residents, is typically accompanied by daytime sleepiness, and may be caused by a multitude of factors. Causal factors include medical and psychiatric illness, medications, circadian rhythm abnormalities, sleep disordered breathing and other primary sleep disorders, environmental factors, and lifestyle habits. There is some suggestion that these factors are amenable to treatment; however, further research on the implementation of treatments within the long-term care setting is needed. Additional work is also needed to understand the administrative and policy factors that might lead to systemic changes in how sleep is viewed and sleep problems are addressed in long-term care settings. C1 [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92093 USA. [Ancoli-Israel, Sonia] Vet Affairs San Diego Healthcare Syst, Dept Psychiat, San Diego, CA 92161 USA. [Martin, Jennifer L.] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, North Hills, CA 91343 USA. [Martin, Jennifer L.] Univ Calif, Los Angeles Sch Med, Multicampus Program Geriatr Med & Gerontol, North Hills, CA 91343 USA. RP Ancoli-Israel, S (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, San Diego, CA 92093 USA. EM sancoliisrael@ucsd.edu FU NCI NIH HHS [R01 CA112035-03, CA112035, R01 CA112035]; NCRR NIH HHS [M01 RR000827-301082, M01 RR00827, M01 RR000827]; NIA NIH HHS [5 P60 AG010415, AG08415, P60 AG010415, R01 AG008415, R01 AG008415-16A2] NR 39 TC 29 Z9 31 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD FEB PY 2008 VL 24 IS 1 BP 39 EP + DI 10.1016/j.cger.2007.08.001 PG 13 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 246TB UT WOS:000252028900005 PM 18035230 ER PT J AU Conhaim, RL Watson, KE Spiegel, CA Dovi, WF Harms, BA AF Conhaim, Robert L. Watson, Kal E. Spiegel, Carol A. Dovi, William F. Harms, Bruce A. TI Bacteremic sepsis disturbs alveolar perfusion distribution in the lungs of rats SO CRITICAL CARE MEDICINE LA English DT Article DE rheology; bacteremia; pulmonary circulation; pulmonary edema; microcirculation; thromboembolism ID VASCULAR-RESISTANCE; INJURY; TRANSFUSION; CIRCULATION; THROMBOXANE; SHOCK AB Objective: Sepsis often leads to lung injury, although the mechanisms that initiate this are unclear. One preinjury phenomenon that has not been explored previously is the effect of bacterial (nonlipopolysaccharide) sepsis on the distribution of alveolar perfusion. The goals of our studies were to measure this. Design: Randomized, controlled, prospective animal study. Setting: University animal laboratory. Subjects: Male Sprague-Dawley rats (450-550 g). Interventions: We induced sepsis by placing gelatin capsules containing Escherichia coli and Bacteroides fragilis into the abdomens of rats (n = 9). Empty capsules (n = 6) were placed into the abdomens of controls. After 24 hrs, 4-mu m-diameter fluorescent latex particles (2 x 10(8)) were infused into the pulmonary circulation. Sepsis was induced in additional rats and controls to assess lung injury, as follows: Lung histology was performed on eight septic rats and on seven controls; lung lavage was performed on three septic rats and three controls after their plasma albumin had been labeled with Evans blue dye. Measurements and Main Results: Confocal microscopy was used to prepare digital maps of latex particle trapping patterns (eight per lung). Analysis of these patterns revealed statistically more clustering (perfusion inhomogeneity) down to tissue volumes less than that of ten alveoli in septic lungs compared with controls (p <= .05). Bacterial counts and neutrophil counts were significantly higher in the circulation of septic rats (p <= .05). Blood pressures and arterial Po2S were unchanged. Cell counts in histological images were three-fold higher in septic lungs than in controls (p <= .05). Lung lavage revealed 0.41 +/- 0.03 mL of plasma in the lungs of septic rats, and 0.06 +/- 0.05 mL in the lungs of controls (p <= .05). Conclusions: Bacterial sepsis caused significant maldistribution of interalveolar perfusion in the lungs of rats in the absence of significant lung injury. C1 [Conhaim, Robert L.; Watson, Kal E.; Harms, Bruce A.] Univ Wisconsin, Sch Med, Dept Surg, Madison, WI 53706 USA. [Spiegel, Carol A.] Univ Wisconsin, Sch Med, Dept Pathol, Madison, WI USA. [Spiegel, Carol A.] Univ Wisconsin, Sch Med, Lab Med, Madison, WI USA. [Conhaim, Robert L.; Dovi, William F.; Harms, Bruce A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Conhaim, RL (reprint author), Univ Wisconsin, Sch Med, Dept Surg, Madison, WI 53706 USA. EM conhaim@surgery.wisc.edu NR 31 TC 13 Z9 13 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2008 VL 36 IS 2 BP 511 EP 517 DI 10.1097/01.CCM.0000300082.75334.48 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 257JB UT WOS:000252794000020 PM 18091533 ER PT J AU Slemmer, JE Shacka, JJ Sweeney, MI Weber, JT AF Slemmer, J. E. Shacka, J. J. Sweeney, M. I. Weber, J. T. TI Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging SO CURRENT MEDICINAL CHEMISTRY LA English DT Review DE anthocyanins; natural products; NXY-059; oxidative stress; oxyresveratrol; reactive nitrogen species; reactive oxygen species; superoxide ID ACUTE ISCHEMIC-STROKE; FOCAL CEREBRAL-ISCHEMIA; LONG-TERM POTENTIATION; NEURONAL SIGNAL-TRANSDUCTION; TISSUE-PLASMINOGEN ACTIVATOR; STABLE NITROXIDE TEMPOL; AGE-RELATED DECREASE; SEVERE HEAD-INJURY; OXIDATIVE STRESS; VITAMIN-E AB The overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS) is a common underlying mechanism of many neuropathologies, as they have been shown to damage various cellular components, including proteins, lipids and DNA. Free radicals, especially superoxide (O(2)(center dot-)), and non-radicals, such as hydrogen peroxide (H(2)O(2)), can be generated in quantities large enough to overwhelm endogenous protective enzyme systems, such as superoxide dismutase (SOD) and reduced glutathione (GSH). Here we review the mechanisms of ROS and RNS production, and their roles in ischemia, traumatic brain injury and aging. In particular, we discuss several acute and chronic pharmacological therapies that have been extensively studied in order to reduce ROS/RNS loads in cells and the subsequent oxidative stress, so-called "free-radical scavengers." Although the overall aim has been to counteract the detrimental effects of ROS/RNS in these pathologies, success has been limited, especially in human clinical studies. This review highlights some of the recent successes and failures in animal and human studies by attempting to link a compound's chemical structure with its efficacy as a free radical scavenger. In particular, we demonstrate how antioxidants derived from natural products, as well as long-term dietary alterations, may prove to be effective scavengers of ROS and RNS. C1 [Weber, J. T.] Mem Univ Newfoundland, Sch Pharm, Hlth Sci Ctr, St John, NF A1B 3V6, Canada. [Slemmer, J. E.; Sweeney, M. I.] Univ Prince Edward Isl, Dept Biol, Charlottetown, PE C1A 4P3, Canada. [Shacka, J. J.] Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA. [Shacka, J. J.] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA. [Weber, J. T.] Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, St John, NF A1B 3V6, Canada. RP Weber, JT (reprint author), Mem Univ Newfoundland, Sch Pharm, Hlth Sci Ctr, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada. EM jweber@mun.ca NR 224 TC 196 Z9 215 U1 3 U2 40 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 0929-8673 J9 CURR MED CHEM JI Curr. Med. Chem. PD FEB PY 2008 VL 15 IS 4 BP 404 EP 414 PG 11 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 274GR UT WOS:000253990300009 PM 18288995 ER PT J AU Green, GM Reeve, JR AF Green, Gary M. Reeve, Joseph R., Jr. TI Unique activities of cholecystokinin-58; physiological and pathological relevance SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY LA English DT Article DE acute pancreatitis; cholecystokinin; exocrine pancreatic secretion; gastrointestinal hormones AB Purpose of review Cholecystokinin, a regulatory peptide found in multiple molecular forms in brain and small intestine, is responsible for integration of functions associated with the intake, digestion and absorption of food. Whether the different molecular forms have identical biological activities is controversial. New information suggests that CCK58, the largest form of cholecystokinin detected in blood and tissue, has unique functions compared with other forms, and may be the predominant, perhaps only, circulating form in mammals. Recent findings CCK58 has highly distinctive actions compared with shorter forms, most notably the strong stimulation of water secretion from the pancreas, and the lack of induction of pancreatitis by supramaximal doses of the peptide. Because CCK58 may be the main endogenous form of cholecystokinin, these recent findings have far reaching implications because almost all studies carried out with cholecystokinin have been done with shorter forms, predominately CCK8. Conclusions of studies using CCK8 or other shorter forms of cholecystokinin, therefore, may need to be reevaluated. Summary There is a compelling reason to reevaluate the role of cholecystokinin in health and disease because the predominant form of cholecystokinin, CCK58, has unique biological activities compared with forms of cholecystokinin used in previous basic and clinical studies. C1 [Green, Gary M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Reeve, Joseph R., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst &, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. RP Green, GM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM greeng@uthscsa.edu NR 37 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1752-296X J9 CURR OPIN ENDOCRINOL JI Curr. Opin. Endocrinol. Diabetes Obes. PD FEB PY 2008 VL 15 IS 1 BP 48 EP 53 DI 10.1097/MED.0b013e3282f3d92b PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA V14SR UT WOS:000207754600006 PM 18185062 ER PT J AU Marra, DE Fincher, EF Iwasaki, J Moy, RL AF Marra, Diego E. Fincher, Edgar F. Iwasaki, Julie Moy, Ronald L. TI Repair of a large, exposed-cartilage nasal tip defect using nasalis-based subcutaneous pedicle flaps and full-thickness skin grafting SO DERMATOLOGIC SURGERY LA English DT Editorial Material ID RECONSTRUCTION; NOSE C1 [Moy, Ronald L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Moy, RL (reprint author), 100 UCLA Med Plaza,Suite 590, Los Angeles, CA 90024 USA. EM rmoy@ucla.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1076-0512 J9 DERMATOL SURG JI Dermatol. Surg. PD FEB PY 2008 VL 34 IS 2 BP 249 EP 253 DI 10.1111/j.1524-4725.2007.34046.x PG 5 WC Dermatology; Surgery SC Dermatology; Surgery GA 254LC UT WOS:000252587100018 PM 18093192 ER PT J AU Bilimoria, KY Palis, B Stewart, AK Bentrem, DJ Freel, AC Sigurdson, ER Talamonti, MS Ko, CY AF Bilimoria, Karl Y. Palis, Bryan Stewart, Andrew K. Bentrem, David J. Freel, Andrew C. Sigurdson, Elin R. Talamonti, Mark S. Ko, Clifford Y. TI Impact of tumor location on nodal evaluation for colon cancer SO DISEASES OF THE COLON & RECTUM LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Society-of-Colon-and-Rectal-Surgeons CY JUN 02-06, 2007 CL St Louis, MO SP Amer Soc Colon & Rectal Surg DE colon neoplasms; surgery; colectomy; National Cancer Data Base; lymph nodes; staging ID LYMPH-NODES; COLORECTAL-CANCER; MINIMUM NUMBER; HOSPITAL VOLUME; SURVIVAL; RESECTION; SURGERY; RECOMMENDATIONS; PROGNOSIS; MORTALITY AB PURPOSE: Adequate lymph node evaluation is important to stage colon cancers and make adjuvant treatment decisions. Studies have demonstrated improved survival when >= 12 nodes are examined. Our objective was to assess differences in the adequacy of nodal evaluation for right vs. left colon cancers. METHODS: From the National Cancer Data Base (1998-2004), 142,009 N0M0 colon cancer patients were identified. Logistic regression was used to evaluate the number of nodes examined for right vs. left colectomies. Multivariable modeling was used to determine the impact of examining >= 12 nodes on survival. RESULTS: Of 142,009 patients, 79,444 (56 percent) had right colectomies, and 62,565 (44 percent) patients had left colectomies. More nodes were examined during right colectomies than left (median 12 vs. 8, Pe < 0.0001). When adjusted for patient, tumor, and hospital factors, patients undergoing left colectomy were less likely to have >= 12 nodes identified (P < 0.0001). Patients were more likely to have >= 12 nodes identified for right and left colon cancers at high-volume hospitals. Survival was better with examination of >= 12 nodes for right and left colon cancers (P < 0.0001). CONCLUSIONS: Evaluating >= 12 nodes for right and left colon cancers is a feasible, clinically relevant, and modifiable factor that will likely improve patient outcomes. C1 [Bilimoria, Karl Y.; Palis, Bryan; Stewart, Andrew K.; Freel, Andrew C.; Ko, Clifford Y.] Amer Coll Surg, Natl Ctr Data Base, Canc Programs, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Bentrem, David J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Sigurdson, Elin R.] Fox Chase Canc Ctr, Dept Surg, Philadelphia, PA 19111 USA. [Talamonti, Mark S.] Evanston NW Healthcare, Dept Surg, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Natl Ctr Data Base, Canc Programs, 636 N St Clair St,25th Floor, Chicago, IL 60611 USA. NR 34 TC 60 Z9 61 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-3706 J9 DIS COLON RECTUM JI Dis. Colon Rectum PD FEB PY 2008 VL 51 IS 2 BP 154 EP 161 DI 10.1007/s10350-007-9114-2 PG 8 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 259XW UT WOS:000252975200002 PM 18172729 ER PT J AU Garcia, JM Cata, JP Dougherty, PM Smith, RG AF Garcia, Jose M. Cata, Juan P. Dougherty, Patrick M. Smith, Roy G. TI Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia SO ENDOCRINOLOGY LA English DT Article ID GROWTH-HORMONE SECRETAGOGUE; TUMOR-NECROSIS-FACTOR; PERIPHERAL NEUROPATHY; CANCER-PATIENTS; FOOD-INTAKE; CELLS; APPETITE; RECEPTOR; PLACEBO; RATS AB Complications induced by the chemotherapeutic agent cisplatin, such as neuropathy and cachexia, occur frequently, are often dose limiting, and have an impact on quality of life and survival in cancer patients. The recently discovered hormone ghrelin is a potent GH secretagogue with orexigenic and neuroprotective properties that may prevent or ameliorate these complications. The objective of this study was to determine the effects of ghrelin administration on mechanical hyperalgesia, anorexia, and cachexia induced by cisplatin. Adult male Sprague-Dawley rats were given cisplatin, ghrelin, ghrelin-cisplatin, or vehicle ip. Food intake and body weight were measured daily. Behavioral tests to assess the development of hyperalgesia were conducted by measuring mechanical and thermal sensitivity. Plasma ghrelin and IGF-I levels were also measured. Our results indicate that ghrelin coadministration inhibited the development of cisplatin-induced mechanical hyperalgesia, anorexia, and cachexia induced by cisplatin. Although ghrelin treatment had no effect on plasma IGF-I levels in control rats, it prevented the decrease in IGF-I levels induced by cisplatin. The attenuation of cisplatin-induced mechanical hyperalgesia induced by ghrelin was correlated with the prevention of cisplatin-induced lowering of IGF-I. In conclusion, ghrelin administration may be useful in the treatment or prevention of chemotherapy induced neuropathy and cachexia. Attenuation of mechanical hyperalgesia in the rat by the hormone ghrelin provides a unique model for elucidating the mechanisms involved, which are essential toward our understanding of these complications. C1 [Garcia, Jose M.] Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Garcia, Jose M.; Smith, Roy G.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA. [Cata, Juan P.; Dougherty, Patrick M.] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Pain Med, Houston, TX 77002 USA. RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,Bldg 100,Room 3B-243, Houston, TX 77030 USA. EM jgarcia1@bcm.edu OI Dougherty, Patrick/0000-0002-2177-2734 FU NINDS NIH HHS [R01 NS039933] NR 31 TC 49 Z9 49 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 2008 VL 149 IS 2 BP 455 EP 460 DI 10.1210/en.2007-0828 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 253GN UT WOS:000252506800003 PM 17962345 ER PT J AU Zhao, CM Martinez, V Piqueras, L Wang, LX Tache, Y Chen, D AF Zhao, Chun-Mei Martinez, Vicente Piqueras, Laura Wang, Lixin Tache, Yvette Chen, Duan TI Control of gastric acid secretion in somatostatin receptor 2 deficient mice: Shift from endocrine/paracrine to neurocrine pathways SO ENDOCRINOLOGY LA English DT Article ID ENTEROCHROMAFFIN-LIKE CELLS; STOMACH ECL CELLS; RAT PARIETAL-CELLS; HISTIDINE-DECARBOXYLASE; KNOCKOUT MICE; CIRCULATING PANCREASTATIN; AMINOPYRINE ACCUMULATION; NEUROHORMONAL REGULATION; GASTROINTESTINAL-TRACT; HISTAMINE-RELEASE AB The gastrin-enterochromaffin-like (ECL) cell-parietal cell axis is known to play an important role in the regulation of gastric acid secretion. Somatostatin, acting on somatostatin receptor type 2 (SSTR2), interferes with this axis by suppressing the activity of the gastrin cells, ECLcells, and parietal cells. Surprisingly, however, freely fed SSTR2 knockout mice seem to display normal circulating gastrin concentration and unchanged acid output. In the present study, we compared the control of acid secretion in these mutant mice with that in wild-type mice. In SSTR2 knockout mice, the number of gastrin cells was unchanged; whereas the numbers of somatostatin cells were reduced in the antrum (-55%) and increased in the oxyntic mucosa (35%). The ECL cells displayed a reduced expression of histidine decarboxylase and vesicle monoamine transport type 2 ( determined by immunohistochemistry), and an impaired transformation of the granules to secretory vesicles ( determined by electron microscopic analysis), suggesting low activity of the ECL cells. These changes were accompanied by an increased expression of galanin receptor type 1 in the oxyntic mucosa. The parietal cells were found to respond to pentagastrin or to vagal stimulation ( evoked by pylorus ligation) with increased acid production. In conclusion, the inhibitory galanin-galanin receptor type 1 pathway is up-regulated in the ECL cells, and the direct stimulatory action of gastrin and vagal excitation is enhanced on the parietal cells in SSTR2 knockout mice. We suggest that there is a remodeling of the neuroendocrine mechanisms that regulate acid secretion in these mutant mice. C1 [Zhao, Chun-Mei; Chen, Duan] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, NO-7006 Trondheim, Norway. [Martinez, Vicente] AstraZeneca R&D, Safety Assessment Safety Pharmacol, Alderley Pk SK10 4TF, Cheshire, England. [Martinez, Vicente; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Digest Dis Res Ctr, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA. [Martinez, Vicente; Wang, Lixin; Tache, Yvette] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Piqueras, Laura] Univ Valencia, Res Fdn Univ Clin Hosp, Valencia 46022, Spain. RP Zhao, CM (reprint author), Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, NO-7006 Trondheim, Norway. EM chun-mei.zhao@ntnu.no RI Martinez, Vicente/N-1189-2014 FU NIDDK NIH HHS [DK30110, DK41301, P30 DK041301] NR 58 TC 12 Z9 12 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 2008 VL 149 IS 2 BP 498 EP 505 DI 10.1210/en.2007-0238 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 253GN UT WOS:000252506800010 PM 17974627 ER PT J AU Pang, SH Leung, WK Graham, DY AF Pang, S. H. Leung, W. K. Graham, D. Y. TI Ulcers and gastritis SO ENDOSCOPY LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HELICOBACTER-PYLORI ERADICATION; RANDOMIZED-TRIAL; HIGH-RISK; THERAPY; INHIBITORS; INFECTION; CYCLOOXYGENASE-2; COMBINATION; DICLOFENAC C1 [Graham, D. Y.] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Graham, D. Y.] Baylor Coll Med, Houston, TX 77030 USA. [Pang, S. H.; Leung, W. K.] Chinese Univ Hong Kong, Inst Digest Dis, Shatin, Hong Kong, Peoples R China. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu NR 21 TC 4 Z9 4 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X J9 ENDOSCOPY JI Endoscopy PD FEB PY 2008 VL 40 IS 2 BP 136 EP 139 DI 10.1055/s-2007-995318 PG 4 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 269UW UT WOS:000253676800009 PM 18058616 ER PT J AU Lee, CL Frost, JD Swann, JW Hrachovy, RA AF Lee, Chong L. Frost, James D., Jr. Swann, John W. Hrachovy, Richard A. TI A new animal model of infantile spasms with unprovoked persistent seizures SO EPILEPSIA LA English DT Article DE epilepsy; infantile spasms; TTX; hypsarrhythmia; animal model ID POSITRON-EMISSION-TOMOGRAPHY; BINOCULAR IMPULSE BLOCKADE; WEST-SYNDROME; BRAIN; EPILEPSY; ACTH; RATS; PATHOGENESIS; AMYGDALA; NEURONS AB Purpose: Infantile spasms is one of the most severe epileptic syndromes of infancy and early childhood. Progress toward understanding the pathophysiology of this disorder and the development of effective therapies has been hindered by the lack of a relevant animal model. We report here the creation of such a model. Methods: The sodium channel blocker, tetrodotoxin (TTX), was chronically infused into the developing neocortex or hippocampus of infant rats by way of an osmotic minipump starting on postnatal day 10-12. Results: After a minimum of 10 days of infusion, approximately one-third of these rats began to display very brief (1-2 s) spasms, which consisted of symmetric or asymmetric flexion or extension of the trunk and sometimes involvement of one or both forelimbs. The typical ictal EEG pattern associated with the behavioral spasms consisted of an initial generalized, high amplitude, slow wave followed by an electrodecrement with superimposed fast activity. The interictal EEG revealed multifocal spikes and sharp waves, and in most animals that had spasms a hypsarrhythmic pattern was seen, at least intermittently, during NREM sleep. Like in humans, the spasms in the rat often occurred in clusters especially during sleep-wake transitions. Comparison of the ictal and interictal EEGs recorded in this model and those from humans with infantile spasms revealed that the patterns and the frequency components of both the ictal events and hypsarrhythmia were very similar. Discussion: The TTX model of infantile spasms should be of value in furthering an understanding of the pathophysiology of this seizure disorder. C1 [Frost, James D., Jr.; Hrachovy, Richard A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Lee, Chong L.; Swann, John W.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Frost, James D., Jr.; Swann, John W.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA. [Hrachovy, Richard A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Lee, Chong L.; Swann, John W.] Baylor Coll Med, Cain Fdn Labs, Houston, TX 77030 USA. RP Hrachovy, RA (reprint author), Baylor Coll Med, Dept Neurol, 1 Baylor Plaza,NB302, Houston, TX 77030 USA. EM hrachovy@bcm.edu FU NINDS NIH HHS [NS 18309, NS 37171] NR 39 TC 46 Z9 48 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD FEB PY 2008 VL 49 IS 2 BP 298 EP 307 DI 10.1111/j.1528-1167.2007.01377.x PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 256FG UT WOS:000252712500011 PM 17941850 ER PT J AU McMurray, JJV Carson, PE Komajda, M McKelvie, R Zile, MR Ptaszynska, A Staiger, C Donovan, JM Massie, BM AF McMurray, John J. V. Carson, Peter E. Komajda, Michel McKelvie, Robert Zile, Michael R. Ptaszynska, Agata Staiger, Christoph Donovan, J. Mark Massie, Barry M. TI Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE heart failure; diastolic heart failure; clinical trial; ejection fraction; epidemiology ID VENTRICULAR SYSTOLIC FUNCTION; NATRIURETIC PEPTIDE; MORTALITY; MORBIDITY; DYSFUNCTION; CANDESARTAN; PROGNOSIS; OUTCOMES; PREVALENCE; MANAGEMENT AB Background: We describe the baseline characteristics of subjects randomised in the largest placebo-controlled, morbidity-mortality trial to date in patients with heart failure and preserved ejection fraction - the irbesartan in heart failure with preserved systolic function trial (I-PRESERVE). Methods and results: 4133 patients with a mean age of 72 years (a third were 75 years or older) were randomised and 60% were women. The mean (SD) LVEF was 59 (9)% and almost 80% of patients were in NYHA Class III or IV Approximately 80% of patients were also overweight or obese. Heart failure was reported by investigators to have a hypertensive aetiology in 64% of patients. Prior myocardial infarction was relatively uncommon (24%), as was coronary revascularisation (13%). Atrial fibrillation and diabetes each occurred in between a quarter and a third of patients. The following treatments were used at baseline: diuretic 83%, beta-blocker 59%, calcium channel blocker 40%, ACE inhibitor 25%, spironolactone 15% and digoxin 14%. Conclusions: Patients in I-PRESERVE are broadly representative of those seen in epidemiological studies and, because of this, the results of this trial should be generally applicable to "real world" patients with heart failure and preserved ejection fraction. (C) 2008 European Society of Cardilogy. Published by Elsevier B.V. All rights reserved. C1 [McMurray, John J. V.] Univ Glasgow, Fac Med, BHF Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. [McMurray, John J. V.] Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G12 8TA, Lanark, Scotland. [Carson, Peter E.] Washington Vet Affairs Med Ctr, Washington, DC USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Komajda, Michel] Univ Paris 06, Paris 6, France. [Komajda, Michel] Hop La Pitie Salpetriere, Paris, France. [McKelvie, Robert] McMaster Univ, Hamilton, ON, Canada. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Zile, Michael R.] Vet Affairs Med Ctr, Charleston, SC 29403 USA. [Ptaszynska, Agata] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA. [Staiger, Christoph] Sanofi Aventis, Bridgewater, NJ USA. [Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP McMurray, JJV (reprint author), Univ Glasgow, Fac Med, BHF Cardiovasc Res Ctr, 126 Univ Pl, Glasgow G12 8TA, Lanark, Scotland. EM j.mcmurray@bio.gla.ac.uk OI mcmurray, john/0000-0002-6317-3975 NR 35 TC 93 Z9 96 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1388-9842 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD FEB PY 2008 VL 10 IS 2 BP 149 EP 156 DI 10.1016/j.ejheart.2007.12.010 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 280JS UT WOS:000254423200007 PM 18279770 ER PT J AU Hutter, CM Samii, A Factor, SA Nutt, JG Higgins, DS Bird, TD Griffith, A Roberts, JW Leis, BC Montimurro, JS Kay, DM Edwards, KL Payami, H Zabetian, CP AF Hutter, Carolyn M. Samii, Ali Factor, Stewart A. Nutt, John G. Higgins, Donald S. Bird, Thomas D. Griffith, Alida Roberts, John W. Leis, Berta C. Montimurro, Jennifer S. Kay, Denise M. Edwards, Karen L. Payami, Haydeh Zabetian, Cyrus P. TI Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE case-control study; neuroepidemiology; Parkinson's disease; UCHL1 ID TERMINAL HYDROLASE-L1 GENE; UCH-L1 GENE; SUSCEPTIBILITY GENE; L1 GENE; POLYMORPHISM; RISK AB UCHL1 has been proposed as a candidate gene for Parkinson's disease (PD). A meta-analysis of white and Asian subjects reported an inverse association between the non-synonymous UCHL1 S18Y polymorphism and PD risk. However, this finding was not replicated in a large case-control study and updated meta-analysis restricted to white subjects. We performed a case-control study of 1757 PD patients recruited from movement disorder clinics and 2016 unrelated controls from four regions of the United States. All subjects self-reported as white. We did not observe evidence for an association between S18Y genotypes and PD (overall P-value for association: P = 0.42). After adjustment for age, sex, and recruitment region, the odds ratio for Y/S versus S/S was 0.91 (95% CI: 0.78-1.06) and for Y/Y versus S/S was 0.87 (95% CI: 0.58-1.29). We also did not observe a significant association for recessive or dominant models of inheritance, or after stratification by age at onset, age at blood draw, sex, family history of PD, or recruitment region. Our results suggest that UCHL1 S18Y is not a major susceptibility factor for PD in white populations although we cannot exclude the possibility that the S18Y variant exerts weak effects on risk, particularly in early-onset disease. C1 [Samii, Ali; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin S 1820, Seattle, WA 98108 USA. [Hutter, Carolyn M.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Samii, Ali; Bird, Thomas D.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Higgins, Donald S.] Albany Med Ctr, Parkinsons Dis & Movement Disorder Clin, Albany, NY USA. [Griffith, Alida; Leis, Berta C.] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Montimurro, Jennifer S.; Kay, Denise M.; Payami, Haydeh] New York State Dept Hlth, Genom Inst, Wadsworth Ctr, Albany, NY USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin S 1820, 1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu OI Zabetian, Cyrus/0000-0002-7739-4306; Kay, Denise/0000-0002-9928-2698 FU NIA NIH HHS [P30 AG008017]; NINDS NIH HHS [K08 NS044138, K08 NS044138-05, R01 NS036960] NR 26 TC 21 Z9 21 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1351-5101 J9 EUR J NEUROL JI Eur. J. Neurol. PD FEB PY 2008 VL 15 IS 2 BP 134 EP 139 DI 10.1111/j.1468-1331.2007.02012.x PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 253ZX UT WOS:000252557200012 PM 18093156 ER PT J AU Guerra, CE McDonald, VJ Ravenell, KL Asch, DA Shea, JA AF Guerra, Carmen E. McDonald, Vanessa J. Ravenell, Karima L. Asch, David A. Shea, Judy A. TI Effect of race on patient expectations regarding their primary care physicians SO FAMILY PRACTICE LA English DT Article DE communication; expectations; health literacy; patient; physician relationships; race ID HEALTH LITERACY; AFRICAN-AMERICAN; GENERAL-PRACTICE; OFFICE VISITS; SATISFACTION; COMORBIDITY; INTERVENTIONS; PERCEPTIONS; DIFFERENCE; MORBIDITY AB Background. Fulfilment of patients' expectations has been associated with greater patient satisfaction with care and greater adherence to medical advice. However, little is know about how race influences patient expectations. Objective. To determine the association between patient race and patient expectations of their primary care physician. Methods. The design was a cross-sectional study. Setting and participants were sample of 709 primary care patients from four clinic sites at the Philadelphia Veterans Affairs Medical Center and the University of Pennsylvania Health System. The measures were an expectations instrument asking patients to rate the necessity of the physician performing 13 activities during the index visit, self-reported race, demographics, the Rapid Estimate of Adult Literacy in Medicine, the Charlson Comorbidity Index and SF-12. Results. After adjusting for age, sex, education, clinic site, comorbidity, health literacy and health status, African Americans were more likely to report it was absolutely necessary for the physician to refer them to a specialist [AOR 1.55 (95% confidence interval, CI, 1.09-2.21), P = 0.01], order tests [AOR 1.59 (95% CI 1.11-2.27), P = 0.01] and conduct each of the six physical exam components. Conclusions. African American race is associated with greater expectations of the primary care physicians. More research is needed to confirm the differential expectations by race and determine the reasons for the differential expectations. C1 [Guerra, Carmen E.; McDonald, Vanessa J.; Ravenell, Karima L.; Asch, David A.; Shea, Judy A.] Univ Penn, Philadelphia, PA 19104 USA. [Guerra, Carmen E.; McDonald, Vanessa J.; Ravenell, Karima L.; Asch, David A.; Shea, Judy A.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Guerra, Carmen E.; Asch, David A.; Shea, Judy A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.; Shea, Judy A.] Philadelphia Vet Affairs Med, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Guerra, CE (reprint author), Univ Penn, 1221 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM carmen.guerra@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X FU NCI NIH HHS [K01 CA-097925] NR 47 TC 5 Z9 5 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0263-2136 J9 FAM PRACT JI Fam. Pr. PD FEB PY 2008 VL 25 IS 1 BP 49 EP 55 DI 10.1093/fampra/cmn005 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 278NQ UT WOS:000254294000009 PM 18304974 ER PT J AU Amory, JK Coviello, AD Page, ST Anawalt, BD Matsumoto, AM Bremner, WJ AF Amory, John K. Coviello, Andrea D. Page, Stephanie T. Anawalt, Bradley D. Matsumoto, Alvin M. Bremner, William J. TI Serum 17-hydroxyprogesterone strongly correlates with intratesticular testosterone in gonadotropin-suppressed normal men receiving various dosages of human chorionic gonadotropin SO FERTILITY AND STERILITY LA English DT Article DE intratesticular testosterone; 17-hydroxyprogesterone; male infertility; male contraception ID SPERM PRODUCTION; ESTROGEN-TREATMENT; PROSTATIC-CANCER; HCG STIMULATION; STEROID-LEVELS; HUMAN TESTIS; SPERMATOGENESIS; ANDROGENS; HORMONE; INFERTILITY AB Objective: To determine if serum concentrations of testosterone precursors would correlate with intratesticular testosterone (ITT) concentration measured directly by testicular aspiration and allow for a less invasive means of inferring ITT. Design: Controlled clinical study. Setting: Healthy volunteers in an academic research environment. Patient(s): Twenty-nine normal men. Intervention(s): We determined ITT concentration by testicular aspiration before and after treatment in men receiving exogenous T to block endogenous gonadotropin production and randomly assigned to one of four doses of hCG (0, 125 IU, 250 IU, or 500 IU every other day) for 3 weeks. Main Outcome Measure(s): The association between serum 17-hydroxyprogesterone (17OH-P), androstenedione, and DHEA and ITT. Result(s): With T administration alone, serum 17OH-P decreased significantly and increased significantly when 500 IU hCG was administered. End-of-treatment ITT strongly correlated with serum 17OH-P. Moreover, serum 17OH-P, but not androstenedione or DHEA, was independently associated with end-of-treatment ITT by multivariate linear regression. Conclusion(s): Serum 17OH-P is highly correlated with ITT in gonadotropin-suppressed normal men receiving T and stimulated with hCG. Serum 17OH-P is a surrogate biomarker of ITT and may be useful in research and in men receiving gonadotropin therapy for infertility. (Fertil Steril (R) 2008;89:380-6. (c) 2008 by American Society for Reproductive Medicine.) C1 [Amory, John K.; Anawalt, Bradley D.; Matsumoto, Alvin M.; Bremner, William J.] Univ Washington, Dept Med, Seattle, WA USA. [Coviello, Andrea D.] Boston Univ, Dept Med, Boston, MA 02215 USA. [Page, Stephanie T.; Anawalt, Bradley D.; Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Amory, JK (reprint author), Univ Washington, Box 356429, 1959 NE Pacific, Seattle, WA 98195 USA. EM jamory@u.washington.edu FU NCRR NIH HHS [M01-RR-00037, M01 RR000037]; NIA NIH HHS [K23 AG027238, K23 AG027238-04]; NICHD NIH HHS [U54 HD042454, U54-HD-12629, U54 HD-42454, U54 HD042454-080001, K23 HD045386, U54 HD012629, K23 HD45386, K23 HD045386-04] NR 25 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD FEB PY 2008 VL 89 IS 2 BP 380 EP 386 DI 10.1016/j.fertnstert.2007.02.059 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 263WB UT WOS:000253246100016 PM 17462643 ER PT J AU Guo, Z Ran, Q Roberts, LJ Zhou, L Richardson, A Sharan, C Wu, D Yang, H AF Guo, ZhongMao Ran, Qitao Roberts, L. Jackson, II Zhou, Lichun Richardson, Arlan Sharan, Chakradhari Wu, DongFan Yang, Hong TI Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE glutathione peroxidase-4; atherosclerosis; lipid peroxidation; monocyte adhesion; necrosis; apoptosis; free radicals ID SMOOTH-MUSCLE-CELLS; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; ANTIOXIDANT ENZYMES; INDUCED APOPTOSIS; MAMMALIAN-CELLS; TRANSGENIC MICE; HYDROPEROXIDE; ATHEROSCLEROSIS; EXPRESSION AB Accmulation of oxidized lipids in the arterial wall contributes to atherosclerosis. Glutathione peroxidase-4 (GPx4) is a hydroperoxide scavenger that removes oxidative modifications from lipids such as free fatty acids, cholesterols, and phospholipids. Here, we set Out to assess the effects of GPx4 overexpression on atherosclerosis in apolipoprotein E-deficient (ApoE(-/-)) mice. The results revealed that atherosclerotic lesions in the aortic tree and aortic sinus of ApoE(-/-) mice overexpressing GPx4 (hGPx4Tg/ApoE(-/-)) were significantly smaller than those of ApoE(-/-)control mice. GPx4 overexpression also diminished signs of advanced lesions in the aortic sinus, as seen by a decreased occurrence of fibrous caps and acellular areas among hGPx4Tg/ApoE(-/-) animals. This delay of atherosclerosis in hGPx4Tg/ApoE(-/-) mice con-elated with reduced aortic F(2)-isoprostane levels (R(2)=0.75, p<0.01). In addition, overexpression of GPx4 lessened atherogenic events induced by the oxidized lipids lysophosphatidylcholine and 7-ketocholesterol, including upregulated expression of adhesion molecules in endothelial cells and adhesion of monocytes to endothelial cells, as well as endothelial necrosis and apoptosis. These results suggest that overexpression of GPx4 inhibits the development of atherosclerosis by decreasing lipid peroxidation and inhibiting the sensitivity of vascular cells to oxidized lipids. Published by Elsevier Inc. C1 [Guo, ZhongMao; Zhou, Lichun; Sharan, Chakradhari; Wu, DongFan; Yang, Hong] Meharry Med Coll, Dept Cardiovasc Biol, Nashville, TN 37208 USA. [Ran, Qitao; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ran, Qitao; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Ran, Qitao; Richardson, Arlan] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX 78229 USA. [Roberts, L. Jackson, II] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA. RP Yang, H (reprint author), Meharry Med Coll, Dept Cardiovasc Biol, Nashville, TN 37208 USA. EM hyaiig@mmc.edu FU NHLBI NIH HHS [K01 HL076623-04, K01 HL076623, HL076623]; NIEHS NIH HHS [ES014471, R01 ES014472]; NIGMS NIH HHS [S06 GM008037, GM08037] NR 42 TC 35 Z9 36 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD FEB 1 PY 2008 VL 44 IS 3 BP 343 EP 352 DI 10.1016/j.frecradbiomed.2007.09.009 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 257WM UT WOS:000252829500012 PM 18215741 ER PT J AU Valente, AJ Zhou, Q Lu, Z He, W Qiang, M Ma, W Li, G Wang, L Banfi, B Steger, K Krause, KH Clark, RA Li, S AF Valente, Anthony J. Zhou, Qing Lu, Zhenhua He, Weijing Qiang, Mei Ma, Wuqiong Li, Guiming Wang, Long Banfi, Botond Steger, Klaus Krause, Karl-Heinz Clark, Robert A. Li, Senlin TI Regulation of NOX1 expression by GATA, HNF-1 alpha, and Cdx transcription factors SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE NOX1; NADPH oxidase; GATA; HNF-1 alpha; Cdx; transcriptional regulation; colon ID COLON EPITHELIAL-CELLS; SEQUENCE-BINDING PROTEIN; NADPH-OXIDASE; HOMEOBOX GENE; INTERFERON-GAMMA; GP91(PHOX) EXPRESSION; INTESTINAL EPITHELIUM; NAD(P)H OXIDASE-1; ISOMALTASE GENE; REACTIVE OXYGEN AB NOX1, a member of the NOX family of NADPH oxidases, is expressed primarily in colon epithelium, where it may function in host defense and growth regulation. We investigated factors responsible for its transcriptional regulation in vitro and its expression in vivo. Analysis of promoter constructs in the CaCo2 cell line identified a complex element between -422 and - 291 critical for promoter activity. This element contained four sites that bound GATA-4, -5, and -6 in vitro with varied affinities. One site also bound the caudal-related homeodomain proteins Cdx1 and Cdx2, whereas another also bound hepatocyte nuclear factor-1 alpha (HNF-1 alpha). GATA-6, HNF-1 alpha, and Cdx2 also bound to this region in the intact chromatin of CaCo2 cells. These factors demonstrated cooperativity when transactivating the NOX1 promoter. NOX1 mRNA was detected in human colon epithelial cells along the crypt-villus axis. A gradient of NOX1 mRNA expression was seen in the colons of normal as well as germ-free mice, with significantly higher levels in distal compared with proximal segments. The expression gradients of NOX1 mRNA in the colon paralleled those of GATA-6, HNF- 1 alpha, and Cdx1. These data indicate that developmental, tissue-restricted transcription factors play a key role in NOX1 regulation in vivo. (c) 2007 Elsevier Inc. All rights reserved. C1 [Valente, Anthony J.; Zhou, Qing; Lu, Zhenhua; He, Weijing; Ma, Wuqiong; Li, Guiming; Clark, Robert A.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Valente, Anthony J.; Zhou, Qing; Lu, Zhenhua; He, Weijing; Ma, Wuqiong; Li, Guiming; Clark, Robert A.; Li, Senlin] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Qiang, Mei] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Wang, Long] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Banfi, Botond] Univ Iowa, Inflammat Program, Dept Anat & Cell Biol, Iowa City, IA 52242 USA. [Banfi, Botond] Univ Iowa, Inflammat Program, Dept Med, Iowa City, IA 52242 USA. [Steger, Klaus] Inst Vet Anat, D-35392 Giessen, Germany. [Krause, Karl-Heinz] Univ Geneva, Dept Pathol, CH-1211 Geneva, Switzerland. [Krause, Karl-Heinz] Univ Geneva, Dept Immunol, CH-1211 Geneva, Switzerland. [Krause, Karl-Heinz] Univ Geneva, Dept Clin Pathol, CH-1211 Geneva, Switzerland. RP Valente, AJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM valente@uthscsa.edu; lisl@uthscsa.edu RI Krause, Karl-Heinz/E-8030-2011 FU NIA NIH HHS [AG019519, AG024579, R01 AG019519]; NIAID NIH HHS [AI020866, R01 AI020866]; NINDS NIH HHS [NS046004] NR 46 TC 17 Z9 18 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD FEB 1 PY 2008 VL 44 IS 3 BP 430 EP 443 DI 10.1016/j.freeradbiomed.2007.10.035 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 257WM UT WOS:000252829500020 PM 18005670 ER PT J AU Leung, FW AF Leung, Felix W. TI Double-EMR-derived full-thickness biopsy and functional GI disorders SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID BAND LIGATION; NEUROPATHY; RESECTION C1 Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Hlthcare Syst, Sepulveda Ambulatory Care Ctr, GI Blood Flow Res Lab, Los Angeles, CA 90095 USA. RP Leung, FW (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Hlthcare Syst, Sepulveda Ambulatory Care Ctr, GI Blood Flow Res Lab, Los Angeles, CA 90095 USA. NR 12 TC 2 Z9 2 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD FEB PY 2008 VL 67 IS 2 BP 304 EP 306 DI 10.1016/j.gie.2007.08.031 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 265OB UT WOS:000253368100021 PM 18226693 ER PT J AU Schelbert, EB Rumsfeld, JS Krumholz, HM Canto, JG Magid, DJ Masoudi, FA Reid, KJ Spertus, JA AF Schelbert, E. B. Rumsfeld, J. S. Krumholz, H. M. Canto, J. G. Magid, D. J. Masoudi, F. A. Reid, K. J. Spertus, J. A. TI Ischaemic symptoms, quality of care and mortality during myocardial infarction SO HEART LA English DT Editorial Material CT 6th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 14-16, 2005 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Councils Cardiovasc Nursing, Councils Cardiovasc Surg & Anesthesia, Councils Clin Cardiol, Councils Epidemiol & Prevent & Stroke, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs ID ACUTE CORONARY SYNDROMES; HEART-ASSOCIATION; CHEST-PAIN; GUIDELINES; TROPONIN; COMMITTEE; REGISTRY; COLLEGE; DISEASE; EVENTS AB Objective: To study in myocardial infarction (MI) whether documentation of ischaemic symptoms is associated with quality of care and outcomes, and to compare patient reports of ischaemic symptoms during interviews with chart documentation. Design: Observational acute MI study from 2003 to 2004 (Prospective Registry Evaluating Myocardial Infarction: Event and Recovery). Setting: 19 diverse US hospitals. Patients: 2094 consecutive patients with MI (10 911 patients screened; 3953 patients were eligible and enrolled) with both positive cardiac enzymes and other evidence of infarction (eg, symptoms, electrocardiographic changes). Transferred patients and those with confounding non-cardiac comorbidity were not included (n=1859). Main outcome measures: Quality of care indicators and adjusted in-hospital survival. Results: The records of 10% of all patients with MI (217/2094) contained no documented ischaemic symptoms at presentation. Patients without documented symptoms were less likely (p<0.05) to receive aspirin (89% vs 96%) or beta-blockers (77% vs 90%) within 24 hours, reperfusion therapy for ST-elevation MI (7% vs 58%) or to survive their hospitalisation (adjusted odds ratio= 3.2, 95% CI 1.8 to 5.8). Survivors without documented symptoms were also less likely (p< 0.05) to be discharged with aspirin (87% vs 93%), beta-blockers (81% vs 91%), ACE/ARB (67% vs 80%), or smoking cessation counselling (46% vs 66%). In the subset of 1356 (65%) interviewed patients, most of those without documented ischaemic symptoms (75%) reported presenting symptoms consistent with ischaemia. Conclusions: Failure to document patients' presenting MI symptoms is associated with poorer quality of care from admission to discharge, and higher in-hospital mortality. Symptom recognition may represent an important opportunity to improve the quality of MI care. C1 [Schelbert, E. B.] Univ Iowa, Iowa City, IA USA. [Rumsfeld, J. S.] Denver VA Med Ctr, Denver, CO USA. [Krumholz, H. M.] Yale Univ, New Haven, CT USA. [Canto, J. G.] Watson Clin, Ctr Cardiovasc Prevent Res & Educ, Lakeland, FL USA. [Canto, J. G.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Magid, D. J.] Colorado Permanente Med Grp, Denver, CO USA. [Masoudi, F. A.] Denver Hlth Med Ctr, Denver, CO USA. [Reid, K. J.; Spertus, J. A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Reid, K. J.; Spertus, J. A.] Univ Missouri, Kansas City, MO 64110 USA. RP Schelbert, EB (reprint author), NHLBI, NIH, 10 Ctr Dr,Room B1D416,MSC 1061, Bethesda, MD 20892 USA. EM schelberteb@nhlbi.nih.gov FU NHLBI NIH HHS [HL 07121, P50 HL077113, K30 HL004117, K30HL04117-01A1, T32 HL007121] NR 24 TC 7 Z9 8 U1 0 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 J9 HEART JI Heart PD FEB PY 2008 VL 94 IS 2 AR e2 DI 10.1136/hrt.2006.111674 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 256QX UT WOS:000252745800045 PM 17639097 ER PT J AU Dutta, A Kobetic, R Triolo, RJ AF Dutta, Anirban Kobetic, Rudi Triolo, Ronald J. TI Ambulation after incomplete spinal cord injury with EMG-triggered functional electrical stimulation SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE functional electrical stimulation (FES); spinal cord injury (SCI); electromyogram (EMG); gait event detector AB Individuals with incomplete spinal cord injury (iSCI) retain some control of the partially paralyzed muscles, necessitating careful integration of functional electrical stimulation (FES) with intact motor function. In this communication, the volitional surface electromyogram (sEMG) from partially paralyzed muscle was used to detect the intent to step in an iSCI volunteer. The classifier was able to trigger the FES-assisted swing phase with a false positive rate less than 1% and true positive rate of 82% for left foot-off (FO) and 83% for right FO over 110 steps taken during three testing sessions spread over a week. C1 [Dutta, Anirban; Triolo, Ronald J.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA. [Dutta, Anirban; Kobetic, Rudi; Triolo, Ronald J.] Cleveland VA Med Ctr, Cleveland, OH 44106 USA. [Dutta, Anirban; Kobetic, Rudi; Triolo, Ronald J.] Cleveland FES Ctr, Cleveland, OH 44106 USA. [Triolo, Ronald J.] US Dept Vet Affairs, Adv Platform Technol Ctr Excellence, Cleveland, OH USA. RP Dutta, A (reprint author), Case Western Reserve Univ, Dept Biomed Engn, 319 Wickenden Bldg, Cleveland, OH 44106 USA. EM adutta@case.edu; rkobetic@fes.case.edu; rxt24@case.edu NR 11 TC 21 Z9 22 U1 0 U2 4 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD FEB PY 2008 VL 55 IS 2 BP 791 EP 794 DI 10.1109/TBME.2007.902225 PN 1 PG 4 WC Engineering, Biomedical SC Engineering GA 254XV UT WOS:000252622200045 PM 18270018 ER PT J AU Sonnenberg, A Chang, J AF Sonnenberg, Amnon Chang, Joanne TI Time trends of physician visits for Crohn's disease and ulcerative colitis in the United States, 1960-2006 SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE epidemiology; environmental influences; incidence; prevalence; physician visits; time trends ID INFLAMMATORY-BOWEL-DISEASE; MANAGED CARE; HOSPITALIZATION; PREVALENCE; RATES AB Background: The purpose of this study was to analyze physician visits associated with inflammatory bowel disease in the United States in order to shed light on the underlying disease time trends in the United States. Methods: The National Diseases and Therapeutic Index of IMS America from 1960 until 2006 was used as the data source. Survey data had been obtained from a representative sample of U.S. physicians 4 times per year during a 48-hour period and extrapolated to a national level. All physician visits for Crohn's disease and ulcerative colitis were expressed as rates per 100,000 people living in the United States. Results: Physician visits for Crohn's disease increased almost 5-fold between 1960-1964 and 1990-1994 and have leveled off since then. Except for a slight decrease between 1960-1964 and 1980-1984, physician visits for ulcerative colitis have remained largely unchanged, especially during the most recent 15 years. Similar trends were observed for both men and women. Conclusions: U.S. time trends of physician visits are similar to other previously published time trends of inflammatory bowel disease. It appears that the overall incidence of inflammatory bowel disease has remained stable in the past 15 years. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Chang, Joanne] Bayer Healthcare Pharmaceut, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3 GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 17 TC 14 Z9 14 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD FEB PY 2008 VL 14 IS 2 BP 249 EP 252 DI 10.1002/ibd.20273 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 259ML UT WOS:000252943300012 PM 17879275 ER PT J AU Kellum, JA Cerda, J Kaplan, LJ Nadim, MK Palevsky, PM AF Kellum, J. A. Cerda, J. Kaplan, L. J. Nadim, M. K. Palevsky, P. M. TI Fluids for prevention and management of acute kidney injury SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS LA English DT Article; Proceedings Paper CT 5th International Acute Dialysis Quality Initiative Conference CY JAN, 2007 CL Tambor, COSTA RICA DE acute kidney injury; fluids; colloids; crystalloids; starch; renal replacement therapy; dialysis; hemofiltration ID ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; LACTATED RINGERS SOLUTION; LARGE-VOLUME PARACENTESIS; ACID-BASE-BALANCE; SPONTANEOUS BACTERIAL PERITONITIS; HYPERTONIC SALINE RESUSCITATION; RANDOMIZED CONTROLLED-TRIAL; ABDOMINAL AORTIC-ANEURYSM AB Fluids are the only known method of attenuating renal injury. Furthermore, whether for hydration, resuscitation or renal replacement therapy, fluid prescriptions must be tailored to the fluid and electrolyte, cardiovascular status and residual renal function of the patient. Different fluids have significantly different effects both on volume expansion as well as on the electrolyte and acid-base balance; while controversial, different fluids may even influence renal function differently. This systematic review focuses on fluids for prevention and management of acute kidney injury. We have reviewed the available evidence and have made recommendations for clinical practice and future studies. C1 [Kellum, J. A.] Univ Pittsburgh, Dept Crit Care Med, Sch Med, Pittsburgh, PA 15261 USA. [Cerda, J.] Albany Med Coll & Capital Dist Renal Physicians, Div Nephrol, Albany, NY USA. [Kaplan, L. J.] Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06510 USA. [Nadim, M. K.] Univ So Calif, Keck Sch Med, Dept Med, Div Nephrol, Los Angeles, CA 90033 USA. [Palevsky, P. M.] VA Pittsburgh Healthcare Syst, Univ Dr Div, Pittsburgh, PA USA. RP Kellum, JA (reprint author), Univ Pittsburgh, Dept Crit Care Med, Sch Med, 608 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM kellumja@ccm.upmc.edu NR 118 TC 17 Z9 19 U1 1 U2 5 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0391-3988 J9 INT J ARTIF ORGANS JI Int. J. Artif. Organs PD FEB PY 2008 VL 31 IS 2 BP 96 EP 110 PG 15 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA 268DS UT WOS:000253559200004 PM 18311727 ER PT J AU Steinberg, M Shao, H Zandi, P Lyketsos, CG Welsh-Bohmer, KA Norton, MC Breitner, JCS Steffens, DC Tschanz, JT AF Steinberg, Martin Shao, Huibo Zandi, Peter Lyketsos, Constantine G. Welsh-Bohmer, Kathleen A. Norton, Maria C. Breitner, John C. S. Steffens, David C. Tschanz, JoAnn T. CA Investigators, CC TI Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE dementia; neuropsychiatric; prevalence ID ALZHEIMERS-DISEASE; BEHAVIORAL DISTURBANCES; DIAGNOSTIC-CRITERIA; CONSORTIUM; CAREGIVERS; INVENTORY AB Background Neuropsychiatric symptoms are nearly universal in dementia, yet little is known about their longitudinal course in the community. Objective To estimate point and 5-year period prevalence of neuropsychiatric symptoms in an incident sample of 408 dementia participants from the Cache County Study. Methods The Neuropsychiatric Inventory assessed symptoms at baseline and at 1.5 years, 3.0 years, 4.1 years, and 5.3 years. Point prevalence, period prevalence and mean symptom severity at each time point were estimated. Results Point prevalence for delusions was 18% at baseline and 34 - 38% during the last three visits; hallucinations, 10% at baseline and 19 - 24% subsequently; agitation/aggression fluctuated between 13% and 24%; depression 29% at baseline and 41 - 47% subsequently; apathy increased from 20% at baseline to 51% at 5.3 years; elation never rose above 1%; anxiety 14% at baseline and 24 - 32% subsequently; disinhibition fluctuated between 2% and 15%; irritability between 17% and 27%; aberrant motor behavior gradually increased from 7% at baseline to 29% at 5.3 years. Point prevalence for any symptom was 56% at baseline and 76 - 87% subsequently. Five-year period prevalence was greatest for depression (77%), apathy (71%), and anxiety (62%); lowest for elation (6%), and disinhibition (31 %). Ninety-seven percent experienced at least one symptom. Symptom severity was consistently highest for apathy. Conclusions Participants were most likely to develop depression, apathy, or anxiety, and least likely to develop elation or disinhibition. Give converging evidence that syndromal definitions may more accurately capture neuropsychiatric co-morbidity in dementia, future efforts to validate such syndromes are warranted. Copyright ((c) 2007 John Wiley & Sons, Ltd. C1 [Steinberg, Martin; Lyketsos, Constantine G.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Shao, Huibo; Zandi, Peter] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Welsh-Bohmer, Kathleen A.; Steffens, David C.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA. [Norton, Maria C.; Tschanz, JoAnn T.] Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. [Norton, Maria C.; Tschanz, JoAnn T.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. [Norton, Maria C.] Utah State Univ, Dept Family & Human Dev, Logan, UT 84322 USA. [Breitner, John C. S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Steinberg, M (reprint author), 550 N Broadway,Suite 308, Baltimore, MD 21205 USA. EM martins@jhmi.edu RI Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513 FU NIA NIH HHS [AG-11380, AG-21136, R01 AG011380, R01 AG011380-06, R01 AG021136, R01 AG021136-01] NR 24 TC 180 Z9 184 U1 2 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD FEB PY 2008 VL 23 IS 2 BP 170 EP 177 DI 10.1002/gps.1858 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 266XV UT WOS:000253472100008 PM 17607801 ER PT J AU Sartippour, MR Seeram, NP Rao, JY Moro, A Harris, DM Henning, SM Firouzi, A Rettig, MB Aronson, WJ Pantuck, AJ Heber, D AF Sartippour, Maryam R. Seeram, Navindra P. Rao, Jian Yu Moro, Aune Harris, Diane M. Henning, Susanne M. Firouzi, Amita Rettig, Matthew B. Aronson, William J. Pantuck, Allan J. Heber, David TI Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE hypoxia inducible factor-1 alpha; pomegranate; angiogenesis; vascular endothelial growth factor; prostate cancer ID HYPOXIA-INDUCIBLE FACTOR-1; BREAST-CANCER; FACTOR 1-ALPHA; GREEN TEA; TUMOR-GROWTH; HIF-ALPHA; KAPPA-B; ACTIVATION; JUICE; TRANSCRIPTION AB Angiogenesis is critical to tumor growth and is stimulated by tissue hypoxia due to poor oxygen delivery. In turn, cellular hypoxia leads to angiogenesis via the induction of hypoxia-inducible factor-1 alpha (HIF-alpha) and vascular endothelial growth factor (VEGF) at a cellular level. Pomegranate juice and extracts, which are rich sources of ellagitannins, have been shown to have chemopreventive potential against prostate cancer, but there have been no studies on the effects of an ellagitannin-rich pomegranate extract on angiogenesis. Human prostate cancer cells (LNCaP) and human umbilical vein endothelial cells (HUVEC) were incubated with a pomegranate extract standardized to ellagitannin content (POMx), under normoxic and hypoxic conditions in vitro. Human prostate cancer cells (LAPC4) were injected subcutaneously into severe combined immunodeficient (SCID) mice and the effects of oral administration of POMx on tumor growth, microvessel density, and HIF-1 alpha and VEGF expression were determined after 4 weeks of treatment. POMx inhibited the proliferation of LNCaP and HUVEC cells significantly under both normoxic and hypoxic conditions. HIF-1 alpha and VEGF protein levels were also reduced by POMx under hypoxic conditions. POMx decreased prostate cancer xenograft size, tumor vessel density, VEGF peptide levels and HIF-1 alpha expression after 4 weeks of treatment in SCID mice. These results demonstrate that an ellagitannin-rich pomegranate extract can inhibit tumor-associated angiogenesis as one of several potential mechanisms for slowing the growth of prostate cancer in chemopreventive applications. Further studies in humans are needed to confirm that angiogenesis can be inhibited by an ellagitannin-rich pomegranate extract administered orally as a dietary supplement. C1 [Sartippour, Maryam R.; Seeram, Navindra P.; Moro, Aune; Harris, Diane M.; Henning, Susanne M.; Firouzi, Amita; Heber, David] Univ Calif Los Angeles, Ctr Human Nutr, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rao, Jian Yu] Univ Calif Los Angeles, Dept Pathol, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rettig, Matthew B.] Univ Calif Los Angeles, Div Hematol Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rettig, Matthew B.; Aronson, William J.; Pantuck, Allan J.] Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rettig, Matthew B.] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Heber, D (reprint author), Univ Calif Los Angeles, Ctr Human Nutr, David Geffen Sch Med, Box 951742, Los Angeles, CA 90095 USA. EM dheber@mednet.ucla.edu FU NCI NIH HHS [P50 CA 92131, CA 42710]; NIDDK NIH HHS [T32 DK 07688] NR 37 TC 56 Z9 58 U1 0 U2 9 PU PROFESSOR D A SPANDIDOS PI ATHENS PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE SN 1019-6439 J9 INT J ONCOL JI Int. J. Oncol. PD FEB PY 2008 VL 32 IS 2 BP 475 EP 480 PG 6 WC Oncology SC Oncology GA 254XI UT WOS:000252620900022 PM 18202771 ER PT J AU Cardenas, J Frye, MA Marusak, SL Levander, EM Chirichigno, JW Lewis, S Nakelsky, S Hwang, S Mintz, J Altshuler, LL AF Cardenas, Jeffrey Frye, Mark A. Marusak, Susan L. Levander, Eric M. Chirichigno, Jason W. Lewis, Stryder Nakelsky, Shoshanna Hwang, Sun Mintz, Jim Altshuler, Lori L. TI Modal subcomponents of metabolic syndrome in patients with bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article; Proceedings Paper CT 159th Annual Meeting of the American-Psychiatric-Association CY MAY 20-25, 2006 CL Toronto, CANADA SP Amer Psychiat Assoc DE bipolar disorder; metabolic syndrome; psychotropic ID CORONARY-HEART-DISEASE; MIDDLE-AGED MEN; CARDIOVASCULAR-DISEASE; LIPID-LEVELS; LIFE-STYLE; RISK; INTERVENTION; ADULTS; CARBAMAZEPINE; APPROPRIATE AB Background: The metabolic syndrome is a growing global public health problem. Objective: To evaluate the prevalence rate and modal subcomponents of the metabolic syndrome in subjects treated at the West Los Angeles Veterans Administration Medical Center Bipolar Clinic. Methods: In this cross-sectional design study, using the National Cholesterol Education Program definition, metabolic syndrome prevalence rates were calculated. Results: 48/98 (49%) of subjects met criteria for metabolic syndrome. There was no difference in prevalence rate by gender or race. Almost 70% of the cohort met criteria for metabolic syndrome by the components of reduced HDL and increased waist circumference. Treatment with carbamazepine at study entry was associated with a lower prevalence rate of metabolic syndrome. Limitations and conclusions: This study is limited by its small size and non-structured assessment of Axis I diagnosis. Nonetheless, bipolar patients in this select cohort have high rates of metabolic syndrome; given this cardiovascular risk, close clinical monitoring for these parameters is recommended. While not controlling for genetics, environmental influences, and/or medical factors such as additional comorbidity and treatment duration, psychotropic drug use may confer differential risk for developing the metabolic syndrome. (c) 2007 Published by Elsevier B.V. C1 [Frye, Mark A.] Mayo Coll Med, Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA. [Cardenas, Jeffrey; Marusak, Susan L.; Levander, Eric M.; Chirichigno, Jason W.; Lewis, Stryder; Nakelsky, Shoshanna; Hwang, Sun; Mintz, Jim; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Mood Disorders Res Program, Dept Psychiat, Los Angeles, CA USA. [Cardenas, Jeffrey; Marusak, Susan L.; Levander, Eric M.; Chirichigno, Jason W.; Lewis, Stryder; Nakelsky, Shoshanna; Hwang, Sun; Mintz, Jim; Altshuler, Lori L.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Frye, MA (reprint author), Mayo Coll Med, Mayo Clin, Dept Psychiat & Psychol, 200 1st St SW, Rochester, MN 55905 USA. EM mfrye@mayo.edu NR 26 TC 52 Z9 55 U1 2 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2008 VL 106 IS 1-2 BP 91 EP 97 DI 10.1016/j.jad.2007.05.030 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 258YC UT WOS:000252905300008 PM 17628693 ER PT J AU Esch, RE Bush, RK Skoner, D Gentile, D McLaughlin, A Fasano, MB AF Esch, R. E. Bush, R. K. Skoner, D. Gentile, D. McLaughlin, A. Fasano, M. B. TI Parallel, randomized, double-blind, placebo-controlled, dose-response phase IIb trial in adults for short ragweed sublingual-oral immunotherapy (SLIT) SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY MAR 14-18, 2008 CL Philadelphia, PA SP Amer Acad Allergy, Asthma & Immunol C1 [Esch, R. E.] Greer Labs, Lenoir, NC USA. [Bush, R. K.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI USA. [Skoner, D.; Gentile, D.] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [McLaughlin, A.] Welborn Clin Res Ctr, Evansville, IL USA. [Fasano, M. B.] Univ Iowa, Dept Internal Med, Iowa City, IA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2008 VL 121 IS 2 SU 1 MA 492 BP S127 EP S127 DI 10.1016/j.jaci.2007.12.505 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 266HZ UT WOS:000253426400491 ER PT J AU Lee, CH Corren, J AF Lee, C. H. Corren, J. TI Effects of nasal allergen challenge upon airway responsiveness to exercise SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY MAR 14-18, 2008 CL Philadelphia, PA SP Amer Acad Allergy, Asthma & Immunol C1 [Lee, C. H.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Corren, J.] Allergy Res Fdn, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2008 VL 121 IS 2 SU 1 MA 1008 BP S260 EP S260 DI 10.1016/j.jaci.2007.12.1034 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 266HZ UT WOS:000253426401471 ER PT J AU McEldowney, SJ Bush, RK AF McEldowney, S. J. Bush, R. K. TI House dust mite-specific IgA and exhaled nitric oxide are elevated in allergic asthma and rhinitis patients with positive: Methacholine challenges SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY MAR 14-18, 2008 CL Philadelphia, PA SP Amer Acad Allergy, Asthma & Immunol C1 [McEldowney, S. J.; Bush, R. K.] Univ Wisconsin Hosp & Clins, Madison, WI USA. [McEldowney, S. J.; Bush, R. K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2008 VL 121 IS 2 SU 1 MA 761 BP S198 EP S198 DI 10.1016/j.jaci.2007.12.737 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 266HZ UT WOS:000253426401225 ER PT J AU Sheinkopf, LE Rafi, AW Do, LT Klaustermeyer, WB Katz, RM AF Sheinkopf, L. E. Rafi, A. W. Do, L. T. Klaustermeyer, W. B. Katz, R. M. TI Reasons for discontinuation of Omalizumab therapy in the treatment of patients with moderate to severe persistent asthma SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY MAR 14-18, 2008 CL Philadelphia, PA SP Amer Acad Allergy, Asthma & Immunol C1 [Sheinkopf, L. E.; Klaustermeyer, W. B.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Rafi, A. W.; Do, L. T.; Katz, R. M.] Allergy Asthma Care Ctr Inc, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2008 VL 121 IS 2 SU 1 MA 537 BP S139 EP S139 DI 10.1016/j.jaci.2007.12.552 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 266HZ UT WOS:000253426401001 ER PT J AU Watson, C Rafi, A Do, L Sheinkopt, L Katz, R AF Watson, C. Rafi, A. Do, L. Sheinkopt, L. Katz, R. TI Efficacy of Omalizumab for the treatment of food allergy SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY MAR 14-18, 2008 CL Philadelphia, PA SP Amer Acad Allergy, Asthma & Immunol C1 [Watson, C.; Sheinkopt, L.] Univ Calif Los Angeles, Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. [Rafi, A.; Do, L.; Katz, R.] Allergy Asthma Care Ctr, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2008 VL 121 IS 2 SU 1 MA 975 BP S252 EP S252 DI 10.1016/j.jaci.2007.12.1000 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 266HZ UT WOS:000253426401438 ER PT J AU Moran, A Katz, R Smith, NL Fried, LF Sarnak, MJ Seliger, SL Psaty, B Siscovick, DS Gottdiener, JS Shlipak, MG AF Moran, Andrew Katz, Ronit Smith, Nicolas L. Fried, Linda F. Sarnak, Mark J. Seliger, Stephen L. Psaty, Bruce Siscovick, David S. Gottdiener, John S. Shlipak, Michael G. TI Cystatin C concentration as a predictor of systolic and diastolic heart failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE cystatin C; diastolic heart failure; ejection fraction; elderly; estimated glomerular filtration rate; heart failure; systolic heart failure ID LEFT-VENTRICULAR HYPERTROPHY; CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; BLOOD-PRESSURE CONTROL; CHRONIC RENAL-DISEASE; CARDIOVASCULAR MORTALITY; COMPETING RISKS; INSUFFICIENCY; PROGRESSION; DYSFUNCTION AB Background: Risk factors for heart failure (HF) may differ according to ejection fraction (EF). Higher cystatin C, a marker of kidney dysfunction, is associated with incident HF, but previous studies did not determine EF at diagnosis. We hypothesized that kidney dysfunction would predict diastolic HF (DHF) better than systolic HF (SHF) in the Cardiovascular Health Study. Methods and Results: Cystatin C was measured in 4453 participants without HF at baseline. Incident HF was categorized as DHF (EF >= 50%) or SHF (EF < 50%). We compared the association of cystatin C with the risk for DHF and SHE after adjustment for age, sex, race, medications, and HF risk factors. During 8 years of follow-up, 167 participants developed DHF and 206 participants developed SHE After adjustment, sequentially higher quartiles of cystatin C were associated with risk for SHF (competing risks hazard ratios 1.0 [reference], 1.99 [95% confidence interval 1.14-3.48], 2.32 [1.32-4.07], 3.17 [1.82-5.50], P for trend < .001). The risk for DHF was apparent only at the highest cystatin C quartile (hazard ratios 1.0 [reference], 1.09 [0.62-1.89], 1.08 [0.61-1.93], and 1.83 [1.07-3.11]). Conclusions: Cystatin C levels are linearly associated with the incidence of systolic HF, whereas only the highest concentrations of cystatin C predict diastolic HF. C1 [Moran, Andrew; Shlipak, Michael G.] Vet Adm Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Moran, Andrew; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Smith, Nicolas L.; Psaty, Bruce; Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Med Serv, Pittsburgh, PA USA. [Sarnak, Mark J.] Tufts Univ New England Med Ctr, Boston, MA USA. [Seliger, Stephen L.] Univ Maryland, Baltimore, MD 21201 USA. [Gottdiener, John S.] Univ Maryland, Sch Med, Div Cardiol, Baltimore, MD 21201 USA. RP Shlipak, MG (reprint author), Vet Adm Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. FU NHLBI NIH HHS [N01-HC-85086, N01 HC035129, N01 HC015103, N01HC75150, N01-HC-85079, N01HC85086, N01HC85079, N01 HC045133, N01-HC-75150]; NIDDK NIH HHS [R01 DK066488, R01 DK066488-04] NR 39 TC 29 Z9 34 U1 0 U2 5 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD FEB PY 2008 VL 14 IS 1 BP 19 EP 26 DI 10.1016/j.cardfail.2007.09.002 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 261HW UT WOS:000253070700004 PM 18226769 ER PT J AU Das, F Ghosh-Choudhury, N Venkatesan, B Li, XN Mahimainathan, L Choudhury, GG AF Das, Falguni Ghosh-Choudhury, Nandini Venkatesan, Balachandar Li, Xiaonan Mahimainathan, Lenin Choudhury, Goutam Ghosh TI Akt kinase targets association of CBP with SMAD 3 to regulate TGF beta-induced expression of plasminogen activator inhibitor-1 SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID GROWTH-FACTOR-BETA; GLOMERULAR MESANGIAL CELLS; PAI-1 GENE-EXPRESSION; TUMOR-SUPPRESSOR PTEN; COLLAGEN-I EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; EXTRACELLULAR-MATRIX; BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION AB Transforming growth factor-P (TGF beta) controls expression of plasminogen activator inhibitor type 1 (PAI-1), which regulates degradation of extracellular matrix proteins in fibrotic diseases. The TGF beta receptor-specific Smad 3 has been implicated in the PAI-1 expression. The mechanism by which non-Smad signaling contributes to this process is not known. We studied the cross-talk between Smad 3 and PI 3 kinase/Akt signaling in TGF beta-induced PAI-1 expression in renal mesangial cells. Inhibition of PI 3 kinase and Akt kinase blocked TGF beta- and Smad 3-mediated expression of PAI-1. In contrast, constitutively active PI 3 kinase and Akt kinase increased PAI-1 expression, similar to TGF beta. Inhibition of PI 3 kinase and Akt kinase had no effect on TGF beta-induced Smad 3 phosphorylation and its translocation to the nucleus. Notably, inhibition of PI 3 kinase-dependent Akt kinase abrogated TGF beta-induced PAI-1 transcription, without affecting binding of Smad 3 to the PAI-1 Smad binding DNA element. However, PI 3 kinase inhibition and dominant negative Akt kinase antagonized the association of the transcriptional coactivator CBP with Smad 3 in response to TGF beta, resulting in inhibition of Smad 3 acetylation. Together our findings identify TGF beta-induced PI 3 kinase/Akt signaling as a critical regulator of Smad 3-CBP interaction and Smad 3 acetylation, which cause increased PAI-1 expression. C1 [Das, Falguni; Venkatesan, Balachandar; Li, Xiaonan; Mahimainathan, Lenin; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU NIAMS NIH HHS [R01 AR52425]; NIDDK NIH HHS [R01 DK50190] NR 91 TC 42 Z9 42 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD FEB PY 2008 VL 214 IS 2 BP 513 EP 527 DI 10.1002/jcp.21236 PG 15 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 248OM UT WOS:000252163400026 PM 17671970 ER PT J AU Thase, ME Jonas, A Khan, A Bowden, CL Wu, XL McQuade, RD Carson, WH Marcus, RN Owen, R AF Thase, Michael E. Jonas, Alan Khan, Arif Bowden, Charles L. Wu, Xiaoling McQuade, Robert D. Carson, William H. Marcus, Ronald N. Owen, Randall TI Aripiprazole monotherapy in non-psychotic bipolar I depression SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article ID SEROTONIN REUPTAKE INHIBITORS; DOUBLE-BLIND; PARTIAL AGONIST; SCHIZOAFFECTIVE DISORDER; PLACEBO; EFFICACY; SCHIZOPHRENIA; AUGMENTATION; SAFETY; TRIAL AB Although most treatment research on bipolar disorder has focused on mania, depressive episodes occur more frequently among patients with bipolar disorder. Here, we report the results of 2 identically designed, 8-week, multicenter, randomized, double-blind, placebo-controlled studies (CN138-096 and CN138-146) to evaluate the efficacy and safety of aripiprazole monotherapy in outpatients with bipolar I disorder experiencing a major depressive episode without psychotic features. Patients were randomized to placebo or aripiprazole (initiated at 10 mg/d, then flexibly dosed at 5-30 mg/d based on clinical effect and tolerability). The primary end point was mean change from baseline to Week 8 (last observation carried forward) in the Montgomery-Asberg Depression Rating Scale total score. In Studies 1 and 2, respectively, 186 and 187 patients were randomized to aripiprazole, and 188 and 188 to placebo. Although statistically significant differences were observed during Weeks 1 to 6, aripiprazole did not achieve statistical significance versus placebo at Week 8 in either study in the change in Montgomery-Asberg Depression Rating Scale total (primary end point). In addition, despite early statistical separation on the Clinical Global Impressions Bipolar Version Severity of Illness-Depression score (key secondary end point), aripiprazole was not superior to placebo at end point. Aripiprazole was associated with a higher incidence of akathisia, insomnia, nausea, fatigue, restlessness, and dry mouth versus placebo. More patients discontinued with aripiprazole versus placebo in Study 1 (46.8% vs 35.1%) and Study 2 (41.2% vs 29.8%). Aripiprazole monotherapy - as dosed in this study design was - not significantly more effective than placebo in the treatment of bipolar depression at end point (Week 8). C1 [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Jonas, Alan] PharmaSite Res Inc, Baltimore, MD USA. [Khan, Arif] NW Clin Res Ctr, Bellevue, WA USA. [Khan, Arif] Duke Univ, Med Ctr, Durham, NC USA. [Bowden, Charles L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Wu, Xiaoling; Marcus, Ronald N.; Owen, Randall] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. [McQuade, Robert D.; Carson, William H.] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA. RP Thase, ME (reprint author), Univ Penn, Sch Med, 3535 Market St,Room 689, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu NR 28 TC 147 Z9 150 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD FEB PY 2008 VL 28 IS 1 BP 13 EP 20 DI 10.1097/jcp.0b013e3181618eb4 PG 8 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 252XN UT WOS:000252481100003 PM 18204335 ER PT J AU Kilzieh, N Todd-Stenberg, JA Kennedy, A Wood, AE Tapp, AM AF Kilzieh, Nael Todd-Stenberg, Jeffrey A. Kennedy, Annette Wood, Amanda E. Tapp, Andre M. TI Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article ID SCHIZOAFFECTIVE DISORDER; 2ND-GENERATION ANTIPSYCHOTICS; FOLLOW-UP; MEDICATION; NONADHERENCE; EFFICACY AB Background: Although efficacy of antipsychotic medications is well documented, their effectiveness in real-world practice is less robust. We examined the effectiveness of olanzapine and risperidone in schizophrenia in a naturalistic setting. Methods: We used an electronic medical records database at a Veterans Affairs Medical Center to conduct a retrospective study of all new outpatient medication trials of olanzapine (n = 221) and risperidone (n = 274) over a 2-year period beginning January 1999 in patients diagnosed with schizophrenia or schizoaffective disorder. We defined medication discontinuation as a switch between the 2 agents (most switches) or self-discontinuation when a patient is without medication supply for longer than 1 month. Results: Sample mean age (+/- SD) was 48.4 (+/- 11.6) years; 91% were men. Discontinuation rates were high (73%), trending lower in olanzapine (70%) than risperidone (76%) (P = 0.12). Median time to discontinuation was 120 days (95% confidence interval [CI], 105-135), longer for olanzapine (150 days, 95% CI, 120-180) than risperidone (90 days; 95% CI, 71-109) (P = 0.04). Self-discontinuation was high (48%), with no significant difference between olanzapine (50%) and risperidone (46%). Switching rate was 25% and more likely to occur in risperidone (30%) than olanzapine (20%) (odds ratio, 1.72; 95% CI, 1.13-2.61). Conclusions: Effectiveness of antipsychotic medications in schizophrenia may be hampered by high rates of medication self-discontinuation in outpatient practice settings. Time to discontinuation C1 [Kilzieh, Nael; Todd-Stenberg, Jeffrey A.; Kennedy, Annette; Wood, Amanda E.; Tapp, Andre M.] Univ Washington, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst,Vet Integrated Serv, Amer Lake Div,Mental Illness Res Educ & Clin Ctr, Tacoma, WA 98493 USA. [Kennedy, Annette] Seattle Inst Biomed & Clin Res, Seattle, WA USA. RP Kilzieh, N (reprint author), Univ Washington, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst,Vet Integrated Serv, Amer Lake Div,Mental Illness Res Educ & Clin Ctr, 116-A, Tacoma, WA 98493 USA. EM nael.kilzieh@va.gov NR 16 TC 12 Z9 12 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD FEB PY 2008 VL 28 IS 1 BP 74 EP 77 DI 10.1097/jcp.0b013e3181602cf3 PG 4 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 252XN UT WOS:000252481100013 PM 18204345 ER PT J AU Bolton, LE Reed, A Volpp, KG Armstrong, K AF Bolton, Lisa E. Reed, Americus, II Volpp, Kevin G. Armstrong, Katrina TI How does drug and supplement marketing affect a healthy lifestyle? SO JOURNAL OF CONSUMER RESEARCH LA English DT Article ID DIETARY-SUPPLEMENTS; SELF-EFFICACY; CONSEQUENCES; PERCEPTION; BEHAVIOR; REMEDIES; WEIGHT; MODEL AB This research investigates consumer reactions to the marketing of drugs and supplements and the consequences for a healthy lifestyle. A series of experiments provides evidence that drug marketing undermines intentions to engage in health-protective behaviors (i.e., a boomerang effect). The boomerang arises from two psychological mechanisms: (1) drugs reduce risk perceptions and perceived importance of, and motivation to engage in, complementary health-protective behaviors, and (2) drugs are associated with poor health that reduces self-efficacy and perceived ability to engage in complementary health-protective behaviors. A combined intervention accompanying a drug remedy that targets both motivation and ability mitigates the drug boomerang on a healthy lifestyle. C1 [Bolton, Lisa E.; Reed, Americus, II] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Armstrong, Katrina] Univ Penn, Leonard Davis Inst, Philadelphia, PA 19104 USA. [Armstrong, Katrina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. RP Bolton, LE (reprint author), Univ Penn, Wharton Sch, 3730 Walnut St,700 Jon M Huntsman Hall, Philadelphia, PA 19104 USA. EM boltonl@wharton.upenn.edu NR 33 TC 23 Z9 23 U1 4 U2 20 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0093-5301 J9 J CONSUM RES JI J. Consum. Res. PD FEB PY 2008 VL 34 IS 5 BP 713 EP 726 DI 10.1086/521906 PG 14 WC Business SC Business & Economics GA 249QP UT WOS:000252244300012 ER PT J AU Rose, AJ Shimada, SL Rothendler, JA Reisman, JI Glassman, PA Berlowitz, DR Kressin, NR AF Rose, Adam J. Shimada, Stephanie L. Rothendler, James A. Reisman, Joel I. Glassman, Peter A. Berlowitz, Dan R. Kressin, Nancy R. TI The accuracy of clinician perceptions of "Usual" blood pressure control SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE hypertension; ambulatory care; informatics; quality of care; chronic disease ID PRIMARY-CARE; AFRICAN-AMERICANS; CORONARY-DISEASE; MANAGEMENT; HYPERTENSION; INERTIA; INTERVENTION; GUIDELINES; PHYSICIANS; ADHERENCE AB BACKGROUND: The term "clinical inertia" is used to describe the failure to manage a chronic condition aggressively enough to bring it under control. The underlying mechanisms for clinical inertia remain poorly understood. OBJECTIVE: To describe one potential mechanism for clinical inertia, seen through the lens of clinician responses to a computerized hypertension reminder. DESIGN: Cohort study. PARTICIPANTS: A total of 509 hypertensive patients from 2 primary care clinics in urban Veterans Health Administration (VA) Medical Centers. All patients had elevated blood pressure (BP) values that triggered a computerized reminder. Given a set of possible responses to the reminder, clinicians asserted at least once for each patient that medication adjustments were unnecessary because the BP was "usually well controlled". MEASUREMENTS: Using recent BP values from the electronic medical record, we assessed the accuracy of this assertion. RESULTS: In most instances (57%), recent BP values were not well controlled, with the systolic BP (56%) much more likely to be elevated than the diastolic BP (13%). Eighteen percent of recent systolic BP values were 160 mmHg or greater. CONCLUSIONS: When clinicians asserted that the BP was "usually well controlled", objective evidence frequently suggested otherwise. This observation provides insight into one potential mechanism underlying clinical inertia. C1 [Rose, Adam J.; Shimada, Stephanie L.; Rothendler, James A.; Reisman, Joel I.; Berlowitz, Dan R.; Kressin, Nancy R.] Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Rose, Adam J.; Berlowitz, Dan R.; Kressin, Nancy R.] Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02215 USA. [Shimada, Stephanie L.; Rothendler, James A.; Berlowitz, Dan R.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA. [Glassman, Peter A.] VA Greater Los Angeles, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. [Glassman, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Rose, AJ (reprint author), Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, 200 Springs Rd,Bldg 70, Bedford, MA 01730 USA. EM adamrose@bu.edu OI Kressin, Nancy/0000-0003-2767-4286 NR 18 TC 24 Z9 24 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2008 VL 23 IS 2 BP 180 EP 183 DI 10.1007/s11606-007-0464-1 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 259MY UT WOS:000252944600012 PM 18043980 ER PT J AU Khurana, HS Chaux, G Kole, A Falk, J Simsir, S Cheng, W Kass, RM Khurana, J Soohoo, G AF Khurana, H. S. Chaux, G. Kole, A. Falk, J. Simsir, S. Cheng, W. Kass, R. M. Khurana, J. Soohoo, G. TI Low dose valganciclovir for CMV prophylaxis after lung transplantation SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Meeting Abstract CT 28th Annual Meeting of the International-Society-for-Heart-and-Lung-Transplantation CY APR 09-12, 2008 CL Boston, MA SP Int Soc Heart & Lung Transplantat C1 [Khurana, H. S.; Chaux, G.; Kole, A.; Falk, J.; Simsir, S.; Cheng, W.; Kass, R. M.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Khurana, J.; Soohoo, G.] W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 EI 1557-3117 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD FEB PY 2008 VL 27 IS 2 SU S MA 35 BP S72 EP S72 DI 10.1016/j.healun.2007.11.039 PG 1 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA 265EQ UT WOS:000253342300036 ER PT J AU Lieber, CS DeCarli, LM Leo, MA Mak, KM Ponomarenko, A Ren, C Wang, XL AF Lieber, Charles S. DeCarli, Leonore M. Leo, Maria A. Mak, Ki M. Ponomarenko, Anatoly Ren, Chaoling Wang, Xiaolei TI Beneficial effects versus toxicity of medium-chain triacylglycerols in rats with NASH SO JOURNAL OF HEPATOLOGY LA English DT Article DE long-chain triacylglycerols; medium-chain triacylglycerols; non-alcoholic steatohepatitis; TNF-alpha ID HEPATIC CYTOCHROME-P450 2E1; NONALCOHOLIC STEATOHEPATITIS; DIMINISHED DEPOSITION; OXIDATIVE STRESS; LIVER-INJURY; IN-VIVO; TRIGLYCERIDES; FAT; ETHANOL; THERMOGENESIS AB Background/Aims: Replacing long-chain triacylglycerols (LCT) with medium-chain triacylglycerols (MCT) reduces alcohol-induced liver injury. Because of the similarity of the pathogenesis of alcohol-induced liver damage and non-alcoholic steatohepatitis (NASH), our aim was to assess whether MCT is also beneficial in NASH. Methods: We used a rat NASH model in which corn oil (35% of total calories) was isocalorically replaced with MCT. Results: Partial replacement of LCT did not ameliorate hepatic fat accumulation, 4-hydroxynonenal, collagen type I and its mRNA but it increased TNF-alpha( and its mRNA (p < 0.001). However, in rats given the high-fat diet restricted to 2/3 of the amount they were consuming, these adverse effects decreased, with and without MCT including less liver steatosis and lower triacylglycerols, but without beneficial effects of MCT. When 70% of the fat calories were replaced with MCT with no LCT remaining in the diet, no steatosis developed and hepatic TNF-alpha was low. When all MCT were given with carbohydrates (instead of LCT) hepatic TNF-alpha also decreased (p < 0.001). Conclusions: MCT are not hepatotoxic, provided the diet contains no significant amount of LCT. Total replacement of dietary LCT with MCT fed ad libitum is beneficial whereas partial replacement becomes hepatotoxic, unless the dietary intake is restricted. (c) 2007 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 [Lieber, Charles S.; DeCarli, Leonore M.; Leo, Maria A.; Ponomarenko, Anatoly] James J Peters VA Med Ctr, Alcohol Res Ctr, Bronx, NY 10468 USA. [Lieber, Charles S.; Leo, Maria A.; Mak, Ki M.; Ren, Chaoling; Wang, Xiaolei] Mt Sinai Sch Med, New York, NY USA. RP Lieber, CS (reprint author), James J Peters VA Med Ctr, Alcohol Res Ctr, 130 W Kingsbridege Rd 151-2, Bronx, NY 10468 USA. EM liebercs@aol.com FU NCCIH NIH HHS [AT001583] NR 32 TC 6 Z9 6 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD FEB PY 2008 VL 48 IS 2 BP 318 EP 326 DI 10.1016/j.jhep.2007.09.016 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 264XS UT WOS:000253324300017 PM 18093684 ER PT J AU Corry, DB Eslami, P Yamamoto, K Nyby, MD Makino, H Tuck, ML AF Corry, Dalila B. Eslami, Pirooz Yamamoto, Kei Nyby, Michael D. Makino, Hirofumi Tuck, Michael L. TI Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system SO JOURNAL OF HYPERTENSION LA English DT Article DE oxidative stress; renin-angiotensin system; uric acid; vascular smooth muscle cells ID ACTIVATED PROTEIN-KINASE; ESSENTIAL-HYPERTENSION; INSULIN; HYPERURICEMIA; SUPEROXIDE; GROWTH; HUMANS AB Background Plasma uric acid has been associated with hypertension in a variety of disorders, and has been shown to be predictive of hypertension. The mechanistic role of uric acid in the development of hypertension is not known however. Method We tested the hypothesis that uric acid stimulates vascular smooth muscle cell (VSMC) proliferation and oxidative stress by stimulating the vascular renin angiotensin system (RAS). Rat VSMC were exposed to 0-300 mu mol uric acid for 48 h. Results Uric acid (200 and 300 mu mol) stimulated the proliferation of VSMC as measured by thymidine uptake. This effect was prevented by 10(-6) mol losartan or by 10(-6) mol captopril. Incubation of VSMC with uric acid for 48 h also increased angiotensinogen messenger RNA expression and intracellular concentrations of angiotensin II. These responses were also inhibited by losartan and captopril. Increased expression of angiotensinogen mRNA was also inhibited by co-incubation with PD 98059, a mitogen-activated protein (MAP) kinase inhibitor. Uric acid stimulated the production of hydrogen peroxide and 8-isoprostane in VSMC. These increases in oxidative stress indicators were significantly reduced by co-incubating the cells with captopril or losartan. Uric acid also decreased nitrite and nitrate concentrations in the culture medium, an effect that was prevented by losartan and captopril. Conclusion These results demonstrate that uric acid stimulates proliferation, angiotensin II production, and oxidative stress in VSMC through tissue RAS. This suggests that uric acid causes cardiovascular disorders by stimulating the vascular RAS, and this stimulation may be mediated by the MAP kinase pathway. C1 [Eslami, Pirooz; Yamamoto, Kei; Nyby, Michael D.; Makino, Hirofumi; Tuck, Michael L.] VA Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. [Corry, Dalila B.] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. [Eslami, Pirooz; Yamamoto, Kei; Nyby, Michael D.; Makino, Hirofumi; Tuck, Michael L.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Nyby, MD (reprint author), VA Greater Los Angeles Healthcare Syst, 16111 Plummer St, Sepulveda, CA 91343 USA. EM mnyby@ucla.edu NR 28 TC 230 Z9 258 U1 7 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD FEB PY 2008 VL 26 IS 2 BP 269 EP 275 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 257CZ UT WOS:000252778100019 PM 18192841 ER PT J AU Young, MRL AF Young, M. Rita L. TI Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer SO JOURNAL OF IMMUNOTHERAPY LA English DT Article DE oral cancer; OSCC; oral lesions; premalignant; vaccine ID CD34(+) PROGENITOR CELLS; NECK-CANCER; PROSTATE-CANCER; PRECANCEROUS LESIONS; CLINICAL-RESPONSES; GROWTH-FACTOR; T-CELL; HEAD; IMMUNOTHERAPY; EXPRESSION AB Select groups of premalignant oral lesions carry a high risk of development of secondary premalignant lesions and oral squamous cell carcinoma (OSCC). The goal of the present study was to determine the feasibility of using premalignant lesion-pulsed dendritic cells as a treatment option to prevent development of secondary lesions and development of OSCC. Mice that were treated with the carcinogen 4-nitroquinoline-l-oxide (4NQO) developed premalignant oral lesions and, subsequently, OSCC. Immunohistochemical analyses showed that these 4NQO-induced lesions and OSCC both overexpressed the tumor antigens epidermal growth factor receptor, RAGE and, to a lesser extent, MUC1. Because there was shared overexpression of tumor antigens on premalignant oral lesions and OSCC, dendritic cells pulsed with lysates of 4NQO-induced premalignant lesion cells were tested in vitro and in vivo for their capacity to stimulate T-cell reactivity to premalignant lesion cells and to OSCC. Spleen cells that were sensitized during coculture or in vivo with premalignant lesion-pulsed dendritic cells were cytolytic toward both premalignant lesion cells and OSCC, and secreted increased levels of interferon -gamma in response to challenge with premalignant lesion cells or OSCC as compared with spleen cells that were sensitized with keratinocyte-pulsed dendritic cells. Levels of CD8(+) Tcells and interferon-gamma release were also increased in lesions of mice that were vaccinated with premalignant lesion-pulsed dendritic cells. The mice that were vaccinated against premalignant lesions were also more resistant to OSCC challenge. These studies show the feasibility of using premalignant oral lesions to stimulate immune reactivity against both premalignant oral lesions and OSCC. C1 [Young, M. Rita L.] Ralph H Johnson Vet Affairs Hosp, Res Serv, Charleston, SC 29401 USA. [Young, M. Rita L.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Young, M. Rita L.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Young, MRL (reprint author), Ralph H Johnson Vet Affairs Hosp, Res Serv, 151,109 Bee St, Charleston, SC 29401 USA. EM rita.young@med.va.gov FU NCI NIH HHS [CA85266, CA97813] NR 33 TC 7 Z9 7 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1524-9557 J9 J IMMUNOTHER JI J. Immunother. PD FEB-MAR PY 2008 VL 31 IS 2 BP 148 EP 156 PG 9 WC Oncology; Immunology; Medicine, Research & Experimental SC Oncology; Immunology; Research & Experimental Medicine GA 266KE UT WOS:000253433300004 PM 18481384 ER PT J AU Sun, W Xu, RJ Hu, W Jin, JF Crellin, HA Bielawski, J Szulc, ZM Thiers, BH Obeid, LM Mao, CG AF Sun, Wei Xu, Ruijuan Hu, Wei Jin, Junfei Crellin, Heather A. Bielawski, Jacek Szulc, Zdzislaw M. Thiers, Bruce H. Obeid, Lina M. Mao, Cungui TI Upregulation of the human alkaline ceramidase 1 and acid ceramidase mediates calcium-induced differentiation of epidermal keratinocytes SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID CULTURED HUMAN KERATINOCYTES; STEM-CELLS; SPHINGOMYELIN HYDROLYSIS; PROLIFERATION; SPHINGOSINE; APOPTOSIS; CLONING; SPHINGOLIPIDS; EXPRESSION; ENZYME AB Extracellular calcium (Ca-o(2+)) potently induces the growth arrest and differentiation of human epidermal keratinocytes (HEKs). We report that Ca-o(2+) markedly upregulates the human alkaline ceramidase 1 (haCER1) in HEKs; and its upregulation mediates the Cao2_-induced growth arrest and differentiation of HEKs. haCER1 is the human ortholog of mouse alkaline ceramidase 1 that we previously identified. haCER1 catalyzed the hydrolysis of very long-chain ceramides to generate sphingosine (SPH). This in vitro activity required Ca2+. Ectopic expression of haCER1 in HEKs decreased the levels of D-e-C-24:1-ceramide and D-e-C-24:0-ceramide but elevated the levels of both SPH and its phosphate (S1P), whereas RNA interference-mediated knockdown of haCER1 caused the opposite effects on the levels of these sphingolipids in HEKs. Similar to haCER1 overexpression, Ca-o(2+) increased the levels of SPH and S1P, and this was attenuated by haCER1 knockdown. haCER1 knockdown also inhibited the Ca-o(2+)-induced growth arrest of HEKs and the Ca-o(2+)-induced expression of keratin 1 and involucrin in HEKs. In addition, the acid ceramidase (AC) was also upregulated by Ca-o(2+); and its knockdown attenuated the Ca-o(2+)-induced expression of keratin 1 and involucrin in HEKs. These results strongly suggest that upregulation of haCER1 and AC mediates the Ca-o(2+)-induced growth arrest and differentiation of HEKs by generating SPH and S1P. C1 [Sun, Wei; Xu, Ruijuan; Hu, Wei; Jin, Junfei; Crellin, Heather A.; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Div Gen Internal Med, Dept Med, Charleston, SC 29425 USA. [Bielawski, Jacek; Szulc, Zdzislaw M.; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Thiers, Bruce H.; Mao, Cungui] Med Univ S Carolina, Dept Dermatol, Charleston, SC 29425 USA. [Obeid, Lina M.] Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA. RP Mao, CG (reprint author), Med Univ S Carolina, Div Gen Internal Med, Dept Med, 114 Doughty St,Room 646,STD,POB 250779, Charleston, SC 29425 USA. EM maoc@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [R01CA104834]; NCRR NIH HHS [P20RR017677] NR 28 TC 38 Z9 39 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD FEB PY 2008 VL 128 IS 2 BP 389 EP 397 DI 10.1038/sj.jid.5701025 PG 9 WC Dermatology SC Dermatology GA 252NH UT WOS:000252452700019 PM 17713573 ER PT J AU Grubaugh, AL Cain, GD Elhai, JD Patrick, SL Frueh, BC AF Grubaugh, Anouk L. Cain, Gregory D. Elhai, Jon D. Patrick, Sarah L. Frueh, B. Christopher TI Attitudes toward medical and mental health care delivered via Telehealth applications among rural and urban primary care patients SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Telehealth; primary care; telepsychiatry; telepsychology; rural health; access to care; patient attitudes; posttraumatic stress disorder (PTSD). ID POSTTRAUMATIC-STRESS-DISORDER; TELEPSYCHIATRY; OUTCOMES; ISSUES AB Adequate health care services are often not available in rural and remote areas, and this problem is expected to grow worse in the near future. "Telehealth" interventions represent a strategy for addressing access to care problems. We examined and compared attitudes toward medical and mental health care delivered via telehealth applications among adult rural (n=112) and urban (n=78) primary care patients. We also examined attitudes toward telehealth applications among a subset of patients with posttraumatic stress disorder (PTSD) - a group likely in need of specialized services. Both urban and rural patients were receptive to receiving medical and psychiatric services via telehealth. There were few meaningful differences across variables between urban and rural patients, and there were no meaningful differences by PTSD status. These findings support the feasibility of telehealth applications, particularly for rural patients who may not otherwise receive needed services. C1 [Grubaugh, Anouk L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Grubaugh, Anouk L.; Cain, Gregory D.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Elhai, Jon D.] Univ S Dakota, Disaster Mental Hlth Inst, Vermillion, SD 57069 USA. [Patrick, Sarah L.] Univ S Dakota, Ctr Rural Hlth Improvement, Sch Med, Sioux Falls, SD USA. [Patrick, Sarah L.] Univ S Dakota, Dept Family Med, Sch Med, Sioux Falls, SD USA. [Frueh, B. Christopher] Univ Hawaii, Hilo, HI 96720 USA. RP Grubaugh, AL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, POB 250861,67 President St, Charleston, SC 29425 USA. EM grubaugh@musc.edu NR 18 TC 31 Z9 31 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD FEB PY 2008 VL 196 IS 2 BP 166 EP 170 DI 10.1097/NMD.0b013e318162aa2d PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264FO UT WOS:000253272500013 PM 18277227 ER PT J AU Lacan, G De Salles, AAF Gorgulho, AA Krahl, SE Frighetto, L Behnke, EJ Melega, WP AF Lacan, Goran De Salles, Antonio A. F. Gorgulho, Alessandra A. Krahl, Scott E. Frighetto, Leonardo Behnke, Eric J. Melega, William P. TI Modulation of food intake following deep brain stimulation of the ventromedial hypothalamus in the vervet monkey SO JOURNAL OF NEUROSURGERY LA English DT Article DE anorexia nervosa; feeding behavior; nonhuman primate; obesity ID GLOBUS-PALLIDUS INTERNUS; PARKINSONS-DISEASE; ELECTRICAL-STIMULATION; CLUSTER HEADACHE; POSTERIOR HYPOTHALAMUS; SUBSTANTIA-NIGRA; SEXUAL-BEHAVIOR; PEDUNCULOPONTINE NUCLEUS; DOPAMINERGIC DEFICITS; LATERAL HYPOTHALAMUS AB Object. Deep brain stimulation (DBS) has become an effective therapy for an increasing number of brain disorders. Recently demonstrated DBS of the posterior hypothalamus as a safe treatment for chronic intractable cluster headaches has drawn attention to this target, which is involved in the regulation of diverse autonomic functions and feeding behavior through complex integrative mechanisms. In this study, the authors assessed the feasibility of ventromedial hypothalamus (VMH) DBS in freely moving vervet monkeys to modulate food intake as a model for the potential treatment of eating disorders. Methods. Deep brain stimulation electrodes were bilaterally implanted into the VMH of 2 adult male vervet monkeys by using the stereotactic techniques utilized in DBS in humans. Stimulators were implanted subcutaneously on the upper back, allowing ready access to program stimulation parameters while the animal remained conscious and freely moving. In anesthetized animals, intraoperatively and 6-10 weeks postsurgery, VMH DBS parameters were selected according to minimal cardiovascular and autonomic nervous system responses. Thereafter, conscious animals were subjected to 2 cycles of VMH DBS for periods of 8 and 3 days, and food intake and behavior were monitored. Animals were then killed for histological verification of probe placement. Results. During VMH DBS, total food consumption increased. The 3-month bilateral implant of electrodes and subsequent periods of high-frequency VMH stimulation did not result in significant adverse behavioral effects. Conclusions. This is the first study in which techniques of hypothalamic DBS in humans have been applied in freely moving nonhuman primates. Future studies can now be conducted to determine whether VMH DBS can change hypothalamic responsivity to endocrine signals associated with adiposity for long-term modulation of food intake. C1 [De Salles, Antonio A. F.; Gorgulho, Alessandra A.; Krahl, Scott E.; Frighetto, Leonardo; Behnke, Eric J.] Univ Calif Los Angeles, David Gaffen Sch Med, Dept Surg, Div Neurosurg, Los Angeles, CA 90024 USA. [Lacan, Goran; Melega, William P.] Univ Calif Los Angeles, David Gaffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA. [De Salles, Antonio A. F.; Krahl, Scott E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP De Salles, AAF (reprint author), 200 UCLA Med Plaza,Suite 504, Los Angeles, CA 90095 USA. EM adesalles@mednet.ucla.edu NR 56 TC 28 Z9 29 U1 0 U2 4 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD FEB PY 2008 VL 108 IS 2 BP 336 EP 342 DI 10.3171/JNS/2008/108/2/0336 PG 7 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 259JB UT WOS:000252934500020 PM 18240931 ER PT J AU Casarett, D Pickard, A Bailey, FA Ritchie, C Furman, C Rosenfeld, K Shreve, S Shea, JA AF Casarett, David Pickard, Amy Bailey, F. Amos Ritchie, Christine Furman, Christian Rosenfeld, Ken Shreve, Scott Shea, Judy A. TI Important aspects of end-of-life care among veterans: Implications for measurement and quality improvement SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE end-of-life care; quality improvement; measurement; veterans ID ILL HOSPITALIZED ADULTS; FAMILY-MEMBERS; CARDIOPULMONARY-RESUSCITATION; ADVANCE DIRECTIVES; SYMPTOM ASSESSMENT; CANCER-PATIENTS; PATIENT; PREFERENCES; SATISFACTION; VALIDATION AB To identify aspects of end-of-life care in the U.S. Department of Veterans Affairs (VA) health care system that are not assessed by existing survey instruments and to identify issues that may be unique to veterans, telephone interviews using open-ended questions were conducted with family members of veterans who had received care from a VA facility in the last month of life. Responses were compared to validated end-of-life care assessment instruments in common use. The study took place in four VA medical centers and one family member per patient was invited to participate, selected from medical records using predefined eligibility criteria. These family members were asked to describe positive and negative aspects of the care the veteran received in the last month of life. Interview questions elicited perceptions of care both at VA sites and at non-VA sites. Family reports were coded and compared with items in five existing prospective and retrospective instruments that assess the quality of care that patients receive near the end of life. Interviews were completed with 66 family members and revealed 384 codes describing both positive and negative aspects of care during the last month of life. Almost half of these codes were not represented in any of the five reference instruments (n = 174; 45%). These codes, some of which are unique to the veteran population, were grouped into eight categories: information about VA benefits (n = 36; 55%), inpatient care (n = 36; 55%), access to care (n = 33; 50%), transitions in care (n = 32; 48%), care that the veteran received at the time of death (n = 31; 47%), home care (n = 26; 40%), health care facilities (n = 12; 18%), and mistakes and complications (n = 18; 27%). Although most of the reference instruments assessed some aspect of these categories, they did not fully capture the experiences described by our respondents. These data suggest that many aspects of veterans' end-of-life care that are important to their families are-not assessed by existing survey instruments. VA efforts to evaluate end-of-life care for veterans should not only measure common aspects of care (e.g., pain management), but also examine performance in areas that are more specific to the veteran population. C1 [Casarett, David] Childrens Hosp, Philadelphia, PA 19104 USA. [Casarett, David; Pickard, Amy; Shea, Judy A.] Philadelphia Vet Affairs Ctr Hlth Equity Res, Philadelphia, PA USA. [Bailey, F. Amos; Ritchie, Christine] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Furman, Christian] Louisville Vet Affairs Med Ctr, Louisville, KY USA. [Rosenfeld, Ken] Greater Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. [Shreve, Scott] Lebanon Vet Affairs Ctr, Lebanon, PA USA. RP Casarett, D (reprint author), Childrens Hosp, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu NR 42 TC 20 Z9 20 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2008 VL 35 IS 2 BP 115 EP 125 DI 10.1016/j.jpainsymman.2007.03.008 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 262YZ UT WOS:000253186100001 PM 18053680 ER PT J AU Kellogg, DL Zhao, JL Wu, Y AF Kellogg, Dean L., Jr. Zhao, Joan L. Wu, Yubo TI Neuronal nitric oxide synthase control mechanisms in the cutaneous vasculature of humans in vivo SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID SYMPATHETIC VASODILATOR NERVES; VASOACTIVE-INTESTINAL-PEPTIDE; SKIN BLOOD-FLOW; HEAT-STRESS; ACTIVE VASODILATION; 7-NITRO INDAZOLE; SWEAT GLANDS; BODY; INHIBITION; ACETYLCHOLINE AB The physiological roles of constituitively expressed nitric oxide synthase (NOS) isoforms in humans, in Vivo, are unknown. Cutaneous vasodilatation during both central nervous system-mediated, thermoregulatory reflex responses to whole-body heat stress and during peripheral axon reflex-mediated, local responses to skin warming in humans depend on nitric oxide (NO) generation by constituitively expressed NOS of uncertain isoform. We hypothesized that neuronal NOS (nNOS, NOS 1) effects cutaneous vasodilatation during whole-body heat stress, but not during local skin warming. We examined the effects of the nNOS inhibitor 7-nitroindazole (7-NI) administered by intradermal microdialysis on vasodilatation induced by whole-body heat stress or local skin warming. Skin blood flow (SkBF) was monitored by laser-Doppler flowmetry (LDF). Blood pressure (MAP) was monitored and cutaneous vascular conductance calculated (CVC = LDF/MAP). In protocol 1, whole-body heat stress was induced with water-perfused suits. In protocol 2, local skin warming was induced through local warming units at LDF sites. At the end of each protocol, 56 mM sodium nitroprusside was perfused at microdialysis sites to raise SkBF to maximal levels for data normalization. 7-NI significantly attenuated CVC increases during whole-body heat stress (P < 0.05), but had no effect on CVC increases induced by local skin warming (P > 0.05). These diametrically opposite effects of 7-NI on two NO-dependent processes verify selective nNOS antagonism, thus proving that the nNOS isoform affects NO increases and hence vasodilatation during centrally mediated, reflex responses to whole-body heat stress, but not during locally mediated, axon reflex responses to local skin warming. We conclude that the constituitively expressed nNOS isoform has distinct physiological roles in cardiovascular control mechanisms in humans, in vivo. C1 [Zhao, Joan L.; Wu, Yubo] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78229 USA. [Kellogg, Dean L., Jr.] Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Kellogg, DL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr & Gerontol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kelloggd@uthscsa.edu NR 60 TC 66 Z9 69 U1 1 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD FEB 1 PY 2008 VL 586 IS 3 BP 847 EP 857 DI 10.1113/jphysiol.2007.144642 PG 11 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 265PL UT WOS:000253373300018 PM 18048451 ER PT J AU Pan, S Rush, J Peskind, ER Galasko, D Chung, K Quinn, J Jankovic, J Leverenz, JB Zabetian, C Pan, C Wang, Y Oh, JH Gao, J Zhang, JP Montine, T Zhang, J AF Pan, Sheng Rush, John Peskind, Elaine R. Galasko, Douglas Chung, Kathryn Quinn, Joseph Jankovic, Joseph Leverenz, James B. Zabetian, Cyrus Pan, Catherine Wang, Yan Oh, Jung Hun Gao, Jean Zhang, Jianpeng Montine, Thomas Zhang, Jing TI Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE mass spectrometry; quantitative proteomics; matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (MALDI TOF/TOF); cerebrospinal fluid; biomarker; aging; Parkinson's disease; Alzheimer's disease ID PROTEIN BIOMARKER DISCOVERY; NOVO SEQUENCE-ANALYSIS; ION TRAP-TIME; FRAGMENTATION CHARACTERISTICS; DESORPTION IONIZATION; CONTAINING PEPTIDES; ALZHEIMER-DISEASE; HIGH-RESOLUTION; MS/MS ANALYSIS; FTICR-MS AB Targeted quantitative proteomics by mass spectrometry aims to selectively detect one or a panel of peptides/proteins in a complex sample and is particularly appealing for novel biomarker verification/validation because it does not require specific antibodies. Here, we demonstrated the application of targeted quantitative proteomics in searching, identifying, and quantifying selected peptides in human cerebrospinal spinal fluid (CSF) using a matrix-assisted laser desorption/ ionization time-of-flight tandem mass spectrometer (MALDI TOF/TOF)-based platform. The approach involved two major components: the use of isotopic-labeled synthetic peptides as references for targeted identification and quantification and a highly selective mass spectrometric analysis based on the unique characteristics of the MALDI instrument. The platform provides high confidence for targeted peptide detection in a complex system and can potentially be developed into a high-throughput system. Using the liquid chromatography (LC) MALDI TOF/TOF platform and the complementary identification strategy, we were able to selectively identify and quantify a panel of targeted peptides in the whole proteome of CSF without prior depletion of abundant proteins. The effectiveness and robustness of the approach associated with different sample complexity, sample preparation strategies, as well as mass spectrometric quantification were evaluated. Other issues related to chromatography separation and the feasibility for high-throughput analysis were also discussed. Finally, we applied targeted quantitative proteomics to analyze a subset of previously identified candidate markers in CSF samples of patients with Parkinson's disease (PD) at different stages and Alzheimer's disease (AD) along with normal controls. C1 [Pan, Sheng; Pan, Catherine; Wang, Yan; Zhang, Jianpeng; Montine, Thomas; Zhang, Jing] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Rush, John] Cell Signaling Technol Inc, Danvers, MA 01915 USA. [Peskind, Elaine R.; Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Chung, Kathryn; Quinn, Joseph] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Quinn, Joseph] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Leverenz, James B.; Zabetian, Cyrus] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, James B.; Zabetian, Cyrus] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA 98108 USA. [Zabetian, Cyrus] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Oh, Jung Hun; Gao, Jean] Univ Texas Arlington, Dept Comp Sci & Engn, Arlington, TX 76019 USA. RP Pan, S (reprint author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA. EM span@u.washington.edu; zhangj@u.washington.edu OI Zabetian, Cyrus/0000-0002-7739-4306 FU NIA NIH HHS [AG025327, AG05136, NIA AG05136]; NIEHS NIH HHS [ES012703]; NINDS NIH HHS [NS060252] NR 69 TC 46 Z9 50 U1 1 U2 17 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD FEB PY 2008 VL 7 IS 2 BP 720 EP 730 DI 10.1021/pr700630x PG 11 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 258JO UT WOS:000252864400025 PM 18186601 ER PT J AU Logemanin, JA Gensler, G Robbins, J Lindblad, AS Brandt, D Hind, JA Kosek, S Dikernan, K Kazandiian, M Grarnigna, GD Lundy, D McGarvey-Toler, S Gardner, PJM AF Logemanin, Jeri A. Gensler, Gary Robbins, JoAnne Lindblad, Anne S. Brandt, Diane Hind, Jacqueline A. Kosek, Steven Dikernan, Karen Kazandiian, Marto Grarnigna, Gary D. Lundy, Donna McGarvey-Toler, Susan Gardner, Patricia J. Miller TI A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article DE dementia; Parkinson's disease; aspiration; thickened liquids; posture ID SPEECH-LANGUAGE PATHOLOGIST; ALZHEIMERS-DISEASE; THICKENED LIQUIDS; PRACTICE PATTERNS; HEAD ROTATION; DYSPHAGIA; SWALLOW; MANAGEMENT; MANEUVERS; SEVERITY AB Purpose: This study was designed to identify which of 3 treatments for aspiration on thin liquids-chin-down posture, nectar-thickened liquids, or honey-thickened liquids-results in the most successful immediate elimination of aspiration on thin liquids during the videofluorographic swallow study in patients with dementia and/or Parkinson's disease. Method: This randomized clinical trial included 711 patients ages 50 to 95 years who aspirated on thin liquids as assessed videofluorographically. All patients received all 3 interventions in a randomly assigned order during the videofluorographic swallow study. Results: immediate elimination of aspiration on thin liquids occurred most often with honey-thickened liquids for patients in each diagnostic category, followed by nectar-thickened liquids and chin-down posture. Patients with most severe dementia exhibited least effectiveness on all interventions. Patient preference was best for chin-down posture followed closely by nectar-thickened liquids. Conclusion: To identify best short-term intervention to prevent aspiration of thin liquid in patients with dementia and/or Parkinson's disease, a videofluorographic swallow assessment is needed. Evidence-based practice requires taking patient preference into account when designing a dysphagic patient's management plan. The longer-term impact of short-term prevention of aspiration requires further study. C1 [Logemanin, Jeri A.] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL 60208 USA. [Gensler, Gary; Lindblad, Anne S.; Brandt, Diane] EMMES Corp, Rockville, MD USA. [Robbins, JoAnne] Univ Wisconsin, Madison, WI USA. [Hind, Jacqueline A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Kosek, Steven] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Dikernan, Karen; Kazandiian, Marto] New York Hosp Med Ctr, Flushing, NY USA. [Grarnigna, Gary D.] VA Boston Healthcare Syst, Roxbury, MA USA. [Lundy, Donna] Univ Miami, Med Ctr, Miami, FL 33152 USA. [McGarvey-Toler, Susan] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Gardner, Patricia J. Miller] Amer Speech Language Hearing Assoc, Clin Trials Res Grp, Rockville, MD USA. RP Logemanin, JA (reprint author), Northwestern Univ, Dept Commun Sci & Disorders, 2240 Campus Dr,3-358, Evanston, IL 60208 USA. EM j-logemann@northwestem.edu FU NCRR NIH HHS [M01 RR003186-190295, M01 RR003186]; NIDCD NIH HHS [U01 DC003206, U01 DC003206-07] NR 38 TC 105 Z9 110 U1 2 U2 18 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD FEB PY 2008 VL 51 IS 1 BP 173 EP 183 DI 10.1044/1092-4388(2008/013) PG 11 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 265PN UT WOS:000253373500013 PM 18230864 ER PT J AU Raymer, AM Beeson, P Holland, A Kendall, D Maher, LM Martin, N Murray, L Rose, M Thompson, CK Turkstra, L Altmann, L Boyle, M Conway, T Hula, W Kearns, K Rapp, B Simmons-Mackie, N Rothi, LIG AF Raymer, Anastasia M. Beeson, Pelogie Holland, Audrey Kendall, Diane Maher, Lynn M. Martin, Nadine Murray, Laura Rose, Miranda Thompson, Cynthia K. Turkstra, Lyn Altmann, Lori Boyle, Mary Conway, Tim Hula, William Kearns, Kevin Rapp, Brenda Simmons-Mackie, Nina Rothi, Leslie J. Gonzalez TI Translational research in aphasia: from neuroscience to neurorehabilitation SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Review DE aphasia; rehabilitation; plasticity ID INDUCED MOVEMENT THERAPY; LEXICAL ACCESS; POSTSTROKE APHASIA; SPEECH PRODUCTION; BRAIN PLASTICITY; CORTICAL REORGANIZATION; LANGUAGE TREATMENT; NONFLUENT APHASIA; RIGHT-HEMISPHERE; FLUENT APHASIA AB Purpose: In this article, the authors encapsulate discussions of the Language Work Group that took place as part of the Workshop in Plasticity/NeuroRehabilitation Research at the University of Florida in April 2005. Method: In this narrative review, they define neuroplasticity and review studies that demonstrate neural changes associated with aphasia recovery and treatment. The authors then summarize basic science evidence from animals, human cognition, and computational neuroscience that is relevant to aphasia treatment research. They then turn to the aphasia treatment literature in which evidence exists to support several of the neuroscience principles. Conclusion: Despite the extant aphasia treatment literature, many questions remain regarding how neuroscience principles can be manipulated to maximize aphasia recovery and treatment. They propose a framework, incorporating some of these principles, that may serve as a potential roadmap for future investigations of aphasia treatment and recovery. In addition to translational investigations from basic to clinical science, the authors propose several areas in which translation can occur from clinical to basic science to contribute to the fundamental knowledge base of neurorehabilitation. This article is intended to reinvigorate interest in delineating the factors influencing successful recovery from aphasia through basic, translational, and clinical research. C1 [Raymer, Anastasia M.] Old Dominion Univ, Norfolk, VA 23529 USA. [Beeson, Pelogie; Holland, Audrey] Univ Arizona, Tucson, AZ USA. [Kendall, Diane; Rothi, Leslie J. Gonzalez] VA Brain Rehabil Res Ctr, Gainesville, FL USA. [Kendall, Diane; Altmann, Lori; Conway, Tim; Rothi, Leslie J. Gonzalez] Univ Florida, Gainesville, FL USA. [Maher, Lynn M.] DeBakey VA Med Ctr, Houston, TX USA. [Turkstra, Lyn] Baylor Coll Med, Houston, TX 77030 USA. [Martin, Nadine] Temple Univ, Philadelphia, PA 19122 USA. [Murray, Laura] Indiana Univ, Bloomington, IN 47405 USA. [Rose, Miranda] La Trobe Univ, Melbourne, Vic, Australia. [Thompson, Cynthia K.] Northwestern Univ, Chicago, IL 60611 USA. [Turkstra, Lyn] Univ Wisconsin, Madison, WI USA. RP Raymer, AM (reprint author), Old Dominion Univ, 110 Child Study Ctr, Norfolk, VA 23529 USA. EM sraymer@odu.edu RI Maher, Lynn/L-7074-2015; Rose, Miranda/P-7995-2015 OI Rose, Miranda/0000-0002-8892-0965 NR 132 TC 60 Z9 65 U1 7 U2 38 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD FEB PY 2008 VL 51 IS 1 BP S259 EP S275 DI 10.1044/1092-4388(2008/020) PG 17 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 265PN UT WOS:000253373500020 PM 18230850 ER PT J AU Bilimoria, KY Stewart, AK Palis, BE Bentrern, DJ Talamonti, MS Ko, CY AF Bilimoria, Karl Y. Stewart, Andrew K. Palis, Bryan E. Bentrern, David J. Talamonti, Mark S. Ko, Clifford Y. TI Adequacy and importance of lymph node evaluation for colon cancer in the elderly SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID COLORECTAL-CANCER; MINIMUM NUMBER; STAGE-III; ADJUVANT CHEMOTHERAPY; HOSPITAL VOLUME; SURVIVAL; SURGERY; RESECTION; RECOMMENDATIONS; PROGNOSIS AB BACKGROUND: Studies have demonstrated improved survival when 12 or more nodes are examined for colon cancer. The elderly comprise a major proportion of patients with colon cancer, but it is unknown if examination of 12 or more nodes is appropriate for older patients. Our objective was to assess differences in lymph node evaluation by age and to determine whether adequate nodal evaluation (12 or more nodes) is associated with improved survival in the elderly. STUDY DESIGN: From the National Cancer Data Base (1998 to 2004), we identified 142,009 N0M0 patients who underwent colectomy for adenocarcinoma. Logistic regression was used to determine whether age is associated with adequate nodal examination. Multivariable modeling stratified by age was used to determine whether evaluation of 12 or more nodes is associated with improved survival. RESULTS: The median number of nodes examined was similar with increasing age (less than 67 years: 11 nodes; 67 to 78 years: 10 nodes; greater than 78 years: 10 nodes). Patients older than 78 years underwent evaluation of 12 or more nodes less frequently than patients less than 67 years old: 47.7% versus 41.4% (p < 0.0001). When adjusted for patient, tumor, treatment, and hospital characteristics, patients greater than 78 years were less likely to have 12 or more nodes examined (odds ratio 0.68, 95% CI 0.65 to 0.70, p < 0.0001). Regardless of age, patients who had 12 or more nodes examined had better survival than those with less than 12 nodes examined (p < 0.0001). CONCLUSIONS: The elderly account for nearly half of patients with colon cancer. Older patients undergo inadequate lymph node evaluation more frequently than younger patients do. Improving lymph node evaluation will result in more accurate pathologic staging for the elderly. C1 [Bilimoria, Karl Y.; Bentrern, David J.; Talamonti, Mark S.] NW Mem Hosp, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Stewart, Andrew K.; Palis, Bryan E.; Ko, Clifford Y.] Amer Coll Surg, Canc Program, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), NW Mem Hosp, Dept Surg, Feinberg Sch Med, 251 E Huron St,Galter 3-150, Chicago, IL 60611 USA. NR 30 TC 45 Z9 45 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD FEB PY 2008 VL 206 IS 2 BP 247 EP 254 DI 10.1016/j.jamcollsurg.2007.07.044 PG 8 WC Surgery SC Surgery GA 257UA UT WOS:000252822900006 PM 18222376 ER PT J AU Gray, SL Anderson, ML Crane, PK Breitner, JCS McCormick, W Bowen, JD Teri, L Larson, E AF Gray, Shelly L. Anderson, Melissa L. Crane, Paul K. Breitner, John C. S. McCormick, Wayne Bowen, James D. Teri, Linda Larson, Eric TI Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT Alzheimers-Associations International Conference on Prevention of Dementia CY JUN 09-12, 2007 CL Washington, DC SP Alzheimers Assoc DE Alzheimer's disease; antioxidant supplements; pharmacoepidemiology ID DIETARY-INTAKE; COGNITIVE FUNCTION; APOLIPOPROTEIN-E; CONTROLLED-TRIAL; METAANALYSIS; TOCOPHEROL; MORTALITY AB OBJECTIVES: To examine whether use of vitamins C or E alone or in combination was associated with lower incidence of dementia or Alzheimer's disease (AD). DESIGN: Prospective cohort study. SETTING: Group Health Cooperative, Seattle, Washington. PARTICIPANTS: Two thousand nine hundred sixty-nine participants aged 65 and older without cognitive impairment at baseline in the Adult Changes in Thought study. MEASUREMENTS: Participants were followed biennially to identify incident dementia and AD diagnosed according to standard criteria. Participants were considered to be users of vitamins C or E if they self-reported use for at least 1 week during the month before baseline. RESULTS: Over a mean follow-up +/- standard deviation of 5.5 +/- 2.7 years, 405 subjects developed dementia (289 developed AD). The use of vitamin E was not associated with dementia (adjusted hazard ratio (HR)=0.98, 95% confidence interval (CI)=0.77-1.25) or with AD (HR=1.04; 95% CI=0.78-1.39). No association was found between vitamin C alone (dementia: HR=0.90, 95% CI=0.71-1.13; AD: HR=0.95, 95% CI=0.72-1.25) or concurrent use of vitamin C and E (dementia: HR=0.93, 95% CI=0.72-1.20; AD: HR=1.00, 95% CI=0.73-1.35) and either outcome. CONCLUSION: In this study, the use of supplemental vitamin E and C, alone or in combination, did not reduce risk of AD or overall dementia over 5.5 years of follow-up. C1 [Gray, Shelly L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Crane, Paul K.; Breitner, John C. S.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [McCormick, Wayne] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Bowen, James D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Teri, Linda] Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA. [Teri, Linda] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Teri, Linda] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Anderson, Melissa L.; Larson, Eric] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. [Breitner, John C. S.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Gray, SL (reprint author), Univ Washington, Sch Pharm, Box 357630, Seattle, WA 98195 USA. EM slgray@u.washington.edu RI Crane, Paul/C-8623-2014 OI Crane, Paul/0000-0003-4278-7465 FU PHS HHS [AL 06781] NR 24 TC 49 Z9 53 U1 1 U2 12 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2008 VL 56 IS 2 BP 291 EP 295 DI 10.1111/j.1532-5415.2007.01531.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 256FO UT WOS:000252713300014 PM 18047492 ER PT J AU Krysan, K Lee, JM Dohadwala, M Gardner, BK Reckamp, KL Garon, E John, MS Sharma, S Dubinett, SM AF Krysan, Kostyantyn Lee, Jay M. Dohadwala, Mariam Gardner, Brian K. Reckamp, Karen L. Garon, Edward John, Maie St. Sharma, Sherven Dubinett, Steven M. TI Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance SO JOURNAL OF THORACIC ONCOLOGY LA English DT Editorial Material DE EGFR TK inhibitor; G-protein coupled receptors; inflammation; cyclooxygenase-2; PGE2; epithelial to mesenchymal transition; drug resistance; NSCLC ID CELL LUNG-CANCER; PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE-CELLS; CYCLOOXYGENASE-2-DEPENDENT INVASION; TUMOR PROGRESSION; EGF RECEPTOR; E-CADHERIN; GEFITINIB; TRANSACTIVATION; SENSITIVITY AB Inflammation is an important contributor to lung tumor development and progression. In addition, inflammatory signaling may promote epithelial to mesenchymal transition, development of aggressive metastatic tumor phenotypes, and play a role in resistance to targeted therapies. New insights in inflammatory signaling have led to the evaluation of combination therapies that target these specific pathways. In addition to developing the optimal combination of targeted agents, biomarker-based selection of patients who will likely benefit will be critical to the success of this strategy. Here we focus on the potential contribution of inflammatory mediator-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors. C1 [Krysan, Kostyantyn; Dohadwala, Mariam; Gardner, Brian K.; Garon, Edward] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Lee, Jay M.; John, Maie St.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Lee, Jay M.; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90095 USA. [Reckamp, Karen L.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA. [Sharma, Sherven; Dubinett, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. RP Krysan, K (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. EM KKrysan@mednet.ucla.edu OI Reckamp, Karen/0000-0002-9213-0325 FU NCI NIH HHS [5 K12 CA076095, K23 CA131577]; PHS HHS [P50 90388] NR 44 TC 26 Z9 27 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD FEB PY 2008 VL 3 IS 2 BP 107 EP 110 DI 10.1097/JTO.0b013e3181630ece PG 4 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 264MS UT WOS:000253292300003 PM 18303428 ER PT J AU Kudsk, KA Hermsen, JL Genton, L Faucher, L Gomez, FE AF Kudsk, Kenneth A. Hermsen, Joshua L. Genton, Laurence Faucher, Lee Gomez, F. Enrique TI Injury stimulates an innate respiratory immunoglobulin A immune response in humans SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 66th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma CY SEP 27-29, 2007 CL Las Vegas, NV SP Amer Assoc Surg Trauma DE immunoglobulin A; injury; mucosal immunity; innate immunity; respiratory tract ID NOSOCOMIAL PNEUMONIA; SEPTIC MORBIDITY; MUCOSAL IMMUNITY; ABDOMINAL-TRAUMA; LYMPHOID-TISSUE; TRACT IMMUNITY; NUTRITION; IGA; CYTOKINES; SEPSIS AB Background: Secretory immunoglobulin A (SIgA) is the specific immune antibacterial defense. Since pneumonia frequently complicates the course of trauma patients, we studied early airway immune responses after injury. Methods: Twelve severely injured, intubated (expected for >= 5 d) patients had tracheal and bilateral lung lavage (BAL) within 30 hours of injury (n=12). Epithelial lining fluid (ELF) volume and SIgA were measured by urea dilution and enzyme-linked immunosorbent assay (ELISA), respectively. Control BAL specimens were obtained from eight healthy elective surgical patients. Anatomically based comparisons were made between groups with Welch's impaired t test. To verify human data, 30 male mice received no injury (time 0, n=7) or injury with abdominal and neck incisions and were killed for airway IgA at 4 (n=7), 8 (n=8), and 24 (n=8) hours. Analysis of variance (ANOVA) and Fisher's protected least significant difference testing was used to analyze animal data. Results: Initial trauma patient SIgA concentration (SIgA/mL ELF) increased compared with control in the lungs bilaterally (p < 0.05 both right and left). ELF volume was significantly higher in the right lung (p=0.02) and just missed statistical significance (p=0.07) on the left. Mouse IgA increased 8 hours after stress (p < 0.05 versus 0, 4, and 24 hours) and returned to normal by 24 hours. Conclusion: A previously unrecognized innate human airway mucosal immune response with increased airway SIgA and ELF occurs after severe injury and is reproducible experimentally. This accessible, quantifiable human response allows study of clinical strategies to reduce infections via mucosal immune therapies. C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Kudsk, Kenneth A.; Hermsen, Joshua L.; Genton, Laurence; Faucher, Lee; Gomez, F. Enrique] Univ Wisconsin, Coll Med & Publ Hlth, Dept Surg, Madison, WI USA. [Genton, Laurence] Univ Hosp Geneva, Dept Clin Nutr, Geneva, Switzerland. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU NIGMS NIH HHS [R01 GM53439] NR 35 TC 14 Z9 15 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD FEB PY 2008 VL 64 IS 2 BP 316 EP 323 DI 10.1097/TA.0b013e3181627586 PG 8 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 264KV UT WOS:000253287100014 PM 18301193 ER PT J AU Turley, RS Hamilton, RJ Terris, MK Kane, CJ Aronson, WJ Presti, JC Amling, CL Freedland, SJ AF Turley, Ryan S. Hamilton, Robert J. Terris, Martha K. Kane, Christopher J. Aronson, William J. Presti, Joseph C., Jr. Amling, Christopher L. Freedland, Stephen J. CA SEARCH Database Study Grp TI Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: Results from the SEARCH database SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; biopsy; needle; prostatectomy ID CANCER; BIOPSY; GRADE; SPECIMENS; SIZE; RISK AB Purpose: Needle biopsy Gleason scores are often upgraded after pathological examination of the prostate following radical prostatectomy. It has been suggested that larger prostates would be associated with a greater risk of upgrading since a smaller percentage of the gland is sampled and, thus, the highest grade disease would more likely be missed, assuming an equal number of cores is taken from similar locations. We examined the likelihood of clinically relevant upgrading after radical prostatectomy as a function of transrectal ultrasound volume. Materials and Methods: We examined the association between transrectal ultrasound volume and upgrading (higher Gleason score category in the radical prostatectomy specimen than in the biopsy) in 586 men treated with radical prostatectomy between 1995 and 2006 in the SEARCH database who underwent at least a sextant biopsy using multivariate logistic regression. Transrectal ultrasound volume was categorized as 20 or less (in 71), 21 to 40 (in 334), 41 to 60 (in 123) and greater than 60 cm(3) (in 58). Gleason score was examined as a categorical variable of 2-6, 3 + 4 and 4 + 3 or greater. Results: Overall 138 cases (24%) were upgraded, 80 (14%) were downgraded, and 368 (62%) had identical biopsy and pathological Gleason sum groups. Larger transrectal ultrasound volume was significantly associated with decreased likelihood of upgrading (p trend < 0.001). For transrectal ultrasound volumes greater than 60, 41 to 60, 21 to 40 and 20 cm(3) or less, the estimated multivariate adjusted probability of upgrading was 12.6%, 27.5%, 36.4% and 45.5% for Gleason 2-6 tumors, and 6.1%, 8.5%, 18.9% and 20.9% for Gleason 3 + 4 tumors, respectively. Conclusions: Larger transrectal ultrasound volumes were at decreased risk for clinically significant upgrading after radical prostatectomy. This fact should be kept in mind when deciding on treatment decisions for men with apparently low grade prostate cancer on biopsy. C1 [Turley, Ryan S.; Hamilton, Robert J.; Freedland, Stephen J.] Duke Prostate Ctr, Div Urol Surg, Durham, NC USA. [Freedland, Stephen J.] Duke Univ, Sch Med, Dept Pathol, Div Urol, Durham, NC 27710 USA. [Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Kane, Christopher J.] Vet Affairs Med Ctr, Urol Sect, San Francisco, CA 94121 USA. [Kane, Christopher J.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. [Amling, Christopher L.] Univ Alabama, Div Urol, Birmingham, AL USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Dept Pathol, Div Urol, Box 2626, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Hamilton, Robert/0000-0002-6715-5934; Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [P50 CA92131-01A1, R01CA100938] NR 17 TC 37 Z9 41 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD FEB PY 2008 VL 179 IS 2 BP 523 EP 527 DI 10.1016/j.juro.2007.09.078 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 251JP UT WOS:000252369600036 PM 18076952 ER PT J AU Shoskes, DA Berger, R Elmi, A Landis, JR Propert, KJ Zeitlin, S AF Shoskes, Daniel A. Berger, Richard Elmi, Angelo Landis, J. Richard Propert, Kathleen J. Zeitlin, Scott CA Chronic Prostatitis Collaborative TI Muscle tenderness in men with chronic prostatitis/chronic pelvic pain syndrome: The chronic prostatitis cohort study SO JOURNAL OF UROLOGY LA English DT Article DE prostatitis; pelvic pain AB Purpose: Myofascial pain is a possible etiology for category III chronic prostatitis/chronic pelvic pain syndrome, either secondary to infection/inflammation or as the primary cause. We documented tenderness on physical examination in a large multicenter cohort of patients with chronic pelvic pain syndrome and compared to controls. Materials and Methods: Data were reviewed from the National Institutes of Health Chronic Prostatitis Cohort study on 384 men with chronic pelvic pain syndrome and 121 asymptomatic controls who had complete unblinded physical examination data from 7 clinical centers between October 1998 and August 2001. Tenderness in 11 sites including prostate, genitals, abdomen and pelvic floor together with prostate size and consistency was evaluated. Data were correlated with cultures and symptoms. Results: Overall 51% of patients with chronic pelvic pain syndrome and 7% of controls had any tenderness. The most common site was prostate (41% chronic pelvic pain syndrome, 5% controls), followed by external and internal pelvic floor (13% and 14% chronic pelvic pain syndrome, 0 controls) and suprapubic area (9% chronic pelvic pain syndrome, 0 controls). Of patients with chronic pelvic pain syndrome 25% had 1 tender site, 11% had 2 and 6% had 3 tender sites. Tenderness did not correlate with inflammation or infection in the prostate fluid. Prostate consistency was normal in 79% of patients with chronic pelvic pain syndrome and in 95% of controls, and did not correlate with symptom severity. Patients with chronic pelvic pain syndrome with any tenderness had significantly higher Chronic Prostatitis Symptom Index scores at baseline and at 1 year (24.1 vs 21.2 and 20.2 vs 17.5, p < 0.0001) compared to patients without tenderness. Conclusions: Abdominal/pelvic tenderness is present in half of the patients with chronic pelvic pain syndrome but only 7% of controls. Extraprostatic tenderness may identify a cohort of patients with a neuromuscular source of pain. C1 [Shoskes, Daniel A.] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44915 USA. [Berger, Richard] Univ Washington, Seattle, WA 98195 USA. [Elmi, Angelo; Landis, J. Richard; Propert, Kathleen J.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Zeitlin, Scott] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [Zeitlin, Scott] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Shoskes, DA (reprint author), Cleveland Clin, Glickman Urol & Kidney Inst, 9500 Euclid Ave,Desk A100, Cleveland, OH 44915 USA. EM dshoskes@mac.com RI Landis, J. Richard/A-9330-2010 OI Landis, J Richard/0000-0001-8099-0988 FU NIDDK NIH HHS [R01 DK53732, R01 DK053732, R01 DK053752, R01 DK053752-03S1, R01 DK53730, R01 DK53734, R01 DK53736, R01 DK53746, R01 DK53752, U01 DK065189-04] NR 7 TC 34 Z9 39 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD FEB PY 2008 VL 179 IS 2 BP 556 EP 560 DI 10.1016/j.juro.2007.09.088 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 251JP UT WOS:000252369600045 PM 18082223 ER PT J AU Fuhr, P Martinez, B Williams, M AF Fuhr, Patti Martinez, Bethany Williams, Michael TI Caregivers with visual impairments: A preliminary study SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS LA English DT Editorial Material ID QUALITY-OF-LIFE; MACULAR DEGENERATION; OLDER-ADULTS; VISION REHABILITATION; CARE; SATISFACTION; POPULATION; DISTRESS; PATTERNS; OUTCOMES C1 [Fuhr, Patti; Martinez, Bethany] Birmingham VA Med Ctr, Low Vis Optometry Dept, Birmingham, AL 35233 USA. [Williams, Michael] Atlanta VA Med Ctr, Rehabil Res & Dev Ctr Excellence Aging Vet Vis Lo, Decatur, GA 30033 USA. RP Fuhr, P (reprint author), Birmingham VA Med Ctr, Low Vis Optometry Dept, Room 124,700 S 19th St, Birmingham, AL 35233 USA. EM patti.fuhr@va.gov; bethany.martinez@va.gov; mike.williams2@va.gov NR 37 TC 3 Z9 3 U1 1 U2 2 PU AMER FOUNDATION BLIND PI NEW YORK PA J VISUAL IMPAIRMENT BLINDNESS 11 PENN PLAZA SUITE 300, NEW YORK, NY 10001 USA SN 0145-482X J9 J VISUAL IMPAIR BLIN JI J. Vis. Impair. Blind. PD FEB PY 2008 VL 102 IS 2 BP 89 EP 96 PG 8 WC Rehabilitation SC Rehabilitation GA 268CN UT WOS:000253555600005 ER PT J AU Singh, N Wannstedt, C Keyes, L Mayher, D Tickerhoof, L Akoad, M Wagener, MM Cacciarelli, TV AF Singh, Nina Wannstedt, Cheryl Keyes, Lois Mayher, Debra Tickerhoof, Lisa Akoad, Mohamed Wagener, Marilyn M. Cacciarelli, Thomas V. TI Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts SO LIVER TRANSPLANTATION LA English DT Article ID DISEASE; INFECTION; PROPHYLAXIS; GANCICLOVIR; PREVENTION; EFFICACY; METAANALYSIS; IMPACT AB The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient-negative/donor-positive (R-/D+) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institution since July 2001, 36 (19.2%) belonged to the R-/D+ group. Surveillance tests for CMV were performed on all patients at weeks 2, 4, 6, 8, 10,12, and 16. In all, 27 patients with asymptomatic viremia received preemptive therapy with valganciclovir. At a total follow-up of 62.8 patient years (median: 19 months, range: 3 months to 5.6 years), no episodes of CMV disease were documented in these patients. The incidence of rejection, retransplantation, and bacterial or fungal infections and the probability of survival did not differ for R-/D+ patients and all non-R-/D+ patients treated preemptively with valganciclovir (P > 0.20 for all variables). Thus, preemptive therapy with valganciclovir in R-/D+ patients was not associated with CMV disease during the period of surveillance monitoring or at anytime thereafter (late-onset CMV disease). The indirect outcomes with the use of valganciclovir in R-/D+ patients were comparable to the outcomes of other subgroups of liver transplant recipients receiving preemptive therapy. C1 [Singh, Nina; Wagener, Marilyn M.] VA Pittsburgh Healthcare Syst, Dept Med, Div Infect Dis, Pittsburgh, PA USA. [Wannstedt, Cheryl; Keyes, Lois; Mayher, Debra; Tickerhoof, Lisa; Akoad, Mohamed; Cacciarelli, Thomas V.] VA Pittsburgh Healthcare Syst, Dept Surg, Div Liver Transplant, Pittsburgh, PA USA. RP Singh, N (reprint author), Vet Adm Med Ctr, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu NR 17 TC 39 Z9 42 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD FEB PY 2008 VL 14 IS 2 BP 240 EP 244 DI 10.1002/lt.21362 PG 5 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 260WA UT WOS:000253039900020 PM 18236404 ER PT J AU Helmer, DA Tseng, CL Rajan, M Crystal, S Shen, YJ Miller, DR Safford, MM Tiwari, A Pogach, L AF Helmer, Drew A. Tseng, Chin-Lin Rajan, Mangala Crystal, Stephen Shen, Yujing Miller, Donald R. Safford, Monika M. Tiwari, Anjali Pogach, Leonard TI Can ambulatory care prevent hospitalization for metabolic decompensation? SO MEDICAL CARE LA English DT Article DE diabetes mellitus; ambulatory care; quality indicators; health care; diabetic ketoacidosis; veterans ID DIABETIC-KETOACIDOSIS; SENSITIVE CONDITIONS; INSULIN THERAPY; HEALTH-CARE; VETERANS; ACCESS AB Objective: Metabolic decompensations (MD) are hospitalizations considered preventable with appropriate ambulatory care. We tested for associations between diabetes care and MD. Research Design: We retrospectively compared care between cases (MD; n = 2714) and controls (without MD; n = 10,856) using merged Veterans Health Administration and Medicare data. Logistic regression tested for associations between MD and diabetes care controlling for patient characteristics. Subjects: Veterans Health Administration users with diabetes stratified into high [hemoglobin Alc (HA1c) >= 9%; n = 2532] and low (HA1c <9%; n = 6176) risk groups. Measures: The outcome was hospitalization for MD. Care was defined as quarterly or semiannual diabetes visits and HAIc testing during individualized 12-month baseline periods. Results: Cases averaged more diabetes visits and HAIc tests than controls (P < 0.001 for both) in the 12-month baseline period. Among the high-risk, 29.8% of cases made 4 quarterly visits compared with 29.6% of controls (P = 0.004); among the low-risk, there was no difference in semiannual visits. Among the high-risk, models showed having no visit was associated with higher odds of MD (adjusted odds ratio: 3.05; 95% confidence interval: 1.69-5.49) compared with 4 visits; individuals with 1-4 visits had similar odds of MD. More HA1c testing was weakly associated with higher odds of MD. Conclusions: MD was associated with more diabetes care, even controlling for patient characteristics. This inconsistency with the theoretical association between appropriate ambulatory care and lower MD rates indicates that MD rates may not accurately reflect diabetes care quality. C1 [Helmer, Drew A.; Tseng, Chin-Lin; Rajan, Mangala; Shen, Yujing; Tiwari, Anjali; Pogach, Leonard] Vet Adm New Jersey Hlth Care Syst, Ctr Healthcare Knowledge Management, E Orange, NJ USA. [Helmer, Drew A.; Tseng, Chin-Lin; Pogach, Leonard] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. [Crystal, Stephen; Shen, Yujing] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. [Miller, Donald R.] VA New England Hlth Care Syst, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Miller, Donald R.] Boston Univ, Boston, MA 02215 USA. [Safford, Monika M.] Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. [Safford, Monika M.] Univ Alabama, Birmingham, AL USA. RP Helmer, DA (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 111PC, Houston, TX 77030 USA. EM drew.helmer@va.gov NR 31 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD FEB PY 2008 VL 46 IS 2 BP 148 EP 157 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 258AQ UT WOS:000252841200008 PM 18219243 ER PT J AU Pugh, MJV Rosen, AK Montez-Rath, M Amuan, ME Fincke, BG Burk, M Bierman, A Cunningham, F Mortensen, EM Berlowitz, DR AF Pugh, Mwy Jo V. Rosen, Amy K. Montez-Rath, Maria Amuan, Megan E. Fincke, Benjamin G. Burk, Muriel Bierman, Arlene Cunningham, Francesca Mortensen, Eric M. Berlowitz, Dan R. TI Potentially inappropriate prescribing for the elderly - Effects of geriatric care at the patient and health core system level SO MEDICAL CARE LA English DT Article DE geriatric health services; quality of health care; innovation diffusion; clinical practice variation ID MEDICATION USE; EXPLICIT CRITERIA; DRUG-USE; VETERANS; POPULATION; MORTALITY; QUALITY; US AB Background: Many studies have identified patient characteristics associated with potentially inappropriate prescribing in the elderly (PIPE), however, little attention has been directed toward how health care system factors such as geriatric care may affect this patient safety issue. Objective: This study examines the association between geriatric care and PIPE in a community dwelling elderly population. Research Design: Cross-sectional retrospective database study. Subjects: Veterans age >= 65 years who received health care in the VA system during Fiscal Years (FY99-00), and also received at medications from the Veterans Administration in FY00. Measures: PIPE was identified using the Zhan adaptation of the Beers criteria. Geriatric care penetration was calculated as the proportion of patients within a facility who received at least I geriatric outpatient clinic or inpatient visit. Analyses: Logistic regression models with generalized estimating equations were used to assess the relationship between geriatric care and PIPE after controlling for patient and health care system characteristics. Results: Patients receiving geriatric care were less likely to have PIPE exposure (odds ratio, 0.64; 95% confidence interval, 0.59-0.73). There was also a weak effect for geriatric care penetration, with a trend for patients in low geriatric care penetration facilities having higher risk for PIPE regardless of individual geriatric care exposure (odds ratio, 1.14; 95% confidence interval, 0.99-1.30). Conclusions: Although geriatric care is associated with a lower risk of PIPE, additional research is needed to determine if heterogeneity in the organization and delivery of geriatric care resulted in the weak effect of geriatric care penetration, or whether this is a result of low power. C1 [Pugh, Mwy Jo V.; Mortensen, Eric M.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Pugh, Mwy Jo V.; Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Rosen, Amy K.; Montez-Rath, Maria; Amuan, Megan E.; Fincke, Benjamin G.; Berlowitz, Dan R.] Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Rosen, Amy K.; Berlowitz, Dan R.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Burk, Muriel; Cunningham, Francesca] Pharm Benefits Managements Strateg Hlth Grp, Dept Vet Affairs, Hines, IL USA. [Bierman, Arlene] Ctr Res Inner City Hlth, Toronto, ON, Canada. RP Pugh, MJV (reprint author), STVHCS ALMD, VERDICT, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA. EM pughm@uthscsa.edu OI Mortensen, Eric/0000-0002-3880-5563 NR 35 TC 25 Z9 26 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD FEB PY 2008 VL 46 IS 2 BP 167 EP 173 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 258AQ UT WOS:000252841200010 PM 18219245 ER PT J AU Hawkins, VN Foster-Schubert, K Chubak, J Sorensen, B Ulrich, CM Stancyzk, FZ Plymate, S Stanford, J White, E Potter, JD McTiernan, A AF Hawkins, Vivian N. Foster-Schubert, Karen Chubak, Jessica Sorensen, Bess Ulrich, Cornelia M. Stancyzk, Frank Z. Plymate, Stephen Stanford, Janet White, Emily Potter, John D. McTiernan, Anne TI Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE aerobic exercise; androgens; human males; adiposity ID MIDDLE-AGED MEN; BODY-FAT DISTRIBUTION; BINDING GLOBULIN; RESISTANCE EXERCISE; OLDER MEN; METABOLIC SYNDROME; ADIPOSE-TISSUE; ENDURANCE EXERCISE; INSULIN-RESISTANCE; ELDERLY-MEN AB Purpose: The effect of exercise on androgens in middle-aged to older men is poorly understood, and it could have implications for several aspects of health. This analysis was conducted to examine the effects of long-term aerobic exercise on serum sex hormones in middle-aged to older men. Methods: One hundred two sedentary men, ages 40-75 yr, were randomly assigned to a 12-month exercise intervention or a control group (no change in activity). The combined facility- and home-based exercise program consisted of moderate/vigorous-intensity aerobic activity for 60 min.d(-1), 6 d.wk(-1). Serum concentrations of testosterone, free testosterone, dilrydrotestosterone (DHT), 3 alpha-androstanediol glucuronide (3 alpha-Diol-G), estradiol, free estradiol, and sex hormone binding globulin (SHBG) were measured at baseline, 3, and 12 months. Results: Exercisers trained a mean of 370 min.wk(-1) (102% of goal), with only two dropouts. Cardiopulmonary fitness (VO2max) increased 10.8% in exercisers and decreased by 1.8% in controls (P<0.001). DHT increased 14.5% in exercisers versus 1.7% in controls at 3 months (P=0.04); at 12 months, it remained 8.6% above baseline in exercisers versus a 3.1% decrease in controls (P=0.03). SHBG increased 14.3% in exercisers versus 5.7% in controls at 3 months (P=0.04); at 12 months, it remained 8.9% above baseline in exercisers versus 4.0% in controls (P=0.13). There were significant trends toward increasing DHT and SHBG, with greater increases in VO2max at 3 and 12 months in exercisers. No statistically significant differences were observed for testosterone, free testosterone, 3a-Diol-G, estradiol, or free estradiol in exercisers versus controls. Conclusions: A yearlong, moderate-intensity aerobic exercise program increased DHT and SHBG, but it had no effect on other androgens in middle-aged to older men. C1 [Hawkins, Vivian N.; Foster-Schubert, Karen; Chubak, Jessica; Sorensen, Bess; Ulrich, Cornelia M.; White, Emily; Potter, John D.; McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA. [Hawkins, Vivian N.; Chubak, Jessica; Ulrich, Cornelia M.; Stanford, Janet; White, Emily; Potter, John D.; McTiernan, Anne] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA. [Foster-Schubert, Karen; Ulrich, Cornelia M.; Plymate, Stephen; McTiernan, Anne] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Stancyzk, Frank Z.] Univ So Calif, Sch Med, Los Angeles, CA USA. [Plymate, Stephen] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res & Educ Clin Ctr, Seattle, WA USA. [Stanford, Janet] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. RP McTiernan, A (reprint author), Fred Hutchinson Canc Res Ctr, Canc Prevent Program, POB 19024,M4-B402, Seattle, WA 98109 USA. EM amctiern@fhcrc.org RI Perez , Claudio Alejandro/F-8310-2010 OI Perez , Claudio Alejandro/0000-0001-9688-184X; Potter, John/0000-0001-5439-1500 FU NCATS NIH HHS [TL1 TR000422, UL1 TR000423]; NCI NIH HHS [R01 CA077572, P20 CA 103728, P20 CA103728, R01 CA 77572, R25 CA 94880, R25 CA094880, U54 CA 116847, U54 CA116847]; NCRR NIH HHS [K12 RR 023265-03, K12 RR023265, KL2 RR025015, KL2 RR025015-01] NR 66 TC 27 Z9 31 U1 7 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD FEB PY 2008 VL 40 IS 2 BP 223 EP 233 DI 10.1249/mss.0b013e31815cbba9 PG 11 WC Sport Sciences SC Sport Sciences GA 254SM UT WOS:000252608300006 PM 18202581 ER PT J AU Ko, S Shi, L Kim, S Song, CS Chatterjee, B AF Ko, Soyoung Shi, Liheng Kim, Soyoung Song, Chung S. Chatterjee, Bandana TI Interplay of nuclear factor-kappa B and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID PROSTATE-CANCER CELLS; ACID-SULFOTRANSFERASE SULT2A1; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; INDUCED APOPTOSIS; N-COR; GENE; RESISTANCE; GROWTH; RNA AB Increased androgen receptor (AR) levels are associated with prostate cancer progression to androgen independence and therapy resistance. Evidence has suggested that chronic inflammation is closely linked to various cancers including prostate cancer. Herein we show that the proinflammatory cytokine TNF alpha negatively regulates AR mRNA and protein expression and reduces androgen sensitivity in androgen-dependent LNCaP human prostate cancer cells. Decreased AR expression results from transcription repression involving essential in cis interaction of nuclear factor-kappa B (NF-kappa B) with the B- myb transcription factor at a composite genomic element in the 5'-untranslated region of AR. The negative regulation was abrogated when NF-kappa B activity was inhibited by a superrepressor of the inhibitory kappa B protein. In contrast, androgen- independent C4-2 (LNCaP-derived) cells fail to show AR down- regulation by TNF alpha, despite expression of B-myb and TNF alpha-induced NF-kappa B activity similar to that in LNCaP cells. The negatively regulated AR gene chromatin region showed TNF alpha-dependent enrichment of B-myb and the NF-kappa B proteins p65 and p50. In parallel, the histone deacetylase 1, corepressor silencing mediator of retinoid and thyroid hormone receptor and the corepressor-associated scaffold protein mSin3A were recruited to the inhibitory site. In C4-2 cells, neither NF-kappa B and B-myb, nor any of the corepressor components, were detected at the negative site in response to TNF alpha. Apoptosis was induced in TNF alpha- treated LNCaP cells, likely in part due to the down- regulation of AR. The androgen- independent, AR-expressing C4-2 and C4-2B (derived from C4-2) cells were resistant to TNF alpha- induced apoptosis. The results linking androgen dependence to the NF- kappa B and AR pathways may be insightful in identifying novel treatment targets for prostate cancer. C1 [Ko, Soyoung; Shi, Liheng; Kim, Soyoung; Song, Chung S.; Chatterjee, Bandana] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA. [Chatterjee, Bandana] Audie L Murphy Vet Affairs Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Chatterjee, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM chatterjee@uthscsa.edu FU NIA NIH HHS [AG 19660, R01 AG010486, AG 10486, R01 AG019660, R37 AG010486] NR 40 TC 25 Z9 25 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD FEB PY 2008 VL 22 IS 2 BP 273 EP 286 DI 10.1210/me.2007-0332 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 255SV UT WOS:000252678600006 PM 17975021 ER PT J AU Moore, EE Jackson, SL Boyko, EJ Scholes, D Fihn, SD AF Moore, Elya E. Jackson, Sara L. Boyko, Edzvard J. Scholes, Delia Fihn, Stephan D. TI Urinary incontinence and urinary tract infection - Temporal relationships in postmenopausal women SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID RISK-FACTORS; HYSTERECTOMY; PREVALENCE; PREDICTORS; STRESS; URGE AB OBJECTIVE: To estimate the temporal relationship between self-reported urine loss and incident, symptomatic, microbiologically confirmed urinary tract infection (UTI). METHODS: We used daily diaries to collect information on incontinent episodes during a 2-year prospective study of incident UTI among 913 healthy postmenopausal health maintenance organization enrollees. We calculated the monthly rate of urine loss to assess for association with incident UTI. We also estimated the basal rate of urinary incontinence among women who experienced a UTI (excluding the 14-day time period pre- and post-UTI) and compared this to urine loss during the 3-day time period after UTI, to evaluate changes after infection. RESULTS: Sixty percent of women reported urinary incontinence, at a mean rate of 4.7 times per month. The monthly mean rate of urine loss was 2.64 times per month among women who did not experience a UTI compared with 4.60 times per among women who developed a UTI (P=.04). Among women who developed a UTI (n=78), the rate of urine loss during the 3 days after UTI onset was 1.5 times higher than the basal rate (0.23 compared with 0.15 reports per day, P=.26). CONCLUSION: After eliminating episodes of incontinence surrounding a UTI, the basal rate of urine loss was higher among women who experienced UTIs compared with those who did not. Additionally, among women who experienced a UTI, an increase in urine loss occurred in the immediate 3-day time period post-UTI, compared with infection-free periods. Urinary incontinence characterizes women who experience UTIs, both intercurrently and during an acute episode. C1 [Moore, Elya E.; Jackson, Sara L.; Boyko, Edzvard J.; Scholes, Delia; Fihn, Stephan D.] Grp Hlth Ctr Hlth Studies, Grp Hlth Cooperat, Seattle, WA USA. [Moore, Elya E.; Jackson, Sara L.; Boyko, Edzvard J.; Scholes, Delia; Fihn, Stephan D.] Univ Washington, Hlth Serv Res & Dev Ctr Excellence, VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98195 USA. [Moore, Elya E.; Jackson, Sara L.; Boyko, Edzvard J.; Scholes, Delia; Fihn, Stephan D.] Seattle ERIC, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Moore, EE (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia. EM elya.moore@mcri.edu.au OI Boyko, Edward/0000-0002-3695-192X FU NIAID NIH HHS [T32AI07140]; NIDDK NIH HHS [K23DK02660, R01 DK43134] NR 26 TC 24 Z9 24 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD FEB PY 2008 VL 111 IS 2 BP 317 EP 323 DI 10.1097/AOG.0b013e318160d64a PN 1 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 256XD UT WOS:000252762300009 PM 18238968 ER PT J AU Huang, CK Huang, W Zuk, P Jarrahy, R Rudkin, GH Ishida, K Yamaguchi, DT Miller, TA AF Huang, Catherine K. Huang, Weibiao Zuk, Pat Jarrahy, Reza Rudkin, George H. Ishida, Kenji Yamaguchi, Dean T. Miller, Timothy A. TI Genetic markers of osteogenesis and angiogenesis are altered in processed lipoaspirate cells when cultured on three-dimensional scaffolds SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article; Proceedings Paper CT 28th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 15-19, 2006 CL Philadelphia, PA SP Amer Soc Bone & Mineral Res ID MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; HUMAN ADIPOSE-TISSUE; BONE REGENERATION; BIODEGRADABLE SCAFFOLDS; TRICALCIUM PHOSPHATE; BIOACTIVE GLASS; IN-VIVO; PART II; DIFFERENTIATION AB Background: Liposuction-derived stem cells (processed lipoaspirate) have recently been shown to be capable of differentiating into bone. Most studies on osteoblastic growth and differentiation have been conducted in a conventional two-dimensional culture system; however, in native bone, osteoblasts are situated in a three-dimensional configuration. There have been limited studies of processed lipoaspirate behavior in three-dimensional systems. The authors studied the influence a three-dimensional scaffold has on the expression of genes related to osteogenesis and angiogenesis in processed lipoaspirate cells. Methods: One million processed lipoaspirate cells were seeded onto two-dimensional poly(L-lactide-co-glycolide) films or in three-dimensional poly (L-lactide-co-glycolide) scaffolds and incubated in osteogenic medium up to 21 days. RNA was extracted and analyzed with quantitative real-time polymerase chain reaction. Results: When an inert three-dimensional poly(L-lactide-co-glycolide) scaffold was introduced, the pattern and sequence of gene expression changed significantly. Processed lipoaspirate cells cultured onto three-dimensional scaffolds had increased expression of interleukin-8 and vascular endothelial growth factor compared with two-dimensional controls at early time points. Osteogenesis markers-alkaline phosphatase, collagen type I, osteocalcin, osteonectin, and osteopontin-were significantly up-regulated in three-dimensional cultures relative to two-dimensional controls after 24 hours and persisted throughout the 21 days. Conclusions: In human processed lipoaspirate cells, the introduction of a three-dimensional scaffold significantly enhances gene markers of angiogenesis and osteogenesis. On three-dimensional scaffolds, processed lipoaspirate cells first upregulate genes involved with vascular ingrowth and then those involved in bone formation. We believe these differences will significantly impact the design of a bone graft substitute for clinical application. C1 [Huang, Catherine K.; Huang, Weibiao; Zuk, Pat; Jarrahy, Reza; Rudkin, George H.; Ishida, Kenji; Yamaguchi, Dean T.; Miller, Timothy A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Hlthcare Syst, Plast Surg Res Lab, Los Angeles, CA 90095 USA. [Huang, Catherine K.; Huang, Weibiao; Zuk, Pat; Jarrahy, Reza; Rudkin, George H.; Ishida, Kenji; Yamaguchi, Dean T.; Miller, Timothy A.] Univ Calif Los Angeles, Dept Head & Neck Surg, Los Angeles, CA USA. [Huang, Catherine K.; Huang, Weibiao; Zuk, Pat; Jarrahy, Reza; Rudkin, George H.; Ishida, Kenji; Yamaguchi, Dean T.; Miller, Timothy A.] Univ Calif Los Angeles, Div Plast & Reconstruct Surg, Los Angeles, CA USA. RP Huang, CK (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Hlthcare Syst, Plast Surg Res Lab, Los Angeles, CA 90095 USA. NR 32 TC 10 Z9 12 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD FEB PY 2008 VL 121 IS 2 BP 411 EP 423 DI 10.1097/01.prs.0000298510.03226.5f PG 13 WC Surgery SC Surgery GA 261KC UT WOS:000253076500007 PM 18300957 ER PT J AU Carpizo, KH Saran, MJ Huang, W Ishida, K Roostaeian, J Bischoff, D Huang, CK Rudkin, GH Yamaguchi, DT Miller, TA AF Carpizo, Katherine H. Saran, Madeleine J. Huang, Weibiao Ishida, Kenji Roostaeian, Jason Bischoff, David Huang, Catherine K. Rudkin, George H. Yamaguchi, Dean T. Miller, Timothy A. TI Pretreatment of poly(L-lactide-co-glycolide) scaffolds with sodium hydroxide enhances osteoblastic differentiation and slows proliferation of mouse preosteoblast cells SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article; Proceedings Paper CT 51st Annual Meeting of the Research-Council-of-Plastic-Surgery CY MAY 17-20, 2006 CL Dana Point, CA SP Res Council Plast Surg ID GROWTH-FACTORS; IN-VITRO; ADHESION; EXPRESSION; POLYMER; HYDROLYSIS; REPAIR AB Background: Surface topography is important in the creation of a scaffold for tissue engineering. Chemical etching of poly (L-lactide-co-glycolide) with sodium hydroxide has been shown to enhance adhesion and function of numerous cell types. The authors investigated the effects of sodium hydroxide pretreatment of three-dimensional poly (L-lactide-co-glycolide) scaffolds on the adhesion, differentiation, and proliferation of MC3T3-E1 murine preosteoblasts. Methods: MC3T3-E1 cells were seeded onto three-dimensional poly(L-lactide-co-glycolide) scaffolds with and without 1 M sodium hydroxide pretreatment. Cells were then cultured in osteogenic medium and harvested at varying time points for RNA extraction. Quantitative real-time reverse-transcriptase polymerase chain reaction was performed to measure mRNA expression of several osteogenic marker genes. In addition, cell numbers were determined at varying time points during the culture period. All experiments were performed in triplicate. Results: Pretreatment of three-dimensional poly(L-lactide-co-glycolide) scaffolds with sodium hydroxide resulted in statistically significant up-regulation of mRNA expression of alkaline phosphatase, bone sialoprotein, osteocalcin, and vascular endothelial growth factor during the first 10 days of culture. Histologic analysis demonstrated a striking increase in mineralized cell matrix deposition in the sodium hydroxide-treated group. Cell number was statistically higher in the sodium hydroxide-treated group immediately after cell seeding, suggesting improved adhesion. During the first 24 hours of culture, cells grew faster in the control group than in the sodium hydroxide-treated group. Conclusions: Chemical etching of poly (L-lactide-co-glycolide) scaffolds with sodium hydroxide strongly influences the behavior of MC3T3-E1 preosteoblasts in vitro by enhancing adhesion and differentiation and slowing proliferation. Sodium hydroxide treatment may represent a simple and inexpensive way of improving scaffolds for use in bone tissue engineering. C1 [Carpizo, Katherine H.; Saran, Madeleine J.; Huang, Weibiao; Ishida, Kenji; Roostaeian, Jason; Bischoff, David; Huang, Catherine K.; Rudkin, George H.; Yamaguchi, Dean T.; Miller, Timothy A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Hlthcare Syst, Plast Surg Sect, Los Angeles, CA 90095 USA. [Carpizo, Katherine H.; Saran, Madeleine J.; Huang, Weibiao; Ishida, Kenji; Roostaeian, Jason; Bischoff, David; Huang, Catherine K.; Rudkin, George H.; Yamaguchi, Dean T.; Miller, Timothy A.] Univ Calif Los Angeles, Dept Surg, Div Plast & Reconstruct Surg, Los Angeles, CA USA. RP Carpizo, KH (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Hlthcare Syst, Plast Surg Sect, Los Angeles, CA 90095 USA. NR 18 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD FEB PY 2008 VL 121 IS 2 BP 424 EP 434 DI 10.1097/01.prs.0000298366.74273.da PG 11 WC Surgery SC Surgery GA 261KC UT WOS:000253076500008 PM 18300958 ER PT J AU Gold, MC Ehlinger, HD Cook, MS Smyk-Pearson, SK Wille, PT Ungerleider, RM Lewinsohn, DA Lewinsohn, DM AF Gold, Marielle C. Ehlinger, Heather D. Cook, Matthew S. Smyk-Pearson, Susan K. Wille, Paul T. Ungerleider, Ross M. Lewinsohn, Deborah A. Lewinsohn, David M. TI Human innate mycobacterium tuberculosis reactive alpha beta TCR(+) thymocytes SO PLOS PATHOGENS LA English DT Article ID T-CELL RESPONSE; DENDRITIC CELLS; LYMPHOCYTES-T; IFN-GAMMA; INFECTION; THYMUS; RECOGNITION; ACTIVATION; RESISTANCE; IMMUNOLOGY AB The control of Mycobacterium tuberculosis (Mtb) infection is heavily dependent on the adaptive Th1 cellular immune response. Paradoxically, optimal priming of the Th1 response requires activation of priming dendritic cells with Th1 cytokine IFN-gamma. At present, the innate cellular mechanisms required for the generation of an optimal Th1 T cell response remain poorly characterized. We hypothesized that innate Mtb-reactive T cells provide an early source of IFN-gamma to fully activate Mtb-exposed dendritic cells. Here, we report the identification of a novel population of Mtb-reactive CD4(-) alpha beta TCR(+) innate thymocytes. These cells are present at high frequencies, respond to Mtb-infected cells by producing IFN-gamma directly ex vivo, and display characteristics of effector memory T cells. This novel innate population of Mtb-reactive T cells will drive further investigation into the role of these cells in the containment of Mtb following infectious exposure. Furthermore, this is the first demonstration of a human innate pathogen-specific alpha beta TCR(+) T cell and is likely to inspire further investigation into innate T cells recognizing other important human pathogens. C1 [Gold, Marielle C.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Pulm & Crit Care Med, Portland VA Med Ctr, Portland, OR 97201 USA. [Ehlinger, Heather D.; Cook, Matthew S.; Smyk-Pearson, Susan K.; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA. [Wille, Paul T.; Lewinsohn, Deborah A.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Ungerleider, Ross M.] Oregon Hlth & Sci Univ, Doernbecher Mem Hosp Children, Portland, OR 97201 USA. RP Gold, MC (reprint author), Oregon Hlth & Sci Univ, Dept Pulm & Crit Care Med, Portland VA Med Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM goldm@ohsu.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494; Gold, Marielle/0000-0003-2505-3291 FU NHLBI NIH HHS [F32 HL087129, F32 HL087129-01]; NIAID NIH HHS [R01 AI048090-06, R01 AI048090] NR 42 TC 10 Z9 10 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD FEB PY 2008 VL 4 IS 2 AR e39 DI 10.1371/journal.ppat.0040039 PG 9 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 294OR UT WOS:000255415900022 PM 18282101 ER PT J AU Taylor, SA Charman, SC Lefere, P McFarland, EG Paulson, EK Yee, J Aslam, R Barlow, JM Gupta, A Kim, DH Miller, CM Halligan, S AF Taylor, Stuart A. Charman, Susan C. Lefere, Philippe McFarland, Elizabeth G. Paulson, Erik K. Yee, Judy Aslam, Rizwan Barlow, John M. Gupta, Arun Kim, David H. Miller, Chad M. Halligan, Steve TI CT colonography: Investigation of the optimum reader paradigm by using computer-aided detection software SO RADIOLOGY LA English DT Article; Proceedings Paper CT 92nd Scientific Assembly and Annual Meeting of the Radiological-Society-of-North-America CY NOV 26-DEC 01, 2006 CL Chicago, IL SP Radiol Soc N Amer ID TOMOGRAPHIC COLONOGRAPHY; POLYP DETECTION; DIAGNOSIS SCHEME; COLONIC POLYPS; 1 CM; PERFORMANCE; COLONOSCOPY; SMALLER AB Purpose: To prospectively compare the diagnostic performance and time efficiency of both second and concurrent computer-aided detection (CAD) reading paradigms for retrospectively obtained computed tomographic (CT) colonography data sets by using consensus reading (three radiologists) of colonoscopic findings as a reference standard. Materials and Methods: Ethical permission, HIPAA compliance (for U.S. institutions), and patient consent were obtained from all institutions for use of CT colonography data sets in this study en radiologists each read 25 CT colonography data sets (12 men, 13 women; mean age, 61, years) containing 69 polyps (28 were 1-5 mm, 41 were >= 6 mm) by using workstations integrated with CAD software. Reading was randomized to either "second read" CAD (applied only after initial unassisted assessment) or "concurrent read" CAD (applied at. the start of assessment). Data sets were reread 6 weeks later by using the opposing paradigm. Polyp sensitivity and reading times were compared by using multilevel logistic and linear regression, respectively. Receiver operating characteristic (ROC) curves were generated. Results: Compared with the unassisted read, odds of improved polyp (>= 6 mm) detection were 1.5 (95 % confidence, interval [CI]: 1.0, 2.2) and 1.3 (95% CI: 0.9, 1.9) by using CAD as second and concurrent reader, respectively. Detection odds by using CAD concurrently were 0.87 (95% CI: 0.59, 1.3) 0.76 (95% CI: 0.57, 1.01) those of second read CAD excluding and including polyps 1-5 mm, respectively. The concurrent read took 2.9 minutes (95% CI: -3.8, -1.9 less than did second read. The mean areas under the ROC curve (95% CT) for the unassisted read, 1, second read CAD, and concurrent read CAD were 0.83 (95% CI: 0.78, 0.87), 0.86 (95% CI: 0.82, 0.90), and 0.88 (95% CI: 0.83, 0.92), respectively. Conclusion: CAD is more time efficient when used concurrently than when used as a second reader, with similar sensitivity for polyps 6 mm or larger. However, use of second read CAD maximizes sensitivity, particularly for smaller lesions. (C) RSNA, 2007. C1 [Taylor, Stuart A.; Halligan, Steve] UCL Hosp, Dept Specialist Xray, London NW1 2BU, England. [Charman, Susan C.] UCL Hosp, Med Stat Unit, London NW1 2BU, England. [Lefere, Philippe] Stedelijk Ziekenhuis, Dept Radiol, Roeselare, Belgium. [McFarland, Elizabeth G.] Edward Mallinckrodt Inst Radiol, Dept Radiol, St Louis, MO 63110 USA. [Paulson, Erik K.; Miller, Chad M.] Duke Univ, Med Ctr, Abdominal Imaging Sect, Durham, NC USA. [Yee, Judy; Aslam, Rizwan] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. [Barlow, John M.] Mayo Clin, Coll Med, Dept Radiol, Rochester, MN USA. [Gupta, Arun] St Marks Hosp, Dept Intestinal Imaging, Harrow, Middx, England. [Kim, David H.] Univ Wisconsin, Sch Med, Dept Radiol, Madison, WI USA. RP Taylor, SA (reprint author), UCL Hosp, Dept Specialist Xray, 235 Euston Rd,2F Podium, London NW1 2BU, England. EM csytaylor@yahoo.co.uk RI Halligan, Steve /C-5875-2009 NR 20 TC 41 Z9 42 U1 0 U2 1 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD FEB PY 2008 VL 246 IS 2 BP 463 EP 471 DI 10.1148/radio1.2461070190 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 257JW UT WOS:000252796300016 PM 18094263 ER PT J AU Phelps, LF Williams, RM Raichle, KA Turner, AP Ehde, DM AF Phelps, Lori F. Williams, Rhonda M. Raichle, Katherine A. Turner, Aaron P. Ehde, Dawn M. TI The importance of cognitive processing to adjustment in the 1st year following amputation SO REHABILITATION PSYCHOLOGY LA English DT Article DE amputees; posttraumatic stress disorder; trauma; adjustment; depression ID POSTTRAUMATIC-STRESS-DISORDER; LOWER-LIMB AMPUTATION; BREAST-CANCER; PRIMARY-CARE; RISK-FACTORS; HAND INJURY; PSYCHOSOCIAL ADAPTATION; PSYCHOMETRIC PROPERTIES; DEPRESSIVE SYMPTOMS; INTRUSIVE THOUGHTS AB Objective: To describe depressive symptoms, posttraumatic stress disorder (PTSD), and posttraumatic growth at 6 and 12 months following amputation and to explore differences by demographic variables and cognitive processing of trauma. Participants: 83 adults with newly acquired limb loss. Setting: Two large metropolitan hospitals. Main Outcome Measures: The Patient Health Questionnaire depression module, PTSD Checklist, and Posttraumatic Growth Inventory. Results: Significant depressive and PTSD symptoms were reported by 15%-25% of participants. Relatively low levels of posttraumatic growth were reported. Negative cognitive processing predicted depressive and PTSD symptoms at 6 months. Positive cognitive processing predicted posttraumatic growth at 12 months. Conclusion: Cognitive processing appears to be integral to positive and negative psychosocial outcomes following amputation and should be targeted by clinical interventions. C1 [Phelps, Lori F.; Williams, Rhonda M.; Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Williams, Rhonda M.; Turner, Aaron P.; Ehde, Dawn M.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. [Raichle, Katherine A.] Seattle Univ, Dept Psychol, Seattle, WA USA. RP Phelps, LF (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM Lori.Phelps2@va.gov OI Turner, Aaron/0000-0001-6897-8003 NR 89 TC 36 Z9 37 U1 7 U2 16 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD FEB PY 2008 VL 53 IS 1 BP 28 EP 37 DI 10.1037/0090-5550.53.1.28 PG 10 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA 266JR UT WOS:000253431900004 ER PT J AU Siegel, SD Turner, AP Haselkorn, JK AF Siegel, Scott D. Turner, Aaron P. Haselkorn, Jodie K. TI Adherence to disease-modifying therapies in multiple sclerosis: Does caregiver social support matter? SO REHABILITATION PSYCHOLOGY LA English DT Article DE multiple sclerosis; medication adherence; social support; caregiver ID ANTIRETROVIRAL THERAPY; PATIENT ADHERENCE; MEDICATION; IMPAIRMENT; DISABILITY; MS AB Objective: To evaluate the relationship between caregiver-specific social support and adherence to disease-modifying therapies (DMT) for multiple sclerosis (MS). Design: Telephone survey with 6 monthly follow-up assessments. Setting: Veterans Health Administration. Participants: 54 veterans with MS who identified a primary caregiver and who were currently prescribed DMT. Measures: Demographic information. Caregiver supportive and conflictual qualities were assessed with the Quality of Relationships Inventory-Short Form. Medication-specific support was assessed with 4 items developed from qualitative focus groups. DMT adherence was assessed with a single item that requested missed doses in the past month. Results: Adherence in this population of ongoing DMT users was relatively high, with 85.1% (95% confidence interval = 75.6%-94.8%) reporting adherence >= 80% of prescribed doses. Using logistic regression adjusting for disability, type of DMT, and length of time on current DMT, the authors predicted longitudinal adherence by supportive qualities of the caregiver-care recipient relationship but not by conflictual qualities or medication-specific support. Conclusion: Supportive qualities of the caregiver-care recipient relationship represent an important predictor of DMT adherence and a potential target in adherence-based interventions. C1 [Siegel, Scott D.; Turner, Aaron P.; Haselkorn, Jodie K.] Vet Affairs Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. [Turner, Aaron P.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98108 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98108 USA. [Siegel, Scott D.] Helen F Graham Canc Ctr, Newark, DE USA. RP Turner, AP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@med.va.gov OI Turner, Aaron/0000-0001-6897-8003 NR 28 TC 8 Z9 8 U1 3 U2 6 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD FEB PY 2008 VL 53 IS 1 BP 73 EP 79 DI 10.1037/0090-5550.53.1.73 PG 7 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA 266JR UT WOS:000253431900009 ER PT J AU Bartzokis, G Lu, PH Nuechterlein, KH Gitlin, M Doi, C Edwards, N Lieu, C Altshuler, LL Mintz, J AF Bartzokis, George Lu, Po H. Nuechterlein, Keith H. Gitlin, Michael Doi, Clarissa Edwards, Nancy Lieu, Christopher Altshuler, Lori L. Mintz, Jim TI Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia (vol 93, pg 13, 2007) SO SCHIZOPHRENIA RESEARCH LA English DT Correction C1 [Bartzokis, George; Lu, Po H.; Doi, Clarissa; Edwards, Nancy; Lieu, Christopher] Univ Calif Los Angeles, Alzheimers Dis Ctr, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Bartzokis, George] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Div Brain Mapping,Lab Neuroimaging, Los Angeles, CA 90095 USA. [Bartzokis, George; Lu, Po H.; Doi, Clarissa; Edwards, Nancy; Lieu, Christopher] Greater Los Angeles VA Hlthcare Syst, Los Angeles, CA 90073 USA. [Bartzokis, George] Univ Calif Los Angeles, Inst Brain Res, Los Angeles, CA 90095 USA. [Nuechterlein, Keith H.; Gitlin, Michael; Altshuler, Lori L.; Mintz, Jim] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Nuechterlein, Keith H.; Altshuler, Lori L.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. RP Bartzokis, G (reprint author), Univ Calif Los Angeles, Alzheimers Dis Ctr, David Geffen Sch Med, Dept Neurol, 710 Westwood Pl,Room 2-238, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2008 VL 99 IS 1-3 BP 379 EP 379 DI 10.1016/j.schres.2007.09.023 PG 1 WC Psychiatry SC Psychiatry GA 278SM UT WOS:000254306600049 ER PT J AU Guzman-Marin, R Suntsova, N Bashir, T Nienhuis, R Szymusiak, R McGinty, D AF Guzman-Marin, Ruben Suntsova, Natalia Bashir, Tariq Nienhuis, Robert Szymusiak, Ronald McGinty, Dennis TI Rapid eye movement sleep deprivation contributes to reduction of neurogenesis in the hippocampal dentate gyrus of the adult rat SO SLEEP LA English DT Article DE adult neurogenesis; hippocampus; dentate gyrus ID LONG-TERM POTENTIATION; CELL-PROLIFERATION; EXPRESSION; PLASTICITY; RECOVERY; EXERCISE; STRESS; PERIOD; BRAIN; BDNF AB Study Objectives: The dentate gyrus (DG) of the adult hippocampus contains progenitor cells, which have potential to differentiate into neurons. Previously we reported that 96 hours of total sleep deprivation reduces neurogenesis in the DG of adult rats. Loss of either non-rapid eye movement (NREM) or rapid eye movement (REM) sleep could have contributed to the effect of total sleep deprivation. The present study assessed the effect of 4 days of REM sleep deprivation (REMD) on neurogenesis. Design: REMD was achieved by brief treadmill movement initiated by automatic online detection of REM sleep. A yoked-control (YC) rat was placed in the same treadmill and experienced the identical movement regardless the stage of the sleep-wake cycle. The thymidine analog 5-bromo-2'-deoxy-uridine and the intrinsic proliferation marker, Ki-67, were both used to label proliferating cells. Setting: Basic neurophysiology laboratory. Participants: Male Sprague-Dawley male rats (300 - 320 g) Results: REM sleep was reduced by 85% in REMD rats and by 43% in YC, compared with cage control animals and by 79% in REMD rats compared with YC. NREM sleep and slow wave activity within NREM did not differ in REMD and YC groups. Cell proliferation was reduced by 63 % in REMD compared with YC rats, and by 82% and 51 %, respectively, in REMD and YC rats compared with cage controls. Across all animals, cell proliferation exhibited a positive correlation with the percentage of REM sleep (r = 0.84, P < 0.001). Reduced cell proliferation in REMD rats was confirmed with the intrinsic proliferation marker, Ki-67. REMD also reduced the percentage of proliferating cells that later expressed a mature neuronal marker. Conclusions: The present findings support a hypothesis that REM sleep-associated processes facilitate proliferation of granule cells in the adult hippocampal DG. C1 [Guzman-Marin, Ruben; Suntsova, Natalia; Bashir, Tariq; Nienhuis, Robert; Szymusiak, Ronald; McGinty, Dennis] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Guzman-Marin, Ruben; Suntsova, Natalia; Bashir, Tariq; McGinty, Dennis] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Szymusiak, Ronald] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Suntsova, Natalia] Rostov State Univ, AB Kogan Res Inst Neurocybernet, Rostov Na Donu, Russia. RP McGinty, D (reprint author), VA Greater Los Angeles Healthcare Syst, REs Serv 151A3, 16111 Plummer St, Los Angeles, CA 91343 USA. EM dmcginty@ucla.edu FU NHLBI NIH HHS [P50 HL060296, HL 60296]; NIMH NIH HHS [MH 075076, R01 MH075076] NR 35 TC 49 Z9 53 U1 0 U2 6 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD FEB 1 PY 2008 VL 31 IS 2 BP 167 EP 175 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 257HZ UT WOS:000252791100003 PM 18274263 ER PT J AU Levine, DA Safford, MM Allison, JJ Houston, TK Reker, DM King, PH Williams, LS Litaker, MS Kiefe, CI AF Levine, Deborah A. Safford, Monika M. Allison, Jeroan J. Houston, Thomas K. Reker, Dean M. King, Peter H. Williams, Linda S. Litaker, Mark S. Kiefe, Catarina I. TI Long-term use of secondary stroke prevention therapies among US veterans SO STROKE LA English DT Meeting Abstract CT 33rd International Stroke Conference CY FEB 19-21, 2008 CL New Orleans, LA SP Amer Stroke Assoc, Amer Heart Assoc C1 [Levine, Deborah A.; Safford, Monika M.; Allison, Jeroan J.; Houston, Thomas K.; Litaker, Mark S.; Kiefe, Catarina I.] Univ Alabama, Birmingham, AL USA. [Reker, Dean M.] Kansas VA Med Ctr, Kansas City, MO USA. [King, Peter H.] Birmingham VA Med Ctr, Birmingham, AL USA. [Williams, Linda S.] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD FEB PY 2008 VL 39 IS 2 MA 13 BP 531 EP 531 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 256JY UT WOS:000252726100074 ER PT J AU Wintermark, M Jawadi, SS Rapp, JH Tihan, T Tong, E Glidden, D Abedin, S Schaeffer, S Acevedo-Bolton, G Orwoll, B Pan, X Saloner, D AF Wintermark, Max Jawadi, Sumayya S. Rapp, Joseph H. Tihan, Tarik Tong, Elizabeth Glidden, David Abedin, Sami Schaeffer, Sarah Acevedo-Bolton, Gabriel Orwoll, Benjamin Pan, XianMang Saloner, David TI High-resolution CT imaging of carotid artery atherosclerotic plaques SO STROKE LA English DT Meeting Abstract CT 33rd International Stroke Conference CY FEB 19-21, 2008 CL New Orleans, LA SP Amer Stroke Assoc, Amer Heart Assoc C1 [Wintermark, Max; Tihan, Tarik; Tong, Elizabeth; Glidden, David; Schaeffer, Sarah; Acevedo-Bolton, Gabriel; Orwoll, Benjamin; Saloner, David] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Jawadi, Sumayya S.; Abedin, Sami] Univ Missouri, Kansas City, KS USA. [Rapp, Joseph H.; Pan, XianMang] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD FEB PY 2008 VL 39 IS 2 MA 105 BP 554 EP 554 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 256JY UT WOS:000252726100166 ER PT J AU Kohen, R Millard, SP Becker, KJ Buzaitis, A Cain, KC Teri, L Tirschwell, D Veith, R Mitchell, PH AF Kohen, Ruth Millard, Steven P. Becker, Kyra J. Buzaitis, Ann Cain, Kevin C. Teri, Linda Tirschwell, David Veith, Richard Mitchell, Pamela H. TI Polymorphisms of the serotonin transporter are associated with increased risk for post-stroke depression SO STROKE LA English DT Meeting Abstract CT 33rd International Stroke Conference CY FEB 19-21, 2008 CL New Orleans, LA SP Amer Stroke Assoc, Amer Heart Assoc C1 [Kohen, Ruth; Becker, Kyra J.; Buzaitis, Ann; Cain, Kevin C.; Teri, Linda; Tirschwell, David; Veith, Richard; Mitchell, Pamela H.] Univ Washington, Seattle, WA 98195 USA. [Millard, Steven P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD FEB PY 2008 VL 39 IS 2 MA P286 BP 641 EP 641 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 256JY UT WOS:000252726100505 ER PT J AU Khan, M Hoda, MN Giri, S Singh, I Singh, AK AF Khan, Mushfiquddin Hoda, Md Nasrul Giri, Shailendra Singh, Inderjit Singh, Avtar K. TI Lipid aldehydes contribute to acute stroke injury via protein carbonyl formation and glutathione depletion in a rat model of focal cerebral ischemia and reperfusion SO STROKE LA English DT Meeting Abstract CT 33rd International Stroke Conference CY FEB 19-21, 2008 CL New Orleans, LA SP Amer Stroke Assoc, Amer Heart Assoc C1 [Khan, Mushfiquddin; Hoda, Md Nasrul; Giri, Shailendra; Singh, Inderjit] Med Univ S Carolina, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD FEB PY 2008 VL 39 IS 2 MA P420 BP 671 EP 671 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 256JY UT WOS:000252726100632 ER PT J AU Baruch, L Gage, B Horrow, J AF Baruch, Lawrence Gage, Brian Horrow, Jay TI Can patients with atrial fibrillation be optimally risk stratified for stroke and thromboembolism? Response to letter by Taggar et al SO STROKE LA English DT Letter C1 [Baruch, Lawrence] Bronx Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. [Baruch, Lawrence] Mt Sinai Sch Med, New York, NY USA. [Gage, Brian] Washington Univ, Dept Med, St Louis, MO USA. [Horrow, Jay] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA. RP Baruch, L (reprint author), Bronx Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD FEB PY 2008 VL 39 IS 2 BP E26 EP E26 DI 10.1161/STROKEAHA.107.504191 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 256JY UT WOS:000252726100897 ER PT J AU Hart, SL Latini, DM Cowan, JE Carroll, PR AF Hart, Stacey L. Latini, David M. Cowan, Janet E. Carroll, Peter R. CA CaPSURE Investigators TI Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer SO SUPPORTIVE CARE IN CANCER LA English DT Article DE prostate cancer; treatment satisfaction; fear of recurrence; quality-of-life ID SURVIVORS; UNCERTAINTY; ANXIETY; RADIATION; DATABASE; CAPSURE; SCALE; CARE AB Goals of work Fear of cancer recurrence (FOR) is common in prostate cancer patients, but little research has examined the impact of FOR on quality of life (QOL) or the mechanism by which these fears become intensified. The objective of this study was to examine treatment satisfaction (TS) as a moderator of the relationship between FOR and QOL. Patients and methods Data were drawn from the CaPSURE (TM) database, a 12,000-man national observational prostate cancer registry. Three hundred and thirty-three patients who underwent radical prostatectomy (RP) to treat their prostate cancer completed self-report measures. TS was measured 0-6 months post-RP with a nine-item scale developed for this study, FOR was measured 6-12 months post-RP with a previously validated five-item scale, and QOL was measured 12-18 months post-RP with the Short Form 36. Main results After controlling for age, education, number of comorbid medical conditions, and cancer severity, lower FOR (B=-0.12, p < 0.0001), higher TS (B=0.09, p < 0.001), and the interaction of TS x FOR (B=0.87, p < 0.05) significantly predicted higher mental health QOL scores. Furthermore, lower FOR (B=-0.08, p < 0.01), and the interaction of TS x FOR (B=-1.11, p < 0.01) significantly predicted higher physical health QOL scores. Conclusions TS levels mitigated the impact of high FOR on lower levels of QOL. Specifically, patients who reported lower TS and greater FOR endorsed significantly lower levels of QOL compared to other patients in the sample. C1 [Hart, Stacey L.] Ryerson Univ, Dept Psychol, Toronto, ON M5B 2K3, Canada. [Latini, David M.] Baylor Coll Med, Scott Dept Urol, Houston, TX USA. [Latini, David M.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX USA. [Latini, David M.] VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. [Cowan, Janet E.; Carroll, Peter R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. [Cowan, Janet E.; Carroll, Peter R.] Univ Calif San Francisco, Programs Urol Oncol & Genitourinary Canc Epidemio, Ctr Comprehens Canc, San Francisco, CA 94143 USA. RP Hart, SL (reprint author), Ryerson Univ, Dept Psychol, 350 Victoria St, Toronto, ON M5B 2K3, Canada. EM stacey.hart@ryerson.ca RI Hart, Stacey/E-4819-2011 OI Macaluso, Joseph/0000-0001-7383-1321; Latini, David/0000-0002-6161-4861 FU NIMH NIH HHS [K08 MH 068257]; PHS HHS [P50 C89520] NR 24 TC 41 Z9 41 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD FEB PY 2008 VL 16 IS 2 BP 161 EP 169 DI 10.1007/s00520-007-0296-x PG 9 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 252TX UT WOS:000252470600008 PM 17638026 ER PT J AU Hermsen, JL Sano, Y Gomez, FE Maeshima, Y Kang, W Kudsk, KA AF Hermsen, Joshua L. Sano, Yoshifumi Gomez, F. Enrique Maeshima, Yoshinori Kang, Woodae Kudsk, Kenneth A. TI Parenteral Nutrition Inhibits Tumor Necrosis Factor-alpha-Mediated IgA Response to Injury SO SURGICAL INFECTIONS LA English DT Article AB Background: Parenteral nutrition (PN) increases the incidence of pneumonia in severely injured patients compared with enteral feeding (ENT). Injury induces an innate airway IgA response in severely injured patients; similar responses occur in mice. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) stimulate the production of polymeric immunoglobulin receptor (pIgR), the protein required to transport immunoglobulin A (IgA) to mucosal surfaces. We have shown that PN alters levels of lung and nasal passage IgA and several IgA-stimulating cytokines. We hypothesized that TNF-alpha and IL-1 beta blockade, as well as PN, would blunt the airway IgA response to injury. Methods: Male Institute of Cancer Research (ICR) mice were randomized to uninjured controls (n = 10) or to intra-peritoneal phosphate-buffered saline (PBS) (n = 9), antagonistic TNF-alpha antibody (100 mcg, n = 7), or antagonistic IL-1 beta antibody (50 mcg, n = 8) 30 min prior to surgical stress with laparotomy and neck incisions. Mice were sacrificed at 8 h for nasal and bronchoalveolar lavage (NAL, BAL) to measure IgA by enzyme-linked immunosorbent assay. In a separate experiment, 12 mice underwent intravenous cannulation followed by chow (n = 5) or PN (n = 7) feeding for 5 days prior to the same stress and IgA measurement. Results: Injury significantly increased NAL and BAL IgA (225 +/- 104 ng) compared with baseline (145 +/- 38 ng; p = 0.01). Blockade of TNF-alpha eliminated the innate airway IgA response to injury (130 +/- 47 ng; p = 0.01), whereas IL-1 beta blockade blunted and PN eliminated it completely. Conclusions: Tumor necrosis factor-alpha is involved in the respiratory IgA immune response to injury. Both TNF-alpha blockade and PN impair this innate response, and blockade of IL-1 beta impairs it to a degree. We hypothesize that these cytokines blunt this response via their known effects on the polymeric immunoglobulin receptor (pIgR), whereas the PN-induced deficit likely is multifactorial. C1 [Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Coll Med & Publ Hlth, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Dept Surg, Coll Med & Publ Hlth, 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU U.S. National Institutes of Health [2R01GM53439]; Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs FX This research was supported by U.S. National Institutes of Health grant 2R01GM53439 and work supported in part by the Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs. NR 42 TC 15 Z9 16 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 J9 SURG INFECT JI Surg. Infect. PD FEB PY 2008 VL 9 IS 1 BP 33 EP 40 DI 10.1089/sur.2007.029 PG 8 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA V18FO UT WOS:000207990900005 PM 18363466 ER PT J AU Frank, JA Pittet, JF Wray, C Matthay, MA AF Frank, J. A. Pittet, J-F Wray, C. Matthay, M. A. TI Protection from experimental ventilator-induced acute lung injury by IL-1 receptor blockade SO THORAX LA English DT Article ID RESPIRATORY-DISTRESS-SYNDROME; NITRIC-OXIDE SYNTHASE; TIDAL VOLUME VENTILATION; MECHANICAL VENTILATION; NEUTROPHIL INFILTRATION; CONTROLLED-TRIAL; FLUID CLEARANCE; DOUBLE-BLIND; RAT LUNGS; INTERLEUKIN-1 AB Background: Clinical studies have shown that injurious mechanical ventilation is associated with increased airspace and plasma levels of interleukin-1b (IL-1 beta); however, the potential therapeutic value of IL-1 inhibition in acute lung injury has not been thoroughly investigated. A study was undertaken to determine if IL-1 signalling is a necessary early event in the pathogenesis of experimental ventilator-induced lung injury. Methods: Mice deficient in IL-1 receptor type 1 (IL1R1) and rats treated with IL-1 receptor antagonist (IL-1Ra) were mechanically ventilated with high tidal volume (30 ml/kg) and the effect of IL-1 signalling blockade on the severity of lung injury was determined. Results: Permeability, as measured by radiolabelled albumin flux, was significantly lower in IL1R1 null mice than in wild-type mice during injurious ventilation (p<0.05). IL-1Ra significantly decreased protein permeability and pulmonary oedema in rats during injurious ventilation and also decreased airspace and plasma levels of the chemokine CXCL1 and airspace neutrophils. IL-1Ra decreased expression of NOS2 and ICAM-1 mRNA in whole lung. Bronchoalveolar lavage fluid levels of RT140, a marker of type I cell injury, were 2.5 times lower following IL-1Ra treatment (p<0.05). In isolated type II pneumocytes, IL-1 beta reduced electrical resistance and increased transepithelial permeability. Conclusions: IL-1 contributes to alveolar barrier dysfunction in VILI by promoting lung neutrophil recruitment and by increasing epithelial injury and permeability. Because preserved alveolar barrier function is associated with better outcomes in patients with acute lung injury, these data support further testing of IL-1Ra for the treatment of acute lung injury. C1 [Frank, J. A.; Pittet, J-F; Matthay, M. A.] Univ Calif San Francisco, San Francisco VA Med Ctr, No Calif Inst Res & Educ, Cardiovasc Res Inst, San Francisco, CA 94121 USA. [Frank, J. A.; Matthay, M. A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Pittet, J-F; Matthay, M. A.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. [Pittet, J-F] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RP Frank, JA (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, No Calif Inst Res & Educ, Cardiovasc Res Inst, 4150 Clement St,Box 111D, San Francisco, CA 94121 USA. EM james.frank@ucsf.edu FU NHLBI NIH HHS [HL51854, HL69900, R01 HL088440, R01 HL088440-01A1, R56 HL088440] NR 44 TC 73 Z9 75 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 J9 THORAX JI Thorax PD FEB PY 2008 VL 63 IS 2 BP 147 EP 153 DI 10.1136/thx.2007.079608 PG 7 WC Respiratory System SC Respiratory System GA 256HH UT WOS:000252718500012 PM 17901159 ER PT J AU Zhou, XH Li, SM Gatsonis, CA AF Zhou, Xiao-Hua Li, Sierra M. Gatsonis, Constantine A. TI Wilcoxon-based group sequential designs for comparison of areas under two correlated ROC curves SO STATISTICS IN MEDICINE LA English DT Article DE group sequential design; ROC curve areas; non-parametric ID OPERATING CHARACTERISTIC CURVES; CLINICAL-TRIALS AB Clinical studies to evaluate the relative accuracies of two diagnostic modalities via their receiver operating characteristic (ROC) curves are currently conducted using fixed sample designs: cases are accrued until a predetermined sample size is achieved and, at that point, the areas under the ROC curves are computed and compared (Radiology 1982; 143:29-36; Radiology 1983; 148:839-843). In prospective ROC studies (Radiology 1990; 175:571-575), participants are recruited from a clinically defined cohort and diagnostic test information is obtained and interpreted in advance of ascertaining the definitive proof of diagnosis ('gold standard'). In retrospective studies, cases are selected from a set of patient records and their diagnostic tests are interpreted without knowledge of the 'gold standard'. The conduct of ROC studies requires considerable effort and resources, particularly for the collection of 'gold standard' information. Thus, it is highly desirable to search for designs which are more efficient than using a fixed sample. In this paper, we discuss the formulation and application of group sequential designs (GSDs) to comparative ROC studies based on non-parametric Wilcoxon estimators of the area under the ROC curves. The approach is applicable to comparisons of ROC curve areas of two tests measured on either continuous or ordinal scales on same cases ('paired' designs) with one reader. The adoption of GSDs may lead to substantial savings in the number of required cases, thus resulting in both time and resource use efficiency. Copyright (c) 2007 John Wiley & Sons, Ltd. C1 [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiao-Hua; Li, Sierra M.] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. [Gatsonis, Constantine A.] Brown Univ, Ctr Stat Sci, Providence, RI USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA. EM azhou@u.washington.edu FU NIBIB NIH HHS [R01 EB005829] NR 11 TC 5 Z9 5 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD JAN 30 PY 2008 VL 27 IS 2 BP 213 EP 223 DI 10.1002/sim.2856 PG 11 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 261RY UT WOS:000253098900010 PM 17357988 ER PT J AU Mukherjee, P Thomas, S Pasinetti, GM AF Mukherjee, Piali Thomas, Sunil Pasinetti, Giulio Maria TI Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo SO JOURNAL OF NEUROINFLAMMATION LA English DT Article ID ACTIVATED PROTEIN-KINASE; CEREBELLAR GRANULE CELLS; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; STATUS EPILEPTICUS; INDUCED APOPTOSIS; CORTICAL-NEURONS; MESSENGER-RNA; NEURODEGENERATION; KAINATE AB Background: The complement system is thought to be involved in the pathogenesis of numerous neurological diseases. We previously reported that pre-treatment of murine cortico-hippocampal neuronal cultures with the complement derived anaphylatoxin C5a, protects against glutamate mediated apoptosis. Our present study with C5a receptor knock out (C5aRKO) mice corroborates that the deficiency of C5a renders C5aRKO mouse more susceptible to apoptotic injury in vivo. In this study we explored potential upstream mechanisms involved in C5a mediated neuroprotection in vivo and in vitro. Methods: Based on evidence suggesting that reduced expression of glutamate receptor subunit 2 (GluR2) may influence apoptosis in neurons, we studied the effect of human recombinant C5a on GluR2 expression in response to glutamate neurotoxicity. Glutamate analogs were injected into C5aRKO mice or used to treat in vitro neuronal culture and GluR2 expression were assessed in respect with cell death. Results: In C5aRKO mice we found that the neurons are more susceptible to excitotoxicity resulting in apoptotic injury in the absence of the C5a receptor compared to WT control mice. Our results suggest that C5a protects against apoptotic pathways in neurons in vitro and in vivo through regulation of GluR2 receptor expression. Conclusion: Complement C5a neuroprotects through regulation of GluR2 receptor subunit. C1 [Mukherjee, Piali; Thomas, Sunil; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriat Res & Clin Ctr, Bronx, NY 10468 USA. [Mukherjee, Piali] Cornell Univ, Weill Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, New York, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustav L,Levy Pl, New York, NY 10029 USA. EM pim2001@med.cornell.edu; sunil.thomas@mssm.edu; giulio.pasinetti@mssm.edu OI Mukherjee, Piali/0000-0003-2737-4849 FU NIA NIH HHS [AG14766, AG14239, AG13799, R01 AG014766, R01 AG013799] NR 35 TC 30 Z9 31 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD JAN 29 PY 2008 VL 5 AR 5 DI 10.1186/1742-2094-5-5 PG 7 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 267UR UT WOS:000253535200001 PM 18230183 ER PT J AU Peterson, PN Magid, DJ Ross, C Ho, PM Rumsfield, JS Lauer, MS Lyons, EE Smith, SS Masoudi, FA AF Peterson, Pamela N. Magid, David J. Ross, Colleen Ho, P. Michael Rumsfield, John S. Lauer, Michael S. Lyons, Ella E. Smith, Scott S. Masoudi, Frederick A. TI Association of exercise capacity on treadmill with future cardiac events in patients referred for exercise testing SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CARDIOVASCULAR-DISEASE MORTALITY; HEART-RATE RECOVERY; PROGNOSTIC VALUE; CARDIORESPIRATORY FITNESS; ALL-CAUSE; METABOLIC EQUIVALENTS; FUNCTIONAL-CAPACITY; FOLLOW-UP; MEN; PREDICTOR AB Background: Little is known about the association between exercise capacity and nonfatal cardiac events in patients referred for exercise treadmill testing (ETT). Our objective was to determine the prognostic importance of exercise capacity for nonfatal cardiac events in a clinical population. Methods: A cohort study was performed of 9191 patients referred for ETT. Median follow-up was 2.7 years. Exercise capacity was quantified as the proportion of age- and sex-predicted metabolic equivalents achieved and categorized as less than 85%, 85% to 100%, and greater than 100%. Individual primary outcomes were myocardial infarction, unstable angina, and coronary revascularization. All-cause mortality was a secondary outcome. Results: Patients with lower exercise capacity were more likely to be female (55.38% vs 42.62%); to have comorbidities such as diabetes (23.16% vs 9.61%) and hypertension (59.43% vs 44.05%); and to have abnormal ETT findings such as chest pain on the treadmill (12.09% vs 7.63%), abnormal heart rate recovery (82.74% vs 64.13%), and abnormal chronotropic index (32.89% vs 12.20%). In multivariable analysis, including other ETT variables, lower exercise capacity (< 85% of predicted) was associated with increased risk of myocardial infarction (hazard ratio [HR], 2,36; 95% confidence interval [01, 1.55-3.60), unstable angina (HR, 2.39; 95% Cl, 1.78-3.21), coronary revascularization (HR, 1.75; 95% CI, 1.46-2.08), and all-cause mortality (HR, 2.90; 95% CI, 1.88-4.47) compared with exercise capacity greater than 100% of predicted. Conclusions: Adjusting for patient characteristics and other ETT variables, reduced exercise capacity was associated with both nonfatal cardiovascular events and mortality in patients referred for ETT. C1 [Peterson, Pamela N.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Dept Med, Div Cardiol, Denver, CO 80204 USA. [Peterson, Pamela N.; Ho, P. Michael; Rumsfield, John S.; Masoudi, Frederick A.] Univ Colorado, Denver Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO USA. [Peterson, Pamela N.; Magid, David J.; Ross, Colleen; Ho, P. Michael; Rumsfield, John S.; Lyons, Ella E.; Masoudi, Frederick A.] Kaiser Permanente, Clin Res Unit, Denver, CO USA. [Smith, Scott S.] Kaiser Permanente, Dept Internal Med, Denver, CO USA. [Ho, P. Michael; Rumsfield, John S.] Denver Vet Affairs Med Ctr, Dept Med, Div Cardiol, Denver, CO 80220 USA. [Lauer, Michael S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. RP Peterson, PN (reprint author), Denver Hlth Med Ctr, Dept Med, Div Cardiol, Mail Code 0960,777 Bannock St, Denver, CO 80204 USA. EM Pamela.Peterson@uchsc.edu RI Lauer, Michael/L-9656-2013 OI Lauer, Michael/0000-0002-9217-8177 NR 26 TC 35 Z9 36 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JAN 28 PY 2008 VL 168 IS 2 BP 174 EP 179 DI 10.1001/archinternmed.2007.68 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 254NR UT WOS:000252593800010 PM 18227364 ER PT J AU Wright, JT Harris-Haywood, S Pressel, S Barzilay, J Bairnbridge, C Bareis, CJ Basile, JN Black, HR Dart, R Gupta, AK Hamilton, BP Einhorn, PT Haywood, LJ Jafri, SZA Louis, GT Whelton, PK Scott, CL Sinnnons, DL Stanford, C Davis, BR AF Wright, Jackson T. Harris-Haywood, Sonja Pressel, Sara Barzilay, Joshua Bairnbridge, Charles Bareis, Charles J. Basile, Jan N. Black, Henry R. Dart, Richard Gupta, Alok K. Hamilton, Bruce P. Einhorn, Paula T. Haywood, L. Julian Jafri, Syed Z. A. Louis, Gail T. Whelton, Paul K. Scott, Cranford L. Sinnnons, Debra L. Stanford, Carol Davis, Barry R. TI Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome - Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 21st Annual Meeting of the International-Society-for-Hypertension-in-Blacks CY JUN 23, 2006 CL Atlanta, GA ID CALCIUM-CHANNEL BLOCKER; PROSPECTIVELY-DESIGNED OVERVIEWS; ISOLATED SYSTOLIC HYPERTENSION; MAJOR CARDIOVASCULAR EVENTS; CONVERTING ENZYME-INHIBITOR; DIABETES-MELLITUS; RANDOMIZED-TRIALS; RISK; ASSOCIATION; GLUCOSE AB Background: Antihypertensive drugs with favorable metabolic effects are advocated for first-line therapy in hypertensive patients with metabolic/cardiometabolic syndrome (MetS). We compared outcornes by race in hypertensive individuals with and without MetS treated with a thiazide-type diuretic (chlorthalidone), a calcium channel blocker (amlodipine besylate), an a-blocker (doxazosin mesylate), or an angiotensin-converting enzyme inhibitor (lisinopril). Methods: A subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind hypertension treatment trial of 42 4.18 participants. We defined MetS as hypertension plus at least 2 of the following: fasting serum glucose level of at least 100 mg/dL, body mass index (calculated as weight in kilograms divided by height in meters squared) of at least 30, fasting triglyceride levels of at least 150 mg/dL, and high-density lipoprotein cholesterol levels of less than 40 mg/dL in men or less than 50 mg/dL in women. Results: Significantly higher rates of heart failure were consistent across all treatment comparisons those with MetS. Relative risks (RRs) were 1.50 (95% confidence interval, 1.1.8-1.90), 1.49 (1.17-1.90), and 1.88 (1.42-2.47) in black participants and 1.25 (1.06-1.47), 1.20 (1.01-1.41), and 1.82 (1.51-2.19) in nonblack participants for amlodipine, lisinopril, and doxazosin comparisons with chlorthalidone, respectively. Higher rates for combined cardiovascular disease were observed with lisinopril-chlorthalidone (RRs, 1.24 [1.09-1.40] and 1.10 [1.02-1.19], respectively) and doxazosin-chlorthalidone comparisons (RRs, 1.37 [1.19-1.58] and 1.18 [1.081.30], respectively) in black and nonblack participants with MetS. Higher rates of stroke were seen in black participants only (RR, 1.37 [1.07-1.76] for the lisinopril-chlorthalidone comparison, and RR, 1.49 [1.09-2.03] for the doxazosin-chlorthalidone comparison). Black patients with MetS a] so had higher rates of end-stage renal disease (RR, 1.70 [1.13-2.55]) with lisinopril compared with chlorthalidone. Conclusions: The ALLHAT findings fail to support the preference for calcium channel blockers, alpha-blockers, or angiotensin-converting enzyme inhibitors compared with thiazide-type diuretics in patients with the MetS, despite their more favorable metabolic profiles. This was particularly true for black participants. C1 [Pressel, Sara; Bairnbridge, Charles; Davis, Barry R.] Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, Coordnating Ctr Clin Trials, Houston, TX 77030 USA. [Wright, Jackson T.] Case Western Reserve Univ, Dept Med, Gen Clin Res Ctr, Cleveland, OH 44106 USA. [Harris-Haywood, Sonja] Case Western Reserve Univ, Dept Family Med, Cleveland, OH 44106 USA. [Barzilay, Joshua] Kaiser Permanente, Tucker, GA USA. [Bareis, Charles J.] MacNeal Ctr Clin Res, Dept Med, Berwyn, IL USA. [Basile, Jan N.] Med Univ S Carolina, Charleston, SC 29425 USA. [Basile, Jan N.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Black, Henry R.] NYU, Dept Internal Med, Cardiol Sect, New York, NY USA. [Dart, Richard] Marshfield Clin Fdn Med Res & Educ, Dept Nephrol, Marshfield, WI USA. [Gupta, Alok K.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Hamilton, Bruce P.] Vet Affairs Med Ctr, Endocrine Hypertens Unit, Baltimore, MD USA. [Einhorn, Paula T.] NHLBI, Div Prevent & Populat Sci, Bethesda, MD 20892 USA. [Haywood, L. Julian] Univ So Calif, Div Cardiovasc Med, Los Angeles, CA USA. [Jafri, Syed Z. A.] Vet Affairs Med Ctr, Dept Cardiol, Fargo, ND USA. [Louis, Gail T.] Tulane Univ, Hlth Sci Ctr, New Orleans, LA USA. [Whelton, Paul K.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Sinnnons, Debra L.] Univ Arkansas Med Sci, Dept Endocrinol, Little Rock, AR 72205 USA. [Stanford, Carol] Univ Missouri, Sch Med, Kansas City, MO USA. RP Pressel, S (reprint author), Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, Coordnating Ctr Clin Trials, 1200 Herman Pressel St,Ste E801, Houston, TX 77030 USA. EM Sara.L.Pressel@uth.tmc.edu FU NHLBI NIH HHS [N01 HC035130, N01HC35130, N01-HC-35130]; NIMHD NIH HHS [P60 MD002265] NR 35 TC 54 Z9 54 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JAN 28 PY 2008 VL 168 IS 2 BP 207 EP 217 DI 10.1001/archinternmed.2007.66 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 254NR UT WOS:000252593800016 PM 18227370 ER PT J AU Lee, MH El-Shewy, HM Luttrell, DK Luttrell, LM AF Lee, Mi-Hye El-Shewy, Hesham M. Luttrell, Deirdre K. Luttrell, Louis M. TI Role of beta-arrestin-mediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PROTEIN-COUPLED RECEPTOR; NUCLEAR EXPORT SIGNAL; REGULATED KINASES; ERK1/2 ACTIVATION; EGF RECEPTOR; BETA-ARRESTIN-2; ENDOCYTOSIS; PATHWAYS; MAPK; PHOSPHORYLATION AB Heptahelical G protein-coupled receptors employ several mechanisms to activate the ERK1/2 cascade and control gene transcription. Previous work with the angiotensin AT1a receptor has shown that G(q/11) activation leads to a rapid and transient rise in ERK1/2 activity, whereas beta-arrestin binding supports sustained ERK1/2 activation by scaffolding a Raf center dot MEK center dot ERK complex associated with the internalized receptor. In this study, we compared the role of the two beta-arrestin isoforms in AT1a receptor desensitization, ERK1/2 activation and transcription using selective RNA interference. In HEK293 cells, both the native AT1a receptor and a G protein-coupling deficient DRY/AAY mutant recruited beta-arrestin1 and beta-arrestin2 upon angiotensin binding and internalized with the receptor. In contrast, only beta-arrestin2 supported protein kinase C-independent ERK1/2 activation by both the AT1a and DRY/AAY receptors. Using focused gene expression filter arrays to screen for endogenous transcriptional responses, we found that silencing beta-arrestin1 or beta-arrestin2 individually did not alter the response pattern but that silencing both caused a marked increase in the number of transcripts that were significantly up-regulated in response to AT1a receptor activation. The DRY/AAY receptor failed to elicit any detectable transcriptional response despite its ability to stimulate beta-arrestin2- dependent ERK1/2 activation. These results indicate that the transcriptional response to AT1a receptor activation primarily reflects heterotrimeric G protein activation. Although beta-arrestin1 and beta-arrestin2 are functionally specialized with respect to supporting G protein-independent ERK1/2 activation, their common effect is to dampen the transcriptional response by promoting receptor desensitization. C1 [Lee, Mi-Hye; El-Shewy, Hesham M.; Luttrell, Deirdre K.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Lee, Mi-Hye; El-Shewy, Hesham M.; Luttrell, Deirdre K.; Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA. [Lee, Mi-Hye; El-Shewy, Hesham M.; Luttrell, Deirdre K.; Luttrell, Louis M.] Med Univ S Carolina, Dept Mol Biol, Charleston, SC 29425 USA. [Lee, Mi-Hye; El-Shewy, Hesham M.; Luttrell, Deirdre K.; Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St, Charleston, SC 29425 USA. EM luttrell@musc.edu FU NIDDK NIH HHS [DK55524] NR 49 TC 43 Z9 47 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 25 PY 2008 VL 283 IS 4 BP 2088 EP 2097 DI 10.1074/jbc.M706892200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 253EH UT WOS:000252501000036 PM 18006496 ER PT J AU Vagin, O Tokhtaeva, E Yakubov, I Shevchenko, E Sachs, G AF Vagin, Olga Tokhtaeva, Elmira Yakubov, Iskandar Shevchenko, Eugenia Sachs, George TI Inverse correlation between the extent of N-glycan branching and intercellular adhesion in epithelia - Contribution of the Na,K-ATPase beta(1) subunit SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SEPTATE JUNCTION FUNCTION; TUBE-SIZE CONTROL; ACETYLGLUCOSAMINYLTRANSFERASE-V; CELL-ADHESION; PARACELLULAR TRANSPORT; ADHERENS JUNCTIONS; NA+/K+ ATPASE; EXPRESSION; CADHERIN; COMPLEX AB The majority of cell adhesion molecules are N-glycosylated, but the role of N-glycans in intercellular adhesion in epithelia remains ill-defined. Reducing N-glycan branching of cellular glycoproteins by swainsonine, the inhibitor of N-glycan processing, tightens and stabilizes cell-cell junctions as detected by a 3-fold decrease in the paracellular permeability and a 2-3-fold increase in the resistance of the adherens junction proteins to extraction by non-ionic detergent. In addition, exposure of cells to swainsonine inhibits motility of MDCK cells. Mutagenic removal of N-glycosylation sites from the Na,K-ATPase beta(1) subunit impairs cell-cell adhesion and decreases the effect of swainsonine on the paracellular permeability of the cell monolayer and also on detergent resistance of adherens junction proteins, indicating that the extent of N-glycan branching of this subunit is important for intercellular adhesion. The N-glycans of the Na,K-ATPase beta(1) subunit and E-cadherin are less complex in tight renal epithelia than in the leakier intestinal epithelium. The complexity of the N-glycans linked to these proteins gradually decreases upon the formation of a tight monolayer from dispersed MDCK cells. This correlates with a cell-cell adhesion-induced increase in expression of GnT-III (stops N-glycan branching) and a decrease in expression of GnTs IVC and V (promote N-glycan branching) as detected by real-time quantitative PCR. Consistent with these results, partial silencing of the gene encoding GnT-III increases branching of N-glycans linked to the Na,K-ATPase beta(1) subunit and other glycoproteins and results in a 2-fold increase in the paracellular permeability of MDCK cell monolayers. These results suggest epithelial cells can regulate tightness of cell junctions via remodeling of N-glycans, including those linked to the Na,K-ATPase beta(1)-subunit. C1 [Vagin, Olga; Tokhtaeva, Elmira; Yakubov, Iskandar; Shevchenko, Eugenia; Sachs, George] Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. [Vagin, Olga; Tokhtaeva, Elmira; Yakubov, Iskandar; Shevchenko, Eugenia; Sachs, George] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. RP Vagin, O (reprint author), VAGLAHS W LA, 11301 Wilshire Blvd,Rm 324,Bldg 113, Los Angeles, CA 90073 USA. EM olgav@ucla.edu FU NIDDK NIH HHS [R01 DK053642-10, DK077149, DK46917, DK58333, R01 DK046917, R01 DK046917-09S2, R01 DK053642, R01 DK058333, R01 DK058333-09, R01 DK077149, R01 DK077149-01A1, R01 DK077149-02, R56 DK058333]; PHS HHS [D53642] NR 42 TC 58 Z9 58 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 25 PY 2008 VL 283 IS 4 BP 2192 EP 2202 DI 10.1074/jbc.M704713200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 253EH UT WOS:000252501000047 PM 18025087 ER PT J AU Habib, SL Simone, S Barnes, JJ Abboud, HE AF Habib, Samy L. Simone, Simona Barnes, Jeff J. Abboud, Hanna E. TI Tuberin haploinsufficiency is associated with the loss of OGG1 in rat kidney tumors SO MOLECULAR CANCER LA English DT Article ID OXIDATIVE DNA-DAMAGE; RENAL-CELL CARCINOMA; FPG PROTEIN; EKER RAT; REPAIR; GENE; EXPRESSION; MUTATIONS; 8-HYDROXYGUANINE; GLYCOSYLASE AB Background: Tuberous sclerosis complex (TSC) is caused by defects in one of two tumor suppressor genes, TSC-1 or TSC-2. TSC-2 gene encodes tuberin, a protein involved in the pathogenesis of kidney tumors. Loss of heterozygosity (LOH) at the TSC2 locus has been detected in TSC-associated renal cell carcinoma (RCC) and in RCC in the Eker rat. Tuberin downregulates the DNA repair enzyme 8-oxoguanine DNA-glycosylase (OGG1) with important functional consequences, compromising the ability of cells to repair damaged DNA resulting in the accumulation of the mutagenic oxidized DNA, 8-oxo-dG. Loss of function mutations of OGG1 also occurs in human kidney clear cell carcinoma and may contribute to tumorgenesis. We investigated the distribution of protein expression and the activity of OGG1 and 8-oxo-dG and correlated it with the expression of tuberin in kidneys of wild type and Eker rats and tumor from Eker rat. Results: Tuberin expression, OGG1 protein expression and activity were higher in kidney cortex than in medulla or papilla in both wild type and Eker rats. On the other hand, 8-oxo-dG levels were highest in the medulla, which expressed the lowest levels of OGG1. The basal levels of 8-oxo-dG were also higher in both cortex and medulla of Eker rats compared to wild type rats. In kidney tumors from Eker rats, the loss of the second TSC2 allele is associated with loss of OGG1 expression. Immunostaining of kidney tissue shows localization of tuberin and OGG1 mainly in the cortex. Conclusion: These results demonstrate that OGG1 localizes with tuberin preferentially in kidney cortex. Loss of tuberin is accompanied by the loss of OGG1 contributing to tumorgenesis. In addition, the predominant expression of OGG1 in the cortex and its decreased expression and activity in the Eker rat may account for the predominant cortical localization of renal cell carcinoma. C1 [Habib, Samy L.; Simone, Simona] Univ Texas Hlth Sci Ctr San Antonio, OBrien Kidney Res Ctr, Dept Med, San Antonio, TX 78229 USA. [Habib, Samy L.; Barnes, Jeff J.; Abboud, Hanna E.] S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA. [Simone, Simona] Univ Bari, Dept Emergency Transplantat, Bari, Italy. [Habib, Samy L.; Barnes, Jeff J.; Abboud, Hanna E.] Ctr Clin, San Antonio, TX 78229 USA. RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, OBrien Kidney Res Ctr, Dept Med, San Antonio, TX 78229 USA. EM habib@uthscsa.edu; simones@uthscsa.edu; barnes@uthscsa.edu; abboud@uthscsa.edu FU NIDDK NIH HHS [P50 DK061597, R37 DK33665] NR 26 TC 12 Z9 12 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-4598 J9 MOL CANCER JI Mol. Cancer PD JAN 24 PY 2008 VL 7 AR 10 DI 10.1186/1476-4598-7-10 PG 9 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 272LX UT WOS:000253862000001 PM 18218111 ER PT J AU Cummings, DE Flum, DR AF Cummings, David E. Flum, David R. TI Gastrointestinal surgery as a treatment for diabetes SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID GASTRIC-BYPASS-SURGERY; BARIATRIC SURGERY; HYPERINSULINEMIC HYPOGLYCEMIA; NESIDIOBLASTOSIS; PREVALENCE; MORTALITY; MELLITUS; THERAPY; WEIGHT; HEALTH C1 [Cummings, David E.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Flum, David R.] Univ Washington, Dept Surg, Seattle, WA 98108 USA. RP Cummings, DE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way,S-111 Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu NR 23 TC 36 Z9 51 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 23 PY 2008 VL 299 IS 3 BP 341 EP 343 DI 10.1001/jama.299.3.341 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 253DB UT WOS:000252497800028 PM 18212321 ER PT J AU Sprenger, CC Plymate, SR Reed, MJ AF Sprenger, C. C. Plymate, S. R. Reed, M. J. TI Extracellular influences on tumour angiogenesis in the aged host SO BRITISH JOURNAL OF CANCER LA English DT Review DE prostate cancer; microenvironment; senescence; angiogenesis; growth factors; matrix metalloproteinases ID ENDOTHELIAL GROWTH-FACTOR; HUMAN PROSTATE-CANCER; GENE-EXPRESSION; DEPENDENT IMPAIRMENT; MMP-2 EXPRESSION; FACTOR RECEPTOR; BREAST-CANCER; FACTOR-I; INSULIN; CELLS AB Whether tumours are epithelial or non-epithelial in origin, it is generally accepted that once they reach a certain size all solid tumours are dependent upon a vascular supply to provide nutrients. Accordingly, there is great interest in how the extracellular environment enhances or inhibits vascular growth. In this minireview, we will examine key extracellular components, their changes with ageing, and discuss how these alterations may influence the subsequent development of tumour vasculature in the aged host. Because of the tight correlation between advanced age and development of prostate cancer, we will use prostate cancer as the model throughout this review. C1 [Sprenger, C. C.; Plymate, S. R.; Reed, M. J.] Univ Washington, Harborview Med Ctr, Dept Med, Div Gerontol, Seattle, WA 98104 USA. [Sprenger, C. C.] Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA. [Plymate, S. R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Reed, MJ (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Div Gerontol, 325 9th Ave,Box 359625, Seattle, WA 98104 USA. EM mjr@u.washington.edu FU NCI NIH HHS [U54 CA126540, U54CA126540-01]; NIA NIH HHS [R01AG15837, R01 AG015837] NR 52 TC 14 Z9 14 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-0920 J9 BRIT J CANCER JI Br. J. Cancer PD JAN 22 PY 2008 VL 98 IS 2 BP 250 EP 255 DI 10.1038/sj.bjc.6604144 PG 6 WC Oncology SC Oncology GA 259IQ UT WOS:000252933400002 PM 18182993 ER PT J AU Singh, M Gersh, BJ Li, S Rumsfeld, JS Spertus, JA O'Brien, SM Suri, RM Peterson, ED AF Singh, Mandeep Gersh, Bernard J. Li, Shuang Rumsfeld, John S. Spertus, John A. O'Brien, Sean M. Suri, Rakesh M. Peterson, Eric D. TI Mayo clinic risk score for percutaneous coronary intervention predicts in-hospital mortality in patients undergoing coronary artery bypass graft surgery SO CIRCULATION LA English DT Article DE angiography; angioplasty; mortality; revascularization; complications; risk factors ID EVALUATION EUROSCORE; EUROPEAN SYSTEM; STRATIFICATION; COMPLICATIONS; MORBIDITY; MODELS AB Background-Current risk models predict in-hospital mortality after either coronary artery bypass graft surgery or percutaneous coronary interventions separately, yet the overlap suggests that the same variables can define the risks of alternative coronary reperfusion therapies. Our goal was to seek a preprocedure risk model that can predict in-hospital mortality after either percutaneous coronary intervention or coronary artery bypass graft surgery. Methods and Results-We tested the ability of the recently validated, integer-based Mayo Clinic Risk Score (MCRS) for percutaneous coronary intervention, which is based solely on preprocedure variables (age, creatinine, ejection fraction, myocardial infarction <= 24 hours, shock, congestive heart failure, and peripheral vascular disease), to predict in-hospital mortality among 370 793 patients in the Society of Thoracic Surgeons database undergoing isolated coronary artery bypass graft surgery from 2004 to 2006. For the Society of Thoracic Surgeons coronary artery bypass graft surgery population studied, the median age was 66 years (quartiles 1 to 3, 57 to 74 years), with 37.2% of patients >= 70 years old. A high prevalence of comorbid conditions, including diabetes mellitus (37.1%), hypertension (80.5%), peripheral vascular disease (15.3%), and renal disease (creatinine >= 1.4 mg/dL; 11.8%), was present. A strong association existed between the MCRS and the observed mortality in the Society of Thoracic Surgeons database. The in-hospital mortality ranged between 0.3% (95% confidence interval 0.3% to 0.4%) with a score of 0 on the MCRS and 33.8% (95% confidence interval 27.3% to 40.3%) with an MCRS score of 20 to 24. The discriminatory ability of the MCRS was moderate, as measured by the area under the receiver operating characteristic curve (C-statistic = 0.715 to 0.784 among various subgroups); performance was inferior to the Society of Thoracic Surgeons model for most categories tested. Conclusions-This model, which is based on 7 preprocedure risk variables, may be useful for providing patients with individualized, evidence-based estimates of procedural risk as part of the informed consent process before percutaneous or surgical revascularization. C1 [Singh, Mandeep; Gersh, Bernard J.; Suri, Rakesh M.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA. [Li, Shuang; O'Brien, Sean M.; Peterson, Eric D.] Duke Univ, Clin Res Inst, Durham, NC USA. [Spertus, John A.] Mid Amer Heart Inst UMKC, Kansas City, MO USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. RP Singh, M (reprint author), Mayo Clin, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA. RI O'Brien, Sean/H-6268-2013 NR 16 TC 27 Z9 27 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JAN 22 PY 2008 VL 117 IS 3 BP 356 EP 362 DI 10.1161/CIRCULATIONAHA.107.711523 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 254QE UT WOS:000252601600013 PM 18172033 ER PT J AU Foland, LC Altshuler, LL Sugar, CA Lee, AD Leow, AD Townsend, J Narr, KL Asuncion, DM Toga, AW Thompson, PM AF Foland, Lara C. Altshuler, Lori L. Sugar, Catherine A. Lee, Agatha D. Leow, Alex D. Townsend, Jennifer Narr, Katherine L. Asuncion, Dina M. Toga, Arthur W. Thompson, Paul M. TI Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium SO NEUROREPORT LA English DT Article DE amygdala; bipolar disorder; emotion; hippocampus; lithium; magnetic resonance imaging; mood disorder ID TEMPORAL-LOBE STRUCTURES; DISORDER; MATTER; MRI; SCHIZOPHRENIA; ABNORMALITIES; ADOLESCENTS; ADULTS AB Previous structural neuroimaging studies of bipolar disorder have reported conflicting findings in limbic structures. Medication heterogeneity of patient samples may have contributed to these inconsistencies. Using structural magnetic resonance imaging we assessed whether lithium treatment was associated with differences in amygdala and hippocampal volumes in a sample of bipolar adults. A total of 49 magnetic resonance imaging scans were collected from patients who were currently treated with or without lithium. Amygdala and hippocampal volumes were analyzed using tensor-based morphometry. Statistical between-group comparisons of deformation maps showed that patients treated with lithium exhibited significantly increased volumes of the amygdala and hippocampus compared with patients who were not taking lithium. Our findings may help to explain previous inconsistencies in the bipolar literature. C1 [Foland, Lara C.; Lee, Agatha D.; Leow, Alex D.; Narr, Katherine L.; Toga, Arthur W.; Thompson, Paul M.] Univ Calif Los Angeles, Lab Neuroimaging, Dept Neurol, Los Angeles, CA USA. [Altshuler, Lori L.; Asuncion, Dina M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA. [Altshuler, Lori L.] Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Hlthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Townsend, Jennifer] Univ Calif Los Angeles, Sch Med, Ahmanson Lovelace Brain Mappinng Ctr, Los Angeles, CA USA. RP Altshuler, LL (reprint author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu RI Leow, Alex/K-3236-2014 OI Leow, Alex/0000-0002-5660-8651 FU NCRR NIH HHS [R21 RR019771, R21 RR019771-02, RR019771]; NIBIB NIH HHS [EB01651]; NICHD NIH HHS [R01 HD050735-05, HD050735, R01 HD050735]; NIEHS NIH HHS [U13 ES016515-01]; NIMH NIH HHS [F31 MH078556, F31 MH078556-03, K24 MH001848, K24 MH001848-08, K24 MH001848-10, MH01848, MH078556] NR 25 TC 82 Z9 84 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD JAN 22 PY 2008 VL 19 IS 2 BP 221 EP 224 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 255GF UT WOS:000252645000017 PM 18185112 ER PT J AU Chiao, EY Giordano, TP Richardson, P El-Serag, HB AF Chiao, Elizabeth Y. Giordano, Thomas P. Richardson, Peter El-Serag, Hashem B. TI Human immunodeficiency virus-associated squamous cell cancer of the anus: Epidemiology and outcomes in the highly active Antiretroviral therapy era SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID HIV-POSITIVE PATIENTS; ANAL CANCER; INTRAEPITHELIAL LESIONS; INFECTED PATIENTS; CARCINOMA; RISK; AIDS; MEN; CHEMORADIATION; TOLERANCE AB Purpose To evaluate and determine predictors of squamous cell carcinoma of the anus (SCCA) outcomes in the highly active antiretroviral therapy ( HAART) era for HIV-positive and -negative individuals using large national Veterans Affairs (VA) Administration databases. Patients and Methods We used the VA administrative databases to perform a retrospective cohort study in 1,184 veterans diagnosed with SCCA between 1998 and 2004. We calculated HIV infection rates and used logistic regression to identify epidemiologic factors that were associated with HIV infection. Kaplan-Meier curves and Cox proportional hazards models were calculated to compare survival between HIV-positive and HIV-negative veterans. Results In our cohort, 175 patients (15%) were HIV positive. The median age of the HIV-negative and -positive patients was 63 and 49 years, respectively ( P =.001). Individuals with HIV were eight times more likely to be male ( P =.01) and three times more likely to be African American ( P =.001). There were no differences between HIV-positive and HIV-negative individuals in the receipt of treatment. The 2-year observed survival rates were 77% and 75% among HIV-positive and HIV-negative individuals, respectively. In multivariate Cox analysis, significant predictors of survival were age, sex, metastasis at diagnosis, and comorbidity score. HIV infection did not affect survival. Conclusion A noteworthy proportion of individuals with SCCA in the VA system are HIV positive. HIV-associated SCCA seems mainly to be a disease among younger men. Survival of SCCA is equivalent between HIV-positive and HIV-negative individuals in the HAART era. Treatment should not be withheld or deintensified based on HIV status. C1 Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Quality Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Chiao, EY (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Quality Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM echiao@bcm.edu FU NCI NIH HHS [K23CA124318]; NIMH NIH HHS [K23MH67505] NR 29 TC 64 Z9 64 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 20 PY 2008 VL 26 IS 3 BP 474 EP 479 DI 10.1200/JCO.2007.14.2810 PG 6 WC Oncology SC Oncology GA 276XO UT WOS:000254177200024 PM 18202423 ER PT J AU Loftis, JM Huckans, M Ruimy, S Hinrichs, DJ Hauser, P AF Loftis, Jennifer M. Huckans, Marilyn Ruimy, Samantha Hinrichs, David J. Hauser, Peter TI Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1 beta and tumor necrosis factor-alpha SO NEUROSCIENCE LETTERS LA English DT Article DE cytokines; inflammation; chronic infection; beck depression inventory; hypothalamic-pituitary-adrenal axis; serotonin ID OF-THE-LITERATURE; MAJOR DEPRESSION; MULTIPLE-SCLEROSIS; CYTOKINES; INFLAMMATION; ASSOCIATION; NEUROTOXICITY; HYPOTHESIS; DISORDER; THERAPY AB Studies suggest that cytokines have a role in the biology of depression. In this study, we evaluated depression and cytokine levels in patients with and without chronic hepatitis C (HCV) to better assess how chronic infection alters cytokines levels and may contribute to depressive symptomotology. Twenty-three adults with (n=16) and without (n=7) HCV were recruited through the Portland VA Medical Center. Research participants were excluded for current substance abuse, psychotic disorder, liver cirrhosis, or interferon (IFN) therapy. Participants completed the Beck Depression Inventory-II (BDI-II) and a blood draw to evaluate plasma cytokine levels [i.e., interleukin (IL)-1 beta, IL-10 and tumor necrosis factor (TNF)-alpha]. t-Tests were performed to compare cytokine levels in patients with or without HCV. HCV patients showed higher TNF-alpha values compared to patients without HCV (group means =7.94 vs. 3.41 pg/mL, respectively, p=0.047). There were no significant differences between the groups for the other cytokines assessed. In patients with HCV, TNF-alpha and IL-1 beta levels (but not IL-10) were correlated with BDI-II scores [r=0.594, p=0.020 and r=0.489, p=0.055 (trend), respectively]. Taken together, these results show an association between severity of depressive symptoms and expression of pro-inflammatory cytokines in patients with HCV. Future studies should investigate how inflammatory mediators play a role in the expression of specific depressive symptoms in patients with chronic infection. Patients with HCV represent an interesting model to examine this relationship. Published by Elsevier Ireland Ltd. C1 [Loftis, Jennifer M.; Huckans, Marilyn; Ruimy, Samantha; Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Psychiat, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Loftis, Jennifer M.; Huckans, Marilyn; Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. [Loftis, Jennifer M.; Huckans, Marilyn; Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Dept Psychiat,Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. RP Loftis, JM (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Psychiat, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. EM loftisj@ohsu.edu FU NIMH NIH HHS [F32 MH071137, F32 MH071137-02] NR 30 TC 65 Z9 67 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD JAN 17 PY 2008 VL 430 IS 3 BP 264 EP 268 DI 10.1016/j.neulet.2007.11.001 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 261IH UT WOS:000253071800015 PM 18063307 ER PT J AU Leung, JW Mann, SK Leung, FW AF Leung, J. W. Mann, S. K. Leung, F. W. TI Sedation during colonoscopy and the benefits of lubrication: authors' reply SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Letter C1 [Leung, J. W.; Mann, S. K.] Sacramento VA Med Ctr, VA Calif Hlth Care Syst, Gastroenterol Sect, Mather, CA 95655 USA. [Leung, J. W.; Mann, S. K.] Univ Calif Davis, Ctr Med, Div Gastroenterol & Hepatol, Sacramento, CA USA. [Leung, F. W.] Sepulveda Ambulatory Care Ctr, VA Greater Los Angeles Hlthcare Syst, Div Gastroenterol, North Hills, CA USA. [Leung, F. W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Leung, JW (reprint author), Sacramento VA Med Ctr, VA Calif Hlth Care Syst, Gastroenterol Sect, Mather, CA 95655 USA. EM jwleung@ucdavis.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD JAN 15 PY 2008 VL 27 IS 2 BP 208 EP 209 DI 10.1111/j.1365-2036.2007.03571.x PG 2 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 266EI UT WOS:000253416900011 ER PT J AU Shalaby, A Voigt, A El-Saed, A Saba, S AF Shalaby, Alaa Voigt, Andrew El-Saed, Aiman Saba, Samir TI Usefulness of pulmonary artery pressure by echocardiography to predict outcome in patients receiving cardiac resynchronization therapy heart failure SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID TRICUSPID REGURGITATION; DOPPLER ULTRASOUND; SYSTOLIC PRESSURE AB Secondary pulmonary hypertension is a marker of advanced heart failure (HF) that confers a poor prognosis. Consecutive patients from 2004 through 2005 who underwent echocardiographic assessments of systolic pulmonary arterial pressure (SPAP) before the implantation of cardiac resynchronization therapy defibrillators were included: Patients were divided into tertiles according to baseline SPAP. Patients in the lowest (group 1, 20 to 29 mm Hg) and highest (group III, 45 to 88 mm Hg) tertiles were compared for the end points or death or transplantation and for HF hospital admission. Two hundred seventy patients were evaluated, of whom 95% were Caucasians and 91% men. The mean age was 66.5 +/- 11.6 years, the mean QRS duration was 155 +/- 30 ms, the mean left ventricular ejection fraction was 22.6 +/- 9.7%, and the mean New York Heart Association functional class was 3.0 +/- 0.4. In a multivariate model, death or transplantation was significantly more likely in group III (hazard ratio 2.62, 95% confidence interval 1.1 to 6.4, p = 0.036), as was HF admission (hazard ratio 6.35, 95% confidence interval 2.6 to 15.8, p <0.001). In patients with follow-up echocardiographic assessments, a reduction in SPAP was a significant predictor of freedom from the combined end point (hazard ratio 0.29, 95% confidence interval 0.12 to 0.76, p = 0.011). In conclusion, elevated baseline SPAP in patients who underwent cardiac resynchronization therapy is an independent predictor of all-cause mortality or transplantation and HF admission. A decrease in SPAP on follow-up echocardiography is an independent positive prognostic marker. (C) 2008 Elsevier Inc. All rights reserved. C1 [Shalaby, Alaa; Voigt, Andrew; Saba, Samir] Univ Pittsburgh, Med Ctr, Cardiovasc Inst, Pittsburgh, PA 15260 USA. [El-Saed, Aiman] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Shalaby, Alaa] VA Pittsburgh Healthcare Syst, Div Cardiol, Pittsburgh, PA USA. RP Shalaby, A (reprint author), Univ Pittsburgh, Med Ctr, Cardiovasc Inst, Pittsburgh, PA 15260 USA. EM alaa.shalaby@med.va.gov OI El-Saed, Aiman/0000-0002-1781-2203 NR 6 TC 29 Z9 34 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JAN 15 PY 2008 VL 101 IS 2 BP 238 EP 241 DI 10.1016/j.amjcard.2007.07.064 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 251NF UT WOS:000252379600019 PM 18178413 ER PT J AU Washko, GR Fan, VS Ramsey, SD Mohsenifar, Z Martinez, F Make, BJ Sciurba, FC Criner, GJ Minai, O DeCamp, MM Reilly, JJ AF Washko, George R. Fan, Vincent S. Ramsey, Scott D. Mohsenifar, Zab Martinez, Fernando Make, Barry J. Sciurba, Frank C. Criner, Gerald J. Minai, Omar DeCamp, Malcolm M. Reilly, John J. CA Natl Emphysema Treatment Trial Res TI The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE COPD; LVRS; exacerbation ID BRONCHIAL EPITHELIAL-CELLS; RANDOMIZED-TRIAL; EMPHYSEMA; FLUTICASONE; BUDESONIDE; PROPIONATE; SALMETEROL; FORMOTEROL AB Rationale: Lung volume reduction surgery (LVRS) has been demonstrated to provide a functional and mortality benefit to a select group of subjects with chronic obstructive pulmonary disease (COPD). The effect of LVRS on COPD exacerbations has not been as extensively studied, and whether improvement in postoperative lung function alters the risk of disease exacerbations is not known. Objectives: To examine the effect, and mechanism of potential benefit, of LVRS on COPD exacerbations by comparing the medical and surgical cohorts of the National Emphysema Treatment Trial (NETT). Methods A COPD exacerbation was defined using Centers for Medicare and Medicaid Services data and International Classification of Diseases, Ninth Revision, discharge diagnosis. Measurements and Main Results: There was no difference in exacerbation rate or time to first exacerbation between the medical and surgical cohorts during the year before study randomization (P = 0.58 and 0.85, respectively). Postrandomization, the surgical cohort experienced an approximate 30% reduction in exacerbation frequency (P = 0.0005). This effect was greatest in those subjects with the largest postoperative improvement in FEV1 (P = 0.04) when controlling for changes in other spirometric measures of lung function, lung capacities, and room air arterial blood gas tensions. Finally, LVRS increased the time to first exacerbation in both those subjects with and those without a prior history of exacerbations (P = 0.0002 and P < 0.0001, respectively). Conclusions: LVRS reduces the frequency of COPD exacerbations and increases the time to first exacerbation. One explanation for this benefit may be the postoperative improvement in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT 00000606). C1 [Washko, George R.; Reilly, John J.] Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA. [Fan, Vincent S.; Ramsey, Scott D.] Univ Washington, Seattle, WA 98195 USA. [Fan, Vincent S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Mohsenifar, Zab] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Martinez, Fernando] Univ Michigan, Ann Arbor, MI 48109 USA. [Make, Barry J.] Natl Jewish Med & Res Ctr, Denver, CO USA. [Sciurba, Frank C.] Univ Pittsburgh, Pittsburgh, PA USA. [Criner, Gerald J.] Temple Univ, Philadelphia, PA 19122 USA. [Minai, Omar] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [DeCamp, Malcolm M.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Washko, GR (reprint author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA. EM gwashko@partners.org FU NHLBI NIH HHS [HL 007633, HL 074428, HL 082541, N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, N01HR76119] NR 25 TC 39 Z9 40 U1 0 U2 5 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JAN 15 PY 2008 VL 177 IS 2 BP 164 EP 169 DI 10.1164/rccm.200708-1194OC PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 251BJ UT WOS:000252345300007 PM 17962632 ER PT J AU Esteban, A Ferguson, ND Meade, MO Frutos-Vivar, F Apezteguia, C Brochard, L Raymondos, K Nin, N Hurtado, J Tomicic, V Gonzalez, M Elizalde, J Nightingale, P Abroug, F Pelosi, P Arabi, Y Moreno, R Jibaja, M D'Empaire, G Sandi, F Matamis, D Montanez, AM Anzueto, A AF Esteban, Andres Ferguson, Niall D. Meade, Maureen O. Frutos-Vivar, Fernando Apezteguia, Carlos Brochard, Laurent Raymondos, Konstantinos Nin, Nicolas Hurtado, Javier Tomicic, Vinko Gonzalez, Marco Elizalde, Jose Nightingale, Peter Abroug, Fekri Pelosi, Paolo Arabi, Yaseen Moreno, Rui Jibaja, Manuel D'Empaire, Gabriel Sandi, Fredi Matamis, Dimitros Montanez, Ana Maria Anzueto, Antonio CA VENTILA Grp TI Evolution of mechanical ventilation in response to clinical research SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE mechanical ventilation; mortality; acute respiratory distress syndrome; noninvasive positive-pressure ventilation; weaning ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; CARDIOGENIC PULMONARY-EDEMA; TIDAL VOLUMES; HEALTH-CARE; METAANALYSIS; STRATEGIES; PRESSURES; MORTALITY; MEDICINE AB Rationale: Recent literature in mechanical ventilation includes strong evidence from randomized trials. Little information is available regarding the influence of these trials on usual clinical practice. Objectives: To describe current mechanical ventilation practices and to assess the influence of interval randomized trials when compared with findings from a 1998 cohort. Methods: A prospective international observational cohort study, with a nested comparative study performed in 349 intensive care units in 23 countries. We enrolled 4,968 consecutive patients receiving mechanical ventilation over a 1-month period. We recorded demographics and daily data related to mechanical ventilation for the duration of ventilation. We systematically reviewed the literature and developed 11 practice-change hypotheses for the comparative cohort study before seeing these results. In assessing practice changes, we only compared data from the 107 intensive care units (1,675 patients) that also participated in the 1998 cohort (1,383 patients). Measurements and Main Results: In 2004 compared with 1998, the use of noninvasive ventilation increased (11.1 vs. 4.4%, P < 0.001). Among patients with acute respiratory distress syndrome, tidal volumes decreased (7.4 vs. 9.1 ml/kg, P < 0.001) and positive end-expiratory pressure levels increased slightly (8.7 vs. 7.7 cm H2O, P = 0.02). More patients were successfully extubated after their first attempt of spontaneous breathing (77 vs. 62%, P < 0.001). Use of synchronized intermittent mandatory ventilation fell dramatically (1.6 vs. 11%, P < 0.001). Observations confirmed 10 of our 11 practice-change hypotheses. Conclusions: The strong concordance of predicted and observed practice changes suggests that randomized trial results have advanced mechanical ventilation practices internationally. C1 [Esteban, Andres; Frutos-Vivar, Fernando; Nin, Nicolas] Univ Hosp, Intens Care Unit, CIBER Enfermedades Respiratorias, Madrid 28905, Spain. [Ferguson, Niall D.] Univ Toronto, Univ Hlth Network, Dept Med, Div Respirol, Toronto, ON, Canada. [Ferguson, Niall D.] Univ Toronto, Interdepartmental Div Crit Care, Toronto, ON, Canada. [Meade, Maureen O.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Apezteguia, Carlos] Hosp Profesor A Posadas, Buenos Aires, DF, Argentina. [Brochard, Laurent] Univ Paris 12, INSERM U 841, AP HP, Ctr Hosp Albert Chenvier Henri Mondor, Paris, France. [Raymondos, Konstantinos] Med Hsch, Hannover, Germany. [Hurtado, Javier] Hosp Clin Montevideo, Montevideo, Uruguay. [Tomicic, Vinko] Clin Alemana Santiago, Santiago, Chile. [Gonzalez, Marco] Clin Medellin & Univ Pontificia Bolivariana, Medellin, Colombia. [Elizalde, Jose] Hosp ABC, Mexico City, DF, Mexico. [Nightingale, Peter] Wythenshawe Hosp, Manchester M23 9LT, Lancs, England. [Abroug, Fekri] Fattouma Bourguiba Monastir, Monastir, Tunisia. [Pelosi, Paolo] Univ Insubria, Osp Circolo, Varese, Italy. [Arabi, Yaseen] King Fahad Natl Guard Hosp, Riyadh, Saudi Arabia. [Moreno, Rui] Hosp Santo Antonio Capuchos, Lisbon, Portugal. [Jibaja, Manuel] Hosp Militar Quito, Quito, Ecuador. [D'Empaire, Gabriel] Hosp Clin, Caracas, Venezuela. [Sandi, Fredi] Hosp Obrero Numero 1, La Paz, Bolivia. [Matamis, Dimitros] Papageorgiou Gen Hosp, Thessaloniki, Greece. [Montanez, Ana Maria] Sociedad Peruana Med Intens, Lima, Peru. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Esteban, A (reprint author), Univ Hosp, Intens Care Unit, CIBER Enfermedades Respiratorias, Carretera Toledo Km 12500, Madrid 28905, Spain. EM aesteban@ucigetafe.com RI Lapinsky, Stephen/C-4624-2015; koca, ugur/F-1265-2016 OI Lapinsky, Stephen/0000-0002-6930-0306; koca, ugur/0000-0002-2949-4265; Frutos-Vivar, Fernando/0000-0002-4648-9636; Ferguson, Niall/0000-0002-6213-5264 NR 27 TC 319 Z9 338 U1 1 U2 17 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JAN 15 PY 2008 VL 177 IS 2 BP 170 EP 177 DI 10.1164/rccm.200706-893OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 251BJ UT WOS:000252345300008 PM 17962636 ER PT J AU Lorenz, KA Lynn, J Dy, SM Shugarman, LR Wilkinson, A Mularski, RA Morton, SC Hughes, RG Hilton, LK Maglione, M Rhodes, SL Rolon, C Sun, VC Shekelle, PG AF Lorenz, Karl A. Lynn, Joanne Dy, Sydney M. Shugarman, Lisa R. Wilkinson, Anne Mularski, Richard A. Morton, Sally C. Hughes, Ronda G. Hilton, Lara K. Maglione, Margaret Rhodes, Shannon L. Rolon, Cony Sun, Virginia C. Shekelle, Paul G. TI Evidence for improving palliative care at the end of life: A systematic review SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; CONGESTIVE-HEART-FAILURE; PLACEBO-CONTROLLED CROSSOVER; ILL HOSPITALIZED ADULTS; NURSING-HOME RESIDENTS; CANCER-PATIENTS; DOUBLE-BLIND; AROMATHERAPY MASSAGE AB Background: Many persons and their families are burdened by serious chronic illness in late life. How to best support quality of life is an important consideration for care. Purpose: To assess evidence about interventions to improve palliative and end-of-life care. Data Sources: English-language citations (January 1990 to November 2005) from MEDLINE, the Database of Abstracts of Reviews of Effects, the National Consensus Project for Quality Palliative Care bibliography, and November 2005 to January 2007 updates from expert reviews and literature surveillance. Study Selection: Systematic reviews that addressed "end of life," including terminal illness (for example, advanced cancer) and chronic, eventually fatal illness with ambiguous prognosis (for example, advanced dementia), and intervention studies (randomized and nonrandomized designs) that addressed pain, dyspnea, depression, advance care planning, continuity, and caregiving. Data Extraction: Single reviewers screened 24423 titles to find 6381 relevant abstracts and reviewed 1274 articles in detail to identify 33 high-quality systematic reviews and 89 relevant intervention studies. They synthesized the evidence by using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) classification. Data Synthesis: Strong evidence supports treating cancer pain with opioids, nonsteroidals, radionuclides, and radiotherapy; dyspnea from chronic lung disease with short-term opioids; and cancer-associated depression with psychotherapy, tricyclics, and selective serotonin reuptake inhibitors. Strong evidence supports multicomponent interventions to improve continuity in heart failure. Moderate evidence supports advance care planning led by skilled facilitators who engage key decision makers and interventions to alleviate caregiver burden. Weak evidence addresses cancer-related dyspnea management, and no evidence addresses noncancer pain, symptomatic dyspnea management in advanced heart failure, or short-acting antidepressants in terminal illness. No direct evidence addresses improving continuity for patients with dementia. Evidence was weak for improving caregiver burdens in cancer and was absent for heart failure. Limitations: Variable literature indexing for advanced chronic illness and end of life limited the comprehensiveness of searches, and heterogeneity was too great to do meta-analysis. Conclusion: Strong to moderate evidence supports interventions to improve important aspects of end-of-life care. Future research should quantify these effects and address the generalizability of insights across the conditions and settings of the last part of life. Many critical issues lack high-quality evidence. C1 [Lorenz, Karl A.] Vet Affairs Greater Los Angeles Hlthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, Los Angeles, CA 90073 USA. RP Lorenz, KA (reprint author), Vet Affairs Greater Los Angeles Hlthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, 11031 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM karl.lorenz@med.va.gov FU NCI NIH HHS [K07-CA096 783]; PHS HHS [290-02-0003] NR 152 TC 264 Z9 268 U1 20 U2 133 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 15 PY 2008 VL 148 IS 2 BP 147 EP 159 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 254NZ UT WOS:000252594600008 PM 18195339 ER PT J AU Muller, FL Liu, YH Abdul-Ghani, MA Lustgarten, MS Bhattacharya, A Jang, YC Van Remmen, H AF Muller, Florian L. Liu, Yuhong Abdul-Ghani, Muhammad A. Lustgarten, Michael S. Bhattacharya, Arunabh Jang, Youngmok C. Van Remmen, Holly TI High rates of superoxide production in skeletal-muscle mitochondria respiring on both complex I- and complex II-linked substrates SO BIOCHEMICAL JOURNAL LA English DT Article DE complex I; electron transport chain; H(2)O(2); mitochondria; oxaloacetate; superoxide ID HYDROGEN-PEROXIDE PRODUCTION; ELECTRON-TRANSPORT CHAIN; NADH-UBIQUINONE REDUCTASE; BRAIN MITOCHONDRIA; HEART-MITOCHONDRIA; SUCCINATE-DEHYDROGENASE; H2O2 PRODUCTION; BC(1) COMPLEX; SERUM ALBUMIN; FATTY-ACIDS AB Despite the considerable interest in superoxide as a potential cause of pathology, the mechanisms of its deleterious production by mitochondria remain poorly understood. Previous studies in purified mitochondria have found that the highest rates of superoxide production are observed with succinate-driven reverse-electron transfer through complex I, although the physiological importance of this pathway is disputed because it necessitates high concentrations of succinate and is thought not to occur when NAD is in the reduced state. However, very few studies have examined the rates of superoxide production with mitochondria respiring on both NADH-linked (e.g. glutamate) and complex II-linked substrates. In the present study, we find that the rates of superoxide production (measured indirectly as H,02) with glutamate + succinate (similar to 1100 pmol of H(2)O(2) center dot min(-1) mg(-1)) were unexpectedly much higher than with succinate (similar to 400 pmol of H(2)O(2) center dot min(-1) . mg(-1)) or glutamate (similar to 80 pmol of H(2)O(2) center dot min(-1) . mg(-1)) alone. Superoxide production with glutamate + succinate remained high even at low substrate concentrations (< 1 mM), was decreased by rotenone and was completely eliminated by FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone), indicating that it must in large part originate from reverse-electron transfer through complex I. Similar results were obtained when glutamate was replaced with pyruvate, a-ketoglutarate or palmitoyl carnitine. In contrast, superoxide production was consistently lowered by the addition of malate (malate + succinate - 30 pmol of H(2)O(2) - min(-1) - mg(-1)). We propose that the inhibitory action of malate on superoxide production can be explained by oxaloacetate inhibition of complex II. In summary, the present results indicate that reverse-electron transfer-mediated superoxide production can occur under physiologically realistic substrate conditions and suggest that oxaloacetate inhibition of complex 11 may be an adaptive mechanism to minimize this. C1 [Muller, Florian L.; Bhattacharya, Arunabh; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Liu, Yuhong; Bhattacharya, Arunabh; Jang, Youngmok C.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Abdul-Ghani, Muhammad A.; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. [Lustgarten, Michael S.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. RP Muller, FL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78229 USA. EM aettius@aol.com FU NIA NIH HHS [1P30-AG13319, 5T3-AG021890-02, P01AG020591, P01AG19316] NR 57 TC 90 Z9 91 U1 0 U2 4 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD JAN 15 PY 2008 VL 409 BP 491 EP 499 DI 10.1042/BJ20071162 PN 2 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 259BV UT WOS:000252915000017 PM 17916065 ER PT J AU Boyd, LB Atmar, RL Randall, GL Hamill, RJ Steffen, D Zechiedrich, L AF Boyd, Lauren Becnel Atmar, Robert L. Randall, Graham L. Hamill, Richard J. Steffen, David Zechiedrich, Lynn TI Increased fluoroquinolone resistance with time in Escherichia coli from > 17,000 patients at a large county hospital as a function of culture site, age, sex, and location SO BMC INFECTIOUS DISEASES LA English DT Article ID GRAM-NEGATIVE BACILLI; URINARY-TRACT-INFECTIONS; UNITED-STATES; ANTIBIOTIC-RESISTANCE; ANTIMICROBIAL RESISTANCE; QUINOLONE RESISTANCE; SUSCEPTIBILITY; CIPROFLOXACIN; SURVEILLANCE; PATHOGENS AB Background: Escherichia coli infections are common and often treated with fluoroquinolones. Fluoroquinolone resistance is of worldwide importance and is monitored by national and international surveillance networks. In this study, we analyzed the effects of time, culture site, and patient age, sex, and location on fluoroquinolone resistance in E. coli clinical isolates. Methods: To understand how patient factors and time influenced fluoroquinolone resistance and to determine how well data from surveillance networks predict trends at Ben Taub General Hospital in Houston, TX, we used Perl to parse and MySQL to house data from antibiograms (n congruent to 21,000) for E. coli isolated between 1999 to 2004 using Chi Square, Bonferroni, and Multiple Linear Regression methods. Results: Fluoroquinolone resistance (i) increased with time; (ii) exceeded national averages by 2- to 4- fold; (iii) was higher in males than females, largely because of urinary isolates from male outpatients; (iv) increased with patient age; (v) was 3% in pediatric patients; (vi) was higher in hospitalized patients than outpatients; (vii) was higher in sputum samples, particularly from inpatients, than all other culture sites, including blood and urine, regardless of patient location; and (viii) was lowest in genital isolates than all other culture sites. Additionally, the data suggest that, with regard to susceptibility or resistance by the Dade Behring MicroScan system, a single fluoroquinolone suffices as a "surrogate marker" for all of the fluoroquinolone tested. Conclusion: Large surveillance programs often did not predict E. coli fluoroquinolone resistance trends at a large, urban hospital with a largely indigent, ethnically diverse patient population or its affiliated community clinics. C1 [Boyd, Lauren Becnel; Atmar, Robert L.; Hamill, Richard J.; Zechiedrich, Lynn] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Atmar, Robert L.; Hamill, Richard J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Randall, Graham L.; Zechiedrich, Lynn] Baylor Coll Med, Interinstitut Program Struct & Computat Biol & Mo, Houston, TX 77030 USA. [Steffen, David] Baylor Coll Med, Bioinformat Resource Ctr, Houston, TX 77030 USA. [Hamill, Richard J.] Michael E Debakey Vet Adm Med Ctr, Houston, TX 77030 USA. RP Zechiedrich, L (reprint author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. EM lb144335@bcm.edu; ratmar@bcm.edu; grandall@bcm.edu; richard.hamill@med.va.gov; steffen@bcm.edu; elz@bcm.edu FU NIAID NIH HHS [R01 AI054830]; NIDDK NIH HHS [T90DK070109, T90 DK070109]; NLM NIH HHS [T15 LM007093, T15 LM07093] NR 32 TC 43 Z9 44 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD JAN 15 PY 2008 VL 8 AR 4 DI 10.1186/1471-2334-8-4 PG 7 WC Infectious Diseases SC Infectious Diseases GA 274EJ UT WOS:000253984300001 PM 18197977 ER PT J AU Franco, AT Johnston, E Krishna, U Yamaoka, Y Israel, DA Nagy, TA Wroblewski, LE Piazuelo, MB Correa, P Peek, RM AF Franco, Aime T. Johnston, Elizabeth Krishna, Uma Yamaoka, Yoshio Israel, Dawn A. Nagy, Toni A. Wroblewski, Lydia E. Piazuelo, Maria Blanca Correa, Pelayo Peek, Richard M., Jr. TI Regulation of gastric carcinogenesis by helicobacter pylori virulence factors SO CANCER RESEARCH LA English DT Article ID OUTER-MEMBRANE PROTEINS; EPITHELIAL-CELLS; BETA-CATENIN; GENE POLYMORPHISMS; MONGOLIAN GERBIL; INCREASED RISK; IV SECRETION; TRANSCRIPTIONAL ACTIVITY; GASTRODUODENAL DISEASE; VACUOLATING CYTOTOXIN AB Helicobacter pylori is the strongest known risk factor for gastric adenocarcinoma, and strains that possess the cag secretion system, which translocates the bacterial effector CagA into host cells, augment cancer risk. H. pylori strains that express the vacuolating cytotoxin or the outer membrane protein OipA are similarly associated with severe pathologic outcomes. We previously reported that an in vivo adapted H. pylori strain, 7.13, induces gastric adenocarcinoma in rodent models of gastritis. In the current study, we used carcinogenic strain 7.13 as a prototype to define the role of virulence constituents in H. pylori-mediated carcinogenesis. Mongolian gerbils were infected with wild-type strain 7.13 or cagA(-), vacA(-), or oipA(-) mutants for 12 to 52 weeks. All infected gerbils developed gastritis; however, inflammation was significantly attenuated in animals infected with the cagA(-) hut not the vacA(-) or oipA(-) strains. Gastric dysplasia and cancer developed in >50% of gerbils infected with either the wild-type or vacA- strain but in none of the animals infected with the cagA(-) strain. Inactivation of oipA decreased beta-catenin nuclear localization in vitro and reduced the incidence of cancer in gerbils. OipA expression was detected significantly more frequently among H. pylori strains isolated from human subjects with gastric cancer precursor lesions versus persons with gastritis alone. These results indicate that loss of CagA prevents the development of cancer in this model. Inactivation of oipA attenuates P-catenin nuclear translocation and also decreases the incidence of carcinoma. In addition to defining factors that mediate H. pylori-induced cancer, these results provide insight into mechanisms that may regulate the development of other malignancies arising within the context of inflammatory states. C1 [Franco, Aime T.; Krishna, Uma; Israel, Dawn A.; Nagy, Toni A.; Wroblewski, Lydia E.; Piazuelo, Maria Blanca; Correa, Pelayo; Peek, Richard M., Jr.] Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Med, Nashville, TN 37232 USA. [Franco, Aime T.; Krishna, Uma; Israel, Dawn A.; Nagy, Toni A.; Wroblewski, Lydia E.; Piazuelo, Maria Blanca; Correa, Pelayo; Peek, Richard M., Jr.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA. [Johnston, Elizabeth] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA. [Peek, Richard M., Jr.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA. [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. [Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. RP Peek, RM (reprint author), Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Med, 1030C MRB IV 2215B Garland Ave, Nashville, TN 37232 USA. EM richard.peek@vanderbilt.edu FU NCI NIH HHS [CA-028842, P01 CA028842, P01 CA028842-16, R01 CA077955, R01 CA077955-06]; NIDDK NIH HHS [R01 DK062813-01A2, DK-58587, DK-62813, DK-73902, DK-77955, K01 DK077955, R01 DK058587, R01 DK058587-01A1, R01 DK062813, R01 DK062813-04, R01 DK073902, R01 DK073902-01] NR 50 TC 124 Z9 128 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD JAN 15 PY 2008 VL 68 IS 2 BP 379 EP 387 DI 10.1158/0008-5472.CAN-07-0824 PG 9 WC Oncology SC Oncology GA 253FJ UT WOS:000252503800008 PM 18199531 ER PT J AU Gerding, DN Muto, CA Owens, RC AF Gerding, Dale N. Muto, Carlene A. Owens, Robert C., Jr. TI Treatment of Clostridium difficile infection SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID ANTIBIOTIC-ASSOCIATED COLITIS; INTRAVENOUS IMMUNE GLOBULIN; IN-VITRO ACTIVITY; PSEUDOMEMBRANOUS COLITIS; SACCHAROMYCES-BOULARDII; TOXIN-A; MULTIPLE RELAPSES; ANTIBODY-RESPONSE; DOUBLE-BLIND; HYPERVIRULENT STRAIN AB Recent outbreaks of Clostridium difficile infection (CDI) in North America have been due to a more virulent, possibly more resistant strain that causes more-severe disease, making prompt recognition of cases and optimal management of infection essential for a successful therapeutic outcome. Treatment algorithms are presented to help guide the management of patients with CDI. Metronidazole has been recommended as initial therapy since the late 1990s and continues to be the first choice for all but seriously ill patients and those with complicated or fulminant infections or multiple recurrences of CDI, for whom vancomycin is recommended. Other options for recurrent CDI, such as probiotics and currently available anion-exchange resins, have limited efficacy and are potentially harmful. Intravenous immunoglobulin may benefit patients with refractory, recurrent, or severe disease, but no controlled data are available. Two antimicrobials available in the United States for other indications, nitazoxanide and rifaximin, have been used successfully for CDI treatment but, like metronidazole, lack United States Food and Drug Administration approval for this indication. Experimental treatments currently in clinical development include a toxin-binding polymer, tolevamer; 2 poorly absorbed antimicrobials, OPT-80 (formerly known as Difimicin) and ramoplanin; monoclonal antibodies; and a C. difficile vaccine. C1 [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Gerding, Dale N.] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA. [Muto, Carlene A.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Owens, Robert C., Jr.] Maine Med Ctr, Portland, ME 04102 USA. [Owens, Robert C., Jr.] Univ Vermont, Coll Med, Burlington, VT USA. RP Gerding, DN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, 5th Ave & Roosevelt Rd,POB 5000, Hines, IL 60141 USA. EM dale.gerding2@va.gov NR 114 TC 170 Z9 174 U1 1 U2 22 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2008 VL 46 SU 1 BP S32 EP S42 DI 10.1086/521860 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 249YU UT WOS:000252268000005 PM 18177219 ER PT J AU Gerding, DN Muto, CA Owens, RC AF Gerding, Dale N. Muto, Carlene A. Owens, Robert C., Jr. TI Measures to control and prevent Clostridium difficile infection SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID PROTON PUMP INHIBITORS; HOSPITALIZED-PATIENTS; REDUCE TRANSMISSION; CARE FACILITIES; DIARRHEA; DISEASE; RISK; COLITIS; EPIDEMIOLOGY; ACQUISITION AB Control of Clostridium difficile infection (CDI) outbreaks in health care facilities presents significant challenges to infection control specialists and other health care workers. C. difficile spores survive routine environmental cleaning with detergents and hand hygiene with alcohol-based gels. Enhanced cleaning of all potentially contaminated surfaces with 10% sodium hypochlorite reduces the environmental burden of C. difficile, and use of barrier precautions reduces C. difficile transmission. Thorough handwashing with chlorhexidine or with soap and water has been shown to be effective in removing C. difficile spores from hands. Achieving high-level compliance with these measures is a major challenge for infection control programs. Good antimicrobial stewardship complements infection control efforts and environmental interventions to provide a comprehensive strategy to prevent and control outbreaks of CDI. The efficacy of metronidazole or vancomycin prophylaxis to prevent CDI in patients who are receiving other antimicrobials is unproven, and treatment with these agents is ineffective against C. difficile in asymptomatic carriers. C1 [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Gerding, Dale N.] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA. [Muto, Carlene A.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Owens, Robert C., Jr.] Maine Med Ctr, Portland, ME 04102 USA. [Owens, Robert C., Jr.] Univ Vermont, Coll Med, Burlington, VT USA. RP Gerding, DN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, 5th Ave & Roosevelt Rd,POB 5000, Hines, IL 60141 USA. EM dale.gerding2@va.gov NR 50 TC 141 Z9 146 U1 2 U2 21 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2008 VL 46 SU 1 BP S43 EP S49 DI 10.1086/521861 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 249YU UT WOS:000252268000006 PM 18177221 ER PT J AU Yamauchi, K Choi, IJ Lu, H Ogiwara, H Graham, DY Yamaoka, Y AF Yamauchi, Kazuyoshi Choi, Il-Ju Lu, Hong Ogiwara, Hiroaki Graham, David Y. Yamaoka, Yoshio TI Regulation of IL-18 in Helicobacter pylori infection SO JOURNAL OF IMMUNOLOGY LA English DT Article ID GAMMA-INDUCING FACTOR; HUMAN GASTRIC-MUCOSA; IFN-GAMMA; INTERFERON-GAMMA; EPITHELIAL-CELLS; GENE-EXPRESSION; T-CELLS; PROMOTER ACTIVATION; DEFICIENT MICE; MYELOID CELLS AB The gastric mucosal immune response is thought to be comprised predominantly of the Th1 type; however, there are limited data regarding the role of IL-18 in Helicobacter pylori-induced inflammation. We investigated IL-18 levels in gastric mucosal biopsy specimens as well as in isolated gastric epithelial cells and lamina propria mononuclear cells. We also investigated IL-18 levels in gastric epithelial cells and the monocyte cell line THP-1 cocultured with H. pylori. In both systems, IL-18 levels were markedly enhanced in H. pylori-infected epithelial cells and monocytes. IL-18 levels in H. pylori-infected gastric mucosa were well correlated with the severity of gastric inflammation, confirming that H. pylori-induced IL-18 plays an important role in gastric injury. Virulence factors of H. pylori; the cap pathogenicity island and OipA affected IL-18 induction in different manners. Up-regulation of IL-18 mRNA/protein in epithelial cells was dependent on both virulence factors. Interestingly, up-regulation of IL-18 mRNA in monocytes was independent of both factors, whereas IL-18 protein was OipA dependent -cag pathogenicity island independent, indicating that OipA regulates IL-18 induction in monocytes at the posttranscriptional level. IL-18 levels in the gastric biopsy specimens showed similar patterns to those in lamina propria mononuclear cells with respect to virulence factors, suggesting that submucosal monocytes/macrophages are the main source of IL-18 induced by H. pylori infection. H. pylori appeared to regulate the ERK/JNK -> AP-1 pathway in both cell types. In addition, OipA and its related p38 pathway may be closely involved in IL-18 induction in H. pylori-infected gastric mucosa and may contribute to gastric injury. C1 [Yamauchi, Kazuyoshi; Choi, Il-Ju; Lu, Hong; Ogiwara, Hiroaki; Graham, David Y.; Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. [Yamauchi, Kazuyoshi; Choi, Il-Ju; Lu, Hong; Ogiwara, Hiroaki; Graham, David Y.; Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. [Choi, Il-Ju] Natl Canc Ctr, Res Inst & Hosp, Gyeonggi, South Korea. [Lu, Hong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Dis, Renji Hosp,Dept Gastroenterol, Shanghai 200030, Peoples R China. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, 2002 Holcombe Blvd,111D Room,3A-320, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [DK 62813, P30 DK056338, DK56338, R01 DK062813-04, R01 DK062813-05, R01 DK062813] NR 46 TC 31 Z9 33 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 15 PY 2008 VL 180 IS 2 BP 1207 EP 1216 PG 10 WC Immunology SC Immunology GA 250HG UT WOS:000252290000058 PM 18178861 ER PT J AU Atkinson, C Qiao, F Song, H Gilkeson, GS Tomlinson, S AF Atkinson, Carl Qiao, Fei Song, Hongbin Gilkeson, Gary S. Tomlinson, Stephen TI Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice SO JOURNAL OF IMMUNOLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; PULMONARY INFLAMMATION; CARDIAC ALLOGRAFTS; MURINE LUPUS; EXPRESSION; RECEPTOR; GLOMERULONEPHRITIS; DEFICIENCY; SURVIVAL; SUSCEPTIBILITY AB Complement appears to play a dual role in the progression of systemic lupus erythematosus, serving a beneficial role in enhancing immune complex clearance, while serving a pathogenic role in inducing local inflammation. To investigate these different roles of complement in a therapeutic setting, MRL/lpr mice were treated with the targeted murine C3 complement inhibitor, CR2-Crry, from 16 to 24 wk of age (after the development of proteinuria). The targeting moiety, CR2, binds to C3 breakdown products deposited at sites of complement activation and has the potential to provide complement inhibition locally without causing systemic inhibition. Administration of CR2-Crry i.v., at a dose of 0.25 mg once a week, was associated with a significant survival benefit, improved kidney function, and a significant reduction in glomerulonephritis and renal vasculitis. The presence of skin lesions and lung bronchiolar and vascular inflammation was also dramatically reduced by CR2-Crry treatment. CR2-Crry treatment also resulted in a significant reduction in autoantibody production, as measured by anti-dsDNA Ab levels, and did not cause an increase in circulating immune complex levels. These effects on autoimmunity and circulating immune complexes represent significant potential advantages over the use of Crry-Ig in MRL/lpr mice, a systemic counterpart of CR2-Crry. CR2-Crry localized preferentially to the kidneys in 16-wk MRL/lpr mice with a kidney-localized half-life of similar to 24 h. Thus, targeted complement inhibition at the C3 level is an effective treatment in murine lupus, even beginning after onset of disease. C1 [Atkinson, Carl; Qiao, Fei; Song, Hongbin; Tomlinson, Stephen] Med Univ S Carolina, Childrens Res Inst, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29425 USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Childrens Res Inst, Dept Microbiol & Immunol, Charleston, SC 29425 USA. EM tomlinss@musc.edu RI Song, Hongbin/C-1963-2013 FU NCRR NIH HHS [C06 RR015455] NR 28 TC 41 Z9 41 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 15 PY 2008 VL 180 IS 2 BP 1231 EP 1238 PG 8 WC Immunology SC Immunology GA 250HG UT WOS:000252290000060 PM 18178863 ER PT J AU Huan, J Kaler, LJ Mooney, JL Subramanian, S Hopke, C Vandenbark, AA Rosloniec, EF Burrows, GG Offner, H AF Huan, Jianya Kaler, Laurie J. Mooney, Jeffery L. Subramanian, Sandhya Hopke, Corwyn Vandenbark, Arthur A. Rosloniec, Edward F. Burrows, Gregory G. Offner, Halina TI MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis SO JOURNAL OF IMMUNOLOGY LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; SHARED EPITOPE HYPOTHESIS; RHEUMATOID-ARTHRITIS; SELF-TOLERANCE; PASSIVE TRANSFER; PEPTIDE; INDUCTION; ACTIVATION; MOLECULES AB We previously demonstrated the therapeutic effects of MHC class II derived recombinant T cell receptor ligands (RTL), single-chain two domain complexes of the alpha 1 and beta 1 domains of MHC class II molecules genetically linked with an immunodominant peptide, in experimental autoimmune encephalomyelitis. In the current study, we produced a monomeric murine I-A(q)-derived RTL construct covalently linked with bovine collagen type II peptide (bCII257-270) suitable for use in DBA/1LacJ mice that develop collagen-induced arthritis (CIA), an animal model of human rheumatoid arthritis, after immunization with bCII protein in CFA. In this study, we demonstrate that the I-A(q)-derived RTLs reduced the incidence of the disease, suppressed the clinical and histological signs of CIA and induced long-term modulation of T cells specific for arthritogenic Ags. Our results showed that the I-A(q)/bCII257-270 molecule could systemically reduce proinflammatory IL-17 and IFN-gamma production and significantly increase anti-inflammatory IL-10, IL-13, and FoxP3 gene expression in splenocytes. Moreover, I-A(q)/bCII257-270 molecule could also selectively inhibit IL-1 beta, IL-6, and IL-23 expression in local joint tissue. This is the first report demonstrating effective prevention of joint inflammation and clinical signs of CIA with an I-A(q)-derived RTL, thus supporting the possible clinical use of this approach for treating rheumatoid arthritis in humans. C1 [Huan, Jianya; Kaler, Laurie J.; Subramanian, Sandhya; Hopke, Corwyn; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA. [Huan, Jianya; Mooney, Jeffery L.; Vandenbark, Arthur A.; Burrows, Gregory G.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Rosloniec, Edward F.] Vet Affairs Med Ctr, Memphis, TN 38104 USA. RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIAID NIH HHS [R01 AI043960, AI43960]; NIDDK NIH HHS [R42 DK068881, R41 DK068881, DK068881]; NIMHD NIH HHS [R41 MD001833, MD001833]; NINDS NIH HHS [NS41965, R01 NS041965] NR 70 TC 18 Z9 20 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 15 PY 2008 VL 180 IS 2 BP 1249 EP 1257 PG 9 WC Immunology SC Immunology GA 250HG UT WOS:000252290000062 PM 18178865 ER PT J AU John, JF Lindsay, JA AF John, Joseph F., Jr. Lindsay, Jodi A. TI Clones and drones: Do variants of Panton-Valentine leukocidin extend the reach of community-associated methicillin-resistant Staphylococcus aureus? SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID SOFT-TISSUE INFECTIONS; PNEUMONIA; GENES; SKIN; EVOLUTION; LINEAGES; STRAINS; GENOME C1 [John, Joseph F., Jr.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [John, Joseph F., Jr.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [John, Joseph F., Jr.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Lindsay, Jodi A.] St Georges Univ London, Dept Cellular & Mol Med, Ctr Infect, London, ON, Canada. RP John, JF (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. EM joseph.john2@va.gov RI Lindsay, Jodi/B-9565-2008 OI Lindsay, Jodi/0000-0002-5219-1625 NR 30 TC 6 Z9 6 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JAN 15 PY 2008 VL 197 IS 2 BP 175 EP 178 DI 10.1086/524693 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 251TX UT WOS:000252399200001 PM 18177251 ER PT J AU Mamikonyan, E Siderowf, AD Duda, JE Potenza, MN Horn, S Stem, MB Weintraub, D AF Mamikonyan, Eugenia Siderowf, Andrew D. Duda, John E. Potenza, Marc N. Horn, Stacy Stem, Matthew B. Weintraub, Daniel TI Long-term follow-up of impulse control disorders in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE dopamine agonist; gambling; impulse control disorders; Parkinson's disease ID SUBTHALAMIC NUCLEUS STIMULATION; DOPAMINE AGONIST THERAPY; PREVALENCE; ASSOCIATION AB Recent studies have linked dopamine agonist (DA) usage with the development of impulse control disorders (ICDs) in Parkinson's disease (PD). Little is known about optimal management strategies or the long-term outcomes of affected patients. To report on the clinical interventions and long-term outcomes of PD patients who developed an ICD after DA initiation. Subjects contacted by telephone for a follow-up interview after a mean time period of 29.2 months. They were administered a modified Minnesota Impulse Disorder Interview for compulsive buying, gambling, and sexuality, and also self-rated changes in their ICD symptomatology. Baseline and follow-up dopamine replacement therapy use was recorded and verified by chart review. Of 18 subjects, 15 (83.3%) participated in the follow-up interview. At follow-up, patients were receiving a significantly lower DA levodopa equivalent daily dosage (LEDD) (Z = -3. 1, P = 0.002) and a higher daily levodopa dosage (Z = -1.9, P = 0.05), but a similar total LEDD dosage (Z = -0.47, P = 0.64) with no changes in Unified Parkinson's Disease Rating Scale motor score (Z = -1.3, P = 0.19). As part of ICD management, 12 (80.0%) patients discontinued or significantly decreased DA treatment, all of whom experienced full or partial remission of ICD symptoms by self-report, and 10 (83.3%) of whom no longer met diagnostic criteria for an ICD. For PD patients who develop an ICD in the context of DA treatment, discontinuing or significantly decreasing DA exposure, even when offset by an increase in levodopa treatment, is associated with remission of or significant reduction in ICD behaviors without worsening in motor symptoms. (c) 2007 Movement Disorder Society. C1 [Mamikonyan, Eugenia; Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.; Duda, John E.; Horn, Stacy; Stem, Matthew B.; Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.; Duda, John E.; Stem, Matthew B.; Weintraub, Daniel] Vet Affairs Med Ctr, PADRECC, Philadelphia, PA USA. [Potenza, Marc N.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Potenza, Marc N.] Vet Affairs Med Ctr, MIRECC, West Haven, CT USA. [Weintraub, Daniel] Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. EM weintrau@upenn.edu FU NIDA NIH HHS [R01 DA019039, R01 DA019039-05]; NIMH NIH HHS [K23 MH067894-05, K23 MH067894]; PHS HHS [NIMH 067894] NR 21 TC 115 Z9 119 U1 1 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN 15 PY 2008 VL 23 IS 1 BP 75 EP 80 DI 10.1002/mds.21770 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 258WS UT WOS:000252901400011 PM 17960796 ER PT J AU Powers, KM Kay, DM Factor, SA Zabetian, CP Higgins, DS Samii, A Nutt, JG Griffith, A Leis, B Roberts, JW Martinez, ED Montimurro, JS Checkoway, H Payami, H AF Powers, Karen M. Kay, Denise M. Factor, Stewart A. Zabetian, Cyrus P. Higgins, Donald S. Samii, All Nutt, John G. Griffith, Alida Leis, Berta Roberts, John W. Martinez, Erica D. Montimurro, Jennifer S. Checkoway, Harvey Payami, Haydeh TI Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; smoking; coffee; NSAIDs; nonsteroidal anti-inflammatory drugs ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CAFFEINE INTAKE; DOPAMINERGIC-NEURONS; CIGARETTE-SMOKING; NICOTINE; CONSUMPTION; RELIABILITY; PROTECTS; ALCOHOL; TRAITS AB Inverse associations of Parkinson's disease (PD) with cigarette smoking, coffee drinking, and nonsteroidal anti-inflammatory drug (NSAID) use have been reported individually. but their joint effects have not been examined. To quantify associations with PD for the individual, two-way and three-way combinations of these factors, a case-control association study with 1,186 PD patients and 928 controls was conducted. The study setting was the NeuroGenetics Research Consortium. Subjects completed a structured questionnaire regarding smoking. coffee, and NSAID consumption. Odds ratios were calculated using unconditional logistic regression. Smoking, coffee, and over the counter NSAID use as individual factors exhibited significantly reduced risks of 20% to 30%. The two-way and three-way combinations were associated with risk reduction of 37% to 49%, and 62%, respectively. Smoking and coffee exhibited significant inverse risk trends with increasing cumulative exposures, suggesting dose-response relations. With respect to the combination of all three exposures, persons who were at the highest exposure strata for smoking and coffee and used NSAIDs had an estimated 87% reduction in risk (OR 0.13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated. (c) 2007 Movement Disorder Society. C1 [Kay, Denise M.; Montimurro, Jennifer S.; Payami, Haydeh] New York State Dept Hlth, Genom Inst, Wadsworth Ctr, Albany, NY 12201 USA. [Powers, Karen M.; Checkoway, Harvey] Univ Washington, Sch Publ Hlth & Community Med, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Factor, Stewart A.; Higgins, Donald S.] Albany Med Ctr, Parkinsons Dis & Movement Disorder Ctr, Albany, NY USA. [Zabetian, Cyrus P.; Martinez, Erica D.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Zabetian, Cyrus P.; Samii, All; Martinez, Erica D.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Samii, All] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Griffith, Alida; Leis, Berta] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Washington, DC USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. RP Payami, H (reprint author), New York State Dept Hlth, Genom Inst, Wadsworth Ctr, POB 22002, Albany, NY 12201 USA. EM hpayami@wadsworth.org OI Zabetian, Cyrus/0000-0002-7739-4306; Kay, Denise/0000-0002-9928-2698 FU NIA NIH HHS [AG 08017]; NINDS NIH HHS [K08-NS044138, R01NS036960] NR 27 TC 75 Z9 78 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN 15 PY 2008 VL 23 IS 1 BP 88 EP 95 DI 10.1002/mds.21782 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 258WS UT WOS:000252901400013 PM 17987647 ER PT J AU Foland, LC Altshuler, LL Bookheimer, SY Eisenberger, N Townsend, J Thompson, PM AF Foland, Lara C. Altshuler, Lori L. Bookheimer, Susan Y. Eisenberger, Naomi Townsend, Jennifer Thompson, Paul M. TI Evidence for deficient modulation of amygdala response by prefrontal cortex in bipolar mania SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE bipolar disorder; fMRI; functional connectivity; emotion regulation ID FACIAL AFFECT RECOGNITION; FUNCTIONAL CONNECTIVITY; ORBITOFRONTAL CORTEX; NEGATIVE AFFECT; RATING-SCALE; BLOOD-FLOW; DISORDER; BRAIN; FMRI; ACTIVATION AB Several studies have implicated the involvement of two major components of emotion regulatory networks, the ventrolateral prefrontal cortex (VLPFC) and amygdala, in the pathophysiology of bipolar disorder. In healthy subjects, the VLPFC has been shown to negatively modulate amygdala response when subjects cognitively evaluate an emotional face by identifying and labeling the emotion it expresses. The current study used such a paradigm to assess whether the strength of this modulation was altered in bipolar subjects when manic. During functional magnetic resonance imaging (fMRI), nine manic subjects with bipolar I disorder and nine healthy subjects either named the emotion shown in a face by identifying one of two words that correctly expressed the emotion (emotion labeling task) or matched the emotion shown in a face to one of two other faces (emotion perception task). The degree to which the VLPFC regulated amygdala response during these tasks was assessed using a psychophysiological interaction (PPI) analysis. Compared with healthy subjects, manic patients had a significantly reduced VLPFC regulation of amygdala response during the emotion labeling task. These findings, taken in context with previous fMRI studies of bipolar mania, suggest that reductions in inhibitory frontal activity in these patients may lead to an increased reactivity of the amygdala. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Foland, Lara C.; Thompson, Paul M.] Univ Calif Los Angeles, Dept Neurol, Lab NeuroImaging, Los Angeles, CA USA. [Altshuler, Lori L.; Bookheimer, Susan Y.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA USA. [Altshuler, Lori L.] W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Bookheimer, Susan Y.; Townsend, Jennifer] Univ Calif Los Angeles, Ahmanson Lovelace Brain Mapping Ctr, Sch Med, Los Angeles, CA USA. [Eisenberger, Naomi] Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. RP Altshuler, LL (reprint author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, 300 Med Plaza,Suite 1544, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu FU NCRR NIH HHS [R21 RR019771, RR019771, U54 RR021813, U54 RR021813-020001]; NIBIB NIH HHS [EB01651, R01 EB007813, R01 EB007813-01A2, R01 EB008281, R01 EB008281-11A1]; NICHD NIH HHS [HD050735, R01 HD050735]; NIMH NIH HHS [F31 MH078556, F31 MH078556-01A1, K24 MH001848, K24 MH001848-01A1, MH01848] NR 62 TC 133 Z9 133 U1 3 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD JAN 15 PY 2008 VL 162 IS 1 BP 27 EP 37 DI 10.1016/j.pscychresns.2007.04.007 PG 11 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 266NM UT WOS:000253442900003 PM 18063349 ER PT J AU Tzermiadianos, MN Mekhail, A Voronov, LI Zook, J Havey, RM Renner, SM Carandang, G Abjornson, C Patwardhan, AG AF Tzermiadianos, Michael N. Mekhail, Anis Voronov, Leonard I. Zook, Jason Havey, Robert M. Renner, Susan M. Carandang, Gerard Abjornson, Celeste Patwardhan, Avinash G. TI Enhancing the stability of anterior lumbar interbody fusion SO SPINE LA English DT Article DE anterior lumbar interbody fusion (ALIF); femoral ring allograft (FRA); anterior tension band plate; transpedicular instrumentation ID DONOR SITE PAIN; BIOMECHANICAL ANALYSIS; LUMBOSACRAL FIXATION; PEDICLE SCREWS; IN-VITRO; SPINE; CAGES; INSTRUMENTATION; STABILIZATION; PRELOAD AB Study Design. Biomechanical study using human cadaver spines. Objective. To assess the stabilizing effect of a supplemental anterior tension band (ATB, Synthes) plate on L5-S1 anterior lumbar interbody fusion (ALIF) using a femoral ring allograft (FRA) under physiologic compressive preloads, and to compare the results with the stability achieved using FRA with supplemental transpedicular instrumentation. Summary of Background Data. Posterior instrumentation can improve the stability of ALIF cages. Anterior plates have been proposed as an alternative to avoid the additional posterior approach. Methods. Eight human specimens (L3 to sacrum) were tested in the following sequence: (i) intact, (ii) after anterior insertion of an FRA at L5-S1, (iii) after instrumentation with the ATB plate, and (iv) after removal of the plate and adding transpedicular instrumentation at the same level. Specimens were tested in flexion-extension, lateral bending, and axial rotation. Flexion-extension was tested under 0 N, 400 N, and 800 N compressive follower preload to simulate physiologic compressive preloads on the lumbar spine. Results. Stand-alone FRAs significantly decreased the range of motion (ROM) in all tested directions (P < 0.05); however, the resultant ROM was large in flexion-extension ranging between 6.1 +/- 3.1 and 5.1 +/- 2.2 under 0 N to 800 N preloads. The ATB plate resulted in a significant additional decrease in flexion-extension ROM under 400 N and 800 N preloads (P < 0.05). The flexion-extension ROM with the ATB plate was 4.1 +/- 2.3 under 0 N preload and ranged from 3.1 +/- 1.8 to 2.4 +/- 1.3 under 400 N to 800 N preloads. The plate did not significantly decrease lateral bending or axial rotation ROM compared with stand-alone FRA (P > 0.05), but the resultant ROM was 2.7 +/- 1.9 degrees and 0.9 +/- 0.6 degrees, respectively. Compared with the ATB plate, the transpedicular instrumentation resulted in significantly less ROM in flexion-extension and lateral bending (P < 0.05), but not in axial rotation (P > 0.05). Conclusion. The ATB plate can significantly increase the stability of the anterior FRA at L5-S1 level. Although supplemental transpedicular instrumentation results in a more stable biomechanical environment, the resultant ROM with the addition of a plate is small, especially under physiologic preload, suggesting that the plate can sufficiently resist motion. Therefore, clinical assessment of the ATB plate as an alternative to transpedicular instrumentation to enhance ALIF cage stability is considered reasonable. C1 [Tzermiadianos, Michael N.; Voronov, Leonard I.; Havey, Robert M.; Patwardhan, Avinash G.] Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA. [Tzermiadianos, Michael N.; Voronov, Leonard I.; Havey, Robert M.; Renner, Susan M.; Carandang, Gerard; Patwardhan, Avinash G.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Mekhail, Anis; Zook, Jason; Renner, Susan M.] Univ Illinois, Chicago, IL USA. [Abjornson, Celeste] Synthes Spine, W Chester, PA USA. RP Patwardhan, AG (reprint author), Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, 2160 S 1st Ave, Maywood, IL 60153 USA. EM apatwar@lumc.edu NR 29 TC 12 Z9 12 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD JAN 15 PY 2008 VL 33 IS 2 BP E38 EP E43 PG 6 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 267XM UT WOS:000253542500023 PM 18197089 ER PT J AU Currie, SL Ryan, JC Tracy, D Wright, TL George, S McQuaid, R Kim, M Shen, H Monto, A AF Currie, Sue L. Ryan, James C. Tracy, Daniel Wright, Teresa L. George, Sally McQuaid, Rosemary Kim, Michael Shen, Hui Monto, Alexander TI A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE hepatitis; hepatitis C virus; IDUs; HCV reinfection; HCV resolution ID HEPATITIS-C VIRUS; UNITED-STATES; IMMUNE-RESPONSE; INFECTION; MANAGEMENT; PREVALENCE AB Background: Many HCV-infected persons with recent or ongoing injection drug use (IDU) do not receive HCV treatment due to the perceived risk of HCV reinfection. There are few prospective studies investigating HCV reinfection among IDUs. Methods: Two hundred and twenty-four persons with past or ongoing IDU were followed from 1997 to 2007. Baseline and every 6-month follow-up data were collected including demographics, IDU, and sexual behaviors. Serum was tested for the presence of HCV antibody and serially for HCV RNA. Resolvers were defined as HCV antibody and RIBA positive and RNA negative at two consecutive time points or as becoming HCV RNA negative after HCV antiviral treatment. Reinfection was defined by the presence of HCV RNA at >= 2 visits. Results: One hundred and eighty-six persons had chronic HCV and 38 had resolved HCV The resolvers were followed for a total of 214 person-years. Forty-two percent of resolvers reported ongoing IDU, representing 58 person-years of IDU. Only one reinfection occurred in the resolvers, for a reinfection rate of 0.47 cases/100 person-years of follow-up. The single reinfection, which occurred in a person who continued to inject drugs, represents a reinfection rate of 1.75 cases/100 person-years of IDU. Conclusion: These data suggest that despite ongoing IDU, persistent HCV reinfection is lower than previously published. This can be attributed to a more clinically relevant definition of reinfection. This information will better help clinicians make informed decisions regarding HCV treatment options for patients who may continue to inject illicit drugs. Published by Elsevier Ireland Ltd. C1 [Currie, Sue L.; Ryan, James C.; Tracy, Daniel; Kim, Michael; Shen, Hui; Monto, Alexander] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Ryan, James C.; Wright, Teresa L.; George, Sally; McQuaid, Rosemary; Kim, Michael; Monto, Alexander] San Francisco VA Med Ctr, Div Gastroenterol, San Francisco, CA USA. RP Currie, SL (reprint author), Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, 111,4150 Clement st, San Francisco, CA 94121 USA. EM sue.currie@va.gov FU NIDA NIH HHS [R01 DA13737-01] NR 19 TC 41 Z9 41 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 11 PY 2008 VL 93 IS 1-2 BP 148 EP 154 DI 10.1016/j.drugalcdep.2007.09.011 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 260SW UT WOS:000253031700017 PM 17977668 ER PT J AU Li, YQ Wang, XY Zhai, HF Zhang, XY Kosten, T Lu, L AF Li, Yan-Qin Wang, Xiao-yi Zhai, Hai-feng Zhang, Xiang Yang Kosten, Therese Lu, Lin TI Sex- and age-dependent effects of early postnatal sibling deprivation on spatial learning and memory in adult rats SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE early postnatal sibling deprivation; development; spatial learning and memory; sex; age ID PYRAMIDAL NEURON MORPHOLOGY; FACTOR MESSENGER-RNA; GUINEA-PIG; ENVIRONMENTAL ENRICHMENT; SOCIAL-ISOLATION; COGNITIVE-DEVELOPMENT; ENTORHINAL CORTEX; ISOLATION STRESS; DENTATE GYRUS; MATERNAL-CARE AB In this study. we investigated the effects of early postnatal sibling deprivation (EPSD) on spatial learning and memory in adult rats. Litters were culled to one pup with its mother on postnatal day (PN) 1 or 7 and their spatial learning and memory ability were examined with Morris water maze in adult. EPSD on PN1 improved, but on PN7 impaired performance of the spatial learning task in adult female rats. However, EPSD did not have any effect on the spatial learning ability in adult male rats. (c) 2007 Elsevier B.V. All rights reserved. C1 [Li, Yan-Qin; Wang, Xiao-yi; Zhai, Hai-feng; Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100083, Peoples R China. [Zhang, Xiang Yang; Kosten, Therese] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, VA Med Ctr, Houston, TX 77030 USA. RP Lu, L (reprint author), Peking Univ, Natl Inst Drug Dependence, 38 Xue Yuan Rd,Haidian Dist, Beijing 100083, Peoples R China. EM linlu@bjmu.edu.cn NR 30 TC 3 Z9 4 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD JAN 10 PY 2008 VL 186 IS 1 BP 138 EP 142 DI 10.1016/j.bbr.2007.07.028 PG 5 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 244MG UT WOS:000251869400018 PM 17765982 ER PT J AU Berman, SM Naliboff, BD Suyenobu, B Labus, JS Stains, J Ohning, G Kilpatrick, L Bueller, JA Ruby, K Jarcho, J Mayer, EA AF Berman, Steven M. Naliboff, Bruce D. Suyenobu, Brandall Labus, Jennifer S. Stains, Jean Ohning, Gordon Kilpatrick, Lisa Bueller, Joshua A. Ruby, Kim Jarcho, Johanna Mayer, Emeran A. TI Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome SO JOURNAL OF NEUROSCIENCE LA English DT Article DE fMRI; brainstem; irritable bowel syndrome; anticipation; pain; corticolimbic inhibition ID ANTERIOR CINGULATE CORTEX; RECTAL PAIN; CEREBRAL ACTIVATION; PREFRONTAL CORTEX; HEALTHY CONTROLS; ANXIETY; PLACEBO; DISORDERS; DEACTIVATION; STIMULATION AB Cognitive factors such as fear of pain and symptom-related anxiety play an important role in chronic pain states. The current study sought to characterize abnormalities in preparatory brain response before aversive pelvic visceral distention in irritable bowel syndrome (IBS) patients and their possible relationship to the consequences of distention. The brain functional magnetic resonance imaging ( fMRI) blood oxygen level-dependent ( BOLD) response to anticipated and delivered mild and moderate rectal distention was recorded from 14 female IBS patients and 12 healthy controls. During cued anticipation of distention, activity decreased in the insula, supragenual anterior cingulate cortex (sACC), amygdala, and dorsal brainstem (DBS) of controls. IBS patients showed less anticipatory inactivation. Group differences were significant in the right posterior insula and bilateral DBS. Self-rated measures of negative affect during scanning were higher in patients than controls (p < 0.001), and the anticipatory BOLD decreases in DBS were inversely correlated with these ratings. During subsequent distention, both groups showed activity increases in insula, dorsal ACC, and DBS and decreases in the infragenual ACC. The increases were more extensive in patients, producing significant group differences in dorsal ACC and DBS. The amplitude of the anticipatory decrease in the pontine portion of DBS was associated with greater activation during distention in right orbitofrontal cortex and bilateral sACC. Both regions have been associated previously with corticolimbic inhibition and cognitive coping. Deficits in preparatory inhibition of DBS, including the locus ceruleus complex and parabrachial nuclei, may interfere with descending corticolimbic inhibition and contribute to enhanced brain responsiveness and perceptual sensitivity to visceral stimuli in IBS. C1 [Berman, Steven M.; Naliboff, Bruce D.; Suyenobu, Brandall; Labus, Jennifer S.; Stains, Jean; Ohning, Gordon; Kilpatrick, Lisa; Bueller, Joshua A.; Ruby, Kim; Jarcho, Johanna; Mayer, Emeran A.] Univ Calif Los Angeles, Los Angeles Ctr Neurovisceral Sci & Womens Hlth, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med,Dept Med, Los Angeles, CA 90073 USA. [Berman, Steven M.; Naliboff, Bruce D.; Suyenobu, Brandall; Labus, Jennifer S.; Stains, Jean; Ohning, Gordon; Kilpatrick, Lisa; Bueller, Joshua A.; Ruby, Kim; Jarcho, Johanna; Mayer, Emeran A.] Univ Calif Los Angeles, Los Angeles Ctr Neurovisceral Sci & Womens Hlth, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Berman, Steven M.; Naliboff, Bruce D.; Suyenobu, Brandall; Labus, Jennifer S.; Stains, Jean; Ohning, Gordon; Kilpatrick, Lisa; Bueller, Joshua A.; Ruby, Kim; Jarcho, Johanna; Mayer, Emeran A.] Univ Calif Los Angeles, Los Angeles Ctr Neurovisceral Sci & Womens Hlth, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90073 USA. [Berman, Steven M.; Naliboff, Bruce D.; Suyenobu, Brandall; Labus, Jennifer S.; Stains, Jean; Ohning, Gordon; Kilpatrick, Lisa; Bueller, Joshua A.; Ruby, Kim; Jarcho, Johanna; Mayer, Emeran A.] Univ Calif Los Angeles, Los Angeles Ctr Neurovisceral Sci & Womens Hlth, David Geffen Sch Med, Dept Behav Sci, Los Angeles, CA 90073 USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, Los Angeles Ctr Neurovisceral Sci & Womens Hlth, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med,Dept Med, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM emayer@ucla.edu RI Kilpatrick, Lisa/E-6995-2015 OI Jarcho, Johanna/0000-0001-9075-6968 FU NCCIH NIH HHS [R24 AT002681]; NIDDK NIH HHS [DK48351, P50DK64539]; NINR NIH HHS [NR04881] NR 59 TC 135 Z9 139 U1 6 U2 16 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JAN 9 PY 2008 VL 28 IS 2 BP 349 EP 359 DI 10.1523/JNEUROSCI.2500-07.2008 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 249QE UT WOS:000252243100004 PM 18184777 ER PT J AU Sharma, V Simpson, RC LoPresti, EF Mostowy, C Olson, J Puhlman, J Hayashi, S Cooper, RA Konarski, E Kerley, B AF Sharma, Vinod Simpson, Richard C. LoPresti, Edmund F. Mostowy, Casimir Olson, Joseph Puhlman, Jeremy Hayashi, Steve Cooper, Rory A. Konarski, Ed Kerley, Barry TI Participatory design in the development of the wheelchair convoy system SO JOURNAL OF NEUROENGINEERING AND REHABILITATION LA English DT Article ID POWER-ASSISTED WHEELCHAIR; SMART WHEELCHAIRS; NAVIGATION AB Background: In long-term care environments, residents who have severe mobility deficits are typically transported by having another person push the individual in a manual wheelchair. This practice is inefficient and encourages staff to hurry to complete the process, thereby setting the stage for unsafe practices. Furthermore, the time involved in assembling multiple individuals with disabilities often deters their participation in group activities. Methods: The Wheelchair Convoy System (WCS) is being developed to allow a single caregiver to move multiple individuals without removing them from their wheelchairs. The WCS will consist of a processor, and a flexible cord linking each wheelchair to the wheelchair in front of it. A Participatory Design approach - in which several iterations of design, fabrication and evaluation are used to elicit feedback from users - was used. Results: An iterative cycle of development and evaluation was followed through five prototypes of the device. The third and fourth prototypes were evaluated in unmanned field trials at J. Iverson Riddle Development Center. The prototypes were used to form a convoy of three wheelchairs that successfully completed a series of navigation tasks. Conclusion: A Participatory Design approach to the project allowed the design of the WCS to quickly evolve towards a viable solution. The design that emerged by the end of the fifth development cycle bore little resemblance to the initial design, but successfully met the project's design criteria. Additional development and testing is planned to further refine the system. C1 [Sharma, Vinod; Simpson, Richard C.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. [Simpson, Richard C.; Olson, Joseph; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Simpson, Richard C.; Olson, Joseph; Puhlman, Jeremy; Hayashi, Steve; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [LoPresti, Edmund F.; Mostowy, Casimir] AT Sci, Pittsburgh, PA USA. [Konarski, Ed; Kerley, Barry] J Iverson Riddle Dev Ctr, Morganton, NC USA. RP Simpson, RC (reprint author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. EM vks3@pitt.edu; ris20@pitt.edu; edlopresti@at-sciences.com; caz@ieee.org; olsonj@herlpitt.org; puhlmanj@herlpitt.org; hayashis@herlpitt.org; rcooper@pitt.edu; Ed.Konarski@ncmail.net; Barry.Kerley@ncmail.net NR 21 TC 11 Z9 11 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-0003 J9 J NEUROENG REHABIL JI J. NeuroEng. Rehabil. PD JAN 2 PY 2008 VL 5 AR 1 DI 10.1186/1743-0003-5-1 PG 10 WC Engineering, Biomedical; Neurosciences; Rehabilitation SC Engineering; Neurosciences & Neurology; Rehabilitation GA 278US UT WOS:000254312400001 PM 18171465 ER PT J AU Gurubhagavatula, I Nkwuo, JE Maislin, G Pack, AI AF Gurubhagavatula, Indira Nkwuo, Jonathan E. Maislin, Greg Pack, Allan I. TI Estimated cost of crashes in commercial drivers supports screening and treatment of obstructive sleep apnea SO ACCIDENT ANALYSIS AND PREVENTION LA English DT Article DE polysomnography; nocturnal pulse oximetry; questionnaire; economics; cost analysis ID QUALITY-OF-LIFE; POSITIVE AIRWAY PRESSURE; MOTOR-VEHICLE COLLISIONS; HEALTH-CARE UTILIZATION; HAUL TRUCK DRIVERS; APNOEA/HYPOPNOEA SYNDROME; TRAFFIC ACCIDENTS; NASAL CPAP; RISK-FACTORS; DIAGNOSIS AB Sleep apnea among commercial drivers may increase the risk of fall-asleep crashes, which incur large expenses. Drivers of passenger cars whose apnea is treated experience lower crash risk. Among community-based holders of commercial driver's licenses, we considered three methods for identifying sleep apnea syndrome: (1) in-lab polysomnography; (2) selective in-lab polysomnography for high-risk drivers, where high risk is first identified by body mass index, age and gender, followed by oximetry in a subset of drivers; (3) not screening. The costs for each of these three programs equaled the sum of the costs of testing, treatment of identified cases, and crashes. Assuming that treatment prevents apnea-related crashes, polysomnography is not cost-effective, because it was more expensive than the cost of crashes when no screening is done. Screening with BMI, age and gender, however, with confirmatory in-lab polysomnography only on high-risk drivers was cost-effective, as long as a high proportion (73.8%) of screened drivers accepts treatment. These findings indicate that strategies that reduce reliance on in-laboratory polysomnography may be more cost-effective than not screening, and that treatment acceptance may need to be a condition of employment for affected drivers. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Gurubhagavatula, Indira; Nkwuo, Jonathan E.; Maislin, Greg; Pack, Allan I.] Univ Penn, Med Ctr, Dept Med,Div Sleep Med, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA USA. RP Gurubhagavatula, I (reprint author), Univ Penn, Med Ctr, Dept Med,Div Sleep Med, Ctr Sleep & Resp Neurobiol, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM gurubhag@mail.med.upenn.edu FU NCRR NIH HHS [K23 RR016068-05, 3-M01-RR00040-39S2, K23 RR016068, K23RR16068-03, M01 RR000040, M01 RR000040-440871]; NHLBI NIH HHS [P01-HL-60287, P50 HL060287] NR 50 TC 21 Z9 21 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0001-4575 J9 ACCIDENT ANAL PREV JI Accid. Anal. Prev. PD JAN PY 2008 VL 40 IS 1 BP 104 EP 115 DI 10.1016/j.aap.2007.04.011 PG 12 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 265GG UT WOS:000253346500013 PM 18215538 ER PT J AU Graham, DP Cardon, AL AF Graham, David P. Cardon, Aaron L. TI An Update on Substance Use and Treatment following Traumatic Brain Injury SO ADDICTION REVIEWS 2008 SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article DE traumatic brain injury; substance abuse; prevalence; treatment outcome; review ID ALCOHOL-USE PATTERNS; ABUSE TREATMENT; HEAD-INJURY; DRUG-USE; REHABILITATION; PREVALENCE; OUTCOMES; PROGRAM; INDIVIDUALS; POPULATION AB Traumatic brain injury (TBI) is a leading cause of mortality and morbidity among young adults. Substance abusers constitute a disproportionate percentage of these patients. A history of substance abuse predicts increased disability, poorer prognosis, and delayed recovery. While consensus in the literature indicates that substance-abuse rates decline following injury, conflicting literature shows a significant history of brain injury in addicts. We reviewed the literature on substance abuse after TBI to explore the state of knowledge on TBI as a risk factor for substance abuse. While recent reviews regarding substance abuse in TBI patients concur that substance-abuse rates decline even after mild TBI, an emerging literature suggests mild TBI may cause subtle impairments in cognitive, executive, and decision-making functions that are often poorly recognized in early diagnosis and treatment. When combined with difficulties in psychosocial adjustment and coping skills, these impairments may increase the risk for chronic substance abuse in a subset of TBI patients. Preliminary results from veterans indicate these patterns hold in a combat-related post-traumatic stress disorder population with TBI. This increasingly prevalent combination presents a specific challenge in rehabilitation. While this comorbidity presents a challenge for the successful treatment and rehabilitation of both disorders, there is sparse evidence to recommend any specific treatment strategy for these individuals. Mild TBI and substance abuse are bidirectionally related both for risks and treatment. Further understanding the neuropsychiatric pathology and different effects of different types of injuries will likely improve the implementation of effective treatments for each of these two conditions. C1 [Graham, David P.] Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res, Houston, TX 77030 USA. [Graham, David P.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Graham, David P.] Menninger Dept Psychiat & Behav Sci, Houston, TX USA. [Graham, David P.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA. [Cardon, Aaron L.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA. RP Graham, DP (reprint author), Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res, 2002 Holcombe, Houston, TX 77030 USA. EM david.graham@med.va.gov RI Graham, David /J-1158-2014 NR 54 TC 48 Z9 50 U1 4 U2 15 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1141 BP 148 EP 162 DI 10.1196/annals.1441.029 PG 15 WC Multidisciplinary Sciences; Neurosciences SC Science & Technology - Other Topics; Neurosciences & Neurology GA BIM56 UT WOS:000260859100008 PM 18991956 ER PT J AU Berman, S O'Neill, J Fears, S Bartzokis, G London, ED AF Berman, Steven O'Neill, Joseph Fears, Scott Bartzokis, George London, Edythe D. TI Abuse of Amphetamines and Structural Abnormalities in the Brain SO ADDICTION REVIEWS 2008 SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article DE brain structure; drug abuse; amphetamine; methamphetamine; ecstasy ID VOXEL-BASED MORPHOMETRY; ABSTINENT METHAMPHETAMINE ABUSERS; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; VESICULAR MONOAMINE TRANSPORTERS; WHITE-MATTER HYPERINTENSITIES; DOPAMINERGIC DRUG TREATMENTS; TEMPORAL-LOBE EPILEPSY; GRAY-MATTER; DECISION-MAKING; LONG-TERM AB We review evidence that structural brain abnormalities are associated with abuse of amphetamines. A brief history of amphetamine use/abuse and evidence for toxicity is followed by a summary of findings from structural magnetic resonance imaging (MRI) studies of human subjects who had abused amphetamines and children who were exposed to amphetamines in utero. Evidence comes from studies that used a variety of techniques including manual tracing, pattern matching, voxel-based, tensor-based, or cortical thickness mapping, quantification of white matter signal hyperintensities, and diffusion tensor imaging. Ten studies compared controls to individuals who were exposed to methamphetamine. Three studies assessed individuals exposed to 3-4-methylenedioxymethamphetamine (MDMA). Brain structural abnormalities were consistently reported in amphetamine abusers, as compared to control subjects. These included lower cortical gray matter volume and higher striatal volume than control subjects. These differences might reflect brain features that could predispose to substance dependence. High striatal volumes might also reflect compensation for toxicity in the dopamine-rich basal ganglia. Prenatal exposure was associated with striatal volume that was below control values, suggesting that such compensation might not occur in utero. Several forms of white matter abnormality are also common and may involve gliosis. Many of the limitations and inconsistencies in the literature relate to techniques and cross-sectional designs, which cannot infer causality. Potential confounding influences include effects of pre existing risk/protective factors, development, gender, severity of amphetamine abuse, abuse of other drugs, abstinence, and differences in lifestyle. Longitudinal designs in which multimodal datasets are acquired and are subjected to multivariate analyses would enhance our ability to provide general conclusions regarding the associations between amphetamine abuse and brain structure. C1 [London, Edythe D.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. [London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA. [Berman, Steven; Bartzokis, George; London, Edythe D.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA. [Berman, Steven; Bartzokis, George] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. RP London, ED (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,Box 175919, Los Angeles, CA 90024 USA. EM elondon@mednet.ucla.edu RI Bartzokis, George/K-2409-2013 FU National Institute on Drug Abuse [R01DA015179, R01DA020726, P20DA022539, R03DA20512, R21DA023192, M01RR00865] FX This work was supported in part by grants from the National Institute on Drug Abuse: R01DA015179, R01DA020726, and P20DA022539 (EDL); R03DA20512 and R21DA023192 JON); and M01RR00865 (UCLA GCRC). NR 133 TC 88 Z9 90 U1 5 U2 28 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1141 BP 195 EP 220 DI 10.1196/annals.1441.031 PG 26 WC Multidisciplinary Sciences; Neurosciences SC Science & Technology - Other Topics; Neurosciences & Neurology GA BIM56 UT WOS:000260859100011 PM 18991959 ER PT J AU Pasinetti, GM Hiller-Sturmhofel, S AF Pasinetti, Giulio M. Hiller-Sturmhoefel, Susanne TI Systems biology in the study of neurological disorders: Focus on Alzheimer's disease SO ALCOHOL RESEARCH & HEALTH LA English DT Article DE Alzheimer's disease (AD); cognitive impairment; dementia; genetic risk factors; biomarkers; complementary DNA (cDNA) microarray analysis; protein array analysis; systems biology; proteomics; alcohol and other drug effects (AODEs) ID MOUSE MODEL; EXPRESSION; BRAIN; RISK; NEUROPATHOLOGY; DEPOSITION; MICROARRAY; ARRAYS AB Systems biology approaches may be useful for studying the mechanisms underlying alcohol's harmful effects on the brain. Such approaches already are used in the study of Alzheimer's disease (AD), a progressive neurodegenerative disorder that, with the overall increase in life expectancy, will affect an increasing proportion of the population and become an increasingly serious public health concern. Systems biology approaches such as complementary DNA (cDNA) microarray analyses have helped identify several genes whose expression is altered in patients exhibiting the earliest stages of AD. Several of these genes are involved in the release of messenger molecules from the ends of nerve cells (Le, in synaptic vesicle functioning), and their particular role in AD must be investigated further using conventional molecular biological approaches. Similarly, protein array analyses have identified candidate proteins that may play a role in the development of AD. Finally, proteomic approaches, such as certain mass spectrometry techniques, have been used to search for biomarkers of the progression from normal cognitive functioning to mild cognitive impairment and AD, which eventually may allow early and reliable diagnosis of the disease. These approaches already have yielded some candidate molecules whose validity and reliability as biomarkers of AD, however, still need to be confirmed. C1 [Pasinetti, Giulio M.] Mt Sinai Sch Med, Ctr Excellence Res Complementary & Alternat Med A, Dept Psychiat, New York, NY USA. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Basic & Biomed Res & Training Program, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Ctr Excellence Res Complementary & Alternat Med A, Dept Psychiat, New York, NY USA. NR 19 TC 4 Z9 4 U1 0 U2 0 PU NATL INST ALCOHOL ABUSE ALCOHOLISM PI ROCKVILLE PA 6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA SN 1535-7414 J9 ALCOHOL RES HEALTH JI Alcohol Res. Health PY 2008 VL 31 IS 1 BP 60 EP 65 PG 6 WC Substance Abuse SC Substance Abuse GA 326LH UT WOS:000257660100007 PM 23584752 ER PT J AU Hitzemann, R Oberbeck, D AF Hitzemann, Robert Oberbeck, Denesa TI STRATEGIES TO STUDY THE NEUROSCIENCE OF ALCOHOLISM: INTRODUCTION SO ALCOHOL RESEARCH & HEALTH LA English DT Editorial Material C1 [Hitzemann, Robert; Oberbeck, Denesa] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Hitzemann, Robert; Oberbeck, Denesa] Portland VA Med Ctr, Res Serv, Portland, OR USA. RP Hitzemann, R (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. FU NIAAA NIH HHS [P60 AA010760] NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATL INST ALCOHOL ABUSE ALCOHOLISM PI ROCKVILLE PA 6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA SN 1535-7414 J9 ALCOHOL RES HEALTH JI Alcohol Res. Health PY 2008 VL 31 IS 3 BP 231 EP 232 PG 2 WC Substance Abuse SC Substance Abuse GA 374TL UT WOS:000261066500004 PM 23584864 ER PT J AU Oberbeck, D AF Oberbeck, Denesa TI LASER-ASSISTED MICRODISSECTION SO ALCOHOL RESEARCH & HEALTH LA English DT Article DE Alcohol-related research; alcohol and other drug effects and consequences; brain; brain cells; brain function; brain structure; laser-assisted microdissection (LMD); laser capture; laser microbeam; reverse-transcription polymerase chain reaction (RT-PCR); expression profiling ID CONSUMPTION; AMYGDALA; C57BL/6J; ETHANOL C1 [Oberbeck, Denesa] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Oberbeck, Denesa] Portland VA Med Ctr, Res Serv, Portland, OR 97201 USA. RP Oberbeck, D (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU NATL INST ALCOHOL ABUSE ALCOHOLISM PI ROCKVILLE PA 6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA SN 1535-7414 J9 ALCOHOL RES HEALTH JI Alcohol Res. Health PY 2008 VL 31 IS 3 BP 249 EP 250 PG 2 WC Substance Abuse SC Substance Abuse GA 374TL UT WOS:000261066500009 PM 23584869 ER PT J AU Hitzemann, R Belknap, JK McWeeney, SK AF Hitzemann, Robert Belknap, John K. McWeeney, Shannon K. TI QUANTITATIVE TRAIT LOCUS ANALYSIS: MULTIPLE CROSS AND HETEROGENEOUS STOCK MAPPING SO ALCOHOL RESEARCH & HEALTH LA English DT Article DE Genetic theory of alcohol and other drug use; genetic factors; environmental factors; behavioral phenotype; behavioral trait; quantitative trait gene (QTG); inbred animal strains; recombinant inbred (RI) mouse strains; quantitative traits; quantitative trait locus (QTL) mapping; multiple cross mapping (MCM); heterogeneous stock (HS) mapping; microsatellite mapping; animal models ID RECOMBINANT INBRED STRAINS; LABORATORY MICE; COMPLEX TRAITS; MOUSE GENOME; GENETIC-MAP; RESOLUTION; IDENTIFICATION; INTERCROSS; BEHAVIOR; ALCOHOL C1 [Hitzemann, Robert; Belknap, John K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Hitzemann, Robert; Belknap, John K.] Portland VA Med Ctr, Res Serv, Portland, OR USA. [McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Preventat Med, Div Biostat, Portland, OR 97201 USA. [McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. RP Hitzemann, R (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. NR 35 TC 3 Z9 3 U1 0 U2 1 PU NATL INST ALCOHOL ABUSE ALCOHOLISM PI ROCKVILLE PA 6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA SN 1535-7414 J9 ALCOHOL RES HEALTH JI Alcohol Res. Health PY 2008 VL 31 IS 3 BP 261 EP 265 PG 5 WC Substance Abuse SC Substance Abuse GA 374TL UT WOS:000261066500013 PM 23584873 ER PT J AU Denmark, DL Milner, LC Buck, KJ AF Denmark, Deaunne L. Milner, Lauren C. Buck, Karl J. TI INTERVAL-SPECIFIC CONGENIC ANIMALS FOR HIGH-RESOLUTION QUANTITATIVE TRAIT LOCI MAPPING SO ALCOHOL RESEARCH & HEALTH LA English DT Article DE Genetic theory of alcohol and other drug use; genetics and heredity; behavioral phenotypes, genetic trait, quantitative traits; quantitative trait locus (QTL); QTL mapping; congenics; interval-specific congenics (ISCs); congenic strains; animal models ID ALCOHOL PHYSICAL-DEPENDENCE; RECOMBINANT INBRED MICE; COMPLEX TRAITS; WITHDRAWAL; GENES; IDENTIFICATION; CONFIRMATION; SENSITIVITY C1 [Denmark, Deaunne L.] Portland VA Med Ctr, Grad Program Neurosci, Portland, OR USA. [Buck, Karl J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Milner, Lauren C.] Portland VA Med Ctr, Behav Neurosci Program, Portland, OR USA. RP Denmark, DL (reprint author), Portland VA Med Ctr, Grad Program Neurosci, Portland, OR USA. FU NIAAA NIH HHS [P60 AA010760, R01 AA011114, R01 AA011114-12, P60 AA010760-16]; NIDA NIH HHS [R01 DA005228-17, R01 DA005228] NR 14 TC 1 Z9 1 U1 0 U2 1 PU NATL INST ALCOHOL ABUSE ALCOHOLISM PI ROCKVILLE PA 6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA SN 1535-7414 J9 ALCOHOL RES HEALTH JI Alcohol Res. Health PY 2008 VL 31 IS 3 BP 266 EP 269 PG 4 WC Substance Abuse SC Substance Abuse GA 374TL UT WOS:000261066500014 PM 23584874 ER PT J AU Walter, NAR McWeeney, SK Peters, ST Belknap, JK Hitzemann, R Buck, KJ AF Walter, Nicole A. R. McWeeney, Shannon K. Peters, Sandra T. Belknap, John K. Hitzemann, Robert Buck, Kari J. TI SINGLE-NUCLEOTIDE POLYMORPHISM MASKING SO ALCOHOL RESEARCH & HEALTH LA English DT Article DE expression; genome; genetic analysis; microarray analysis; singular nucleotide polymorphism (SNP); SNP masking; mouse genome; laboratory mice; animal models C1 [Walter, Nicole A. R.] Oregon Hlth & Sci Univ, Dept Behav Sci, Portland, OR 97201 USA. [McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Preventat Med, Div Biostat, Portland, OR 97201 USA. [McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Peters, Sandra T.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA. [Belknap, John K.; Hitzemann, Robert; Buck, Kari J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Belknap, John K.; Hitzemann, Robert] Portland VA Med Ctr, Res Serv, Portland, OR USA. RP Walter, NAR (reprint author), Oregon Hlth & Sci Univ, Dept Behav Sci, Portland, OR 97201 USA. FU NIAAA NIH HHS [P60 AA010760]; NIDA NIH HHS [R01 DA005228] NR 1 TC 0 Z9 0 U1 0 U2 0 PU NATL INST ALCOHOL ABUSE ALCOHOLISM PI ROCKVILLE PA 6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA SN 1535-7414 J9 ALCOHOL RES HEALTH JI Alcohol Res. Health PY 2008 VL 31 IS 3 BP 270 EP 271 PG 2 WC Substance Abuse SC Substance Abuse GA 374TL UT WOS:000261066500015 PM 23584875 ER PT J AU Singal, AK Rosman, AS Post, JB Bauman, WA Spungen, AM Korsten, MA AF Singal, A. K. Rosman, A. S. Post, J. B. Bauman, W. A. Spungen, A. M. Korsten, M. A. TI The renal safety of bowel preparations for colonoscopy: a comparative study of oral sodium phosphate solution and polyethylene glycol SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID PROSPECTIVE TRIAL; LAVAGE SOLUTION; FAILURE; NEPHROCALCINOSIS; COLON; MULTICENTER; EFFICACY; IMPACT; PEG AB Background Rare cases of nephrotoxicity have been reported with oral sodium phosphate solution (OSPS). Aim To evaluate whether OSPS is associated with changes in renal function. Methods A chart review performed on 311 patients who had colonoscopy at the James J. Peters VA Medical Centre prepared with either OSPS (n = 157) or polyethylene glycol (PEG) (n = 154). Patients had a baseline serum creatinine <= 1.5 mg/dL. Effect of bowel preparation on the renal function was evaluated by measuring the absolute change in levels of serum creatinine and the proportion of patients who developed a 50% or more increase above their baseline serum creatinine value. Results Oral sodium phosphate solution resulted in a slight increase in serum creatinine from 1.0 +/- 0.02 to 1.1 +/- 0.02 mg/dL (P = 0.07) and PEG resulted in a small decrease in serum creatinine from 1.1 +/- 0.02 to 1.0 +/- 0.03 mg/dL (P = 0.03). The absolute change in serum creatinine was slightly higher with OSPS than with PEG (0.04 +/- 0.02 vs. -0.05 +/- 0.02 mg/dL; P = 0.005). However, the proportion of patients who had a >= 50% increase above their baseline creatinine was similar (OSPS vs. PEG, 5% vs. 3%, P = 0.77). Conclusions Oral sodium phosphate solution was associated with a slight increase in serum creatinine, which was not clinically significant. Renal toxicity from OSPS appears to be minimal when used in patients with serum creatinine value <1.5 mg/dL. C1 [Singal, A. K.; Rosman, A. S.; Post, J. B.; Bauman, W. A.; Korsten, M. A.] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. [Rosman, A. S.; Korsten, M. A.] James J Peters Vet Affairs Med Ctr, Div Gastroenterol, Bronx, NY USA. [Post, J. B.] Mt Sinai Sch Med, Div Nephrol, New York, NY USA. [Bauman, W. A.; Korsten, M. A.] James J Peters VA Med Ctr, Dev Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs Rehabilitat Res, Bronx, NY USA. RP Korsten, MA (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM mark.korsten@va.gov NR 22 TC 30 Z9 30 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD JAN 1 PY 2008 VL 27 IS 1 BP 41 EP 47 DI 10.1111/j.1365-2036.2007.03558.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 265UB UT WOS:000253385300005 PM 17956596 ER PT J AU Meinert, CL Breitner, JCS AF Meinert, Curtis L. Breitner, John C. S. TI Chronic disease long-term drug prevention trials: Lessons from the Alzheimer's disease anti-inflammatory prevention trial (ADAPT) SO ALZHEIMERS & DEMENTIA LA English DT Article; Proceedings Paper CT Leon Thal Symposium on the Prevention of Dementia CY DEC 02-04, 2007 CL Las Vegas, NV SP Lou Ruvo Brain Inst DE clinical trials ID MILD COGNITIVE IMPAIRMENT; RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; CLINICAL-TRIALS; CACHE COUNTY; VITAMIN-E; HEALTH; RISK; CELECOXIB; DEMENTIA AB A randomized trial is a randomized trial. The basic ingredients do not change with different purposes whether for treatment or prevention of disease. Likewise, the problems and difficulties are mostly the same. But there are differences in approach and philosophy. Here we discuss problems in trials focused on healthy people to determine whether drugs can delay or prevent adverse health events, with the Alzheimer's Disease Anti -inflammatory Prevention Trial (ADAPT) as an example. An important difference separating treatment trials from prevention trials is the length of time needed to demonstrate a difference with treatment. Related to this is the risk-benefit calculus of the trial. Treatment trials are aimed at "curing" or ameliorating disease, for example, as with trials involving people with Alzheimer's disease (AD) dementia to determine whether treatment is useful in dealing with the AD-induced dementia. Like other treatment trials, those targeting AD dementia balance these benefits against the risks of treatment. But by contrast, benefit in prevention trials, if any, will be found only in the absence or delay in disease onset, often after years of continuous treatment. As in ADAPT, the separation in timing of risk versus benefit often brings difficult decisions about how long to continue the trial in the absence of any apparent benefit to treatment. Other difficulties similarly relate to the length of prevention trials. In hopes that some lessons teamed from ADAPT will assist future prevention trials, especially in the elderly, we describe several conundrums and problems experienced in this trial and attempt when possible to extend our observations to the larger class of long-term drug prevention trials. 0 2008 The Alzheimer's Association. All rights reserved. C1 [Meinert, Curtis L.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Breitner, John C. S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat, Seattle, WA 98195 USA. [Breitner, John C. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Meinert, CL (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. EM cmeinert@jhsph.edu FU NIA NIH HHS [U01 AG15477] NR 40 TC 15 Z9 15 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD JAN PY 2008 VL 4 IS 1 SU 1 BP S7 EP S14 DI 10.1016/j.jalz.2007.10.007 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 256AI UT WOS:000252699700003 PM 18632005 ER PT J AU Deo, R Fyr, CLW Fried, LF Newman, AB Harris, TB Angleman, S Green, C Kritchevsky, SB Chertow, GM Cummings, SR Shlipak, MG AF Deo, Rajat Fyr, Christina L. Wassel Fried, Linda F. Newman, Anne B. Harris, Tamara B. Angleman, Sara Green, Christie Kritchevsky, Stephen B. Chertow, Glenn M. Cummings, Steven R. Shlipak, Michael G. CA Hlth ABC Study TI Kidney dysfunction and fatal cardiovascular disease - an association independent of atherosclerotic events: Results from the Health, Aging, and Body Composition (Health ABC) study SO AMERICAN HEART JOURNAL LA English DT Article ID GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; RENAL-INSUFFICIENCY; CLINICAL EVALUATION; ELDERLY PERSONS; MORTALITY RISK; MARKER; CREATININE; PREDICTOR; PLASMA AB Background Impaired kidney function has been associated with increased risk for death, myocardial infarction, stroke, and heart failure in high-risk populations. We evaluated whether impaired kidney function predicted risk of fatal cardiovascular disease independent of prevalent and incident cardiovascular events. Methods The Health, Aging, and Body Composition study is a cohort of well-functioning, elderly participants aged 70 to 79 years at entry. We measured serum cystatin C and creatinine from baseline plasma samples of 3044 participants and followed them over 6 years, examining the associations among kidney function, cardiovascular death,. and incident cardiovascular events. Cystatin C was categorized as low (< 0.84 mg/L), medium (0.84-1.18 mg/L), or high (>= 1.19 mg/L); serum creatinine (cutoff value of >= 1.3 in women and >= 1.5 in men) and estimated glomerular filtration rate (eGFR; greater and less than 60 mL/min per 1.73 m(2)) were dichotomized. Results During follow-up, 242 cardiovascular deaths occurred, of which 69 were in participants without prior cardiovascular events; 294 incident cardiovascular events occurred including 135 myocardial infarctions and 163 strokes. Higher cystatin C concentrations were significantly associated with cardiovascular death (adjusted hazard ratio [HR] 1.70, 95% confidence interval [CI] 1.05-2.76 for the medium cystatin C group; and HR 2.24, 95% CI 1.30-3.86 for the high cystatin C group, relative to the low cystatin C group). The point estimate was of greater magnitude in the analysis that excluded prevalent cardiovascular disease (adjusted HR 2.68, 95% CI 0.94-7.70 for the medium cystatin C group; and HR 4.91, 95% CI, 1.55-15.54 for the high cystatin C group). Elevated creatinine levels (adjusted HR 1.54, 95% CI 1.02-2.33, and HR 2.28, 95% CI 1.10-4.73 among participants without a history of cardiovascular disease) were also associated with cardiovascular death. No significant association was found between low eGFR and cardiovascular death. In addition, cystatin C, low eGFR, or elevated creatinine levels were not associated with other cardiovascular events. Conclusion Impaired kidney function is a strong predictor of cardiovascular death, particularly among participants without prior history of cardiovascular disease. C1 [Shlipak, Michael G.] Univ Calif San Francisco, Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Kritchevsky, Stephen B.] Wake Forest Univ, Bowman Gray Sch Med, J Paul Sticht Ctr Aging & Rehabil, Winston Salem, NC USA. [Green, Christie] Univ Tennessee, Dept Med, Div Nephrol, Memphis, TN 38104 USA. [Harris, Tamara B.; Angleman, Sara] NIA, Intramural Res Program, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Newman, Anne B.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Fried, Linda F.] VA Pittsburgh Hlth Care Syst, Renal Sect, Pittsburgh, PA USA. [Fried, Linda F.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Fyr, Christina L. Wassel; Chertow, Glenn M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Fyr, Christina L. Wassel; Chertow, Glenn M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Deo, Rajat] Johns Hopkins Univ Hosp, Div Cardiol, Baltimore, MD 21287 USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, VA Med Ctr 111A1, Gen Internal Med Sect, 4150 Clement St, San Francisco, CA 94121 USA. EM Michael.Shlipak@ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Angleman, Sara/0000-0002-9520-5716; Kritchevsky, Stephen/0000-0003-3336-6781 FU Intramural NIH HHS; NIA NIH HHS [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106] NR 17 TC 59 Z9 66 U1 1 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD JAN PY 2008 VL 155 IS 1 BP 62 EP 68 DI 10.1016/j.ahj.2007.08.012 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 242NO UT WOS:000251732400010 PM 18082491 ER PT J AU Haile, CN Kosten, TA Kosten, TR AF Haile, Colin N. Kosten, Therese A. Kosten, Thomas R. TI Pharmacogenetic treatments for drug addiction: Alcohol and opiates SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Review DE genetics; mutations; drug dependence; drug abuse; pharmaceuticals; drug reinforcement ID MU-OPIOID-RECEPTOR; SINGLE-NUCLEOTIDE POLYMORPHISM; STEVENS-JOHNSON-SYNDROME; PITUITARY-ADRENAL AXIS; GENE OPRM1; FUNCTIONAL POLYMORPHISM; SUBSTANCE DEPENDENCE; A118G POLYMORPHISM; HEROIN-ADDICTS; BETA-ENDORPHIN AB Aims: Psychiatric pharmacogenetics involves the use of genetic tests that can predict the effectiveness of treatments for individual patients with mental illness such as drug dependence. This review aims to cover these developments in the pharmacotherapy of alcohol and opiates, two addictive drugs for which we have the majority of our FDA approved pharmacotherapies. Methods: We conducted a literature review using Medline searching terms related to these two drugs and their pharmacotherapies crossed with related genetic studies. Results: Alcohol's physiological and subjective effects are associated with enhanced beta-endorphin release. Naltrexone increases baseline beta-endorphin release blocking further release by alcohol. Naltrexone's action as an alcohol pharmacotherapy is facilitated by a putative functional single nucleotide polymorphism (SNP) in the opioid mu receptor gene (Al18G) which alters receptor function. Patients with this SNP have significantly lower relapse rates to alcoholism when treated with naltrexone. Caucasians with various forms of the CYP2D6 enzyme results in a 'poor metabolizer' phenotype and appear to be protected from developing opioid dependence. Others with a "ultra-rapid metabolizer" phenotype do poorly on methadone maintenance and have frequent withdrawal symptoms. These patients can do well using buprenorphine because it is not significantly metabolized by CYP2D6. Conclusions: Pharmacogenetics has great potential for improving treatment outcome as we identify gene variants that affect pharmacodynamic C1 [Kosten, Thomas R.] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Kosten, TR (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA. EM Kosten@bcm.edu OI Haile, Colin/0000-0001-8293-7291 FU NIDA NIH HHS [K05-DA0454, P50-DA18827] NR 175 TC 41 Z9 42 U1 0 U2 11 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PY 2008 VL 34 IS 4 BP 355 EP 381 DI 10.1080/00952990802122564 PG 27 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 318XA UT WOS:000257124900001 PM 18584566 ER PT J AU Yu, E Miotto, K Akerele, E O'Brien, CP Ling, W Kleber, H Fischman, MW Elkashef, A Herman, BH Al-Ghananeem, AM AF Yu, Elmer Miotto, Karen Akerele, Evaristo O'Brien, Charles P. Ling, Walter Kleber, Herbert Fischman, Marian W. Elkashef, Ahmed Herman, Barbara H. Al-Ghananeem, Abeer M. TI Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE clinical trial; LC-MS/MS; lofexidine; pharmacokinetic; substance abuse ID WITHDRAWAL; CLONIDINE AB Objectives: The objective of this investigation was to characterize the pharmacokinetic profile of lofexidine. Lofexidine is an orally bioavailable alpha 2- adrenergic receptor agonist analogue of clonidine that acts centrally to suppress opiate withdrawal symptoms. Methods: During the detoxification period of a phase 3 placebo-controlled, randomized, double-blind trial, six subjects were entered in this preliminary pharmacokinetic study. Results: Pharmacokinetic analysis of plasma samples collected during study day 7 indicated that Cmax was 3242 +/- 917 ng/L. The mean trough levels between the study days were not significantly different (p > .05), suggesting that the subjects were at steady-state. Conclusions: Although preliminary due to the limited number of subjects, these findings are the first to document lofexidine clinical pharmacokinetics in opiate addicts using a highly sensitive liquid chromatography tandem mass spectrometric analysis. C1 [Al-Ghananeem, Abeer M.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA. [Yu, Elmer; O'Brien, Charles P.] Univ Penn, Philadelphia, PA 19104 USA. [Yu, Elmer; O'Brien, Charles P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Miotto, Karen; Ling, Walter] Univ Calif Los Angeles, Los Angeles, CA USA. [Akerele, Evaristo; Kleber, Herbert; Fischman, Marian W.] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, New York, NY 10032 USA. [Miotto, Karen; Ling, Walter] Long Beach Vet Affairs Med Ctr, Los Angeles, CA USA. [Elkashef, Ahmed; Herman, Barbara H.] NIDA, Div Pharmacotherapeut & Med Consequences Drug Abu, PMC, NIH, Bethesda, MD 20892 USA. RP Al-Ghananeem, AM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA. EM amalg0@email.uky.edu FU NIDA NIH HHS [Y1-DA1001] NR 7 TC 4 Z9 4 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0095-2990 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PY 2008 VL 34 IS 5 BP 611 EP 616 DI 10.1080/00952990802308122 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 353XV UT WOS:000259603400011 PM 18821454 ER PT J AU Baumann, BM McCans, K Stahmer, SA Leonard, MB Shults, J Holmes, WC AF Baumann, Brigitte M. McCans, Kathryn Stahmer, Sarah A. Leonard, Mary B. Shults, Justine Holmes, William C. TI Volumetric bladder ultrasound performed by trained nurses increases catheterization success in pediatric patients SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-of-Academic-Emergency-Medicine CY MAY 16-19, 2007 CL Chicago, IL SP Soc Acad Emergency Med ID URINARY-TRACT-INFECTIONS; CLEAN INTERMITTENT CATHETERIZATION; SPINAL-CORD INJURY; FEBRILE INFANTS; YOUNG-CHILDREN; SUPRAPUBIC ASPIRATION; URETHRAL CATHETERIZATION; LOW-RISK; BACTERIURIA; VALIDATION AB Objective: The objective of the study was to determine whether the use of volumetric ultrasound by trained pediatric emergency department (ED) nurses improves first-attempt urine collection success rates. Methods: This randomized controlled trial was conducted in children aged <= 36 months requiring diagnostic urine samples. Children were randomized to either the conventional (nonimaged) or the ultrasound arm. Demographics, number of catheterizations required for success, postponements, and collection times were recorded. Results: Forty-five children were assigned to the conventional and 48 to the ultrasound arm (n = 93). First-attempt success rates were higher in the ultrasound arm: 67% (conventional) vs 92% (ultrasound) (P = .003). Both urinalysis and culture were less likely to be completed on conventional group specimens (91% vs 100%; P =.04). However, mean conventional group urine collection time was less than the ultrasound group's collection time (12 vs 28 minutes; P <.001). Conclusions: Although there is a time delay, urine collection in the ultrasound arm generated a significant improvement over conventional catheterization in obtaining an adequate urine sample. (c) 2008 Elsevier Inc. All rights reserved. C1 [Baumann, Brigitte M.; McCans, Kathryn; Stahmer, Sarah A.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Emergency Med, Camden, NJ 08103 USA. [Baumann, Brigitte M.; Leonard, Mary B.; Shults, Justine; Holmes, William C.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Leonard, Mary B.] Childrens Hosp Philadelphia, Div Nephrol, Dept Pediat, Philadelphia, PA 19104 USA. [Holmes, William C.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Holmes, William C.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Baumann, BM (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Emergency Med, Camden, NJ 08103 USA. EM baumann-b@cooperhealth.edu NR 34 TC 12 Z9 12 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD JAN PY 2008 VL 26 IS 1 BP 18 EP 23 DI 10.1016/j.ajem.2007.03.020 PG 6 WC Emergency Medicine SC Emergency Medicine GA 248NZ UT WOS:000252161800004 PM 18082776 ER PT J AU Siegel, AB McBride, RB El-Serag, HB Hershman, DL Brown, RS Renz, JF Emond, J Neugut, AI AF Siegel, Abby B. McBride, Russell B. El-Serag, Hashem B. Hershman, Dawn L. Brown, Robert S. Renz, John F. Emond, Jean, Jr. Neugut, Alfred I. TI Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002 SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID RENAL-TRANSPLANTATION; LUNG-CANCER; ACCESS; POPULATION; SURGERY; RACE AB BACKGROUND AND AIMS: The extent of use of liver transplantation on a population scale to treat hepatocellular carcinoma (HCC) in the United States is unknown. We assessed recent predictors of use of liver transplantation and its effect on survival for those with nonmetastatic HCC. METHODS: The Surveillance, Epidemiology, and End Results (SEER) program is a collection of population-based cancer registries. We identified adults registered in SEER with HCC between 1998 and 2002. We examined determinants for receipt of a liver transplant in univariate and multivariable analyses. Kaplan-Meier survival curves were constructed for those who received and did not receive a transplant for HCC. RESULTS: We identified 1,156 adults with small (5 cm or less) nonmetastatic HCC. Approximately 45% were white, 29% Asian, 17% Hispanic, and 9% African American. Only 21% received a transplant. More recent year of diagnosis, younger age, being married, white race, and smaller tumor size each predicted receipt of transplant. African Americans and Asians were about half as likely to receive a transplant as compared with white patients (odds ratio [OR] 0.43, 95% confidence interval [CI] 0.21-0.90 for African Americans, and 0.57, 95% CI 0.36-0.89 for Asians). Hispanics trended in the same direction, but this was not statistically significant (OR 0.66, 95% CI 0.39-1.12). Those who underwent liver transplantation for localized HCC had 3- and 5-yr survivals of 81% and 75%, respectively. CONCLUSIONS: Only one-fifth of those with small, nonmetastatic HCC received liver transplantation. Transplanted patients have long-term survival similar to that of the best single-institution studies. However, marked racial variations were seen, with African Americans and Asians significantly less likely to receive a transplant after controlling for other variables. C1 [Siegel, Abby B.; Hershman, Dawn L.; Brown, Robert S.; Renz, John F.; Emond, Jean, Jr.; Neugut, Alfred I.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. [Siegel, Abby B.; Hershman, Dawn L.; Brown, Robert S.; Renz, John F.; Emond, Jean, Jr.; Neugut, Alfred I.] Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY USA. [McBride, Russell B.; Hershman, Dawn L.; Neugut, Alfred I.] Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY USA. [McBride, Russell B.; Hershman, Dawn L.; Neugut, Alfred I.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA. [El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. [El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA. RP Siegel, AB (reprint author), 622 W 168th St,PH 14, New York, NY 10032 USA. FU NCI NIH HHS [CA89155, CA94061, CA95597]; NCRR NIH HHS [ULI RR024156]; NIDDK NIH HHS [DK58369] NR 22 TC 47 Z9 47 U1 2 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2008 VL 103 IS 1 BP 120 EP 127 DI 10.1111/j.1572-0241.2007.01634.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 247UP UT WOS:000252108400019 PM 18005365 ER PT J AU Young, BA Lin, E Von Korff, M Simon, G Ciechanowski, P Ludman, EJ Everson-Stewart, S Kinder, L Oliver, M Boyko, EJ Katon, WJ AF Young, Bessie Ann Lin, Elizabeth Von Korff, Michael Simon, Greg Ciechanowski, Paul Ludman, Evette J. Everson-Stewart, Siobhan Kinder, Leslie Oliver, Malia Boyko, Edward J. Katon, Wayne J. TI Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CORONARY-HEART-DISEASE; LOWER-EXTREMITY AMPUTATION; MYOCARDIAL-INFARCTION; MANAGED-CARE; CARDIOVASCULAR MORTALITY; ALL-CAUSE; POPULATION; MELLITUS; DEPRESSION; SURVIVAL AB Objective:To determine whether the number and severity of diabetes complications are associated with increased risk of mortality and hospitalizations. Study Design: Validation sample. Methods:The Diabetes Complications Severity Index (DCSI) was developed from automated clinical baseline data of a primary care diabetes cohort and compared with a simple count of complications to predict mortality and hospitalizations. Cox proportional hazard and Poisson regression models were used to predict mortality and hospitalizations, respectively. Results: Of 4229 respondents, 356 deaths occurred during 4 years of follow-up. Those with 1 complication did not have an increased risk of mortality, whereas those with 2 complications (hazard ratio [HR) = 1.90, 95% confidence interval [CI] = 1.27,2.83), 3 complications (HR = 2.66, 95% CI = 1.77, 4.01), 4 complications (HR = 3.41, 95% CI = 2.18, 5.33), and >= 5 complications (HR = 7.18, 95% CI = 4.39, 11.74) had greater risk of death. Replacing the complications count with the DCSI showed a similar mortality risk. Each level of the continuous DCSI was associated with a 1.34-fold (95% CI = 1.28, 1.41) greater risk of death. Similar results were obtained for the association of the DCSI with risk of hospitalization. Comparison of receiver operating characteristic curves verified that the DCSI was a slightly better predictor of mortality than a count of complications (P<.0001). Conclusion: Compared with the complications count, the DCSI performed slightly better and appears to be a useful too] for prediction of mortality and risk of hospitalization. C1 [Young, Bessie Ann; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Young, Bessie Ann; Kinder, Leslie] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Young, Bessie Ann; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Primary & Special Med Care Serv, Seattle, WA 98108 USA. [Lin, Elizabeth; Von Korff, Michael; Simon, Greg; Ludman, Evette J.; Oliver, Malia] Ctr Hlth Studies Grp Hlth Cooperat, Seattle, WA USA. [Ciechanowski, Paul; Katon, Wayne J.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Everson-Stewart, Siobhan] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA. [Young, Bessie Ann; Boyko, Edward J.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. [Young, Bessie Ann] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. RP Young, BA (reprint author), Vet Affairs Puget Sound Hlth Care Syst 152 E, Epidemiol Res & Informat Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM youngb@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU NIMH NIH HHS [K02 MH001643, MH0-1643, MH4-1739, R01 MH041739] NR 43 TC 150 Z9 151 U1 3 U2 15 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JAN PY 2008 VL 14 IS 1 BP 15 EP 24 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 253HZ UT WOS:000252510600002 PM 18197741 ER PT J AU Leaf, DA AF Leaf, David Alexander TI Chylomicronemia and the chylomicronemia syndrome: A practical approach to management SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE chylomicronemia; lipids; pancreatitis ID FATTY-ACIDS; HYPERTRIGLYCERIDEMIA; PERSPECTIVES; CHOLESTEROL; METABOLISM; METFORMIN; OBESITY; INSULIN; ADULTS AB Chylomicronemia is present when triglyceride levels exceed 1000 mg/dL. Chylomicronemia, when accompanied by eruptive xanthoma, lipemia retinalis, or abdominal symptoms, is referred to as the "chylomicronemia syndrome" and can cause acute pancreatitis. Treatment aimed at reducing triglyceride levels includes lifestyle modifications to promote weight loss with diet and physical activity coupled with medications, including fibrates, n-3 polyunsaturated fatty acids, and nicotinic acid. Chylomicronemic patients with acute pancreatitis require insulinization in an inpatient setting to abolish chylomicronemia. (C) 2008 Elsevier Inc. All rights reserved. C1 [Leaf, David Alexander] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. RP Leaf, DA (reprint author), Div Gen Internal Med, Greater Los Angeles VA Healthcare Syst, 111G,Wilshire & Sawtelle Blvds, Los Angeles, CA 90073 USA. EM davidleaf@med.va.gov NR 21 TC 31 Z9 33 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JAN PY 2008 VL 121 IS 1 BP 10 EP 12 DI 10.1016/j.amjmed.2007.10.004 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 249XC UT WOS:000252262600004 PM 18187065 ER PT J AU Shlipak, MG Ix, JH Bibbins-Domingo, K Lin, F Whooley, MA AF Shlipak, Michael G. Ix, Joachim H. Bibbins-Domingo, Kirsten Lin, Feng Whooley, Mary A. TI Biomarkers to predict recurrent cardiovascular disease: The heart and soul study SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE albuminuria; biomarkers; cardiovascular events; coronary artery disease; C-reactive protein; cystatin C; fibrinogen; interleukin-6; N-terminal prohormone brain natriuretic peptide ID C-REACTIVE PROTEIN; ACUTE CORONARY SYNDROMES; NATRIURETIC PEPTIDE; CYSTATIN-C; ARTERY-DISEASE; RISK-FACTORS; FETUIN-A; ASSOCIATION; PREVENTION; EVENTS AB PURPOSE: The study purpose was to evaluate the ability of 6 biomarkers to improve the prediction of cardiovascular events among persons with established coronary artery disease. BACKGROUND: Cardiovascular risk algorithms are designed to predict the initial onset of coronary artery disease but are less effective in persons with preexisting coronary artery disease. METHODS: We examined the association of N-terminal prohormone brain natriuretic peptide (Nt-proBNP), cystatin C, albuminuria, C-reactive protein (CRP), interleukin-6, and fibrinogen with cardiovascular events in 979 Heart and Soul Study participants with coronary artery disease after adjusting for demographic, lifestyle, and behavior variables; cardiovascular risk factors; cardiovascular disease severity; medication use; and left ventricular ejection fraction. The outcome was a composite of stroke, myocardial infarction, and coronary heart disease death during an average of 3.5 years of follow-up. RESULTS: During follow-up, 142 participants (15%) developed cardiovascular events. The highest quartiles ( vs lower 3 quartiles) of 5 biomarkers were individually associated with cardiovascular risk after multivariate analysis: Nt-proBNP hazard ratio (HR) = 2.13 (95% confidence interval [CI], 1.43-3.18); cystatin C HR = 1.72 (95% CI, 1.10-2.70); albuminuria HR = 1.71 (95% CI, 1.15-2.54); CRP HR = 2.00 ( 95% CI, 1.40-2.85); and interleukin-6 HR = 1.76 (95% CI, 1.22-2.53). When all biomarkers were included in the multivariable analysis, only Nt-proBNP, albuminuria, and CRP remained significant predictors of events: HR = 1.88 (95% CI, 1.23-2.85), HR = 1.63 (95% CI, 1.09-2.43), and HR = 1.82 (95% CI, 1.24-2.67), respectively. The area under the receiver operator curve for clinical predictors alone was 0.73 (95% CI, 0.68-0.78); adding Nt-proBNP, albuminuria, and CRP significantly increased the area under the receiver operator curve to 0.77 ( 95% CI, 0.73-0.82, P <. 005). CONCLUSION: Among persons with prevalent coronary artery disease, biomarkers reflecting hemodynamic stress, kidney damage, and inflammation added significant risk discrimination for cardiovascular events. (C) 2008 Elsevier Inc. All rights reserved. C1 [Shlipak, Michael G.; Whooley, Mary A.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.; Lin, Feng; Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA. [Bibbins-Domingo, Kirsten] San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94110 USA. RP Shlipak, MG (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM Michael.shlipak@ucsf.edu FU NHLBI NIH HHS [R01 HL073208-02, R01 HL073208, R03 HL068099, R03 HL068099-01, R01 HL073208-01]; NIDDK NIH HHS [R01 DK066488, R01 DK066488-01, R01 DK066488-02, R01 DK066488-03, R01 DK066488-04] NR 17 TC 81 Z9 86 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JAN PY 2008 VL 121 IS 1 BP 50 EP 57 DI 10.1016/j.amjmed.2007.06.030 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 249XC UT WOS:000252262600012 PM 18187073 ER PT J AU Rosman, AS Korsten, MA AF Rosman, Alan S. Korsten, Mark A. TI Meta-analysis of air contrast barium enema, computed tomography colonography, and colonoscopy - Reply SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter C1 [Rosman, Alan S.; Korsten, Mark A.] James J Peters Vet Affairs Med Ctr, Sect Gastroenterol & Med Program, Bronx, NY 10468 USA. [Rosman, Alan S.; Korsten, Mark A.] NYU, Mt Sinai Sch Med, New York, NY USA. RP Rosman, AS (reprint author), James J Peters Vet Affairs Med Ctr, Sect Gastroenterol & Med Program, Bronx, NY 10468 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JAN PY 2008 VL 121 IS 1 BP E9 EP E9 DI 10.1016/j.amjmed.2007.08.033 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 249XC UT WOS:000252262600022 ER PT J AU Chonchol, M Whittle, J Desbien, A Orner, MB Petersen, LA Kressin, NR AF Chonchol, Michel Whittle, Jeff Desbien, Angela Orner, Michelle B. Petersen, Laura A. Kressin, Nancy R. TI Chronic kidney disease is associated with angiographic coronary artery disease SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE chronic kidney disease; coronary artery disease; coronary angiography ID ISCHEMIC-HEART-DISEASE; CHRONIC-RENAL-FAILURE; PRACTICE GUIDELINES; RACIAL-DIFFERENCES; UNITED-STATES; RISK-FACTORS; TASK-FORCE; PREVALENCE; INSUFFICIENCY; HEMODIALYSIS AB Background/Aims: Patients with chronic kidney disease (CKD) have a dramatically increased risk for cardiovascular mortality. Few prior studies have examined the independent association of CKD with coronary anatomy. Methods: We evaluated the relationship between CKD and severe coronary artery disease (CAD) in 261 male veterans with nuclear perfusion imaging tests suggesting coronary ischemia. We used chart review and patient and provider interviews to collect demographics, clinical characteristics, and coronary anatomy results. We defined CKD as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2, based on the creatinine obtained prior to angiography. We defined significant coronary obstruction as at least one 70% or greater stenosis. We used logistic regression to determine whether CKD was independently associated with significant coronary obstruction. Results: The likelihood of CAD increased monotonically with decreasing eGFR, from 51% among patients with eGFR >= 90 ml/min/1.73 m 2 to 84% in those with eGFR <30 ml/min/1.73 m(2) (p = 0.0046). Patients with CKD were more likely than those without CKD to have at least one significant coronary obstruction (75.9 vs. 60.7%, p = 0.016). Patients with CKD also had more significant CAD, that is, were more likely to have three-vessel and/or left main disease than those without CKD (34.9 vs. 16.9%, p = 0.0035). In logistic regression analysis, controlling for demographics and comorbidity, CKD continued to be independently associated with the presence of significant CAD (p = 0.0071). Conclusion: CKD patients have a high prevalence of obstructive coronary disease, which may contribute to their high cardiovascular mortality. Copyright (C) 2007 S. Karger AG, Basel. C1 Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Clement J Zablocki VA Med Ctr, Primary Care Div, Milwaukee, WI USA. Bedford VA Med Ctr, Ctr Hlth Quality Outcomes & Econ Res, Bedford, MA USA. Baylor Coll Med, Houston VA Med Ctr, Dev Ctr Excellence, Houston Ctr Quality Care & Utilizat Studies, Houston, TX USA. Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA USA. RP Chonchol, M (reprint author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Box C 281, Denver, CO 80262 USA. EM Michel.Chonchol@uchsc.edu OI Kressin, Nancy/0000-0003-2767-4286 NR 28 TC 39 Z9 43 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2008 VL 28 IS 2 BP 354 EP 360 DI 10.1159/000111829 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 238GS UT WOS:000251436000023 PM 18046083 ER PT J AU Fischer, MJ Brimhall, BB Parikh, CR AF Fischer, Michael J. Brimhall, Bradley B. Parikh, Chirag R. TI Uncomplicated acute renal failure and post-hospital care: A not so uncomplicated illness SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE acute renal failure, outcomes; extended facility care; home health care; nephrology clinical ID CRITICALLY ILL PATIENTS; RISK-FACTORS; RESOURCE UTILIZATION; MEDICAL ILLNESS; SERIOUSLY ILL; NURSING-HOME; MORTALITY; MULTICENTER; OUTCOMES; AGE AB Background: Although uncomplicated acute renal failure (ARF) is associated with significant hospital resource utilization, its health care requirements following hospital discharge are not well understood. The goal of this study was to characterize the post-hospital care requirements incurred by patients with uncomplicated ARF and to determine its important influencing factors. Methods: We obtained hospital case mix data sets for a 2-year period (1999-2000) from the Massachusetts Division of Health Care Finance and Policy. Utilizing DRG and ICD-9-CM codes from 23 Massachusetts hospitals, we identified 2,128 adult patients whose primary reason for hospitalization was uncomplicated ARF. Post-hospital care was defined as the receipt of extended facility care or home health care following hospital discharge. Results: Nearly 50% of patients hospitalized with uncomplicated ARF required some type of post-hospital care, of whom 27% underwent extended facility care while 22% received home health care. The post-hospital care requirements for uncomplicated ARF were similar to those for serious medical conditions (e.g. heart failure) and exceeded those of many common illnesses (e.g., bronchitis). Advancing age, worsening severity of illness, female gender, and emergency room admission were independently associated with receipt of post-hospital care (p < 0.05). A trend existed between less frequent post-hospital care requirements and hospitalization at academic medical centers compared with non-academic hospitals. Conclusions: Uncomplicated ARF is frequently associated with prolonged care following hospitalization. As the health care utilization for ARF becomes better characterized, these post-hospital care resources should not be overlooked. Copyright (C) 2008 S. Karger AG, Basel. C1 [Fischer, Michael J.] Univ Illinois, Dept Med, Nephrol Sect, Med Ctr, Chicago, IL 60612 USA. [Fischer, Michael J.] Jesse Brown VA Med Ctr, Nephrol Sect, Dept Internal Med, Chicago, IL USA. [Fischer, Michael J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Brimhall, Bradley B.] Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA. [Brimhall, Bradley B.] Univ New Mexico, Sch Med, Tricore Reference Labs, Albuquerque, NM 87131 USA. [Parikh, Chirag R.] Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06510 USA. [Parikh, Chirag R.] Vet Affairs Med Ctr, New Haven, CT USA. RP Fischer, MJ (reprint author), Univ Illinois, Dept Med, Nephrol Sect, Med Ctr, MC 793,820 S Wood St, Chicago, IL 60612 USA. EM fischerm@uic.edu FU NIDDK NIH HHS [K23-DK064689-01, K23 DK064689] NR 37 TC 9 Z9 14 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2008 VL 28 IS 3 BP 523 EP 530 DI 10.1159/000114005 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 271GU UT WOS:000253777700020 PM 18223306 ER PT J AU Gukovsky, I Lugea, A Shahsahebi, M Cheng, JH Hong, PP Jung, YJ Deng, QG French, BA Lungo, W French, SW Tsukamoto, H Pandol, SJ AF Gukovsky, Ilya Lugea, Aurelia Shahsahebi, Mohammad Cheng, Jason H. Hong, Peggy P. Jung, Yoon J. Deng, Quing-gao French, Barbara A. Lungo, William French, Samuel W. Tsukamoto, Hidekazu Pandol, Stephen J. TI A rat model reproducing key pathological responses of alcoholic chronic pancreatitis SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE ethanol; inflammatory response; pancreatic stellate cells; cerulein; cyclosporin A ID CERULEIN-INDUCED PANCREATITIS; NF-KAPPA-B; ACINAR-CELLS; DIBUTYLTIN DICHLORIDE; CYCLOSPORINE-A; LONG-TERM; TUBULAR COMPLEXES; OXIDATIVE STRESS; STELLATE CELLS; ANIMAL-MODELS AB Although alcohol abuse is the major cause of chronic pancreatitis, the pathogenesis of alcoholic chronic pancreatitis (ACP) remains obscure. A critical obstacle to understanding the mechanism of ACP is lack of animal models. Our objective was to develop one such model. Rats were pair-fed for 8 wk ethanol or control Lieber-DeCarli liquid diet. For the last 2 wk, they received cyclosporin A (CsA; 20 mg/kg once daily) or vehicle. After 1 wk on CsA, one episode of acute pancreatitis was induced by four 20 mu g/kg injections of cerulein (Cer); controls received saline. Pancreas was analyzed 1 wk after the acute pancreatitis. CsA or Cer treatments alone did not result in pancreatic injury in either control (C)- or ethanol (E)- fed rats. We found, however, that alcohol dramatically aggravated pathological effect of the combined CsA+Cer treatment on pancreas, resulting in massive loss of acinar cells, persistent inflammatory infiltration, and fibrosis. Macrophages were prominent in the inflammatory infiltrate. Compared with control-fed C+CsA+Cer rats, their ethanol-fed E + CsA + Cer counterparts showed marked increases in pancreatic NF-kappa B activation and cytokine/ chemokine mRNA expression, collagen and fibronectin, the expression and activities of matrix metalloproteinase-2 and - 9, and activation of pancreatic stellate cells. Thus we have developed a model of alcohol-mediated postacute pancreatitis that reproduces three key responses of human ACP: loss of parenchyma, sustained inflammation, and fibrosis. The results indicate that alcohol impairs recovery from acute pancreatitis, suggesting a mechanism by which alcohol sensitizes pancreas to chronic injury. C1 [Gukovsky, Ilya; Lugea, Aurelia; Shahsahebi, Mohammad; Cheng, Jason H.; Hong, Peggy P.; Jung, Yoon J.; Pandol, Stephen J.] Vet Affairs Greater Los Angels Healthcare Syst, Torrance, CA USA. [Gukovsky, Ilya; Lugea, Aurelia; Shahsahebi, Mohammad; Cheng, Jason H.; Hong, Peggy P.; Jung, Yoon J.; Deng, Quing-gao; French, Barbara A.; Lungo, William; French, Samuel W.; Tsukamoto, Hidekazu; Pandol, Stephen J.] USC UCLA, Res Ctr Alcohol Liver & Pancreat Dis, Torrance, CA USA. [Gukovsky, Ilya; Lugea, Aurelia; Shahsahebi, Mohammad; Cheng, Jason H.; Hong, Peggy P.; Jung, Yoon J.; Pandol, Stephen J.] Univ Calif Los Angeles, Torrance, CA USA. [French, Barbara A.; Lungo, William; French, Samuel W.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. RP Gukovsky, I (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Bldg 258,Rm 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM igukovsk@ucla.edu FU PHS HHS [P50-A11999] NR 74 TC 37 Z9 39 U1 1 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JAN PY 2008 VL 294 IS 1 BP G68 EP G79 DI 10.1152/ajpgi.00006.2007 PG 12 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 252RP UT WOS:000252464600009 PM 17884979 ER PT J AU Parrish, DC Gritman, K Van Winkle, DM Woodward, WR Bader, M Habecker, BA AF Parrish, Diana C. Gritman, Kurt Van Winkle, Donna M. Woodward, William R. Bader, Michael Habecker, Beth A. TI Postinfarct sympathetic hyperactivity differentially stimulates expression of tyrosine hydroxylase and norepinephrine transporter SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE ischemia-reperfusion; sympathetic hyperactivity; autonomic ID ACUTE MYOCARDIAL-INFARCTION; LOW BRAIN ANGIOTENSINOGEN; NERVE GROWTH-FACTOR; TRANSGENIC RATS; TIME-COURSE; HEART-RATE; NEURONS; ISCHEMIA; DEPOLARIZATION; CATECHOLAMINES AB The balance between norepinephrine (NE) synthesis, release, and reuptake is disrupted after acute myocardial infarction, resulting in elevated extracellular NE. Stimulation of sympathetic neurons in vitro increases NE synthesis and the synthetic enzyme tyrosine hydroxylase (TH) to a greater extent than it increases NE reuptake and the NE transporter (NET), which removes NE from the extracellular space. We used TGR(ASrAOGEN) transgenic rats, which lack postinfarct sympathetic hyperactivity, to test the hypothesis that increased cardiac sympathetic nerve activity accounts for the imbalance in TH and NET expression in these neurons after myocardial infarction. TH and NET mRNA levels were identical in the stellate ganglia of unoperated TGR( ASrAOGEN) rats compared with Sprague Dawley (SD) controls, but the threefold increase in TH and twofold increase in NET mRNA seen in the stellate ganglia of SD rats 1 wk after ischemia-reperfusion was absent in TGR( ASrAOGEN) rats. Similarly, the increase in TH and NET protein observed in the base of the SD ventricle was absent in the base of the TGR ( ASrAOGEN) ventricle. Neuronal TH content was depleted in the left ventricle of both genotypes, whereas NET was unchanged. Basal heart rate and cardiac function were similar in both genotypes, but TGR( ASrAOGEN) hearts were more sensitive to the beta-agonist dobutamine. Tyramine-induced release of endogenous NE generated similar changes in ventricular pressure and contractility in both genotypes, but postinfarct relaxation was enhanced in TGR( ASrAOGEN) hearts. These data support the hypothesis that postinfarct sympathetic hyperactivity is the major stimulus increasing TH and NET expression in cardiac neurons. C1 [Parrish, Diana C.; Gritman, Kurt; Habecker, Beth A.] Oregon Hlth & Sci Univ, Sch Med, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Van Winkle, Donna M.] Oregon Hlth & Sci Univ, Sch Med, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Woodward, William R.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97239 USA. [Van Winkle, Donna M.] Portland VA Med Ctr, Portland, OR USA. [Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany. RP Habecker, BA (reprint author), Oregon Hlth & Sci Univ, Sch Med, Dept Physiol & Pharmacol, L334,3181 SW Sam Jackson Pk,Rd, Portland, OR 97239 USA. EM habecker@ohsu.edu OI Habecker, Beth/0000-0002-4658-8730; Bader, Michael/0000-0003-4780-4164 FU NHLBI NIH HHS [R01 HL 68231, R01 HL068231] NR 35 TC 28 Z9 30 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JAN PY 2008 VL 294 IS 1 BP H99 EP H106 DI 10.1152/ajpheart.00533.2007 PG 8 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 249WO UT WOS:000252261200014 PM 17951370 ER PT J AU Rumbaut, RE Mirkovic, D AF Rumbaut, Rolando E. Mirkovic, Dragan TI Magnetic therapy for edema in inflammation: a physiological assessment SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Editorial Material ID FIELD THERAPY; DOUBLE-BLIND; COMPLEMENTARY; PAIN C1 [Rumbaut, Rolando E.] Baylor Coll Med, Childrens Nutr Res Ctr, Dept Med, Houston, TX 77030 USA. [Rumbaut, Rolando E.] Baylor Coll Med, Childrens Nutr Res Ctr, Dept Pediat, Houston, TX 77030 USA. [Rumbaut, Rolando E.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Mirkovic, Dragan] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX USA. RP Rumbaut, RE (reprint author), Baylor Coll Med, Childrens Nutr Res Ctr, Dept Med, 1100 Bates Ave,Rm 6014441, Houston, TX 77030 USA. EM rrumbaut@bcm.tmc.edu NR 20 TC 3 Z9 3 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JAN PY 2008 VL 294 IS 1 BP H19 EP H20 DI 10.1152/ajpheart.01342.2007 PG 2 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 249WO UT WOS:000252261200005 PM 18032520 ER PT J AU Wecht, JM Weir, JP Goldstein, DS Krothe-Petroff, A Spungen, AM Holmes, C Bauman, WA AF Wecht, Jill M. Weir, Joseph P. Goldstein, David S. Krothe-Petroff, Annmarie Spungen, Ann M. Holmes, Courtney Bauman, William A. TI Direct and reflexive effects of nitric oxide synthase inhibition on blood pressure SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE spinal cord injury; nitro-L-arginine methyl ester; norepinephrine; sympathetic nervous system ID SYMPATHETIC NERVOUS-SYSTEM; CONSCIOUS RATS; L-ARGININE; HUMANS; TONE; HYPERTENSION; TETRAPLEGIA; HYPOTENSION; MUSCLE AB Direct effects of vasoactive substances on blood pressure can be examined in individuals with tetraplegia due to disruption of descending spinal pathways to sympathetic preganglionic neurons, as cervical lesions interfere with baroreceptor reflex buffering of sympathetic outflow. In this study, we assessed effects of the nitric oxide synthase inhibitor nitro-L-arginine methyl ester (L- NAME) on mean arterial pressure, heart rate, and plasma norepinephrine concentrations in individuals with tetraplegia vs. effects shown in a neurologically intact control group. Seven individuals with tetraplegia and seven age-matched controls received, on separate visits and in the following order, placebo (30 ml normal saline) and 0.5, 1, 2, and 4 mg/ kg L- NAME intravenously over 60 min. Supine hemodynamic data were collected, and blood was sampled at the end of each infusion and at 120, 180, and 240 min thereafter. L- NAME increased mean arterial pressure, and the relative increase was greater in the tetraplegia group than in the control group. Heart rate was reduced after L- NAME administration in both groups. L- NAME decreased plasma norepinephrine in the control group but not in the group with tetraplegia. These findings suggest that reflexive sympathoinhibition normally buffers the pressor response to nitric oxide synthase inhibition, an effect that is not evident in individuals with tetraplegia as a result of decentralized sympathetic vasomotor control. C1 [Wecht, Jill M.] James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] Mt Sinai Hosp, Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] Mt Sinai Hosp, Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. [Weir, Joseph P.] Des Moines Univ Osteopath Med Ctr, Des Moines, IA USA. [Goldstein, David S.; Holmes, Courtney] Natl Inst Neurol Disorders & Stroke, NIH, Div Intramural Res, Clin Neurosci Program,Clin Neurocardiol Sect, Bethesda, MD USA. RP Wecht, JM (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM jm.wecht@va.gov FU Intramural NIH HHS NR 30 TC 12 Z9 13 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JAN PY 2008 VL 294 IS 1 BP H190 EP H197 DI 10.1152/ajpheart.00366.2007 PG 8 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 249WO UT WOS:000252261200023 PM 17965289 ER PT J AU Habib, SL Riley, DJ Mahimainathan, L Bhandari, B Choudhury, GG Abboud, HE AF Habib, Samy L. Riley, Daniel J. Mahimainathan, Lenin Bhandari, Basant Choudhury, Goutam Ghosh Abboud, Hanna E. TI Tuberin regulates the DNA repair enzyme OGG1 SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article ID RENAL-CELL CARCINOMA; EKER RAT MODEL; SACCHAROMYCES-CEREVISIAE; SCLEROSIS COMPLEX; BASE DAMAGE; GENE; TUMORS; TSC2; EXPRESSION; KIDNEY AB The tuberous sclerosis complex (TSC) is caused by defects in one of two tumor suppressor genes, TSC-1 or TSC-2. The TSC-2 gene encodes tuberin, a protein involved in the pathogenesis of kidney tumors, both angiomyolipomas and renal cell carcinomas. We investigated a potential role for tuberin in regulating a key DNA repair pathway. Downregulation of tuberin in human renal epithelial cells using siRNA resulted in a marked decrease in the abundance of the 8-oxoG-DNA glycosylase (OGG1). Mouse embryonic fibroblasts deficient in tuberin (TSC2(-/-) and TSC2(+/-)) also had markedly decreased OGG1 mRNA and protein expression, as well as undetectable OGG1 activity accompanied by accumulation of 8-oxodG. Gel shift analyses and chromatin immunoprecipatation identified the transcription factor NF-YA as a regulator of OGG1 activity. The binding of NF-YA to the OGG1 promoter was significantly reduced in TSC2(-/-) compared with TSC2(+/+) cells. Introduction of TSC2 cDNA into the tuberin-deficient cells restored NF-YA and OGG1 expression. Transcriptional activity of the OGG1 promoter was also decreased in tuberin-null cells. In addition, mutation of both CAAT boxes, the sites to which NF-YA binds, completely inhibits OGG1 promoter activity. These data provide the first evidence that tuberin regulates a specific DNA repair enzyme, OGG1. This regulation may be important in the pathogenesis of kidney tumors in patients with TSC. C1 [Habib, Samy L.; Riley, Daniel J.; Mahimainathan, Lenin; Bhandari, Basant; Choudhury, Goutam Ghosh; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, George Obrien Kidney Res Ctr, San Antonio, TX 78229 USA. [Habib, Samy L.; Riley, Daniel J.; Choudhury, Goutam Ghosh; Abboud, Hanna E.] S Texas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med MSC 7882, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM habib@uthscsa.edu OI /0000-0001-5077-3552 NR 35 TC 21 Z9 21 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JAN PY 2008 VL 294 IS 1 BP F281 EP F290 DI 10.1152/ajprenal.00370.2007 PG 10 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 249OF UT WOS:000252237500032 PM 17989114 ER PT J AU Yan, E Ko, E Luong, V Wang, HJ Romanova, M Li, ZP AF Yan, Eric Ko, Elizabeth Luong, Vincent Wang, He-Jing Romanova, Maria Li, Zhaoping TI Long-term changes in weight loss and obesity-related comorbidities after Roux-en-Y gastric bypass: a primary care experience SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Roux-en-Y gastric bypass; comorbidities; obesity; veterans affairs ID BARIATRIC SURGERY; VETERANS-AFFAIRS; MORBID-OBESITY; RISK-FACTORS; OUTCOMES; FACILITIES; MORTALITY; OLDER AB Background: Long-term results of Roux-en-Y gastric bypass (RYGB) are nonexistent in the veterans affairs (VA) population. We compare excess weight loss (EWL) success and medical comorbidity changes between the VA and non-VA population after RYGB. Methods: Retrospective review of consecutive subjects undergoing RYGB from 1997 to 2002 at the Los Angeles VA. Weight and comorbidity data were collected every 6 and 12 months, respectively. Results: Fifty-nine subjects were included; 54%, 58%,46.8%, and 44.1% Of Subjects achieved EWL > 50% at years 1 to 4. Hypertension resolved in 23%, 30%, and 32% at months 12 to 36. Obstructive sleep apnea resolved in 37%, 48%, 48%, 44%, and 60% at months 12 to 60. Diabetes mellitus resolved in 86%, 84%, 79%, and 80% at months 12 to 48. Improvements in the lipid panel were observed by month 12 and maintained thereafter. Conclusions: EWL and proportion of subjects with resolved hypertension and obstructive sleep apnea are inferior to the non-VA population. Nevertheless, improvements in measures of success are maintained in the VA population. (c) 2008 Excerpta Medica Inc. All rights reserved. C1 [Yan, Eric; Ko, Elizabeth; Luong, Vincent; Li, Zhaoping] Univ Calif Los Angeles, Ctr Human Nutr, David Geffen Sch Med, Los Angeles, CA USA. [Wang, He-Jing] Univ Calif Los Angeles, Med Ctr, Dept Biomath, Los Angeles, CA 90024 USA. [Romanova, Maria] Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. RP Yan, E (reprint author), Univ Calif Los Angeles, Ctr Human Nutr, David Geffen Sch Med, Los Angeles, CA USA. EM eyan@mednet.ucla.edu NR 20 TC 19 Z9 21 U1 1 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD JAN PY 2008 VL 195 IS 1 BP 94 EP 98 DI 10.1016/j.amjsurg.2007.01.036 PG 5 WC Surgery SC Surgery GA 245WA UT WOS:000251968300018 PM 18082548 ER PT J AU Bakaeen, FG Huh, J Fagan, SP Bellows, CF AF Bakaeen, Faisal G. Huh, Joseph Fagan, Shawn P. Bellows, Charles F. TI Surgical treatment of sternoclavicular joint infections in cirrhotic patients SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE sternoclavicular joint; infection; cirrhosis; surgery ID SEPTIC ARTHRITIS; MANAGEMENT AB Background: Cirrhotic patients with sternoclavicular joint (SCJ) infection pose a unique challenge for which there are no management guidelines. We reviewed our experience with this unusual infection in this high-risk patient population. Methods: We performed a retrospective analysis of all patients with cirrhosis (n = 5) treated surgically for SCJ infection from January 1998 to July 2006. Results: All infections were locally advanced with bone necrosis, complex abscess formation, or mediastinal involvement. En bloc SCJ resection was performed in 3 patients. A more conservative approach of incision and drainage with debridement was performed in 2 patients. Sepsis and/or pulmonary compromise occurred in all patients postoperatively and the surgical mortality rate was 40%. All deaths occurred after en bloc SCJ resection. Conclusions: Sternoclavicular joint infections in cirrhotic patients tend to be extensive in nature and pose a high surgical risk. Adequate surgical drainage and debridement may be better tolerated than a radical en block resection. (c) 2008 Excerpta Medica Inc. All rights reserved. C1 [Bakaeen, Faisal G.; Huh, Joseph; Fagan, Shawn P.; Bellows, Charles F.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. RP Bakaeen, FG (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. EM fbakaeen@bcm.edu NR 10 TC 2 Z9 5 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD JAN PY 2008 VL 195 IS 1 BP 130 EP 133 DI 10.1016/j.amjsurg.2007.04.009 PG 4 WC Surgery SC Surgery GA 245WA UT WOS:000251968300026 PM 18070732 ER PT J AU Merrill, WW AF Merrill, William W. TI From the match to the torch: New progress against an old adversary SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE COPD; oxygen; therapy; lung function ID OBSTRUCTIVE PULMONARY-DISEASE; LUNG-VOLUME-REDUCTION; SEVERE EMPHYSEMA; RANDOMIZED-TRIAL; MEDICAL THERAPY; EXACERBATIONS; COPD; SALMETEROL; SURGERY; SMOKERS AB Chronic obstructive pulmonary disease is a medical problem of significant worldwide importance. Millions of patients are severely affected worldwide, and healthcare costs range in the billions of dollars per year. The importance of this illness and its effect on the world population have recently been emphasized in the report of the international consortium called the Gold Initiative. This group has now published several updates to their original report. The following monograph summarizes this important disease process and review recent research in this significant area of clinical medicine. C1 [Merrill, William W.] Med Univ S Carolina, Dept Med, Charleston, SC 29401 USA. [Merrill, William W.] Med Univ S Carolina, Med Serv, Ralph H Johnson VAMC, Charleston, SC 29401 USA. RP Merrill, WW (reprint author), Med Univ S Carolina, Med Serv, Ralph H Johnson VAMC 111, 109 Bee St, Charleston, SC 29401 USA. EM William.merrill2@va.gov NR 26 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD JAN PY 2008 VL 335 IS 1 BP 2 EP 6 DI 10.1097/MAJ.0b013e31815f1e24 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 251NJ UT WOS:000252380000002 PM 18195576 ER PT J AU Gordon, AJ Liberto, J Granda, S Salmon-Cox, S Andree, T McNicholas, L AF Gordon, Adam J. Liberto, Joseph Granda, Stephanie Salmon-Cox, Sara Andree, Tykia McNicholas, Laura TI Outcomes of DATA 2000 Certification Trainings for the Provision of Buprenorphine Treatment in the Veterans Health Administration SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article AB Despite the high numbers of veterans with opioid dependence, few receive pharmacologic treatment for this disorder. The adoption of buprenorphine treatment within the Veterans Health Administration (VHA) has been slow. To expand capacity for buprenorphine treatment, the VHA sponsored two eight-hour credentialing courses for the Drug Addiction Treatment Act of 2000. We sought to describe the outcomes of such training. Following the training sessions, 29 participants (18 physicians) were highly satisfied with course content and affirmed their intention to prescribe buprenorphine; after nine-month follow-up, two physicians were prescribing. We conclude that providing credentialing courses, while popular, did not markedly promote the prescription of buprenorphine. C1 [Gordon, Adam J.; Salmon-Cox, Sara; Andree, Tykia] VA Pittsburgh Healthcare Syst, VISN 4, Ctr Hlth Equ Res & Promot, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. [Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Liberto, Joseph] VA Maryland Healthcare Syst, Baltimore, MD USA. [Liberto, Joseph] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Granda, Stephanie] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA. [McNicholas, Laura] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, VISN 4, Ctr Hlth Equ Res & Promot, Mental Illness Res Educ & Clin Ctr, Mailcode 151 C-H,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM adam.gordon@va.gov NR 12 TC 14 Z9 14 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PY 2008 VL 17 IS 6 BP 459 EP 462 AR PII 905998268 DI 10.1080/10550490802408613 PG 4 WC Substance Abuse SC Substance Abuse GA 376MQ UT WOS:000261188100001 PM 19034736 ER PT J AU Suh, JJ Pettinati, HM Kampman, KM O'Brien, CP AF Suh, Jesse J. Pettinati, Helen M. Kampman, Kyle M. O'Brien, Charles P. TI Gender Differences in Predictors of Treatment Attrition with High Dose Naltrexone in Cocaine and Alcohol Dependence SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; ADDICTION SEVERITY INDEX; OPIOID RECEPTOR GENE; FUNCTIONAL POLYMORPHISM; DRINKING BEHAVIOR; SUBSTANCE-ABUSE; SELF-REPORTS; RELIABILITY; DISORDERS; VALIDITY AB Recently, we reported that naltrexone at 150 mg/day significantly decreased cocaine and alcohol use for men but not women with co-occurring cocaine and alcohol dependence. The present study is an exploratory investigation of predictors that explain the different gender responses to naltrexone, with a particular focus on differential predictors of treatment attrition. No significant predictors were associated with treatment discontinuation in men. Women, however, were more likely to discontinue treatment when reporting severe pre-treatment psychiatric problems or nausea while in treatment. Further research on the impact of pre-treatment and in-treatment gender differences with naltrexone is warranted. C1 [Suh, Jesse J.; Pettinati, Helen M.; Kampman, Kyle M.; O'Brien, Charles P.] Univ Penn, Dept Psychiat, Ctr Studies Addict, Sch Med, Philadelphia, PA 19104 USA. [Suh, Jesse J.; Kampman, Kyle M.; O'Brien, Charles P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Suh, JJ (reprint author), Univ Penn, Dept Psychiat, Ctr Studies Addict, Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM Suh_J@mail.TRC.Upenn.edu FU NIAAA NIH HHS [R01 AA009544, R01 AA014657]; NIDA NIH HHS [P50 DA012756, P50 DA012756-04, P50-DA-012756-04, P60 DA005186, P60 DA005186-17, P60-DA-05186-17, T32 DA007241, T32-DA-07241-13] NR 44 TC 14 Z9 14 U1 4 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PY 2008 VL 17 IS 6 BP 463 EP 468 AR PII 906011123 DI 10.1080/10550490802409074 PG 6 WC Substance Abuse SC Substance Abuse GA 376MQ UT WOS:000261188100002 PM 19034737 ER PT J AU Bernheim, SM Ross, JS Krumholz, HM Bradley, EH AF Bernheim, Susannah M. Ross, Joseph S. Krumholz, Harlan M. Bradley, Elizabeth H. TI Influence of patients' socioeconomic status on clinical management decisions: A qualitative study SO ANNALS OF FAMILY MEDICINE LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; PAY-FOR-PERFORMANCE; HEALTH-CARE; DISPARITIES; INCOME; ASSOCIATION; SERVICES; OUTCOMES; COMMUNICATION; MORTALITY AB PURPOSE Little is known about how patients' socioeconomic status (SES) influences physicians' clinical management decisions, although this information may have important implications for understanding inequities in health care quality. We investigated physician perspectives on how patients' SES influences care. METHODS The study consisted of in-depth semistructured interviews with primary care physicians in Connecticut. Investigators coded interviews line by line and refined the coding structure and interview guide based on successive interviews. Recurrent themes emerged through iterative analysis of codes and tagged quotations. RESULTS We interviewed 18 physicians from varied practice settings, 6 female, 9 from minority racial backgrounds, and 3 of Hispanic ethnicity. Four themes emerged from our interviews: (1) physicians held conflicting views about the effect of patient SES on clinical management, (2) physicians believed that changes in clinical management based on the patient's SES were made in the patient's interest, (3) physicians varied in the degree to which they thought changes in clinical management influenced patient outcomes, and (4) physicians faced personal and financial strains when caring for patients of low SES. CONCLUSIONS Physicians indicated that patient SES did affect their clinical management decisions. As a result, physicians commonly undertook changes to their management plan in an effort to enhance patient outcomes, but they experienced numerous strains when trying to balance what they believed was feasible for the patient with what they perceived as established standards of care. C1 [Bernheim, Susannah M.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT USA. [Bernheim, Susannah M.] Yale New Haven Hlth Syst, New Haven, CT USA. [Bernheim, Susannah M.; Krumholz, Harlan M.; Bradley, Elizabeth H.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Ross, Joseph S.] James J Peter Vet Adm, Div Hlth Policy & Adm, Dept Epidemiol & Publ Hlth, Bronx, NY USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Bernheim, SM (reprint author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St, New Haven, CT USA. EM Susannah.bernheim@yale.edu FU NIA NIH HHS [T32AG1934] NR 39 TC 48 Z9 48 U1 0 U2 6 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672, UNITED STATES SN 1544-1709 J9 ANN FAM MED JI Ann. Fam. Med. PD JAN-FEB PY 2008 VL 6 IS 1 BP 53 EP 59 DI 10.1370/afm.749 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 258BV UT WOS:000252844300009 PM 18195315 ER PT J AU Weintraub, D AF Weintraub, Daniel TI Dopamine and Impulse Control Disorders in Parkinson's Disease SO ANNALS OF NEUROLOGY LA English DT Article ID HEDONISTIC HOMEOSTATIC DYSREGULATION; SUBTHALAMIC NUCLEUS STIMULATION; VENTROMEDIAL PREFRONTAL CORTEX; DECISION-MAKING; PATHOLOGICAL GAMBLERS; AGONIST THERAPY; DRUG-USE; PREVALENCE; MEDICATION; BEHAVIORS AB There is an increasing awareness that impulse control disorders (ICDs), including compulsive gambling, buying, sexual behavior, and eating, can occur as a complication of Parkinson's disease (PD). In addition, other impulsive or compulsive disorders have been reported to occur, including dopamine dysregulation syndrome (DDS) and punding. Case reporting and prospective studies have reported an association between ICDs and the use of dopamine agonists (DAs), particularly at greater dosages, whereas dopamine dysregulation syndrome has been associated with greater dosages of levodopa or short-acting DAs. Data suggest that risk factors for an ICD may include male sex, younger age or younger age at PD onset, a pre-PD history of ICD symptoms, personal or family history of substance abuse or bipolar disorder, and a personality style characterized by impulsiveness. Although psychiatric medications are used clinically in the treatment of ICDs, there is no empiric evidence supporting their use in PD. Therefore, management for clinically significant ICD symptoms should consist of modifications to dopamine replacement therapy, particularly DAs, and there is emerging evidence that Such management is associated with all overall improvement in ICD symptomatology. It is important that PD patients be aware that DA use may lead to the development of an ICD, and that clinicians monitor patients as part of routine clinical care. As empirically validated treatments for ICDs are emerging, it will be important to examine their efficacy and tolerability in individuals with cooccurring PD and ICDs. C1 [Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Weintraub, D (reprint author), Univ Penn, Sch Med, Dept Psychiat, Parkinsons Dis Res Educ & Clin Ctr, 3615 Chestnut St 330, Philadelphia, PA 19104 USA. EM weintrau@mail.med.upenn.edu FU NIH (National Institute of Mental Health) [K23MH067894] FX This work was supported by the NIH (National Institute of Mental Health, K23MH067894). NR 71 TC 79 Z9 79 U1 0 U2 13 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PY 2008 VL 64 IS 6 BP S93 EP S100 DI 10.1002/ana.21454 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 389RN UT WOS:000262112300009 PM 19127573 ER PT S AU Lin, JH Walter, P Yen, TSB AF Lin, Jonathan H. Walter, Peter Yen, T. S. Benedict TI Endoplasmic reticulum stress in disease pathogenesis SO ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE SE Annual Review of Pathology-Mechanisms of Disease LA English DT Review; Book Chapter DE protein misfolding; unfolded protein response; IRE1; PERK; ATF-6 ID UNFOLDED PROTEIN RESPONSE; PANCREATIC BETA-CELLS; HEPATITIS-B-VIRUS; FIBROSING CHOLESTATIC HEPATITIS; DOMINANT RETINITIS-PIGMENTOSA; CAPACITATIVE CALCIUM-ENTRY; BZIP TRANSCRIPTION FACTOR; OXIDE-INDUCED APOPTOSIS; LARGE SURFACE PROTEIN; ER STRESS AB The endoplasmic reticulum (ER) is the site of synthesis and folding of membrane and secretory proteins, which, collectively, represent a large fraction of the total protein output of a mammalian cell. Therefore; the protein flux through the ER must be carefully monitored for abnormalities, including the buildup of misfolded proteins. Mammalian cells have. evolved an intricate set of signaling pathways from the ER to the cytosol and nucleus, to allow the cell to respond to the of fold presence misfold proteins within the ER. These pathways, known collectively as-the unfolded protein response, are important for normal cellular homeostasis and organismal development and may also play key roles in the pathogenesis of many diseases. This review provides background information on the unfolded protein response and discusses a selection of diseases whose pathogenesis involves ER stress. C1 [Lin, Jonathan H.; Walter, Peter] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. [Lin, Jonathan H.; Yen, T. S. Benedict] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. [Walter, Peter] Howard Hughes Med Inst, Chevy Chase, MD USA. [Yen, T. S. Benedict] San Francisco VA Med Ctr, Pathol Serv, San Francisco, CA 94121 USA. RP Lin, JH (reprint author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. EM Jonathan.Lin@ucsf.edu; walter@cgl.ucsf.edu; yen@itsa.ucsf.edu FU Howard Hughes Medical Institute; NEI NIH HHS [K08 EY018313-01, R01 EY020846, K08 EY018313] NR 154 TC 272 Z9 288 U1 2 U2 19 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA SN 1553-4006 BN 978-0-8243-4303-3 J9 ANNU REV PATHOL-MECH JI Annu. Rev. Pathol.-Mech. Dis. PY 2008 VL 3 BP 399 EP 425 DI 10.1146/annurev.patho1.3.121806.151434 PG 27 WC Pathology SC Pathology GA 275QD UT WOS:000254085800015 PM 18039139 ER PT J AU Doyle, PJ McNeil, MR Le, K Hula, WD Ventura, MB AF Doyle, Patrick J. McNeil, Malcolm R. Le, Karen Hula, William D. Ventura, Mary Beth TI Measuring communicative functioning in community-dwelling stroke survivors: Conceptual foundation and item development SO APHASIOLOGY LA English DT Article; Proceedings Paper CT 37th Annual Clinical Aphasiology Conference CY MAY, 2007 CL Scottsdale, AZ ID PSYCHOMETRIC EVALUATION; RASCH ANALYSIS; APHASIA; SCALE; RELIABILITY; VALIDITY AB Background: Studies employing item response theory methods to evaluate communicative functioning assessment items have found that a broad range of communication tasks and activities may fit a unidimensional measurement model, but that additional item content is needed to extend the range of ability effectively measured by the small subset of items that have been evaluated. Aims: To describe the item identification, evaluation, and development process used to substantiate the content relevance and representativeness of a set of communicative functioning assessment items targeting community-dwelling stroke survivors. Methods & Procedures: Electronic and secondary references were searched to identify assessment tools with item content designed to measure communicative functioning in adults with neurogenic communication disorders. Candidate items were evaluated using face-to-face interviewer-assisted survey groups conducted independently with communicatively impaired stroke survivors (n=59) and their communicative partners (n=61). Web-based surveys were employed to evaluate candidate items from the perspective of practising speech-language pathologists (n=114). Outcomes & Results: A total of 673 items were identified from 33 instruments. A total of 426 met the specified concept definition; 211 were determined to be non-redundant; 166 were identified by key stakeholders as unambiguous, relevant, and moderately to very important to daily functioning. Conclusions: The item pool developed samples a representative range of communication behaviours, activities, and life situations that are relevant to community-dwelling stroke survivors. Further research using item response theory methods is required to substantiate the construct dimensionality and range of ability effectively measured by the item pool, and to evaluate dynamic assessment algorithms designed to minimise response burden. C1 [Doyle, Patrick J.; McNeil, Malcolm R.] VA Pittsburgh Hlth Care Syst, Audiol Speech Pathol Serv, Pittsburgh, PA 15260 USA. [Doyle, Patrick J.; McNeil, Malcolm R.; Hula, William D.; Ventura, Mary Beth] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Le, Karen] Univ Connecticut, Storrs, CT USA. RP Doyle, PJ (reprint author), Ctr Geriatr Res Educ & Clin, 7180 Highland Dr, Pittsburgh, PA 15206 USA. NR 23 TC 4 Z9 4 U1 1 U2 4 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PY 2008 VL 22 IS 7-8 BP 718 EP 728 DI 10.1080/02687030701803093 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 318JK UT WOS:000257087200005 ER PT J AU Naleid, AM Grimm, JW Kessler, DA Sipols, AJ Aliakbari, S Bennett, JL Wells, J Figlewicz, DP AF Naleid, Amy M. Grimm, Jeffrey W. Kessler, David A. Sipols, Alfred J. Aliakbari, Sepideh Bennett, Jennifer L. Wells, Jason Figlewicz, Dianne P. TI Deconstructing the vanilla milkshake: The dominant effect of sucrose on self-administration of nutrient-flavor mixtures SO APPETITE LA English DT Article DE self-administration; sucrose; fat; reinforcement; macronutrients; flavor ID PROGRESSIVE RATIO SCHEDULES; NONNUTRITIVE OIL-EMULSIONS; FOOD-INTAKE; NUTRITIONAL-STATUS; FAT APPETITE; BODY-WEIGHT; PLACE PREFERENCE; ENERGY DENSITY; DIETARY-INTAKE; SUGAR AB Rats and humans avidly consume flavored foods that contain sucrose and fat, presumably due to their rewarding qualities. In this study, we hypothesized that the complex mixture of corn oil, sucrose, and flavor is more reinforcing than any of these components alone. We observed a concentration-dependent increase in reinforcers of sucrose solutions received (0%, 3%, 6.25%, and 12.5%) in both fixed ratio and progressive ratio procedures, but with equicaloric corn oil solutions (0%, 1.4%, 2.8%, and 5.6%) this finding was replicated only in the fixed ratio procedure. Likewise, addition of 1.4% oil to 3% or 12.5% sucrose increased fixed ratio, but not progressive ratio, reinforcers received relative to those of sucrose alone. Finally, addition of 3% vanilla flavoring did not change self-administration of 3% sucrose or 3% sucrose + 1.4% oil solutions. These data Suggest that, calorie-for-calorie, sucrose is the dominant reinforcing component of novel foods that contain a mixture of fat, sucrose, and flavor. (c) 2007 Elsevier Ltd. All rights reserved. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Western Washington Univ, Dept Psychol, Bellingham, WA USA. Univ Latvian, Inst Clin & Expt Med, Riga, Latvia. Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, 1660 So Columbian Way, Seattle, WA 98108 USA. EM latte@u.washington.edu FU NCRR NIH HHS [P20 RR020774, P20 RR020774-01, P20 RR020774-02, P20 RR020774-026031, P20RR020774]; NIAAA NIH HHS [T32 AA007455-20, T32 AA007455, T32-AA007455]; NIDA NIH HHS [F32 DA020315, F32 DA020315-01A2, R15 DA016285, R15 DA016285-01]; NIDDK NIH HHS [DK40963, R01 DK040963, R01 DK040963-18, R01 DK040963-18S1, R01 DK040963-19, R01 DK040963-20] NR 36 TC 15 Z9 15 U1 2 U2 7 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0195-6663 J9 APPETITE JI Appetite PD JAN PY 2008 VL 50 IS 1 BP 128 EP 138 DI 10.1016/j.appet.2007.06.011 PG 11 WC Behavioral Sciences; Nutrition & Dietetics SC Behavioral Sciences; Nutrition & Dietetics GA 239IR UT WOS:000251512500015 PM 17707949 ER PT J AU Carlozzi, NE Horner, MD Yang, CW Tilley, BC AF Carlozzi, Noelle E. Horner, Michael David Yang, Chengwu Tilley, Barbara C. TI Factor Analysis of the Repeatable Battery for the Assessment of Neuropsychological Status SO APPLIED NEUROPSYCHOLOGY LA English DT Article DE confirmatory factor analysis; exploratory factor analysis; neuropsychological assessment; neuropsychology; psychometrics repeatable battery for the assessment of neuropsychological status (RBANS) ID VALIDITY AB A sample of 175 veterans' scores on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; Randolph, 1998) was examined to investigate the factor structure of this scale. First, we attempted to replicate a five-factor model to reflect the five Index Scores of the RBANS (immediate memory, visuospatial/constructional, language, attention, and delayed memory) from the 12 individual subtests, using confirmatory factor analysis (CFA). We were unable to identify a five-factor structure of the RBANS. The RBANS subtests were then subjected to an exploratory factor analysis with a maximum likelihood extraction and orthogonal rotation to determine a new dimensional model. Results indicated a two-factor structure that can roughly be described as memory and visuospatial function. CFA of this new structure indicated an adequate fit for this sample. Findings suggest that it may be appropriate to place more emphasis on the individual subtest scores than the index scores during interpretation. C1 [Carlozzi, Noelle E.] Kessler Med Rehabil Res & Educ Ctr, Outcomes & SCI Res Lab, W Orange, NJ 07052 USA. [Carlozzi, Noelle E.] Med Univ S Carolina, H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Horner, Michael David] Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Carlozzi, NE (reprint author), Kessler Med Rehabil Res & Educ Ctr, Outcomes & SCI Res Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA. EM ncarlozzi@mrrec.org OI Yang, Chengwu/0000-0003-0561-2340 FU [U01 NS043127]; [3P30 AG021677] FX Work on this manuscript was supported, in part, by grants U01 NS043127 and 3P30 AG021677. NR 9 TC 10 Z9 10 U1 1 U2 3 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0908-4282 J9 APPL NEUROPSYCHOL JI Appl. Neuropsychol. PY 2008 VL 15 IS 4 BP 274 EP 279 AR PII 905793172 DI 10.1080/09084280802325124 PG 6 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA 375DQ UT WOS:000261094300005 PM 19023744 ER PT J AU Werth, VP Fivenson, D Pandya, AG Chen, D Rico, MJ Albrecht, J Jacobus, D AF Werth, Victoria P. Fivenson, David Pandya, Amit G. Chen, Diana Rico, M. Joyce Albrecht, Joerg Jacobus, David TI Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris SO ARCHIVES OF DERMATOLOGY LA English DT Article ID MYCOPHENOLATE-MOFETIL; AZATHIOPRINE; PREDNISONE; THERAPY AB Objective: To determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris (PV). Design: A randomized, double-blind, placebo-controlled study with a crossover arm for those who failed treatment. Setting: A US multicenter outpatient study Patients: A total of 19 subjects enrolled among 5 centers, 9 randomized to receive dapsone and 10 to receive placebo. Inclusion criteria were biopsy and direct immunofluorescence-proven PV controlled with glucocorticoids and/or cytotoxic agents, disease in maintenance phase, and aged 18 to 80 years. Physicians had tried at least 2 tapers of glucocorticoids unsuccessfully and had 30 days of stable steroid dosage. Treatment for any patient unable to taper glucocorticoids by more than 25% within 4 months was declared a failure, and the patient was allowed to switch to the opposite medication while maintaining the double-blind. Main Outcome Measure: The ability of patients to taper to 7.5 mg/d or less within 1 year of reaching the maximum dosage of the study drug. Results: Of the 9 patients receiving dapsone, 5 were successfully treated, 3 failed treatment, and 1 dropped out of the study. Of the 10 patients receiving placebo, 3 were successfully treated, and 7 failed treatment. This primary end point favored the dapsone-treated group but was not statistically significant (P=.37). Four patients who failed treatment while receiving placebo were switched to treatment with dapsone. Of these, 3 were successfully treated after switching to dapsone treatment, and 1 failed treatment. We found that, overall, 8 of 11 patients (73%) receiving dapsone vs 3 of 10 (30%) receiving placebo reached the primary outcome of a prednisone dosage of 7.5 mg/d or less. Conclusion: This trial demonstrates a trend to efficacy of dapsone as a steroid-sparing drug in maintenance-phase PV. C1 [Werth, Victoria P.; Albrecht, Joerg] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19119 USA. [Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Fivenson, David] Henry Ford Hlth Syst, Detroit, MI USA. [Pandya, Amit G.] Univ Texas SW Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA. [Chen, Diana] NW Mem Hosp, Dept Dermatol, Chicago, IL 60611 USA. [Rico, M. Joyce] NYU, Dept Dermatol, New York, NY 10016 USA. [Jacobus, David] Jacobus Pharmaceut Co, Princeton, NJ USA. RP Werth, VP (reprint author), Univ Penn, Sch Med, Dept Dermatol, 2 Rhodes Pavilion,3600 Spruce St, Philadelphia, PA 19119 USA. EM werth@mail.med.upenn.edu FU NIAMS NIH HHS [K24-AR 02207, K24 AR002207] NR 23 TC 43 Z9 44 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD JAN PY 2008 VL 144 IS 1 BP 25 EP 32 DI 10.1001/archderm.144.1.25 PG 8 WC Dermatology SC Dermatology GA 252IC UT WOS:000252439200003 PM 18209165 ER PT J AU Strasser, DC Falconer, JA Stevens, AB Uomoto, JM Herrin, J Bowen, SE Burridge, AB AF Strasser, Dale C. Falconer, Judith A. Stevens, Alan B. Uomoto, Jay M. Herrin, Jeph Bowen, Susan E. Burridge, Andrea B. TI Team training and stroke rehabilitation outcomes: A cluster randomized trial SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE clinical trial; patient care teams; rehabilitation; stroke; training of trainers; treatment outcome ID MULTIDISCIPLINARY INTERVENTION; MODEL; CARE; MANAGEMENT; HOSPITALS; UNITS AB Objective: To test whether a team training intervention in stroke rehabilitation is associated with improved patient outcomes. Design: A cluster randomized trial of 31 rehabilitation units comparing stroke outcomes between intervention and control groups. Setting: Thirty-one Veterans Affairs medical centers. Participants: A total of 237 clinical staff on 16 control teams and 227 staff on 15 intervention teams. Stroke patients (N=487) treated by these teams before and after the intervention. Intervention: The intervention consisted of a multiphase, staff training program delivered over 6 months, including: an off-site workshop emphasizing team dynamics, problem solving, and the use of performance feedback data; and action plans for process improvement; and telephone and videoconference consultations. Control and intervention teams received site-specific team performance profiles with recommendations to use this information to modify team process. Main Outcome Measures: Three patient outcomes: functional improvement as measured by the change in motor items of the FIM instrument, community discharge, and length of stay (LOS). Results: For both the primary (stroke only) and secondary analyses (all patients), there was a significant difference in improvement of functional outcome between the 2 groups, with the percentage of stroke patients gaining more than a median FIM gain of 23 points increasing significantly more in the intervention group (difference in increase, 13.6%; P=.032). There was no significant difference in LOS or rates of community discharge. Conclusions: Stroke patients treated by staff who participated in a team training program were more likely to make functional gains than those treated by staff receiving information only. Team based clinicians are encouraged to examine their own team. (ClinicalTrials.gov identifier NCT00237757). C1 [Strasser, Dale C.] Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA. [Strasser, Dale C.] Atlanta VA Med Ctr, Atlanta, GA USA. [Falconer, Judith A.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Stevens, Alan B.] Texas A&M Univ Syst, Hlth Sci Ctr, Scott & White Mem Hosp, Temple, TX USA. [Uomoto, Jay M.] VA Puget Sound Hlth Care Syst, Seattle Div, Ctr Polytrauma Care, Seattle, WA USA. [Herrin, Jeph] Yale Univ, New Haven, CT USA. [Herrin, Jeph] Flying Buttress Associates, Charlottesville, VA USA. [Bowen, Susan E.] Atlanta VA Med Ctr, TREP HSR&D, Decatur, GA USA. [Burridge, Andrea B.] Univ Houston, Dept Educ Psychol, Houston, TX USA. RP Strasser, DC (reprint author), 1441 Clifton Rd NE, Atlanta, GA 30322 USA. EM Dale.Strasser@emoryhelathcare.org RI Backscheider Burridge, Andrea/D-9332-2015 OI Backscheider Burridge, Andrea/0000-0001-7502-0047 NR 33 TC 52 Z9 55 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JAN PY 2008 VL 89 IS 1 BP 10 EP 15 DI 10.1016/j.apmr.2007.08.127 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 249LB UT WOS:000252228600003 PM 18164324 ER PT J AU Strasser, DC Uomoto, JM Smits, SJ AF Strasser, Dale C. Uomoto, Jay M. Smits, Stanley J. TI The interdisciplinary team and polytrauma rehabilitation: Prescription for partnership SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE interdisciplinary health team; rehabilitation; trauma; wounds and injuries ID STROKE REHABILITATION; OUTCOMES; HOSPITALS; PROGRAM AB Optimal outcomes for polytrauma survivors depend on the integration of complex medical, psychosocial, financial, educational, and vocational resources across diverse specialties and multiple medical centers, programs, and organizations and all in a setting of high public visibility and family involvement. Well-functioning teams are critical to service integration, and teams are more effective in supportive hospital environments. Here, we offer a model of team functioning relevant to polytrauma and outline a team training program to improve services. Furthermore, we propose a partnership among the team, hospital administrators, and national leaders and with patients and their families. Integrated care requires partnerships among the various stakeholders, and those working in polytrauma have a unique opportunity to create an updated paradigm of the team approach responsive to the complexities of contemporary health care. C1 [Strasser, Dale C.] Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA. [Strasser, Dale C.] VA Med Ctr, Atlanta, GA 30322 USA. [Uomoto, Jay M.] Ctr Polytrauma Care, VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Smits, Stanley J.] Georgia State Univ, Robinson Coll Business, Dept Management Sci, Atlanta, GA 30303 USA. RP Strasser, DC (reprint author), 1441 Clifton Rd NE, Atlanta, GA 30322 USA. EM Dale.Strasser@emoryhealthcare.org NR 19 TC 10 Z9 11 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JAN PY 2008 VL 89 IS 1 BP 179 EP 181 DI 10.1016/j.apmr.2007.06.774 PG 3 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 249LB UT WOS:000252228600030 PM 18164351 ER PT J AU Darkins, A Cruise, C Armstrong, M Peters, J Finn, M AF Darkins, Adam Cruise, Cathy Armstrong, Michael Peters, John Finn, Michael TI Enhancing access of combat-wounded veterans to specialist rehabilitation services: The VA polytrauma Telehealth Network SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE rehabilitation; telecommunication networks; telemedicine; wounds and injuries ID TRAUMATIC BRAIN-INJURY; CASUALTIES AB Operations Iraqi Freedom and Enduring Freedom have resulted in U.S. military personnel sustaining combat wounds of unprecedented severity and complexity that necessitate long-term rehabilitation. To meet what are often conflicting requirements in providing severely wounded veterans with timely and convenient access to specialist rehabilitation care, and to enable them to return to their local communities, the Veterans Health Administration has developed a state-of-the-art Polytrauma Telehealth Network that enhances access to such services by linking Veterans Administration rehabilitation facilities. This article describes the clinical, technical, and business process issues involved in the development of this network. C1 [Darkins, Adam; Peters, John; Finn, Michael] Off Care Coordinat 11CC, Dept Vet Affairs, Vet Hlth Adm, Washington, DC 20420 USA. [Cruise, Cathy] US Dept Vet Affairs, Vet Hlth Adm, Northport, MN USA. [Armstrong, Michael] US Dept Vet Affairs, Vet Hlth Adm, Minneapolis, MN USA. RP Darkins, A (reprint author), Off Care Coordinat 11CC, Dept Vet Affairs, Vet Hlth Adm, 810 Vermont Ave NW, Washington, DC 20420 USA. NR 23 TC 10 Z9 10 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JAN PY 2008 VL 89 IS 1 BP 182 EP 187 DI 10.1016/j.apmr.2007.07.027 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 249LB UT WOS:000252228600031 PM 18164352 ER PT J AU Nademin, E Jobes, DA Pflanz, SE Jacoby, AM Ghahramanlou-Holloway, M Campise, R Joiner, T Wagner, BM Johnson, L AF Nademin, Elicia Jobes, David A. Pflanz, Steven E. Jacoby, Aaron M. Ghahramanlou-Holloway, Marjan Campise, Rick Joiner, Thomas Wagner, Barry M. Johnson, Leigh TI An Investigation of Interpersonal-Psychological Variables in Air Force Suicides: A Controlled-Comparison Study SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE Air Force; interpersonal-psychological theory of suicide; military; self-inflicted harm; suicide; suicide prevention AB Joiner's (2005) theory attributes suicide to an individual's acquired capability to enact self-harm, perceived burdensomeness, and thwarted belongingness. This study evaluated whether Joiner's theory could differentiate United States (US) Air Force (AF) personnel (n = 60) who died by suicide from a living active duty AF personnel comparison sample (n = 122). Responses from AF personnel on several scales assessing Joiner's constructs were compared to data from a random sample of postmortem investigatory files of AF personnel who died by suicide between 1996-2006. This research also introduced a newly designed measure, the Interpersonal-Psychological Survey (IPS), designed to assess the three components of Joiner's theory in one, easy-to-administer instrument. Analyses of the psychometric properties of the IPS support initial validation efforts to establish this scale as a predictive measure for suicide. Findings support that one's score on the Acquired Capability to Commit Suicide subscale of the IPS and the IPS overall score reliably distinguished between the two groups. The implications of these findings in relation to suicide prevention efforts in the US military are discussed. C1 [Nademin, Elicia] Midwestern Univ, Dept Clin Psychol, Glendale, AZ 85308 USA. [Jobes, David A.; Wagner, Barry M.] Catholic Univ Amer, Washington, DC 20064 USA. [Pflanz, Steven E.] USAF, Med Operat Agcy, Washington, DC 20330 USA. [Jacoby, Aaron M.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Ghahramanlou-Holloway, Marjan] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Campise, Rick] USAF, Med Operat Squadron 1, Hampton, VA USA. [Joiner, Thomas] Florida State Univ, Gainesville, FL USA. [Johnson, Leigh] USAF, Newport News, VA USA. RP Nademin, E (reprint author), Midwestern Univ, Dept Clin Psychol, 19555 N 59th Ave, Glendale, AZ 85308 USA. EM EliciaN@Gmail.com NR 35 TC 30 Z9 30 U1 0 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1381-1118 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PY 2008 VL 12 IS 4 BP 309 EP 326 DI 10.1080/13811110802324847 PG 18 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA V11CR UT WOS:000207510200003 PM 18828034 ER PT J AU Gutierrez, PM Brenner, LA Huggins, JA AF Gutierrez, Peter M. Brenner, Lisa A. Huggins, Joseph A. TI A Preliminary Investigation of Suicidality in Psychiatrically Hospitalized Veterans with Traumatic Brain Injury SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE suicide; traumatic brain injury; veterans AB The objective of this study was to explore suicidal behaviors documented at time of discharge from acute psychiatric hospitalization. Data from 114 acute psychiatric admissions were reviewed for 22 veterans with a history of traumatic brain injury (TBI). Information extracted included presence of suicidal ideation, nature of suicide attempts, and TBI characteristics. The Lethality of Suicide Attempt Rating Scale was used to classify veterans' non-lethal self-harm behavior. Post-TBI, 6 patients (27.3%) made a total of 14 suicide attempts. Half of those attempts required wounds being sutured, stomach lavage, or other medical attention. Clinicians and researchers are strongly encouraged to focus increased attention on suicide prevention in those with a history of TBI. C1 [Gutierrez, Peter M.; Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Psychiat,Dept Phys Med & Rehabil,Dept Neurol, Denver VA Med Ctr,MIRECC,VA VISN 19, Denver, CO 80220 USA. [Huggins, Joseph A.] Univ Colorado Denver, Sch Med, Dept Family Med, MIRECC,MSW,MSCIS VA VISN 19, Denver, CO 80220 USA. RP Gutierrez, PM (reprint author), Univ Colorado Denver, Sch Med, Dept Psychiat,Dept Phys Med & Rehabil,Dept Neurol, Denver VA Med Ctr,MIRECC,VA VISN 19, 1055 Clermont St, Denver, CO 80220 USA. EM peter.gutierrez@va.gov OI Huggins, Joe/0000-0001-8151-5062; Gutierrez, Peter/0000-0001-8981-8404 NR 23 TC 19 Z9 19 U1 0 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1381-1118 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PY 2008 VL 12 IS 4 BP 336 EP 343 DI 10.1080/13811110802324961 PG 8 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA V11CR UT WOS:000207510200005 PM 18828036 ER PT J AU Gaffo, AL Saag, KG AF Gaffo, Angelo L. Saag, Kenneth G. TI Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine SO ARTHRITIS RESEARCH & THERAPY LA English DT Editorial Material ID URIC-ACID LEVELS; THERAPY; WOMEN; REPLACEMENT; PLASMA AB The relationship between serum urate, menopause, and aging has not been clearly defined by scientific evidence. In the present issue of Arthritis Research and Therapy, Hak and Choi present a cross-sectional analysis to clarify the effect of menopause and hormone replacement therapy on serum urate in women within the Third National Health and Nutritional Examination Survey. Menopause increased serum urate and hormone replacement therapy significantly decreased serum urate, although the overall level of change was small. The implications of these urate changes on gout and cardiovascular disease outcomes require further study. C1 [Saag, Kenneth G.] Univ Alabama, Div Clin Immunol & Rheumatol, FOT 820, Birmingham, AL 35294 USA. [Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Saag, KG (reprint author), Univ Alabama, Div Clin Immunol & Rheumatol, FOT 820, 1530 3rd Ave S, Birmingham, AL 35294 USA. EM ksaag@uab.edu NR 9 TC 2 Z9 2 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2008 VL 10 IS 5 AR 120 DI 10.1186/ar2524 PG 2 WC Rheumatology SC Rheumatology GA 411JA UT WOS:000263644500005 PM 18983690 ER PT J AU Pessler, F Mayer, CT Jung, SM Behrens, EM Dai, L Menetski, JP Schumacher, HR AF Pessler, Frank Mayer, Christian T. Jung, Sung Mun Behrens, Ed M. Dai, Lie Menetski, Joseph P. Schumacher, H. Ralph TI Identification of novel monosodium urate crystal regulated mRNAs by transcript profiling of dissected murine air pouch membranes SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID INDUCED ACUTE-INFLAMMATION; CUTTING EDGE; NICOTINIC-ACID; IN-VIVO; PUMA-G; RECEPTOR; MACROPHAGES; PROTEIN; GENE; CELLS AB Introduction The murine air pouch is a bursa-like space that resembles the human synovial membrane. Injection of monosodium urate (MSU) crystals into the pouch elicits an acute inflammatory response similar to human gout. We conducted the present study to identify mRNAs that were highly regulated by MSU crystals in the pouch membrane. Methods Air pouch membranes were meticulously dissected away from the overlying skin. Gene expression differences between MSU crystal stimulated and control membranes were determined by oligonucleotide microarray analysis 9 hours after injection of MSU crystals or buffer only. Differential regulation of selected targets was validated by relative quantitative PCR in time course experiments with dissected air pouch membranes and murine peritoneal macrophages. Results Eleven of the 12 most highly upregulated mRNAs were related to innate immunity and inflammation. They included mRNAs encoding histidine decarboxylase (the enzyme that synthesizes histamine), IL-6, the cell surface receptors PUMA-g and TREM-1, and the polypeptides Irg1 and PROK-2. IL-6 mRNA rose 108-fold 1 hour after crystal injection, coinciding with a surge in mRNAs encoding IL-1 beta, tumour necrosis factor alpha and the immediate early transcription factor Egr-1. The other mRNAs rose up to 200-fold within the subsequent 3 to 8 hours. MSU crystals induced these mRNAs in a dose-dependent manner in cultured macrophages, with similar kinetics but lower fold changes. Among the downregulated mRNAs, quantitative PCR confirmed significant decreases in mRNAs encoding TREM-2 (an inhibitor of macrophage activation) and granzyme D (a constituent of natural killer and cytotoxic T cells) within 50 hours after crystal injection. Conclusion This analysis identified several genes that were previously not implicated in MSU crystal inflammation. The marked rise of the upregulated mRNAs after the early surge in cytokine and Egr-1 mRNAs suggests that they may be part of a 'second wave' of factors that amplify or perpetuate inflammation. Transcript profiling of the isolated air pouch membrane promises to be a powerful tool for identifying genes that act at different stages of inflammation. C1 [Pessler, Frank; Behrens, Ed M.] Tech Univ Dresden, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany. [Pessler, Frank] Childrens Hosp Philadelphia, Div Rheumatol, Philadelphia, PA 19104 USA. [Mayer, Christian T.] Tech Univ Munich, Inst Med Mikrobiol Immunol & Hyg, D-81675 Munich, Germany. [Mayer, Christian T.; Jung, Sung Mun; Dai, Lie; Schumacher, H. Ralph] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. [Jung, Sung Mun] Kyung Hee Univ, Coll Oriental Med, Dept Herbal Pharmacol, Fac Oriental Med, Seoul 130701, South Korea. [Dai, Lie] Sun Yat Sen Univ, Affiliated Hosp 2, Div Rheumatol, Guangzhou 510120, Guangdong, Peoples R China. [Menetski, Joseph P.] Merck Res Labs, Rahway, NJ 07065 USA. [Schumacher, H. Ralph] Vet Affairs Med Ctr, Div Rheumatol, Philadelphia, PA 19104 USA. RP Pessler, F (reprint author), Tech Univ Dresden, Klin & Poliklin Kinder & Jugendmed, Fetscherstr, Dresden, Germany. EM Frank.pessler@uniklinikum-dresden.de FU National Institutes of Health Training [T32-AR 007442, T32-CA 09140]; 2007-8 American College of Rheumatology Education and Research Foundation Amgen Pediatric Rheumatology Research; 2006 American College of Rheumatology Health Professional Graduate Student Preceptorship Award FX We thank G Clayburne, Nicole Chartrain and Marlin Camps- Ramirez for technical support; Grace Strazewski and Don Baldwin ( University of Pennsylvania Microarray Core) for microarray hybridization; and John Tobias ( University of Pennsylvania Bioinformatics Core) for help with analyzing the microarray data; Dan Martinez and the staff of the histopathology core of The Children's Hospital of Philadelphia for histology support; and Peri DeRitis and the staff of the VA Medical Center Animal Facility for expert animal care. F Pessler was supported by National Institutes of Health Training Grants T32- AR 007442 and T32- CA 09140 and a 2007- 8 American College of Rheumatology Education and Research Foundation Amgen Pediatric Rheumatology Research Award, and CT Mayer by a 2006 American College of Rheumatology Health Professional Graduate Student Preceptorship Award. NR 50 TC 14 Z9 14 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2008 VL 10 IS 3 AR R64 DI 10.1186/ar2435 PG 13 WC Rheumatology SC Rheumatology GA 354IP UT WOS:000259633000025 PM 18522745 ER PT S AU Maddox, TM Nash, IS Fuster, V AF Maddox, Thomas M. Nash, Ira S. Fuster, Valentin BE Natale, A Jalife, J TI Economic Costs Associated with Atrial Fibrillation SO ATRIAL FIBRILLATION: FROM BENCH TO BEDSIDE SE Contemporary Cardiology LA English DT Article; Book Chapter DE AF hospitalizations; AF cost; Incidence of AF; Prevalence of AF; Stroke ID CORONARY-ARTERY-BYPASS; QUALITY-OF-LIFE; SINUS RHYTHM; RISK-FACTORS; RESOURCE UTILIZATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; SPONTANEOUS CONVERSION; ORAL ANTICOAGULATION; RANDOMIZED-TRIAL; STROKE SEVERITY AB As the population ages, the incidence and prevalence of atrial fibrillation (AF) is expected to increase, resulting in significant societal and economic impact. By 2050, AF is projected to affect 15.9 million individuals in the United States. Atrial fibrillation results in a variety of adverse outcomes, including a fivefold increased risk of stroke, impaired quality of life, decreased work productivity, and increased rates of hospitalization. In 2005, there were 470,000 U.S. hospitalizations secondary to AF. In 2004, over 9 million working days were lost because of AF. Costs of AF and its associated complications are enormous. In 2006, costs attributable to AF-associated stroke equaled $12 billion. In addition, $41,000 to $105,000 per patient was spent on aggregate and individual AF care. Because of its increasing prevalence, numerous complications, and large costs, AF presents a significant challenge for patients, clinicians, and health care policymakers. Finding strategies to best care for these patients will become increasingly important. C1 [Maddox, Thomas M.] Univ Colorado, Denver VAMC, Denver, CO 80202 USA. [Maddox, Thomas M.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Nash, Ira S.] Mt Sinai Sch Med, James J Peters VAMC, New York, NY USA. RP Maddox, TM (reprint author), Univ Colorado, Denver VAMC, Denver, CO 80202 USA. NR 82 TC 2 Z9 2 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1191-7601 BN 978-1-59745-163-5; 978-1-58829-856-0 J9 CONTEMP CARDIOL JI Contemp. Cardiol. PY 2008 BP 13 EP 26 DI 10.1007/978-1-59745-163-5_2 D2 10.1007/978-1-59745-163-5 PG 14 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA BLV22 UT WOS:000271134100002 ER PT J AU Sawalha, AH AF Sawalha, Amr H. TI Epigenetics and T-cell immunity SO AUTOIMMUNITY LA English DT Article DE epigenetics; gene regulation; T-cell immunity; T-cell function; DNA methylation ID LOCUS-CONTROL REGION; RANGE INTRACHROMOSOMAL INTERACTIONS; CYTOKINE GENE-EXPRESSION; IFN-GAMMA PRODUCTION; DNA METHYLATION; TRANSCRIPTION FACTOR; HISTONE ACETYLATION; LINEAGE COMMITMENT; MAMMALIAN DEVELOPMENT; X-INACTIVATION AB Epigenetic mechanisms including DNA methylation and histone modifications are critically involved in immune responses. Antigen stimulation along with a specific cytokine milieu drives helper T-cell differentiation into specific subsets with distinct functional capacities. This process occurs by inducing chromatin remodeling and altering transcriptional accessibility of key cytokine genes such as IFN-, IL-4 and IL-17. These epigenetic changes, by definition, are carried over throughout cell division to ensure selective survival of a cell lineage. Over the past decade, a growing body of literature mechanistically uncovered the central role for epigenetic regulation in immunity. In this review, we focus on epigenetics in T helper cell differentiation, regulatory T-cell function, and IL-2 production. C1 [Sawalha, Amr H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Sawalha, Amr H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Sawalha, Amr H.] Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu FU NCRR NIH HHS [P20-RR015577]; NIAMS NIH HHS [P30 AR053483] NR 71 TC 43 Z9 47 U1 1 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0891-6934 J9 AUTOIMMUNITY JI Autoimmunity PY 2008 VL 41 IS 4 BP 245 EP 252 DI 10.1080/08916930802024145 PG 8 WC Immunology SC Immunology GA 292NV UT WOS:000255274300002 PM 18432405 ER PT J AU Tuxworth, WJ Shiraishi, H Moschella, PC Yamane, K McDermott, PJ Kuppuswamy, D AF Tuxworth, William J., Jr. Shiraishi, Hirokazu Moschella, Phillip C. Yamane, Kentaro McDermott, Paul J. Kuppuswamy, Dhandapani TI Translational activation of 5'-TOP mRNA in pressure overload myocardium SO BASIC RESEARCH IN CARDIOLOGY LA English DT Article DE cardiac hypertrophy; signal transduction; 5'-TOP mRNA; ribosome; mTOR ID KINASE SIGNALING PATHWAY; CARDIAC-MUSCLE-CELLS; S6 KINASE; PROTEIN-SYNTHESIS; GENE-EXPRESSION; AMINO-ACIDS; COMPLEX-FORMATION; MAMMALIAN-CELLS; RAT-LIVER; HYPERTROPHY AB The present study was conducted to determine the magnitude and duration of ribosomal protein translation in response to pressure overload and determine if additional, paracrine events associated with mechanical transduction, such as integrin activation using a bioactive peptide ligand, RGD or endothelin stimulation lead to ribosomal protein translation. Polysome analysis of ventricular tissue samples obtained from an in vivo model of right-ventricular pressure overload (RVPO) showed a significant shift in the proportion of a 5'-terminal oligopyrimidine (5'-TOP) mRNA, rpL32, associated with the polysomal fraction when compared with non-5'-TOP mRNAs, beta-actin and beta-myosin heavy chain ( -MHQ, in the early stages of the hypertrophic response (2448 h). Furthermore, this increase in polysome-bound rpL32 mRNA was accompanied by the phosphorylation of mammalian target of rapamycin (mTOR), p70 S6 kinase (S6K1), and S6 ribosomal protein. In our in vitro studies, treatment of primary cultures of adult feline cardiomyocytes (cardiocytes) with 100 nM endothelin, 9 mM RGD, 100 nM insulin, or 100 nM TPA activated mTOR via distinct signaling pathways and resulted in an increased proportion of polysome-bound rpL32 mRNA. Pre-treatment of cardiocytes with the mTOR inhibitor rapamycin blocked the agonist-induced rpL32 mRNA mobilization to polysomes. These results show that mechanisms that regulate ribosomal biogenesis in the myocardium are dynamically sensitive to pressure overload. Furthermore, our in vitro studies indicate that distinct pathways are operational during the early course of hypertrophic growth and converge to activate mTOR resulting in the translational activation of 5'-TOP mRNA. C1 [Kuppuswamy, Dhandapani] Gazes Cardiac Res Inst, Storm Thurmond Biomed Res, Charleston, SC 29403 USA. [Tuxworth, William J., Jr.; Shiraishi, Hirokazu; Moschella, Phillip C.; Yamane, Kentaro; McDermott, Paul J.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Tuxworth, William J., Jr.; Shiraishi, Hirokazu; Moschella, Phillip C.; Yamane, Kentaro; McDermott, Paul J.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. [McDermott, Paul J.; Kuppuswamy, Dhandapani] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Kuppuswamy, D (reprint author), Gazes Cardiac Res Inst, Storm Thurmond Biomed Res, Bldg,Room 213,114 Doughty St, Charleston, SC 29403 USA. EM kuppusd@musc.edu FU NHLBI NIH HHS [HL-48788, HL-07260] NR 46 TC 12 Z9 13 U1 1 U2 2 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0300-8428 J9 BASIC RES CARDIOL JI Basic Res. Cardiol. PD JAN PY 2008 VL 103 IS 1 BP 41 EP 53 DI 10.1007/s00395-007-0682-z PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 242HX UT WOS:000251717300005 PM 17955327 ER PT J AU Teten, AL Miller, LA Bailey, SD Dunn, NJ Kent, TA AF Teten, Andra L. Miller, Lisa A. Bailey, Sara D. Dunn, Nancy Jo Kent, Thomas A. TI Empathic Deficits and Alexithymia in Trauma-Related Impulsive Aggression SO BEHAVIORAL SCIENCES & THE LAW LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; PSYCHOMETRIC PROPERTIES; ANTISOCIAL-BEHAVIOR; PTSD CHECKLIST; SCALE; DISTURBANCES; ADOLESCENTS; PERSONALITY; RELIABILITY; POPULATION AB Our long term interest is to develop a developmental model of impulsive aggression based on a confluence of social psychological and biological features. This approach incorporates neurobiological research, which has identified language processing deficits as a unique characteristic of impulsive aggressors and extends it to include emotional deficits. As an initial test of this hypothesis, we examined whether empathy and alexithymia were associated with impulsive aggression. Regressions were performed to explore the associations among impaired empathy, alexithymia, impulsive aggression, verbal and physical general aggression. Among impulsive aggressive veterans (n = 38) recruited from a VA trauma clinic, alexithymia predicted impulsive aggression and empathic deficits predicted verbal aggression. Neither emotional awareness deficit predicted general physical aggression in this middle-aged sample. Results suggested that empathic deficits were associated with general verbal aggression, but alexithymia was uniquely associated with impulsive aggression. Consideration of alexithymia in impulsive aggression has implications for its etiology, prevention and treatment. Published in 2008 by John Wiley & Sons, Ltd. C1 [Teten, Andra L.; Miller, Lisa A.; Bailey, Sara D.; Dunn, Nancy Jo; Kent, Thomas A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Teten, Andra L.; Miller, Lisa A.; Bailey, Sara D.; Dunn, Nancy Jo] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Kent, Thomas A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. RP Teten, AL (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS F-63, Atlanta, GA 30341 USA. EM ateten@cdc.gov OI Kent, Thomas/0000-0002-9877-7584 NR 41 TC 29 Z9 29 U1 2 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0735-3936 J9 BEHAV SCI LAW JI Behav. Sci. Law PY 2008 VL 26 IS 6 BP 823 EP 832 DI 10.1002/bsl.843 PG 10 WC Psychology, Applied; Law SC Psychology; Government & Law GA 392AC UT WOS:000262274300010 PM 19039794 ER PT J AU Brewster, LP Washington, C Brey, EM Gassman, A Subramanian, A Calceterra, J Wolf, W Hall, CL Velander, WH Burgess, WH Greisler, HP AF Brewster, Luke P. Washington, Cicely Brey, Eric M. Gassman, Andrew Subramanian, Anu Calceterra, Jen Wolf, William Hall, Connie L. Velander, William H. Burgess, Wilson H. Greisler, Howard P. TI Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen SO BIOMATERIALS LA English DT Article DE angiogenesis; collagen; endothelial cell; endothelialization; fibroblast growth factor; growth factors ID FIBROBLAST-GROWTH-FACTOR; HUMAN-ENDOTHELIAL CELLS; IN-VITRO ENDOTHELIALIZATION; INFRAINGUINAL EPTFE GRAFTS; SMOOTH-MUSCLE-CELLS; DNA-SYNTHESIS; FIBRIN GLUE; INTIMAL HYPERPLASIA; FUSION PROTEIN; FACTOR TYPE-1 AB Humans demonstrate limited spontaneous endothelialization of prosthetic bypass grafts. However the local application of growth factors to prosthetic grafts or to injured blood vessels can provide an immediate effect on endothelialization. Novel chimeric proteins combining potent angiogens with extracellular matrix binding domains may localize to exposed matrices and provide sustained activity to promote endothelial regeneration after vascular interventions. We have ligated a thrombin-resistant mutant of fibroblast growth factor (FGF)-1 (R136K) with a collagen binding domain (CBD) in order to direct this growth factor to sites of exposed vascular collagen or selected bioengineered scaffolds. While FGF-1 and R136K are readily attracted to a variety of matrix proteins, R136K-CBD demonstrated selective and avid binding to collagen similar to 4x that of FGF-1 or R136K alone (P < 0.05). The molecular stability of R136K-CBD was superior to FGF-1 and R136K. Its chemotactic activity was superior to R136K and FGF-1 (11 +/- 1% vs. 6 +/- 2% and 4 +/- 1%; P<0.01). Its angiogenic activity was similar to R136K and significantly greater than control by day 2 (P<0.01). After day 3, FGF-1-treated endothelial cell's (EC) sprouts had regressed back to levels insignificant compared to the control group (P = 0.17), while both R136K and R136K-CBD continued to demonstrate greater sprout lengthening as compared to control (P<0.0002). The mitogenic, activity of all growth factors was greater than control groups (20% PBS); in all comparisons (P<0.0001). This dual functioning angiogen provides proof of concept for the application of designer angiogens to matrix binding proteins to intelligently promote endothelial regeneration of selected matrices. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Brewster, Luke P.; Gassman, Andrew; Greisler, Howard P.] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA. [Brewster, Luke P.; Greisler, Howard P.] Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA. [Washington, Cicely; Subramanian, Anu; Calceterra, Jen; Velander, William H.] Univ Nebraska, Dept Chem & Biomol Engn, Lincoln, NE 68588 USA. [Brey, Eric M.; Wolf, William; Greisler, Howard P.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Brey, Eric M.; Hall, Connie L.] IIT, Dept Biomed Engn, Chicago, IL 60616 USA. [Burgess, Wilson H.] StatSeal Inc, Belleview, WA USA. [Greisler, Howard P.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv, Hines, IL 60141 USA. RP Greisler, HP (reprint author), Loyola Univ, Med Ctr, Dept Surg, 2160 S 1st Ave, Maywood, IL 60153 USA. EM hgreisl@lumc.edu FU NHLBI NIH HHS [R01-HL41272, F32 HL074594, F32 HL078151, F32 HL078151-01, F32 HL078151-02, HL074594, HL078151-01, R01 HL041272, R01 HL041272-16, R01 HL041272-17, R01 HL041272-18] NR 48 TC 16 Z9 17 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 J9 BIOMATERIALS JI Biomaterials PD JAN PY 2008 VL 29 IS 3 BP 327 EP 336 DI 10.1016/j.biomaterials.2007.09.034 PG 10 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 242CY UT WOS:000251703300008 PM 17950455 ER PT J AU Wang, D Stockard, CR Harkins, L Lott, P Salih, C Yuan, K Buchsbaum, D Hashim, A Zayzafoon, M Hardy, RW Hameed, O Grizzle, W Siegal, GP AF Wang, D. Stockard, C. R. Harkins, L. Lott, P. Salih, C. Yuan, K. Buchsbaum, D. Hashim, A. Zayzafoon, M. Hardy, R. W. Hameed, O. Grizzle, W. Siegal, G. P. TI Immunohistochemistry in the evaluation of neovascularization in tumor xenografts SO BIOTECHNIC & HISTOCHEMISTRY LA English DT Article DE angiogenesis; antigen retrieval; CD31/PECAM-1; endothelial cells; factor; VIII/vWf; immunohistochemistry; microvessel density; xenografts ID CELL LUNG-CANCER; GROWTH-FACTOR EXPRESSION; ANTIGEN RETRIEVAL; VASCULOGENIC MIMICRY; MICROVESSEL DENSITY; ENDOTHELIAL-CELLS; MONOCLONAL-ANTIBODIES; FACTOR-VIII; IN-VIVO; ANGIOGENESIS AB Angiogenesis, or neovascularization, is known to play an important role in the neoplastic progression leading to metastasis. CD31 or Factor VIII-related antigen (F VIII RAg) immunohistochemistry is widely used in experimental studies for quantifying tumor neovascularization in immunocompromised animal models implanted with transformed human cell lines. Quantification, however, can be affected by variations in the methodology used to measure vascularization including antibody selection, antigen retrieval (AR) pretreatment, and evaluation techniques. To examine this further, we investigated the microvessel density (MVD) and the intensity of microvascular staining among five different human tumor xenografts and a mouse syngeneic tumor using anti-CD31 and F VIII RAg immunohistochemical staining. Different AR methods also were evaluated. Maximal retrieval of CD31 was achieved using 0.5 M Tris (pH 10) buffer, while maximum retrieval of F VIII RAg was achieved using 0.05% pepsin treatment of tissue sections. For each optimized retrieval condition, anti-CD31 highlighted small vessels better than F VIII RAg. Furthermore, the MVD of CD31 was significantly greater than that of F VIII RAg decorated vessels (p < 0.001). The choice of antibody and AR method has a significant affect on immunohistochemical findings when studying angiogenesis. One also must use caution when comparing studies in the literature that use different techniques and reagents. C1 [Siegal, G. P.] Univ Alabama, Dept Pathol, Div Anat Pathol, Birmingham, AL 35233 USA. [Wang, D.; Lott, P.; Siegal, G. P.] Univ Alabama, Dept Surg, Birmingham, AL 35233 USA. [Buchsbaum, D.] Univ Alabama, Dept Radiat Oncol, Birmingham, AL 35233 USA. [Siegal, G. P.] Univ Alabama, Dept Cell Biol, Birmingham, AL 35233 USA. [Harkins, L.; Siegal, G. P.] Birmingham VA Med Ctr, Dept Pathol & Lab Med, Birmingham, AL 35233 USA. [Wang, D.; Lott, P.; Salih, C.; Zayzafoon, M.] Ctr Metab Bone Dis, Birmingham, AL 35233 USA. [Buchsbaum, D.; Zayzafoon, M.; Hardy, R. W.; Grizzle, W.; Siegal, G. P.] UAB Comprehens Canc Ctr, Birmingham, AL 35233 USA. RP Siegal, GP (reprint author), Univ Alabama, Dept Pathol, Div Anat Pathol, KB 506 619 19th St S, Birmingham, AL 35233 USA. EM gsiegal@path.uab.edu RI Siegal, Gene/A-8653-2009 FU NIAMS NIH HHS [P30 AR046031, P30 AR046031-089002]; NIDDK NIH HHS [P30 DK074038, P30 DK074038-04] NR 34 TC 54 Z9 54 U1 1 U2 6 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1052-0295 J9 BIOTECH HISTOCHEM JI Biotech. Histochem. PY 2008 VL 83 IS 3-4 BP 179 EP 189 DI 10.1080/10520290802451085 PG 11 WC Biotechnology & Applied Microbiology; Cell Biology SC Biotechnology & Applied Microbiology; Cell Biology GA 363HX UT WOS:000260259500007 PM 18846440 ER PT J AU Keller, C Katz, R Cushman, M Fried, LF Shlipak, M AF Keller, Christopher Katz, Ronit Cushman, Mary Fried, Linda F. Shlipak, Michael TI Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: A cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) SO BMC NEPHROLOGY LA English DT Article AB Background: Prior studies using creatinine-based estimated glomerular filtration rate (eGFR) have found limited associations between kidney function and markers of inflammation. Using eGFR and cystatin C, a novel marker of kidney function, the authors investigated the association of kidney function with multiple biomarkers in a diverse cohort. Methods: The Multi-Ethnic Study of Atherosclerosis consists of 6,814 participants of white, African-American, Hispanic, and Chinese descent, enrolled from 2000-2002 from six U. S. communities. Measurements at the enrollment visit included serum creatinine, cystatin C, and six inflammatory and procoagulant biomarkers. Creatinine-based eGFR was estimated using the four-variable Modification of Diet in Renal Disease equation, and chronic kidney disease was defined by an eGFR < 60 mL/min/1.73 m(2). Results: Adjusted partial correlations between cystatin C and all biomarkers were statistically significant: C-reactive protein (r = 0.08), interleukin-6 (r = 0.16), tumor necrosis factor-alpha soluble receptor 1 (TNF-alpha R1; r = 0.75), intercellular adhesion molecule-1 (r = 0.21), fibrinogen (r = 0.14), and factor VIII (r = 0.11; two-sided p < 0.01 for all). In participants without chronic kidney disease, higher creatinine-based eGFR was associated only with higher TNF-alpha R1 levels. Conclusion: In a cohort characterized by ethnic diversity, cystatin C was directly associated with multiple procoagulant and inflammatory markers. Creatinine-based eGFR had similar associations with these biomarkers among subjects with chronic kidney disease. C1 [Keller, Christopher] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Keller, Christopher; Shlipak, Michael] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Cushman, Mary] Univ Vermont, Dept Med, Burlington, VT USA. [Cushman, Mary] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Keller, C (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM Christopher.Keller@ucsf.edu; RKatz@u.washington.edu; Mary.Cushman@uvm.edu; Linda.Fried@va.gov; Michael.Shlipak@ucsf.edu FU National Kidney Foundation; American Heart Association; National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-95159, N01-HC-95169]; [R01 DK066488-01] FX Dr. Keller is funded through a fellowship grant from the National Kidney Foundation. Dr. Shlipak is funded by R01 DK066488-01, as well as by the American Heart Association Established Investigator Award. This research was also supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute (NHLBI). Cystatin C measurements were donated to the NHLBI by Dade Behring Inc., Deer-field, IL. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. NR 33 TC 54 Z9 56 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PY 2008 VL 9 AR 9 DI 10.1186/1471-2369-9-9 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA V13KC UT WOS:000207664700009 PM 18681974 ER PT J AU Eriksson, AL Mellstrom, D Lorentzon, M Orwoll, ES Redlund-Johnell, I Grundberg, E Holmberg, A Ljunggren, O Karlsson, MK Ohlsson, C AF Eriksson, Anna L. Mellstrom, Dan Lorentzon, Mattias Orwoll, Eric S. Redlund-Johnell, Inga Grundberg, Elin Holmberg, Anna Ljunggren, Osten Karlsson, Magnus K. Ohlsson, Claes TI The COMT val158met polymorphism is associated with prevalent fractures in Swedish men SO BONE LA English DT Article DE fracture; polymorphism; COMT; men; estrogen ID CATECHOL-O-METHYLTRANSFERASE; BONE-MINERAL DENSITY; ELDERLY-MEN; FREE TESTOSTERONE; OSTEOPOROTIC FRACTURES; PHYSICAL-ACTIVITY; BODY-COMPOSITION; RISK-FACTORS; SELF-REPORT; WOMEN AB Introduction: Sex steroids are important for growth and maintenance of the skeleton. Catechol-O-methyltransferase (COMT) is an estrogen degrading enzyme. The COMT val158met polymorphism results in a 60-75% difference in enzyme activity between the val (high activity=H) and met (low activity=L) variants. We have previously reported that this polymorphism is associated with bone mineral density (BMD) in young men. The aim of this study was to investigate associations between COMT val158met, BMD and fractures in elderly men. Methods: Population-based study of Swedish men 75.4, SD 3.2, years of age. Fractures were reported using standardized questionnaires. Fracture and genotype data were available from 2822 individuals. Results: Total number of individuals with self-reported fracture was 989 (35.0%). Prevalence of >= 1 fracture was 37.2% in COMTLL, 35.7% in COMTHL and 30.4% in COMTHH (p<0.05). Early fractures (<= 50 years of age) were less common in COMTHH than in the combined COMTLL+HL genotype, OR 0.78 (95% CI 0.63-0.97). No associations were found for late fractures (>50 years of age). The OR for fracture of the non-weight bearing skeleton in COMTHH compared with COMTLL+HL was 0.74 (95% CI 0.59-0.92). No associations between COMT val158met and BMD were found in this cohort of elderly men. Conclusions: The COMT val158met polymorphism is associated with life time fracture prevalence in elderly Swedish men. This association is mainly driven by early fractures (<= 50 years of age). (C) 2007 Elsevier Inc. All rights reserved. C1 [Eriksson, Anna L.; Mellstrom, Dan; Lorentzon, Mattias; Ohlsson, Claes] Gothenburg Univ, Sahlgrenska Acad, Dept Internal Med, Ctr Bone Res,Div Clin Pharmacol, SE-41345 Gothenburg, Sweden. [Eriksson, Anna L.; Mellstrom, Dan; Lorentzon, Mattias; Ohlsson, Claes] Gothenburg Univ, Sahlgrenska Acad, Dept Geriatr, Ctr Bone Res, SE-41345 Gothenburg, Sweden. [Redlund-Johnell, Inga] Lund Univ, Dept Radiol, Lund, Sweden. [Orwoll, Eric S.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Portland, OR 97201 USA. [Orwoll, Eric S.] Portland VA Med Ctr, Portland, OR USA. [Grundberg, Elin; Ljunggren, Osten] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Holmberg, Anna] Malmo Univ Hosp, Dept Orthopaed, Malmo, Sweden. [Karlsson, Magnus K.] Lund Univ, Dept Clin Sci, Clin & Mol Osteoporosis Res Unit, Lund, Sweden. RP Eriksson, AL (reprint author), Gothenburg Univ, Sahlgrenska Acad, Dept Internal Med, Ctr Bone Res,Div Clin Pharmacol, Vita Straket 11, SE-41345 Gothenburg, Sweden. EM anna.eriksson@pharm.gu.se OI Orwoll, Eric/0000-0002-8520-7355 NR 48 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD JAN PY 2008 VL 42 IS 1 BP 107 EP 112 DI 10.1016/j.bone.2007.08.045 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 253KW UT WOS:000252518100014 PM 17962094 ER PT J AU Thannickal, TC Lai, YY Siegel, JM AF Thannickal, Thomas C. Lai, Yuan-Yang Siegel, Jerome M. TI Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinsons disease SO BRAIN LA English DT Letter DE Parkinson; narcolepsy; sleep; hypocretin; orexin; melanin concentrating hormone ID EXCESSIVE DAYTIME SLEEPINESS; HUMAN NARCOLEPSY; LOCUS-COERULEUS; MUSCLE TONE; REM-SLEEP; RATS; HALLUCINATIONS; RELEASE; MICROINJECTIONS; HYPOTHALAMUS C1 Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 91343 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, VAGLAHS, 16111 Plummer St, Los Angeles, CA 91343 USA. EM jsiegel@ucla.edu FU NHLBI NIH HHS [HL41370]; NIMH NIH HHS [MH64109]; NINDS NIH HHS [NS14610] NR 33 TC 25 Z9 25 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD JAN PY 2008 VL 131 AR e87 DI 10.1093/brain/awm221 PN 1 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 244KV UT WOS:000251865700025 PM 17898004 ER PT J AU Wu, Y Humphrey, MB Yao, W Lane, N Lanier, LL Nakamura, MC AF Wu, Y. Humphrey, M. B. Yao, W. Lane, N. Lanier, L. L. Nakamura, M. C. TI Regulation of osteoclastogenesis by innate immune co-receptors SO CALCIFIED TISSUE INTERNATIONAL LA English DT Meeting Abstract C1 [Wu, Y.; Nakamura, M. C.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA USA. [Humphrey, M. B.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, OKC VAMC, Oklahoma City, OK USA. [Humphrey, M. B.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol Immunol, OKC VAMC, Oklahoma City, OK USA. [Yao, W.; Lane, N.] Univ Calif Davis, Dept Med, Sacramento, CA 95817 USA. [Lanier, L. L.] Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0171-967X J9 CALCIFIED TISSUE INT JI Calcif. Tissue Int. PY 2008 VL 82 SU 1 BP S19 EP S20 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 306OS UT WOS:000256258300021 ER PT B AU MacRae, SK Fox, E Slowther, A AF MacRae, Susan K. Fox, Ellen Slowther, Anne BE Singer, PA TI Clinical ethics and systems thinking SO CAMBRIDGE TEXTBOOK OF BIOETHICS LA English DT Article; Book Chapter ID HEALTH-CARE; IMPROVEMENT; SERVICES; QUALITY AB A health region, with multiple hospitals and community healthcare organizations, is faced with increased pressures to improve the ethical care of patients and improve staff experience across the system. Currently the patient satisfaction scores at many of the sites are quite low and recent Health Commission inspections in some hospitals have highlighted management of consent issues and patient-centered care as areas of major concern. The staff's morale is waning and moral distress seems to be increasing. The CEO of the Strategic Health Authority believes that clinical ethics could potentially make a significant difference to the overall culture of the system but feels that the existing mechanisms are not that effective. She begins to consult with experts in the field to discuss how clinical ethics can help her to improve her health system. "ABC Health Care'' has an established clinical ethics program that performs a variety of functions including case consultation, education, policy work, and scholarly writing. Although ABC has received positive accreditation ratings relating to clinical ethics, many within ABC including both administrators and clinical staff - have a general sense that ABC's current clinical ethics program may not be fully addressing the organization's needs. For example, the program tends to focus on a narrow range of ethical concerns, mostly related to high-profile acute situations in the intensive care and emergency units. In contrast, staff experience a much broader range of ethical issues in their work day to day, and many issues and areas go unserved. Although the clinical ethics program devotes many hours to ethics consultation, similar ethical issues continue to recur again and again. At times, ethics program staff seems more concerned about philosophical questions and principles than about the practical realities experienced by patients and healthcare staff. Overall, the clinical ethics program's impact on everyday behavior or on organizational culture is unclear, and no measures exist to evaluate the program's effectiveness. The CEO feels strongly that the clinical ethics program should be held accountable for its effects on the system (or lack thereof). He looks to other organizations for models of how clinical ethics programs can be used to make systems change. C1 [MacRae, Susan K.] Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5S 1A1, Canada. [Fox, Ellen] US Dept Vet Affairs, Natl Ctr Eth Hlth Care, Washington, DC USA. [Slowther, Anne] Univ Warwick, Sch Med, Coventry CV4 7AL, W Midlands, England. RP MacRae, SK (reprint author), Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5S 1A1, Canada. NR 20 TC 4 Z9 4 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69443-8 PY 2008 BP 313 EP 321 DI 10.1017/CBO9780511545566.047 D2 10.1017/CBO9780511545566 PG 9 WC Medical Ethics; Medicine, Legal SC Medical Ethics; Legal Medicine GA BAN30 UT WOS:000304825200047 ER PT J AU Marder, SR Jones, PB AF Marder, Stephen R. Jones, Peter B. BA Tyrer, P Silk, KR BF Tyrer, P Silk, KR TI Pharmacological treatments for schizophrenia SO CAMBRIDGE TEXTBOOK OF EFFECTIVE TREATMENTS IN PSYCHIATRY LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; CONVENTIONAL ANTIPSYCHOTIC-DRUGS; DOUBLE-BLIND; 2ND-GENERATION ANTIPSYCHOTICS; SCHIZOAFFECTIVE DISORDER; RESISTANT SCHIZOPHRENIA; ATYPICAL ANTIPSYCHOTICS; CLOZAPINE; RISPERIDONE; METAANALYSIS C1 [Marder, Stephen R.] W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Jones, Peter B.] Addenbrookes Hosp, Dept Psychiat, Cambridge, England. RP Marder, SR (reprint author), W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. NR 32 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-52184-228-0 PY 2008 BP 461 EP 468 D2 10.1017/CBO9780511544392 PG 8 WC Psychiatry SC Psychiatry GA BYF84 UT WOS:000298475100027 ER PT J AU Jones, PB Marder, SR AF Jones, Peter B. Marder, Stephen R. BA Tyrer, P Silk, KR BF Tyrer, P Silk, KR TI Psychosocial and pharmacological treatments for schizophrenia SO CAMBRIDGE TEXTBOOK OF EFFECTIVE TREATMENTS IN PSYCHIATRY LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; PSYCHOLOGICAL TREATMENTS; SOCIAL-INTERVENTION; FOLLOW-UP; FAMILY; PSYCHOTHERAPY; REMEDIATION; MAINTENANCE; 1ST-EPISODE C1 [Jones, Peter B.] Addenbrookes Hosp, Dept Psychiat, Cambridge, England. [Marder, Stephen R.] W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Jones, PB (reprint author), Addenbrookes Hosp, Dept Psychiat, Cambridge, England. NR 53 TC 2 Z9 2 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-52184-228-0 PY 2008 BP 469 EP 479 DI 10.1017/CBO9780511544392.028 D2 10.1017/CBO9780511544392 PG 11 WC Psychiatry SC Psychiatry GA BYF84 UT WOS:000298475100028 ER PT J AU Habib, SL Danial, E Nath, S Schneider, J Jenkinson, CP Duggirala, R Abboud, HE Thameem, F AF Habib, Samy L. Danial, Elaine Nath, Subrata Schneider, Jennifer Jenkinson, Christopher P. Duggirala, Ravindranath Abboud, Hanna E. Thameem, Farook TI Genetic polymorphisms in OGG1 and their association with angiomyolipoma, a benign kidney tumor in patients with tuberous sclerosis SO CANCER BIOLOGY & THERAPY LA English DT Article DE TSC2; OGG1; angiomyolipoma; SNPs; 8-oxodG ID OXIDATIVE DNA-DAMAGE; REPAIR; 8-HYDROXYGUANINE; EXPRESSION; CANCER; ENZYME; HOGG1; RISK AB The enzyme 8-oxoguanine glycosylase 1 (OGG1) repairs 8-oxo-2-deoxyguanosine residue (8-oxodG) an oxidatively damaged promutagenic base. Genetic variations in OGG1 gene have been shown to modulate DNA repair capacity and are related risk of tumor development. However, epidemiologic findings have been inconsistent. The purpose of this study is to determine whether genetic variants in OGG1 play a role in susceptibility to angiomyolipoma, a benign kidney tumor associated with tuberous sclerosis complex (TSC) patients. To identify genetic variations, all seven exons of the OGG1 gene were amplified by PCR and sequenced in 22 TSC patients with angiomyolipoma (cases) and 18 controls. By direct sequencing, we identified four missense mutations in OGG1: Arg(45) Gln, Ala(85) Ser, Arg(229) Gln and Ser(326) Cys. Genotypic association with angiomyolipoma was performed using the measured genotype approach as implemented in the variance component analytical tools. Association analysis showed the presence of significant association (p = 0.01) only between the Ser(326) Cys polymorphism of OGG1 and angiomyolipoma. We also assessed the presence of oxidative DNA damage in kidney section from normal healthy subjects, normal kidney tissue from TSC patients and kidney angiomyolipoma tissue from TSC patients by immunostaining for 8-oxodG. 8-OxodG staining was highly abundant in kidney angiomyolipoma tissue from TSC patients compared to weak staining in uninvolved tissue from the same TSC patients or normal kidney from healthy subjects. Taken together, our findings suggest that Ser(326) Cys variant of OGG1 may confer risk for development of angiomyolipomas by increasing oxidative DNA damage. C1 [Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, George OBrien Kidney Res Ctr, San Antonio, TX 78229 USA. [Habib, Samy L.; Abboud, Hanna E.] Ctr Geriatr Res Educ & Clin, S Texas Vet Healthcare Syst, San Antonio, TX USA. [Schneider, Jennifer; Duggirala, Ravindranath] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, George OBrien Kidney Res Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM habib@uthscsa.edu FU NIDDK NIH HHS [R01 DK079195] NR 16 TC 11 Z9 11 U1 0 U2 0 PU LANDES BIOSCIENCE PI AUSTIN PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA SN 1538-4047 J9 CANCER BIOL THER JI Cancer Biol. Ther. PD JAN PY 2008 VL 7 IS 1 BP 23 EP 27 PG 5 WC Oncology SC Oncology GA 279OR UT WOS:000254365000005 PM 17932460 ER PT J AU Byers, T Wolf, HJ Franklin, WA Braudrick, S Merrick, DT Shroyer, KR Hirsch, FR Zeng, C Baron, AE Bunn, PA Miller, YE Kennedy, TC AF Byers, Tim Wolf, Holly J. Franklin, Wilbur A. Braudrick, Sarah Merrick, Daniel T. Shroyer, Kenneth R. Hirsch, Fred R. Zeng, Chan Baron, Anna E. Bunn, Paul A. Miller, York E. Kennedy, Timothy C. TI Sputum cytologic atypia predicts incident lung cancer: Defining latency and histologic specificity SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID AIR-FLOW OBSTRUCTION; FOLLOW-UP; COHORT AB Background: There is a need for early detection methods for lung cancer. Radiologic imaging may be more sensitive for peripheral cancers than for cancers arising in the central airways, from which bronchial epithelial cells are exfoliated into the sputum. Methods: Sputum samples were collected at baseline and periodically thereafter in a cohort of smokers and former smokers with chronic obstructive lung disease. The association between cytologic atypia and incident lung cancer was assessed by hazard ratios (HR, 95% confidence intervals) using Cox regression and by odds ratios (95% confidence intervals) using logistic regression, adjusting for potential confounding factors. Results: We observed 174 incident lung cancers in a cohort of 2,521 people over 9,869 person-years of observation. Risk for incident lung cancer was increased among those with cytologic atypia graded as moderate or worse (adjusted HR, 2.37; 1.68-3.34). The association between sputum atypia and lung cancer incidence was greatest for those sputum samples collected 5 months or less before the diagnosis of lung cancer (odds ratio, 10.32; 5.34-19.97). The association was substantially stronger for squamous cell lung cancers (HR, 5.13; 2.89-9.10) than for adenocarcinomas (HR, 1.85; 0.94-3.65). Conclusion: Cytologic atypia is a marker for increased lung cancer risk. These cytologic changes seem to arise from late events that are most apparent for cancers arising in the central respiratory airways. Whether cytologic atypia might complement radiologic imaging in a combined approach to lung cancer, early detection requires additional evaluation of those two methods used together. C1 [Byers, Tim; Wolf, Holly J.; Franklin, Wilbur A.; Braudrick, Sarah; Merrick, Daniel T.; Shroyer, Kenneth R.; Hirsch, Fred R.; Zeng, Chan; Baron, Anna E.; Bunn, Paul A.; Miller, York E.] Univ Colorado, Ctr Comprehens Canc, Sch Med, Hlth Sci Ctr, Aurora, CO 80045 USA. [Merrick, Daniel T.; Miller, York E.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Kennedy, Timothy C.] Lung Canc Inst Colorado, Denver, CO USA. RP Byers, T (reprint author), Univ Colorado, Ctr Comprehens Canc, Sch Med, Hlth Sci Ctr, Box F-519,13001 E 17th Pl, Aurora, CO 80045 USA. EM tim.byers@uchsc.edu FU NCI NIH HHS [P50 CA 58187] NR 19 TC 19 Z9 19 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JAN PY 2008 VL 17 IS 1 BP 158 EP 162 DI 10.1158/1055-9965.EPI-07-0436 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 253FK UT WOS:000252503900020 PM 18199720 ER PT J AU Ferguson-Yates, BE Li, H Dong, TK Hsiao, JL Oh, DH AF Ferguson-Yates, Bridget E. Li, Hongyan Dong, Tiffany K. Hsiao, Jennifer L. Oh, Dennis H. TI Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63 SO CARCINOGENESIS LA English DT Article ID NUCLEOTIDE EXCISION-REPAIR; SQUAMOUS-CELL CARCINOMA; PIGMENTOSUM DDB2 GENE; GLOBAL GENOMIC REPAIR; DNA-DAMAGE; ULTRAVIOLET-RADIATION; TUMOR-SUPPRESSOR; UV-IRRADIATION; HUMAN FIBROBLASTS; STEM-CELLS AB While many p53-deficient cell types are impaired in global genomic nucleotide excision repair of cyclobutane pyrimidine dimers (CPDs), human epidermal keratinocytes expressing human papillomavirus type 16 E6 and E7 are p53 deficient and yet maintain repair of CPD. We hypothesized that the p53 homolog, p63, may participate in governing global repair instead of p53 in keratinocytes. Following ultraviolet radiation (UVR) of E6/E7 keratinocytes, depletion of p63 but not of p73 impaired global genomic repair of CPD relative to control cells. In all cases, repair of pyrimidine(6-4)pyrimidone photoproducts, the other major UVR-induced DNA lesions, was unaffected. In E6/E7 keratinocytes treated with p63 small interfering RNA, reduced global repair of CPD was associated not with reduced levels of messenger RNA-encoding DNA damage recognition proteins but rather with decreased levels of DDB2 and XPC proteins, suggesting that p63 posttranscriptionally regulates levels of these proteins. These results indicate that global repair may be regulated at multiple levels and suggest a novel role for p63 in modulating repair of DNA damage in human keratinocytes. The results may provide insight into mechanisms of genomic stability in epithelia infected with oncogenic human papilloma viruses and may further explain the lack of increased skin cancer incidence in Li-Fraumeni syndrome. C1 [Ferguson-Yates, Bridget E.; Li, Hongyan; Dong, Tiffany K.; Hsiao, Jennifer L.; Oh, Dennis H.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Ferguson-Yates, Bridget E.; Li, Hongyan; Dong, Tiffany K.; Hsiao, Jennifer L.; Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA 94121 USA. RP Oh, DH (reprint author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. EM ohd@derm.ucsf.edu FU NCI NIH HHS [R01 CA105958, CA105958]; NIAMS NIH HHS [T32 AR007175] NR 52 TC 11 Z9 11 U1 1 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD JAN PY 2008 VL 29 IS 1 BP 70 EP 75 DI 10.1093/carcin/bgm244 PG 6 WC Oncology SC Oncology GA 258XQ UT WOS:000252904100010 PM 17984111 ER PT J AU Keene, CD Chang, R Leverenz, JB Kopyov, O Hevner, R Born, D Bird, TD Montine, TJ AF Keene, C. D. Chang, R. Leverenz, J. B. Kopyov, O. Hevner, R. Born, D. Bird, T. D. Montine, T. J. TI Graft overgrowth and ependymal cyst formation despite initial clinical improvement in a Huntington's patient who received fetal neural transplants SO CELL TRANSPLANTATION LA English DT Meeting Abstract CT 15th Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair CY MAY 01-03, 2008 CL Clearwater Beach, FL SP Amer Soc Neural Therapy & Repair C1 [Keene, C. D.; Chang, R.; Born, D.; Montine, T. J.] Univ Washington, Med Ctr, Dept Pathol, Div Neuropathol, Seattle, WA 98195 USA. [Bird, T. D.] Univ Washington, Med Ctr, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, J. B.; Bird, T. D.] VA Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Geriatr Program, Seattle, WA USA. [Leverenz, J. B.] VA Puget Sound Hlth Care Syst, Mental Illness Program, Seattle, WA USA. [Leverenz, J. B.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Program, Seattle, WA USA. [Keene, C. D.; Hevner, R.] Childrens Hosp, Seattle, WA USA. [Keene, C. D.; Hevner, R.] Reg Med Ctr, Seattle, WA USA. [Kopyov, O.] St Johns Reg Med Ctr, Inst Neurosci, Oxnard, CA USA. RI Keene, Christopher/N-1806-2015 NR 0 TC 3 Z9 3 U1 0 U2 0 PU COGNIZANT COMMUNICATION CORP PI ELMSFORD PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA SN 0963-6897 J9 CELL TRANSPLANT JI Cell Transplant. PY 2008 VL 17 IS 4 BP 469 EP 469 PG 1 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA 301XT UT WOS:000255930500047 ER PT J AU Shin, JM Vagin, O Munson, K Kidd, M Modlin, IM Sachs, G AF Shin, J. M. Vagin, O. Munson, K. Kidd, M. Modlin, I. M. Sachs, G. TI Molecular mechanisms in therapy of acid-related diseases SO CELLULAR AND MOLECULAR LIFE SCIENCES LA English DT Review DE gastric acid secretion; peptic ulcer; gastroesophageal reflux disease; proton pump inhibitors; pharmacology; H,K ATPase ID PROTON-PUMP INHIBITORS; GASTROESOPHAGEAL-REFLUX DISEASE; PEPTIC-ULCER DISEASE; GASTRIC H+/K+-ATPASE; HELICOBACTER-PYLORI INFECTION; HEALTHY MALE-VOLUNTEERS; BETA-SUBUNIT; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; CDNA CLONING AB Inhibition of gastric acid secretion is the mainstay of the treatment of gastroesophageal reflux disease and peptic ulceration; therapies to inhibit acid are among the best-selling drugs worldwide. Highly effective agents targeting the histamine H2 receptor were first identified in the 1970s. These were followed by the development of irreversible inhibitors of the parietal cell hydrogen-potassium ATPase (the proton pump inhibitors) that inhibit acid secretion much more effectively. Reviewed here are the chemistry, biological targets and pharmacology of these drugs, with reference to their current and evolving clinical utilities. Future directions in the development of acid inhibitory drugs include modifications of current agents and the emergence of a novel class of agents, the acid pump antagonists. C1 [Shin, J. M.; Vagin, O.; Munson, K.; Sachs, G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Shin, J. M.; Vagin, O.; Munson, K.; Sachs, G.] W LA Med Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Kidd, M.; Modlin, I. M.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA. RP Sachs, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. EM gsachs@ucla.edu FU NIDDK NIH HHS [DK053642, DK058333, R01 DK053642, R01 DK053642-12, R01 DK053642-13, R01 DK058333, R01 DK058333-11, R01 DK077149, R01 DK077149-01A1, R01 DK077149-02, R56 DK058333, R56 DK058333-12] NR 89 TC 30 Z9 34 U1 0 U2 5 PU BIRKHAUSER VERLAG AG PI BASEL PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND SN 1420-682X J9 CELL MOL LIFE SCI JI Cell. Mol. Life Sci. PD JAN PY 2008 VL 65 IS 2 BP 264 EP 281 DI 10.1007/s00018-007-7249-x PG 18 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 255PZ UT WOS:000252671200007 PM 17928953 ER PT J AU Hoo, GWS AF Hoo, Guy W. Soo TI Tight blood glucose control in the ICU - How best to measure glucose control? SO CHEST LA English DT Letter ID INSULIN INFUSION PROTOCOL; IMPLEMENTATION C1 W Los Angeles VA Healthcare Ctr, Pulm & Crit Care Sect 111Q, Los Angeles, CA 90073 USA. RP Hoo, GWS (reprint author), W Los Angeles VA Healthcare Ctr, Pulm & Crit Care Sect 111Q, 11301 Wilshire Blvd 111Q, Los Angeles, CA 90073 USA. EM gity.soohoo@va.gov NR 6 TC 7 Z9 7 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2008 VL 133 IS 1 BP 316 EP 317 DI 10.1378/chest.07-2214 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 251PL UT WOS:000252385600061 PM 18187766 ER PT J AU Holmes, WC AF Holmes, William C. TI Men's self-definitions of abusive childhood sexual experiences, and potentially related risky behavioral and psychiatric outcomes SO CHILD ABUSE & NEGLECT LA English DT Article DE sexual abuse; post-traumatic stress disorder; depression; HIV risk behavior; men ID PARENTAL BONDING INSTRUMENT; RELIABILITY; PREVALENCE; PERCEPTION; ADULTS AB Objectives: To estimate how many heterosexual and gay/bisexual men self-define abusive childhood sexual experiences (CSEs) to be childhood sexual abuse (CSA) and to assess whether CSA self-definition is associated with risky behavioral and psychiatric outcomes in adulthood. Methods: In Philadelphia County, 197 (66%) of 298 recruited men participated in a telephone survey. They were screened for CSEs and then asked if they self-defined abusive CSEs to be CSA; they also were asked about risk behavior histories and post-traumatic stress disorder (PTSD) and depression symptoms. Results: Of 43 (22%) participants with abusive CSEs, 35% did not and 65% did self-define abusive CSEs to be CSA ("Non-Definers" and "Definers," respectively). Heterosexual and gay/bisexual subgroups' CSA self-definition rates did not significantly differ. When self-definition subgroups were compared to those without CSEs ("No-CSEs"), Non-Definers had lower perceived parental care (p =.007) and fewer siblings (p =.03), Definers had more Hispanics and fewer African Americans (p =.04), and No-CSEs had fewer gay/bisexual men (p =.002) and fewer reports of physical abuse histories (p =.02) than comparison groups. Non-Definers reported more sex under the influence (p =.001) and a higher mean number of all lifetime sex partners (p =.004) as well as (only) female sex partners (p =.05). More Non-Definers than Definers reported having experienced penetrative sex as part of their CSA (83% vs. 35%, p =.006). Different explanations about self-definition were provided by subgroups. Conclusions: Many men with abusive CSEs do not self-define these CSEs to be CSA, though not in a way that differs by sexual identity. The process by which men self-define their abusive CSEs to be CSA or not appears to be associated not only with self-explanations that differ by self-definition subgroup, but also with behavioral outcomes that impart risk to Non-Definers. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Holmes, William C.] Univ Penn, Sch Med, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Care, Philadelphia, PA 19104 USA. [Holmes, William C.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Holmes, William C.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Leonard Davis Inst, Philadelphia, PA 19104 USA. RP Holmes, WC (reprint author), 733 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. FU NIDA NIH HHS [DA015635, R03 DA015635, R03 DA015635-02] NR 25 TC 25 Z9 25 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2134 J9 CHILD ABUSE NEGLECT JI Child Abuse Negl. PD JAN PY 2008 VL 32 IS 1 BP 83 EP 97 DI 10.1016/j.chiabu.2007.09.005 PG 15 WC Family Studies; Psychology, Social; Social Work SC Family Studies; Psychology; Social Work GA 263ZM UT WOS:000253255000006 PM 18035415 ER PT J AU Freeman, SR Lundahl, K Schilling, LM Jensen, JD Dellavalle, RP AF Freeman, Scott R. Lundahl, Kristy Schilling, Lisa M. Jensen, J. Daniel Dellavalle, Robert P. TI Human research review committee requirements in medical journals SO CLINICAL AND INVESTIGATIVE MEDICINE LA English DT Article ID BOARD; QUALITY; EDITORS AB Purpose: Independent ethical review committees safeguard participants in human research. The purpose of this study was to describe the current ethical guidelines for human research requirements in the Instructions to Authors of the English language medical journals previously studied in 1995. Methods: The instructions to authors of English language medicine journals from the Abridged Index Medicus were searched for any policies regarding guidance on the ethical treatment of human subjects in research. Results: More medical journals require independent ethics committee approval of human research now [84/101 (83%)] than 10 years ago [48/102 (47%) (P<0.001)], and most journals continue to require that this disclosure appear in the manuscript [71/84 (85%) vs. then 37/48 (77%) (P=0.29)]. Fewer medical journal instructions to authors provide no ethical guidelines for human research now [8/101 (8%)] than 10 years ago [25/102 (24%) (P<0.001)]. No journal required submission of the study approval letter or of the approved protocol. Conclusions: Although medicine journals increasingly require disclosure statements of independent ethics committee approval for human research, they fail to verify such approval beyond taking authors for their word. C1 [Dellavalle, Robert P.] Univ Colorado Denver & Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Sch Med, Denver, CO USA. [Freeman, Scott R.; Lundahl, Kristy; Jensen, J. Daniel; Dellavalle, Robert P.] Univ Colorado Denver & Hlth Sci Ctr, Dept Dermatol, Sch Med, Denver, CO USA. [Schilling, Lisa M.] Univ Colorado Denver & Hlth Sci Ctr, Dept Med, Sch Med, Denver, CO USA. RP Dellavalle, RP (reprint author), 1055 Clermont St,165, Denver, CO 80220 USA. EM robert.dellavalle@uchsc.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X FU NCI NIH HHS [K-07CA92550]; NIAMS NIH HHS [T32 AR07411] NR 22 TC 5 Z9 5 U1 0 U2 2 PU CANADIAN SOC CLINICAL INVESTIGATION PI OTTAWA PA CSCI HEAD OFFICE, 774 ECHO DRIVE, OTTAWA, ON K1S 5N8, CANADA SN 0147-958X J9 CLIN INVEST MED JI Clin. Invest. Med. PY 2008 VL 31 IS 1 BP E49 EP E54 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 282TC UT WOS:000254589100007 PM 18312748 ER PT J AU Andersson, A Buttan, A Batra, R Zhu, L Dubinett, S Sharmax, S AF Andersson, Asa Buttan, Anshu Batra, Raj Zhu, Li Dubinett, Steven Sharmax, Sherven TI IL-7/IL-7R alpha-Fc immune therapy for non small cell lung cancer SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Andersson, Asa; Buttan, Anshu; Zhu, Li; Dubinett, Steven; Sharmax, Sherven] Univ Calif Los Angeles, Los Angeles, CA USA. [Batra, Raj] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S36 EP S36 DI 10.1016/j.clim.2008.03.095 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200099 ER PT J AU Cobb, B Kaufman, K Wang, Y Kelly, J Jonsson, R Bolstad, AI Brun, J Rischmueller, M Lester, S Witte, T Mariette, X Kimberly, R Edberg, J Bae, SC Jacob, C Alarcon-Riquelme, M Vyse, T Gilkeson, G Kamen, D Moser, K Gaffney, P Merrill, J James, J Harley, J AF Cobb, Beth Kaufman, Ken Wang, Yukun Kelly, Jennifer Jonsson, Roland Bolstad, Anne Isine Brun, Johan Rischmueller, Maureen Lester, Sue Witte, Torsten Mariette, Xavier Kimberly, Robert Edberg, Jeffrey Bae, Sang-Cheol Jacob, Chaim Alarcon-Riquelme, Marta Vyse, Timothy Gilkeson, Gary Kamen, Diane Moser, Kathy Gaffney, Patrick Merrill, Joan James, Judith Harley, John TI Association of Sjogren's syndrome (SS) and systemic lupus erythematosus (SLE) with BLK SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Cobb, Beth; Wang, Yukun; Kelly, Jennifer; Moser, Kathy; Gaffney, Patrick; Merrill, Joan; James, Judith; Harley, John] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Kaufman, Ken] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Jonsson, Roland; Bolstad, Anne Isine; Brun, Johan] Univ Bergen, Bergen, Norway. [Rischmueller, Maureen] Queen Elizabeth Hosp, Woodville, SA 5011, Australia. [Lester, Sue] Hanson Inst, Adelaide, SA, Australia. [Witte, Torsten] Hannover Med Sch, D-3000 Hannover, Germany. [Mariette, Xavier] Univ Paris 11, Le Kremlin Bicetre, France. [Kimberly, Robert; Edberg, Jeffrey] Univ Alabama, Birmingham, AL USA. [Bae, Sang-Cheol] Hanyang Univ, Seoul 133791, South Korea. [Jacob, Chaim] Univ So Calif, Los Angeles, CA USA. [Alarcon-Riquelme, Marta] Uppsala Univ, Uppsala, Sweden. [Vyse, Timothy] Univ London Imperial Coll Sci Technol & Med, London, England. [Gilkeson, Gary; Kamen, Diane] Med Univ S Carolina, Charleston, SC 29425 USA. RI Vyse, Tim/G-3887-2011; Witte, Torsten/B-5783-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S41 EP S41 DI 10.1016/j.clim.2008.03.111 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200115 ER PT J AU Sinha, S Burrows, G Vandenbark, A Offner, H AF Sinha, Sushmita Burrows, Gregory Vandenbark, Arthur Offner, Halina TI Inhibition of autoimmune response to multiple antigens in EAE by a single recombinant TCR ligand (RTL) SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Sinha, Sushmita; Vandenbark, Arthur; Offner, Halina] Portland VA Med Ctr, Portland, OR USA. [Burrows, Gregory] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S47 EP S47 DI 10.1016/j.clim.2008.03.125 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200131 ER PT J AU Hersch, EC Merriam, GR AF Hersch, Elizabeth C. Merriam, George R. TI Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus? SO CLINICAL INTERVENTIONS IN AGING LA English DT Review DE growth hormone; growth hormone-releasing hormone; growth hormone secretagogues; aging; sarcopenia; frailty AB Although growth hormone (GH) is primarily associated with linear growth in childhood, it continues to have important metabolic functions in adult life. Adult GH deficiency (AGHD) is a distinct clinical entity, and GH replacement in AGHD can improve body composition, strength, aerobic capacity, and mood, and may reduce vascular disease risk. While there are some hormone-related side effects, the balance of benefits and risks is generally favorable, and several countries have approved GH for clinical use in AGHD. GH secretion declines progressively and markedly with aging, and many age-related changes resemble those of partial AGHD. This suggests that replacing GH, or stimulating GH with GH-releasing hormone or a GH secretagogue could confer benefits in normal aging similar to those observed in AGHD - in particular, could reduce the loss of muscle mass, strength, and exercise capacity leading to frailty, thereby prolonging the ability to live independently. However, while most GH studies have shown body composition effects similar to those in AGHD, functional changes have been much less inconsistent, and older adults are more sensitive to GH side effects. Preliminary reports of improved cognition are encouraging, but the overall balance of benefits and risks of GH supplementation in normal aging remains uncertain. C1 VA Puget Sound Hlth Care Syst, Tacoma, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Sch Med, Tacoma, WA USA. Univ Washington, Sch Med, Seattle, WA USA. RP Merriam, GR (reprint author), A 151 VA Puget Sound Hlth Care Syst, Res Serv, 9600 Vet Dr SW, Tacoma, WA 98493 USA. EM herschec@yahoo.com NR 26 TC 15 Z9 15 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-9092 J9 CLIN INTERV AGING JI Clin. Interv. Aging PY 2008 VL 3 IS 1 BP 121 EP 129 PG 9 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA V21WW UT WOS:000208238700013 PM 18488883 ER PT J AU Iqbal, N Rubenstein, AH AF Iqbal, Nayyar Rubenstein, Arthur H. TI Does lowering of blood glucose improve cardiovascular morbidity and mortality? SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID DEPENDENT DIABETES-MELLITUS; LONG-TERM COMPLICATIONS; CORONARY-HEART-DISEASE; MICROVASCULAR COMPLICATIONS; 10-YEAR INCIDENCE; RISK-FACTORS; PROGRESSION; RETINOPATHY; THERAPY; ROSIGLITAZONE C1 [Iqbal, Nayyar] Philadelphia Vet Affairs Med Ctr, Endocrinol Sect, Philadelphia, PA USA. [Iqbal, Nayyar; Rubenstein, Arthur H.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Iqbal, N (reprint author), 1 Maloney,3400 Spruce St, Philadelphia, PA 19104 USA. EM nayyar.iqbal2@med.va.gov NR 26 TC 3 Z9 3 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2008 VL 3 IS 1 BP 163 EP 167 DI 10.2215/CJN.05041107 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 250IK UT WOS:000252293000024 PM 18178783 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Prevention of contrast-induced nephropathy with volume expansion SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE-RENAL-FAILURE; RANDOMIZED CONTROLLED-TRIAL; WATER DIURESIS; RADIOCONTRAST NEPHROPATHY; CORONARY INTERVENTION; MEDULLARY CIRCULATION; SODIUM-BICARBONATE; MAJOR ANGIOGRAPHY; SALINE HYDRATION; N-ACETYLCYSTEINE AB Background and objectives: Contrast-induced nephropathy is one of the few preventable forms of acute kidney injury. Several pharmacologic agents have been evaluated for the prevention of contrast-induced nephropathy, yet disappointingly, few have been shown conclusively to reduce the risk for this condition. A series of studies have demonstrated that volume expansion, particularly with intravenous fluids, is an effective intervention to reduce the risk for contrast-induced nephropathy. Design, setting, participants, & measurements: This article reviews the clinical trials that have assessed the role of volume expansion for the prevention of contrast-induced nephropathy. Results: The administration of isotonic sodium chloride before and after radiocontrast injection seems to be more protective than equivalent volumes of hypotonic saline and, when feasible, should be administered over a sustained period of time. Recent clinical trials suggested that an abbreviated regimen of intravenous sodium bicarbonate may be superior to a comparable protocol of sodium chloride. Although a small number of studies have found that volume supplementation by mouth may be effective in preventing contrast-induced nephropathy, the routine use of enteral fluids or solute in lieu of intravenous fluids in high-risk patients cannot be recommended at this time. Rather, liberal oral fluid and solute intake should complement intravenous fluid administration to minimize risk. Conclusions: Future studies will be required to define clearly the optimal prophylactic intravenous fluid regimen for contrast-induced nephropathy and further delineate the independent role of oral volume expansion for the prevention of this condition. C1 [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Weisbord, SD (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Mail Stop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 40 TC 64 Z9 77 U1 1 U2 6 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2008 VL 3 IS 1 BP 273 EP 280 DI 10.2215/CJN.02580607 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 250IK UT WOS:000252293000037 PM 17989201 ER PT J AU Lo, B Kriegstein, A Grady, D AF Lo, Bernard Kriegstein, Arnold Grady, Deborah TI Clinical trials in stem cell transplantation: guidelines for scientific and ethical review SO CLINICAL TRIALS LA English DT Article ID PARKINSONS-DISEASE; INFORMED-CONSENT; DRUG; ROFECOXIB; TGN1412; EVENTS; CANCER; ISSUES; ERA AB Background Transplantation of cells derived through the manipulation of pluripotent stem cells may involve great uncertainty and the possibility of serious risks. Purpose To develop guidelines for the ethical conduct of clinical trials using such stem cells. Methods Review of literature on clinical trials ethics and clinical applications of stem cells; critical deliberation on potential guidelines. Results Such transplantation should be allowed in clinical practice only after clinical trials demonstrate efficacy and safety. These clinical trials should follow ethical principles that guide all clinical research. Additional requirements to strengthen trial design, coordinate scientific and ethics review, verify that participants understand key features of the trial, and ensure publication of findings are also warranted because of the highly innovative nature of the intervention, limited experience in humans, and the high hopes of patients who have no alternative effective treatments. Limitations These recommendations will need to be modified in light of actual experience with stem cell clinical trials. Conclusions These recommendations will help guarantee that the efficacy and safety of innovative stem cell interventions will be rigorously established, while also protecting study participants. Clinical Trials 2008; 5: 517-522. http:// ctj.sagepub.com C1 [Lo, Bernard] Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA. [Lo, Bernard] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Kriegstein, Arnold] Univ Calif San Francisco, Program Dev & Stem Cell Biol, San Francisco, CA 94143 USA. [Kriegstein, Arnold] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Lo, B (reprint author), Univ Calif San Francisco, Program Med Eth, 521 Parnassus Ave,Room C126, San Francisco, CA 94143 USA. EM bernie@medicine.ucsf.edu FU National Center for Research Resources (NCRR); NIH [RR024131-01]; Greenwall Foundation FX Supported by National Institutes of Health (NIH) Grant Number 1 UL1 RR024131-01 from the National Center for Research Resources (NCRR) and NIH Roadmap for Medical Research and by the Greenwall Foundation. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR of NIH. NR 45 TC 24 Z9 26 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 J9 CLIN TRIALS JI Clin. Trials PY 2008 VL 5 IS 5 BP 517 EP 522 DI 10.1177/1740774508096705 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 367RN UT WOS:000260570100006 PM 18827044 ER PT J AU Wortzel, HS Oster, TJ Anderson, CA Arciniegas, DB AF Wortzel, Hal S. Oster, Timothy J. Anderson, C. Alan Arciniegas, David B. TI Pathological laughing and crying - Epidemiology, pathophysiology and treatment SO CNS DRUGS LA English DT Review ID SEROTONIN REUPTAKE INHIBITORS; TRAUMATIC BRAIN-INJURY; EMOTIONAL EXPRESSION DISORDER; PSEUDOBULBAR AFFECT; ANTIDEPRESSANT ACTION; CITALOPRAM TREATMENT; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; CONTROLLED-TRIAL; SIGMA-RECEPTORS AB Pathological laughing and crying (PLC) is characterized by frequent, brief, intense paroxysms of uncontrollable crying and/or laughing due to a neurological disorder. When sufficiently frequent and severe, PLC may interfere with the performance of activities of daily living, interpersonal functioning, or both, and is a source of distress for affected patients and their families. PLC is also often misunderstood by patients and their families, and is under-recognized by the clinicians caring for patients with this disorder. However, this syndrome is easily recognized when understood properly and is highly responsive to treatment with a variety of pharmacological agents. This review aims to facilitate the diagnosis and treatment of patients with PLC, and begins by providing definitions of mood and affect that will help clinicians distinguish between mood disorders, such as major depression and mania, and disorders of affect, such as PLC. In addition, the various terms used to describe this syndrome are reviewed and a recommendation for the use of the term PLC is made. The core clinical features of PLC are also presented and the epidemiology of this syndrome is reviewed. A discussion of the pathophysiology of PLC, including the neuroanatomic and neurochemical bases, is provided. Finally, the evaluation and treatment of patients with PLC is described. Based on the pathophysiology of PLC and on a detailed review of published treatment studies, SSRIs are recommended as first-line pharmacotherapy for this disorder. When SSRIs are ineffective or poorly tolerated, other treatment options, including TCAs, noradrenergic reuptake inhibitors, novel antidepressants, dopaminergic agents and uncompetitive NMDA receptor antagonists may be useful second-line treatments. C1 [Wortzel, Hal S.; Oster, Timothy J.; Anderson, C. Alan; Arciniegas, David B.] Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, Denver, CO 80262 USA. [Wortzel, Hal S.; Arciniegas, David B.] HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA. [Wortzel, Hal S.; Anderson, C. Alan; Arciniegas, David B.] Denver Vet Affairs Med Ctr, VISN MIRECC 19, Denver, CO USA. [Oster, Timothy J.; Anderson, C. Alan; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Denver, CO 80262 USA. RP Arciniegas, DB (reprint author), Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, 4200 E Ninth Ave,Campus Box C268-25, Denver, CO 80262 USA. EM David.Arciniegas@UCHSC.edu RI Arciniegas, David/A-3792-2009 NR 110 TC 49 Z9 52 U1 4 U2 20 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1172-7047 J9 CNS DRUGS JI CNS Drugs PY 2008 VL 22 IS 7 BP 531 EP 545 DI 10.2165/00023210-200822070-00001 PG 15 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 322AT UT WOS:000257348300001 PM 18547124 ER PT J AU Sano, M Grossman, H Van Dyk, K AF Sano, Mary Grossman, Hillel Van Dyk, Kathleen TI Preventing Alzheimer's Disease Separating Fact From Fiction SO CNS DRUGS LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; MILD COGNITIVE IMPAIRMENT; LIPID-LOWERING AGENTS; AMYLOID PRECURSOR PROTEIN; MRC/BHF HEART PROTECTION; BETA IMMUNIZATION AN1792; HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; HIGH-RISK INDIVIDUALS AB Alzheimer's disease is an ever-increasing health concern among the aging population, and as we research new and existing treatments for this disease we begin to uncover possibilities for its prevention. Observational studies and animal models have provided promising findings and generated excitement, but placebo-controlled clinical trials are required to demonstrate true efficacy for these treatments. In the past two decades, clinical trials have led to the approval of symptomatic treatments for Alzheimer's disease, including cholinesterase inhibitors and, more recently, an NMDA receptor antagonist. Clinical trials have also examined antioxidants, NSAIDs, hormone replacement, nutritional supplements and non-pharmacological interventions for the treatment and prevention of Alzheimer's disease. While the results of many of these trials have been disappointing, new mechanisms targeting the hallmark pathology of Alzheimer's disease are currently under investigation, including immunotherapy and secretase modulation, targeted at reducing the amyloid burden, for which we await the results. We review the evidence from completed trials, support for ongoing studies and propose directions for future research. C1 [Sano, Mary; Grossman, Hillel; Van Dyk, Kathleen] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, Bronx, NY 10468 USA. [Sano, Mary; Grossman, Hillel; Van Dyk, Kathleen] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Sano, M (reprint author), Mt Sinai Sch Med, Alzheimers Dis Res Ctr, Rm 1F01,130 Kingsbridge Rd, Bronx, NY 10468 USA. EM mary.sano@mssm.edu FU Eisai Pharmaceuticals, Humanetics and Elan; [AG05138]; [AG10483]; [AG15922] FX The authors' work is supported by AG05138, AG10483 and AG15922. Dr Mary Sano has been a consultant to the following companies, which are involved in drug development for Alzheimer's disease: Aventis, Bayer, Forest, Glaxo-SmithKline, Janssen, Ortho-McNeil, Novartis, Pfizer, Bristol-Meyers Squibb, Takeda, Voyager Pharmaceuticals, Medication and Neurochem. These consultancies have been in reference to clinical trial design. Dr Hillel Grossman has been a consultant for the following companies, which are involved in drug development for Alzheimer's disease: Forest Industries and Dainippon America. These consultancies have been in reference to clinical trial design and clinical application. Additionally, Dr Grossman has received research funding from Eisai Pharmaceuticals, Humanetics and Elan. Kathleen van Dyk has no conflicts of interest that are directly relevant to the content of this review. NR 144 TC 14 Z9 14 U1 1 U2 2 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1172-7047 J9 CNS DRUGS JI CNS Drugs PY 2008 VL 22 IS 11 BP 887 EP 902 DI 10.2165/00023210-200822110-00001 PG 16 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 367RK UT WOS:000260569800001 PM 18840031 ER PT J AU Smelson, DA Dixon, L Craig, T Remolina, S Batki, SL Niv, N Owen, R AF Smelson, David A. Dixon, Lisa Craig, Thomas Remolina, Stephen Batki, Steven L. Niv, Noosha Owen, Richard TI Pharmacological Treatment of Schizophrenia and Co-Occurring Substance Use Disorders SO CNS DRUGS LA English DT Review ID PERSISTENT MENTAL-ILLNESS; COCAINE DEPENDENCE; DRUG-ABUSE; ANTIPSYCHOTIC MEDICATIONS; CLINICAL-TRIAL; ALCOHOL-USE; CLOZAPINE; OLANZAPINE; RISPERIDONE; INDIVIDUALS AB Substance abuse among individuals with schizophrenia is common and is often associated with poor clinical outcomes. Comprehensive, integrated pharmacological and psychosocial treatments have been shown to improve these outcomes. While a growing number of studies suggest that second-generation antipsychotic medications may have beneficial effects on the treatment of co-occurring substance use disorders, this review suggests that the literature is still in its infancy. Few existing well controlled trials support greater efficacy of second-generation antipsychotics compared with first-generation antipsychotics or any particular second-generation antipsychotic. This article focuses on and reviews studies involving US FDA-approved medications for co-occurring substance abuse problems among individuals with schizophrenia. Comprehensive treatment for individuals with schizophrenia and co-occurring substance use disorders must include specialized, integrated psychosocial intervention. Most approaches use some combination of cognitive-behavioural therapy, motivational enhancement therapy and assertive case management. The research on antipsychotic and other pharmacological treatments is also reviewed, as well as psychosocial treatments for individuals with schizophrenia and co-occurring substance use disorders, and clinical recommendations to optimize care for this population are offered. C1 [Smelson, David A.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA. [Smelson, David A.] Edith Nourse Rogers Mem Vet Adm Hosp, Dept Vet Affairs, Bedford, MA 01730 USA. [Dixon, Lisa] VISN 4 MIRECC, Dept Vet Affairs, Pittsburgh, PA USA. [Dixon, Lisa] Univ Maryland, Baltimore, MD 21201 USA. [Craig, Thomas] Amer Psychiat Assoc, Arlington, VA USA. [Remolina, Stephen] New Jersey Hlth Care Syst, Dept Vet Affairs, Lyons, NJ USA. [Batki, Steven L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Batki, Steven L.] SUNY Upstate Med Univ, Syracuse, NY USA. [Niv, Noosha] Univ Calif Los Angeles, Los Angeles, CA USA. [Owen, Richard] Cent Arkansas Vet Hlth Care Syst, Ctr Mental Healthcare & Outcomes Res, N Little Rock, AR USA. RP Smelson, DA (reprint author), Univ Massachusetts, Sch Med, Dept Psychiat, 55 Lake Ave N, Worcester, MA 01655 USA. EM David.Smelson@umassmed.edu FU Alkermes, Inc.,; Cephalon, Inc. FX No sources of funding were used to assist in the preparation of this review. Dr David Smelson has received honoraria for consulting for Eli Lilly. Dr Batki has received honoraria and research funding from Alkermes, Inc., and Cephalon, Inc. Neither of these two companies had any input into the preparation of this review, nor did they have a role in reviewing or approving the manuscript. All other authors have no conflicts of interest that are directly relevant to the content of this review. NR 89 TC 11 Z9 12 U1 4 U2 8 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1172-7047 EI 1179-1934 J9 CNS DRUGS JI CNS Drugs PY 2008 VL 22 IS 11 BP 903 EP 916 DI 10.2165/00023210-200822110-00002 PG 14 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 367RK UT WOS:000260569800002 PM 18840032 ER PT J AU Mulrow, CD Chiquette, E Angel, L Grimm, R Cornell, J Summerbell, CD Anagnostelis, BB Brand, M AF Mulrow, Cynthia D. Chiquette, Elaine Angel, L. Grimm, Richard Cornell, John Summerbell, Carolyn D. Anagnostelis, Betsy B. Brand, M. TI Dieting to reduce body weight for controlling hypertension in adults (Withdrawn Paper. 2008, art.no. CD000484) SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Correction C1 [Mulrow, Cynthia D.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. [Chiquette, Elaine] Univ Texas Austin, Coll Pharm, PHR 5 112, Austin, TX 78712 USA. [Angel, L.; Grimm, Richard; Brand, M.] Shapiro Ctr Evidenced Based Med, Minneapolis, MN USA. [Summerbell, Carolyn D.] Univ Teesside, Sch Hlth & Social Care, Middlesbrough, Cleveland, England. [Anagnostelis, Betsy B.] UCL, Royal Free & Univ Coll Med Sch, Med Lib, London, England. RP Mulrow, CD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM mulrowc@uthscsa.edu RI Anagnostelis, Betsy/C-5271-2008 NR 1 TC 5 Z9 5 U1 2 U2 6 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2008 IS 4 AR CD000484 DI 10.1002/14651858.CD000484.pub2 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 358CU UT WOS:000259895000142 PM 18843609 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The communication of palliative care SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 1 EP 19 PG 19 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100003 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI Communication as Comfort Preface SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Editorial Material; Book Chapter ID BREAKING BAD-NEWS; OF-LIFE CARE; TERMINALLY-ILL PATIENTS; PALLIATIVE CARE; CANCER-PATIENTS; SERIOUSLY ILL; CONTROLLED-TRIAL; PATIENTS PERSPECTIVES; MEDICAL-EDUCATION; INCURABLE CANCER C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP VIII EP + PG 16 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100001 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI Communication as Comfort Foreword SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Editorial Material; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP X EP XI PG 2 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100002 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The history and practice of palliative care SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 20 EP 33 PG 14 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100004 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The patient's perspective SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 34 EP 56 PG 23 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100005 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The medical perspective SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 57 EP 86 PG 30 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100006 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The family/caregiver perspective SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 87 EP 107 PG 21 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100007 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The health care team's perspective SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 108 EP 129 PG 22 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100008 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The authors' voices SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 130 EP 148 PG 19 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100009 ER PT J AU Foglia, MB Pearlman, RA AF Foglia, Mary Beth Pearlman, Robert A. BE Ford, PJ Dudzinski, DM TI It's not my responsibility SO COMPLEX ETHICS CONSULTATIONS: CASES THAT HAUNT US LA English DT Article; Book Chapter C1 [Pearlman, Robert A.] Univ Washington, Seattle, WA 98195 USA. [Pearlman, Robert A.] VA Puget Sound Hlth Care Syst, Eth Program, Seattle, WA USA. NR 13 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69715-6 PY 2008 BP 197 EP 204 PG 8 WC Ethics; Medical Ethics SC Social Sciences - Other Topics; Medical Ethics GA BAN43 UT WOS:000304829400027 ER PT J AU Tobin, MJ Jubran, A AF Tobin, Martin J. Jubran, Arnal TI Meta-analysis under the spotlight: Focused on a meta-analysis of ventilator weaning SO CRITICAL CARE MEDICINE LA English DT Article DE meta-analysis; clinical practice guidelines; mechanical ventilation; weaning; systematic error; random error ID PRESSURE SUPPORT VENTILATION; SHALLOW-BREATHING INDEX; MECHANICAL VENTILATION; INSPIRATORY PRESSURE; T-PIECE; SYSTEMATIC REVIEWS; OCCLUSION PRESSURE; ENDOTRACHEAL-TUBE; CLINICAL-TRIALS; EXTUBATION AB Objective. Because the results of a meta-analysis are used to formulate the highest level recommendation in clinical practice guidelines, clinicians should be mindful of problems inherent in this technique. Rather than reviewing meta-analysis in abstract, general terms, we believe readers can gain a more concrete understanding of the problems through a detailed examination of one meta-analysis. The meta-analysis on which we focus is that conducted by an American College of Chest Physicians/American Association for Respiratory Care/American College of Critical Care Medicine Task Force on ventilator weaning. Data Source: Two authors extracted data from all studies included in the Task Force's meta-analysis. Data Synthesis and Overview: The major obstacle to reliable internal validity and, thus, reliable external validity (generalizability) in biological research is systematic error, not random error. If systematic errors are present, averaging (as with a meta-analysis) does not decrease them-instead, it reinforces them, producing artifact. The Task Force's meta-analysis commits several examples of the three main types of systematic error: selection bias (test-referral bias, spectrum bias), misclassification bias (categorizing reintubation as weaning failure, etc.), and confounding (pressure support treated as unassisted breathing). Several additional interpretative errors are present. Conclusions. An increase in study size, as achieved through the pooling of data in a meta-analysis, is mistakenly thought to increase external validity. On the contrary, combining heterogeneous studies poses considerable risk of systematic error, which impairs internal validity and, thus, external validity. The strength of recommendations in clinical practice guidelines is based on a misperception of the relative importance of systematic vs. random error in science. C1 [Tobin, Martin J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Hines, IL USA. RP Tobin, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM mtobin2@lumc.edu FU NINR NIH HHS [R01 NR008782] NR 70 TC 47 Z9 48 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JAN PY 2008 VL 36 IS 1 BP 1 EP 7 DI 10.1097/01.CCM.0000297883.04634.11 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 291YA UT WOS:000255232100001 PM 18007269 ER PT J AU Mendez, MF Shapira, JS Woods, RJ Licht, EA Saul, RE AF Mendez, Mario F. Shapira, Jill S. Woods, Rochelle J. Licht, Eliot A. Saul, Ronald E. TI Psychotic symptoms in frontotemporal dementia: Prevalence and review SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE frontotemporal dementia; psychosis; delusions; hallucinations; paranoia; Alzheimer's disease ID FRONTAL-LOBE DEGENERATION; NON-ALZHEIMER TYPE; PICKS-DISEASE; NEUROPSYCHIATRIC FEATURES; SPECT CHARACTERISTICS; TEMPORAL VARIANTS; CLINICAL PICTURE; WORK GROUP; SCHIZOPHRENIA; DIAGNOSIS AB Background/Aims: Although most patients with frontotemporal dementia (FTD) present with neuropsychiatric symptoms, the frequency of psychotic symptoms is unclear. This study aims to determine the prevalence of psychotic symptoms in a large cohort of well-diagnosed and followed FTD patients compared to age-matched patients with Alzheimer's disease (AD) and to further review the literature on psychosis in FTD. Methods: Delusions, hallucinations and paranoia were evaluated among 86 patients who met consensus criteria for FTD, had frontotemporal changes on functional neuroimaging and were followed for 2 years. They were compared to 23 patients with early-onset AD on a caregiver-administered psychiatric questionnaire. Results: Among the FTD patients, only 2 (2.3%) had delusions, 1 of whom had paranoid ideation; no FTD patient had hallucinations. This was significantly less than the AD patients, 4 (17.4%) of whom had delusions and paranoia. Other investigations fail to establish a significant association of psychosis with FTD. Conclusions: These findings, and a literature review, indicate that psychotic symptoms are rare in FTD, possibly due to limited temporal-limbic involvement in this disorder. Copyright (c) 2008 S. Karger AG, Basel. C1 [Mendez, Mario F.; Woods, Rochelle J.; Licht, Eliot A.; Saul, Ronald E.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA 90073 USA. [Mendez, Mario F.; Shapira, Jill S.; Woods, Rochelle J.; Licht, Eliot A.; Saul, Ronald E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, 116AF,Bldg 500,3S,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu NR 48 TC 46 Z9 48 U1 2 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2008 VL 25 IS 3 BP 206 EP 211 DI 10.1159/000113418 PG 6 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 271GS UT WOS:000253777500002 PM 18204254 ER PT J AU Ringman, JM Romano, JD Medina, LD Rodriguez-Agudelo, Y Schaffer, B Varpetian, A Ortiz, F Fitten, LJ Cummings, JL Baloh, RW AF Ringman, John M. Romano, Joseph D. Medina, Luis D. Rodriguez-Agudelo, Yaneth Schaffer, Barbara Varpetian, Arousiak Ortiz, Freddy Fitten, L. Jamie Cummings, Jeffrey L. Baloh, Robert W. TI Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE familial Alzheimer's disease; headache; migraine; presenilin-1; amyloid precursor protein; Notch3; amyloid angiopathy ID CEREBRAL AMYLOID ANGIOPATHY; PRECURSOR PROTEIN GENE; PRESENILIN-1 MUTATION; SPASTIC PARAPARESIS; PS-1 MUTATIONS; SPECTRUM; DEPOSITION; MIGRAINE; FEATURES AB Background/Aims: A previous study found a high prevalence of headaches in persons with familial Alzheimer's disease (FAD) due to a PSEN1 mutation. In our study we compared the prevalence of headaches between nondemented FAD mutation carriers (MCs) and non-mutation-carrying controls (NCs). Methods: A headache questionnaire that assessed the prevalence of significant headaches and diagnosis of migraine and aura by ICHD-2 criteria was administered to 27 individuals at risk for FAD. Frequency of significant headaches, migraine, and aura were compared between MCs and NCs by chi(2) or Fisher's exact tests. Results: Twenty-three subjects were at risk for PSEN1 mutations and 4 for an APP substitution. The majority of subjects were female (23/27). MCs were more likely to report significant recurrent headache than NCs (67 vs. 25%, p = 0.031). Forty percent of MCs had headaches that met criteria for migraine whereas 17% of NCs met such criteria. The tendency for a higher prevalence of headaches in MCs held for different PSEN1 and APP mutations but was not significant unless all families were combined. Conclusions: In this population, headache was more common in nondemented FAD MCs than NCs. Possible mechanisms for this include cerebral inflammation, aberrant processing of Notch3, or disrupted intracellular calcium regulation. Copyright (C) 2008 S. Karger AG, Basel. C1 [Ringman, John M.; Medina, Luis D.; Schaffer, Barbara; Ortiz, Freddy; Fitten, L. Jamie; Cummings, Jeffrey L.] Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA. [Ortiz, Freddy; Fitten, L. Jamie] Univ Calif Los Angeles, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90095 USA. [Cummings, Jeffrey L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Varpetian, Arousiak] USC, Rancho Los Amigos Natl Rehabilitat Ctr, Keck Sch Med, Dept Neurol, Downey, CA USA. [Ortiz, Freddy; Fitten, L. Jamie] Olive View UCLA Med Ctr, Neuropsychiat Res Memory Clin, Sylmar, CA 91342 USA. [Romano, Joseph D.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA. [Rodriguez-Agudelo, Yaneth] Natl Inst Neurol & Neurosurg, Dept Neuropsychol, Mexico City, DF, Mexico. RP Ringman, JM (reprint author), Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Dept Neurol, 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90095 USA. EM jringman@mednet.ucla.edu FU NCRR NIH HHS [M01-RR00865]; NIA NIH HHS [R01 AG-21055, P50 AG-16570, K08 AG-22228] NR 28 TC 8 Z9 8 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2008 VL 25 IS 4 BP 380 EP 384 DI 10.1159/000121986 PG 5 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 289UD UT WOS:000255078500013 PM 18376127 ER PT J AU Beeri, MS Silverman, JM Schmeidler, J Wysocki, M Grossman, HZ Purohit, DP Perl, DP Haroutunian, V AF Beeri, Michal Schnaider Silverman, Jeremy M. Schmeidler, James Wysocki, Michael Grossman, Hillel Z. Purohit, Dushyant P. Perl, Daniel P. Haroutunian, Vahram TI Clinical dementia rating performed several years prior to death predicts regional Alzheimer's neuropathology SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE dementia severity; Alzheimer's disease; neuropathology; neuritic plaques; neurofibrillary tangles ID MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLES; ENTORHINAL CORTEX; SENILE PLAQUES; DISEASE; RELIABILITY; DECLINE; CA1 AB Aims: To assess the relationships between early and late antemortem measures of dementia severity and Alzheimer disease ( AD) neuropathology severity. Methods: 40 residents of a nursing home, average age at death 82.0, participated in this longitudinal cohort study with postmortem assessment. Severity of dementia was measured by Clinical Dementia Rating ( CDR) at two time points, averaging 4.5 and 1.0 years before death. Densities of postmortem neuritic plaques ( NPs) and neurofibrillary tangles ( NFTs) were measured in the cerebral cortex, hippocampus, and entorhinal cortex. Results: For most brain areas, both early and late CDRs were significantly associated with NPs and NFTs. CDRs assessed proximal to death predicted NFTs beyond the contribution of early CDRs. NPs were predicted by both early and late CDRs. NPs were predictive of both early and late CDRs after controlling for NFTs. NFTs were only associated significantly with late CDR in the cerebral cortex after controlling for NPs. Conclusions: Even if assessed several years before death, dementia severity is associated with AD neuropathology. NPs are more strongly associated with dementia severity than NFTs. NFTs consistently associate better with late than early CDR, suggesting that these neuropathological changes may occur relatively later in the course of the disease. Copyright (c) 2008 S. Karger AG, Basel. C1 [Beeri, Michal Schnaider; Silverman, Jeremy M.; Schmeidler, James; Wysocki, Michael; Grossman, Hillel Z.; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Purohit, Dushyant P.; Perl, Daniel P.] Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA. [Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Psychiat Serv, Bronx, NY USA. RP Beeri, MS (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA. EM michal.beeri@mssm.edu NR 28 TC 3 Z9 3 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2008 VL 25 IS 5 BP 392 EP 398 DI 10.1159/000122586 PG 7 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 289UG UT WOS:000255078800002 ER PT J AU Dombrovski, AY Cyranowski, JM Mulsant, BH Houck, PR Buysse, DJ Andreescu, C Thase, ME Mallinger, AG Frank, E AF Dombrovski, Alexandre Y. Cyranowski, Jill M. Mulsant, Benoit H. Houck, Patricia R. Buysse, Daniel J. Andreescu, Carmen Thase, Michael E. Mallinger, Alan G. Frank, Ellen TI WHICH SYMPTOMS PREDICT RECURRENCE OF DEPRESSION IN WOMEN TREATED WITH MAINTENANCE INTERPERSONAL PSYCHOTHERAPY? SO DEPRESSION AND ANXIETY LA English DT Article DE depressive disorder; depressive symptoms; sleep initiation and maintenance disorders; sleep; anxiety; recurrence ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; CHRONIC PRIMARY INSOMNIA; MAJOR DEPRESSION; RESIDUAL SYMPTOMS; SECONDARY INSOMNIA; SLEEP DISTURBANCE; ELDERLY-PATIENTS; DOUBLE-BLIND; RISK-FACTOR AB Background: Even low levels of residual symptoms are known to increase the risk of relapse and early recurrence of major depression. It is not known if ongoing psychotherapy lessens this risk. We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression. Methods: We analyzed data on 131 women aged 20-60 from a 2-year randomized trial of weekly versus twice-monthly versus monthly IPT-M. Participants achieved remission with IPT alone (n = 99) or IPT plus sequential antidepressant medication (n = 32). Medications were tapered before starting maintenance treatment. Residual symptoms were assessed with the Hamilton Rating Scale for Depression (HRSD; total score and subscales); insomnia was also assessed in 76 women with the Pittsburgh Sleep Quality Index (PSQI). Data analyses used Cox proportional hazards regression models. Results: Neither overall burden of residual symptoms (HRSD total score), nor HRSD mood and anxiety subscale scores predicted recurrence during ongoing IPT-M. In contrast, persistent insomnia measured both by the HRSD-17 insomnia subscale and the PSQI predicted recurrence. Women with persistent insomnia who required sequential pharamacotherapy had the highest recurrence rate (65%) compared to women requiring sequential treatment without insomnia (13%), or women who had recovered with IPT alone but had persistent insomnia (21%) or no insomnia. (18%). Conclusions: Persistent insomnia following the recovery from an episode of recurrent major depression is associated with increased risk of recurrence despite maintenance psychotherapy, particularly for those withdrawn from antidepressant medication. Depression and Anxiety 25:1060-1066, 2008. (C) 2008 Wiley-Liss, Inc. C1 [Dombrovski, Alexandre Y.; Cyranowski, Jill M.; Mulsant, Benoit H.; Houck, Patricia R.; Buysse, Daniel J.; Andreescu, Carmen; Thase, Michael E.; Mallinger, Alan G.; Frank, Ellen] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Mulsant, Benoit H.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M5S 1A1, Canada. [Thase, Michael E.] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada. [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Mallinger, Alan G.] Natl Inst Hlth Intramural Res Program, Mood & Anxiety Disorders Program, Bethesda, MD USA. RP Cyranowski, JM (reprint author), 100 N Bellefield St,852 Bellefield Towers, Pittsburgh, PA 15213 USA. EM cyranowskijm@upmc.edu RI Andreescu, Carmen/J-2379-2016 OI Dombrovski, Alexandre/0000-0002-2054-4772 FU NIMH NIH HHS [MH030915, P30 MH030915, R01 MH049115-08, R01 MH49115, MH049115] NR 57 TC 38 Z9 42 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 12 BP 1060 EP 1066 DI 10.1002/da.20467 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 382HO UT WOS:000261597000010 PM 18781665 ER PT J AU Utzschneider, KM Tong, J Montgomery, B Udayasankar, J Gerchman, F Marcovina, SM Watson, CE Ligueros-Saylan, MA Foley, JE Holst, JJ Deacon, CF Kahn, SE AF Utzschneider, Kristina M. Tong, Jenny Montgomery, Brenda Udayasankar, Jayalakshmi Gerchman, Fernando Marcovina, Santica M. Watson, Catherine E. Ligueros-Saylan, Monica A. Foley, James E. Holst, Jens J. Deacon, Carolyn F. Kahn, Steven E. TI The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose SO DIABETES CARE LA English DT Article ID GLUCAGON-LIKE PEPTIDE-1; IV INHIBITOR; GLYCEMIC CONTROL; TYPE-2; TOLERANCE; INCREASES; LAF237; MODEL AB OBJECTIVE - To evaluate the effect of treatment with the dipeptidyl peptidase (DPP)-4 inhibitor vildagliptin on insulin sensitivity and beta-cell function in subjects with impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS - A total of 22 subjects with IFG (11 female and 11 male, mean +/- SD age 59.6 +/- 11.5 years) were treated orally with 100 mg vildagliptin once daily in a single-blind study. Subjects received placebo for 2 weeks (run-in) followed by vildagliptin for 6 weeks (treatment) and then placebo for 2 weeks (washout). A frequently sampled intravenous glucose tolerance test (FSIGT), followed by a 2-h meal tolerance test (MTT), was performed at 2, 8, and 10 weeks. From the FSIGT, the acute insulin response to glucose (AIR(g)) and insulin sensitivity index (S) were determined and used to compute the disposition index (AIRg X S,) as a measure of beta-cell function. RESULTS - Fasting plasma glucose did not change after 6 weeks of vildagliptin treatment. With treatment, mean +/- SEM AIR(g) increased from 224 +/- 44 to 286 +/- 52 pmol/1(P < 0.05), and S, improved from 2.8 +/- 0.5 to 3.5 0.5 X 10(-5) - min(-1). pmol(-1) center dot 1 (P < 0.01), resulting in an increase in the disposition index from 688 +/- 180 to 1,164 +/- 318 X 10(-5)/min (P < 0.05). These effects were not sustained after washout. During the MTT, the incremental area under the glucose curve was significantly decreased after treatment (240 +/- 15 vs. 191 +/- 14 mmol center dot 1(-1) min-1; P = 0.002), but this effect was not sustained after washout. CONCLUSIONS - The DPP-4 inhibitor vildagliptin improves insulin sensitivity and P-cell function, leading to improved postprandial glycemia in subjects with IFG, who are known to have beta-cell dysfunction. Thus, vildagliptin may prevent progression to diabetes in high-risk subjects. C1 [Utzschneider, Kristina M.; Tong, Jenny; Montgomery, Brenda; Udayasankar, Jayalakshmi; Gerchman, Fernando; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Utzschneider, Kristina M.; Tong, Jenny; Montgomery, Brenda; Udayasankar, Jayalakshmi; Gerchman, Fernando; Kahn, Steven E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Marcovina, Santica M.] Univ Washington, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Watson, Catherine E.] Novartis Inst Biomed Res, Cambridge, MA USA. [Ligueros-Saylan, Monica A.; Foley, James E.] Novartis Pharmaceut, E Hanover, NJ USA. [Holst, Jens J.; Deacon, Carolyn F.] Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen, Denmark. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu OI Holst, Jens Juul/0000-0001-6853-3805 FU NIDDK NIH HHS [DK-17047] NR 20 TC 75 Z9 79 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2008 VL 31 IS 1 BP 108 EP 113 DI 10.2337/dc07-1441 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 248TQ UT WOS:000252178900026 PM 17909087 ER PT B AU Boucher, HW Patterson, TF AF Boucher, Helen W. Patterson, Thomas F. BE Hospenthal, DR Rinaldi, MG TI Aspergillosis SO DIAGNOSIS AND TREATMENT OF HUMAN MYCOSES SE Infectious Disease LA English DT Article; Book Chapter ID INVASIVE PULMONARY ASPERGILLOSIS; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; LIPOSOMAL AMPHOTERICIN-B; CELL TRANSPLANT RECIPIENTS; POLYMERASE-CHAIN-REACTION; GUINEA-PIG MODEL; BETA-D-GLUCAN; FUNGAL-INFECTIONS; ANTIFUNGAL THERAPY; IN-VITRO C1 [Boucher, Helen W.] Tufts Univ, New England Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02111 USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Boucher, HW (reprint author), Tufts Univ, New England Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02111 USA. NR 84 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-822-5 J9 INFECT DIS PY 2008 BP 181 EP 199 DI 10.1007/978-1-59745-325-7_9 D2 10.1007/978-1-59745-325-7 PG 19 WC Immunology; Infectious Diseases; Mycology; Virology SC Immunology; Infectious Diseases; Mycology; Virology GA BKK77 UT WOS:000268394800009 ER PT J AU El-Serag, HB AF El-Serag, Hashem B. TI Epidemiology of non-erosive reflux disease SO DIGESTION LA English DT Article; Proceedings Paper CT Nerd Task Force - Overview and Consensus Meeting CY NOV 30-DEC 02, 2007 CL Vevey, SWITZERLAND DE non-erosive reflux disease, epidemiology; gastroesophageal reflux disease; epidemiological studies; temporal trends ID GASTROESOPHAGEAL-REFLUX; EROSIVE ESOPHAGITIS; RISK-FACTORS; PREVALENCE; POPULATION; SYMPTOMS AB Non-erosive reflux disease (NERD) is a relatively new entity, the definition of which has been evolving and involves the use of symptoms, endoscopy, and objective evidence of reflux or reflux-related damage. The closest entity to NERD that is examined by available epidemiologic studies is defined by the presence of gastroesophageal reflux disease (GERD) symptoms in the absence of esophageal erosions or Barrett's esophagus. In this review, I identified two populationbased studies, one non-community study, and several endoscopy-based studies that provided information on several aspects of NERD. Most of GERD is NERD (50-85%), and therefore one can estimate 11-12% of the general pop ulation and considerably higher proportions of patients presenting to endoscopy (37-87%) may have NERD. Risk factors for NERD including absence of hiatus hernia, low BMI, and presence of Helicobacter pylori indicate that it is a 'milder' part of the GERD spectrum. Other associations of NERD include younger age, female sex, and psychological comorbidities that resemble those of functional gut disorders. The temporal trends in NERD are unclear, and are probably increasing because GERD symptom prevalence has increased. Copyright (C) 2008 S. Karger AG, Basel. C1 [El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [El-Serag, Hashem B.] Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.edu NR 13 TC 34 Z9 36 U1 1 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0012-2823 J9 DIGESTION JI Digestion PY 2008 VL 78 SU 1 BP 6 EP 10 DI 10.1159/000151249 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 356WK UT WOS:000259808100002 PM 18832834 ER PT J AU Graham, DY Lu, H Yamaoka, Y AF Graham, David Y. Lu, Hong Yamaoka, Yoshio TI Therapy for Helicobacter pylori infection can be improved - Sequential therapy and beyond SO DRUGS LA English DT Article ID PROTON-PUMP INHIBITOR; 7-DAY TRIPLE-THERAPY; QUADRUPLE THERAPY; DUAL THERAPY; DOUBLE-BLIND; ANTIBIOTIC-RESISTANCE; UNITED-STATES; CURE RATE; ANTIMICROBIAL SUSCEPTIBILITY; CYP2C19 POLYMORPHISM AB As with other bacterial infections, successful treatment of Helicobacter pylori infections depends on the use of antibacterial agents to which the organism is susceptible. In this article, we use the proposed report card grading scheme (i.e. grade A, B, C, D, F) for the outcome of clinical trials, where intention-to-treat cure rates > 95% = A, 90-95% = B, 85-89% = C, 81-84% = D and < 81% = F. The goal of therapy is to consistently cure >95% of patients (e.g. provide grade A results). Like tuberculosis, H. pylori infections are difficult to cure and successful treatment generally requires the administration of several antibacterial agents simultaneously. Duration of therapy is also important and depends upon whether resistance is present; 14 days is often best. With few exceptions, worldwide increasing macrolide resistance now undermines the effectiveness of the legacy triple therapy (e.g. a proton pump inhibitor [PPI], clarithromycin and amoxicillin) and, in most areas, cure rates have declined to unacceptable levels (e.g. grade F). The development of sequential therapy was one response to this problem. Sequential therapy has repeatedly been shown in head-to-head studies to be superior to legacy triple therapy. Sequential therapy, as originally described, is the sequential administration of a dual therapy (a PPI plus amoxicillin) followed by a Bazzoli-type triple therapy (a PPI plus clarithromycin and tinidazole) and has been shown to be especially useful where there is clarithromycin resistance. However, the cure rates of the original sequential treatment are grade B and can probably be further improved by changes in dose, duration or administration, such as by continuing the amoxicillin into the triple therapy arm. The sequential approach may also be more complicated than necessary, based on the fact that the same four drugs have also been given concomitantly (at least nine publications with > 700 patients) as a quadruple therapy with excellent success. This article discusses the approach to therapy in the modem era where antimicrobial resistance is an increasing problem and legacy triple therapy is no longer an acceptable initial choice. Methods to achieve acceptable eradication rates (e.g. grade A or B results) are discussed and, specifically, sequential therapy is considered both conceptually and practically. Suggestions are provided regarding how sequential therapy might be improved to become a grade A therapy as well as how to identify situations where it can be expected to yield unacceptable results. New uses for current drugs are discussed and suggestions for subsequent randomized comparisons to overcome phenotypic and genotypic resistance are given. We propose a change in focus from comparative studies (designed to prove that a new therapy is superior to a known inferior therapy) to demanding that efficacious therapies meet or exceed a pre-specified level of success (i.e. grade A or B result). To do so, coupled with less concern about the effect of recommendations on the pharmaceutical industry, should provide clinicians with much higher quality information, and improve the quality of medical care and recommendations regarding treatment. Ultimately, there is little or no justification for comparative testing that includes an arm with known unacceptably low results. H. pylori gastritis is an infectious disease and should be approached and treated as such. C1 [Graham, David Y.; Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Graham, David Y.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Lu, Hong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Dis, Renji Hosp,Dept Gastroenterol, Shanghai 200030, Peoples R China. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-320,111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU NIDDK NIH HHS [DK56338] NR 80 TC 58 Z9 62 U1 0 U2 3 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0012-6667 J9 DRUGS JI Drugs PY 2008 VL 68 IS 6 BP 725 EP 736 DI 10.2165/00003495-200868060-00001 PG 12 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 296GQ UT WOS:000255531900001 PM 18416582 ER PT J AU Kovacs, TOG Jensen, DM AF Kovacs, Thomas O. G. Jensen, Dennis M. TI The Short-Term Medical Management of Non-Variceal Upper Gastrointestinal Bleeding SO DRUGS LA English DT Article ID PROTON-PUMP INHIBITORS; CONTINUOUS INTRAVENOUS-INFUSION; PEPTIC-ULCER HEMORRHAGE; INTRAGASTRIC PH; HIGH-RISK; ENDOSCOPIC HEMOSTASIS; ADHERENT CLOTS; LANSOPRAZOLE REGIMENS; COST-EFFECTIVENESS; RANDOMIZED-TRIAL AB Upper gastrointestinal (UGI) bleeding occurs frequently and results in substantial patient morbidity, mortality and medical expense. After initial resuscitation to stabilize the patient, carefully performed endoscopy provides an accurate diagnosis and can identify high-risk subgroups in ulcer patients who are likely to rebleed with medical therapy alone and would benefit most from endoscopic haemostasis. Several different pharmacological therapies have been used for patients with bleeding ulcers, including intravenous histamine H(2)-receptor antagonists, proton pump inhibitors, somatostatin and octreotide, and tranexamic acid. The results of several studies and meta-analyses favour high-dose, intravenous proton pump inhibitors, such as omeprazole or pantoprazole, after successful endoscopic haemostasis. For patients with ulcer bleeding and low-risk endoscopic stigmata, high-dose oral proton pump inhibitor therapy is suggested. Medical management with proton pump inhibitors is not a substitute for appropriate endoscopic therapy for patients with UGI bleeding and high-risk ulcer stigmata. C1 [Kovacs, Thomas O. G.; Jensen, Dennis M.] VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. RP Kovacs, TOG (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 212,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM tkovacs@mednet.ucla.edu NR 48 TC 6 Z9 7 U1 1 U2 2 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0012-6667 J9 DRUGS JI Drugs PY 2008 VL 68 IS 15 BP 2105 EP 2111 DI 10.2165/00003495-200868150-00003 PG 7 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 373IK UT WOS:000260965100003 PM 18840002 ER PT J AU Kasckow, JW Zisook, S AF Kasckow, John W. Zisook, Sidney TI Co-occurring depressive symptoms in the older patient with schizophrenia SO DRUGS & AGING LA English DT Review ID INTENSIVE CASE-MANAGEMENT; QUALITY-OF-LIFE; ELDERLY-PATIENTS; ATYPICAL ANTIPSYCHOTICS; PSYCHOTIC DEPRESSION; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; MAJOR DEPRESSION; BIPOLAR DISORDER; LONG-TERM AB Clinicians treating older patients with schizophrenia are often challenged by patients presenting with both depressive and psychotic features. The presence of co-morbid depression impacts negatively on quality of life, functioning, overall psychopathology and the severity of co-morbid medical conditions. Depressive symptoms in patients with schizophrenia include major depressive episodes (MDEs) that do not meet criteria for schizoaffective disorder, MDEs that occur in the context of schizoaffective disorder and subthreshold depressive symptoms that do not meet criteria for MDE. Pharmacological treatment of patients with schizophrenia and depression involves augmenting antipsychotic medications with anti depressants. Recent surveys suggest that clinicians prescribe antidepressants to 30% of inpatients and 43% of outpatients with schizophrenia and depression at all ages. Recent trials addressing the efficacy of this practice have evaluated selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, fluvoxamine and citalopram. These trials have included only a small number of Subjects and few older Subjects participated; furthermore. the efficacy results have been mixed. Although no published controlled psychotherapeutic studies have specifically targeted major depression or depressive symptoms in older patients with schizophrenia, psychosocial interventions likely play a role in any comprehensive management plan in this population of patients. Our recommendations for treating the older patient with schizophrenia and major depression involve a stepwise approach. First, a careful diagnostic assessment to rule out medical or medication causes is important as well as checking whether patients are adherent to treatments. Clinicians should also consider switching patients to an atypical antipsychotic if they are not taking one already. In addition, dose optimization needs to be targeted towards depressive as well as positive and negative psychotic symptoms. If major depression persists, adding an SSRI is a reasonable next step; one needs to start with a low dose and then cautiously titrate upward to reduce depressive symptoms. If remission is not achieved after an adequate treatment duration (8-12 weeks) or with an adequate close (similar to that used for major depression without schizophrenia), switching to another agent or adding augmenting therapy is recommended. We recommend treating an acute first episode of depression for at least 6-9 months and consideration of longer treatment for patients with residual symptoms, very severe or highly co-morbid major depression, ongoing episodes or recurrent episodes. Psychosocial interventions aimed at improving adherence, quality of life and function are also recommended. For patients with schizophrenia and subsyndromal depression, a similar approach is recommended. Psychosis accompanying major depression in patients without schizophrenia is common in elderly patients and is considered a primary mood disorder; for these reasons, it is an important syndrome to consider in the differential diagnosis of older patients with mood and thought disturbance. Treatment for this condition has involved electroconvulsive therapy (ECT) as well as combinations of antidepressant and antipsychotic medications. Recent evidence suggests that combination treatment may not be any more effective than antidepressant treatment alone and ECT may be more efficacious overall. C1 [Kasckow, John W.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15206 USA. [Kasckow, John W.] Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Zisook, Sidney] VA San Diego Healthcare Syst, San Diego, CA USA. RP Kasckow, JW (reprint author), VA Pittsburgh Hlth Care Syst, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM kasckowjw@upmc.edu FU Mental Illness Research, Education and Clinical Centers; University of California; San Diego Center; Aspect Medical Systems; PamLab; National Institute of Mental Health; [MH063931]; [MH6398]; [VISN 222] FX This work was supported by MH063931 (SZ), MH6398 (JK), the Veterans Integrated Services Network (VISN) 4 (JK) and VISN 222 (SZ) Mental Illness Research, Education and Clinical Centers. and the University of California, San Diego Center for Community-based Research in Older People with Psychoses (SZ). John Kasckow has acted as a consultant for. received honoraria from. and been a recipient of grant Support from Forest, Pfizer, AstraZeneca. Lilly, Bristol-Myers Squibb, and Johnson and Johnson. Sidney Zisook is a consultant for GlaxoSmithKline, has received honoraria from GlaxoSmith Kline, Forest, Pfizer. Wyeth and Eli Lilly, and has received grant support from Aspect Medical Systems, PamLab and the National Institute of Mental Health. NR 115 TC 20 Z9 23 U1 4 U2 14 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-229X J9 DRUG AGING JI Drugs Aging PY 2008 VL 25 IS 8 BP 631 EP 647 PG 17 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 342BE UT WOS:000258758800002 PM 18665657 ER PT J AU Delgado-Escueta, AV Bourgeois, BFD AF Delgado-Escueta, Antonio V. Bourgeois, Blaise F. D. TI Debate: Does genetic information in humans help us treat patients? SO EPILEPSIA LA English DT Article ID SEVERE MYOCLONIC EPILEPSY; FEBRILE SEIZURES PLUS; UNVERRICHT-LUNDBORG-DISEASE; CHILDHOOD ABSENCE EPILEPSY; TONIC-CLONIC SEIZURES; CHANNEL ALPHA-1-SUBUNIT MUTATIONS; NEURONAL SODIUM-CHANNEL; OF-FUNCTION MUTATION; DE-NOVO MUTATIONS; CYSTATIN-B GENE AB In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely ( 1) SCNIA, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); ( 2) laforin ( dual specificity protein phosphatase) and malin ( ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy ( PME); and ( 3) cystatin B in Unverricht-Lundborg type of PME. Laforin, malin, and cystatin B are non-ion channel gene mutations that cause PME. Genotyping ensures accurate diagnosis, helps treatment and genetic counseling, psychological and social help for patients and families, and directs families to organizations devoted to finding cures for specific epilepsy diseases. In SCN1A and cystatin B mutations, treatment with sodium channel blockers ( phenytoin, carbamazepine, oxcarbazepine, lamotrigine) should be avoided. Because of early and correct diagnosis by genotyping of SCN1A mutations, the avoidance of sodium channel blockers, and aggressive treatment of prolonged convulsive status, there is hope that Dravet's syndrome may not be as severe as observed in all past reports. Genotyping also identifies nonsense mutations in Lafora PME. Nonsense mutations can be corrected by premature stop codon readthrough drugs such as gentamicin. The community practitioner together with epilepsy specialists in PME can work together and acquire gentamicin (Barton-Davis et al., 1999) for compassionate use'' in Lafora PME, a generalized lysosome multiorgan storage disorder that is invariably fatal. In Unverricht-Lundborg PME, new cohorts with genotyped cystatin B mutations have led to the chronic use of antioxidant N-acetylcysteine and combination valproate clobazam or clonazepam plus antimyoclonic drugs topiramate, zonisamide, piracetam, levetiracetam, or brivaracetam. These cohorts have minimal ataxia and no dementia, questioning whether the syndrome is truly progressive. In conclusion, not only is genotyping a prerequisite in the diagnosis of Dravet's syndrome and the progressive myoclonus epilepsies, but it also helps us choose the correct antiepileptic drugs to treat seizures in Dravet's syndrome and Unverricht-Lundborg PME. Genotyping also portends a brighter future, helping us to reassess the true course, severity, and progressive nature of Dravet's syndrome and Unverricht-Lundborg PME and helping us craft a future curative treatment for Dravet's syndrome and Lafora disease. Without the genotyping diagnosis of epilepsy causing mutations we are stuck with imprecise diagnosis and symptomatic treatment of seizures. C1 [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Epilepsy Genet Genom Labs, Los Angeles, CA 90073 USA. [Bourgeois, Blaise F. D.] Harvard Univ, Sch Med, Boston, MA USA. [Bourgeois, Blaise F. D.] Childrens Hosp, Div Epilepsy & Clin Neurophysiol, Boston, MA 02115 USA. RP Delgado-Escueta, AV (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Epilepsy Genet Genom Labs, Los Angeles, CA 90073 USA. EM escueta@ucla.edu FU NINDS NIH HHS [R01 NS055057] NR 90 TC 23 Z9 24 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 13 EP 24 DI 10.1111/j.1528-1167.2008.01922.x PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA 392DK UT WOS:000262282900004 PM 19087113 ER PT J AU Hoef, LV AF Hoef, Lawrence Ver TI EFFECT OF SPIKE DETECTION PARAMETERS ON THE EFFECTIVENESS OF SPIKE DETECTION SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Hoef, Lawrence Ver] Univ Alabama, UAB Epilepsy Ctr, Birmingham, AL USA. [Hoef, Lawrence Ver] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 26 EP 26 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600058 ER PT J AU Nguyen, VHV Dergalust, S AF Nguyen, Viet-Huong V. Dergalust, S. TI RETROSPECTIVE CHART REVIEW OF ANTIEPILEPTIC DRUG (AED) MONOTHERAPY IN VETERAN PATIENTS WITH EPILEPSY SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Nguyen, Viet-Huong V.; Dergalust, S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 54 EP 54 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600125 ER PT J AU Shareef, AH Patil, VK AF Shareef, Aisha H. Patil, Vijaya K. TI LEVETIRACETAM MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES: A RETROSPECTIVE ANALYSIS OF A VA POPULATION SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Shareef, Aisha H.; Patil, Vijaya K.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Shareef, Aisha H.; Patil, Vijaya K.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 65 EP 65 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600149 ER PT J AU Van Cott, AC Cramer, J Dersh, JJ Zeber, J Mortensen, E Copeland, LA Steinman, M Glickman, M Pugh, M AF Van Cott, Anne C. Cramer, Joyce Dersh, J. J. Zeber, John Mortensen, E. Copeland, Laurel A. Steinman, M. Glickman, M. Pugh, M. TI SUICIDE IN OLDER VETERANS TREATED WITH ANTIEPILEPTIC DRUGS SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Van Cott, Anne C.] VA Pittsburgh Healthcare Syst, Div Neurol, Pittsburgh, PA USA. [Van Cott, Anne C.] Univ Pittsburgh, Pittsburgh, PA USA. [Cramer, Joyce] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Dersh, J. J.] S Texas Vet Hlth Care Syst, Spinal Cord Injury Unit, Dept Vet Affairs, San Antonio, TX USA. [Zeber, John; Mortensen, E.; Copeland, Laurel A.; Pugh, M.] S Texas Vet Hlth Care Syst, VERDICT HSR& D, Dept Vet Affairs, San Antonio, TX USA. [Zeber, John; Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Mortensen, E.; Pugh, M.] Univ Texas Hlth Sci Ctr San Antonio, Div Med, San Antonio, TX 78229 USA. [Steinman, M.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Steinman, M.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Glickman, M.] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Glickman, M.] Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 69 EP 69 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600160 ER PT J AU Salinsky, MC Munoz, S Storzbach, D AF Salinsky, Martin C. Munoz, S. Storzbach, D. TI PREGABALIN EFFECTS ON THE EEG AND COGNITION: A RANDOMIZED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERS SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Salinsky, Martin C.; Munoz, S.; Storzbach, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Salinsky, Martin C.; Munoz, S.; Storzbach, D.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 139 EP 140 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600319 ER PT J AU Wyeth, MS Zhang, N Huang, CS Houser, CR AF Wyeth, Megan S. Zhang, N. Huang, C. S. Houser, C. R. TI SELECTIVE LOSS OF CHOLECYSTOKININ INNERVATION OF PYRAMIDAL CELL BODIES IN A MODEL OF SPONTANEOUS SEIZURES SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Wyeth, Megan S.; Zhang, N.; Huang, C. S.; Houser, C. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Huang, C. S.; Houser, C. R.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 170 EP 171 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600393 ER PT J AU Spencer, DC Snodgrass, M Salinsky, M AF Spencer, David C. Snodgrass, M. Salinsky, M. TI SURFACE EEG IN PURE MEDIAL TEMPORAL EPILEPSY SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Spencer, David C.; Snodgrass, M.; Salinsky, M.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Spencer, David C.; Salinsky, M.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 192 EP 193 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600451 ER PT J AU Li, Y Peng, ZC Houser, CR AF Li, Yi Peng, Z. C. Houser, C. R. TI ALTERED GABA(A) RECEPTOR delta SUBUNIT EXPRESSION EXTENDS BEYOND THE DENTATE GYRUS IN A MOUSE MODEL OF TEMPORAL LOBE EPILEPSY SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society/2nd Biennial North American Regional Epilepsy Congress CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Li, Yi; Peng, Z. C.; Houser, C. R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Houser, C. R.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 SU 7 BP 346 EP 346 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600830 ER PT J AU Niquet, J Lopez-Meraz, M Wasterlain, C AF Niquet, Jerome Lopez-Meraz, M. Wasterlain, C. TI EXPERIMENTAL STATUS EPILEPTICUS INDUCES CASPASE-8 UPREGULATON AND NECROSIS IN CA1 PYRAMIDS, BUT CASPASE-9 ACTIVATION AND APOPTOSIS IN DENTATE GRANULE CELLS SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Niquet, Jerome; Lopez-Meraz, M.; Wasterlain, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Niquet, Jerome; Lopez-Meraz, M.; Wasterlain, C.] VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 471 EP 471 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306601099 ER PT B AU Berka, C Levendowski, DJ Davis, G Zivkovic, VT Cvetinovic, MM Olmstead, RE AF Berka, Chris Levendowski, Daniel J. Davis, Gene Zivkovic, Vladimir T. Cvetinovic, Milenko M. Olmstead, Richard E. BE Chebykin, OY Bedny, GZ Karwowski, W TI The New Interface of Brain, Mind, and Machine: Will the Emergent Whole Be Greater than the Sum of the Parts? SO ERGONOMICS AND PSYCHOLOGY: DEVELOPMENTS IN THEORY AND PRACTICE SE Ergonomics Design and Management Theory and Applications LA English DT Article; Book Chapter ID SLEEP-DEPRIVATION; COMPUTER INTERFACE; EEG SPECTRUM; PERFORMANCE; ALERTNESS; TASK; DISORDERS; INDEXES; WORKERS C1 [Berka, Chris; Levendowski, Daniel J.; Davis, Gene; Zivkovic, Vladimir T.; Cvetinovic, Milenko M.] Adv Brain Monitoring, Carlsbad, CA USA. [Olmstead, Richard E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Berka, C (reprint author), Adv Brain Monitoring, Carlsbad, CA USA. NR 69 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4200-6700-2 J9 ERGON DES MANAG THEO PY 2008 BP 167 EP 188 D2 10.1201/9781420067019 PG 22 WC Ergonomics; Psychology, Applied SC Engineering; Psychology GA BJY89 UT WOS:000267470200009 ER PT J AU Williams, ES Shah, SJ Ali, S Na, BY Schiller, NB Whooley, MA AF Williams, Eric S. Shah, Sanjiv J. Ali, Sadia Na, Bee Ya Schiller, Nelson B. Whooley, Mary A. TI C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE C-reactive protein; coronary heart disease; heart failure; diastolic dysfunction; inflammation; echocardiography ID TARGETED ANTICYTOKINE THERAPY; INDEPENDENT PROGNOSTIC VALUE; LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; NECROSIS-FACTOR-ALPHA; CARDIOVASCULAR-DISEASE; DEPRESSIVE SYMPTOMS; INFLAMMATION; MARKERS; INTERLEUKIN-6 AB Background: High-sensitivity C-reactive protein (CRP) is an inflammatory marker that predicts coronary heart disease (CHD) and, in recent studies, incident heart failure (HF). Whether the association of inflammation with incident HF is explained by worse baseline left ventricular dysfunction or by underlying CHD is unknown. Methods and results: Serum CRP was measured in a cohort of 985 outpatients with established CHD from the Heart and Soul Study. During 3 years of follow-up, 15% of the participants with elevated CRP levels (>3 mg/L) were hospitalised for HF, compared with 7% of those with CRP <= 3 mg/L. In multivariate analysis, elevated CRP was associated with HF after adjustment for traditional risk factors, baseline CHD severity and interim MI (adjusted HR 2.1, 95% CI, 1.2-3.6; p=0.009). However, elevated CRP was no longer associated with HF after further adjustment for the presence of diastolic dysfunction on echocardiography (adjusted HR 1.6, 95% CI, 0.8-3.2; p=0.1). Conclusions: Among outpatients with stable CHD, elevated CRP levels predict hospitalisation for heart failure, independent of baseline heart failure, medication use, CHD severity, and subsequent MI events. This relationship appears to be at least partly explained by abnormal diastolic function in patients with elevated CRP levels. (c) 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved. C1 [Williams, Eric S.; Shah, Sanjiv J.; Ali, Sadia; Na, Bee Ya; Schiller, Nelson B.; Whooley, Mary A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Williams, Eric S.; Shah, Sanjiv J.; Ali, Sadia; Na, Bee Ya; Schiller, Nelson B.; Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Williams, ES (reprint author), 4150 Clement St,Box 1211, San Francisco, CA 94143 USA. EM eric.williams@ucsf.edu FU NHLBI NIH HHS [R01 HL079235-01A1, R01 HL079235] NR 46 TC 33 Z9 33 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1388-9842 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD JAN PY 2008 VL 10 IS 1 BP 63 EP 69 DI 10.1016/j.ejheart.2007.11.003 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 260VP UT WOS:000253038800010 PM 18160340 ER PT J AU McMurtray, AM Licht, E Yeo, T Krisztal, E Saul, RE Mendez, MF AF McMurtray, Aaron M. Licht, Eliot Yeo, Tuty Krisztal, Erica Saul, Ronald E. Mendez, Mario F. TI Positron emission tomography facilitates diagnosis of early-onset Alzheimer's disease SO EUROPEAN NEUROLOGY LA English DT Article DE positron emission tomography; sensitivity; dementia; Alzheimer's disease ID MILD COGNITIVE IMPAIRMENT; REGIONAL CEREBRAL METABOLISM; ACADEMY-OF-NEUROLOGY; FDG-PET; GLUCOSE-METABOLISM; EARLY DEMENTIA; ASYMMETRIES; PREVALENCE; PARAMETER; PATTERNS AB Background: Clinical positron emission tomography (PET) may help in the evaluation of presenile patients with memory complaints for the presence of Alzheimer's disease (AD). Methods: Clinical PET scans from 27 patients with clinically probable AD and early ages of onset (< 65 years) were compared to PET scans from 27 age-matched controls presenting with memory complaints, but without dementia or mild cognitive impairment. Results: Compared to controls, the AD patients had significant frontal, temporal and parietal hypometabolism bilaterally, and AD diagnosis correlated with left temporal and right temporoparietal hypometabolism. The sensitivity of temporoparietal hypometabolism for AD was 92.6%, the specificity 85.2%. Conclusion: Clinical PET imaging helps distinguish early-onset AD from patients with memory complaints not meeting criteria for dementia or mild cognitive impairment. Copyright (C) 2007 S. Karger AG, Basel. C1 Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA USA. Va Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu NR 31 TC 20 Z9 20 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0014-3022 J9 EUR NEUROL JI Eur. Neurol. PY 2008 VL 59 IS 1-2 BP 31 EP 37 DI 10.1159/000109258 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 238GV UT WOS:000251436400005 PM 17917455 ER PT J AU Hamidi, SA Prabhakar, S Said, SI AF Hamidi, S. A. Prabhakar, S. Said, S. I. TI Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article DE gene expression and regulation; pulmonary hypertension; quantitative PCR; right heart failure ID VASOACTIVE-INTESTINAL-PEPTIDE; ARTERIAL-HYPERTENSION; SMOOTH-MUSCLE; MICE LACKING; EXPRESSION; LUNGS; CELLS; TETRAHYDROBIOPTERIN; SYNTHASE; PATHWAY AB The pathogenesis of idiopathic pulmonary arterial hypertension (PAH) remains poorly understood. The present authors recently reported that mice with vasoactive intestinal peptide (VIP) gene disruption show a spontaneous phenotype of PAH, with pulmonary vascular remodelling and lung inflammation. To explore the underlying molecular mechanisms in this model, it was examined whether absence of the VIP gene might alter the expression of additional genes involved in the pathogenesis of PAH, as single-gene deletions, in the absence of hypoxia, rarely result in significant pulmonary vascular remodelling. Lung tissue from mice with targeted disruption of the vasoactive intestinal peptide gene (VIP-/- mice) and from control mice was subjected to whole-genome gene microarray analysis, and the results validated with quantitative, real-time PCR. Lungs from VIP-/- mice showed a wide range of significant gene expression alterations, including overexpression of genes that promote pulmonary vascular smooth muscle cell proliferation, underexpression of antiproliferative genes and upregulation of pro-inflammatory genes. In conclusion, vasoactive intestinal peptide is a pivotal modulator of genes controlling the pulmonary vasculature, its deficiency alone resulting in gene expression alterations that can readily explain both the vascular remodelling and associated inflammatory response in pulmonary arterial hypertension. The present findings shed more light on the molecular mechanisms of pulmonary arterial hypertension, and could lead to better understanding of the pathogenesis of human pulmonary arterial hypertension, and hence to improved therapy. C1 [Hamidi, S. A.; Said, S. I.] SUNY Hlth Sci Ctr, Stony Brook, NY 11784 USA. [Hamidi, S. A.; Said, S. I.] US Dept Vet Affairs, Med Ctr, Northport, NY USA. [Prabhakar, S.] SuperArray Biosci Corp, Frederick, MD USA. RP Said, SI (reprint author), SUNY Hlth Sci Ctr, T-17-040, Stony Brook, NY 11784 USA. EM sami.i.said@stonybrook.edu FU NHLBI NIH HHS [HL-68188, HL-70212] NR 27 TC 37 Z9 39 U1 0 U2 2 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD JAN PY 2008 VL 31 IS 1 BP 135 EP 139 DI 10.1183/09031936.00105807 PG 5 WC Respiratory System SC Respiratory System GA 251RG UT WOS:000252390800022 PM 18166594 ER PT J AU Ledoux, W AF Ledoux, William BE Harris, GF Smith, PA Marks, RM TI The Biomechanics of the Diabetic Foot SO FOOT AND ANKLE MOTION ANALYSIS: CLINICAL TREATMENT AND TECHNOLOGY SE Biomedical Engineering Series LA English DT Article; Book Chapter ID LIMITED JOINT MOBILITY; SHOE PLANTAR SHEAR; PERIPHERAL NEUROPATHY; TOE DEFORMITY; HIGH-RISK; FAT-PAD; PRESSURE DISTRIBUTION; GAIT CHARACTERISTICS; HEEL-PAD; WALKING C1 Univ Washington, Dept Mech Engn, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Ledoux, W (reprint author), Univ Washington, Dept Mech Engn, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 82 TC 1 Z9 1 U1 0 U2 0 PU BUTTERWORTH-HEINEMANN PI WOBORN PA 225 WILDWOOD AVE, WOBORN, MA 01801 USA J9 BIOMED ENG SER PY 2008 BP 317 EP 345 PG 29 WC Orthopedics SC Orthopedics GA BKX81 UT WOS:000269556400021 ER PT J AU Turner, EH AF Turner, Erick H. TI Publication bias, the first or the final nail into the coffin of evidence-based medicine? SO FORSCHENDE KOMPLEMENTARMEDIZIN LA German DT Editorial Material C1 Portland VA Med Ctr, Portland, OR 97239 USA. RP Turner, EH (reprint author), Portland VA Med Ctr, P3MHDC,3710 SW,US Vet Hosp Rd, Portland, OR 97239 USA. EM turnere@ohsu.edu NR 4 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1021-7096 J9 FORSCH KOMPLEMENTMED JI Forsch. Komplement.med. PY 2008 VL 15 IS 2 BP 110 EP 112 PG 3 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 324KZ UT WOS:000257518800012 ER PT J AU Shacka, JJ Roth, KA Zhang, JH AF Shacka, John J. Roth, Kevin A. Zhang, Jianhua TI The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Review DE macroautophagy; chaperone-mediated autophagy; lysosome; aging; Alzheimer's disease; Parkinson's disease; neurodegeneration; therapeutics; review ID AMYLOID PRECURSOR PROTEIN; CHAPERONE-MEDIATED AUTOPHAGY; APOPTOTIC CELL-DEATH; AGE-RELATED-CHANGES; SPORADIC ALZHEIMERS-DISEASE; GENOME-WIDE ASSOCIATION; CATHEPSIN-D ACTIVITY; PARKINSONS-DISEASE; GRANULOVACUOLAR DEGENERATION; ALPHA-SYNUCLEIN AB Alterations in the autophagy-lysosomal degradation pathway have been described in normal brain aging and in age-related neurodegenerative diseases including Alzheimer's (AD) and Parkinson's (PD). An improper clearance of proteins in AD and PD may result either from a compromise in the autophagy-lysosomal degradation pathway or induce alterations in this pathway, and may result in neuron dysfunction and neuron loss. This review provides an overview of AD and PD with a specific focus on macroautophagy, chaperone-mediated autophagy and lysosome function in human and experimental models of AD and PD. Potential therapies for AD and PD are also discussed that may promote survival by regulating the autophagy and lysosomal degradation pathway. C1 [Shacka, John J.; Roth, Kevin A.; Zhang, Jianhua] Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA. [Shacka, John J.] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35294 USA. RP Shacka, JJ (reprint author), Univ Alabama, Dept Pathol, Div Neuropathol, SC 930, Birmingham, AL 35294 USA. EM shacka@uab.edu RI zhang, jianhua/D-3404-2009 OI Roth, Kevin/0000-0002-0643-995X FU NINDS NIH HHS [NS41962, NS35107, NS47466, NS57098] NR 181 TC 77 Z9 83 U1 1 U2 20 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 718 EP 736 DI 10.2741/2714 PG 19 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700058 PM 17981582 ER PT J AU Meeran, SM Katiyar, SK AF Meeran, Syed Musthapa Katiyar, Santosh Kumar TI Proanthocyanidins inhibit mitogenic and survival-signaling in vitro and tumor growth in vivo SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Article DE grape seed proanthocyanidins; mitogen-activated protein kinases; nuclear factor-kappaB; tumor xenograft; phosphatidylinositol 3-kinase ID NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; GRAPE SEEDS; INDUCE APOPTOSIS; CARCINOMA-CELLS; CANCER-CELLS; PATHWAY; TRANSDUCTION; PHOTOCARCINOGENESIS; INVASIVENESS AB We have previously shown that treatment of human epidermoid carcinoma A431 cells with grape seed proanthocyanidins (GSPs) induces apoptosis of A431 cells. Here, we report that treatment of A431 cells with GSPs inhibits constitutive as well as EGF-induced higher levels of phosphorylated proteins of MAPK family in a dose-dependent manner. This effect is associated with the reactivation of MAP kinase phosphatases. Western blot analysis reveals that GSPs decrease: (i) the levels of phosphatidylinositol 3-kinase (PI3K) and the phosphorylation of Akt at ser(473), and (ii) the constitutive activation of NF-kappaB/p65. As NF-kappaB-targeted genes play crucial roles in tumor cell proliferation and differentiation, we assessed the effect of GSPs on proteins encoded by these genes. Treatment with GSPs results in inhibition of the expression of COX-2, iNOS, PCNA, cyclin D1 and MMP-9 in A431 cells compared with non-GSPs-treated controls. Treatment of athymic nude mice with GSPs by oral gavage (50 or 100 mg/kg body weight/mouse) reduces the growth of A431-xenografts in mice, which is associated with the inhibition of tumor cell proliferation in xenografts as indicated by the inhibition of mRNA expression of PCNA and cyclin D1, and of NF-kappaB activity. Together, the data suggest that GSPs might be effective in the treatment of skin cancers. C1 [Meeran, Syed Musthapa; Katiyar, Santosh Kumar] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh Kumar] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Meeran, SM (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCI NIH HHS [CA104428-01] NR 37 TC 13 Z9 17 U1 1 U2 5 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 887 EP 897 DI 10.2741/2729 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700073 PM 17981597 ER PT J AU Meeran, SM Katiyar, SK AF Meeran, Syed Musthapa Katiyar, Santosh Kumar TI Cell cycle control as a basis for cancer chemoprevention through dietary agents SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Review DE cell cycle; cyclins; cyclin dependent kinases; Cip1/p21; Kip1/p27; apigenin; curcumin; epigallocatechin-3-gallate; grape seed proanthocyanidins; genistein; resveratrol; silymarin; review ID DEPENDENT KINASE INHIBITOR; S-PHASE CHECKPOINT; CARCINOMA A431 CELLS; PROSTATE-CANCER; DNA-DAMAGE; BREAST-CANCER; PANCREATIC-CANCER; INK4 INHIBITORS; CDK INHIBITORS; GRAPE SEEDS AB The development of cancer is associated with disorders in the regulation of the cell cycle. The purpose of this review is to briefly summarize the known sequence of events that regulate cell cycle progression with an emphasis on the checkpoints and the mechanisms cell employ to insure DNA stability in the face of genotoxic stress. Key transitions in the cell cycle are regulated by the activities of various protein kinase complexes composed of cyclin and cyclin-dependent kinases ( CDK) molecules. The cyclins are CDK binding partners which are required for kinase activity and their protein levels are intimately linked to the cell cycle stage. CDK activity can be regulated by other mechanisms, such as phosphorylation events, that may contribute to deregulation of cell cycle and the development of cancer. While fruits and vegetables are recommended for prevention of cancer, their active ingredients and mechanisms of action are less well understood. Here, we briefly present evidence that dietary agents identified from fruits and vegetables can act to modulate the effects of deregulated cell cycle checkpoints, and that this may contribute to the prevention of cancer. The agents include apigenin ( celery, parsley), curcumin ( turmeric), (-)-epigallocatechin-3-gallate ( green tea), resveratrol ( red grape, peanuts and berries), genistein ( soybean), and silymarin ( milk thistle). The teachings of Hippocrates are still true "let food be thy medicine and medicine be thy food". C1 [Meeran, Syed Musthapa; Katiyar, Santosh Kumar] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh Kumar] Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh Kumar] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh Kumar] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCCIH NIH HHS [AT002536, R01 AT002536, R01 AT002536-01A2, R01 AT002536-02]; NCI NIH HHS [CA104428, R21 CA104428, R21 CA104428-01A2, R21 CA104428-02] NR 103 TC 112 Z9 121 U1 1 U2 8 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 2191 EP 2202 DI 10.2741/2834 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700178 PM 17981702 ER PT J AU da Silveira, E Barkun, AN AF da Silveira, Eduardo Barkun, Alan N. TI Self-expandable metal stents in acute malignant colonic obstruction: shall you cross this bridge? SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID VS. EMERGENCY-SURGERY; DECISION-MAKING; CANCER; MANAGEMENT; RESECTION C1 [da Silveira, Eduardo] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Barkun, Alan N.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. RP da Silveira, E (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 23 TC 1 Z9 1 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2008 VL 67 IS 1 BP 74 EP 76 DI 10.1016/j.gie.2007.06.062 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 252AW UT WOS:000252418200014 PM 18054009 ER PT J AU Saha, S Shipman, SA AF Saha, Somnath Shipman, Scott A. TI Race-neutral versus race-conscious workforce policy to improve access to care SO HEALTH AFFAIRS LA English DT Article ID MEDICAL-SCHOOLS; UNDERSERVED POPULATIONS; HEALTH-CARE; GENERALIST PHYSICIANS; AFFIRMATIVE-ACTION; MINORITY; QUALITY AB Access to care for racial and ethnic minority groups, low-income populations, and the un- and underinsured has been problematic despite expansion in the health workforce. Workforce policies that improve access to care are needed, as is funding to support them. Reviewing evidence related to providers' patterns of service to the underserved, this paper concludes that underrepresented minority health professionals have consistently been more likely than those from low socioeconomic backgrounds or the National Health Service Corps to deliver health care to the underserved. These findings have implications for policies and programs that might leverage the workforce to better meet the needs of disadvantaged patients. C1 [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA. [Shipman, Scott A.] Dartmouth Med Sch, Inst Hlth Policy & Clin Practice, Lebanon, NH USA. RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA. EM sahas@ohsu.edu FU PHS HHS [03-BHPR-104] NR 25 TC 35 Z9 35 U1 1 U2 3 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2008 VL 27 IS 1 BP 234 EP 245 DI 10.1377/hlthaff.27.1.234 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 319TZ UT WOS:000257188400028 PM 18180500 ER PT J AU Sayers, SL Riegel, B Goldberg, LR Coyne, JC Samaha, FF AF Sayers, Steven L. Riegel, Barbara Goldberg, Lee R. Coyne, James C. Samaha, Frederick F. TI Clinical exacerbations as a surrogate end point in heart failure research SO HEART & LUNG LA English DT Article ID LEFT-VENTRICULAR DYSFUNCTION; ASSOCIATION; MORTALITY; SURVIVAL; HEALTH; BLACK; RACE AB BACKGROUND: We examined the utility of an index of clinical exacerbations of heart failure (HF) as a surrogate measure of outcome for use in modestly sized clinical trials and observational studies. METHODS: Electronic records of 189 outpatients with HF in a US Veterans Affairs Medical Center were examined over a 2- to 3-year period. Data collected included patient characteristics, clinical exacerbations of HF, hospitalizations, and deaths. Subsets of patient were also assessed for HF-related level of functioning. RESULTS: Episodes of clinical exacerbation could be detected reliably (kappa = .83). An index of episodes (number of episodes divided by the time in years) was associated with lower quality of life, higher functional class, increased rate of HF hospitalization, poorer exercise tolerance, and up to 30% increased risk of mortality across 2 years. CONCLUSIONS: The index of HF exacerbations is potentially a useful surrogate end point for use in clinical HF research. C1 [Sayers, Steven L.; Samaha, Frederick F.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Sayers, Steven L.; Coyne, James C.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Riegel, Barbara] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Goldberg, Lee R.; Samaha, Frederick F.] Univ Penn, Dept Internal Med, Div Cardiol, Philadelphia, PA 19104 USA. RP Sayers, SL (reprint author), Philadelphia Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. OI Goldberg, Lee/0000-0002-7906-9638 NR 25 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-9563 J9 HEART LUNG JI Heart Lung PD JAN-FEB PY 2008 VL 37 IS 1 BP 28 EP 35 DI 10.1016/j.hrtlng.2007.02.002 PG 8 WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System SC Cardiovascular System & Cardiology; Nursing; Respiratory System GA 254TC UT WOS:000252609900004 PM 18206524 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Structure and Function of Hematopoietic Tissues SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID MESENCHYMAL STEM-CELLS; SPLENIC MARGINAL ZONE; PERIPHERAL-BLOOD FILM; BONE-MARROW; T-CELL; PROGENITOR CELLS; DENDRITIC CELLS; MAST-CELLS; ERYTHROID-CELLS; FLOW-CYTOMETRY C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 129 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 1 EP 26 PG 26 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800002 ER PT B AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Hematopathology Morphology, Immunophenotype, Cytogenetics and Molecular Approaches Preface SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Editorial Material; Book Chapter C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP IX EP IX PG 1 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800001 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Principles of Immunophenotyping SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; G-CSF-RECEPTOR; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; NATURAL CYTOTOXICITY RECEPTORS; MULTIPARAMETER FLOW-CYTOMETRY; SURFACE ANTIGEN-EXPRESSION C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 197 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5; 978-0-12-370607-2 PY 2008 BP 27 EP 55 DI 10.1016/B978-0-12-370607-2.00002-8 PG 29 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800003 ER PT B AU Grody, WW Rao, PN Naeim, F AF Grody, Wayne W. Rao, P. Nagesh Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Principles of Molecular Techniques SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID DNA-POLYMERASE; ARRAY CGH; AMPLIFICATION; CYTOGENETICS; MICROARRAYS; SEQUENCES; LEUKEMIA; FUSION C1 [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. [Rao, P. Nagesh; Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Grody, WW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. NR 23 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5; 978-0-12-370607-2 PY 2008 BP 65 EP 79 DI 10.1016/B978-0-12-370607-2.00004-1 PG 15 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800005 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Morphology of Abnormal Bone Marrow SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID OF-THE-LITERATURE; SICKLE-CELL-DISEASE; GELATINOUS TRANSFORMATION; MULTIPLE-MYELOMA; AMYLOID DEPOSITS; BETA-FIBRILLOSES; AL AMYLOIDOSIS; BREAST-CANCER; STEM-CELLS; Q-FEVER C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 73 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5; 978-0-12-370607-2 PY 2008 BP 81 EP 99 DI 10.1016/B978-0-12-370607-2.00005-3 PG 19 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800006 ER PT J AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Reactive Lymphadenopathies SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ROSAI-DORFMAN DISEASE; CAT-SCRATCH DISEASE; LANGERHANS-CELL HISTIOCYTOSIS; LYMPH-NODE HYPERPLASIA; SINUS HISTIOCYTOSIS; MASSIVE LYMPHADENOPATHY; CASTLEMANS-DISEASE; HEMOPHAGOCYTIC SYNDROME; DERMATOPATHIC LYMPHADENOPATHY; TOXOPLASMIC LYMPHADENITIS C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 61 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 101 EP 113 DI 10.1016/B978-0-12-370607-2.00006-5 PG 13 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800007 ER PT J AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Bone Marrow Aplasia SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; SHWACHMAN-DIAMOND-SYNDROME; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; FANCONI-ANEMIA; DYSKERATOSIS-CONGENITA; FLOW-CYTOMETRY; CYTOGENETIC ABNORMALITIES; ANTITHYMOCYTE GLOBULIN; FAILURE SYNDROMES C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 115 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 115 EP 127 DI 10.1016/B978-0-12-370607-2.00007-7 PG 13 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800008 ER PT B AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Myelodysplastic Syndromes SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE MYELOID-LEUKEMIA; IN-SITU HYBRIDIZATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNATIONAL WORKING GROUP; BONE-MARROW; CLINICAL CHARACTERISTICS; RESPONSE CRITERIA; SCORING SYSTEM; FLOW-CYTOMETRY; SYNDROME MDS C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 97 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 129 EP 154 DI 10.1016/B978-0-12-370607-2.00008-9 PG 26 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800009 ER PT J AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Chronic Myeloproliferative Diseases SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID CHRONIC NEUTROPHILIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; IDIOPATHIC-HYPEREOSINOPHILIC-SYNDROME; CHRONIC EOSINOPHILIC LEUKEMIA; IN-SITU HYBRIDIZATION; BONE-MARROW HISTOPATHOLOGY; TYROSINE KINASE MUTATION; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 135 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 155 EP 189 DI 10.1016/B978-0-12-370607-2.00009-0 PG 35 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800010 ER PT B AU Naeim, F Rao, PN AF Naeim, Faramarz Rao, P. Nagesh BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Myelodysplastic/Myeloproliferative Diseases SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; PEDIATRIC MYELODYSPLASTIC SYNDROMES; CHRONIC MYELOGENOUS LEUKEMIA; MARROW MONOCYTIC NODULES; RETROSPECTIVE ANALYSIS; MYELOPROLIFERATIVE DISEASES; PTPN11 MUTATIONS; RECEPTOR-BETA; RAS C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 71 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 191 EP 205 DI 10.1016/B978-0-12-370607-2.00010-7 PG 15 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800011 ER PT J AU Naeim, F Rao, PN AF Naeim, Faramarz Rao, P. Nagesh BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Acute Myeloid Leukemia SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE BASOPHILIC LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; OF-THE-LITERATURE; THERAPY-RELATED MYELODYSPLASIA; COOPERATIVE-ONCOLOGY-GROUP C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 260 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 207 EP 255 DI 10.1016/B978-0-12-370607-2.00011-9 PG 49 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800012 ER PT J AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI The Neoplasms of Precursor Lymphoblasts SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE LYMPHOCYTIC-LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; POLYMERASE-CHAIN-REACTION; CHILDRENS CANCER GROUP; OF-THE-LITERATURE; CLINICAL-SIGNIFICANCE; GENE REARRANGEMENTS; MOLECULAR-GENETICS; FUSION GENE; PHILADELPHIA-CHROMOSOME C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 92 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 257 EP 277 DI 10.1016/B978-0-12-370607-2.00012-0 PG 21 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800013 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Acute Leukemias of Ambiguous Lineage SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE LYMPHOBLASTIC-LEUKEMIA; BIPHENOTYPIC ACUTE-LEUKEMIA; ACUTE MYELOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ABERRANT EXPRESSION; SWITCH; T(4/11); CD79A; GENE; DIFFERENTIATION C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 39 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 279 EP 286 DI 10.1016/B978-0-12-370607-2.00013-2 PG 8 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800014 ER EF